<SEC-DOCUMENT>0001193125-22-086634.txt : 20220328
<SEC-HEADER>0001193125-22-086634.hdr.sgml : 20220328
<ACCEPTANCE-DATETIME>20220328160843
ACCESSION NUMBER:		0001193125-22-086634
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		84
FILED AS OF DATE:		20220328
DATE AS OF CHANGE:		20220328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hyperfine, Inc.
		CENTRAL INDEX KEY:			0001833769
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262300
		FILM NUMBER:		22775547

	BUSINESS ADDRESS:	
		STREET 1:		351 NEW WHITFIELD STREET
		CITY:			GUILFORD
		STATE:			CT
		ZIP:			06437
		BUSINESS PHONE:		866-796-6767

	MAIL ADDRESS:	
		STREET 1:		351 NEW WHITFIELD STREET
		CITY:			GUILFORD
		STATE:			CT
		ZIP:			06437

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HealthCor Catalio Acquisition Corp.
		DATE OF NAME CHANGE:	20201124
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d284543dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:hypr="http://hyperfine.io/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>POS AM</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:LiquidationBasisOfAccountingLiquidationPlan" id="hidden41719881" contextRef="P01_01_2021To12_31_2021">In the event of any liquidation, dissolution or winding up of Legacy Hyperfine, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Legacy Hyperfine&#8217;s assets, or a transaction which the holders of capital stock of Legacy Hyperfine hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Legacy Hyperfine available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issue price of such Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Legacy Hyperfine common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock.</ix:nonNumeric><ix:nonNumeric name="us-gaap:OpenTaxYear" id="hidden41720084" contextRef="P01_01_2021To12_31_2021">2017 2018 2019</ix:nonNumeric><ix:nonNumeric name="dei:DocumentType" id="hidden41773682" contextRef="P01_01_2021To12_31_2021">POS AM</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2021To12_31_2021">true</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2021To12_31_2021">0001833769</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="hypr-20211231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_07_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To01_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2021To12_12_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-12</xbrli:startDate> <xbrli:endDate>2021-12-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_16_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-05-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerDMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerDMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerFMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerFMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerGMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerGMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerHMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerHMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:ResearchDevicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:SalesAndMarketingDevicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:TradeShowAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LeasedDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:LeasedDevicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis" >us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis" >us-gaap:TransferredOverTimeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:CostOfSalesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:CostOfSalesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >hypr:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:FederalAndStateNetOperatingLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:CatalyzerCorporation4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FourBionicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:FourBionicsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >hypr:PreTwoThaousandEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:LiminalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AUsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LiminalMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:LiminalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:LiminalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >hypr:AllocationOfExpenseIncurredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:ConnecticutOthersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >hypr:FederalOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:LiminalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ShareBasedPaymentArrangementSeparateOptionAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:ShareBasedPaymentArrangementSeparateOptionAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsTwoMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:StockOptionsTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_StockOptionsOneMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:StockOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ServiceAndPerformanceSharesMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:ServiceAndPerformanceSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsOneMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:StockOptionsOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IncentiveUnitActivityMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:IncentiveUnitActivityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:FourBionicsTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:SeriesATwoConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:SeriesA1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesBCAndDConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:SeriesBCAndDConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:LegacyHyperfineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:TradeShowAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:SalesAndMarketingDevicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:ResearchDevicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >hypr:PreTwoThaousandEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >hypr:PostTwoThaousandSeventeenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LiminalMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:LiminalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >hypr:PostTwoThaousandSeventeenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:LiminalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DividendsAxis" >us-gaap:DividendDeclaredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" > <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain >2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_2023-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" > <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain >2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:ConnecticutResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:ConnecticutOthersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >hypr:FederalOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:HyperfineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:LiminalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_LiminalMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:ConnecticutResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >hypr:LiminalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:SeriesATwoConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:SeriesA1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >hypr:ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:CatalyzerCorporation4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TechnologyAndServicesExchangeAgreementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:TechnologyAndServicesExchangeAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >hypr:AmendedAndRestatedTechnologyServicesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >hypr:ResearchDevicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DividendsAxis" >us-gaap:DividendDeclaredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:CatalyzerCorporation4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >hypr:AmendedAndRestatedTechnologyServicesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2021To07_07_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:LegacyHyperfineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-07</xbrli:startDate> <xbrli:endDate>2021-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2021To07_07_2021_LiminalMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:LiminalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-07</xbrli:startDate> <xbrli:endDate>2021-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2021To07_07_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-07</xbrli:startDate> <xbrli:endDate>2021-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-12</xbrli:startDate> <xbrli:endDate>2021-12-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2021To12_12_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-12</xbrli:startDate> <xbrli:endDate>2021-12-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >hypr:SubscriptionAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-12</xbrli:startDate> <xbrli:endDate>2021-12-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerDMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerDMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerFMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerFMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerGMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerGMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerHMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >hypr:CustomerHMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis" >us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis" >us-gaap:TransferredOverTimeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OutstandingLegacyHyperfineConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >hypr:OutstandingLegacyHyperfineConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:FederalAndStateNetOperatingLossesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:CatalyzerCorporation4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis" >us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >hypr:AllocationOfExpenseIncurredMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >hypr:LiminalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >hypr:FourBionicsTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >hypr:SubscriptionAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:ClassBOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:LegacyHyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:LegacyHyperfineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:SeriesA1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:PIPEInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >hypr:ImmediatelyPriorToEffectiveTimeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >hypr:ImmediatelyPriorToEffectiveTimeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >hypr:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2021_ClassAOrdinarySharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:ClassAOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:ClassBOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HealthCorCatalioAcquisitionCorpMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >hypr:HealthCorCatalioAcquisitionCorpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021_HealthCorMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >hypr:HealthCorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2021To12_22_2021_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >hypr:PIPEInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-22</xbrli:startDate> <xbrli:endDate>2021-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_11_2022To01_11_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-11</xbrli:startDate> <xbrli:endDate>2022-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2002To04_30_2022_ScenarioForecastMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >srt:ScenarioForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2002-04-01</xbrli:startDate> <xbrli:endDate>2022-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2017_FederalNetOperatingLossMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >hypr:FederalNetOperatingLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2017_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To04_01_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2020To08_31_2020_PayrollProtectionProgramLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >hypr:PayrollProtectionProgramLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-08-01</xbrli:startDate> <xbrli:endDate>2020-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_10_2020_HyperfinePayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >hypr:HyperfinePayrollProtectionProgramLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-08-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2020_LiminalPayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >hypr:LiminalPayrollProtectionProgramLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021_MaximumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021_MinimumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2021To07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-06</xbrli:startDate> <xbrli:endDate>2021-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001833769</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>hypr:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Site" > <xbrli:measure>hypr:Site</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Subsidiary" > <xbrli:measure>hypr:Subsidiary</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Vote" > <xbrli:measure>hypr:Vote</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Option" > <xbrli:measure>hypr:Option</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Ownership" > <xbrli:measure>hypr:Ownership</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the U.S. Securities and Exchange Commission on March 28, 2022 </div></div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-262300</div> </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">POST-EFFECTIVE AMENDMENT NO. 1 TO </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden41773682">S-1</span></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2021To12_31_2021">Hyperfine, Inc.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Delaware</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3845</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">98-1569027</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification Number)</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">351 New Whitfield Street </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Guilford, Connecticut 06437 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Telephone: (203) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">458-7100</div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">President and Chief Executive Officer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">351 New Whitfield Street </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Guilford, Connecticut 06437 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Telephone: (203) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">458-7100</div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael L. Fantozzi, Esq. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">John P. Condon, Esq. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Mintz, Levin, Cohn, Ferris, </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Glovsky and Popeo, P.C. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">One Financial Center </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Boston, Massachusetts 02111 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Telephone: (617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">542-6000</div> </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;">Approximate date of commencement of proposed sale to the public: <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As soon as practicable after the effective date of this registration statement.</div></div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.&#160;&#160; &#9746; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div> accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 15%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 62%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2021To12_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2021To12_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2021To12_31_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</div></div> </div><div style="font-size: 5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXPLANATORY NOTE </div></div></div> <ix:nonNumeric name="dei:AmendmentDescription" contextRef="P01_01_2021To12_31_2021"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;24, 2022, the registrant filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-262300),</div> which was subsequently declared effective by the U.S. Securities and Exchange Commission on February&#160;1, 2022 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Registration Statement</div>&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This post-effective amendment is being filed to update the Registration Statement to include information contained in the registrant&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2021 and certain other information in such Registration Statement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No additional securities are being registered under this post-effective amendment and all applicable registration and filing fees were paid at the time of the original filing of the Registration Statement. </div><br/></div></ix:nonNumeric> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Arial Narrow; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(255, 67, 56); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The information in this preliminary prospectus is not complete and may be changed. Neither we nor the selling securityholders may sell these securities until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(255, 67, 56); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SUBJECT TO COMPLETION, DATED MARCH 28, 2022 </div></div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRELIMINARY PROSPECTUS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g284543g22s22.jpg" style="width: 263px; height: 33px;"/></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 41,775,946 Shares of Class&#160;A Common Stock </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 15,055,288 Shares of Class&#160;B Common Stock </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Selling Securityholders</div>&#8221;) of up to (i) 5,025,000 shares of Class&#160;A common stock, par value $0.0001 per share (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Class</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A common stock</div>&#8221;), held by the sponsor of our predecessor company, HealthCor Catalio Acquisition Corp., a Delaware corporation (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor</div>&#8221;), HC Sponsor LLC (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sponsor</div>&#8221;), and certain of its transferees (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares</div>&#8221;), (ii) 12,122,000 shares of Class&#160;A common stock issued in the PIPE Investment (as defined below), (iii) 23,714,946 shares of Class&#160;A common stock issued to our directors, officers and affiliates and the directors, officers and affiliates of Legacy Hyperfine (as defined below) pursuant to the Business Combination Agreement (as defined below), including shares of Class&#160;A common stock that may be issued upon the exercise of stock options (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Options</div>&#8221;) and the vesting of restricted stock units or upon the conversion of Class&#160;B common stock, par value $0.0001 per share (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Class</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;B common stock</div>&#8221;), (iv) 614,000 shares of Class&#160;A common stock issued in the Private Placement (as defined below), (v) 300,000 shares issued following the closing of the Business Combination (as defined below) in lieu of $3.0&#160;million of deferred underwriting compensation payable to the sole bookrunning manager of HealthCor&#8217;s initial public offering (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Letter Agreement Shares</div>&#8221;), and (vi) 15,055,288 shares of Class&#160;B common stock issued pursuant to the Business Combination Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus provides you with a general description of such securities and the general manner in which we and the Selling Securityholders may offer or sell the securities. More specific terms of any securities that we and the Selling Securityholders may offer or sell may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will not receive any proceeds from the sale of shares of Class&#160;A common stock or shares of Class&#160;B common stock by the Selling Securityholders, except with respect to amounts received by us upon exercise of the Options. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, we will pay the expenses, other than any underwriting discounts and commissions, associated with the sale of securities pursuant to this prospectus. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are registering the securities for resale pursuant to the Selling Securityholders&#8217; registration rights under certain agreements between us and the Selling Securityholders. Our registration of the securities covered by this prospectus does not mean that either we or the Selling Securityholders will issue, offer or sell, as applicable, any of the securities. The Selling Securityholders may offer and sell the securities covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Securityholders may sell the shares in the section entitled &#8220;Plan of Distribution.&#8221; </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Class&#160;A common stock is listed on Nasdaq under the symbol &#8220;HYPR&#8221;. On March 25, 2022, the closing price of our Class&#160;A common stock was $3.29. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing in our securities involves a high degree of risk. See &#8220;<a href="#toc284543_5">Risk Factors</a>&#8221; beginning on page 13 of this prospectus and in the other documents that are incorporated by reference in this prospectus. </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The date of this prospectus is&#160;&#160;&#160;&#160;, 2022. </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 96%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_1">CERTAIN DEFINED TERMS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_3">SUMMARY OF THE PROSPECTUS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_4">THE OFFERING</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_5">RISK FACTORS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_6">USE OF PROCEEDS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_7">DETERMINATION OF OFFERING PRICE</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_8">MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_9">BUSINESS OF HYPERFINE</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">60</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">98</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_11">DESCRIPTION OF OUR CAPITAL STOCK</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">111</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_12">SECURITIES ACT RESTRICTIONS ON RESALE OF COMMON STOCK</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">121</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_13">BENEFICIAL OWNERSHIP OF SECURITIES</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">122</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_14">SELLING SECURITYHOLDERS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">124</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_15">MANAGEMENT</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">130</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_16">EXECUTIVE AND DIRECTOR COMPENSATION</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">136</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_17">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">146</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_18">U.S. FEDERAL INCOME TAX CONSIDERATIONS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">151</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_19">PLAN OF DISTRIBUTION</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">157</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_20">LEGAL MATTERS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">160</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_21">EXPERTS</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">160</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc284543_22">WHERE YOU CAN FIND MORE INFORMATION</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">160</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc284543_22a">INDEX TO FINANCIAL STATEMENTS </a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">F-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0pt; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should rely only on the information contained in this prospectus. No one has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For investors outside the United States: </div></div>We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- i - </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN DEFINED TERMS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In this document: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Business Combination&#8221; refers to the transactions contemplated by the Business Combination Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Business Combination Agreement&#8221; refers to the Business Combination Agreement, dated as of July&#160;7, 2021, by and among HealthCor, Merger Sub I, Merger Sub II, Legacy Hyperfine and Liminal, as the same may be amended, modified, supplemented or waived from time to time in accordance with its terms. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Cayman Islands Companies Act&#8221; refers to the Cayman Islands Companies Act (As Revised) of the Cayman Islands, as the same may be amended from time to time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Charter&#8221; means the certificate of incorporation, as amended, of Hyperfine, Inc. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Class&#160;A common stock&#8221; means the shares of Class&#160;A common stock, par value $0.0001 per share, of Hyperfine, which shares have the same economic terms as the shares of Hyperfine Class&#160;B common stock, but are only entitled to one (1)&#160;vote per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Class&#160;B common stock&#8221; means the shares of Class&#160;B common stock, par value $0.0001 per share, of Hyperfine, which shares have the same economic terms as the shares of Hyperfine Class&#160;A common stock, but are entitled to twenty (20)&#160;votes per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Class&#160;A ordinary shares&#8221; refers to the Class&#160;A ordinary fully paid shares of par value $0.0001 each per share in the capital of HealthCor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Class&#160;B ordinary shares&#8221; or &#8220;founder shares&#8221; refers to the Class&#160;B ordinary fully paid shares of par value $0.0001 each per share in the capital of HealthCor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Closing&#8221; refers to the closing of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Closing Date&#8221; refers to the closing date of the Business Combination, which occurred on December&#160;22, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Code&#8221; refers to the Internal Revenue Code of 1986, as amended. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;common stock&#8221; means, collectively, the Hyperfine Class&#160;A common stock and the Hyperfine Class&#160;B common stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Company,&#8221; &#8220;our,&#8221; &#8220;we&#8221; or &#8220;us&#8221; refer to Hyperfine, Inc. and its subsidiaries following the Business Combination, or to Legacy Hyperfine or Liminal prior to the Business Combination, as the case may be. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;DGCL&#8221; refers to the Delaware General Corporation Law, as amended. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Domestication&#8221; refers to the change of HealthCor&#8217;s jurisdiction of incorporation from the Cayman Islands to the State of Delaware by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation, incorporated under the laws of the State of Delaware on December&#160;21, 2021. Upon Domestication, the Class&#160;A ordinary shares of HealthCor became shares of Class&#160;A common stock of the Delaware corporation and the Class&#160;B ordinary shares of HealthCor became shares of Class&#160;B common stock of the Delaware corporation under the applicable provisions of the Cayman Islands Companies Act and the DGCL. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Effective Time&#8221; refers to the effective time of the Mergers. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Exchange Act&#8221; refers to the Securities Exchange Act of 1934, as amended. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;GAAP&#8221; refers to United States generally accepted accounting principles, consistently applied. &#8220;HealthCor&#8221; refers to HealthCor Catalio Acquisition Corp., a Cayman Islands exempted company with limited liability (which, after the Closing is known as Hyperfine, Inc.). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;HSR Act&#8221; means the Hart-Scott Rodino Antitrust Improvements Act of 1976. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Hyperfine&#8221; refers to Hyperfine, Inc., a Delaware corporation and the combined company following the consummation of the Business Combination, and its consolidated subsidiaries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Hyperfine Board&#8221; refers to the board of directors of Hyperfine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Hyperfine Equity Incentive Plan&#8221; refers to the Hyperfine, Inc. 2021 Equity Incentive Plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Hyperfine Exchange Ratio&#8221; means 0.3275, which was determined in accordance with the Business Combination Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Hyperfine Merger&#8221; refers to that certain merger of Merger Sub I with and into Legacy Hyperfine, with Legacy Hyperfine surviving as a wholly owned subsidiary of Hyperfine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Initial Public Offering&#8221; or &#8220;IPO&#8221; refers to HealthCor&#8217;s initial public offering of its Public Shares pursuant to the IPO registration statement and completed on January&#160;29, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Initial Shareholders&#8221; refer to the Sponsor and HealthCor&#8217;s independent directors who own all of HealthCor&#8217;s founder shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Investment Company Act&#8221; refers to the Investment Company Act of 1940, as amended, and the rules and regulations promulgated thereunder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Legacy Articles&#8221; refers to HealthCor&#8217;s Amended and Restated Memorandum and Articles of Association, effective as of January&#160;26, 2021, as may hereafter be amended. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Legacy Hyperfine&#8221; refers to Hyperfine Operations, Inc. (formerly Hyperfine, Inc.), a Delaware corporation that is wholly-owned subsidiary of Hyperfine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Letter Agreement&#8221; refers to the letter agreement, dated as of December&#160;22, 2021, by and between HealthCor and Jefferies LLC, the lead financial advisor, capital markets advisor and placement agent to HealthCor in connection with the Business Combination and the PIPE Investment, pursuant to which Hyperfine issued to Jefferies LLC 300,000 shares of Class&#160;A common stock (the &#8220;Letter Agreement Shares&#8221;) in lieu of $3.0&#160;million of deferred underwriting compensation payable to Jefferies LLC from HealthCor&#8217;s Initial Public Offering, and provides substantially the same registration rights for the Letter Agreement Shares as provided in the Subscription Agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Liminal&#8221; refers to Liminal Sciences, Inc., a Delaware corporation that is a wholly-owned subsidiary of Hyperfine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Liminal Exchange Ratio&#8221; means 0.1796, which was determined in accordance with the Business Combination Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Liminal Merger&#8221; refers to that certain merger of Merger Sub II with and into Liminal, with Liminal surviving as a wholly owned subsidiary of Hyperfine. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Mergers&#8221; refers to the Hyperfine Merger and the Liminal Merger. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Merger Sub I&#8221; refers to Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Merger Sub II&#8221; refers to Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Nasdaq&#8221; refers to The Nasdaq Stock Market. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ordinary shares&#8221; refers to the Class&#160;A ordinary shares and the Class&#160;B ordinary shares, collectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;PIPE Investment&#8221; means the private placement pursuant to which PIPE Investors purchased, immediately prior to the Closing, an aggregate of 12,610,000 shares of Class&#160;A common stock at a purchase price of $10.00 per share for an aggregate of $126,100,000 on the terms and conditions set forth in the Subscription Agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;PIPE Investors&#8221; refers to the investors that executed the Subscription Agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;PIPE Securities&#8221; refers to the shares of Class&#160;A common stock sold to the PIPE Investors pursuant to the Subscription Agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Private Placement Shares&#8221; refers to the 614,000 Class&#160;A ordinary shares acquired by the Sponsor for an aggregate purchase price of $6,140,000 in a private placement simultaneously with the closing of the IPO. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Public Shares&#8221; refers to the Class&#160;A ordinary shares issued in the IPO to the Public Shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Public Shareholders&#8221; refers to the holders of the Public Shares that were sold in the IPO. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Registration Rights Agreement&#8221; means the amended and restated registration rights agreement entered into as of the Closing by and among Hyperfine, the Sponsor, certain affiliates of the Sponsor, certain Legacy Hyperfine equityholders and certain Liminal equityholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SEC&#8221; refers to the U.S. Securities and Exchange Commission. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Sponsor&#8221; refers to HC Sponsor LLC, a Delaware limited liability company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Subscription Agreements&#8221; refers to the subscription agreements, dated as of July&#160;7, 2021, by and among HealthCor and the PIPE Investors, pursuant to which HealthCor agreed to issue an aggregate of 12,610,000 shares of Class&#160;A common stock to the PIPE Investors immediately before the Closing at a purchase price of $10.00 per share, as the same may be amended, modified, supplemented or waived from time to time in accordance with its terms. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;transfer agent&#8221; refers to Continental Stock Transfer&#160;&amp; Trust Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Trust Account&#8221; refers to the trust account of HealthCor that held the net proceeds from the IPO and certain of the proceeds from the sale of the Private Placement Shares, including interest earned on the funds in the Trust Account and not previously released to HealthCor to pay its taxes. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of Hyperfine. These statements are based on the beliefs and assumptions of the management of Hyperfine. Although Hyperfine believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, Hyperfine cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;expects&#8221;, &#8220;projects&#8221;, &#8220;forecasts&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;seeks&#8221;, &#8220;plans&#8221;, &#8220;scheduled&#8221;, &#8220;anticipates&#8221; or &#8220;intends&#8221; or similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the anticipated benefits of the Business Combination; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the success, cost and timing of our product development activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the commercialization and adoption of our existing products and the success of our future product offerings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential attributes and benefits of our products and services; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our ability to identify, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire additional technology; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to maintain our existing licensing, manufacturing and supply agreements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to compete with other companies currently marketing or engaged in the development of magnetic resonance imaging technologies, many of which have greater financial and marketing resources than us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the size and growth potential of the markets for our products and services, and the ability of each to serve those markets, either alone or in partnership with others; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the pricing of our products and services and reimbursement for medical procedures conducted using our products and services; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in applicable laws or regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our estimates regarding expenses, revenue, capital requirements and needs for additional financing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to raise financing in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our financial performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our success in retaining or recruiting, or changes required in, our officers, key employees or directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">intense competition and competitive pressures from other companies in the industry in which we operate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market conditions and global and economic factors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effect of legal, tax and regulatory changes; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our business and operations. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These forward-looking statements are based on information available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements such as those contained in documents we have filed with the U.S. Securities and Exchange Commission. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. For a discussion of the risks involved in our business and investing in our common stock, see the section entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Factors</div></div>.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may vary in material respects from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div id="toc284543_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY OF THE PROSPECTUS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">This summary highlights selected information included in this prospectus and does not contain all of the information that may be important to you in making an investment decision. This summary is qualified in its entirety by the more detailed information included in this prospectus. Before making your investment decision with respect to our securities, you should carefully read this entire prospectus, including the information under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements included elsewhere in this prospectus. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are an innovative digital health business with a mission to provide affordable and accessible imaging and monitoring and through magnetic resonance imaging (&#8220;MRI&#8221;) to revolutionize healthcare for people around the world. Our Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Portable Magnetic Resonance (&#8220;MR&#8221;) Imaging System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> (&#8220;Swoop scanner&#8221;) produces high-quality images at a lower magnetic field strength than conventional MRI systems, and can be used by healthcare professionals to make effective clinical diagnoses on a patient in a variety of settings where MRI devices have previously been inaccessible. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> interface and portable design of our Swoop scanner make it accessible for use anywhere in a hospital, clinic or patient care site. We are working to realize our vision of providing affordable and accessible imaging of health conditions around the world. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Background and Business Combination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company was originally known as HealthCor Catalio Acquisition Corp. (&#8220;HealthCor&#8221;). On December&#160;21, 2021, HealthCor changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware (the &#8220;Domestication&#8221;) by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On December&#160;22, 2021, we, after domesticating as a Delaware corporation on December&#160;21, 2021, consummated a business combination (the &#8220;Business Combination&#8221;) pursuant to the terms of the business combination agreement dated as of July&#160;7, 2021 (the &#8220;Business Combination Agreement&#8221;) by and among HealthCor, Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor (&#8220;Merger Sub I&#8221;), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor (&#8220;Merger Sub II&#8221;), Hyperfine, Inc., a Delaware corporation (&#8220;Legacy Hyperfine&#8221;), and Liminal Sciences, Inc., a Delaware corporation (&#8220;Liminal&#8221;). In connection with the Business Combination, HealthCor changed its name to &#8220;Hyperfine, Inc.&#8221;, Legacy Hyperfine changed its name to &#8220;Hyperfine Operations, Inc.&#8221; and Liminal changed its name to &#8220;Liminal Operations, Inc.&#8221; (which was subsequently changed to &#8220;Liminal Sciences, Inc.&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a consequence of the Domestication, and in accordance with the terms of the Business Combination Agreement, each Class&#160;A ordinary share of HealthCor that was issued and outstanding as of immediately prior to the Domestication was converted, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into a share of HealthCor&#8217;s Class&#160;A common stock, and each Class&#160;B ordinary share of HealthCor that was issued and outstanding as of immediately prior to the Domestication was converted, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into a share of the HealthCor&#8217;s Class&#160;B common stock, and immediately prior to the Effective Time, each such share of HealthCor&#8217;s Class&#160;B common stock was converted, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into a share of the Company&#8217;s Class&#160;A common stock (the &#8220;Conversion&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a consequence of the Business Combination, at the Effective Time, (i)&#160;each share of Legacy Hyperfine capital stock (other than shares of Legacy Hyperfine Series A preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to 0.3275 (the &#8220;Hyperfine Exchange Ratio&#8221;), rounded down to the nearest whole number of shares; (ii)&#160;each share of Legacy Hyperfine Series A preferred stock that was issued and outstanding as of immediately prior to the Effective Time was </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Hyperfine Exchange Ratio, rounded down to the nearest whole number of shares; (iii)&#160;each share of Liminal capital stock (other than shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to 0.1796 (the &#8220;Liminal Exchange Ratio&#8221;), rounded down to the nearest whole number of shares; (iv)&#160;each share of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Liminal Exchange Ratio, rounded down to the nearest whole number of shares; (v)&#160;each option to purchase shares of Legacy Hyperfine common stock and each option to purchase shares of Liminal common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such option immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded up to the nearest whole cent; and (vi)&#160;each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, pursuant to the Business Combination Agreement, the Company will issue to holders of Legacy Hyperfine and Liminal securities as of immediately prior to the Effective Time, in accordance with their pro rata share, up to 10,000,000 shares of Class&#160;A common stock as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> consideration (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Shares&#8221;), if at any time during the period between the Closing Date and the third anniversary of the Closing Date (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Period&#8221;), (i) the last share price of the Class&#160;A common stock is greater than or equal to $15.00 for any 20 trading days within any 30 consecutive trading day period, or (ii)&#160;there is a transaction that will result in shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value greater than or equal to $15.00. During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Period, if there is a transaction (other than for stock splits, stock dividends, special cash dividends, reorganizations, recapitalizations or similar transactions affecting the Class&#160;A common stock) that will result in the shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value less than $15.00, then the right to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will terminate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, concurrently with the execution of the Business Combination Agreement, on July&#160;7, 2021, HealthCor entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain institutional investors and accredited investors (the &#8220;PIPE Investors&#8221;), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of 12,610,000 shares of HealthCor Class&#160;A common stock at a purchase price of $10.00 per share (the &#8220;PIPE Investment&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on December&#160;22, 2021, the Company, HC Sponsor LLC (the &#8220;Sponsor&#8221;), Legacy Hyperfine and Liminal entered into a Forfeiture Agreement (the &#8220;Forfeiture Agreement&#8221;), pursuant to which, immediately prior to the Closing, 150,000 shares of HealthCor&#8217;s Class&#160;B common stock held by the Sponsor were irrevocably forfeited and automatically cancelled (the &#8220;Forfeiture&#8221;). </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Exchange Listing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine Class&#160;A common stock is listed for trading on Nasdaq under the symbol &#8220;HYPR&#8221;. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Risk Factors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investing in our securities involves risks. You should carefully consider the risks described in &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Factors</div></div>&#8221; beginning on page 13 before making a decision to invest in our securities. If any of these risks actually occurs, our business, financial condition and results of operations would likely be materially adversely affected. Some of the risks related our business and industry are summarized below. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an early-stage life sciences technology company with a history of net losses, which we expect to continue, and we may not be able to generate meaningful revenues or achieve and sustain profitability in the future. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a limited operating history, which may make it difficult to evaluate the prospects for our future viability and predict our future performance. As such, you cannot rely upon our historical operating performance to make an investment or voting decision regarding us. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may need to raise additional capital to fund commercialization plans for our products, including manufacturing, sales and marketing activities, expand our investments in research and development, and commercialize new products and applications. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success depends upon market acceptance of our products and services, our ability to develop and commercialize existing and new products and services and generate revenues, and our ability to identify new markets for our technology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medical device development is costly and involves continual technological change, which may render our current or future products obsolete. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will be dependent upon the success of our sales and customer acquisition and retention strategies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not successfully manage the commercialization of our products and services, including continuing to build our sales force, and the development and launch of new products and services, we will not meet the long term forecasts and our business, operating and financial results and condition could be adversely affected. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to attract, recruit, train, retain, motivate and integrate key personnel as we expand our organization, our operations may be disrupted and we may not achieve our goals. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited experience in marketing and selling our products and related services, and if we are unable to successfully commercialize our products and related services, our business and operating results will be adversely affected. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on a single contract manufacturer, Benchmark Electronics, Inc. (&#8220;Benchmark&#8221;), to test, assemble and supply our finished products. If Benchmark fails to fulfill its obligations under its existing contractual arrangements with us or does not perform satisfactorily, our ability to source our devices could be negatively and adversely affected. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on a limited number of suppliers for our products. A loss of any of these suppliers could negatively affect our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pricing pressures from contract suppliers or manufacturers on which we rely may impose pricing pressures. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not successfully optimize and operate our sales and potential future distribution channels or we do not effectively expand and update our infrastructure, our operating results and customer experience may be negatively impacted. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market for our products and services is new, rapidly evolving, and increasingly competitive, as the healthcare industry in the United States is undergoing significant structural change, which makes it difficult to forecast demand for our products and services. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As international expansion of our business occurs, it will expose us to market, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has and could continue to negatively affect various aspects of our business, make it more difficult for us to meet our obligations to our customers, and result in reduced demand for our products and services, which could have a material adverse effect on our business, financial condition, results of operations, or cash flows. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to extensive government regulation, which could restrict the development, marketing, sale and distribution of our products and could cause us to incur significant costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to obtain regulatory authorizations in other countries for existing products or products under development, we will not be able to commercialize these products in those countries. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may be subject to enforcement action if we engage in improper or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> marketing or promotion of our commercial medical device products, including fines, penalties and injunctions. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we do not require extensive training for users of our current products, although they are limited under the FDA&#8217;s marketing clearances to use by, and that images generated from the scanner be interpreted by, trained healthcare practitioners, there exists a potential for misuse of these products, misinterpretation of images by untrained professionals or misuse of these products by untrained professionals, which could ultimately harm our reputation and business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in customer growth or engagement, or otherwise harm our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under federal or state law, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain and maintain and enforce sufficient intellectual property protection for our products and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently rely on licenses from third parties, and in the future may rely on additional licenses from other third parties, and if we lose any of these licenses, then we may be subjected to future litigation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We identified material weaknesses in our internal control over financial reporting. If our remediation measures are ineffective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to report our financial condition or results of operations accurately or in a timely manner and we may be unable to maintain compliance with applicable stock exchange listing requirements, which may adversely affect investor confidence in us and, as a result, materially and adversely affect our business and the value of our Class&#160;A common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing rules, our stockholders may not have certain corporate governance protections that are available to stockholders of companies that are not controlled companies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The dual class structure of our common stock has the effect of concentrating voting power with Jonathan M. Rothberg, Ph.D., Vice Chairman of our board of directors and the Founder of Legacy Hyperfine and Liminal, which will limit an investor&#8217;s ability to influence the outcome of important transactions, including a change in control. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor was incorporated as a Cayman Islands exempted company on November&#160;18, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine was incorporated under the laws of the State of Delaware on February&#160;25, 2014 under the name &#8220;Hyperfine Research, Inc.&#8221; On May&#160;25, 2021, the name of the corporation was changed to &#8220;Hyperfine, Inc.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal was incorporated under the laws of the State of Delaware on September&#160;21, 2018 under the name &#8220;EpilepsyCo Inc.&#8221; On July&#160;20, 2020, the name of the corporation was changed to &#8220;Liminal Sciences, Inc.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2021, HealthCor, Legacy Hyperfine and Liminal completed the Business Combination, pursuant to which each of Legacy Hyperfine and Liminal became a wholly owned subsidiary of HealthCor, HealthCor&#8217;s corporate name was changed to &#8220;Hyperfine, Inc.&#8221;, Legacy Hyperfine&#8217;s name was changed to &#8220;Hyperfine Operations, Inc.&#8221;, Liminal&#8217;s name was changed to &#8220;Liminal Operations, Inc.&#8221;, and the business of Legacy Hyperfine and Liminal became the business of the Company. On March 21, 2022, Liminal&#8217;s name was changed to &#8220;Liminal Sciences, Inc.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our principal executive offices are located at 351 New Whitfield Street, Guilford, Connecticut 06437, and our telephone number is (203) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">458-7100.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is not an emerging growth company or is an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earlier of: (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of HealthCor&#8217;s Initial Public Offering, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> is $700&#160;million or more as of the end of that fiscal year&#8217;s second fiscal quarter; and (2)&#160;the date on which we have issued more than $1.00&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div id="toc284543_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE OFFERING </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Hyperfine, Inc.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Resale of Class A common stock and Class B common stock</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares of Class A common stock offered by the Selling Securityholders (representing the Founder Shares, the Private Placement Shares, shares issued in the PIPE Investment, the shares issued to our directors, officers and affiliates and the directors, officers and affiliates of Legacy Hyperfine or Liminal pursuant to the Business Combination Agreement, including shares that may be issued upon the exercise of stock options and the vesting of restricted stock units or upon the conversion of shares of Class B common stock, and the Letter Agreement Shares)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41,775,946 shares</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Shares of Class B common stock offered by the Selling Securityholders</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15,055,288 shares</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Use of proceeds</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">We will not receive any proceeds from the sale of the Class A common stock and Class B common stock to be offered by the Selling Securityholders. With respect to shares of Class A common stock underlying the options, we will not receive any proceeds from such shares except with respect to amounts received by us upon exercise of such options to the extent such options are exercised for cash.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up agreements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Certain of our stockholders are subject to certain restrictions on transfer until the termination of applicable lock-up periods. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan of Distribution &#8212; Amended and Restated Registration Rights Agreement</div></div>&#8221; for further discussion</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ticker symbol</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#8220;HYPR&#8221; for the Class A common stock.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc284543_5">RISK FACTORS </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">An investment in our securities involves a high degree of risk. You should carefully consider the risks described below before making an investment decision. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not known to us or that we consider immaterial as of the date of this prospectus. The trading price of our securities could decline due to any of these risks, and, as a result, you may lose all or part of your investment. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Unless the context otherwise requires, references in this section to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to Hyperfine, Inc. and its subsidiaries following the Business Combination, or to Legacy Hyperfine, Liminal, or HealthCor prior to the Business Combination, as the case may be. </div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">We are an early-stage life sciences technology company with a history of net losses, which we expect to continue, and we may not be able to generate meaningful revenues or achieve and sustain profitability in the future. </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an early-stage life sciences technology company, and have incurred significant losses since Legacy Hyperfine and Liminal formed in 2014 and 2018, respectively, and expect to continue to incur losses in the future. We incurred net losses of $64.9&#160;million and $23.4&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $136.3&#160;million. These losses and accumulated deficit were primarily due to the substantial investments made to develop and improve our technology and products. Over the next several years, we expect to continue to devote substantially all of our resources towards continuing development and commercialization of our products and research and development efforts for additional products. These efforts may prove more costly than we currently anticipate. We have just begun generating product revenue but may never generate revenue sufficient to offset our expenses, or at all. In addition, as a public company, we will incur significant legal, accounting, administrative, insurance and other expenses that we did not incur as a private company. Accordingly, we cannot assure you that we will achieve profitability in the future or that, if we become profitable, will sustain profitability. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">We have a limited operating history, which may make it difficult to evaluate the prospects for our future viability and predict our future performance. As such, you cannot rely upon our historical operating performance to make an investment or voting decision regarding us. </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated limited revenue from the sale of our products and services to date and have incurred significant losses. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We have not yet achieved wide market acceptance for our products, produced our products at scale, refined our sales model, or conducted at scale sales and marketing activities necessary for successful mass product adoption. Consequently, predictions about our future success or viability are highly uncertain and may not be as accurate as they could be if we had a longer operating history or a company history of successfully developing and commercializing products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. We will need to transition from a company in the early commercialization stage to large scale commercialization, and we may not be successful in such a transition. We have encountered in the past, and will encounter in the future, risks and uncertainties frequently experienced by growing companies with limited operating histories in emerging and rapidly changing industries. If our assumptions regarding these risks and uncertainties, which we will use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations, and our business, financial condition and results of operations could be adversely affected. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may need to raise additional capital to fund commercialization plans for our products, including manufacturing, sales and marketing activities, expand our investments in research and development, and commercialize new products and applications. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operations have consumed substantial amounts of cash since inception. We expect to use the funds received in connection with the Business Combination to develop and further commercialize our products, develop new products, and for working capital and general corporate purposes. We may require additional capital to further develop and commercialize our products and to develop new products. In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any future financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our Class&#160;A common stock to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or products or otherwise agree to terms that are unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. In addition, raising additional capital through the issuance of equity or convertible debt securities would cause dilution to holders of our equity securities, and may affect the rights of then-existing holders of our equity securities. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside our control, including, but not limited to: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing and amount of expenditures that we may incur to develop, commercialize or acquire additional products and technologies or for other purposes, such as the expansion of our sales team and our facilities; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in governmental funding of life sciences research and development or changes that impact budgets or budget cycles; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing actions, such as the pricing adjustments we made to our subscription plus ownership model during the first quarter of 2022 in which we increased the price of the device while lowering the price of the monthly subscription; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seasonal spending patterns of our customers; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing of when we recognize any revenues; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">future accounting pronouncements or changes in our accounting policies; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome of any future litigation or governmental investigations involving the Company, our industry or both; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">higher than anticipated service, replacement and warranty costs; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the economy, investment in the life sciences and medical technology industries, our business operations, and resources and operations of our suppliers, future distributors and current and potential customers; </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the impact of political instability and military conflict, such as the conflict in Ukraine, which has resulted in instability in the global financial markets and export controls, and which could result in supply disruptions for us, including because one key custom-made component in our Swoop scanner is the magnet, which is manufactured by a single source supplier in Europe, and which could also have a material adverse impact on our sales in affected markets; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">general industry, economic and market conditions and other factors, including factors unrelated to our operating performances or the operating performance of our competitors. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cumulative effects of the factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-to-period</div></div> basis may not be meaningful. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This variability and unpredictability could also result in us failing to meet the expectations of industry or financial analysts or investors for any period. If we are unable to further commercialize products or generate revenue, or if our operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the market price of our Class&#160;A common stock could decline. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Businesses </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our success depends upon market acceptance of our products and services, our ability to develop and commercialize existing and new products and services and generate revenues, and our ability to identify new markets for our technology. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have developed, and are engaged in the development of, MRI solutions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> neural monitoring technology. We are commercializing our Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Portable MRI System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> to address limitations of current imaging technologies. Other product candidates, such as our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> brain vital sensors, are currently under development. Our success will depend on the acceptance of our products and services in the U.S. and international healthcare markets. The marketplace may not be receptive to our products and services over competing products, including conventional MRI systems used in hospitals, imaging centers and physicians&#8217; offices, and we may be unable to compete effectively. Factors that could affect our ability to successfully further commercialize our current products and services and to commercialize any potential future products and services include: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">challenges of developing (or acquiring externally-developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dependence upon physicians&#8217; and other healthcare practitioners&#8217; acceptance of our products. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot assure investors that our current products and services or any future products and services will gain broad market acceptance. If the market for our current products and services or any future products and services fails to develop or develops more slowly than expected, or if any of our products or services do not achieve or sustain market acceptance, our business and operating results would be materially and adversely affected. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medical device development is costly and involves continual technological change, which may render our current or future products obsolete. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The market for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> medical devices is characterized by rapid technological change, medical advances and evolving industry standards. Any one of these factors could reduce the demand for our devices or </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">services or require substantial resources and expenditures for research, design and development to avoid technological or market obsolescence. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success will depend on our ability to enhance our current technology, products and services and develop or acquire and market new technologies to keep pace with technological developments and evolving industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements or new devices that will address changing technologies and customer requirements adequately, or to introduce such devices on a timely basis, may have a material adverse effect on our business, financial condition and results of operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We might have insufficient financial resources to improve existing devices, advance technologies and develop new devices at competitive prices. Technological advances by one or more competitors or future entrants into the field may result in our current devices becoming <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive</div> or obsolete, which may decrease revenues and profits and adversely affect our business and results of operations. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may encounter significant competition across our existing and future planned products and services and in each market in which we sell or plan to sell our products and services from various companies, many of which have greater financial and marketing resources than us. Our primary competitors include several large companies which currently dominate the medical imaging market, including General Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba, Canon and Hitachi. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our competitors, some of which are well-established manufacturers with significant resources, may engage in aggressive marketing tactics. Competitors may also possess the ability to commercialize additional lines of products, bundle products or offer higher discounts and incentives to customers in order to gain a competitive advantage. If the prices of competing products are lowered as a result, we may not be able to compete effectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will be dependent upon the success of our sales and customer acquisition and retention strategies. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business is dependent upon the success of our sales and customer acquisition and retention strategies, and our marketing efforts are focused on developing a strong reputation with healthcare providers and increasing awareness of our products and services. If we fail to maintain a high quality of service or a high quality of device technology, we may fail to retain existing users or add new users. If we do not successfully continue our sales efforts and promotional activities, particularly to health systems and large institutions, or if existing users decrease their level of engagement, our revenue, financial results and business may be significantly harmed. Our future success depends upon continued expansion of our commercial operations in the United States and internationally, as well as entering additional markets to commercialize our products and services. We believe that our growth will depend on the further development and commercialization of our current products and services and regulatory authorization for our future products and services. If we fail to expand the use of our products and services in a timely manner, we may not be able to expand our market share or to grow our revenue. Our financial performance will be substantially dictated by our success in adding, retaining and engaging active users of our products. If customers do not perceive our products or services to be useful, reliable and trustworthy, we may not be able to attract or retain customers or otherwise maintain or increase the frequency and duration of their engagement. As our business model is predicated on device hardware sales, software subscriptions, and subscriptions for use of device hardware and software, there is risk that any decline in sales, subscriptions and subscription renewal rates will adversely impact our business. A decrease in customer retention, growth or engagement with our products and services may have a material and adverse impact on our revenue, business, financial condition and results of operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any number of factors could negatively affect customer retention, growth and engagement, including: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customers choosing competing products or choosing to use conventional MRI systems over our products; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to introduce new and improved products and services; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to continue to develop products that customers find effective and that achieve a high level of market acceptance; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in customer sentiment about the quality or usefulness of our products and services or concerns related to safety, security, privacy and data sharing or other factors; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adverse changes in our products that are mandated by legislation or regulatory agencies, both in the United States and internationally; or </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">technical or other problems preventing us from delivering products or services in a rapid and reliable manner or otherwise affecting the user experience. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we do not successfully manage the commercialization of our products and services, including continuing to build our sales force, and the development and launch of new products and services, we will not meet the long term forecasts and our business, operating and financial results and condition could be adversely affected. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face risks associated with commercializing existing products and services and launching new products and services. If we encounter commercialization, development or manufacturing challenges or discovers errors during our product development cycle, the product launch dates of new products may be delayed, which will cause delays in our ability to achieve our forecasted results. The expenses or losses associated with unsuccessful product development or launch activities or lack of market acceptance of our products and services could adversely affect our business or financial condition. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We expect to generate an increasing portion of our revenue internationally in the future and may become subject to various additional risks relating to our international activities, which could adversely affect our business, operating results and financial condition. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that a substantial percentage of our future revenue will come from international sources as we seek regulatory authorization for our products beyond the United States and expands our sales and marketing opportunities internationally. Our success will depend, in part, upon our ability to succeed in differing legal, regulatory, economic, social and political conditions by developing, implementing and maintaining policies and strategies that are effective in each location where we do business. We have limited experience operating internationally and engaging in international business involves a number of difficulties and risks, including: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the challenges associated with building local brand awareness, obtaining local key opinion leader support and clinical support, implementing reimbursement strategies and building local marketing and sales teams; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">required compliance with foreign regulatory requirements and laws, including regulations and laws relating to patient data and medical devices; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trade relations among the United States and those foreign countries in which our current or future customers, distributors, manufacturers and suppliers have operations, including protectionist measures such as tariffs and import or export licensing requirements, whether imposed by the United States or such foreign countries, in particular the strained trade relations between United States and China since 2018; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties and costs of staffing and managing foreign operations; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties protecting, procuring or enforcing intellectual property rights internationally; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act, data privacy requirements, labor laws and anti-competition regulations; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">laws and business practices that may favor local companies; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">political and economic instability; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, our business may be impacted by the conflict in Ukraine, any economic or other sanctions imposed on Russia and others for aggression in Ukraine, and any economic or other countermeasures by affected countries. Any such conflict may also impact our ability to secure raw materials and finished products and create supply chain disruptions. For example, one key custom-made component in our Swoop scanner is the magnet, which is manufactured by a single source supplier in Europe. In the event of interruption from any of our suppliers or manufacturers, we may not be able to obtain capacity from other sources or develop alternate or secondary sources without incurring material additional costs and substantial delays. As we seek to expand into international markets, the conflict in Ukraine and any related economic or other sanctions or related countermeasures could limit our ability to expand our business and have a material adverse impact on demand for our products and sales in affected markets. In addition, sanctions imposed on Russia and others in response to such conflict may also adversely impact the financial markets and the global economy, and any economic countermeasures by Russia and others could exacerbate market and economic instability. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we dedicate significant resources to our international operations and are unable to manage these risks effectively, our business, operating results and financial condition may be adversely affected. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to export and import control laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate such laws and regulations. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to comply with export and import control laws, which may affect our ability to enter into or complete transactions with certain customers, business partners, and other persons. In certain circumstances, export control regulations may prohibit the export of certain products, services, and technologies. We may be required to obtain an export license before exporting a controlled item, and granting of a required license cannot be assured. Compliance with the import laws that apply to our businesses may restrict our access to, and may increase the cost of obtaining, certain products and could interrupt our supply of imported inventory. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exported technologies necessary to develop and manufacture certain products are subject to U.S. export control laws and similar laws of other jurisdictions. We may be subject to adverse regulatory consequences, including government oversight of facilities and export transactions, monetary penalties, and other sanctions for violations of these laws. In certain instances, these regulations may prohibit us from developing or manufacturing certain of our products for specific applications outside the United States. Failure to comply with any of these laws and regulations could result in civil and criminal, monetary, and nonmonetary penalties; disruptions to our business; limitations on our ability to import and export products and services; or damage to our reputation. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we experience decreasing prices for our products and are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may experience decreasing prices for our products due to pricing pressure from managed care organizations and other third-party payors and suppliers, increased market power of our payors as the medical device industry consolidates, and increased competition among suppliers, including manufacturing services providers. If the prices for our products and services decrease and we are unable to reduce our expenses, including the cost of sourcing materials, logistics and the cost to manufacture our products, our business, results of operations, financial condition and cash flows may be adversely affected. To the extent that we engage in enterprise sales, we may be subject to procurement discounts, which could have a negative impact on the prices of our products. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to attract, recruit, train, retain, motivate and integrate key personnel as we expand our organization, our operations may be disrupted and we may not achieve our goals. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future success depends on our ability to attract, recruit, train, retain, motivate and integrate key personnel, including our Vice Chairman and the Founder of Legacy Hyperfine and Liminal, Dr.&#160;Jonathan Rothberg, our Executive Chairman, Scott Huennekens, and our President and Chief Executive Officer, Dave Scott, as well as our recently expanded management team and our research and development, manufacturing, software engineering and sales and marketing personnel. As our development and commercialization plans and strategies develop, we will need additional managerial, operational, sales, marketing, financial, legal and other resources. Competition for qualified personnel in the medical device industry is intense. Due to this intense competition, we may be unable to attract and retain the qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that our management team must be able to act decisively to apply and adapt our business model in the rapidly changing markets in which we compete. In addition, we rely upon technical and scientific employees or third-party contractors to effectively establish, manage and grow our business. Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly skilled managerial, sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees to our employees or consultants than we currently expect, and such higher compensation payments may have a negative effect on our operating results. Competition for experienced, high-quality personnel is intense, and we cannot assure investors that we will be able to recruit and retain such personnel. Our growth depends, in particular, on attracting and retaining highly-trained sales personnel with the necessary technical background and ability to understand our products and services at a technical level to effectively identify and sell to potential new customers and develop new products. Because of the technical nature of our products and the dynamic market in which we compete, any failure to attract, recruit, train, retain, motivate and integrate qualified personnel could materially harm our operating results and growth prospects. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our management may need to divert a disproportionate amount of our attention away from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional products. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize products and services and compete effectively will depend, in part, on our ability to effectively manage any future growth. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have limited experience in marketing and selling our products and related services, and if we are unable to successfully commercialize our products and related services, our business and operating results will be adversely affected. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited experience marketing and selling our products and related services. We began selling our Swoop MRI scanner in 2020 and currently sell the device directly to customers through direct sales. Future sales of our products will depend in large part on our ability to effectively market and sell our products and services, successfully manage and expand our sales force, and increase the scope of our marketing efforts. We may also enter into distribution arrangements in the future. Because we have limited experience in marketing and selling our products, our ability to forecast demand, the infrastructure required to support such demand and the sales cycle to customers is unproven. If we do not build an efficient and effective marketing and sales force, our business and operating results will be adversely affected. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on a single contract manufacturer, Benchmark Electronics, Inc. (&#8220;Benchmark&#8221;), to test, assemble and supply our finished products. If Benchmark fails to fulfill its obligations under its existing contractual arrangements with us or does not perform satisfactorily, our ability to source our devices could be negatively and adversely affected. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2018, Legacy Hyperfine entered into a Manufacture and Supply Agreement with Benchmark (the &#8220;MSA&#8221;). Under the MSA, Benchmark agreed to manufacture our products pursuant to binding purchase orders. The parties have agreed to meet periodically regarding any minimum order quantities of components under the MSA. We also have certain inventory related obligations, including the obligation to purchase excess and obsolete components from Benchmark. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business of Hyperfine - Key Agreements - Manufacture and Supply Agreement with Benchmark Electronics, Inc.</div></div>&#8221; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event it becomes necessary to utilize a different contract manufacturer for our component products, we would experience additional costs, delays and difficulties in obtaining such components as a result of identifying and entering into an agreement with a new contract manufacturer as well as preparing such new manufacturer to meet the logistical requirements associated with manufacturing our devices, and our business would suffer. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on a limited number of suppliers for our products. A loss of any of these suppliers could negatively affect our business. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on a limited number of suppliers to manufacture components for our products, including in some cases only a single supplier for some of our components. One key custom-made component in our Swoop scanner is the magnet, which is manufactured by a single source supplier in Europe. Our reliance on a limited number of suppliers increases our risks, since we do not currently have alternative or replacement suppliers beyond these key parties. In the event of interruption from any of our suppliers, we may not be able to increase capacity from other sources or develop alternate or secondary sources without incurring material additional costs and substantial delays. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we experience a significant increase in demand for our products, or if we need to replace an existing supplier or manufacturer, we may be unable to supplement or replace them on terms that are acceptable to us, which may undermine our ability to deliver our products to customers in a timely manner. Identifying suitable suppliers and manufacturers is an extensive process that requires us to become satisfied with their quality control, technical capabilities, responsiveness and service, financial stability, regulatory compliance, and labor and other ethical practices. Accordingly, a loss of any of our suppliers or our device manufacturer could have an adverse effect on our business, financial condition and operating results. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pricing pressures from contract suppliers or manufacturers on which we rely may impose pricing pressures. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third party suppliers utilized by our manufacturer such as Benchmark Electronics, Inc. may also impose pricing pressures. Because we currently also rely on Benchmark Electronics, Inc. to manufacture, test and ship all of the Swoop scanners and on a limited number of suppliers to supply our components, including a single source supplier of the magnet used in the scanner, such pricing pressures from a third party such as Benchmark Electronics, Inc. could increase our costs and could force us to increase the prices of our products if we are unable to enter into alternative arrangements with other suppliers or manufacturers, potentially leading to decreased customer demand. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we do not successfully optimize and operate our sales and potential future distribution channels or we do not effectively expand and update our infrastructure, our operating results and customer experience may be negatively impacted. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not adequately predict market demand or otherwise optimize and operate our sales and potential future distribution channels successfully, it could result in excess or insufficient inventory or fulfillment capacity, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased costs, or immediate shortages in product or component supply, or harm our business in other ways. In addition, if we do not maintain adequate infrastructure to enable us to, among other things, manage our purchasing and inventory, it could negatively impact our operating results and customer experience. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The market for our products and services is new, rapidly evolving, and increasingly competitive, as the healthcare industry in the United States is undergoing significant structural change, which makes it difficult to forecast demand for our products and services. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market for our products and services is new and rapidly evolving, and it is uncertain whether we will achieve and sustain high levels of demand and market adoption. Our future financial performance will depend in part on growth in this market and on our ability to adapt to the changing demands of customers. It is difficult to predict the future growth rate and size of our target market. As a result, our commercial expectations may not be achieved. Negative publicity concerning our products could limit market acceptance of our products and services. If our customers do not perceive the benefits of our products and services, or if our products and services do not attract new customers, then our market may not develop at all, or we may develop more slowly than we expect. Our success will depend to a substantial extent on the willingness of healthcare organizations to increase their use of our technology and our ability to demonstrate the value of our technology relative to competing products and services to existing and potential customers. If healthcare organizations do not recognize or acknowledge the benefits of our products and services or if we are unable to reduce healthcare costs or drive positive health outcomes, then the market for our solutions might not develop at all, or might develop more slowly than we expect. Similarly, negative publicity regarding patient confidentiality and privacy in the context of technology-enabled healthcare or concerns experienced by competitors could limit market acceptance of our products and services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry in the United States is undergoing significant structural change and is rapidly evolving. Our products and services are offered on a subscription basis, and the adoption of subscription business models is still relatively new, especially in the healthcare industry. If companies do not shift to subscription business models and subscription health management tools do not achieve widespread adoption, or if there is a reduction in demand for subscription products and services or subscription health management tools, our business, financial condition, and results of operations could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quality problems could lead to recalls or safety alerts and/or reputational harm and could have a material adverse effect on our business, results of operations, financial condition and cash flows. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Quality of our products is very important to us and our customers due to the serious and costly consequences of product failure. Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. Product or component failures, manufacturing nonconformities, design defects, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use, or inadequate disclosure of product-related risks or product-related information with respect to our products, if they were to occur, could result in inaccurate imaging and safety risks. These problems could lead to the recall of, or the issuance of a safety alert relating to, our products, and could result in product liability claims and lawsuits. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the manufacture and production of our products must occur in a highly controlled and clean environment to minimize particles and other yield- and quality-limiting contaminants. Weaknesses in process control or minute impurities in materials may cause defective products. If we are not able to maintain stringent quality controls, or if contamination problems arise, our development and commercialization efforts could be delayed, which would harm our business and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to meet any applicable product quality standards and our products are the subject of recalls or safety alerts, our reputation could be damaged, we could lose customers, and our revenue and results of operations could decline. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are not able to develop and release new products and services, or successful enhancements, new features and modifications to our existing products and services, to successfully implement our software subscription solutions or to achieve adequate clinical utility, our business, financial condition and results of operations could be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The markets in which we operate are characterized by rapid technological change, frequent new product and service introductions and enhancements, changing customer demands, and evolving industry standards. The introduction of products and services embodying new technologies can quickly make existing products and services, including software subscriptions, obsolete and unmarketable. Additionally, changes in laws and regulations could impact the usefulness of our products and could necessitate changes or modifications to our products to accommodate such changes. We invest substantial resources in researching and developing new products and enhancing existing products by incorporating additional features, improving functionality, and adding other improvements to meet customers&#8217; evolving needs. The success of any enhancements or improvements to our existing products or any new products depends on several factors, including timely completion, competitive pricing, adequate quality testing, integration with new and existing technologies and third-party partners&#8217; technologies and overall market acceptance. We may not succeed in developing, marketing and delivering on a timely and cost-effective basis enhancements or improvements to our existing products or any new products that respond to continued changes in market demands or new customer requirements, and any enhancements or improvements to our products or any new solutions may not achieve market acceptance. Since developing our products is complex, the timetable for the release of new products and enhancements to existing products is difficult to predict, and we may not offer new products and updates as rapidly as our customers require or expect. Any new products that we develop may not be introduced in a timely or cost-effective manner, may contain errors or defects, or may not achieve the broad market acceptance necessary to generate sufficient revenue. Moreover, even if we introduce new products, we may experience a decline in revenue from our existing products that is not offset by revenue from the new products. For example, customers may delay making purchases of new products to permit them to make a more thorough evaluation of these products or until industry and marketplace reviews become widely available. Customers may also delay purchasing a new product because their existing product or other device continues to meet their needs. Some customers may hesitate to migrate to a new product due to concerns regarding the performance of the new product. In addition, we may lose existing customers who choose a competitor&#8217;s products and services. This could result in a temporary or permanent revenue shortfall and adversely affect our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The introduction of new products and solutions by competitors, the development of entirely new technologies to replace existing offerings or shifts in healthcare benefits trends could make our products obsolete or adversely affect our business, financial condition and results of operations. We may experience difficulties with software development, industry standards, design or marketing that could delay or prevent our development, introduction or implementation of new products, enhancements, additional features or capabilities. If customers do not widely purchase and adopt our products, we may not be able to realize a return on our investment. If we do not accurately anticipate customer demand or if we are unable to develop, license or acquire new features and capabilities on a timely and cost-effective basis, or if such enhancements do not achieve market acceptance, it could result in adverse publicity, loss of revenue or market acceptance or claims by customers brought against us, each of which could have a material and adverse effect on our reputation, business, results of operations and financial condition. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are party to Technology and Services Exchange Agreements with certain affiliated companies, pursuant to which the parties agreed to share personnel and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies. The sharing arrangements under the agreements may prevent us from fully utilizing our personnel and/or the technologies shared under the agreements. Furthermore, if these agreements were to terminate, or if we were to lose access to these technologies and services, our business could be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We entered into Technology and Services Exchange Agreements (each, a &#8220;TSEA&#8221; and collectively, the &#8220;TSEA&#8221;) with other participant companies controlled by the Rothbergs. A TSEA by and among Butterfly Network, Inc., AI Therapeutics, Inc., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, 4Bionics, Tesseract Health, Inc., Detect, Inc. (f/k/a Homodeus Inc.), Legacy Hyperfine and Liminal was signed in November 2020; a TSEA by and among <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, AI Therapeutics, Inc., 4Bionics, Tesseract Health, Inc., Detect, Inc., Legacy Hyperfine and Liminal was signed in February 2021 (and which Protein Evolution, Inc. joined in August 2021); and a TSEA by and among Legacy Hyperfine, Liminal, AI Therapeutics, Inc., Tesseract Health, Inc. and Detect, Inc. was signed in July 2021 and became effective upon the Closing. Under the TSEA, we and the other participant companies may, in their discretion, permit the use of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which include any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant, such as software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists, with the other participant companies. The TSEA provides that ownership of each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technology shared by us or another participant company will remain with the company that originally shared the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technology. In addition, any participant company (including us) may, in its discretion, permit its personnel to be engaged by another participant company to perform professional, technical or consulting services for such participant. Unless otherwise agreed to by us and the other participant company, all rights, title and interest in and to any inventions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">works-of-authorship,</div></div> idea, data or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> invented, made, created or developed by the personnel (employees, contractors or consultants) in the course of conducting services for a participant company (&#8220;Created IP&#8221;) will be owned by the participant company for which the work was performed, and the recipient participant company grants to the party that had its personnel provide the services that resulted in the creation of the Created IP a royalty-free, perpetual, limited, worldwide, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable</div> (and with respect to software, sub- licensable in object code only) license to utilize the Created IP only in the core business field of the originating participant company, including a license to create and use derivative works based on the Created IP in the originating participant&#8217;s core business field, subject to any agreed upon restrictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The technology and personnel-sharing arrangements under the TSEA may prevent us from fully utilizing our personnel if such personnel are also being used by the other participant companies and may also cause our personnel to enter into agreements with or provide services to other companies that interfere with their obligations to us. Created IP under the TSEA may be relevant to our business and created by our personnel but owned by the other participant companies. Furthermore, if the TSEA were to terminate, or if we were to lose access to the technologies and services available pursuant to the TSEA, our business could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may acquire other companies or technologies, which could fail to result in a commercial product or net sales, divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities. However, we cannot assure you that we would be able to successfully complete any acquisition we choose to pursue, or that we would be able to successfully integrate any acquired business, product or technology in a cost-effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disruptive</div> manner. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies. We may not be able to successfully integrate any acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial condition may suffer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">As international expansion of our business occurs, it will expose us to market, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our long-term strategy is to increase our international presence, including securing the necessary regulatory authorizations in the United Kingdom and Australia. We recently received regulatory authorization in Canada, New Zealand and Pakistan. This strategy may include establishing and maintaining physician outreach and education capabilities outside of the United States and expanding our relationships with international customers. Doing business internationally involves a number of risks, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Difficulties in staffing and managing our international operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reduced or varied protection for intellectual property rights in some countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining regulatory clearance where required for our products in various countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Requirements to maintain data and the processing of that data on servers located within such countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limits on our ability to penetrate international markets if we are required to manufacture our products locally; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial risks, such as longer payment cycles, difficulty collecting accounts receivable, foreign tax laws and complexities of foreign value-added tax systems, the effect of local and regional financial pressures on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Restrictions on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">site-of-service</div></div> for use of our products and the economics related thereto for physicians and other healthcare practitioners; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Natural disasters and economic instability, including outbreak of disease, boycotts, curtailment of trade and other market restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wars, terrorism and political unrest, such as the conflict in Ukraine, which has resulted in instability in the global financial markets and export controls, and which could result in supply disruptions for us, including because one key custom-made component in our Swoop scanner is the magnet, which is manufactured by a single source supplier in Europe, and which could also have a material adverse impact on our sales in affected markets; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory and compliance risks that relate to maintaining accurate information and control over activities subject to regulation under the U.S. Foreign Corrupt Practices Act, and comparable laws and regulations in other countries. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these factors could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has and could continue to negatively affect various aspects of our business, make it more difficult for us to meet our obligations to our customers, and result in reduced demand for our products and services, which could have a material adverse effect on our business, financial condition, results of operations, or cash flows. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, and it has since spread throughout other parts of the world, including the United States. Any outbreak of contagious diseases, or other adverse public health developments, could have a material adverse effect on our business operations. These impacts to our operations have included, and could again in the future include disruptions or restrictions on the ability of our employees&#8217; and customers&#8217; to travel or of us to pursue collaborations and other business transactions, travel to customers and/or conduct live demonstrations of our products at promotional events, oversee the activities of our third-party manufacturers and suppliers and make shipments of materials. We may also be impacted by the temporary closure of the facilities of suppliers, manufacturers or customers. In addition, many hospitals and other healthcare providers continue to focus their attention on addressing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which we believe has resulted in lower sales volume. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may also continue to have an impact on customers, as elective healthcare visits and procedures have been postponed and there is greater focus on areas of care with lower profitability, leading, as a consequence, to lower expenditures on new products and devices by healthcare institutions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In an effort to halt the outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> a number of countries, including the United States, have placed significant restrictions on travel and many businesses have announced extended closures. These travel restrictions and business closures have and may in the future adversely impact our operations locally and worldwide, including our ability to manufacture, market, sell or distribute our products, and such restrictions and closure have caused or may cause temporary closures of facilities of suppliers, manufacturers or customers. During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, our suppliers agreed to shift new work to domestic suppliers to help reduce the risk of manufacturing delays. Our supplier and sub tier suppliers have been adversely affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Any disruption in the operations of our employees, suppliers, customers, manufacturers or access to customers would likely impact our sales and operating results. In addition, travel restrictions have made it more difficult for us to monitor the quality of our third party manufacturing operations when we are unable to conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> quality audits of those facilities. We have also experienced increases in product costs as raw materials have been constrained. Prices have risen sharply over the past year, and lead times have extended dramatically, particularly on semiconductor products. Over the next 12 months, we expect prices to increase due to the raw material demand surges across numerous industries, along with labor and transportation related constraints. We also expect lead times to reduce as component production levels recover to meet demand. In addition, future regulatory authorizations by the FDA may take longer because of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic-related delays. We are continuing to monitor and assess the effects of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our commercial operations. However, we cannot at this time accurately predict what effects these conditions will ultimately have on our operations due to uncertainties relating to variants such as Omicron, the severity of the disease, the duration of the outbreak, and the length of the travel restrictions and business closures imposed by the governments of impacted countries. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could continue to adversely affect the economies and financial markets of many countries, which could result in an economic downturn that could affect demand for our products and likely impact our operating results. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions and uncertainties. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers. Inflation could also adversely affect the ability of our customers to purchase our products. An economic downturn, including as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> could result in a variety of risks to our business, including weakened demand for our products and our inability to raise additional </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our manufacturers and suppliers, possibly resulting in supply disruption, or cause future customers to delay making payments for our products. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The enactment of legislation implementing changes in the U.S. Taxation of international business activities, the adoption of other tax reform policies or changes in tax legislation or policies in jurisdictions outside of the United States could materially impact our results of operations and financial condition. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to income tax in the numerous jurisdictions in which we operate. Reforming the taxation of international businesses has been a priority for politicians, and a wide variety of potential changes have been proposed. Some proposals, several of which have been enacted, impose incremental taxes on gross revenue, regardless of profitability. Furthermore, it is reasonable to expect that global taxing authorities will be reviewing current legislation for potential modifications in reaction to the implementation of the 2017 Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) in the United States. Due to the expanding scale of our international business activities, changes in the taxation of such activities may increase our worldwide effective tax rate and the amount of taxes we pay and harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the Tax Act enacted on December&#160;22, 2017 significantly affected U.S. Tax law by changing how the United States imposes income tax on multinational corporations. The U.S. Department of Treasury has broad authority to issue regulations and interpretative guidance that may significantly impact how we will apply the law and impact our results of operations in the period issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Tax Act requires complex computations not previously provided in U.S. Tax law. As such, the application of accounting guidance for such items remains uncertain. Further, compliance with the Tax Act and the accounting for such provisions requires an accumulation of information not previously required or regularly produced. As additional regulatory guidance is issued by the applicable taxing authorities, as accounting treatment is clarified, and as we perform additional analysis on the application of the law, our effective tax rate could be materially different. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Taxation of international business activities or the adoption of tax reform policies could materially impact our future financial position and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limitations on the ability of taxpayers to claim and utilize foreign tax credits and the deferral of certain tax deductions until earnings outside of the United States are repatriated to the United States, as well as changes to U.S. Tax laws that may be enacted in the future, could impact the tax treatment of future foreign earnings. Should the scale of our international business activities expand, any changes in the U.S. Taxation of such activities could increase our worldwide effective tax rate and harm our future financial position and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may face exposure to foreign currency exchange rate fluctuations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we have historically transacted in U.S. Dollars with the majority of our customers and suppliers, we have transacted in some foreign currencies and may transact in more foreign currencies in the future. Accordingly, changes in the value of foreign currencies relative to the U.S.&#160;Dollar may affect our revenue and operating results. As a result of such foreign currency exchange rate fluctuations, it could be more difficult to detect underlying trends in our business and operating results. In addition, to the extent that fluctuations in currency exchange rates cause our operating results to differ from our expectations or the expectations of our investors, the trading price of our stock could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ability to use net operating losses to offset future taxable income may be subject to certain limitations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, Legacy Hyperfine had federal net operating loss carryforwards (&#8220;NOLs&#8221;) to offset future taxable income of approximately $103.4&#160;million, of which $12.1&#160;million will begin to expire in 2034 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">if not utilized. Liminal had federal NOLs to offset future taxable income of approximately $12.3&#160;million. A lack of future taxable income would adversely affect our ability to utilize these NOLs. In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> NOLs and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> tax attributes (such as research tax credits) to offset post-change taxable income. For these purposes, an ownership change generally occurs where the equity ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a three-year period (calculated on a rolling basis). Our existing NOLs may be subject to limitations arising out of previous ownership changes and we may be limited as to the amount that can be utilized each year as a result of such previous ownership changes, including the Business Combination and related transactions. In addition, future changes in our stock ownership, including future offerings, as well as other changes that may be outside of our control, could result in additional ownership changes under Section&#160;382 of the Code. Our NOLs may also be impaired under similar provisions of state law. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the limitations discussed above under Sections 382 of the Code, the utilization of NOLs incurred in taxable years beginning after December&#160;31, 2017, are subject to limitations adopted by the Tax Cuts and Jobs Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;). Under the Tax Act, in general, NOLs generated in taxable years beginning after December&#160;31, 2017 may offset no more than 80&#160;percent of such year&#8217;s taxable income and there is no ability for such NOLs to be carried back to a prior taxable year. The CARES Act modifies the Tax Act with respect to the Tax Act&#8217;s limitation on the deduction of NOLs and provides that NOLs arising in taxable years beginning after December&#160;31, 2017 and before January&#160;1, 2021, may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&#160;31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80&#160;percent of current year taxable income for taxable years beginning before January&#160;1, 2021. As a result of such limitation, we may be required to pay federal income tax in some future year notwithstanding that we had a net loss for all years in the aggregate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Healthcare Industry Shifts and Changing Regulations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to extensive government regulation, which could restrict the development, marketing, sale and distribution of our products and could cause us to incur significant costs. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our medical devices and associated services are subject to extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> and post-market regulation by the FDA and various other federal, state, local and foreign government authorities. Government regulation of medical devices is meant to assure their safety and effectiveness, and includes requirements for, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">design, development and manufacturing processes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">labeling, content and language of instructions for use and storage; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product testing, nonclinical studies and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">regulatory clearances and approvals, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> clearance or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> approval; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishment registration, device listing and ongoing compliance with the QSR requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advertising and promotion; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing, sales and distribution; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conformity assessment procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product traceability and record-keeping procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">review of product complaints, complaint reporting, recalls and field safety corrective actions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">post-market studies (if applicable); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product import and export. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The laws and regulations to which we and our products are subject are complex and subject to periodic changes. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Before a new medical device, or a significant modification of a medical device, including a new use of or claim for an existing product, can be marketed in the United States, we must first receive either 510(k) clearance or premarket approval (&#8220;PMA&#8221;) from the FDA, unless an exemption applies. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. Legacy Hyperfine received 510(k) clearance from the FDA for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system in 2020. In addition, Legacy Hyperfine&#8217;s proprietary BrainInsight product is a fully automated MR imaging post-processing medical software that is regulated as a picture archiving and communications system, which may include both hardware and software components, and which is classified by FDA as a Class&#160;II medical device. BrainInsight received 510(k) marketing clearance in January 2021 for use in automatic labeling, spatial measurement, and volumetric quantification of brain structures from a set of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> MR images and to return annotated and segmented images, color overlays, and reports. More recently, in November 2021, Legacy Hyperfine received 510(k) clearance for its new advanced image reconstruction technology using deep learning. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be required to obtain a new 510(k) clearance or PMA approval for significant post-market modifications to our products, including any modifications made to the commercially marketed our devices. In addition, Liminal does not have any commercial products. When Liminal&#8217;s products are marketed for clinical monitoring or therapeutic uses, they will be regulated by the FDA as medical devices. Because the products are still in development, it is presently unclear what level of risk the agency will assign to such products, what special controls may be imposed on such products (if any), and what regulatory requirements would be applicable to such products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining 510(k) clearance or PMA approval for medical devices can be expensive and time-consuming, and entails significant user fees, unless an exemption is available. The FDA&#8217;s process for obtaining 510(k) clearance usually takes three to 12 months, but it can last longer. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including but not limited to, technical, nonclinical, clinical trial, manufacturing and labeling data. The process for obtaining a PMA is more costly and uncertain and approval can take anywhere from at least one year to, in some cases, multiple years from the time the application is initially filed with the FDA. Modifications to products that are approved through a PMA application generally require further FDA approval. Some of our future products may require PMA approval. In addition, the FDA may demand that we obtain a PMA prior to marketing future changes of our existing products. Further, we may not be able to obtain additional 510(k) clearances or PMAs for new products or for modifications to, or additional indications for, our products in a timely fashion or at all. Delays in obtaining future clearances or approvals could adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn could harm our revenue and future profitability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a medical device, if necessary, for a PMA application or 510(k) notification, a company must, among other things, apply for and obtain institutional review board (&#8220;IRB&#8221;) approval of the proposed investigation. In addition, if the clinical study involves a &#8220;significant risk&#8221; (as defined by the FDA) to human health, the sponsor of the investigation must also submit and obtain FDA approval of an investigational </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">device exemption (&#8220;IDE&#8221;) application and follow applicable IDE regulations. Unless <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IDE-exempt,</div> nonsignificant risk devices are still subject to certain abbreviated IDE requirements, however, an IDE application is not required if such abbreviated requirements are met. We may not be able to obtain any necessary FDA and/or IRB approval to undertake clinical trials in the United States for future devices we develop and intend to market in the United States. If we do obtain such approvals, the FDA may find that our studies do not comply with the IDE or other regulations governing clinical investigations or the data from any such trials may not support clearance or approval of the investigational device. Moreover, certainty that clinical trials will meet desired endpoints, produce meaningful or useful data and be free of unexpected adverse effects, or that the FDA will accept the validity of foreign clinical study data (if applicable) cannot be assured, and such uncertainty could preclude or delay market clearance or authorizations resulting in significant financial costs and reduced revenue. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are also subject to numerous post-marketing regulatory requirements, which include quality system regulations related to the manufacture of our devices, labeling regulations and medical device reporting (&#8220;MDR&#8221;) regulations. The last of these regulations requires us to report to the FDA if our devices cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury if the malfunction recurred. If we fail to comply with present or future regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA, which may include any of the following sanctions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customer notification, or orders for repair, replacement or refunds; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">voluntary or mandatory recall or seizure of our current or future products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrative detention by the FDA of medical devices believed to be adulterated or misbranded; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operating restrictions, suspension or shutdown of production; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of our requests for 510(k) clearance or PMA of new products, new intended uses or modifications to existing products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">rescission of 510(k) clearance or suspension or withdrawal of PMAs that have already been granted; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">criminal prosecution. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The occurrence of any of these events may have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our employees, independent contractors, consultants, manufacturers and suppliers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are exposed to the risk that our employees, independent contractors, consultants, manufacturers and suppliers may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&#160;the laws of the FDA and other similar foreign regulatory bodies, including those laws requiring the reporting of true, complete and accurate information to such regulators; (ii)&#160;manufacturing standards; (iii)&#160;healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or (iv)&#160;laws that require the true, complete and accurate reporting of financial information or data. These laws may impact, among other things, future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We adopted a code of business conduct and ethics in connection with the Business Combination. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, additional integrity reporting and oversight obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of our new or modified products will require FDA clearance of a 510(k) notification or FDA approval of a PMA application. The FDA may refuse our requests for 510(k) clearance or PMA of new products or may not clear or approve these products for the indications that are necessary or desirable for successful commercialization. Early stage review may also result in delays or other issues. For example, the FDA has issued guidance intended to explain the procedures and criteria used in assessing whether 510(k) and PMA submissions should be accepted for substantive review. Under the &#8220;Refuse to Accept&#8221; guidance, the FDA conducts an early review against specific acceptance criteria to inform 510(k) and PMA submitters if the submission is administratively complete, or if not, to identify the missing element(s). Submitters are given the opportunity to provide the FDA with any information identified as missing. If the information is not provided within a specified time, the submission will not be accepted for FDA review. The FDA may also change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions that may prevent or delay approval or clearance of our products under development or impact our ability to gain clearance or approval for modifications to our currently approved or cleared products in a timely manner. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent initiatives by the FDA to enhance and modernize various regulatory pathways for device products and its overall approach to safety and innovation in the medical technology industry creates the possibility of changing product development costs, requirements, and other factors and additional uncertainty for our future products and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory requirements may change in the future in a way that adversely affects us. Any change in the laws or regulations that govern the clearance and approval processes or the post-market compliance requirements relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, the FDA and other government agencies have been focusing on the cybersecurity risks associated with certain medical devices and encouraging device manufacturers to take a more proactive approach to assessing the cybersecurity risks of their devices both during development and on a periodic basis after the devices are in commercial distribution. These regulatory efforts could lead to new FDA requirements in the future or additional product liability or other litigation risks if any of our products is considered to be susceptible to third-party tampering. In December 2016, Congress passed the 21st Century Cures Act, which made multiple </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">changes to the FDA&#8217;s rules for medical devices as well as for clinical trials, and in August 2017, Congress passed the Medical Device User Fee reauthorization package, which affects medical device regulation both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post-approval and could have certain impacts on our business. Since that time, the FDA has announced a series of efforts to modernize and streamline the 510(k) notification and regulatory review process and monitoring post-market safety, and issued a final rule to formalize the De Novo classification process to provide clarity to innovative device developers. Changes in the FDA 510(k) process could make clearance more difficult to obtain, increase delay, add uncertainty and have other significant adverse effects on our ability to obtain and maintain clearance for our products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">It is unclear at this time whether and how various activities initiated or announced by the FDA to modernize the U.S. medical device regulatory system could affect our business, as some of the FDA&#8217;s new medical device safety and innovation initiatives have not been formalized and remain subject to change. For example, a 2018 Medical Device Safety Action Plan announced by former FDA Commissioner Gottlieb included a particular focus on post-market surveillance and how to respond when new safety concerns emerge once a product is on the market. The increased attention that the medical technology industry is receiving from FDA leadership that understands the challenging and rapidly changing nature of the U.S. healthcare system creates the possibility of unanticipated regulatory and other potential changes to our products and our overall business. In response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> public health emergency, the FDA&#8217;s device and diagnostic center leadership has exercised a significant amount of enforcement discretion to meet the medical community&#8217;s and patients&#8217; needs for remote monitoring and other innovative solutions that involve digital health products. In December 2021, FDA issued draft guidance documents describing a phased transition process for medical devices that were developed or modified during the course of the pandemic to treat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients or allow greater access to patients, including medical imaging devices that were developed or modified in accordance with FDA&#8217;s <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Enforcement Policy for Imaging Systems During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Public Health Emergency</div></div>. It is unclear how these policies could impact the medical device industry in the future. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to obtain regulatory authorizations in other countries for existing products or products under development, we will not be able to commercialize these products in those countries. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order for us to market our products in countries outside of the United States, we must comply with extensive safety and quality regulations in other countries regarding the quality, safety and efficacy of our products. These regulations, including the requirements for marketing authorizations, and the time required for regulatory review, vary from country to country. Failure to obtain regulatory authorization in any foreign country in which we plan to market our products may harm our ability to generate revenue and harm our business. Marketing authorization requirements vary between countries and can involve additional product testing and additional administrative review periods. The time required to obtain marketing authorization in other countries might differ from that required to obtain FDA clearance or other marketing authorization. The regulatory process in other countries may include all of the risks detailed above regarding FDA clearance in the United States. Regulatory authorization of a product in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory authorization in one country may negatively impact the regulatory process in others. Failure to obtain regulatory authorization in other countries or any delay or setback in obtaining such authorization could have the same adverse effects described above regarding FDA clearance in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary regulatory environment in Europe is that of the European Economic Area (&#8220;EEA&#8221;), which is comprised of the Member States of the European Union, Iceland, Liechtenstein and Norway. We cannot be certain that we will be successful in meeting and continuing to meet the requirements to market a medical device in the EEA in light of the current transition period between the prior system, called the Medical Device Directive (&#8220;MDD&#8221;), to the current system, called the Medical Device Regulation. The Medical Device Regulation went into force in May 2017 but allowed a three-year transition period until May 2020 for Member States, regulatory authorities, and medical device stakeholders to come into compliance with the new requirements. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> delay of the compliance date of the Medical Device Regulation was implemented in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, which made May 2021 the final deadline for industry compliance. Compared to the MDD, the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medical Device Regulation promotes a shift from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> stage (i.e., the path to CE Marking) to a life-cycle approach and places greater emphasis on clinical data and clinical evaluations to assure the safety and performance of new medical devices. Moreover, the Medical Device Regulation includes elements intended to strengthen the conformity assessment procedures, assert greater control over notified bodies and their standards, increase overall system transparency, and impose more robust device vigilance requirements on manufacturers and distributors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Among other changes, many device manufacturers will need to switch notified bodies to one that has received its designation under the Medical Device Regulation, which will require those manufacturers to undergo an audit and have all their documentation reviewed by the new notified body before it can assess their medical device products under the new standards. The new rules and procedures that have been created under the overhauled European regulations will likely result in increased regulatory oversight of all medical devices marketed in the European Union, and this may, in turn, increase the costs, time and requirements that need to be met in order to place an innovative or high-risk medical device on the EEA market. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we, our current or future contract manufacturers, or our current or future component suppliers are unable to manufacture our products in sufficient quantities, on a timely basis, at acceptable costs and in compliance with regulatory and quality requirements, the manufacturing and distribution of our devices could be interrupted, and our product sales and operating results could suffer. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When producing and distributing commercial medical device products, we, our contract manufacturer, and our component suppliers are required to comply with the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;), which is a complex regulatory framework that covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage, shipping and servicing of our devices. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic, sometimes unannounced, inspections by the FDA. We cannot assure investors that our facilities or our third-party manufacturers&#8217; or suppliers&#8217; facilities would pass any future quality system inspection. Failure of us or our third-party manufacturers and component suppliers to adhere to QSR requirements or take adequate and timely corrective action in response to an adverse quality system inspection finding could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could have a material adverse effect on our business, financial condition or results of operations. Any such failure, including the failure of our current or any future contract manufacturers, to achieve and maintain the required high manufacturing standards could result in further delays or failures in product testing or delivery, cost overruns, increased warranty costs or other problems that could harm our business and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any of our products shipped internationally are also required to comply with the International Organization for Standardization (&#8220;ISO&#8221;) quality system standards as well as European Directives and norms in order to produce products for sale in the European Union. In addition, many countries such as Canada and Japan have very specific additional regulatory requirements for quality assurance and manufacturing. If we fail to continue to comply with current good manufacturing requirements, as well as ISO or other regulatory standards, we may be required to cease all or part of our operations until we comply with these regulations. Maintaining compliance with multiple regulators adds complexity and cost to our manufacturing and compliance processes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our current or future products may be subject to product recalls even after receiving FDA clearance or approval. A recall of our products, either voluntarily or at the direction of the FDA, or the discovery of serious safety issues with our products, could have a significant adverse impact on us. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA and similar governmental bodies in other countries have the authority to require the recall of our products if we or our third party manufacturers fail to comply with relevant regulations pertaining to, among other things, manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning the safety or efficacy of these products. For example, under the FDA&#8217;s Medical Device </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reporting regulations, we are required to report to the FDA any incident in which our marketed products may have caused or contributed to a death or serious injury or in which our marketed products malfunctioned in a manner likely to cause or contribute to death or serious injury if that malfunction were to recur. Repeated adverse events or product malfunctions may result in a voluntary or involuntary product recall, or administrative or judicial seizure or injunction, when warranted. A government-mandated recall may be ordered if the FDA finds that there is a reasonable probability that the device would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of any material deficiency in a device, such as manufacturing defects, labeling deficiencies, packaging defects or other failures to comply with applicable regulations. In general, if we decide to make a change to our marketed product, we are responsible for determining whether to classify the change as a recall. It is possible that the FDA could disagree with our initial classification. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. If a change to a device addresses a violation of the federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), that change would generally constitute a medical device recall and require submission of a recall report to the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands. We may also be subject to product liability claims, be required to bear other costs, or be required to take other actions that may have a negative impact on our future sales and our ability to generate profits. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification to the FDA. If the FDA disagrees with our determinations, the FDA could require us to report those actions as recalls. A future recall, withdrawal, or seizure of any product could materially and adversely affect consumer confidence in our brands, lead to decreased demand for our products and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report recalls when they were conducted by us or one of our agents. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to enforcement action if we engage in improper or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> marketing or promotion of our commercial medical device products, including fines, penalties and injunctions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition of the promotion of unapproved, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label,</div> uses of lawfully marketed medical device products. Physicians may, however, use our commercial products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label,</div> as the FDA does not restrict or regulate a physician&#8217;s practice of medicine. Medical device manufacturers and distributors are permitted to promote their products in a way that is consistent with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-authorized</div> labeling and indications for use. However, if the FDA determines that our promotional materials or training materials promote a 510(k)-cleared or approved medical device in a manner inconsistent with our labeling, the agency could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an Untitled Letter, a Warning Letter, injunction, seizure, civil fine or criminal penalties. In addition to ensuring that the claims we make are consistent with our regulatory clearances or approvals, the FDA also ensures that promotional labeling for all regulated medical devices is neither false nor misleading. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged, and adoption of our products could be impaired. Although our policy is to refrain from making statements or from disseminating promotional material that could be considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion of our commercial medical device products, the FDA or another regulatory agency could disagree and conclude that we have engaged in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend and could divert our management&#8217;s attention, result in substantial damage awards against us, and harm our reputation. Recent court decisions have impacted the FDA&#8217;s enforcement activity regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">in light of First Amendment considerations, although there are still significant risks in this area in part due to the potential False Claims Act exposure. Further, this area is subject to ongoing policy changes at the federal level, resulting in some degree of uncertainty for regulated businesses. For example, in August 2021 the FDA issued a final rule revising the agency&#8217;s regulation governing the types of evidence relevant to determining the &#8220;intended use&#8221; of a drug or device under the FDCA, which has significant implications for when a manufacturer or distributor has engaged in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> marketing. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Digital marketing and social media efforts may expose us to additional regulatory scrutiny, including from the Federal Trade Commission (the &#8220;FTC&#8221;) and other consumer protection agencies and regulators. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to the laws and regulations enforced by the FDA, advertising for various services and for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-restricted</div> medical devices is subject to federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">truth-in-advertising</div></div> laws enforced by the FTC, as well as comparable state consumer protection laws. Our efforts to promote prescription medical device products via social media initiatives may subject us to additional scrutiny of our practices. For example, the FTC and other consumer protection agencies scrutinize all forms of advertising (whether in digital or traditional formats) for business services, consumer-directed products, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-restricted</div> medical devices to ensure that advertisers are not making false, misleading or unsubstantiated claims or failing to disclose material relationships between the advertiser and its products&#8217; endorsers, among other potential issues. The FDA oversees the advertising and promotional labeling for restricted medical devices and ensures, among other things, that there is effective communication of, and a fair and balanced presentation of, the risks and benefits of such high-risk medical devices. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Federal Trade Commission Act (&#8220;FTC Act&#8221;), the FTC is empowered, among other things, to (a)&#160;prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b)&#160;seek monetary redress and other relief for conduct injurious to consumers; and (c)&#160;gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution. We plan to increase our advertising activities that may be subject to these federal and state <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">truth-in-advertising</div></div> laws. Any actual or perceived <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with those laws could lead to an investigation by the FTC or a comparable state agency, or could lead to allegations of misleading advertising by private plaintiffs. Any such action against us could disrupt our business operations, cause damage to our reputation, and result in a material adverse effects on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we do not require extensive training for users of our current products, although they are limited under the FDA&#8217;s marketing clearances to use by, and that images generated from the scanner be interpreted by, trained healthcare practitioners, there exists a potential for misuse of these products, misinterpretation of images by untrained professionals or misuse of these products by untrained professionals, which could ultimately harm our reputation and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Federal regulations allow us to sell our medical device products to or on the order of practitioners licensed by law to use or order the use of a prescription device. The definition of &#8220;licensed practitioners&#8221; varies from state to state. As a result, our current products may be purchased or operated by physicians with varying levels of training and, in many states, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-physicians,</div> including nurse practitioners, chiropractors and technicians. The FDA clearances of the products require interpretation of images by trained physicians and use of that information in determining a diagnosis. Outside the United States, many jurisdictions do not require specific qualifications or training for purchasers, or operators or interpreters, of medical device products. We do not supervise the procedures performed with our products, nor can we require that direct medical supervision occur. Although product training is offered, we do not require purchasers or operators of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> products to attend training sessions. The lack of required training and the purchase and use of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> products by </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-physicians</div> may result in product misuse and adverse treatment outcomes, which could harm our reputation and expose us to costly product liability litigation. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to federal, state and foreign laws prohibiting &#8220;kickbacks&#8221; and false or fraudulent claims, and other fraud and abuse laws, transparency laws, and other healthcare laws and regulations, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our relationships with customers and third-party payors are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs and certain customer and product support programs, we may have with hospitals, physicians or other purchasers of medical devices. Other federal and state laws generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, or are for items or services that were not provided as claimed. These laws include, among others, the federal healthcare Anti-Kickback Statute, the federal civil False Claims Act, other federal healthcare false statement and fraud statutes, the Open Payments program, the Civil Monetary Penalties Law, and analogous fraud and abuse and transparency laws in most states, as described in &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business of Hyperfine -</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Regulation.</div></div>&#8221; Although the federal laws generally apply only to products or services for which payment may be made by a federal healthcare program, state laws often apply regardless of whether federal funds may be involved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we believe and strive to ensure that our business arrangements with third parties and other activities and programs comply with all applicable laws, these laws are complex, and our activities may be found not to be compliant with one or more of these laws, which may result in significant civil, criminal and/or administrative penalties, fines, damages and exclusion from participation in federal healthcare programs. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity, and be costly to respond to, and thus could have a material adverse effect on our business, financial condition and results of operations. Our compliance with Medicare and Medicaid regulations may be reviewed by federal or state agencies, including the Office of Inspector General for the U.S. Department of Health and Human Services (&#8220;OIG&#8221;), Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), and the Department of Justice, or may be subject to whistleblower lawsuits under federal and state false claims laws. To ensure compliance with Medicare, Medicaid and other regulations, government agencies conduct periodic audits of the Company to ensure compliance with various supplier standards and billing requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Similarly, our international operations are subject to the provisions of the FCPA, which prohibits U.S. companies and their intermediaries from making payments in violation of law to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In many countries, the healthcare professionals that medical device distributors regularly interact with may meet the definition of a foreign official for purposes of the FCPA. International business operations are also subject to various other international anti-bribery laws such as the U.K. Anti-Bribery Act. Despite meaningful measures that we undertake to facilitate lawful conduct, which include training and compliance programs and internal policies and procedures, we may not always prevent unauthorized, reckless or criminal acts by our employees or agents, or employees or agents of businesses or operations we may acquire. Violations of these laws, or allegations of such violations, could disrupt operations, involve significant management distraction and have a material adverse effect on our business, financial condition and results of operations, among other adverse consequences. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are found to have violated laws protecting the confidentiality of health information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are a number of federal and state laws protecting the confidentiality of certain health information and restricting the use and disclosure of that protected information. In particular, the U.S. Department of Health and Human Services promulgated privacy rules under the Health and Insurance Portability and Accountability Act </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;HIPAA&#8221;). These privacy rules protect medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend and seek accounting of their own health information and limiting most use and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. We are not subject to HIPAA, but our customers and research collaborators and other healthcare provider partners are, which means that there are restrictions on our ability to receive and use health information from our healthcare provider partners. If we are found to be in violation of applicable privacy rule requirements, we could subject our customers or healthcare provider partners to civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in customer growth or engagement, or otherwise harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are subject to a variety of laws and regulations in the United States and abroad that involve matters central to our business, including laws and regulations relating to privacy, data sharing and data protection, artificial intelligence and use of machine learning, rights of publicity, content, intellectual property, advertising, marketing, distribution, data security, data retention and deletion, personal information, electronic contracts and other communications, competition, protection of minors, consumer protection, telecommunications, product liability, taxation, economic or other trade prohibitions or sanctions, corrupt practices, fraud, waste and abuse restrictions, and securities law compliance. The introduction of new products or expansion of our activities in certain jurisdictions may subject us to additional laws and regulations. For example, in addition to data protection laws passed by the federal government, many states and foreign countries have implemented their own data protection laws, some of which may apply simultaneously and conflict with federal law. Many of these laws create consumer rights including the right to know what personal information is collected, the right to know whether the data is sold or disclosed and to whom, the right to request that a company delete personal information collected, the right to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> of the sale of personal information and the right to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-discrimination</div> in terms of price or service when a consumer exercises a privacy right. If we fail to comply with these regulations, we could be subject to civil sanctions, including fines and penalties for noncompliance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, foreign data protection, privacy, and other laws and regulations can be more restrictive than those in the United States. Data localization laws in some countries generally mandate that certain types of data collected in a particular country be stored and/or processed within that country. We could be subject to audits in Europe and around the world, particularly in the areas of consumer and data protection, as we continue to grow and expand our operations. Legislators and regulators may make legal and regulatory changes, or interpret and apply existing laws, in ways that make our products less useful to customers, require us to incur substantial costs, expose us to unanticipated civil or criminal liability, or cause us to change our business practices. These changes or increased costs could negatively impact our business and results of operations in material ways. For example, the general data privacy regulation (&#8220;GDPR&#8221;) imposes requirements in the EEA relating to, among other things, consent to process personal data of individuals, the information provided to individuals regarding the processing of their personal data, the security and confidentiality of personal data, notifications in the event of data breaches and use of third party processors. If we fail to comply with these standards, we could be subject to criminal penalties and civil sanctions, including fines and penalties and amounts could be significant. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under federal or state law, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cyber incidents can result from deliberate attacks or unintentional events. We collect and store on our networks sensitive information, including intellectual property, proprietary business information and personally </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identifiable information of individuals, such as our employees and customers. The secure maintenance of this information and technology is critical to our business operations. As a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> company, Liminal&#8217;s security infrastructure is evolving consistent with its business operations and security risk profile. Legacy Hyperfine has implemented multiple layers of security measures to protect the confidentiality, integrity and availability of these data and the systems and devices that store and transmit such data. Legacy Hyperfine utilizes current security technologies, including encryption and data depersonalization, and its defenses are monitored and routinely tested. Despite these efforts, threats from malicious persons and groups, new vulnerabilities and advanced new attacks against information systems create risk of cybersecurity incidents. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cybersecurity threats can come from a variety of sources, and may range in sophistication from an individual hacker to malfeasance by employees, consultants or other service providers to state-sponsored attacks. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past several years, cyber-attacks have become more prevalent and much harder to detect and defend against. Our network and storage applications, as well as those of our contractors, may be vulnerable to cyber-attack, malicious intrusion, malfeasance, loss of data privacy or other significant disruption and may be subject to unauthorized access by hackers, employees, consultants or other service providers. In addition, hardware, software or applications that we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security. Unauthorized parties may also attempt to gain access to our systems or facilities through fraud, trickery or other forms of deceiving employees, contractors and temporary staff. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There can be no assurance that we will not be subject to cybersecurity incidents that bypass our security measures, impact the integrity, availability or privacy of health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to deliver services to our users. As a result, cybersecurity, physical security and the continued development and enhancement of our controls, processes and practices designed to protect our enterprise, information systems and data from attack, damage or unauthorized access remain a priority for us. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any cybersecurity vulnerabilities. The occurrence of any of these events could result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">harm to customers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-users;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business interruptions and delays; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the loss, misappropriation, corruption or unauthorized access of data; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">litigation, including potential class action litigation, and potential liability under privacy, security and consumer protection laws or other applicable laws; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reputational damage; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increase to insurance premiums; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">foreign, federal and state governmental inquiries, any of which could have a material, adverse effect on our financial position and results of operations and harm our business reputation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of our business, we collect and store sensitive data, and intellectual property and proprietary business information owned or controlled by us or our users. This data encompasses a wide variety of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business-critical information, including research and development information, commercial information, and business and financial information. We face four primary risks relative to protecting this critical information: loss of access; inappropriate disclosure; inappropriate modification; and inadequate monitoring of our controls over the first three risks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses, breaches, interruptions due to employee error, malfeasance, lapses in compliance with privacy and security mandates, or other disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost, or stolen. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any such security breach or interruption, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business, could result in enforcement actions by U.S. states, the U.S. federal government or foreign governments, liability or sanctions under data privacy laws that protect personally identifiable information, regulatory penalties, other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to our development programs, business operations and collaborations, diversion of management efforts and damage to us and our brands&#8217; reputation, which could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity threats, our measures to prevent, respond to and minimize such risks may be unsuccessful. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to medical information, we follow HIPAA guidelines when applicable and separate personal information from medical information, and employ additional measures such as encryption tools to protect the privacy of our users and medical data. However, hackers may attempt to penetrate our computer systems, and, if successful, misappropriate personal or confidential business information. In addition, an associate, contractor or other third party with whom we do business may attempt to circumvent our security measures in order to obtain such information, and may purposefully or inadvertently cause a breach involving such information. While we continue to implement additional protective measures to reduce the risk of and detect cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the European Parliament and the Council of the European Union adopted the comprehensive GDPR in 2016 to replace the current European Union Data Protection Directive and related country-specific legislation. The GDPR took effect in May 2018 and governs the collection and use of personal data in the European Union. The GDPR, which is wide-ranging in scope, imposes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, enhances enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20&#160;million or 4% of the annual global revenues of the infringer, whichever is greater. While we comply with the GDPR, including reviewing our security procedures and entering into data processing agreements with relevant contractors, there can be no assurance that as our operations evolve, our efforts to comply or to remain in compliance will be fully successful. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, unauthorized access, loss or dissemination of sensitive personal data, such as health information, could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business and damage our reputation, any of which could adversely affect our business and reputation. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our products could be delayed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Broad-based domestic and international government initiatives to reduce spending, particularly those related to healthcare costs, may reduce reimbursement rates for medical procedures, which will reduce the cost-effectiveness of our products and services. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare reforms, changes in healthcare policies and changes to third-party coverage and reimbursements, including legislation enacted reforming the U.S. healthcare system and both domestic and foreign healthcare cost containment legislation, and any future changes to such legislation, may affect demand for our products and services and may have a material adverse effect on our financial condition and results of operations. The ongoing implementation of the Affordable Care Act, in the United States, as well as state-level healthcare reform proposals could reduce medical procedure volumes and impact the demand for medical device products or the prices at which we can sell products. These reforms include a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. The impact of this healthcare reform legislation, and practices including price regulation, competitive pricing, comparative effectiveness of therapies, technology assessments, and managed care arrangements are uncertain. There can be no assurance that current levels of reimbursement will not be decreased in the future, or that future legislation, regulation, or reimbursement policies of third parties will not adversely affect the demand for our products and services or our ability to sell products and provide services on a profitable basis. The adoption of significant changes to the healthcare system in the United States, the EEA or other jurisdictions in which we may market our products and services, could limit the prices we are able to charge for our products and services or the amounts of reimbursement available for our products and services, could limit the acceptance and availability of our products and services, reduce medical procedure volumes and increase operational and other costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, following judicial and Congressional challenges to certain aspects of the Affordable Care Act, certain sections of the Affordable Care Act, as a result, have not been fully implemented or were effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the Affordable Care Act when it dismissed a legal challenge to the constitutionality of the Affordable Care Act. Further legislative and regulatory changes under the Affordable Care Act remain possible, although the new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Democrat-led</div> presidential administration has been taking steps to strengthen the Affordable Care Act and the 117th Congress is not expected to have the same interest in repealing the law, in part due to the healthcare economic impacts of the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In addition to the Affordable Care Act, there have been and will likely continue to be other federal and state changes that affect the provision of healthcare goods and services in the United States. While we are unable to predict what changes may ultimately be enacted, to the extent that future changes affect how our products and services are paid for and reimbursed by government and private payers, our business could be adversely impacted. Moreover, complying with any new legislation or reversing changes implemented under the Affordable Care Act could be time-intensive and expensive, resulting in a material adverse effect on the business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain and maintain and enforce sufficient intellectual property protection for our products and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property right protection and contractual restrictions to protect our proprietary products and technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to obtain, maintain and sufficiently enforce our intellectual property, third parties may be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover damages or restrict use of our intellectual property. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage against our competitors&#8217; products, our competitive position could be adversely affected, as could our business, financial condition, results of operations and prospects. Both the patent application process and the process of managing patent and other intellectual property disputes can be time-consuming and expensive. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain protection of the intellectual property we may own solely or jointly with, or license from, third parties, particularly patents, in the United States and other countries directed to our products and technologies. We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, we may not develop additional proprietary products, methods and technologies that are patentable. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed from or to third parties. Therefore, these patents and applications may not be prosecuted, obtained and enforced by such third parties in a manner consistent with the best interests of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the patent position of life sciences and medical technology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights presents some degree of uncertainty. It is possible that some of our pending patent applications will not result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide any competitive advantages, or may be challenged, narrowed and/or invalidated by third parties. There exists some degree of uncertainty over the breadth of claims that may be allowed or enforced in our patents or in third-party patents. It is possible that third parties will attempt to design around our current or future patents such that we cannot prevent such third parties from using similar technologies and commercializing similar products to compete with us. Some of our owned or licensed patents or patent applications may be challenged at a future point in time and we may not be successful in defending any such challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in the narrowing, unenforceability or invalidity of such patents and increased competition to our business. The outcome of patent litigation or other proceedings can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, regardless of success, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. Any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The U.S. law relating to the patentability of certain inventions in the life sciences and medical technology industry is uncertain and rapidly changing, which may adversely impact our existing patents or our ability to obtain patents in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enforcement or defense of issued patents. For instance, under the Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;), enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. These changes include allowing third-party submission of prior art to the United States Patent and Trademark Office (&#8220;USPTO&#8221;) during patent prosecution and additional procedures to challenge the validity of a patent through USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Various courts, including the U.S. Supreme Court, have rendered decisions that impact the scope of patentability of certain inventions or discoveries relating to life sciences and medical technology. Specifically, these decisions stand for the proposition that patent claims that recite laws of nature, natural phenomena, and abstract ideas are not themselves patentable unless those patent claims have sufficient additional features that provide practical assurance that the processes are genuine inventive applications of those laws, phenomena, and abstract ideas rather than patent drafting efforts designed to monopolize the law of nature, natural phenomenon, or abstract idea itself. What constitutes a &#8220;sufficient&#8221; additional feature is somewhat uncertain. Furthermore, in view of these decisions, since December 2014, the USPTO has published and continues to publish revised guidelines for patent examiners to apply when examining process claims for patent eligibility. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to some degree of uncertainty with regard to Company&#8217;s ability to obtain patents in the future, this combination of events has created a degree of uncertainty with respect to the value of patents, once obtained. Depending on relevant laws enacted by the U.S. Congress, and decisions by the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may have a material adverse effect on our ability to obtain new patents and to defend and enforce our existing patents and patents that we might obtain in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our patent portfolio may be negatively impacted by current uncertainties in the state of the law, new court rulings or changes in guidance or procedures issued by the USPTO or other similar patent offices around the world. From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability, scope and validity of patents within the life sciences and medical technology and any such changes, or any similar adverse changes in the patent laws of other jurisdictions, could have a negative impact on our business, financial condition, prospects and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect our intellectual property rights throughout the world. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The laws of some foreign countries do not offer intellectual property rights to the same extent as the laws of the United States, and we and our licensors may encounter difficulties in obtaining, enforcing and defending such rights in foreign jurisdictions. Consequently, we and our licensors may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in some or all countries outside the United States, or from selling or importing products made using our or our licensors&#8217; inventions in other jurisdictions. Competitors and other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and technologies and may also export infringing products to territories where we have patent protection, but enforcement practices or laws are not as strong as those in the United States. These products may compete with our products. Our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain other countries are not as developed or as favorable as the United States in the enforcement of patents and other intellectual property rights, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. The legal systems in certain countries may also favor state-sponsored companies or companies headquartered in particular jurisdictions over our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-time</div></div> patents and other intellectual property rights. The absence of harmonized intellectual property protection laws and effective enforcement makes it difficult to ensure consistent respect for patent, trade secret, and other intellectual property rights on a worldwide basis. As a result, it is possible that we will not be able to enforce our rights against third parties that misappropriate our proprietary technology in those countries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceedings to enforce our or our licensors&#8217; patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put us and our licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217; patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We and our licensors may not prevail in any lawsuits that we or our licensors initiate, or that are initiated against us or our licensors, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our products, services and other technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issued patents covering our products could be found invalid or unenforceable if challenged. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our owned and licensed patents and patent applications may be subject to validity, enforceability and priority disputes. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents and patent applications) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference or other similar proceedings, as applicable. Any successful third-party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents, which may lead to increased competition to our business, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, if we or our licensors initiate legal proceedings against a third party to enforce a patent covering our products, the defendant could counterclaim that such patent covering our products, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. There are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-enablement.</div> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent intentionally withheld relevant information from the relevant patent office, or knowingly made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include ex parte <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examination,</div> inter partes review, post-grant review, derivation and equivalent proceedings in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> jurisdictions, such as opposition proceedings. Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover and protect our products. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant or other third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our products and technologies, which could have a material adverse effect on our business, financial condition, results of operations and </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prospects. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license intellectual property, or develop or commercialize current or future products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may not be aware of all third-party intellectual property rights potentially relating to our products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate, as applicable, in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO, or other similar proceedings in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> jurisdictions that could result in substantial cost to us and the loss of valuable patent protection. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, regardless of the merit of such proceedings and regardless of whether we are successful, we could experience significant costs and our management may be distracted. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely heavily on trade secrets and confidentiality agreements to protect our unpatented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other confidential proprietary information, and to maintain our competitive position. However, trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> can be difficult to protect. In particular, we anticipate that with respect to our technologies, these trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors or other third parties will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could materially and adversely impact our ability to establish or maintain a competitive advantage in the market, and our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had wrongfully obtained and was using our trade secrets, it would be expensive and time-consuming, it could distract our personnel, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets or may not recognize certain claims of intellectual property infringement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent and copyright protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Competitors or third parties could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology, develop their own competitive technologies that fall outside the scope of our intellectual property rights or independently develop our technologies without reference to our trade secrets. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could materially and adversely affect our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims challenging the inventorship and ownership of our patents and other intellectual property. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, trade secrets or other intellectual property as an inventor or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inventor.</div> For example, we or our licensors may have inventorship disputes arise from alleged inventors such as employees, consultants, advisors or others who are involved in developing our products, some of whom may have conflicting intellectual property ownership obligations. In addition, counterparties to our consulting, sponsored research, software development and other agreements may assert that they have an ownership interest in intellectual property developed under such arrangements. In particular, certain software development agreements pursuant to which certain third parties have developed parts of our proprietary software may not include provisions that expressly assign to us ownership of all intellectual property developed for us by such third parties. Furthermore, certain of our sponsored research agreements pursuant to which we provide certain research services for third parties do not assign to us all intellectual property developed under such agreements. As such, we may not have the right to use all such developed intellectual property under such agreements, we may be required to obtain licenses from third parties and such licenses may not be available on commercially reasonable terms or at all, or may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive.</div> If we are unable to obtain such licenses and such licenses are necessary for the development, manufacture and commercialization of our products and technologies, we may need to cease the development, manufacture or commercialization of our products and technologies. Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors&#8217; ownership of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. In such an event, we may be required to obtain licenses from third parties and such licenses may not be available on commercially reasonable terms or at all, or may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive.</div> If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture or commercialization of our products and technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and loss of time and be a distraction to management and other employees, and certain customers or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic or otherwise fail to function as a mark, lapsed or determined to be confusingly similar to or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties have filed, and may in the future file, for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to consumer confusion. If such third parties were to succeed in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">registering or developing common law rights in any other trademarks that are similar or identical to our trademarks, and if we are not successful in challenging such rights and defending against challenges to Company&#8217;s trademarks, we may not be able to use such trademarks to develop brand recognition of our technologies, products or services. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business, financial condition, results of operations and prospects may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a utility patent is generally 20 years from its earliest U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. While extensions may be available, the life of a patent, and the protection it affords, is limited. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. Even if patents covering our products are obtained, once the patent life has expired, we may be open to competition from competitive products. If one of our products requires extended development, testing and/or regulatory review, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our products, which could have a material adverse effect on our business, financial condition and results of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their other clients or former employers, which could subject us to costly litigation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As is common in the life sciences and medical industry, we engage the services of consultants and independent contractors to assist us in the development of our products. Many of these consultants and independent contractors were previously employed at, or may have previously or may be currently providing consulting or other services to, universities or other technology, biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may become subject to claims that we, a consultant or an independent contractor inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may similarly be subject to claims stemming from similar actions of an employee, such as one who was previously employed by another company, including a competitor or potential competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team. If we are not successful we could lose access or exclusive access to valuable intellectual property. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become involved in lawsuits to defend against third-party claims of infringement, misappropriation or other violations of intellectual property rights or to protect or enforce our intellectual property, any of which could be expensive, time consuming and unsuccessful, and may prevent or delay our development and commercialization efforts. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success depends in part on our ability and the ability of future collaborators to develop, manufacture, market and sell our product and use our products and technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the life sciences and medical technology sector, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our products, manufacturing methods, software and/or technologies infringe, misappropriate or otherwise violate their intellectual property rights. Numerous issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our products and technologies. It is not always clear to industry participants, including us, the claim scope that may issue from pending patent applications owned by third parties or which patents cover various types of products, technologies or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties, including our competitors, may allege they have patent rights encompassing our products, technologies or methods and that we are employing technology protected by such patent rights without authorization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If third parties, including our competitors, believe that our products or technologies infringe, misappropriate or otherwise violate their intellectual property rights, such third parties may seek to enforce against us their intellectual property rights, including patent rights, by filing against us an intellectual property-related lawsuit, including a patent infringement lawsuit. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. If any third parties were to assert these or any other patents against us and we are unable to successfully defend against any such assertions, we may be required, including by court order, to cease the development and commercialization of the infringing products or technology and we may be required to redesign such products and technologies so they do not infringe such patents, which may not be possible or may require substantial monetary expenditures and time. We could also be required to pay damages, which could be significant, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such patents. We could also be required to obtain a license to such patents in order to continue the development and commercialization of the infringing product or technology. However, such a license may not be available on commercially reasonable terms or at all, including because certain of these patents may be held by or exclusively licensed to our competitors. Even if such a license were available, it may require substantial payments or cross-licenses under our intellectual property rights, and it may only be available on a nonexclusive basis, in which case third parties, including our competitors, could use the same licensed intellectual property to compete with us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operation and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may choose to challenge, including in connection with any allegation of patent infringement by a third party, the patentability, validity, ownership or enforceability of any third-party patent that we believe may have applicability in our field, and any other third-party patent that may at some future time possibly be asserted against us. Such challenges may be brought either in court or by requesting that the USPTO, European Patent Office (&#8220;EPO&#8221;), or other foreign patent offices review the patent claims, such as in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-parte</div> reexamination, inter partes review, post-grant review proceeding or opposition proceeding or other similar proceedings. However, there can be no assurance that any such challenge by us or any third party will be successful. Even if such proceedings are successful, these proceedings are expensive and may consume our time or other resources, distract our management and technical personnel, and the costs of these opposition proceedings could be </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">substantial. There can be no assurance that our defenses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement,</div> invalidity or unenforceability will succeed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Third parties, including our competitors, could be infringing, misappropriating or otherwise violating our solely owned and/or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> intellectual property rights. Monitoring unauthorized use of intellectual property is difficult and costly. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. From time to time, we seek to analyze our competitors&#8217; products and services, and may in the future seek to enforce our rights based on potential infringement, misappropriation or violation of our intellectual property. However, the steps we take to protect our intellectual property rights may not be adequate to enforce our rights against such infringement, misappropriation or violation of our intellectual property. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Litigation proceedings may be necessary for us to enforce our patent and other intellectual property rights. In any such proceeding, a court may refuse to stop the other party from using the technology at issue on the grounds that our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents do not cover the technology in question. Further, in such a proceeding, the defendant could counterclaim that our intellectual property is invalid or unenforceable and the court may agree, in which case we could lose valuable intellectual property rights, which could allow third parties to commercialize technology or products similar to ours and compete directly with us, without payment to us. Alternatively or additionally such a proceeding could result in requiring us to license rights from the prevailing party in order to be able to manufacture or commercialize our products without infringing such party&#8217;s intellectual property rights, and if we are unable to obtain such a license, we may be required to cease commercialization of our products and technologies, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. The outcome in any such proceeding is somewhat unpredictable. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regardless of whether we are defending against or asserting an intellectual property-related claim in an intellectual property-related proceeding that may be necessary in the future, and regardless of outcome, substantial costs and diversion of resources may result which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Class&#160;A common stock. Some of our competitors and other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. We may not have sufficient financial or other resources to adequately conduct these types of litigation or proceedings. Any of the foregoing, or any uncertainties resulting from the initiation and continuation of any litigation, could have a material adverse effect on our business, financial condition, results of operations and prospects. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. The USPTO and various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensors </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to pay these fees due to the U.S. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> patent agencies and to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> can result in an irrevocable abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We currently rely on licenses from third parties, and in the future may rely on additional licenses from other third parties, and if we lose any of these licenses, then we may be subjected to future litigation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are, and may in the future become, a party to license agreements that grant us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success may depend in part on the ability of our licensors and any future licensors to obtain, maintain and enforce patent protection for our licensed intellectual property. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products and technologies for sale, which could materially adversely affect our competitive business position and harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current license agreements impose, and future agreements may impose, various diligence, commercialization, milestone payment, royalty, insurance and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. If we fail to comply with these obligations, our licensor(s) may have the right to terminate our license, in which event we would not be able to develop or market products or technology covered by the licensed intellectual property. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our financial or other obligations under the license agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether, and the extent to which, our products, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the inventorship and ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the joint creation or use of intellectual property by our licensor(s); and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the priority of invention of patented technology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements, experience significant delays in the development and commercialization of our products and technologies, or incur liability for damages, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. In addition, we may seek to obtain additional licenses from our licensor(s) and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensor(s), including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our products. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the agreements under which we currently and in the future license intellectual property or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize any affected products or services, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#8217; fees or costs and expenses and royalties, which could adversely affect our ability to offer products or services, our ability to continue operations and our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may identify third-party technology that we may need to license or acquire in order to develop or commercialize our products or technologies. However, we may be unable to secure such licenses or acquisitions. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. In return for the use of a third party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our products or services. Royalties are a component of cost of products or technologies and affect the margins on our products. We may also need to negotiate licenses to patents or patent applications before or after introducing a commercial product. We may not be able to obtain necessary licenses to patents or patent applications, and our business may suffer if we are unable to enter into the necessary licenses on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensor fails to abide by the terms of the license or fails to prevent infringement by third parties, or if the licensed intellectual property rights are found to be invalid or unenforceable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents are, and our future owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents may be, subject to a reservation of rights by one or more third parties, including government <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights, that may limit our ability to exclude third parties from commercializing products similar or identical to ours. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition, our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents may be subject to a reservation of rights by one or more third parties. When new technologies are developed with government funding, in order to secure ownership of such patent rights, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. Any failure to timely elect title to such inventions may permit the U.S. government to, at any time, take title to such inventions. Additionally, the U.S. government generally obtains certain rights in any resulting patents, including a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> royalty-free license authorizing the government to use the invention or to have others use the invention on its behalf. If the government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. In addition, these rights may permit the U.S. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">government to disclose our confidential information to third parties and to exercise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights to use or allow third parties to use our licensed technology free of charge. The U.S. government can exercise its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of any of the foregoing rights could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our products contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products and provide third parties access to our proprietary software. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our products may contain software licensed by third parties under open source software licenses. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source software licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source software licenses contain requirements that the licensee make its source code publicly available if the licensee creates modifications or derivative works using the open source software, depending on the type of open source software the licensee uses and how the licensee uses it. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source software licenses, be required to release the source code of our proprietary software to the public for free. This would allow our competitors and other third parties to create similar products with less development effort and time and ultimately could result in a loss of our product sales and revenue, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, some companies that use third-party open source software have faced claims challenging their use of such open source software and their compliance with the terms of the applicable open source license. We may be subject to suits by third parties claiming ownership of what we believe to be open source software, or claiming <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with the applicable open source licensing terms. Use of open source software may also present additional security risks because the public availability of such software may make it easier for hackers and other third parties to compromise or attempt to compromise our technology and systems. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although we review our use of open source software to avoid subjecting our proprietary software to conditions we do not intend, the terms of many open source software licenses have not been interpreted by United States courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our products and proprietary software. Moreover, our processes for monitoring and controlling our use of open source software in our products may not be effective. If we are held to have breached the terms of an open source software license, we could be subject to damages or be required to seek licenses from third parties to continue offering our products on terms that are not economically feasible, to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-engineer</div> our products, to discontinue the sale of our products if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-engineering</div> could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property rights do not necessarily address all potential threats. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make products that are similar to products and technologies we may develop or utilize similar technology that are not covered by the claims of the patents that we own or license now or in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we, or our licensor(s), might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="break-inside: avoid; font-size: 0px;">
<td style="width: 5%;"></td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; font-size: 0px;"></td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we, or our licensor(s), might not have been the first to file patent applications covering certain of our or their inventions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our owned or licensed intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">issued patents that we own, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license,</div> or otherwise hold rights to may be held invalid or unenforceable or have their scope narrowed, including as a result of legal challenges by our competitors; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not develop additional proprietary technologies that are patentable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may harm our business; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may choose not to file a patent application for certain trade secrets or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and a third party may subsequently file a patent application covering such intellectual property. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should any of these events occur, they could materially adversely affect our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Litigation Risks </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business exposes us to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of medical devices, including those which may arise from the misuse (including system hacking or other unauthorized access by third parties to our systems) or malfunction of, or design flaws in, our hardware and software products. This liability may vary based on the FDA classification associated with our devices and with the state law governing product liability standards applied to specification developers and/or manufacturers in a given negligence or strict liability lawsuit. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury. Claims may be made by patients, healthcare providers or others selling our products. The risk of product liability claims may also increase if our products are subject to a product recall or seizure. Product liability claims may be brought by individuals or by groups seeking to represent a class. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although we have insurance at levels that we believe to be appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, the coverage may not be adequate to protect us against any future product liability claims. Further, if additional medical device products are approved or cleared for marketing, or if we launch additional 510(k)-exempt device products or products that are not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-regulated</div> medical devices, we may seek additional insurance coverage. If we are unable to obtain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may harm our business. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be subject to claims against us even if the apparent injury is due to the actions of others or misuse of the device or a partner device. Healthcare providers may use our products in a manner inconsistent with the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">products&#8217; labeling and that differs from the manner in which they were used in clinical studies and authorized by the FDA. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-label</div> use of products by healthcare providers is common, and any such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use of our products could subject us to additional liability, or require design changes to limit this potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use once discovered. Defending a suit, regardless of merit, could be costly, could divert management attention and might result in adverse publicity, which could result in the withdrawal of, or result in reduced acceptance of, our products in the market. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we have entered into various agreements where we indemnify third parties for certain claims relating to our products. These indemnification obligations may require us to pay significant sums of money for claims that are covered by these indemnification obligations. We are not currently subject to any product liability claims; however, any future product liability claims against us, regardless of their merit, may result in negative publicity about us that could ultimately harm our reputation and could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Securities and to Being a Public Company </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We identified material weaknesses in our internal control over financial reporting. If our remediation measures are ineffective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to report our financial condition or results of operations accurately or in a timely manner and we may be unable to maintain compliance with applicable stock exchange listing requirements, which may adversely affect investor confidence in us and, as a result, materially and adversely affect our business and the value of our Class&#160;A common stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with Legacy Hyperfine&#8217;s and Liminal&#8217;s combined financial statement close process for the years ended December&#160;31, 2020 and 2019, we identified a material weakness in our internal control over financial reporting. We outsourced our accounting and financial reporting to 4Catalyzer and as of and during the years ended December&#160;31, 2020 and 2019, did not have our own finance function to appropriately perform the supervision and review of the information received from 4Catalyzer and assess its reasonableness and accuracy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, HealthCor previously recorded a portion of its Class&#160;A ordinary shares subject to possible redemption in permanent equity. Notwithstanding the presence of maximum redemption thresholds or charter provisions common in SPACs that provide a limitation on redemptions that would cause a SPAC&#8217;s net tangible assets to be less than $5,000,001, in accordance with SEC Staff guidance on redeemable equity instruments, ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div>&#8221;, and EITF Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-98,</div> &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and Measurement of Redeemable Securities</div></div>&#8221;, and, according to the SEC Staff communications with certain independent auditors, redemption provisions not solely within the control of the issuing company require ordinary shares subject to redemption to be classified outside of permanent equity. Although HealthCor did not specify a maximum redemption threshold in its Articles and Restated Memorandum and Articles of Association (the &#8220;HealthCor Articles&#8221;), the HealthCor Articles provided that HealthCor could not redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. In light of the recent SEC Staff communications with certain independent auditors, HealthCor&#8217;s management <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> the effectiveness of its disclosure controls and procedures as of September&#160;30, 2021. Based upon that evaluation, HealthCor concluded that the misclassification of the Class&#160;A ordinary shares was quantitatively material to individual line items within the balance sheet. This resulted in a restatement of the initial carrying value of the Class&#160;A ordinary shares subject to possible redemption, with the offset recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available), accumulated deficit and ordinary shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foregoing represents a material weakness in our internal controls over financial reporting. A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In light of the material weakness identified and the resulting restatement, we plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our management is in the process of developing a remediation plan, which includes, without limitation, the hiring of additional accounting and finance personnel with technical public company accounting and financial reporting experience. The material weaknesses will not be considered remediated until management designs and implements effective controls that operate for a sufficient period of time and management has concluded through testing that these controls are effective. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects or that other material weaknesses and control deficiencies will not be discovered in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our efforts are not successful or other material weaknesses or control deficiencies occur in the future, we may be unable to report our financial results accurately on a timely basis or help prevent fraud, which could cause our reported financial results to be materially misstated and result in the loss of investor confidence or delisting and cause the market price of our shares to decline. We cannot assure you that the initiatives we have taken to date, or any initiatives we may take in the future, will be sufficient to avoid potential future material weaknesses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing rules, our stockholders may not have certain corporate governance protections that are available to stockholders of companies that are not controlled companies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">So long as more than 50% of the voting power for the election of our directors is held by an individual, a group or another company, we will qualify as a &#8220;controlled company&#8221; under the Nasdaq listing rules. As of February&#160;15, 2022, Dr.&#160;Rothberg controls approximately 84.8% of the voting power of our outstanding capital stock. As a result, we are a &#8220;controlled company&#8221; under the Nasdaq rules and are not subject to the requirements that would otherwise require us to have: (i)&#160;a majority of our board of directors consist of independent directors; (ii)&#160;director nominees selected, or recommended for our board of directors&#8217; selection, either by a majority of the independent directors or a nominating committee comprised solely of independent directors; and (iii)&#160;a compensation committee comprised solely of independent directors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Rothberg may have his interest in the Company diluted due to future equity issuances or his own actions in selling shares of our Class&#160;B common stock, in each case, which could result in a loss of the &#8220;controlled company&#8221; exemption under the Nasdaq listing rules. We would then be required to comply with those provisions of the Nasdaq listing rules. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The dual class structure of our common stock has the effect of concentrating voting power with Jonathan M.&#160;Rothberg, Ph.D., Vice Chairman of our board of directors and the Founder of Legacy Hyperfine and Liminal, which will limit an investor&#8217;s ability to influence the outcome of important transactions, including a change in control. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares of our Class&#160;B common stock have 20 votes per share, while shares of our Class&#160;A common stock have one vote per share. Dr.&#160;Rothberg holds all of the issued and outstanding shares of our Class&#160;B common stock, and as of February&#160;15, 2022, Dr.&#160;Rothberg holds approximately 84.8% of the voting power of our capital stock and is able to control matters submitted to our stockholders for approval, including the election of directors, amendments of our organizational documents and any merger, consolidation, sale of all or substantially all of our assets or other major corporate transactions. Dr.&#160;Rothberg may have interests that differ from yours and may vote in a way with which you disagree and which may be adverse to your interests. This concentrated control may have the effect of delaying, preventing or deterring a change in control of the Company, could deprive our stockholders of an opportunity to receive a premium for their capital stock as part of a sale of the Company, and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">might ultimately affect the market price of shares of our Class&#160;A common stock. If additional shares of our Class&#160;B common stock are issued, your shares and your votes may be significantly diluted. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential conflicts of interest may arise among the holders of our Class&#160;B common stock and the holders of our Class&#160;A common stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Rothberg holds all of our Class&#160;B common stock following the Business Combination. As a result, conflicts of interest may arise among Dr.&#160;Rothberg, on the one hand, and the Company and holders of our Class&#160;A common stock on the other hand. Dr.&#160;Rothberg has the ability to influence our business and affairs through his ownership of the high vote shares of our common stock, his general ability to elect our board of directors, and provisions in the Charter requiring his approval for certain corporate actions (in addition to approval by our board of directors). If the holders of our Class&#160;A common stock are dissatisfied with the performance of our board of directors, they have no ability to remove any of our directors, with or without cause. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, through his ability to elect our board of directors and as well as his service on our board of directors, Dr.&#160;Rothberg has the ability to influence the determination of the amount and timing of our investments and dispositions, cash expenditures, indebtedness, issuances of shares of common stock, tax liabilities and amounts of reserves. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Delaware law and provisions in our Charter and bylaws could make a takeover proposal more difficult. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our organizational documents are governed by Delaware law. Certain provisions of Delaware law and of our Charter and bylaws could discourage, delay, defer or prevent a merger, tender offer, proxy contest or other change of control transaction that a stockholder might consider in its best interest, including those attempts that might result in a premium over the market price for the shares of our Class&#160;A common stock held by our stockholders. These provisions provide for, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of our board of directors to issue one or more series of preferred stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stockholder action by written consent only until the first time when Dr.&#160;Rothberg and his permitted transferees cease to beneficially own shares of Class&#160;B common stock representing 50% or more of the voting power of the outstanding shares of our capital stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain limitations on convening special stockholder meetings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at our annual meetings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">amendment of certain provisions of the organizational documents only by the affirmative vote of holders of (i)&#160;a majority of the voting power of the shares of our capital stock so long as Dr.&#160;Rothberg and his permitted transferees beneficially own shares of Class&#160;B common stock representing 50% or more of the voting power of the outstanding shares of our capital stock and (ii)&#160;at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the voting power of the shares of capital stock from and after the time that Dr.&#160;Rothberg and his permitted transferees cease to beneficially own shares of Class&#160;B common stock representing 50% or more of the voting power of our voting stock; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a dual-class common stock structure with 20 votes per share of our Class&#160;B common stock, the result of which is that Dr.&#160;Rothberg has the ability to control the outcome of matters requiring stockholder approval, even though Dr.&#160;Rothberg owns less than a majority of the outstanding shares of our capital stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These anti-takeover provisions as well as certain provisions of Delaware law could make it more difficult for a third party to acquire the Company, even if the third party&#8217;s offer may be considered beneficial by many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares. If prospective takeovers are not consummated for any reason, we may experience negative reactions from </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the financial markets, including negative impacts on the price of our Class&#160;A common stock. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and to cause us to take other corporate actions that our stockholders desire. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Description of our Capital Stock</div></div>.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our Charter designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings and the federal district courts as the sole and exclusive forum for other types of actions and proceedings, in each case, that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain what such stockholders believe to be a favorable judicial forum for disputes with the Company or our directors, officers or other employees. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Charter provides that, unless we consent to the selection of an alternative forum, any (i)&#160;derivative action or proceeding brought on behalf of us; (ii)&#160;action asserting a claim of breach of a fiduciary duty owed by, or any other wrongdoing by, any current or former director, officer, other employee or stockholder of us; (iii)&#160;action asserting a claim against us arising pursuant to any provision of the DGCL or our Charter or our bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery; (iv)&#160;action to interpret, apply, enforce, or determine the validity of any provisions in the certificate of incorporation of bylaws; or (v)&#160;action asserting a claim governed by the internal affairs doctrine, shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject matter jurisdiction thereof, the federal district court of the State of Delaware. Subject to the foregoing, the federal district courts of the United States are the exclusive forum for the resolution of any action, suit or proceeding asserting a cause of action under the Securities Act. The exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act. Any person or entity purchasing or otherwise acquiring or holding an interest in any shares of our capital stock shall be deemed to have notice of and to have consented to the forum provisions in our Charter. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">choice-of-forum</div></div> provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that he, she or it believes to be favorable for disputes with the Company or our directors, officers or other employees or stockholders, which may discourage such lawsuits. We note that there is uncertainty as to whether a court would enforce these provisions and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alternatively, if a court were to find these provisions of our Charter inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Charter does not limit the ability of the Sponsor to compete with the Company. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor&#8217;s sponsor, HC Sponsor LLC (the &#8220;Sponsor&#8221;) and its affiliates engage in a broad spectrum of activities, including investments in the life sciences and medical technology industries. In the ordinary course of their business activities, the Sponsor and its affiliates may engage in activities where their interests conflict with our interests or those of our stockholders. The Charter does not provide that the Sponsor and its affiliates have any duty to refrain from engaging, directly or indirectly, in the same business activities or similar business activities or lines of business in which we operate. The Sponsor and its affiliates also may pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to the Company. In addition, the Sponsor may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve risks to you. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and we may take or continue to take advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, which could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the JOBS Act, and we may take or continue to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our Class&#160;A common stock held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> is $700&#160;million or more as of the last business day of the most recently completed second fiscal quarter, in which case we would no longer be an emerging growth company as of the end of that fiscal year. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is not an emerging growth company or is an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We are required to reflect a determination that we are no longer a smaller reporting company in our quarterly report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> for the first fiscal quarter of the next fiscal year after the fiscal year in which (i)&#160;the market value of our common stock held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> is greater than or equal to $250&#160;million as of the end of that fiscal year&#8217;s second fiscal quarter, and (ii)&#160;if our annual revenues are not greater than or equal to $100&#160;million during the last completed fiscal year, the market value of our common stock held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> is $700&#160;million or more as of the end of that fiscal year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our Class&#160;A common stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities research analysts may establish and publish their own periodic projections for us. Those projections may vary widely and may not accurately predict the results we actually achieve. Our share price may </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decline if our actual results do not match the projections of these securities research analysts. Similarly, if one or more of the analysts who write reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business, our share price could decline. In addition, securities research analysts may compare us to companies that are not appropriately comparable, which could lead to lower than expected valuations. If one or more analysts cease coverage of us or fail to publish reports on us regularly, our share price or trading volume could decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business and operations could be negatively affected if we become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of our business and growth strategy and impact our stock price. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Shareholder activism, which could take many forms or arise in a variety of situations, has been increasing recently. Volatility in the stock price of our Class&#160;A common stock or other reasons may in the future cause us to become the target of securities litigation or shareholder activism. Securities litigation and shareholder activism, including potential proxy contests, could result in substantial costs and divert management&#8217;s and the board of directors&#8217; attention and resources from our business. Additionally, such securities litigation and shareholder activism could give rise to perceived uncertainties as to our future, adversely affect our relationships with service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to incur significant legal fees and other expenses related to any securities litigation and activist shareholder matters. Further, our stock price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities litigation and shareholder activism. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The grant of registration rights pursuant to the Registration Rights Agreement, the PIPE Subscription Agreements and the Letter Agreement, and the future exercise of such rights, may adversely affect the market price of our Class&#160;A common stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Closing, we, the Sponsor, certain affiliates of the Sponsor and certain stockholders of Legacy Hyperfine and Liminal entered into the Registration Rights Agreement, pursuant to which, among other things, the parties to the Registration Rights Agreement agreed not to effect any sale or distribution of any our equity securities held by any of them (except with respect to shares of our Class&#160;A common stock acquired in open market transactions or pursuant to the PIPE Investment) during the respective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period described therein and were granted certain registration rights with respect to their respective shares of our common stock, in each case, on the terms and subject to the conditions therein. The parties to the Registration Rights Agreement and their permitted transferees have customary registration rights (including demand and piggy-back rights, subject to cooperation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-back</div> provisions). In particular, the Registration Rights Agreement provides that promptly, but in any event within forty-five (45)&#160;days following the Closing Date, we are required to use our commercially reasonable efforts to file a registration statement under the Securities Act to permit the public resale of all registrable securities as permitted by Rule 415 of the Securities Act and to cause such registration statement to be declared effective as soon as practicable after the filing thereof, but in no event later than forty-five (45)&#160;days following the filing deadline (or sixty (60)&#160;days following the filing deadline if the registration statement is reviewed by and receives comments from the Securities and Exchange Commission (the &#8220;SEC&#8221;)). The registration statement was filed on January&#160;24, 2022 and declared effective by the SEC on February&#160;1, 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, pursuant to the Subscription Agreements and the Letter Agreement, we agreed (i)&#160;to file within 45&#160;days after the closing of the Business Combination a registration statement with the SEC for the resale of the PIPE Securities by the PIPE Investors and the Letter Agreement Shares by Jefferies LLC, (ii)&#160;to use commercially reasonable efforts to cause such registration statement to be declared effective as soon as practicable after the filing thereof, but no later than the earlier of (a)&#160;the 45th calendar day (or 60th calendar day if the SEC notifies us that it will &#8220;review&#8221; the registration statement) and (b)&#160;the 10th business day after the date we are notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;reviewed&#8221; or will not be subject to further review and (iii)&#160;to maintain the effectiveness of such registration statement until the earlier of (a)&#160;five years from the date of effectiveness of the initial registration statement, (b)&#160;the date on which PIPE Investors cease to hold the securities covered thereby, and (c)&#160;the date all of the securities covered thereby can be sold publicly without restriction or limitation under Rule 144 under the Securities Act. We will bear the cost of registering these securities. The registration statement was filed on January&#160;24, 2022 and declared effective by the SEC on February&#160;1, 2022. The registration and availability of such a significant number of securities for trading in the public market may have an adverse effect on the market price of our Class&#160;A common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The obligations associated with being a public company will involve significant expenses and will require significant resources and management attention, which may divert from our business operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. The Exchange Act requires the filing of annual, quarterly and current reports with respect to a public company&#8217;s business and financial condition. The Sarbanes-Oxley Act requires, among other things, that a public company establish and maintain effective internal control over financial reporting. As a result, we are incurring, and will continue to incur significant legal, accounting and other expenses that Legacy Hyperfine and Liminal did not previously incur. Our management team and many of our other employees will need to devote substantial time to compliance, and may not effectively or efficiently manage our transition into a public company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not intend to pay cash dividends for the foreseeable future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, and future agreements and financing instruments, business prospects and such other factors as our board of directors deems relevant. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USE OF PROCEEDS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the Class&#160;A common stock and Class&#160;B common stock offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. We will not receive any of the proceeds from these sales. </div></div> <div id="toc284543_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DETERMINATION OF OFFERING PRICE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot currently determine the price or prices at which shares of Class&#160;A common stock or shares of Class&#160;B common stock may be sold by the Selling Securityholders under this prospectus. </div></div> <div id="toc284543_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Price and Ticker Symbol </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Class&#160;A common stock is currently listed on Nasdaq under the symbol &#8220;HYPR&#8221;. The closing price of the Class&#160;A common stock on March&#160;25, 2022 was $3.29. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;15, 2022, there were approximately 199 holders of record of our Class&#160;A common stock and approximately two holders of record of our Class&#160;B common stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Such numbers do not include beneficial owners holding our securities through nominee names. There is no public market for our Class&#160;B common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not paid any cash dividends on our Class&#160;A common stock or Class&#160;B common stock to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of our board of directors at such time. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS OF HYPERFINE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion reflects the business of Hyperfine and its wholly owned subsidiaries. In this section, &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to Hyperfine and its wholly owned subsidiaries, including Legacy Hyperfine and Liminal, as the case may be. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to December&#160;22, 2021, we were a blank check company incorporated as a Cayman Islands exempted company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On December&#160;21, 2021, we changed our jurisdiction of incorporation from the Cayman Islands to the State of Delaware by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation, incorporated under the laws of the State of Delaware. On December&#160;22, 2021, we completed the Business Combination pursuant to the Business Combination Agreement dated July&#160;7, 2021 that we entered into with Legacy Hyperfine and Liminal. Upon the completion of the Business Combination, we changed our name to &#8220;Hyperfine, Inc.&#8221; and the business of Legacy Hyperfine and Liminal became our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are an innovative digital health business with a mission to provide affordable and accessible imaging and monitoring and through magnetic resonance imaging (&#8220;MRI&#8221;) to revolutionize healthcare for people around the world. Our Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Portable Magnetic Resonance (&#8220;MR&#8221;) Imaging System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM</div> (&#8220;Swoop scanner&#8221;) produces high-quality images at a lower magnetic field strength than conventional MRI systems, and can be used by healthcare professionals to make effective clinical diagnoses on a patient in a variety of settings where MRI devices have previously been inaccessible. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> interface and portable design of our Swoop scanner make it accessible for use anywhere in a hospital, clinic or patient care site. We are working to realize our vision of providing affordable and accessible imaging of health conditions around the world. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">MRI is a medical imaging technique used in radiology to image the anatomy and the physiological processes of the human body. It is typically used in a variety of clinical settings for medical diagnosis, staging of disease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> treatment. Unlike <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-ray</div> computed tomography (&#8220;CT&#8221;) or positron emission tomography (&#8220;PET&#8221;), MRI does not expose patients to harmful ionizing radiation. We believe MRI offers the most sensitive and objective measures of brain tissue and injury. Despite its advantages, many healthcare institutions throughout the world lack the facilities, qualified operators and capital necessary to acquire and maintain expensive MRI devices. For healthcare institutions that do have conventional MRI systems, disadvantages of conventional MRI systems include their high cost, facility requirements for a specialized MRI suite, and the scheduling delays, personnel resources and risk of adverse events that result from the need to transport critically ill patients to the MRI suite. The Swoop scanner is intended for use at the patient&#8217;s bedside in any hospital room or clinical setting, such as a physician&#8217;s office or a local urgent care facility. The demand for MRI has been augmented by the aging population and rising prevalence of cancer and cardiovascular, neurologic and orthopedic conditions. Healthcare professionals and insurers are recognizing imaging as a cost-effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> diagnostic tool for evaluation and ongoing monitoring. Swoop is a next generation of these devices designed to drive costs down and expand the current $15.9&#160;billion imaging market. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the adoption of the Swoop scanner by healthcare professionals has benefits across healthcare communities both in the high and low resource settings. Through our collaborations with the healthcare community, we have begun to optimize our software ecosystem to harness Artificial Intelligence (&#8220;AI&#8221;) to transform the system into a true bedside clinical decision support platform. These efforts seek to improve image quality, help users analyze images, and reduce time to diagnosis. Our technology allows us to provide decision support and rapid feedback for diagnostic insight for clinicians of various levels of expertise. In the future, we hope to develop an ecosystem of products, expanding the capabilities of our core MRI product platform while introducing a brain sensing platform, subject to regulatory authorization, to offer a more complete solution and increase access to lifesaving technology across the care continuum. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine received 510(k) clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in 2020 for its Swoop Portable MR Imaging System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical, in order to provide imaging information to trained physicians that may be useful in determining a diagnosis. The system is commercially available in the United&#160;States. In 2021, we also obtained a Medical Device License issued by Health Canada and expanded into the Canadian market. In addition, we are seeking necessary regulatory authorizations in other major markets, including the United Kingdom, Australia and other countries. We recently received regulatory authorization in New Zealand and Pakistan. We are building our direct commercial infrastructure in the United States and also have plans to sell our products in other countries either through direct sales or through distributors. Furthermore, we possess a portfolio of 141 issued patents worldwide as well as 293 patents pending as of February&#160;15, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Legacy Hyperfine and Liminal were founded in 2014 and 2018, respectively, by Dr.&#160;Jonathan Rothberg, a serial entrepreneur who received the Presidential Medal of Technology&#160;&amp; Innovation in 2016 for inventing a novel next generation DNA sequencing method and has founded more than 10 healthcare and technology companies, including 454 Life Sciences, Ion Torrent, CuraGen, Butterfly Network and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si.</div> Legacy Hyperfine has raised over $160&#160;million in equity investments and partnership milestones from leading institutional investors, including GV (formerly Google Ventures), and grants, including the Bill&#160;&amp; Melinda Gates Foundation (the &#8220;BMGF&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Liminal was founded as a wholly-owned subsidiary of 4Bionics LLC (&#8220;4Bionics&#8221;). 4Bionics was an early startup incubator founded in 2018 and controlled by the Rothberg family, and was designed for the funding and development needs of seed stage companies. When Liminal was founded, Legacy Hyperfine was focused on developing its own products. As Liminal was developing its platform for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> monitoring and sensing of key brain health vitals, Legacy Hyperfine was beginning to commercialize the Swoop scanner and expanded its vision to include intervention and sensing to cover the care continuum. We believe that the synergies between Legacy Hyperfine&#8217;s MRI platform and Liminal&#8217;s brain sensing technology provide Hyperfine with the potential to connect the care continuum from MRI imaging to sensing, and could ultimately provide patients with affordable care and healthcare practitioners with a single source access to brain scanning and monitoring. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Competitive Strengths </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that our competitive strengths include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">There is a large and growing MRI market and we have the potential to augment conventional MRI capacity and benefit patients around the world.</div></div> We believe our solution addresses a vast unmet need across the global market by expanding accessibility to MRI and augmenting the existing capacity of conventional high-field MRI systems as imaging rates continue to increase across the population and the need for efficient utilization of MRI scanners increases. Our solution is designed to complement conventional MRI scanners currently used in the market, as it seamlessly integrates into relevant hospital systems. Our system was designed to allow users to upload images directly onto hospital systems, such as the picture archiving and communication system (&#8220;PACS&#8221;) or directly onto our cloud PACS, which then makes images available for diagnostic purposes. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the Swoop scanner can expand the existing $15.9&#160;billion global imaging market (expected to grow at a 5.2% CAGR from 2021 to 2028) by making MRI available to a larger set of patients in both developed and emerging markets, as well as increase the utilization of conventional MRIs through decreased wait times and facilitation of patient flow. Our primary focus is to expand the availability of MRI globally and across the care continuum, particularly to patients who are in intensive care units and in the emergency department, where timeliness is critical and an MRI scan can be essential for diagnosis and urgent intervention. The Swoop scanner can be wheeled directly to a patient&#8217;s bedside and offers a prompt solution for those patients who require an MRI scan but are too critically ill to be transported for a conventional MRI scan, and who may otherwise be forced to forego a scan or wait until their condition stabilizes. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">We have also initiated a global research program supported by grant funding from the BMGF to assess the clinical feasibility of our Swoop scanner in providing immediate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> brain imaging to infants between the ages of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0-24</div> months in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-medium</div> income countries. We were awarded a $1.6&#160;million grant from the BMGF for the provision and equipping of 20 sites with our portable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system to enable the performance of a multi-site study focused on optimizing diagnostic image quality (the &#8220;Project&#8221;). During the third quarter of 2021, we were awarded an additional $3.3&#160;million grant, of which $2.5&#160;million was received from the BMGF in September 2021,with the remainder expected to be received by April 2022. Both of these grants are designed to support the deployment of a total of 25 Swoop devices and other services to investigators, which commenced in the spring of 2021, and is expected to fund the program for approximately two years. The ongoing investigation is designed to provide data to validate the use of our Swoop system in measuring the impact of maternal anemia, malnutrition, infection and birth related injury. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Swoop scanner is designed to create value for stakeholders across the care continuum: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g284543g23s23.jpg" style="width: 571px; height: 205px;"/><br/></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our innovative technology has the potential to markedly improve quality of care for patients worldwide.</div></div> We believe our smaller, portable, low cost yet effective MRI scanner can broaden access to quality care, leading to improved health outcomes. In many cases, other imaging modalities, such as computerized tomography (&#8220;CT&#8221;) scanners, are used due to lack of availability of MRI scanners or their lower cost profile, even though CT provides lower soft tissue contrast for evaluating abnormalities in the brain. Our point of care Swoop scanner, however, has a significantly lower price point than both conventional MRI and CT scanners, making the Swoop scanner affordable for hospitals and care centers that are not financially able to acquire a conventional MRI or CT scanner. Compared to CT scans, MRI has a greater range of soft tissue contrast, depicts anatomy in greater detail and is more sensitive and specific for abnormalities within the brain itself. Our Swoop scanner is designed primarily for urgent cases, and it can benefit <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> cases as well. Among the neurological conditions for which the Swoop scanner can provide first-line diagnostic capability, we expect the Swoop scanner&#8217;s top three clinical use cases will continue to be: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI in acute mental change assessment and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> in an ICU setting; stroke workflow; and pediatric and adult <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> assessment of hydrocephalus, an abnormal buildup of fluid within the brain. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">Our solution has the potential to improve the diagnosis and lives of the approximately 15&#160;million annual new stroke sufferers worldwide. The Swoop scanner does not emit ionizing radiation and therefore does not have the increased risk of cancer that comes with CT imaging. This is particularly important for conditions that require regular <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> with multiple scans per year, such as hydrocephalus. In certain circumstances, such as in the management of patients with delirium or altered mental status, familiarity, or keeping the surrounding environment as similar as possible, can be critical, which we believe makes bedside scanners like our Swoop scanner particularly useful since patients do not need to be moved to often distant radiology suites for conventional MRI scans. Studies </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">show that 37% of patients report anxiety-related reactions when moved to an isolated room for imaging. With our system, we can offer a quieter, calmer experience with the option of a family member or other caregiver to be present by the patient&#8217;s bedside during the scanning process. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our point of care scanner also helps avoid the risk of patient injury during transport through the ability to bring the scanner to the patient. By performing scans for urgent and critically ill patients at the bedside, we can help prevent the adverse incidents that occur to approximately 33% of critically ill patient cases during transport. The Swoop scanner also obviates the labor-intensive and high-risk process of transporting patients on ventilators or who are connected to other life-sustaining devices. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our proprietary, disruptive and revolutionary product is designed with healthcare professionals in mind.</div></div> We have commercially launched our Swoop scanner, a point of care MRI device capable of producing diagnostic quality images at a lower magnetic field strength than conventional MRI scanners. The use of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ultra-low</div> magnetic field strength provides a significant reduction in safety concerns regarding projectiles and therefore should reduce the length of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-safety</div> checks typically conducted by healthcare professionals. We designed our product with the physician workflow in mind, reducing the on average 25.8 hour conventional MRI process to a total of 90 minutes of workflow time with our Swoop scanner. With a 94% reduction in total workflow time, physicians can reduce the time to diagnoses for timely treatment, which can result in improved health outcomes for the patient. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For healthcare professionals who are already facing demanding time constraints, dealing with lengthy and sometimes confusing MRI protocols adds to their time spent on logistics rather than caring for patients. Additionally, conventional MRIs require specially trained technicians who are fully dedicated to operate those systems and increase the time and cost related to nurses and porters transporting patients to the MRI unit. Our Swoop scanner is designed to simplify the image acquisition process. We have designed our scanner to be user-friendly and require minimal training to be operated. Our platform can be controlled by a tablet, smartphone or any other WiFi capable device. The Swoop scanner&#8217;s portability and accessibility at the bedside can further allow more time for healthcare professionals to focus on other important activities related to patient care, diagnosis and treatment. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">state-of-the-art</div></div></div> product provides an attractive return on investment for various care settings.</div></div> We created the Swoop scanner not to replace conventional MRI devices but rather to supplement their existing capacity. By enabling imaging at the bedside, patients can be treated earlier and discharged sooner, potentially leading to increased hospital savings consistent with the growing shift to value-based care. In addition, by conducting more <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-patient</div> MRI scans at the bedside, our Swoop scanner can help free up capacity in the MRI suite for additional outpatient procedures, which generate higher revenues for hospitals or other healthcare facilities than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-patient</div> imaging. In studies we have conducted in hospital settings, use of our Swoop scanner has helped to make capacity available that has resulted in 20% increased usage of the existing MRI suite for additional outpatient procedures. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">As healthcare costs continue to rise, we believe our Swoop scanner will allow for significant potential cost reductions that can benefit the entire imaging ecosystem. Our Swoop scanner has dramatically reduced hardware costs through design <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trade-off</div> and compensation with the use of modern computational power and deep learning advances. The cost benefits of our Swoop scanner are not limited to a customer&#8217;s initial purchase of the scanner, as our customers continue to benefit by not having to spend on additional cooling, power and maintenance expenses throughout the lifetime of conventional MRI. Unlike conventional MRI systems, use of the Swoop scanner also does not require a specialized radio frequency (RF) room to safely house the MRI scanner, allowing space to be used for other important patient care activities. The use of the Swoop scanner in the ICU can also increase utilization by allowing critically ill patients to receive immediate access to an MRI instead of increasing congestion in the schedule of the conventional MRI systems due to complications in the patients&#8217; condition and unexpected changes in their condition or treatment. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Our validated platform and business model allows for potential widespread adoption.</div></div> Over 41 conference presentations and publications have discussed the clinical benefits for point of care, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> MRI for patients with stroke, hydrocephalus, hematoma, multiple sclerosis and tumor resection. We generate sales revenue by selling the Swoop scanner with subscription services including cloud based tools, repairs and maintenance, and, if and when available, upgrades. We also offer the opportunity to bundle the system within the subscription fees. We believe this makes a convenient and positive experience for our customers. As more healthcare professionals adopt our technology, we anticipate improvements in gross margin due to the recurring subscription base of the business. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">We have a strong executive leadership team and experienced financial partner with deep expertise in Healthcare.</div></div> The Founder of Legacy Hyperfine and Liminal, Dr.&#160;Jonathan Rothberg, has dedicated his career to enabling breakthrough technologies to revolutionize healthcare. He has founded more than 10 healthcare and technology companies and has received numerous awards, including the Presidential Medal of Technology&#160;&amp; Innovation in 2016. He is supported by a world-class management team, including our executive officers and other senior management, with decades of cumulative experience in healthcare and consumer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-markets.</div> We believe this leadership team positions us well to be a disruptive force in revolutionizing MRI. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our strategies include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Engage the medical imaging market through strategic partnerships for accelerated international expansion.</div></div> In line with our vision to democratize healthcare imaging by providing affordable and accessible imaging of health conditions around the world, we are building an international sales strategy that includes direct sales to customers and through distribution partners in target regions. Through our multi-factor market analysis of countries and regions, we analyze the market based on available MRIs per population base and plan to deploy a sales and distribution approach designed to maximize our potential for commercial success. In preparation for our commercial launch in a particular country or region, we plan to build out the foundations necessary for business and regulatory functions to support our commercialization strategy. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our plans for international commercial expansion, the countries in which we plan initially to commercialize our Swoop scanner include the United Kingdom, Australia, New Zealand and Pakistan. Through grant funding from the BMGF, we are deploying Swoop scanners in these target areas for research and clinical settings. The utilization of our Swoop scanners as part of the programs will allow us to begin building relationship across key stakeholders in these countries or regions to better understand and meet required regulatory hurdles in anticipation of filing for regulatory authorization and ultimately expand into clinical use with patients. In addition, we are considering commercial expansion into several of the larger European Union (&#8220;EU&#8221;) countries following our initial international commercial expansion. We believe these countries have the market size, regulatory environment, commercial access, and mature healthcare systems necessary, subject to regulatory authorization, for a successful launch of our Swoop scanner. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">Our commitment to the vision of providing affordable and accessible imaging that enables earlier detection and remote management of health conditions around the world is in part made possible by grant funding from the BMGF. Through our engagement with nonprofit organizations, we aim to deploy the Swoop scanner to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-middle</div> resource settings without readily-accessible MRI technology. The grants provided by the BMGF are designed to support the deployment of 25 Swoop scanners to investigators, which commenced in the spring of 2021, and are expected to fund the program for two years. The ongoing investigation is designed to provide data to validate the potential use of our Swoop scanner in measuring the impact of maternal anemia, malnutrition, infection and birth related injury. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expand clinical validation data and publications.</div></div> There are over 41 conference presentations and publications discussing the clinical benefits of our Swoop scanner. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Journal of American Medical</div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Association</div></div> (JAMA) published a detailed study conducted at the Yale New Haven Hospital on how the Swoop scanner successfully detected abnormal neuroimaging findings at the bedside of patients in the ICU, demonstrating the capability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field,</div> point of care MRI to obtain neuroimaging at the bedside in intensive care settings. We also recently partnered with Penn Medicine in an ongoing study to examine the efficacy of the Swoop scanner in the care of patients with hydrocephalus and whether the Swoop scanner provides for a simple, safe and cost effective way to follow patients through their treatment. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Swoop scanner has been used for diagnoses across various neurological pathologies, and we believe that the Swoop scanner could ultimately enable a new paradigm in the standard of care for these diseases that could be lifesaving. We believe early diagnosis of these diseases has cost saving benefits for multiple stakeholders including patients, providers and payors, as it can lead to earlier intervention of treatment and fewer patient visits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Examples of use cases for our Swoop scanner include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acute changes in mental status, which in an ICU setting refers to the sudden onset of a change in cognitive function or level of consciousness. The incidence rate for acute changes in mental status in ICU patients is high, with a substantial portion developing into a coma. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Large vessel occlusion (&#8220;LVO&#8221;) stroke, which includes acute blockages of the intracranial internal carotid artery (&#8220;ICA&#8221;), proximal posterior, middle, anterior cerebral arteries, intracranial vertebral artery and basilar artery, leading to stroke. LVO stroke is responsible for between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-46%</div> of acute ischemic strokes (&#8220;AIS&#8221;) and leads to a 4.5 times increase in the risk of death from a future stroke. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Postoperative hematoma, which is the collection of blood due to an injury of one or more blood vessels and is a potentially severe complication of cranial surgery. It has an overall mortality rate of 32% after neurosurgical operation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hydrocephalus, which is the buildup of cerebrospinal fluid (&#8220;CSF&#8221;) in cerebral ventricles, which leads to an increase in size and subsequent intracranial pressure. It occurs in two of every 1,000 births in the United States or may develop in adults over time as a result of injury or disease with an incidence rate of 17 per 100,000 adult patients in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Focus on our customers through success programs.</div></div> Our Swoop scanner is designed to make the customer experience as easy as possible through our integrated, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> interface that portrays images on a tablet device. In addition to this design, our team is focused on customer success programs to help integrate the Swoop scanner into any hospital or clinic workflow. We believe that the use of our Swoop scanner within hospitals will provide us with opportunities to cross sell our product and services across departments and reduce customer acquisition costs as customers become more accustomed to the use of our Swoop scanner across their facilities and observe the improved health outcomes and reduced costs that the use of our Swoop scanner may provide. We expect our customer success programs also to increase our customer referral rates across the medical imaging market as our product continues to become validated and supported by healthcare professionals in the field. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">Our customer success program is designed to ensure that our customers achieve their desired outcomes while using our Swoop scanner. Our team seeks to foster long-term relationships, highlight key product benefits and manage expectations with our customers. The program is designed to guide customers to achieve maximum utilization of the product and enhance their experience through ongoing educational tools and opportunities. Our customer success team aims to ensure a smooth path to obtain customer loyalty and continue to grow our install base with subscription renewals, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> sales, and new Swoop scanner placements. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Demonstrate our commitment to continued technical innovation and leadership across the care continuum.</div></div> Our advanced technology in imaging is supported by an internal team of scientists and engineers dedicated to continuous innovation. We believe that as the Swoop scanner becomes </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">integrated into ICUs and sites across medical practices, we will gain more insights into our product&#8217;s usability and potentially develop automated analysis of images that we believe will lead to further efficiencies in patient diagnosis. We plan to continue developing our technology to expand into new imaging applications to enable us to reach the broader care continuum through diagnosis and treatment. In the future, we plan to introduce a further enhanced MRI system designed to conduct neuroimaging and imaging of other extremities for interventional procedures. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Brain Sensing Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to our efforts to disrupt the MRI market, we see a significant opportunity to help patients in the neuromonitoring space. Current methods to monitor the brain directly include drilling a hole through the skull to insert sensors. This method introduces risk to the patient and is highly impractical outside of specialized hospitals, which severely limits access to critical information about a patient&#8217;s neurological health. We intend to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> brain sensing technology that is more affordable, accessible, and safer, to enable healthcare professionals to more easily monitor key brain vital signs such as cerebral blood flow and intracranial pressure throughout patient care. We expect this new form of neural monitoring will provide clinicians with valuable feedback and insight into various neurologic conditions such as altered mental status, stroke and traumatic brain injury. We expect this technology will be synergistic with our MRI platform as we connect the care continuum from MRI imaging to sensing. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Industry and Market </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">MRI is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-ionizing</div> radiation risk imaging modality widely used by healthcare professionals across various clinical settings for medical diagnosis of a patient, staging of disease and continued assessment following treatment. MRI is noninvasive, and in some cases, eliminates the need for surgical intervention or invasive procedures when used correctly, and offers superior soft tissue contrast resolution compared to other imaging modalities like CT. It is a more sensitive and potentially objective measure of brain tissue and injury. MRI is used to examine central nervous system (&#8220;CNS&#8221;), musculoskeletal, and other diseases. The prevalence and incidence rates of these diseases has increased across the globe. According to a United Nations report, up to one billion people, nearly one in six of the world&#8217;s population, suffer from neurological disorders, including Alzheimer&#8217;s and Parkinson&#8217;s disease, stroke, multiple sclerosis, epilepsy, migraine, brain injuries and neuroinfections, with some 6.8&#160;million dying of these disorders each year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The demand for MRI has been augmented by the aging population and rising prevalence of cancer, cardiovascular, neurological and orthopedic conditions. Healthcare professionals and insurers are recognizing imaging as a cost-effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> diagnostic for prevention and ongoing monitoring. Swoop is the next generation of these devices that we believe will drive costs down and expand the current $15.9&#160;billion imaging market. Given the significant patient populations in need of diagnostic imaging, we have positioned ourselves in an underpenetrated market with substantial room for growth. In total, we estimate that the global imaging market will increase to a more than $20&#160;billion opportunity across all of our potential use cases. This estimate includes over 100,000 hospitals and outpatient locations that we believe could serve as installation sites for our system. While the current imaging market is mainly limited to high-resource countries, we believe our scanner can help make MRI technology more accessible globally, leading to an increase in both MRI penetration rates and the size of the overall market opportunity. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market needs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite MRI&#8217;s advantages to diagnose and monitor patients through treatment, access to MRI scanners can be problematic. Numerous challenges are associated with the use of conventional MRI devices: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">High cost</div></div>: The average cost of conventional MRI scanners is $1.2&#160;million, and conventional MRIs can cost more than $3&#160;million, significantly more than our Swoop scanner. In addition, conventional MRIs typically are not offered with our lower cost of entry subscription-based pricing model. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Complex site requirements and upgrades</div></div>: Due to the use of strong <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(1.5-3.0</div> T) magnetic fields in conventional MRIs, there are various requirements and restrictions on radiation therapy (&#8220;RT&#8221;) facilities size, location, and ongoing maintenance, including the need to build a specialized radio frequency room to safely house the MRI scanner. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scheduling delays</div></div>: A high level of coordination is required between the MRI facility and the ICU to have patients scheduled for a conventional MRI scan. This is further complicated with patients who are unstable in the ICU and require multiple medical procedures in a timely manner. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consumption of valuable personnel resources</div></div>: Several personnel between departments within an institution are required to transport a patient across departments and additional personnel are required for transport a patient across facilities, including doctors, technicians, nurses, and emergency medical technicians. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk of adverse events during transportation</div></div>: Adverse incidents occur to approximately 33% of critically ill patient cases during transport. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maintaining connection to life support equipment</div></div>: Patients in the ICU are often connected to life-sustaining devices that complicate the conventional MRI procedure and transportation to and from the conventional MRI scanner. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to these challenges, adoption of conventional MRIs has been limited across medical settings in the United States and globally, especially in rural locations where many individuals only have access to small clinics. MRI systems also include additional charges of establishing an MRI suite, patient support areas, machine installation and servicing, software upgrading, and maintenance that burden hospitals and clinics with limited ongoing funding. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There are significant benefits of diagnosing a disease in its early stages, which can reduce time to treatment and improve the quality of life for those patients. We have taken advantage of technological advances in electronics and computing to develop an MRI device that is not only portable, but also uses a very low magnetic field strength, 64 mT (0.064T), which is much lower than the 1.5T or higher field strength of conventional MRI scanners. Our advanced technology provides the ability for healthcare professionals to conduct an MRI scan at the patient&#8217;s bedside in the hospital or any clinical setting to begin early diagnosis, intervention and ongoing treatment. Many small- and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">medium-sized</div> hospitals also consider leasing advanced MRI systems to provide MRI imaging services without undertaking the potentially more costly long-term commitment of purchasing an MRI system. Our Swoop scanner is available for purchase or subscription bundle by medical facilities in the United States with flexible payment options. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">According to a 2008 report from the World Health Organization, 90% of the world does not have access to MRI at all largely due to socio-economic factors. Many <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-resource</div> countries recognize the benefit of investing in their healthcare infrastructure and it is expected to cause a spur in growth for the global MRI market. For example, China is one of the fastest growing markets that is building their healthcare infrastructure in rural areas. The ability for these countries to build the facilities needed to house these large systems and train highly specialized personnel to operate conventional MRI systems presents a challenge. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential market expansion </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Brain Sensing Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">One area for potential market expansion is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> neural monitoring or sensing to assess critical brain health metrics such as cerebral blood flow and intracranial pressure in any clinical, outpatient or home setting. Understanding the vital signs of the brain is paramount in the diagnosis and management of brain disorders yet current care has limited access to important measurements of brain health. Post-operative and general neurological conditions such as stroke, traumatic brain injury, hydrocephalus, removal of brain and spinal tumors, neural tube </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">defects, seizures, CNS vascular anomalies and CNS infections, require extensive monitoring in the ICU and longer-term care to ensure the patient does not experience infection or worsening of their condition. Our technology currently in development has the potential to provide hospitals with real-time monitoring and continuous trend analysis to provide data-backed treatment. To accomplish this, we are building a flexible and extendable noninvasive brain-monitoring platform, creating access to critical brain vital signs throughout the patient care from diagnosis to full recovery. Our approach is to create the neurological equivalent of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stick-on</div> electrocardiogram heart monitor that is a staple in virtually every medical environment. There is a large unmet need in the market for continuous monitoring of chronic neurological conditions. According to market research, the market for global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> brain trauma monitoring devices is expected to grow from approximately $10.1&#160;billion in 2019 to $18.3&#160;billion by 2027, at a CAGR of 7.7%. In addition, we have the potential to ultimately expand our capability to diagnose and manage chronic conditions beyond acute neurological conditions. Our next generation device is expected to contain electroencephalography alongside hemodynamic assessment capabilities to improve quality of care for chronic conditions such as epilepsy, which affects around 50&#160;million people of all ages worldwide. We are currently in product development of our brain sensing technology and hardware platform. We are working toward a clinical proof of concept to demonstrate the technological performance and have begun the process of engaging with the FDA to clarify the regulatory pathway. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products and Services </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Swoop Portable MR Imaging System </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Swoop Portable MR Imaging System is designed to address an unmet need in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> medical imaging through a unique combination of hardware and software services. Our hardware is powered by the use of modern computational power and deep learning advances. Our software addresses the traditional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ease-of-use</div></div> and integration challenges often presented by specialized medical technologies. Our system operates from a tablet, smartphone or other WiFi capable device and integrates with picture archiving and communication system (&#8220;PACS&#8221;) to enable fast and confident clinical decision-making. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g284543g26s26.jpg" style="width: 386px; height: 179px;"/><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Features </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Point-of-care</div></div> neuroimaging&#160;-&#160;FDA cleared for MRI of the brain and head in patients of all ages </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neuroimaging at the point of care has only been possible using CT, which delivers a significant amount of ionizing radiation. Exposing patients to radiation increases the risk of developing cancer, which limits CT&#8217;s use to critically ill patients and makes it particularly hazardous for pediatric patients. CT can visualize bones or blood vessels well when the patient is injected with a contrast agent but is not as sensitive as MRI at imaging the anatomy of the brain. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The gold standard for neuroimaging is MRI, which can provide excellent high-resolution images of the soft tissues on the brain without being obscured by the skull. MRI can provide critical insight into trauma and disease in the brain but historically has simply not been available at the point of care. Because of their size, weight and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">safety issues, conventional MRI systems were only available in hospitals and major medical centers and outpatient imaging providers, and so patients typically must be transported to the MRI. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have developed a new category of medical imaging&#160;-&#160;point of care MRI&#160;-&#160;that is smaller, lighter weight, and lower cost than conventional MRI, yet maintains the soft tissue visualization capabilities that is critical for neuroimaging. Advanced neuroimaging is now available for patients of all ages at the point of care since we launched our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-cleared</div> portable Swoop MRI system in 2020. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g284543g27s27.jpg" style="width: 459px; height: 195px;"/><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Low field system </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To engineer this new category of point of care MRI, we made several significant design changes with respect to conventional MRI, particularly the magnetic field strength. Over the past 40 years, the goal for improving conventional MRI systems has been to attain higher magnetic field strength. In 2017, the FDA cleared the first 7T MRI, after 20 years of development to establish clinical relevance. It was noted that the added field strength allows for better visualization of smaller structures and subtle pathologies that may improve disease diagnosis. We have taken a different approach by developing our Swoop scanner to have a very low field magnet of 0.064T, which enables MRI to become portable because, unlike conventional MRIs, the field strength of the magnet in our system does not require a specialized radio frequency room to safely house the MRI scanner. This field strength comes from a unique optimization of the magnet size, weight, field uniformity and patented design of the permanent magnet structure that provides sufficient image clarity for diagnostic purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There are additional benefits of operating an MRI system with low field magnet, as it reduces the risk of iron-containing objects becoming projectile and injuring patients or operators, which is a typical concern of conventional MRI systems. Furthermore, the radiofrequency pulses used in conventional MRI are responsible for 55% of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-reported</div> adverse events from MRI, causing skin and internal burns in some patients. Operating at 0.064T means using lower energy radiofrequency pulses and significantly reduced associated safety risks. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Motion correction </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conventional MRI scans regularly suffer from quality problems due to patient motion, with approximately 30% of all scans from inpatient or emergency department exams having moderate or severe image quality issues. Portable MRI at the point of care can provide MRI insights to more critically ill patients than previously possible. We have developed a motion compensation technology to improve image quality in the most challenging and often most in need patients that we recently received FDA clearance for clinical use. We believe that with continued development, our technology can produce diagnostic scans without requiring the operator to make expert adjustments to the scanning procedure due to typical patient movements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Noise-cancellation technology </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Designing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> magnet is not sufficient to enable portable MRI. Portable MRI must also address the electromagnetic interference that surrounds us and makes effective conventional MRI outside of a shielded room </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">impossible. Conventional MRI systems are permanently installed in a special room where the walls, floor and ceiling are encased in copper or aluminum to provide a special environment for conventional MRI machines to operate, in which all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made</div> and natural electromagnetic interference is prevented from entering. Installation of these shielded rooms typically costs more than $100,000. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have developed proprietary and patented noise cancellation technology to enable portable MRI. Our technology works by measuring the external electromagnetic interference and subtracting that from the interference that swamps the MRI signals. The image below shows one slice of an MRI image acquired a) outside a shielded room without noise cancellation, b) outside a shielded room with noise cancellation and c) inside a shielded room without noise cancellation. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g284543g28s28.jpg" style="width: 401px; height: 105px;"/><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Delivery of multiple sequences with tissue contrasts </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">MRI has the unique capability of providing images with different soft tissue contrasts through a variety of different sequences that can highlight a range of pathologies clearly. Our Swoop portable MRI system generates images with contrast weightings with which physicians are most familiar and which are most clinically useful for the target use cases: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T1-weighted,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T2-weighted,</div> Fluid-attenuated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T2-weighted</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(T2-FLAIR),</div> and diffusion-weighted (&#8220;DWI&#8221;) with apparent diffusion coefficient (&#8220;ADC&#8221;) map images. These contrasts are standard in conventional MRI and allow for differentiation of various tissue types aiding in establishing the diagnosis. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Image quality </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We deliver diagnostic quality images to healthcare professionals. The images from our Swoop portable MRI system are higher in contrast resolution than other portable medical neuroimaging systems, such as portable CT scanners. Our portable MRI system also delivers comparable image resolution at 1.5 mm x 1.5 mm x 5 mm relative to the typical image resolution of a conventional MRI at 1.0 mm x 1.0 mm x 5 mm. Our MRI signal is produced at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.064-Tesla</div> (&#8220;T&#8221;) compared to 1.5T or higher produced by conventional, fixed MRI scanners. We believe that Swoop provides the potential to improve the quality of care for patients who have limited to no accessibility to conventional MRI, which includes 90% of the world&#8217;s population. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Controlled by an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> wireless tablet </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe it is important to consider usability when significantly changing the way in which a medical device is used, specifically in MRI where conventionally the operator is required to have several years of training. As we seek to reach new markets and new users with our Swoop scanner, we have sought to make the operation of the device as simple and easy to use as possible. We believe this is particularly important when used in emergency situations such as stroke, where time can be critical. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The interfaces to the device are simple intuitive buttons, joystick controls to drive the scanner, and a familiar tablet controller for image acquisition and viewing. The user interface provided on the touch-screen display provides a playlist of protocols based on the use case that can be started, stopped and rearranged, as needed. In addition to being <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> and the consequential acceleration of hospital workflows that can result, our system provides for standardized images across all placement sites due to our uniform manufacturing specifications and a consistent set of sequences that are not customized by individual operators. Conventional </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MRIs are sequenced by highly-trained technologists and can have variations in image resolution and contrast weighting across sites due to institutional policies and radiologist preferences. We believe the standardization of images across scanners and sites will greatly benefit the ability of radiologists and other healthcare professionals to efficiently read our images and to ultimately build a repository of homogenized image data from which to extract value using data mining and deep learning. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Integration with picture archiving and communication system (PACS) and secure image upload to the Cloud </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar to many hospital medical devices, our product is designed to seamlessly integrate with the hospital informational technology (&#8220;IT&#8221;) infrastructure, such that scans can be ordered easily and sent to PACS to be read by a radiologist. For applications where access to such infrastructure is not available, we also offer our own secure cloud based PACS where healthcare professionals including teleradiology service providers can view images from anywhere in the world. We believe that the combination of portable MRI, where scans can be obtained outside the conventional MRI suite, and teleradiology can significantly improve patient care and increase access. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fully Automated MRI Post-Processing Software </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We received FDA clearance for BrainInsight, our first AI applications in January 2021. These applications for automatic labelling, spatial measurements, and volumetric quantification operate on images from our Swoop portable MRI system, automatically add additional insights and associate those insights to the images in the PACS. Using this approach, we intend to grow our portfolio of applications with internal and external development and leveraging the uniquely standardized (and fully anonymized) record of image data we plan to create with our portable MRI system. We believe that bringing the power of AI to MRI has the potential to significantly improve the efficiency of medical imaging in a wide array of use cases, which can benefit the patient by potentially helping to improve outcomes and result in shorter hospital stays. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Design </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Location flexibility </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Despite the weight of our Swoop scanner being 1,400 lbs., its powered drive system means that it can be transported around the hospital with minimal effort. The Swoop scanner can be moved from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bed-to-bed</div></div> and easily positioned in tight spaces because it can be turned on the spot with a zero turn radius. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Open layout designed to reduce patient anxiety </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For an MRI scan in a traditional setting, a patient arrives at the radiology department of a hospital and typically enters through a door covered with radiation warning and other hazard symbols. The patient then proceeds through to a waiting room where they undergo a lengthy safety questionnaire and are asked to remove all clothes and jewelry down to their underwear and put on a hospital gown. Wait times vary from a half hour to several hours before the patient enters the console room and then is led through a large metal door into the RF screen room by themselves. Typical conventional MRI systems are long tubes where the patient is positioned on a motorized bed and RF coils are attached around the patient who has been instructed to lay still. The MRI technician uses the motorized bed to push the patient into the long tube of the large superconducting magnet, leaves the room, closes the metal door to the scan room and tells the patient over an intercom that the scan is about to start. The patient hears the steady mechanical thumping of the cryocooler in the magnet room until the scanning starts, which is then accompanied by often extremely loud acoustic noises. The conventional MRI procedure is often a daunting experience for the patient that can cause significant anxiety, especially for pediatric patients who are separated from their family during this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlike conventional MRI, our Swoop portable MRI is entirely contained in a system that is just 55 inches tall and 34 inches wide and is designed to scan patients in their own beds. Parents, family, or caregivers can be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">close by the patient as they are scanned with just their head in the transparent head RF coil. The system is quiet enough to allow constant verbal contact with the patient, and which overall can create a considerably less distressing experience for the patient than conventional MRI. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Powered by a standard wall outlet </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">To be operable throughout any hospital environment, our Swoop scanner plugs into a standard wall outlet <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(100-230</div> VAC, 50/60 Hz, 15A) and uses less than 900W of electricity. This is achieved with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-power</div> electronics, including efficient power supplies and power amplifiers, coupled with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-power</div> consumption permanent magnet. Our Swoop scanner does not require many of the components of conventional MRI, including the liquid helium used in conventional MRI superconducting magnets or the associated safety and supporting infrastructure, the chilled water-cooling systems for the power electronics and gradient coils and the room air conditioning needed to extract the heat generated in the separate electronics machine room, or the special 480 V, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-phase,</div> 200A power supply. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unlimited training / support resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through our subscription model, we offer a number of services to complement the advanced features of our product. As part of our subscription, we offer unlimited user training during the subscription period to make it as easy as possible for healthcare professionals to operate our system. We offer this support primarily as reassurance to our customers although we are confident our customers will be able to operate our user-friendly device with ease and efficiency; in our experience so far, the user training on the system is generally simple and only requires a few hours. Our subscription also provides for unlimited service and maintenance support during the subscription period to offer peace of mind for our customers. In addition to these support services, our subscription includes our Cloud PACS, an unlimited Cloud archive that users can use to upload images for storage purposes, and grants access to our future software upgrades. Recent upgrades include our FDA cleared motion correction technology that improves the quality of images in the presence of motion, as well as other potential future upgrades designed to improve the patient workflow and diagnosis. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Liminal&#8217;s noninvasive platform is being developed, subject to regulatory authorization, to aid in the diagnosis and management of brain disorders. We believe that understanding the vital signs of the brain for diagnosis and treatment is essential, but the current standard of care is invasive, which limits access. Although there are some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> techniques for measuring the brain such as transcranial doppler (TCD), which has been available since the 1980s, they require specialized technicians to obtain measurements, making them expensive and only available in specialized centers. We are in the early phases of creating our first AEG<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> device through the development of novel acoustic sensing techniques and innovative algorithms for measuring key metrics of brain health. We are working to develop a way to monitor the brain and enable access to key brain vital signs, such as cerebral blood flow and intercranial pressure, more easily than currently available technologies. The device is designed to gather continuous data, and is intended to be easy to use and be applied without specialized training. This technology is designed to provide the clinician with valuable feedback and insight into many brain conditions. Its features are designed to increase the accessibility of key brain vitals which could allow clinicians to diagnose earlier, monitor more effectively and intervene. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar to Legacy Hyperfine&#8217;s Swoop scanner, we expect the use of the AEG<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> device will not require any specialized training and will expand access to real-time brain monitoring in patients across the care continuum. We are designing the AEG<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> device to enable first responders in the field to use the sensors with ease and to enable healthcare practitioners to monitor the brain during triage, operations, treatment and recovery. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g284543g29s29.jpg" style="width: 247px; height: 175px;"/></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our goal is to create an easy to use but powerful brain monitoring platform that can be used anytime, anywhere. We believe this technology will be synergistic with Legacy Hyperfine&#8217;s MRI platform in developing products for patients across the care continuum in sensing, imaging and intervention, in addition to further expanding the growth potential for both businesses in imaging and sensing. We are currently in product development of our brain sensing technology and hardware platform. We are working toward a clinical proof of concept to demonstrate the technological performance and have begun the process of engaging with the FDA to clarify the regulatory pathway. Liminal has not commercialized or obtained regulatory authorization for any of its products and its operations to date have been limited to developing its technology and products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our People </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine was founded in 2014 and Liminal was founded in 2018 by Dr.&#160;Jonathan Rothberg. Our mission is to provide affordable and accessible imaging and monitoring through MRI to revolutionize healthcare for people around the world. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;15, 2022, we had 193 employees, 186 of whom were full-time employees and of whom 56 work in sales, clinical and marketing, 97 work in research, development, manufacturing and operations, and 33 work in general and administrative capacities. As of February&#160;15, 2022, 190 of our employees were located in the United States, two were located in the United Kingdom and one was located in Pakistan. None of our employees are represented by a labor union or are subject to a collective bargaining agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Dr.&#160;Rothberg and our business have been recognized for leadership. Legacy Hyperfine and Liminal were founded in 2014 and 2018, respectively, by Dr.&#160;Jonathan Rothberg, a serial entrepreneur that received the Presidential Medal of Technology&#160;&amp; Innovation in 2016 for inventing a novel next generation DNA sequencing method and has founded more than 10 healthcare and technology companies, including 454 Life Sciences, Ion Torrent, CuraGen, Butterfly Network and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environmental, Social and Governance Practices </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As we work toward our mission, we are increasingly focused on providing transparency around our environmental, social and governance (&#8220;ESG&#8221;) practices and identifying risks related thereto. We are committed to human capital management, patient advocacy and community outreach efforts, corporate governance, and implementing environmental sustainability initiatives. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environmental Stewardship:</div></div> We recognize the importance of taking measures to reduce our environmental footprint. As we grow our business, we have initiated certain projects to begin tracking our environmental impact, and where feasible, have taken measures to increase our sustainability efforts. Some of our efforts include our commitment to reduce, reuse or recycle where possible or appropriate and energy efficient projects to lower energy use within our office areas and laboratories. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Human Capital Management:</div></div> We believe that our people are the reason for our success and we have organized ourselves to maximize productivity and performance. We maintain a high bar for talent and actively work to build diversity within our workforce. Critical to achieving our strategic goals is our ability to build and retain an exceptional team in which each member plays a unique and important role. Employees of Legacy Hyperfine and Liminal continue as employees following the Business Combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We recognize that maintaining an engaged and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-notch</div> workforce and a connection with the communities we serve is critical to our success. Comradery and cohesion are at the core of who we are as a company and are integral facets of our human capital management strategy. We are inspired by each other and the possibilities of what we can achieve together. We understand that in order to drive innovation, we must continuously improve our human capital management strategies and find ways to foster engagement and growth within our organization. To this end, below are some of our initiatives: </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Professional Development Programs and Opportunities:</div></div> Our greatest asset is our employees and we aspire to provide them with opportunities so they can continue to grow and excel in their functions and our company. Professional growth of our employees leads to engagement, development and allows us to leverage opportunities so we can hire and promote key talent from within. Through development planning, we strive for employees at all levels to focus on strengthening the skills required in their current role and potentially their next role. We are focused on building a culture of continuous coaching, feedback and open communication between managers and their direct reports throughout the entire year. We provide managers and employees with training on how to conduct effective forward-looking performance conversations and to set effective goals that are realistic, measurable, attainable, relevant and timebound. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diversity, Equity and Inclusion:</div></div> Our commitment to maintaining a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-performing</div> company means investing in and creating ongoing opportunities for employee development in a diverse and inclusive workplace. We believe that a diverse workforce not only positively impacts our performance, fosters innovation, inspires us to achieve greater results, increases our collective capabilities and strengthens our culture, but it also cultivates an essential pipeline of experienced leaders for management. Hiring for diversity of thought, background and experience, and diversity of personal characteristics such as gender, race and ethnicity is intentional and continues to be an area of focus as we build and grow our workforce. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compensation, Equity and Benefits:</div></div> We have designed a broad-based compensation program that is designed to attract, retain and motivate our employees to deliver sustainable long-term value. We seek to deliver performance-driven, market competitive reward opportunities commensurate with company and individual performance. Many of our employees receive equity grants and cash bonuses in addition to base salaries and our benefits package. We believe that providing employees with an ownership interest in our company further strengthens the level of employee engagement. Furthermore, equity awards help align the interests of our employees with the long-term interests of our stockholders. We also offer employees a health insurance package. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Governance, Ethics, and Compliance:</div></div> Our board of directors is committed to robust corporate governance practices, risk oversight, stockholder rights, diversity, equity and inclusion, corporate sustainability, ethics and compliance in order to protect the long-term interests of our company, stockholders and the patients we serve. Our board of directors adopted corporate governance principles applicable to us, including responsible oversight and management of the Company, effective controls and processes, compliance with SEC and Nasdaq Stock Market rules and regulations, maintaining an engaged board of directors and a board structure that recognizes the importance of diversity, appropriate compensation practices, and succession planning, among other matters. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to evolve and strengthen our human capital management strategies, increase our environmental efforts, maintain and continue to improve our corporate governance practices, and anticipate reporting on other corporate sustainability measures over time. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales, Pricing and Marketing </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our marketing efforts are focused on accelerating awareness of our products and capabilities in order to create a strong reputation with clinicians and healthcare administrators. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">go-to-market</div></div> approach features a targeted sales organization complemented by an array of promotional activities including media coverage, tradeshow exhibition, advertising, and live product demonstration. We principally target acute care hospitals and health systems. In the future, we plan to leverage this approach for both our Swoop Scanner and our future products that have similar end markets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize the role of education in accelerating clinical adoption of our products across the patient care pathway, including healthcare professionals who currently may not themselves be primary users of MRI technology. To support adoption of our product and in addition to our simplified product interface, we have developed training curriculum and tutorials and built a team of clinically trained customer success managers to guide and coach clinicians on the unique features of our device and on the specific clinical application of our technologies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales and Pricing </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Swoop scanner is commercially available in the United States, and we are seeking necessary regulatory authorizations in other major markets, including the United Kingdom, Australia and other countries. We recently received regulatory authorization in New Zealand and Pakistan. We are building our direct commercial infrastructure in the United States and also have plans to sell our products in other countries either through direct sales or through distributors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are commercializing our device through two business models: (i)&#160;the subscription bundle model, and (ii)&#160;the subscription plus ownership model. For both models, we offer subscriptions with software upgrades for 36 or 60 months and an annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-payment</div> discount. We have specifically selected these business models to create convenience and widespread adoption. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription bundle model:</div></div> This model includes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> subscription or a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-month</div> subscription. The subscription bundle model includes the use of a Swoop scanner and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> tablet for use with the scanner, plus the same subscription benefits provided in the subscription plus ownership model. The subscription fee is based on the term of the subscription, whether prepayment is made, and whether the Swoop scanner will be for commercial or research use. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription plus ownership model:</div></div> This model provides for the sale of the Swoop scanner, along with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> tablet for use with the scanner, to the customer for an initial payment, which is substantially less expensive than the average cost of $1.2&#160;million for conventional MRI scanners. In addition to purchasing ownership of the system, the customer purchases a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> subscription or a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-month</div> subscription. The subscription fee is based on the term of the subscription, whether prepayment is made, and whether the Swoop scanner will be for commercial or research use. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe our subscription-based model has the potential to generate a more predictable recurring revenue stream while helping to foster an ongoing relationship with our customers. To help ensure our customers receive the highest level of customer service, we plan to continue to sell directly to customers and providing ongoing customer support. However, as we expand internationally subject to regulatory authorization in those countries, we may leverage distributors to sell our product depending on the commercial strategy for each country assessed on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis. Through our subscription-based model, we aim to provide MRI systems that are much less expensive than conventional MRI systems and achieve our vision of increasing accessibility to MRI worldwide. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Suppliers and Manufacturing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Swoop scanner is built using both custom-made and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> components supplied by outside manufacturers and vendors located in the United States, Europe and Asia. One key custom-made component in our Swoop scanner is the magnet, which is manufactured by a single source supplier in Europe. The majority of the other components for the Swoop scanner are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> or made using standard processes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We purchase some of our components and materials used in manufacturing, including magnets, field programmable gate arrays (&#8220;FPGAs&#8221;), central processing units (&#8220;CPUs&#8221;) and molded plastics, from single sources. Although we believe that alternative sources of these components and materials would be available, it would take time to identify and validate replacement components, which could negatively affect our ability to supply the Swoop scanner on a timely basis. We cannot give assurances that any alternative supplier would be able to recreate the manufacturing processes currently in use. To mitigate this risk, we typically carry a significant inventory of critical components. We also plan to work with our Swoop scanner device manufacturer, Benchmark Electronics, Inc. (&#8220;Benchmark&#8221;), to add an additional magnet supplier to the manufacturing process to mitigate the risk to supply of our magnets by the current use of a single supplier. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our Swoop scanner devices are manufactured, tested, shipped and supported by Benchmark from its facilities in Nashua, NH. We believe that this manufacturing strategy is efficient and conserves capital. However, in the event it becomes necessary to utilize a different contract manufacturer for our Swoop products, we would experience additional costs, delays and difficulties in doing so, and our business could be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key Agreements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacture and Supply Agreement with Benchmark Electronics, Inc. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2018, Legacy Hyperfine entered into a Manufacture and Supply Agreement with Benchmark (the &#8220;MSA&#8221;). Under the MSA, Benchmark agreed to manufacture our products pursuant to binding purchase orders. Each month, we have agreed to provide Benchmark with a binding purchase order for a period specified by the MSA, as well as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> forecast for each month within such period. If we do not provide the monthly purchase order and forecast update, then the first forecast month of the then-current forecast becomes binding so that a rolling binding commitment to purchase product for the specified period is maintained. The parties have agreed to meet periodically regarding any minimum order quantities of components under the MSA. We also have certain inventory related obligations, including the obligation to purchase excess and obsolete components from Benchmark. Excess components are determined based upon the amount of component inventory that exceeds the build plan for the specified period discussed above. We would be required to purchase such excess inventory and be credited back against future purchases of finished products as the inventory of components is reduced to the amount needed to meet the rolling build plan. Obsolete materials are immediately invoiced once identified. As of February&#160;15, 2022, we have paid approximately $2.2&#160;million for excess components. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the MSA, we granted Benchmark a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> revocable, fully-paid, royalty-free license, without the right to sublicense, to use our technology solely to manufacture our products. The MSA provides that we will own any right, title and interest in any improvements or modifications to our technology made in the course of performance of Benchmark&#8217;s obligations under the MSA. We and Benchmark also agreed to indemnify each other against certain third-party claims. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The MSA has an initial three-year term and will renew automatically for additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> terms unless either party gives 180 days&#8217; prior written notice before the end of the then-current term to the other party electing not to renew the agreement. The MSA or any purchase order under the MSA may be terminated by either party for convenience upon 90 days&#8217; prior written notice to the other party. The MSA may also be terminated by either party by written notice upon the occurrence of (i)&#160;a breach by the other party under the agreement which is not cured within 30 days after written notice by the terminating party, (ii)&#160;the other party becomes insolvent, dissolves, liquidates or ceases to conduct business or (iii)&#160;the occurrence of payment-related breaches. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benchmark may also terminate the agreement upon the filing of any petition against us under bankruptcy or similar laws, where such petition is not vacated within 10 days via court order. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Several large companies, such as General Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba, Canon and Hitachi currently dominate the medical imaging market. High regulatory, distribution, manufacturing and service-related long-term contractual costs represent significant barriers to entry for any new player. We expect that the existing market participants will remain key players in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a general matter, we view competition on two levels: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conventional MRI systems with which the general public is familiar; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development of other portable MRI systems with the same or better attributes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary competition comes from established market participants offering conventional MRI systems. While in developing countries we are experiencing keen interest, the United States and other Western regions already have major market participants that are well entrenched in the market with strong political influence and the ability to delay deployment of our systems. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are not aware of any competing company that has achieved a portable MRI system. To our knowledge, there are several companies currently in the process of developing this technology, including Promaxo, Neuro42 and Huami. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Protection of our intellectual property is a strategic priority for our business. We rely on a combination of patents, trademarks, trade secrets and other intellectual property rights protections and contractual restrictions to protect our proprietary technologies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The patents owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> by us are generally directed to the architecture of Legacy Hyperfine&#8217;s MRI systems and related technology, and Liminal&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> brain sensing and treatment devices and related technology. We have developed a portfolio of issued patents and pending patent applications directed to commercial products and technologies for potential development. We believe that our intellectual property is a core strength of our business, and our strategy includes the continued development of our patent portfolio. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and Related Technology </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;15, 2022, Legacy Hyperfine owned approximately 141 issued patents and approximately 293 pending patent applications. Of Legacy Hyperfine&#8217;s approximately 141 issued patents, approximately 80 were issued U.S. utility patents and approximately two were issued U.S. design patents. Of Legacy Hyperfine&#8217;s approximately 293 pending patent applications, approximately 81 were pending U.S. utility patent applications. In addition, Legacy Hyperfine owned approximately 59 issued patents in foreign jurisdictions, including Australia, Canada, Japan, China, Taiwan, Korea, Hong Kong, Israel, France, Germany, Ireland, Switzerland/Liechtenstein, and the United Kingdom, and approximately 212 pending patent applications in foreign jurisdictions, including Australia, Canada, Europe, Japan, China, Taiwan, Korea, Hong Kong, Israel, and New&#160;Zealand, corresponding to the foregoing. In total, Legacy Hyperfine owns approximately 69 patent families generally directed to its MRI system, including magnet design and manufacturing, electronics and circuitry, mechanical aspects, safety features, noise compensation technology, image formation and analysis software, and various other aspects of MRI systems. These issued patents and pending patent applications (if they were to issue as patents) have expected expiration dates ranging between 2035 and 2042. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine patents and pending patent applications (including types of patent protection and jurisdictions where Legacy Hyperfine has been granted patents or has patent applications pending) directed to its material products are detailed in the table below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Family <br/>Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent <br/>Protection Type</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions&#160;with <br/>Pending Applications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Granted Patents</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA (2), CN, EP, HK, IL, JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU&#160;(2),&#160;CA, CN, HK, JP (2), US (4)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Low field magnetic resonance imaging methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CA, CN, EP, HK, IL, JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, HK, IL, JP (2), US (6)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Noise suppression methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA (2), CN, EP, HK (2), KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, JP (2), US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Pulse sequences for low field magnetic resonance</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">4</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Low field magnetic resonance methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">5</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Methods and apparatus for thermal management of an MRI component by reducing eddy currents</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">6</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CA, EP, HK (2), KR</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CN, JP, MX, TW, US (5)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Magnetic coil power methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">7</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">EP, HK (2), KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, JP, TW, US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Radio frequency coil methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">8</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CA, CN, EP, HK, IL, KR, US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CN, HK, JP, TW (2), US (6)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Automatic configuration of a low field magnetic resonance imaging system</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">9</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CN, EP, HK, JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CA, TW (2), US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Radio frequency coil tuning methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CN, EP, HK (2), JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, HK, JP, IL, TW, US (3)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Ferromagnetic augmentation for magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">11</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, IL, IN, JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CH/LI, DE, FR, GB, IE, TW, US&#160;(6)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems and methods for automated detection in magnetic resonance images</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">12</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA (2), EP, IL, MX, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">CA, CN, HK, JP, KR, TW (2), US&#160;(4)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Methods and apparatus for magnetic field shimming</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">13</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA (6), CN, EP, HK, IL, JP, KR,</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">TW (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Portable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> magnetic resonance imaging methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">14</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, counterpart foreign cases in 13 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (5)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Electromagnetic shielding for magnetic resonance imaging methods and apparatus</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Family <br/>Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent <br/>Protection Type</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions&#160;with <br/>Pending Applications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Granted Patents</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">15</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, counterpart foreign cases in 13 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (4)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Portable magnetic resonance imaging methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">16</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, IL, JP, KR, TW, US (4)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Methods and apparatus for patient positioning in magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">17</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (1), counterpart foreign cases in 13 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (12)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-field</div> magnetic resonance imaging methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">18</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Counterpart foreign cases in 13 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (5)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Rotatable magnet methods and apparatus for a magnetic resonance imaging system</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">19</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, IL, JP, KR, TW, US (3)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (3)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Radio-frequency coil signal chain for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> MRI system</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">20</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, IL, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">TW, US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Deployable guard for portable magnetic resonance imaging devices</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">21</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, IL, JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">B0 magnet methods and apparatus for a magnetic resonance imaging system</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">22</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, JP, KR, TW, US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Deep learning techniques for magnetic resonance image reconstruction</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">23</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Medical imaging device messaging service</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">24</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-field</div> diffusion weighted imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">25</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, HK, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Deep learning techniques for suppressing artefacts in magnetic resonance images</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">26</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, EP, NZ, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">System and methods for grounding patients during magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">27</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, IL, JP, KR, NZ, TW, US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Correcting for hysteresis in magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">28</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, IL, JP, KR, NZ, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Techniques for dynamic control of a magnetic resonance imaging system</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Family <br/>Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent <br/>Protection Type</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions&#160;with <br/>Pending Applications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Granted Patents</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">29</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">System and methods for detecting electromagnetic interference in patients during magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">30</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, IL, JP, KR, NZ, TW, US,</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems and methods for magnetic resonance imaging of infants</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">31</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, counterpart foreign cases in 32 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Deep learning techniques for alignment of magnetic resonance images</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">32</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, IL, JP, KR, NZ, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Deep learning techniques for generating magnetic resonance images from spatial frequency data</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">33</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Low noise gradient amplification components for mr systems</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">34</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AU, CA, CN, EP, IL, JP, KR, NZ, US&#160;(2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems, devices, and methods for magnetic resonance imaging of infants</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">35</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, counterpart foreign cases in 16 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Patient support bridge methods and apparatus</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">36</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems and methods for detecting patient motion during magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">37</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, counterpart foreign cases in 32 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Multi-coil magnetic resonance imaging using deep learning</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">38</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Eddy current mitigation systems and methods</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">39</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (3), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Artefact reduction in magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">40</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Techniques for displaying medical image data</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">41</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems and methods for generating three-dimensional medical images using ray tracing</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">42</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), counterpart foreign cases in 32 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Self ensembling techniques for generating magnetic resonance images from spatial frequency data</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">43</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">TW, US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Magnetic resonance imaging magnet assembly systems and methods</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">44</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Ferromagnetic frame for magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">45</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Permanent magnet assembly for magnetic resonance imaging with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-ferromagnetic</div> frame</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 46%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 46%;"></td> </tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Family <br/>Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent <br/>Protection Type</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions&#160;with <br/>Pending Applications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Granted Patents</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">46</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Swaged component magnet assembly for magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">47</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Techniques for noise suppression in an environment of a magnetic resonance imaging system</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">48</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Design</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Frame for magnets in magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">49</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Design</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Frame for magnets in magnetic resonance imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">50</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2), PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gradient waveform design for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> magnetic resonance imaging systems</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">51</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems and methods for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> fast spin echo imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">52</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT, TW</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Systems and methods for providing operating power to a magnetic resonance imaging (MRI) system</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">53</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Deep learning methods for noise suppression in medical imaging</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">54</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">55</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">56</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">57</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">58</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">59</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">60</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">61</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">62</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">63</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">64</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">65</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">66</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">67</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">68</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td>
<td colspan="2" style="height: 3.75pt; font-size: 0px;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;">69</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">US (2)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title not publicly available</td> </tr> </table> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liminal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Invasive</div> Brain Sensor and Related Technology </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;15, 2022, Liminal owned approximately 87 pending patent applications. Of Liminal&#8217;s approximately 87 pending patent applications, approximately 22 were pending U.S. utility patent applications. In addition, Liminal owned approximately 65 pending patent applications in foreign jurisdictions, including Australia, Canada, China, Europe, Israel, Japan, Korea, and Taiwan, corresponding to the foregoing. In total, Liminal owns approximately 21 patent families generally directed to its brain sensing products, including stimulation and monitoring components, electronics and circuitry, mechanical aspects, and software including AI software algorithms, and various additional features. These pending patent applications (if they were to issue as patents) have expected expiration dates ranging between 2039 and 2041. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal&#8217;s patents and pending patent applications (including types of patent protection and jurisdictions where Liminal has been granted patents or has patent applications pending) directed to its material products are detailed in the table below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 15%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Family <br/>Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent <br/>Protection Type</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Pending Applications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Granted Patents</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, CN, EP, IL, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a wearable device including stimulation and monitoring components</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, CN, EP, IL, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a wearable device for substantially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-destructive</div> acoustic stimulation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, CN, EP, IL, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a wearable device for acoustic stimulation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">4</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, EP, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a wearable device for treating a health condition using ultrasound stimulation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">5</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, CN, EP, IL, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a device for steering acoustic stimulation using machine learning</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">6</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, CN, EP, IL, JP, KR, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a device using a statistical model trained on annotated signal data</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">7</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, EP, TW, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a device for energy efficient monitoring of the brain</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">8</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, EP, TW, US,</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for monitoring brain health</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">9</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">TW, US, counterpart foreign cases in 8 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for monitoring brain health</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">10</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">AU, CA, CN, EP, IL, JP, KR, US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a brain acoustic resonance intracranial pressure monitor</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">11</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, counterpart foreign cases in 10 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a skull lamb waves intracranial pressure monitor</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 15%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Family <br/>Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent <br/>Protection Type</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Pending Applications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdictions with <br/>Granted Patents</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">12</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, counterpart foreign cases in 10 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for a brain acoustic resonance seizure monitor</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">13</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, counterpart foreign cases in 10 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for tumor detection</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">14</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, counterpart foreign cases in 10 family</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Systems and methods for mapping distribution of intracranial pressure</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">15</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">TW, US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Device and methods for treating neurological disorders and brain conditions</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">16</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Ultrasound annular array device for neuromodulation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">17</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Methods and apparatus for pulsatility-mode sensing</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">18</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US, PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Methods and apparatus for smart beam-steering</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">19</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 2pt; vertical-align: top;">20</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Title not publicly available</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 2pt; vertical-align: top;">21</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Utility (prov)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; white-space: nowrap;">Title not publicly available</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to patents, we also rely on trade secrets, technical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and continuing innovation to develop and maintain our competitive position. We seek to protect our proprietary information and other intellectual property by generally requiring our employees, consultants, contractors, suppliers, outside scientific collaborators and other advisors to execute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and assignment of invention agreements on commencement of their employment or engagement. Agreements with our employees also forbid them from using or incorporating the proprietary rights of third parties during their engagement with us. We also generally require confidentiality or material transfer agreements from third parties that receive our confidential data or materials. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License Agreements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into licenses in the ordinary course of business relating to our technologies or other intellectual property rights or assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive License Agreements with The General Hospital Corporation (d/b/a Massachusetts General Hospital) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Legacy Hyperfine entered into an exclusive license agreement with The General Hospital Corporation (d/b/a Massachusetts General Hospital) (&#8220;MGH&#8221;) effective in May 2014 (the &#8220;May Agreement&#8221;) and an exclusive license agreement with MGH effective in June 2014 (the &#8220;June Agreement&#8221;), respectively, under each of which Legacy Hyperfine acquired an exclusive and worldwide license to specified patent rights owned by MGH relating to MRI technology. The licenses granted to us are subject to the right of MGH and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-for-profit</div></div> academic, government and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-for-profit</div></div> institutions to make and to use the subject matter described or claimed in the rights granted under the licensed patents for research and educational purposes and, for any licensed patents that are supported by federal funding, the licenses granted to us are subject to certain rights, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">conditions and limitations imposed by U.S. law, including a royalty-free, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license granted to the U.S. government and a requirement that any products used or sold in the United States must be manufactured substantially in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of each of the license agreements, we have agreed to pay MGH an annual maintenance fee and agreed to reimburse MGH for certain patent related fees and costs incurred by MGH, including past patent fees and costs. If we enter into a sublicense under either license agreement, we will be obligated to pay MGH a percentage in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div> of certain consideration paid to us by the sublicensee. As of February&#160;15, 2022, the aggregate amounts paid under the May Agreement and June Agreement were $25,522 and $19,762, respectively. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to use commercially reasonable efforts to develop and commercialize licensed products and licensed processes under each of the license agreements. In particular, we were required to achieve a specified development and commercialization milestone by a specified date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of each of the license agreements, MGH has retained the right to practice the licensed patent rights within the licensed fields for research and educational purposes only. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of the license agreements expires upon the expiration of the last to expire licensed patent, which is set to expire in 2035. We have the right to terminate either agreement for any reason by giving advance written notice to MGH. MGH has the right to terminate either agreement if we fail, subject to a specified cure period, to pay any amounts due and payable under either agreement to MGH, we otherwise materially breach either agreement and fail to cure such breach within a specified cure period, we fail to maintain insurance coverage as required under either agreement, we become insolvent, or make an assignment for the benefit of our creditors, or have a petition in bankruptcy filed for or against us, or we or a sublicensee challenges the licensed patent rights in a legal or administrative proceeding. Either agreement otherwise terminates upon the expiration or abandonment of all licensed patents and patent applications. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diagnostic and therapeutic medical devices like those we developed and distributed are subject to regulation by numerous regulatory bodies, including the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable international regulatory agencies. These agencies require developers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, packaging, labeling, marketing and distribution of medical devices. Devices are generally subject to varying levels of regulatory control, the most comprehensive of which requires that a clinical evaluation program be conducted before a device can be approved for marketing and commercial distribution. In addition, healthcare regulatory bodies in the United States and around the world impose a range of requirements related to paying for medical devices and the procedures in which they are used, including laws intended to prevent fraud, waste, and abuse of healthcare dollars. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Laws and Regulations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the United States, medical devices are subject to extensive regulation at the federal level by the FDA under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The laws and regulations govern, among other things, medical device design and development, nonclinical and clinical testing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> clearance, authorization or approval, establishment registration and product listing, product manufacturing, product packaging and labeling, product storage, advertising and promotion, product distribution, recalls and field actions, servicing and post-market clinical surveillance. A number of U.S. states also impose licensing and compliance regimes on companies that manufacture or distribute prescription devices into or within the state. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of our products are also subject to the Radiation Control for Health and Safety Act, administered by the FDA, which imposes performance standards and record keeping, reporting, product testing and product labeling requirements for electronic products that emit radiation, such as magnetic resonance imaging systems. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the commercialization and use of our devices in the United States is subject to regulation by the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and state agencies responsible for reimbursement and regulation of payment for healthcare items and services. Federal laws and regulations apply primarily in connection with government payer programs such as the Medicare and Medicaid programs, but state laws apply more broadly, encompassing healthcare items and services covered by private payers. At the state and federal level, the government&#8217;s interest is in regulating the quality and cost of healthcare and protecting the independent clinical judgment of licensed healthcare providers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Federal Trade Commission (&#8220;FTC&#8221;) also oversees the advertising and promotion of our products pursuant to broad authority to police deceptive advertising for goods or services within the United States. Under the Federal Trade Commission Act, the FTC is empowered, among other things, to (a)&#160;prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b)&#160;seek monetary redress and other relief for conduct injurious to consumers; and (c)&#160;gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. In the context of performance claims for products such as our goods and services, compliance with the FTC Act includes ensuring that there is scientific data to substantiate the claims being made, that the advertising is neither false nor misleading, and that any user testimonials or endorsements we or our agents disseminate related to the goods or services comply with disclosure and other regulatory requirements. In addition, with respect to our commercial products and any future products that are marketed as clinical products, FDA&#8217;s regulations applicable to medical device products prohibit them from being promoted for uses not within the scope of a given product&#8217;s intended use(s), among other promotional and labeling rules applicable to products subject to the FDCA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, medical device systems that include wireless radio frequency transmitters and/or receivers are subject to equipment authorization requirements in the United States. The Federal Communications Commission (&#8220;FCC&#8221;) requires advance clearance of all radio frequency devices before they can be sold or marketed in the United States. These clearances ensure that the proposed products comply with FCC radio frequency emission and power level standards and will not cause interference. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When Liminal&#8217;s products are marketed for clinical monitoring or therapeutic uses, they will be regulated by the FDA as medical devices. It is presently unclear what level of risk the agency will assign to such products, what special controls may be imposed on such products (if any), and what regulatory requirements would be applicable to such products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FDA Regulation of Medical Devices </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Medical devices must undergo <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> review by and receive clearance, authorization, or approval from the FDA prior to commercialization, unless the device is of a type exempted from such review by statute, regulation, or an FDA exercise of enforcement discretion. The FDA classifies medical devices into three classes based on risk. Regulatory control increases from Class&#160;I (lowest risk) to Class&#160;III (highest risk). The FDA generally must clear or approve the commercial sale of most new medical devices that fall within product categories designated as Class&#160;II and III. Commercial sales of most Class&#160;II and III medical devices within the United States must be preceded either by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification and FDA clearance pursuant to Section&#160;510(k) of the FDCA (Class II) or by the granting of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> approval (&#8220;PMA&#8221;) (Class III), after a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> application is submitted. Both 510(k) notifications and PMA applications must be submitted to FDA with significant user fees (over $12,000 for a 510(k) and $374,000 for a PMA in FY 2022), although reduced fees for small businesses are available. Class&#160;I devices are generally exempt from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> review and notification, as are some moderate-risk Class&#160;II devices. Manufacturers of all classes of devices must comply with FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;), establishment registration, medical device listing, labeling requirements, and medical device reporting (&#8220;MDR&#8221;) regulations, which are collectively referred to as medical device general controls. Class&#160;II devices may also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Some Class&#160;I and Class&#160;II devices may be exempted by regulation from the requirement of compliance with substantially all of the QSR. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">510(k) Clearance Pathway </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A 510(k) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification must contain information sufficient to demonstrate that the new device is substantially equivalent to a device commercially distributed prior to May&#160;28, 1976 or to a device that has been determined by the FDA to be substantially equivalent to such a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;pre-amendments&#8221;</div> device. To obtain 510(k) clearance for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exempt</div> Class&#160;II device, the product developer must submit a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification to FDA demonstrating that its product is substantially equivalent to such a predicate device. The FDA&#8217;s 510(k) clearance process generally takes from three to 12 months from the date the application is submitted, but it may take significantly longer if FDA has significant questions or needs more information about the new device or its manufacturing or quality controls. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the 510(k) notification process for Class&#160;II devices that have an existing classification regulation available for purposes of the regulatory filing, the FDA may require the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development of comprehensive product description and indications for use. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Completion of extensive nonclinical tests and/or animal studies, performed in accordance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations, as well as any performance standards or other testing requirements established by FDA through regulations or device-specific guidance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive review of one or more predicate devices and development of data supporting the new product&#8217;s substantial equivalence to such predicate devices. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Assuming successful completion of all required testing, a detailed 510(k) notification is submitted to the FDA requesting clearance to market the product. This premarket notification includes all relevant data from pertinent nonclinical studies and clinical trials (if applicable), together with detailed information relating to the product&#8217;s manufacturing controls and proposed labeling, and other relevant documentation. The FDA evaluates all 510(k) submissions prior to filing for substantive review based on specific acceptance criteria and may issue a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">refuse-to-accept</div></div> notification if the submission is deficient with respect to any of the established criteria. If the FDA determines that the applicant&#8217;s device is substantially equivalent to the identified predicate device(s), the agency will issue a 510(k) clearance letter that authorizes commercial marketing of the device for one or more specific indications for use. If the FDA determines that the applicant&#8217;s device is not substantially equivalent to the predicate device(s), the agency will issue a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-substantially-equivalent</div> letter stating that the new device may not be commercially distributed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After a new medical device receives 510(k) clearance from the FDA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require the submission of a PMA. The FDA requires each manufacturer to make the determination of whether a device modification requires a new 510(k) notification or PMA in the first instance, but the FDA may review any such decision. If the FDA disagrees with a manufacturer&#8217;s decision not to seek a new 510(k) clearance or PMA for a particular change, the FDA may retroactively require the manufacturer to submit a 510(k) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification or a PMA. The FDA may also require the manufacturer to cease U.S. marketing and/or recall any distributed units of the modified device until 510(k) clearance or PMA approval for the modification is obtained. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">De Novo Classification </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If a previously unclassified new medical device does not qualify for the 510(k) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class&#160;III. However, if such a device would be considered low or moderate risk (in other words, it does not rise to the level of requiring the approval of a PMA), it may be eligible for the De Novo classification process. The De Novo classification process allows a device developer to request that the novel medical device be reclassified as either a Class&#160;I or Class&#160;II device, rather than having it regulated as a high-risk Class&#160;III device subject to the PMA requirements. If the manufacturer seeks reclassification into Class&#160;II, the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">classification request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the FDCA, the FDA is required to classify a device within 120 days following receipt of the De Novo classification request from an applicant; however, the most recent FDA performance review goals state that in fiscal year 2022, FDA will attempt to issue a decision within 150 days of receipt on 70% of De Novo requests received during fiscal year 2022. De Novo classification requests are subject to user fees, unless a specific exemption applies (over $112,000 in FY 2022). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As with the 510(k) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification process described above, any modification to a device authorized through the De Novo process that could significantly affect the safety or effectiveness of such device, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require the submission of a PMA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, FDA issued a final rule that would formally codify requirements for the medical device De Novo process and the procedures and criteria for product developers to file a De Novo classification request (86 Fed. Reg. 54,826). Over the twenty years preceding the final rule, the De Novo process has been implemented by FDA pursuant to statutory authorities and somewhat organically through informal guidance and iterative changes by Congress. Although the final rule does not affect marketed products such as our marketed products, and likely will not be expected to impact products in current development, the FDA&#8217;s goals in promulgating the final rule are to create a predictable, consistent, and transparent De Novo classification process for innovative medical device developers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As an alternative to the De Novo classification process, a company could also file a reclassification petition seeking to change the automatic Class&#160;III designation of a novel post-amendment device under Section&#160;513(f)(3) of the FDCA. FDA can also initiate reclassification of an existing device type on its own initiative. In December 2018, FDA issued a final rule to clarify the administrative process through which the FDA reclassifies a medical device. To reclassify a device under Section&#160;513(e) of the FDCA, the FDA must first publish a proposed reclassification order that includes a summary of the valid scientific evidence that supports the reclassification; convene a device classification panel meeting; and consider comments to the public docket before it then publishes a final reclassification order in the Federal Register. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-market</div> Approval Pathway </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI systems have been classified and are regulated as Class&#160;II devices, although future products that we develop may be classified as Class&#160;III devices. Products classified by FDA as Class&#160;III generally require marketing approval via a PMA. A PMA application must be supported by valid scientific evidence, which typically requires extensive data, including technical, nonclinical, clinical, manufacturing and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the device for its intended use(s). A PMA application also must include a complete description of the device and its components, a detailed description of the methods, facilities and controls used to manufacture the device, and proposed labeling. After a PMA application is submitted and found to be sufficiently complete, it is considered &#8220;filed&#8221; and the FDA begins an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> review of the submitted information. During this substantive review period, the FDA may request additional information or clarification of information already provided. Also during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA. In addition, the FDA generally will conduct a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility to evaluate compliance with the QSR, which requires manufacturers to implement and follow design, testing, control, documentation and other quality assurance procedures. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review of a PMA application is required to be completed within 180 days of the application&#8217;s filing date although the process generally takes between one and three years, but may take significantly longer. The current user fee agreement between FDA and the medical device industry sets as a target for PMA reviews to be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completed in under one year. The FDA can delay, limit or deny approval of a PMA application for many reasons, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the product may not be safe or effective for its intended use(s) to the FDA&#8217;s satisfaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the data from the applicant&#8217;s nonclinical studies and clinical trials may be insufficient to support approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the manufacturing process or facilities that the applicant uses may not meet applicable requirements; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in FDA approval policies or adoption of new regulations may require additional data to demonstrate the safety or effectiveness of the device. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an FDA evaluation of a PMA application or manufacturing facilities is favorable, the FDA will either issue an approval letter, or approvable letter, which usually contains a number of conditions which must be met in order to secure final approval of the PMA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of a device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA may also determine that additional trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA. The PMA process can be expensive, uncertain and lengthy. PMA approval may also be granted with post-approval requirements such as the need for additional patient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> for an indefinite period of time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New PMA applications or PMA supplements may be required for modifications to the manufacturing process, labeling, device specifications, materials or design of a device that is approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive clinical data or the convening of an advisory panel. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Investigations Using Devices in Development </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Clinical trials are almost always required to support a PMA application and are sometimes required for a De Novo classification request or 510(k) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification. In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a medical device, an investigator acting on behalf of the company must, among other things, apply for and obtain Institutional Review Board (&#8220;IRB&#8221;) approval of the proposed investigation. In addition, if the clinical study involves a &#8220;significant risk&#8221; (as defined by the FDA) to human health, the company sponsoring the investigation (referred to as the &#8220;sponsor&#8221;) must also submit and obtain FDA approval of an Investigational Device Exemption (&#8220;IDE&#8221;) application. An IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of study participants, unless the product is deemed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-significant</div> risk device and eligible for abbreviated IDE requirements. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by a duly-appointed IRB for clinical trial site. FDA&#8217;s IDE regulations govern investigational device labeling, prohibit promotion, and specify an array of Good Clinical Practice (&#8220;GCP&#8221;) requirements, which include, among other things, recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#8217;s regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable or, even if the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant approval or clearance of a product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commencement or completion of any of our clinical trials may be delayed or halted, or be inadequate to support approval of a PMA application (or FDA&#8217;s grant of a De Novo classification request or clearance of a 510(k) notification, as applicable), for numerous reasons, including, but not limited to, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA, the IRB(s), or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">participants do not enroll in clinical trials at the expected rate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">participants do not comply with trial protocols; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">participant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> is not at the expected rate; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patients experience adverse side effects; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">participants die during a clinical trial, even though their death may not be related to the investigational products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IRBs and third-party clinical investigators may delay or reject the sponsor&#8217;s trial protocol; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third-party clinical investigators decline to participate in a trial or do not perform a trial on the sponsor&#8217;s anticipated schedule or consistent with the clinical trial protocol, GCPs or other FDA requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sponsor or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third-party clinical investigators have significant financial interests related to the sponsor or the study that the FDA deems to make the study results unreliable, or the sponsor or investigators fail to disclose such interests; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unfavorable regulatory inspections of the sponsor&#8217;s clinical trial sites or manufacturing facilities, which may, among other things, require the sponsor to undertake corrective action or suspend or terminate the sponsor&#8217;s clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in governmental regulations or administrative actions applicable to the sponsor&#8217;s trial protocols; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA concludes that the results from the sponsor&#8217;s trial and/or trial design are inadequate to demonstrate safety and effectiveness of the product. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ongoing Post-Market Regulatory Requirements and FDA Enforcement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2020, Legacy Hyperfine received 510(k) clearance from the FDA for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system. In addition, our proprietary BrainInsight product is fully automated MRI post-processing medical software that is regulated as a picture archiving and communications system, which may include both hardware and software components, and which is classified by FDA as a Class&#160;II medical device. BrainInsight received 510(k) marketing clearance in January 2021 for use in automatic labeling, spatial measurement, and volumetric quantification of brain structures from a set of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-field</div> MR images and to return annotated and segmented images, color overlays, and reports. More recently, in November 2021, Legacy Hyperfine received 510(k) clearance for its new advanced image reconstruction technology using deep learning. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After a medical device is authorized for marketing and placed in commercial distribution (or, for 510(k)-exempt products, placed into commerce without first obtaining FDA clearance or approval), numerous regulatory requirements apply. These general controls that must be met for all device classes include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishment registration and device listing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the QSR, which requires manufacturers, including third-party manufacturers, to follow design, testing, control, storage, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">labeling regulations, which govern the mandatory elements of the device labels and packaging (including Unique Device Identifier markings for certain categories of products); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">FDA&#8217;s prohibitions against the promotion of products for uncleared, unapproved or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-label&#8221;</div> uses and other requirements related to promotional activities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the MDR regulations, which require that manufacturers report to the FDA if a device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">voluntary and mandatory device recalls to address problems when a device is defective and/or could be a risk to health; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">post-market surveillance regulations, which apply to certain Class&#160;II or III devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA&#8217;s MDR requirements also extend to healthcare facilities that use medical devices in providing care to patients, or &#8220;device user facilities,&#8221; which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient treatment facilities, but not physician offices. A device user facility must report any device-related death to both the FDA and the device manufacturer, or any device-related serious injury to the manufacturer (or, if the manufacturer is unknown, to the FDA) within 10 days of the event. Device user facilities are not required to report device malfunctions that would likely cause or contribute to death or serious injury if the malfunction were to recur but may voluntarily report such malfunctions through MedWatch, the FDA&#8217;s Safety Information and Adverse Event Reporting Program. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-scheduled</div> and unannounced inspections by the FDA and certain state authorities. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may lead to any of the following sanctions: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warning Letters or Untitled Letters that require corrective action; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines and civil penalties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unanticipated expenditures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in approving/clearing or refusal to approve/clear any of our future products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA refusal to issue certificates to foreign governments needed to export our products for sale in other countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension or withdrawal of FDA approval or clearance (as may be applicable); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recall or seizure; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">partial suspension or total shutdown of production; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="break-inside: avoid; font-size: 0px;">
<td style="width: 4%;"></td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operating restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or consent decrees; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">civil or criminal prosecution. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We and any of our contract manufacturers, and some suppliers of components or device accessories, are required to manufacture medical device products in compliance with current Good Manufacturing Practice requirements set forth in the QSR, unless explicitly exempted by regulation. The QSR requires a quality system for the design, manufacture, packaging, labeling, storage, installation and servicing of marketed devices, and includes extensive requirements with respect to quality management and organization, device design, buildings, equipment, purchase and handling of components or services, production and process controls, packaging and labeling controls, device evaluation, distribution, installation, complaint handling, servicing, and record keeping. The FDA evaluates compliance with the QSR through periodic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-scheduled</div> or unannounced inspections that may include registered manufacturing facilities of our subcontractors. Following such inspections, FDA may issue reports known as Forms FDA 483 or Notices of Inspectional Observations, which list instances where the FDA inspector believes the manufacturer has failed to comply with applicable regulations and/or procedures. If the observations are sufficiently serious or the manufacturer fails to respond appropriately, the FDA may issue Warning Letters, which are notices of intended enforcement actions against the manufacturer. For less serious violations that may not rise to the level of regulatory significance, FDA may issue Untitled Letters. FDA may take more significant administrative or legal action if a manufacturer continues to be in substantial noncompliance with applicable regulations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, if the FDA believes we or any of our contract manufacturers or regulated suppliers are not in compliance with these requirements and patients are being subjected to serious risks, it can shut down manufacturing operations, require recalls of our medical device products, refuse to approve new marketing applications, initiate legal proceedings to detain or seize products, enjoin future violations, or assess civil and criminal penalties against us or our officers or other employees. Any such action by the FDA would have a material adverse effect on our business. We may be unable to comply with all applicable FDA regulations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Fraud and Abuse Laws and Other Compliance Requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successfully commercializing a medical device or technology depends not on only FDA approval, but also on broad health insurance or third party payor coverage. Government and private payors institute coverage criteria to ensure the appropriate utilization of products and services and to control costs. Limited third party payor coverage for a technology or procedure may limit adoption and commercial viability, while broader coverage supports optimal market uptake. Favorable coverage decisions by government payors like Medicare or Medicaid is critical because private payors typically follow the government&#8217;s lead regarding reimbursement. However, manufacturers whose technology is reimbursed by government payors are subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse. These laws can be implicated by inappropriate sales and marketing arrangements with healthcare providers. Many commonly accepted commercial practices are illegal in the healthcare industry and violations of these laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in U.S. federal and state healthcare programs, including Medicare and Medicaid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-kickback Laws.</div></div> The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration directly or indirectly to induce either the referral of an individual, or the furnishing, recommending, or arranging of a good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, credit arrangements, waiver of payments, and providing anything at less than its fair market value. The Department of Health and Human Services&#160;-&#160;Office of the Inspector General, has issued regulations, commonly known as safe harbors, which set forth certain provisions that, if satisfied in their entirety, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">will assure healthcare providers and other parties that they will not be prosecuted under the federal Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable safe harbor element may result in increased scrutiny by government enforcement authorities or invite litigation by private citizens under federal whistleblower laws. The Anti-Kickback law is broadly interpreted and aggressively enforced with the result that beneficial commercial arrangements can be criminalized in the healthcare industry because of the Anti-Kickback law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The penalties for violating the federal Anti-Kickback Statute include imprisonment for up to ten years, fines of up to $100,000 per violation and possible exclusion from federal healthcare programs such as Medicare and Medicaid. Many states have adopted prohibitions similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not only by the government programs such as Medicare and Medicaid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Federal False Claims Act.</div></div> The federal False Claims Act prohibits knowingly presenting, or causing to be presented a false claim or the knowing use of false statements or records to obtain payment from the federal government. When an entity is determined to have violated the False Claims Act, it must pay three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,181 and $22,363 for each separate false claim. Suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals (known as &#8220;relators&#8221; or, more commonly, as &#8220;whistleblowers&#8221;) may share in any amounts paid by the entity to the government in fines or settlement. In addition, certain states have enacted laws modeled after the federal False Claims Act. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim action, even before the validity of the claim is established and even if the government decides not to intervene in the lawsuit. Healthcare companies may decide to agree to large settlements with the government and/or whistleblowers to avoid the cost and negative publicity associated with litigation. In addition, the Affordable Care Act amended federal law to provide that a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Criminal prosecution is possible for knowingly making or presenting a false or fictitious or fraudulent claim to the federal government. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Federal Physician Self-Referral Law.</div></div> The Federal Physician Self-Referral Law, also referred to as the Stark Law, prohibits a physician (or an immediate family member of a physician) who has a financial relationship with an entity from referring patients to that entity for certain designated health services, including durable medical equipment and supplies, payable by Medicare, unless an exception applies. The Stark Law also prohibits such an entity from presenting or causing to be presented a claim to the Medicare program for such designated health services provided pursuant to a prohibited referral, and provides that certain collections related to any such claims must be refunded in a timely manner. Exceptions to the Stark Law include, among other things, exceptions for certain financial relationships, including both ownership and compensation arrangements. The Stark Law is a strict liability statute: to the extent that the statute is implicated and an exception does not apply, the statute is violated. In addition to the Stark Law, many states have implemented similar physician self-referral prohibitions that may extend to Medicaid, third party payors, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-pay</div> patients. Violations of the Stark Law must be reported and unauthorized claims must be refunded to Medicare in order to avoid potential liability under the federal False Claims Act for avoiding a known obligation to return identified overpayments. Violations of the Stark Law, the Anti-Kickback Statute, the Civil Monetary Penalties Law and/or the federal False Claims Act can also form the basis for exclusion from participation in federal and state healthcare programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Civil Monetary Penalties Law.</div></div> The Civil Monetary Penalties Law (&#8220;CMPL&#8221;) authorizes the imposition of substantial civil money penalties against an entity that engages in certain prohibited activities including but not limited to violations of the Stark Law or Anti-Kickback Statute, knowing submission of a false or fraudulent claim, employment of an excluded individual, and the provision or offer of anything of value to a Medicare or Medicaid beneficiary that the transferring party knows or should know is likely to influence beneficiary selection of a particular provider for which payment may be made in whole or part by a federal healthcare program, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commonly known as the Beneficiary Inducement CMP. Remuneration is defined under the CMPL as any transfer of items or services for free or for less than fair market value. There are certain exceptions to the definition of remuneration for offerings that meet the Financial Need, Preventative Care, or Promoting Access to Care exceptions (as defined in the CMPL). Sanctions for violations of the CMPL include civil monetary penalties and administrative penalties up to and including exclusion from participation in federal healthcare programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">State Analogs of Federal Fraud and Abuse Laws.</div></div> Many U.S. states have their own laws intended to protect against fraud and abuse in the healthcare industry and more broadly. In some cases these laws prohibit or regulate additional conduct beyond what federal law affects. Penalties for violating these laws can range from fines to criminal sanctions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">HIPAA.</div></div> The Health Insurance Portability and Accountability Act of 1996, as amended by the American Recovery and Reinvestment Act of 2009, and implementing regulations (&#8220;HIPAA&#8221;), created two new federal crimes: healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government sponsored programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FCPA and Other Anti-Bribery and Anti-Corruption Laws.</div></div> The U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA would include interactions with certain healthcare professionals or organizations in many countries. Our present and future business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Physician Payment Sunshine Act.</div></div> Manufacturers of U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-regulated</div> devices reimbursable by federal healthcare programs are subject to the Physician Payment Sunshine Act, which requires manufacturers to track and annually report certain payments and other transfers of value made to U.S.-licensed physicians or U.S. teaching hospitals. As a manufacturer of U.S. FDA regulated devices reimbursable by federal healthcare programs, we are subject to this law. We are also required to report certain ownership interests held by physicians and their immediate family members. In 2018, the law was extended to require tracking and reporting of transfers of value to physician assistants, nurse practitioners, and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> practitioners. The law carries penalties of up to $1.15&#160;million per year for violations, depending on the circumstances, and payments reported also have the potential to draw scrutiny on payments to and relationships with physicians, which may have implications under the Anti-Kickback Statute, Stark Law and other healthcare laws. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, there has been a recent trend of increased federal and state regulation of payments and other transfers of value provided to healthcare professionals and entities. Similar to the federal law, certain states also have adopted marketing and/or transparency laws relevant to device manufacturers, some of which are broader in scope. Certain states also mandate that device manufacturers implement compliance programs. Other states impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation, and other remuneration to healthcare professionals and entities. The need to build and maintain a robust compliance program with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of the requirements, resulting in fines and penalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. and European Data Security and Data Privacy Laws </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, as well as a number of other federal and state privacy-related laws, extensively regulate the use and disclosure of individually identifiable health information, known as &#8220;protected health information&#8221; or &#8220;PHI.&#8221; HIPAA applies to health plans, healthcare providers who engage in certain standard healthcare transactions </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">electronically, such as electronic billing, and healthcare clearinghouses, all of which are referred to as &#8220;covered entities&#8221; under HIPAA. State imposed health information privacy and security laws typically apply based on licensure, for example, licensed providers or licensed entities are limited in their ability to use and share health information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, all states have enacted legislation protecting the privacy and security of &#8220;personal information&#8221; such as identifiable financial or health information, social security number and credit card information. These laws overlap and apply simultaneously with federal privacy and security requirements and regulated entities must comply with all of them. The California Consumer Privacy Act (&#8220;CCPA&#8221;), which went into effect January&#160;1, 2020, is one of the most restrictive state privacy laws, protecting a wide variety of personal information and granting significant rights to California residents with respect to their personal information. In dealing with health information for the development of its technology or for commercial purposes, we will be indirectly affected by HIPAA and state-imposed health information privacy and security laws because these laws regulate the ability of our customers and research collaborators to share health information with us. Additionally, we must identify and comply with all applicable state laws for the protection of personal information with respect to employee information or other personal information that we collect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the European Union, increasingly stringent data protection and privacy rules that have and will continue to have substantial impact on the use of personal and patient data across the healthcare industry became stronger in May 2018. The EU General Data Protection Regulation, (&#8220;GDPR&#8221;) applies across the European Union and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance.</div> The GDPR fine framework can be up to 20&#160;million euros, or up to 4% of our total global turnover of the preceding fiscal year, whichever is higher. The GDPR sets out a number of requirements that must be complied with when handling the personal data of such European Union-based data subjects including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g. access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual are all classified as &#8220;special category&#8221; data under the GDPR and are afforded greater protection and require additional compliance measures. Noncompliance could result in the imposition of fines, penalties, data lockup or orders to stop noncompliant activities. We may be subject to GDPR if we undertake operations in the EU, offer products or services to individuals in the EU or monitor the behavior of individuals within the EU. Our research activities in the EU currently implicate the GDPR and if we undertake commercial operations in the EU, offer products or services to individuals in the EU or monitor the behavior of individuals within the EU, we will have additional compliance obligations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We could also be subject to evolving European Union laws on data export, for transfers of data outside the European Union to themselves, group companies or third parties. The GDPR only permits exports of data outside the European Union to jurisdictions that ensure an adequate level of data protection. The United States has not been deemed to offer an adequate level of protection, so in order for us to transfer personal data from the EU to the United States, we must identify a legal basis for data transfer (e.g., the European Union Commission approved Standard Contractual Clauses). On July&#160;16, 2020, the Court of Justice of the European Union or the CJEU, issued a landmark opinion in the case <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maximilian Schrems vs. Facebook</div></div> (Case <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-311/18),</div> called <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Schrems II</div></div>. This decision (a)&#160;calls into question commonly relied upon data transfer mechanisms as between the European Union member states and the United States (such as the Standard Contractual Clauses) and (b)&#160;invalidates the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-U.S.</div> Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the United States. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of European Union data protection authorities are difficult to predict. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, while the Data Protection Act of 2018 that &#8220;implements&#8221; and complements the GDPR achieved Royal Assent on May&#160;23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area to the United Kingdom will remain lawful under GDPR. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Regulation of Medical Devices </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International marketing and distribution of medical devices are subject to regulation by foreign governments, and such regulations may vary substantially from country to country. The time required to obtain marketing authorization in a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ. There is a trend towards harmonization of quality system standards among the European Union, United States, Canada and various other industrialized countries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary regulatory environment in Europe is that of the European Economic Area (the &#8220;EEA&#8221;), which is comprised of the 27 Member States of the European Union (the &#8220;EU&#8221;), Iceland, Liechtenstein and Norway. In the EEA, medical devices were previously required to comply with the Essential Requirements defined in Annex I to the EU Medical Devices Directive (&#8220;MDD&#8221;) (applicable in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-EU</div> EEA Member States via the Agreement on the European Economic Area), a coordinated system for the authorization of medical devices. The directives and standards outlined in the MDD regulate the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Devices that comply with the requirements of a relevant directive are entitled to bear the CE conformity marking, indicating that the device conforms to the essential requirements of the applicable directives and, accordingly, can be commercially distributed throughout the EEA. The method of assessing conformity varies depending on the class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a &#8220;Notified Body,&#8221; an organization designated by an EU country to assess a product&#8217;s conformity with the applicable legal requirements. This third-party assessment may consist of an audit of the manufacturer&#8217;s quality system and specific testing of the manufacturer&#8217;s product. An assessment by a Notified Body of one country within the EU is required in order for a manufacturer to commercially distribute the product throughout the EU. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2017, European Union regulatory bodies finalized a new Medical Device Regulation, which replaced the existing MDD framework and provided three years for transition and compliance, for a final effective date of May&#160;26, 2020. As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, however, the European Parliament voted in April 2020 to postpone implementation of the Medical Device Regulation by one year, giving the medical device industry and Notified Bodies until May&#160;26, 2021 to come into compliance. The Medical Device Regulation changes several aspects of the existing regulatory framework for medical device marketing in Europe and is expected to result in increased regulatory oversight of all medical devices marketed in the EU, which may, in turn, increase the costs, time and requirements that need to be met in order to place an innovative or high-risk medical device on the European market. In particular, the new regulations, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">establish explicit provisions on manufacturers&#8217; responsibilities for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> of the quality, performance and safety of devices placed on the market; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">improve the traceability of medical devices throughout the supply chain to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-user</div> or patient through a unique identification number; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">strengthen the rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">European medical device manufacturers and distributors are currently benefiting from a grace period for legacy MDD certificates that lasts until May&#160;26, 2024. For a product to qualify for the grace period, there must be no significant changes to such a legacy medical device as described in its existing MDD certificate; the recertification process under the Medical Device Regulation requires a demonstration that the performance and the safety of the currently marketed medical device has been maintained and that the system meets the new regulatory requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Outside of the European Union, regulatory authorization needs to be sought on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis in order for the company to market their products. Some countries have adopted medical device regulatory regimes, such as the Classification Rules for Medical Devices published by the Hong Kong Department of Health, the Health Sciences Authority of Singapore regulation of medical devices under the Health Products Act, and Health Canada&#8217;s risk classification system for invasive devices, among others. Each country may have its own processes and requirements for medical device licensing, approval/clearance, and regulation, therefore requiring the company to seek marketing authorizations on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, as previously noted, the United Kingdom left the European Union on January&#160;31, 2020, with a transitional period that expired on December&#160;31, 2020. The United Kingdom and the European Union entered into a trade agreement known as the Trade and Cooperation Agreement (&#8220;TCA&#8221;), which came into effect on January&#160;1, 2021. The TCA does not specifically refer to medical devices. However, as a result of Brexit, the Medical Device Regulation will not be implemented in the UK, and previous legislation that mirrored the Medical Device Regulation in the UK law has been revoked. The regulatory regime for medical devices in the UK will continue to be based on the requirements derived from EU legislation as of January&#160;21, 2020, and the UK may choose to retain regulatory flexibility or align with the Medical Device Regulation going forward. CE markings will continue to be recognized in the UK, and certificates issued by EU recognized Notified Bodies will be valid in the UK, until June&#160;30, 2023. For medical devices placed on the UK market after this period, the UK Conformity Assessment (&#8220;UKCA&#8221;) marking will be mandatory. In contrast, UKCA marking and certificates issued by UK Notified Bodies will not be recognized on the EU market. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including market surveillance, enforcement activities and measures, standardization related activities, exchanges of officials, and coordinated product recalls (or other similar actions). Depending on which countries products will ultimately be sold in, manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for placing medical devices on the Northern Ireland market will differ from those in the UK. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, outside the United States, a range of anti-bribery and anti-corruption laws, as well as some industry-specific laws and codes of conduct, apply to the medical device industry and interactions with government officials and entities and healthcare professionals. Such laws include, but are not limited to the UK Bribery Act of 2010. Further, the European Union member countries have emphasized a greater focus on healthcare fraud and abuse and have indicated greater attention to the industry by the European Anti-Fraud Office. Countries in Asia have also become more active in their enforcement of anti-bribery laws and with respect to procurement and supply chain fraud. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;15, 2022, we were not a party to any material legal proceedings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor was incorporated as a Cayman Islands exempted company on November&#160;18, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. Legacy Hyperfine was incorporated under the laws of the State of Delaware on February&#160;25, 2014 under the name &#8220;Hyperfine Research, Inc.&#8221; On May&#160;25, 2021, the name of Legacy Hyperfine was changed to &#8220;Hyperfine, Inc.&#8221; Liminal was incorporated under the laws of the State of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Delaware on September&#160;21, 2018 under the name &#8220;EpilepsyCo Inc.&#8221; On July&#160;20, 2020, the name of Liminal was changed to &#8220;Liminal Sciences, Inc.&#8221; On December&#160;21, 2021, HealthCor changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation, incorporated under the laws of the State of Delaware. On December&#160;22, 2021, HealthCor, Legacy Hyperfine and Liminal completed the Business Combination, pursuant to which each of Legacy Hyperfine and Liminal became a wholly owned subsidiary of HealthCor, HealthCor&#8217;s corporate name was changed to Hyperfine, Inc., Legacy Hyperfine&#8217;s corporate name was changed to Hyperfine Operations, Inc., Liminal&#8217;s corporate name was changed to Liminal Operations, Inc. (which was subsequently changed to Liminal Sciences, Inc.), and the business of Legacy Hyperfine and Liminal became the business of the Company. Our principal executive offices are located at 351 New Whitfield Street, Guilford, Connecticut 06437, and our telephone number is (203) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">458-7100.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information Available on the Internet </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our internet address is https://hyperfine.io, to which we regularly post copies of our press releases as well as additional information about us. Our annual reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> quarterly reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> current reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</div> and all amendments to those reports, will be available to you free of charge through the Investors section of our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission (the &#8220;SEC&#8221;). The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. We include our web site address in this prospectus only as an inactive textual reference. Information contained in our website does not constitute a part of this prospectus or our other filings with the SEC. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion and analysis of the financial condition and results of operations Hyperfine, Inc. and its subsidiaries (for purposes of this section, collectively referred as the &#8220;Company&#8221;, &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) should be read together with the audited combined and consolidated financial statements as of and for the years ended December&#160;31, 2021 and 2020, together with the related notes thereto, included elsewhere in this prospectus. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described under the heading &#8220;Risk Factors.&#8221; Actual results may differ materially from those contained in any forward-looking statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are an innovative digital health business with a mission to provide affordable and accessible imaging and monitoring and through magnetic resonance imaging (&#8220;MRI&#8221;) to revolutionize healthcare for people around the world. Our Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Portable Magnetic Resonance (&#8220;MR&#8221;) Imaging System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM</div> (&#8220;Swoop&#8221;) produces high-quality images at a lower magnetic field strength than conventional MRI systems, and can be used by healthcare professionals to make effective clinical diagnoses on a patient in a variety of settings where MRI devices have previously been inaccessible. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> interface and portable design of our Swoop system make it accessible for use anywhere in a hospital, clinic or patient care site. We are working to realize our vision of providing affordable and accessible imaging of health conditions around the world. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">MRI is a medical imaging technique used in radiology to image the anatomy and the physiological processes of the human body. It is typically used in a variety of clinical settings for medical diagnosis, staging of disease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> treatment. Unlike <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-ray</div> computed tomography (&#8220;CT&#8221;) or positron emission tomography (&#8220;PET&#8221;), MRI does not expose patients to harmful ionizing radiation. We believe MRI offers the most sensitive and objective measures of brain tissue and injury. Despite its advantages, many healthcare institutions throughout the world lack the facilities, qualified operators and capital necessary to acquire and maintain expensive MRI devices. The Swoop system is intended for use at the patient&#8217;s bedside in any hospital room or clinical setting, such as a physician&#8217;s office or a local urgent care facility. The demand for MRI has been augmented by the aging population and rising prevalence of cancer and cardiovascular, neurological and orthopedic conditions. Healthcare professionals and insurers are recognizing imaging as a cost-effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> diagnostic tool for evaluation and ongoing monitoring. Swoop is a next generation of these devices designed to drive costs down and expand the current $15.9&#160;billion imaging market. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the adoption of the Swoop system by healthcare professionals has benefits across healthcare communities in both high and low resource settings. Through our collaborations with the healthcare community, we have begun to optimize Hyperfine&#8217;s software ecosystem to harness Artificial Intelligence (&#8220;AI&#8221;) to transform the system into a true bedside clinical decision support platform. These efforts seek to improve image quality, help users analyze images, and reduce time to diagnosis. Our technology allows us to provide decision support and immediate feedback for diagnostic insight for clinicians of all levels of expertise. In the future, we hope to develop an ecosystem of products, expanding the capabilities of our core MRI product platform while introducing a brain sensing platform to offer a more complete solution and increase access to life saving technology across the care continuum. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine received 510(k) clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in 2020 for its Swoop Portable MR Imaging System, which is commercially available in the United States. In 2021, we also obtained a Medical Device License issued by Health Canada and expanded into the Canadian market. We also recently received regulatory authorization in New Zealand and Pakistan. In addition, we are initially seeking necessary regulatory authorizations in other major markets, including the United Kingdom, Australia and other countries. We are building our direct commercial infrastructure in the United States and also have plans to sell our products in other countries either through direct sales or through distributors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, the World Health Organization declared the global outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to be a pandemic. We continue to closely monitor the recent developments surrounding the continued spread and potential resurgence of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had, and is expected to continue to have, an adverse impact on our operations, particularly as a result of preventive and precautionary measures that we, other businesses, and governments are taking. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> created multiple commercial challenges in 2020 and has continued to do so in 2021 and 2022. We expect to see restrictions on our salesforce&#8217;s ability to visit sites to continue during 2022. Commercially, many hospitals and other healthcare providers decreased spending and limited physical access to facilities, slowing our ability to demonstrate our Swoop device. In addition, many hospitals and other healthcare providers continue to focus their attention on addressing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which we believe has resulted in lower sales volume. Trade shows and conferences moved to a virtual platform creating difficulty in demonstrating our device to key stakeholders. We moved to create a product demonstration roadshow using demonstration trucks, but were not able to scale due to truck shortages. It was not uncommon to host virtual product demonstrations with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-10</div> physicians, something that would ordinarily not happen or would take many weeks of planning to produce. With physician society conferences offline and slowing our commercial launch, we used the concept of &#8220;Demo at Your Door&#8221; &#8212; providing target customers <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hands-on</div> device experience at a place of their choosing. Virtual demonstrations, even though they generated a lot of interest in our product, often did not result in sales, and all sales required an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> product demonstration. As more conferences begin to be held <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person,</div> we expect to improve our ability to provide product demonstrations to potential customers. It is unclear whether or not conferences will have the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> attendance as they would have had in the past. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because the manufacturing of our Swoop system was developed, and our commercial launch of our Swoop system occurred, during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic market and manufacturing conditions, we did not have to materially adjust our existing resource allocation or our factors of production because of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, if there are further waves of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic driven by variants like Delta, Omicron or otherwise, we may experience a greater negative impact in our supply chain than we have previously. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the variants that followed, our suppliers agreed to shift new work to domestic suppliers to help reduce the risk of manufacturing delays. Our supplier and sub tier suppliers have been adversely affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Although we work closely with our suppliers to attempt to ensure continuity of supply, the supply of certain components and raw materials used in our product has been and may continue to be slowed as a direct result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and its variants. We have also experienced increases in product costs as raw materials have been constrained. Prices have risen sharply over the past year, and lead times have extended dramatically, particularly on semiconductor products. Over the next 12 months, we expect prices to increase due to the raw material demand surges across numerous industries, along with labor and transportation related constraints. We also expect lead times to reduce as component production levels recover to meet demand. We helped to minimize the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the manufacturing of our product and operations by using our manufacturer&#8217;s preferred suppliers, increasing communications with suppliers and freight carriers, and providing advanced forecasts and purchase orders for new and existing devices. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, future regulatory authorizations by the FDA or other regulatory authorities may take longer because of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic-related delays, though we have not been impacted by such delays to date. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Please refer to the section titled, &#8220;Risk Factors&#8221; included elsewhere in this prospectus for more information. We are unable to predict the full impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will have on our future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic and actions that may be taken by government authorities across the United States. We will continue to monitor the performance of our business and reassess the impacts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key Performance Metrics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We review the key performance measures discussed below to evaluate the business and measure performance, identify trends, formulate plans and make strategic decisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Installed Base </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Swoop total installed base consists of three components, discussed in further detail below: Commercial system installations (which make up total revenue), grant fulfillment installations, and research unit installations. The Swoop total installed base (or total installed units) is the number of Swoop devices deployed to hospitals, other healthcare providers, and research institutions. We view the total installed base as a key metric of the growth of our business and is measured from period over period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented below is a breakout of total Swoop systems installed during 2020 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TOTAL&#160;INSTALLED&#160;UNITS</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TOTAL</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial systems installations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant fulfillment installations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research units</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Installed Units</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercial system installations</div></div> reflect device sales and subscription services through commercial agreements (commercial sales) or through research transfer agreements (&#8220;RTA&#8221;) sales. Commercial sales are made to hospitals and other healthcare providers as direct sales of devices and software subscription services or through subscriptions for the use of the device and software. RTA sales represent the sale of Swoop units for research use purposes. Our revenue for the years ended December&#160;31, 2021, and 2020 is derived from commercial sales and RTA sales. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant fulfillment installations</div></div> consist of shipments of Swoop units to hospitals and other clinical facilities designated by the Bill&#160;&amp; Melinda Gates Foundation (&#8220;BMGF&#8221;). The corresponding funding for these installations from BMGF is recorded as a reduction in the research and development expenses when realized during the period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research units</div></div> represent installed units, at no cost to the institutions, to expand clinical use cases. The installation of research units is recorded as a fixed asset with the related depreciation recorded as R&amp;D expense over the life of the research unit. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors Affecting Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following factors have been important to our business and we expect them to impact our results of operations and financial condition in future periods: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Strategic partnerships and accelerated international expansion </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that market expansion is a key to our continued growth and the success of our device. In line with our vision to democratize healthcare imaging by providing affordable and accessible imaging of health conditions around the world, we are building an international sales strategy that includes direct sales to customers and sales through distribution partners in target regions. In 2021, we obtained a Medical Device License issued by Health Canada and expanded into the Canadian market. We recently also received regulatory authorization in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">New Zealand and Pakistan. In our plans for international commercial expansion, the other countries in which we plan initially to commercialize our Swoop system include, subject to the regulatory authorization, the United Kingdom and Australia. Through the Bill and Melinda Gates Foundation (&#8220;BMGF&#8221;) partnership, we are deploying Swoop systems in these target areas for research and clinical settings. The utilization of our Swoop systems as part of the programs will allow us to begin building relationships across key stakeholders in these countries or regions to better understand and meet required regulatory hurdles in anticipation of filing for regulatory authorization and ultimately expand into clinical use with patients. In addition, we are considering commercial expansion into several of the larger EU countries following our initial international commercial expansion. We believe these countries have the market size, regulatory environment, commercial access, and mature healthcare systems necessary, subject to regulatory authorization, for a successful launch of our Swoop system. We believe our partnership with the BMGF demonstrates our commitment to the vision of providing affordable and accessible imaging that enables earlier detection and remote management of health conditions around the world. Through our engagement with nonprofit organizations, we aim to deploy the Swoop system to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-middle</div> resource settings without readily-accessible MRI technology. During 2020, we were awarded a $1.6&#160;million grant from the BMGF for the provision and equipping of 20 sites with the Hyperfine portable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system to enable the performance of a multi-site study focused on optimizing diagnostic image quality (the &#8220;Project&#8221;). During the third quarter of 2021, we were awarded an additional $3.3&#160;million grant, of which $2.5&#160;million was received from the BMGF in September 2021, with the remainder expected to be received by April 2022. Both of the grants are designed to support the deployment of a total of 25 Swoop devices and other services to investigators, which commenced in the spring of 2021, and is expected to fund the program for approximately two years. At December&#160;31, 2021, 18 Swoop system units were provisioned and delivered to BMGF. These grants are designed to provide data to validate the use of our Swoop system in measuring the impact of maternal anemia, malnutrition, infection and birth related injury. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Technical innovation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have developed our device through extensive research and development activities. Our Swoop system is designed to make the customer experience as easy as possible through our integrated, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">easy-to-use</div></div> interface that portrays images on a tablet, smartphone or other WiFi capable device. In addition to this design, our team is focused on customer success programs that help integrate the Swoop system into any hospital or clinic workflow. We believe that as the Swoop system becomes integrated into ICUs and sites across medical practices, we will gain more insights into our product&#8217;s usability and potentially develop automated analysis of images that we believe will lead to further efficiencies in patient diagnosis. We plan to continue developing our technology to expand into new imaging applications to enable us to reach the broader care continuum through diagnosis and treatment. In the future, we plan to introduce a further enhanced MRI system designed to conduct neuroimaging and imaging of other extremities for interventional procedures. In addition to our efforts to disrupt the MRI market, we see a significant opportunity to help patients in the neuromonitoring space. Although we expect these activities in technical innovation of the current device and new devices will increase our research and development expenses, we expect it to positively impact our results of operations and profitability in the future. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Certain Components of Financial Data </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We derive our sales from the following sources: device sales and service sales as described in more detail below. Our revenue recognition policies are discussed in more detail under &#8220;Summary of Significant Accounting Policies&#8221; in Note 2 to our combined and consolidated financial statements and notes thereto for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device: Device sales primarily consist of sales of our MRI devices. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service: Service sales primarily consists of sales from subscriptions of bundled devices, maintenance, and software. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of sales </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales consists of product and service costs including personnel cost and benefits including stock-based compensation, product costs, production setup expenses, depreciation and amortization expenses, inventory excess and obsolescence expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs consist of production costs for prototype, test and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-production</div> units, lab supplies, consulting and personnel costs, including salaries, stock-based compensation, bonuses and benefit costs. Most of our research and development expenses are related to developing new products and services as well as to enhance our current product and software capabilities. Consulting expenses are related to research and development activities as well as clinical and regulatory activities. Fabrication services include certain third-party engineering costs. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in product development. As a result, research and development expenses are expected to increase in absolute dollars as the research and development efforts increase. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses primarily consist of personnel costs and benefits including stock-based compensation, patent and filing fees, office expenses, technology expenses and outside services. Outside services consist of professional services, legal and other professional fees. We expect that general and administrative expenses will increase in absolute dollars as a result of operating as a public company, including adding hires in accounting, human resources, and legal. Other related costs include additional facilities expenses and general corporate overhead to support the employee base. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales and marketing </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing costs primarily consist of personnel costs and benefits including stock-based compensation, advertising, promotional costs, as well as costs for conferences, meetings, and other events. We expect sales and marketing expenses will increase in absolute dollars in the near term as we build our internal sales and marketing teams, promote our brand through marketing and advertising initiatives and expand our market presence and awareness. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest income </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income primarily consists of interest earned on our cash equivalents invested in money market securities. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other expense, net </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net primarily relates to interest on a related party note payable. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provision for income taxes </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We utilize the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification (&#8220;ASC&#8221;) 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that some or all of the net deferred tax assets will not be realized. We recorded a full valuation allowance as of December&#160;31, 2021 and 2020. Based on available evidence, we believe that it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that we will be unable to utilize all of our deferred tax assets in the future. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted which included provisions related to net operating loss (&#8220;NOL&#8221;) carryovers and carrybacks. The CARES Act amended the NOL carryback rules by allowing NOLs arising in tax years beginning after December&#160;31, 2017 and before January&#160;1, 2021 to be carried back to each of the 5 years preceding the year of the loss to generate a refund of previously paid income taxes. In addition, the CARES Act temporarily removed the 80% limitation under which NOLs generated post-2017 could be used to offset no more than 80% of taxable income, and allows for full use of such NOLs for tax years before January&#160;1, 2021. We have evaluated the relevant provisions of the CARES Act and have determined that we do not expect to recognize any benefit related to these provisions due to our net operating losses in the current year and all prior years. Therefore, there are no income tax effects to be recognized in the combined and consolidated financial statements for the years ended December&#160;31, 2021 and 2020. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of our results of operations for the periods shown below, and our accounting policies are described under &#8220;Summary of Significant Accounting Policies&#8221; in Note 2 in our combined and consolidated financial statements for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Change</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">($ Amounts in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2021</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2020</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">%</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Device</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">730.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total sales</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Sales</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Device</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,058</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7462.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">245.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gross margin</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(1,167</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(477</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,842</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">364.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">63,701</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">23,014</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(64,868</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(23,491</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss before provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(64,851</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(23,427</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net loss and comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(64,851</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(23,427</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of the Years Ended December&#160;31, 2021 and 2020 ($ Amounts in thousands) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">687</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">294</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">408.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total sales increased by $1.2&#160;million, or 408.8%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device sales increased by $0.5&#160;million, or 257.5%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven by an increase in the volume of device sales. In the first quarter of 2022, we have taken a pricing action by increasing the price of the device while lowering the price of the annual subscription. We expect this pricing action will result in higher device revenue per unit and lower service revenue per unit for sales under the subscription plus ownership model beginning in the first quarter of 2022. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service sales increased by $0.7&#160;million, or 730.9%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven by an increase in the volume of devices installed as generally all commercial systems installations generate service revenue. Service sales revenue is generally recognized over time as we are providing the customer with ongoing access to our resources throughout the subscription period. This type of revenue is recurring in nature and we expect will continue to grow as more devices are sold. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">763</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,462.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cost of sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">771</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cost of sales increased by $1.9&#160;million, or 245.4%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of device sales increased by $1.3&#160;million, or 169.7%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven primarily by third party manufacturing costs as a result of increased volume of products sold. The increase is comprised of a $0.8&#160;million increase in product hardware costs and a $0.5&#160;million increase in internal overheads and labor costs mostly related to customer support and engineering as a result of an increase in the volume of products sold. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service sales increased by $0.6&#160;million, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven primarily by $0.4&#160;million increase in internal overheads and labor costs and a $0.2&#160;million increase in depreciation of devices installed. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,593</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses increased by $11.2&#160;million, or 77.1%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven primarily by an increase in personnel related costs of $8.1&#160;million as a result of increased headcount, an increase in professional services of $1.1&#160;million, an increase in stock-based compensation of $0.5&#160;million, and an increase in travel expenses of $0.5&#160;million. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">364.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses increased by $21.6&#160;million, or 364.4%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven primarily by an increase in professional services of $4.3&#160;million, an increase in personnel related expenses of $6.7&#160;million, an increase in legal costs of $1.6&#160;million, an increase in stock-based compensation of $5.3&#160;million, an increase in recruiting expenses of $1.5&#160;million as well as an increase of $0.7&#160;million of technology related costs. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,362</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">314.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing expenses increased by $7.9&#160;million, or 314.5%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This increase was driven primarily by an increase in personnel related expenses of $3.3&#160;million due to increased headcount as the business had a full year of commercial operations, an increase in product advertising and marketing expenses of $3.0&#160;million, an increase in professional and other outside service of $0.6&#160;million, and an increase in travel expense of $0.3&#160;million. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(52</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income decreased by $0.1&#160;million, or 74.3%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This decrease was driven primarily by lower interest rates in money market accounts in 2021 as compared to 2020. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(83.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense decreased by $0.01&#160;million, or 83.3%, for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. This decrease was driven primarily by realized gains on foreign currencies. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have funded our operations primarily with proceeds from the issuance of common and preferred stock. We have incurred significant cash burn and recurring net losses, which includes a net loss of $64.9&#160;million for the year ended December&#160;31, 2021, and an accumulated deficit of $136.3&#160;million as of December&#160;31, 2021. In addition, on December&#160;22, 2021, we completed the Business Combination with HealthCor, and as a result we received gross proceeds of approximately $162.1&#160;million and net proceeds of approximately $141.5&#160;million. As of December&#160;31, 2021, we had cash and cash equivalents of $188.5&#160;million. As we continue to invest in research and development of our products and sales and marketing, we expect to continue to incur a significant cash burn and recurring net losses for the foreseeable future until such time that our product and services sales generate enough gross profit to cover our operating expenses. However, we can provide no assurance that our product and service sales will generate a net profit in the future or that our cash resources will be sufficient to continue our commercialization and development activities. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect to continue to incur net losses as we continue to invest in research and development and sales and marketing of our products. Our ability to access capital when needed is not assured and, if capital is not available when, and in the amounts needed, we could be required to delay, scale back or abandon some or all of our development programs, commercialization of our products, and other operations which could materially harm our operations, financial condition and operating results. We expect that our existing cash and cash equivalents, together with proceeds from the sales of our products and services, will enable us to conduct our planned operations for at least the next 12 months. We expect we will require an accelerated amount of spending to enhance the sales and marketing teams, continue to drive development of our products, and build inventory. Other factors that could accelerate cash needs include: (i)&#160;delays in achieving scientific and technical milestones; (ii)&#160;unforeseen capital expenditures and fabrication costs related to manufacturing; (iii)&#160;changes we may make in our business or commercialization and hiring strategy; (iv)&#160;the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; (v)&#160;costs of running a public company; and (vi)&#160;other items affecting our forecasted level of expenditures and use of cash resources including potential acquisitions. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to use our funds to further invest in the development of our products and services, commercial expansion, and for working capital and general corporate purposes. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we had cash and cash equivalents of $188.5&#160;million. Our future capital requirements may vary from those currently planned and will depend on various factors including further development costs, commercialization strategy, international expansion, and regulatory costs. If we need additional funds and are unable to obtain funding on a timely basis, we may need to curtail significantly our product development and commercialization efforts to provide sufficient funds to continue our operations, which could adversely affect our business prospects. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash flows </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our cash flows for the periods indicated: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,525</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176,767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,938</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash, cash equivalents, and restricted cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">126,874</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37,845</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net cash used in operating activities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For the year ended December&#160;31, 2021, net cash used in operating activities of $47.2&#160;million was due primarily to a net loss of $64.9&#160;million, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items of $8.7&#160;million and changes in operating assets and liabilities of $9.0&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> items were primarily stock-based compensation expense of $6.9&#160;million. Changes in operating assets and liabilities were driven primarily by an increase in inventory of $2.7&#160;million, partially offset by an increase in accrued expense and other current liabilities of $6.9&#160;million and amounts due to related parties of $1.8&#160;million. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the year ended December&#160;31, 2020, net cash used in operating activities of $21.5&#160;million was due primarily to a net loss of $23.4&#160;million, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items of $1.6&#160;million and changes in operating assets and liabilities of $0.3&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> items were primarily stock-based compensation expense of $1.1&#160;million. Changes in operating assets and liabilities were driven primarily by an increase in inventory of $1.9&#160;million and amounts due from related parties of $0.8&#160;million, partially offset by an increase in deferred grant funding of $1.6&#160;million. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net cash used for investing activities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2021, net cash used in investing activities of $2.7&#160;million was from fixed assets purchased. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, net cash used in investing activities of $1.6&#160;million was from fixed assets purchased. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net cash provided by financing activities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2021, net cash provided by financing activities of $176.8&#160;million was primarily due to proceeds from issuance of Series D convertible preferred stock of $30.5&#160;million, and net proceed from equity infusion from the Business Combination of $141.5&#160;million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, net cash provided by financing activities of $60.9&#160;million was primarily due to proceeds from issuance of Series D convertible preferred stock of $59.8&#160;million and investment proceeds from 4Bionics of $1.0&#160;million. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contractual obligations </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We sponsor a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. We did not make any matching contributions to the 401(k) plan for the years ended December&#160;31, 2021 and 2020. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In April 2020, we received a $1.6&#160;million grant from the BMGF for the provision and equipping of 20 sites with the Hyperfine portable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system to enable the performance of a multi-site study focused on optimizing diagnostic image quality. During the third quarter of 2021, we were awarded an additional $3.3&#160;million grant, of which $2.5&#160;million was received from the BMGF in September 2021. Refer to Note 16 to our combined and consolidated financial statements and notes thereto for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus for a discussion of the BMGF grant. Any grant funds, plus any income, that have not been used for, or committed to, the Project must be returned promptly to BMGF upon expiration of or termination of the agreement. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We had no other significant contractual obligations as of December&#160;31, 2021. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information on contingencies, refer to Note 16 to our combined and consolidated financial statements and notes thereto for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Judgments and Estimates </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of our financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. While our significant accounting policies are described in more detail in Note 2 in our combined and consolidated financial statements for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue recognition </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We make judgments applying the guidance related to the estimation of variable consideration. We have certain subscription contracts that provide variable discounts to customers (subject to a maximum). These discounts vary and represent variable consideration, and we use the expected value method to estimate this variable consideration. Given the high degree of uncertainty around the occurrence of these events, we determine the variable consideration to be fully constrained until the uncertainty associated with these discounts is resolved. We will recognize revenue from subscription revenue straight line over the subscription period. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories primarily consist of finished goods which are produced by the Company&#8217;s third-party contract manufacturers and raw materials ordered in advance by the third-party contract manufacturer due to long delivery-lead time and were billed to the Company. Inventories are stated at the lower of actual cost, determined using the average cost method, or net realizable value (&#8220;NRV&#8221;). We routinely evaluate quantities and value of our inventories in light of current market conditions and market trends and record a write-down against the cost of inventories for NRV below cost. NRV is based upon an estimated average selling price reduced by the estimated costs of disposal and transportation. The determination of NRV involves numerous judgments including estimating selling prices, existing customer orders, and estimated costs of disposal and transportation. If actual market conditions differ from our estimates, future results of operations could be materially affected. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation of inventory also requires us to estimate excess and obsolete inventory. We periodically review the age, condition and turnover of our inventory to determine whether any inventory has become obsolete or has declined in value and incur a charge to operations for known and anticipated inventory obsolescence. We also consider how quickly customers will transition from older products to newer products, including whether </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">older products can be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-manufactured</div> into new products. The evaluation takes into consideration the effect that new products might have on the sale of existing products, product obsolescence, product merchantability and other factors. Market conditions are subject to change and if actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which would have a negative impact on gross margin. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our stock-based compensation program includes restricted stock unit and stock option grants to our employees, directors and consultants. Stock options are granted at exercise prices not less than the estimated fair market value of our common stock at the dates of grant. For purposes of restricted stock unit grants, the grant date fair value is calculated as the fair market value of the stock on the date of grant. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair values of stock option grants are estimated using a Black-Scholes option-pricing model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and changes in assumptions could have a significant impact in the determination of stock-based compensation expense. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key assumptions include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate: The risk-free interest rate for periods within the contractual life of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield: We have never declared or paid any cash dividends and do not expect to pay any cash dividends in the foreseeable future. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term: We calculate expected term using the &#8220;simplified&#8221; method, which is the simple average of the vesting period and the contractual term. The simplified method is applied as we do not have sufficient historical data to provide a reasonable basis for an estimate of the expected term. We calculate the expected term for employee awards that take into account the effects of employees&#8217; expected exercise and post-vesting employment termination behavior. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility: We determined expected annual volatility based on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the stock- based awards. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, stock options granted to employees fully vest four years from the grant date and have a term of 10 years and stock options granted to non-employees fully vest one year from the grant date or upon performance of a service and have a term of 10&#160;years. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, Liminal was a wholly owned subsidiary of 4Bionics, and as such, 4Bionics granted equity awards in the form of incentive units to Liminal employees and nonemployees under 4Bionics&#8217; stock-based compensation program. On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionics&#8217; 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), Tesseract Health, Inc. and Protein Evolution, Inc. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to the modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after the modification was unchanged. No incremental compensation expense was recognized as a result of the modification. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the dissolution of 4Bionics, a portion of total 4Bionics stock-based compensation expense was allocated to Liminal based on the level of service provided by the relevant employees and nonemployees to </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal over the term of the award. Subsequent to the dissolution of 4Bionics, we recognize the stock-based compensation expense related to the replacement preferred stock awards and no allocation methodology is required. In connection with the Closing of the Business Combination, all replacement preferred stock awards were accelerated to fully vest. We recognized stock-based compensation expense of $0.6&#160;million related to the incentive unit awards and replacement preferred stock awards during the year ended December&#160;31, 2021. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our combined and consolidated financial statements and notes thereto for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative and Qualitative Disclosures about Market Risk </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are exposed to market risk in the ordinary course of business. Market risk represents the risk of loss that may impact our results of operations or financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates. We do not hold, issue or enter into any financial instruments for speculative or trading purposes. We do not have significant exposure to foreign currencies. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate risk </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cash equivalents as of December&#160;31, 2021 consisted of $48.6&#160;million in money market funds. Such interest-earning instruments carry a degree of interest rate risk. The goals of our investment policy are liquidity and capital preservation. We believe that we do not have any material exposure to changes in the fair value of these assets as a result of changes in interest rates due to the short-term nature of our cash equivalents. We do not believe that a hypothetical 10% change in interest rates would have a material effect on our cash flows or operating results. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DESCRIPTION OF OUR CAPITAL STOCK </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following summary of the material terms of the capital stock of Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation, as amended (the &#8220;Charter&#8221;), and our Bylaws, as amended (the &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to the Registration Statement of which this prospectus is a part, and certain provisions of Delaware law. We urge you to read each of our Charter and our Bylaws in their entirety for a complete description of the rights and preferences of our securities. Unless the context requires otherwise, all references to &#8220;we&#8221;, &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;Hyperfine&#8221; in this section refer solely to Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.) and not to our subsidiaries. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Authorized Capital Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are authorized to 628,000,000 shares, consisting of 600,000,000 shares of Class&#160;A common stock, par value $0.0001 per share, 27,000,000 shares of Class&#160;B common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Common Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A common stock are entitled to cast one vote per share. Generally, holders of all classes of common stock vote together as a single class, and an action is approved by stockholders if a majority of votes cast affirmatively or negatively on the action are cast in favor of the action, while directors are elected by a plurality of the votes cast. Holders of Class&#160;A common stock are not entitled to cumulate their votes in the election of directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With limited exceptions in the case of certain stock dividends or disparate dividends approved by the affirmative vote of the holders of a majority of the Class&#160;A common stock and Class&#160;B common stock, each voting separately as a class, holders of Class&#160;A common stock will share ratably (based on the number of shares of Class&#160;A common stock held), together with each holder of Class&#160;B common stock, if and when any dividend is declared by our board of directors out of funds legally available therefor, subject to restrictions, whether statutory or contractual (including with respect to any outstanding indebtedness), on the declaration and payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock or any class or series of stock having a preference over, or the right to participate with, the Class&#160;A common stock with respect to the payment of dividends. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation, Dissolution and Winding Up </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the liquidation, dissolution, distribution of assets or winding up of Hyperfine, each holder of Class&#160;A common stock, together with each holder of Class&#160;B common stock, will be entitled, pro rata on a per share basis, to all assets of Hyperfine of whatever kind available for distribution to the holders of common stock, subject to the designations, preferences, limitations, restrictions and relative rights of any other class or series of preferred stock of Hyperfine then outstanding and unless disparate or different treatment of the shares of Class&#160;A common stock and Class&#160;B common stock is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class&#160;A common stock and Class&#160;B common stock, each voting separately as a class. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Matters </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Holders of shares of Class&#160;A common stock do not have subscription, redemption or conversion rights. All of the outstanding shares of Class&#160;A common stock are validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;B Common Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;B common stock are entitled to cast 20 votes per share of Class&#160;B common stock. Generally, holders of all classes of our common stock vote together as a single class, and an action is approved by our stockholders if a majority of votes cast affirmatively or negatively on the action are cast in favor of the action, while directors are elected by a plurality of the votes cast. Holders of Class&#160;B common stock will not be entitled to cumulate their votes in the election of directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With limited exceptions in the case of certain stock dividends or disparate dividends approved by the affirmative vote of the holders of a majority of the Class&#160;A common stock and Class&#160;B common stock, each voting separately as a class, holders of Class&#160;B common stock will share ratably (based on the number of shares of Class&#160;B common stock held), together with each holder of Class&#160;A common stock, if and when any dividend is declared by our board of directors out of funds legally available therefor, subject to restrictions, whether statutory or contractual (including with respect to any outstanding indebtedness), on the declaration and payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock or any class or series of stock having a preference over, or the right to participate with, the Class&#160;B common stock with respect to the payment of dividends. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Optional Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Holders of Class&#160;B common stock have the right to convert shares of their Class&#160;B common stock into fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Class&#160;A common stock, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> basis, at the option of the holder at any time upon written notice to us. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mandatory Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Holders of Class&#160;B common stock can have their shares of Class&#160;B common stock automatically converted into shares of Class&#160;A common stock, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> basis, upon the occurrence of any of the events described below: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any sale, assignment, transfer, conveyance, hypothecation, or other transfer or disposition, directly or indirectly, of any shares of Class&#160;B common stock or any legal or beneficial interest in such shares, whether or not for value and whether voluntary or involuntary or by operation of law (including by merger, consolidation, or otherwise), including, without limitation the transfer of shares of Class&#160;B common stock to a broker or other nominee or the transfer of, or entering into a binding agreement with respect to, voting control over such shares by proxy or otherwise, other than a permitted transfer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the first date on which Dr.&#160;Rothberg, together with all other qualified stockholders, collectively cease to beneficially own at least 20% of the number of Class&#160;B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination, or recapitalization of the Class&#160;B common stock) collectively beneficially owned by Dr.&#160;Rothberg and permitted transferees of Class&#160;B common stock as of the Closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Upon the date specified by the affirmative vote of the holders of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> (2/3) of the outstanding shares of Class&#160;B common stock, voting as a separate class. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Rights, Dissolution and Winding Up </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the liquidation, dissolution, distribution of assets or winding up of Hyperfine, each holder of Class&#160;B common stock, together with each holder of Class&#160;A common stock, will be entitled, pro rata on a per share basis, to all assets of Hyperfine of whatever kind available for distribution to the holders of common stock, subject to the designations, preferences, limitations, restrictions and relative rights of any other class or series of preferred stock of Hyperfine then outstanding and unless disparate or different treatment of the shares of Class&#160;A common stock and Class&#160;B common stock is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class&#160;A common stock and Class&#160;B common stock, each voting separately as a class. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that our board of directors has the authority, without action by the stockholders, to designate and issue shares of preferred stock in one or more classes or series, and the number of shares constituting any such class or series, and to fix the voting powers, designations, preferences, limitations, restrictions and relative rights of each class or series of preferred stock, including, without limitation, dividend rights, conversion rights, voting rights, redemption privileges and liquidation preferences. There were no shares of preferred stock outstanding as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of authorizing our board of directors to issue preferred stock and determine the rights and preferences of any classes or series of preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The simplified issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Additionally, the issuance of preferred stock may adversely affect the holders of our common stock by restricting dividends on our common stock, diluting the voting power of our common stock or subordinating the dividend or liquidation rights of our common stock. As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2021, we completed the Business Combination contemplated by the Business Combination Agreement, pursuant to which Legacy Hyperfine survived the Hyperfine Merger as a wholly-owned subsidiary of HealthCor and Liminal survived the Liminal Merger as a wholly-owned subsidiary of HealthCor. In connection with the Mergers, HealthCor changed its name to Hyperfine, Inc., Legacy Hyperfine changed its name to &#8220;Hyperfine Operations, Inc.&#8221; and Liminal changed its name to &#8220;Liminal Operations, Inc.&#8221; Liminal subsequently changed its name to &#8220;Liminal Sciences, Inc.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a consequence of the Mergers, at the Effective Time, (i)&#160;each share of Legacy Hyperfine capital stock (other than shares of Legacy Hyperfine Series A preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to the Hyperfine Exchange Ratio, rounded down to the nearest whole number of shares; (ii)&#160;each share of Legacy Hyperfine Series A preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Hyperfine Exchange Ratio, rounded down to the nearest whole number of shares; (iii)&#160;each share of Liminal capital stock (other than shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to the Liminal Exchange Ratio, rounded down to the nearest whole number of shares; (iv)&#160;each share of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Liminal Exchange Ratio, rounded down to the nearest whole number of shares; (v)&#160;each option to purchase shares of Legacy Hyperfine common stock and each option to purchase shares of Liminal common </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such option immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded up to the nearest whole cent; and (vi)&#160;each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exclusive Forum </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that, to the fullest extent permitted by law, unless we otherwise consents in writing, the Court of Chancery (the &#8220;Chancery Court&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on behalf of Hyperfine, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by, or any other wrongdoing by, any current or former director, officer, other employee or stockholder of Hyperfine, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the DGCL, our Charter or Bylaws, or as to which the DGCL confers jurisdiction on the Court of Chancery, (4)&#160;any action to interpret, apply, enforce or determine the validity of any provisions of our Charter or Bylaws, or (5)&#160;any other action asserting a claim governed by the internal affairs doctrine. Notwithstanding the foregoing, the federal district courts of the United States shall be the exclusive forum for the resolution of any action, suit or proceeding asserting a cause of action arising under the Securities Act and the provisions of our Charter described above will not apply to claims arising under the Exchange Act or other federal securities laws for which there is exclusive federal jurisdiction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Takeover Effects of Provisions of our Charter, Bylaws and Applicable Law </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain provisions of our Charter, Bylaws, and laws of the State of Delaware, where we are incorporated, may discourage or make more difficult a takeover attempt that a stockholder might consider in his or her best interest. These provisions may also adversely affect prevailing market prices for the Class&#160;A common stock and the Class&#160;B common stock. We believe that the benefits of increased protection give us the potential ability to negotiate with the proponent of an unsolicited proposal to acquire or restructure us and outweigh the disadvantage of discouraging those proposals because negotiation of the proposals could result in an improvement of their terms. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized but Unissued Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delaware law does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of Nasdaq, which apply so long as the Class&#160;A common stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock. Additional shares that may be issued in the future may be issued for a variety of corporate purposes, including future public offerings, to raise additional capital, or to facilitate acquisitions. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of Hyperfine by means of a proxy contest, tender offer, merger, or otherwise. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dual Class&#160;Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described above, our Charter provides for a dual class common stock structure which provides Dr.&#160;Rothberg with the ability to control the outcome of matters requiring stockholder approval, even though he owns significantly less than a majority of the shares of our outstanding common stock, including the election of directors and significant corporate transactions, such as a merger or other sale of Hyperfine or its assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blank Check Preferred Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides for 1,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of Hyperfine or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our Charter grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of the holders of shares of common stock and may have the effect of delaying, deterring or preventing a change in control of Hyperfine. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Number of Directors </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter and Bylaws provide that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors may be fixed from time to time solely pursuant to a resolution adopted by our board of directors; provided, however, that prior to the first date on which the issued and outstanding shares of Class&#160;B common stock represent less than 50% of the voting power of the then outstanding shares of our capital stock that would be entitled to vote for the election of directors at an annual meeting of stockholders, unless approved by the holders of a majority in voting power of the shares of our capital stock that would then be entitled to vote in the election of directors at an annual meeting or by written consent, the number of directors may not exceed nine (9). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Requirements for Advance Notification of Stockholder Meetings, Nominations and Proposals </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Bylaws establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of the board. In order to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder&#8217;s notice must be delivered to, or mailed and received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the immediately preceding annual meeting of stockholders. Our Bylaws also specify requirements as to the form and content of a stockholder&#8217;s notice. Our Bylaws allow the chairperson of the meeting at a meeting of the stockholders to determine whether a proposal to the meeting was properly brought and to adopt rules and regulations for the conduct of meetings, except to the extent inconsistent with such rules, regulations and procedures as adopted by our board of directors, which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control of Hyperfine. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Limitations on Stockholder Action by Written Consent </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that, subject to the terms of any series our preferred stock, any action required or permitted to be taken by our stockholders must be effected at an annual or special meeting of the stockholders and may not </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">be effected by written consent in lieu of a meeting; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided, however</div></div>, that prior to the first date on which the issued and outstanding shares of Class&#160;B common stock represent less than 50% of the voting power of the then outstanding shares of our capital stock that would then be entitled to vote for the election of directors, any action required or permitted to be taken at any annual or special meeting of our stockholders, may be taken by written consent if such written consent is signed by the holders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such matter were present and voted. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment of our Charter and Bylaws </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The DGCL provides generally that the affirmative vote of a majority of the outstanding shares entitled to vote thereon, voting together a single class, is required to amend a corporation&#8217;s certificate of incorporation, unless the certificate of incorporation requires a greater percentage. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that it may be amended by us in the manner provided therein or prescribed by statute. Our Charter provides that the affirmative vote of the holders of a majority of the voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class, will be required to amend or repeal any provision of our Charter, or adopt any provision of our Charter inconsistent therewith. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If any of the Class&#160;B common stock shares are outstanding, in addition to any vote required by Delaware law, the affirmative vote of the holders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> (2/3) of the outstanding shares of Class&#160;B common stock, voting as a separate class, is required to amend our Charter (1)&#160;in a manner that changes any of the voting, conversion, dividend or liquidation provisions of the shares of Class&#160;B common stock, (2)&#160;to provide for each share of Class&#160;A common stock or any preferred stock to have more than one vote per share or any rights to a separate class vote of the holders of shares of Class&#160;A common stock other than as provided by our Charter or required by the DGCL, or (3)&#160;to otherwise adversely impact the rights, powers, preferences or privileges of the shares of Class&#160;B common stock in a manner that is disparate from the manner in which it affects the rights, powers, preferences or privileges of the shares of Class&#160;A common stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any shares of the Class&#160;A common stock shares are outstanding, we will not, without the prior affirmative vote of the holders of a majority of the outstanding shares of Class&#160;A common stock, voting as a separate class, in addition to any other vote required by applicable law or our Charter, directly or indirectly, whether by amendment, or through merger, recapitalization, consolidation or otherwise amend, alter, change, repeal or adopt any provision of our Charter (1)&#160;in a manner that is inconsistent with, or that otherwise alters or changes the powers, preferences, or special rights of the shares of Class&#160;A common stock so as to affect them adversely; or (2)&#160;to provide for each share of Class&#160;B common stock to have more than twenty (20)&#160;votes per share or any rights to a separate class vote of the holders of shares of Class&#160;B common stock other than as provided by our Charter or required by the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our Charter also provides that our board of directors will have the power to adopt, amend, alter, or repeal our Bylaws by the affirmative vote of a majority of the directors present at any regular or special meeting of our board of directors at which a quorum is present in any manner not inconsistent with the laws of the State of Delaware or our Charter. Our stockholders are prohibited from adopting, amending, altering, or repealing Bylaws, or to adopt any provision inconsistent with Bylaws, unless such action is approved, in addition to any other vote required by our Charter, (i)&#160;when the issued and outstanding shares of Class&#160;B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock that would be entitled to vote for the election of directors, the affirmative vote of the holders of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the voting power of the capital stock that would be entitled to vote in the election of directors or, prior to such time, (ii)&#160;the affirmative vote of the holders of a majority of the voting power of the shares of capital stock that would be entitled to vote in the election of directors. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Section&#160;203 of the DGCL, a corporation will not be permitted to engage in a business combination with any interested stockholder for a period of three years following the time that such interested stockholder became an interested stockholder, unless: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an &#8220;interested stockholder&#8221; is a person who, together with that person&#8217;s affiliates and associates, owns, or within the previous three years owned, 15% or more of our outstanding voting stock. For purposes of this section only, &#8220;voting stock&#8221; has the meaning given to it in Section&#160;203 of the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since we have not opted out of Section&#160;203 of the DGCL, it will apply to us. As a result, this provision will make it more difficult for a person who would be an &#8220;interested stockholder&#8221; to effect various business combinations with us for a three-year period. This provision may encourage companies interested in acquiring us to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if our board of directors approves either the business combination or the transaction which results in the stockholder becoming an interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions, which stockholders may otherwise deem to be in their best interests. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cumulative Voting </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Delaware law, the right to vote cumulatively does not exist unless the charter specifically authorizes cumulative voting. Our Charter does not authorize cumulative voting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limitations on Liability and Indemnification of Officers and Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The DGCL authorizes corporations to limit or eliminate the personal liability of directors of corporations and their stockholders for monetary damages for breaches of directors&#8217; fiduciary duties, subject to certain exceptions. Our Charter includes a provision that eliminates the personal liability of directors for damages for any breach of fiduciary duty as a director where, in civil proceedings, the person acted in good faith and in a manner that person reasonably believed to be in or not opposed to the best interests of Hyperfine or, in criminal proceedings, where the person had no reasonable cause to believe that his or her conduct was unlawful. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that we may indemnify and advance expenses to our directors, officers, employees or agents to the fullest extent permitted by law. Our Bylaws provide that we shall indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We are also expressly authorized to carry directors&#8217; and officers&#8217; liability insurance providing indemnification for our directors, officers, and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The limitation of liability, advancement and indemnification provisions in our Charter and Bylaws may discourage stockholders from bringing lawsuits against directors for any alleged breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officer pursuant to these indemnification provisions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is currently no pending material litigation or proceeding involving any of our directors, officers, or employees for which indemnification is sought. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Opportunities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides for the renouncement by us of any interest or expectancy of Hyperfine in, or being offered an opportunity to participate in any matter, transaction, or interest that is presented to, or acquired, created, or developed by, or which otherwise comes into possession of, any director of Hyperfine who is not an employee of Hyperfine or any of its subsidiaries, unless such matter, transaction, or interest is presented to, or acquired, created, or developed by, or otherwise comes into the possession of a director of Hyperfine expressly and solely in that director&#8217;s capacity as a director of Hyperfine. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dissenters&#8217; Rights of Appraisal and Payment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of Hyperfine. Pursuant to the DGCL, stockholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Derivative Actions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock thereafter devolved by operation of law. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Subscription Agreements, the PIPE Investors purchased HealthCor Class&#160;A ordinary shares immediately prior to the closing of the Business Combination and the PIPE Investors are entitled to certain registration rights. Pursuant to the Letter Agreement, Hyperfine issued the Letter Agreement Shares to Jefferies LLC in lieu of deferred underwriting compensation relating to HealthCor&#8217;s Initial Public Offering and Jefferies LLC is entitled to certain registration rights. In particular, under the Subscription Agreements and the Letter Agreement, Hyperfine agreed to, within 45 calendar days after the closing of the Business Combination, file with the SEC (at Hyperfine&#8217;s sole cost and expense) a registration statement registering the resale of the shares of Class&#160;A common stock issued to the PIPE Investors and pursuant to the Letter Agreement, and to use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i)&#160;the 45th calendar day (or 60th calendar day if the SEC notifies Hyperfine that it will &#8220;review&#8221; such registration statement) following the closing of the Business Combination and (ii)&#160;the 10th business day after the date Hyperfine is notified (orally or in writing) by the SEC that such registration statement will not be &#8220;reviewed&#8221; or will not be subject to further review. The registration statement was filed on January&#160;24, 2022 and declared effective by the SEC on February&#160;1, 2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, Hyperfine, the Sponsor, certain affiliates of the Sponsor (the &#8220;Sponsor Group Holders&#8221;) and certain Legacy Hyperfine equityholders and Liminal equityholders (the &#8220;Legacy Hyperfine Holders&#8221;) entered </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">into an amended and restated registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which, among other things, the parties to the Registration Rights Agreement agreed not to effect any sale or distribution of any equity securities of Hyperfine held by any of them (except with respect to shares of Class&#160;A common stock acquired in open market transactions or pursuant to the PIPE Investment) during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period described therein and below and were granted certain registration rights with respect to their respective shares of our common stock, in each case, on the terms and subject to the conditions therein. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In particular, the Registration Rights Agreement provides for the following registration rights: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration rights</div></div>.&#160;&#160;&#160;&#160;Promptly, but in any event within 45 days following the Closing Date, Hyperfine is required to use its commercially reasonable efforts to file a registration statement under the Securities Act to permit the public resale of all registrable securities as permitted by Rule 415 of the Securities Act and to cause such registration statement to be declared effective as soon as practicable after the filing thereof, but in no event later than 45 days following the filing deadline (or 60 days following the filing deadline if the registration statement is reviewed by and receives comments from the SEC). As soon as practicable following the date of effectiveness of the registration statement, but in any event within two business days of such date, Hyperfine will notify the holders of registrable securities of the effectiveness of such registration statement. The registration statement was filed on January&#160;24, 2022 and declared effective by the SEC on February&#160;1, 2022. At any time at which Hyperfine has an effective shelf registration statement with respect to a holder&#8217;s registrable securities, any such holder may request to sell all or a portion of their registrable securities pursuant to an underwritten offering pursuant to such shelf registration statement, provided that such holder(s) reasonably expect any such sales to generate aggregate gross proceeds in excess of $25&#160;million or reasonably expect to sell all of the registrable securities held by such holder, but in no event for aggregate gross proceeds of less than $5&#160;million in gross proceeds. Hyperfine will enter into an underwriting agreement with a managing underwriter or underwriters selected by the initiating holder(s), after consultation with Hyperfine, and will take all such other reasonable actions as are requested by the managing underwriter to expedite or facilitate the disposition of such registrable securities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Demand registration rights</div></div>.&#160;&#160;&#160;&#160;At any time after the Closing Date, if Hyperfine does not have an effective registration statement outstanding, Hyperfine will be required, upon the written request of the holders of at least a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">majority-in-interest</div></div> of the then-outstanding registrable securities held by the Sponsor Group Holders or the Legacy Hyperfine Holders, as soon as practicable but not more than 45 days after receipt of such written request, to file a registration statement and to effect the registration of all or part of their registrable securities. Hyperfine is not obligated to effect more than an aggregate of (i)&#160;one demand registration at the request of one or more Sponsor Group Holders or (ii)&#160;an aggregate of three registrations pursuant to a demand registration request. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Piggyback registration rights</div></div>.&#160;&#160;&#160;&#160;At any time after the Closing Date, if Hyperfine proposes to file a registration statement under the Securities Act to register any of its equity securities, or securities or other obligations exchangeable or convertible into equity securities, or to conduct a public offering, either for its own account or for the account of any other person, subject to certain exceptions and reductions as described in the Registration Rights Agreement, then Hyperfine will give written notice of such proposed filing to the holders of registrable securities as soon as practicable but not less than 10 days before the anticipated filing of such registration statement. Upon the written request of any holder of registrable securities in response to such written notice, Hyperfine will, in good faith, cause such registrable securities to be included in the registration statement and use its commercially reasonable efforts to cause the underwriters of any proposed underwritten offering to include such holders&#8217; registrable securities on the same terms and conditions as any similar securities of Hyperfine included in such registration. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> Restrictions </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Registration Rights Agreement, each of the Legacy Hyperfine Holders agreed to not transfer securities of the Company, agreed not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of or distribute any such securities or any securities convertible into, exercisable for, exchangeable for or that represent the right to receive such securities, whether then owned or thereafter acquired, that are owned directly by such holder (including securities held as a custodian) or with respect to which such holder has beneficial ownership within the rules and regulations of the SEC, other than certain permitted transfers, including not to engage in any hedging or other transaction with respect to such securities which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such securities, for the period ending on the earlier of (a) 180 days after the Closing, subject to certain customary exceptions, and (b)&#160;subsequent to the Closing, (x)&#160;if the last reported sale price of Hyperfine&#8217;s Class&#160;A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading days after the Closing or (y)&#160;the date on which Hyperfine completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of Hyperfine&#8217;s public stockholders having the right to exchange their shares of Hyperfine&#8217;s common stock for cash, securities or other property. In addition, each Sponsor Group Holder agreed to not transfer any securities of Hyperfine (subject to certain exceptions described above) for the period ending on the earlier of (a)&#160;one year after the Closing, and (b)&#160;subsequent to the Closing, (x)&#160;if the last reported sale price of Hyperfine&#8217;s Class&#160;A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading days commencing at least 180 days after the Closing, or (y)&#160;the date on which Hyperfine completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of Hyperfine&#8217;s public stockholders having the right to exchange their shares of Hyperfine&#8217;s common stock for cash, securities or other property. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer Agent and Registrar </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transfer agent for our capital stock is Continental Stock Transfer&#160;&amp; Trust Company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Exchange Listing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine&#8217;s Class&#160;A common stock is listed for trading on The Nasdaq Stock Market under the symbol &#8220;HYPR.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc284543_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES ACT RESTRICTIONS ON RESALE OF COMMON STOCK </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule 144 </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Rule 144 under the Securities Act (&#8220;Rule 144&#8221;), a person who has beneficially owned restricted Class&#160;A common stock or Class&#160;B common stock of Hyperfine for at least six months would be entitled to sell their securities provided that (i)&#160;such person is not deemed to have been an affiliate of Hyperfine at the time of, or at any time during the three months preceding, a sale and (ii)&#160;Hyperfine is subject to the Exchange Act periodic reporting requirements for at least three months before the sale and has filed all required reports under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as it was required to file reports) preceding the sale. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons who have beneficially owned restricted Class&#160;A common stock or Class&#160;B common stock of Hyperfine for at least six months but who are affiliates of Hyperfine at the time of, or at any time during the three months preceding, a sale would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities of the same class that does not exceed the greater of: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1% of the total number of shares of Hyperfine Class&#160;A common stock (or Hyperfine Class&#160;B common stock, in the case of Hyperfine Class&#160;B common stock) then outstanding; or </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the average weekly reported trading volume of Hyperfine&#8217;s Class&#160;A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales by affiliates of Hyperfine under Rule 144 are also limited by manner of sale provisions and notice requirements and by the availability of current public information about Hyperfine. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule 144 is not available for the resale of securities initially issued by shell companies (other than business- combination related shell companies) or issuers that have been at any time previously a shell company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuer of the securities that was formerly a shell company has ceased to be a shell company; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuer of the securities is subject to the reporting requirements of Section&#160;13 or 15(d) of the Exchange Act; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials) other than Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> reports; and </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">at least one year has elapsed from the time that the issuer filed current Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-type</div> information with the SEC reflecting its status as an entity that is not a shell company. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Closing, Hyperfine is no longer a shell company, and so, once the conditions listed above are satisfied, Rule 144 will become available for the resale of the above-noted restricted securities. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc284543_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENEFICIAL OWNERSHIP OF SECURITIES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information known to the Company regarding the beneficial ownership of the Company&#8217;s common stock as of February&#160;15, 2022 by: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each person known to the Company to be the beneficial owner of more than 5% of outstanding Company common stock; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of the Company&#8217;s executive officers and directors; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all current executive officers and directors of the Company as a group. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options that are currently exercisable or exercisable within 60 days and restricted stock units that vest within 60 days. Shares of Class&#160;A common stock issuable upon exercise of options currently exercisable within 60 days and restricted stock units that vest within 60 days are deemed outstanding solely for purposes of calculating the percentage of total ownership and total voting power of the beneficial owner thereof. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The beneficial ownership of Company common stock is based on 55,277,061 shares of the Company&#8217;s Class&#160;A common stock and 15,055,288 shares of the Company&#8217;s Class&#160;B common stock issued and outstanding as of February&#160;15, 2022. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated, the Company believes that each person named in the table below has sole voting and investment power with respect to all shares of the Company&#8217;s common stock beneficially owned by them. Unless otherwise indicated, the business address of each of the following entities or individuals is c/o Hyperfine, Inc., 351 New Whitfield Street, Guilford, Connecticut 06437. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of Beneficial Owner</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares<br/>of Class&#160;A<br/>Common<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares<br/>Class&#160;B<br/>Common<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Voting<br/>Power**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Directors and Executive Officers:</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,208,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,055,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alok Gupta</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Khan Siddiqui, M.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neela Paykel</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scott White</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R. Scott Huennekens</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John Dahldorf</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruth Fattori<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">891</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maria Sainz</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Daniel J. Wolterman</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All Current Directors and Executive Officers of the Company as a Group (11 Individuals)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,392,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,055,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Five Percent Holders:</div></div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,208,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,055,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HC Sponsor LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,534,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicates beneficial ownership of less than 1%. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage of total voting power represents voting power with respect to all shares of the Company&#8217;s Class&#160;A common stock and the Company&#8217;s Class&#160;B common stock as a single class. Each share of the Company&#8217;s Class&#160;B common stock is entitled to 20 votes per share and each share of the Company&#8217;s Class&#160;A common stock is entitled to 1 vote per share. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of shares of the Company&#8217;s Class&#160;A common stock and Class&#160;B common stock held by Jonathan M. Rothberg, Ph.D., Dr.&#160;Rothberg&#8217;s spouse, 4C Holdings I, LLC, 4C Holdings V, LLC, 2012 JMR Trust Common, LLC and 23rd Century Capital LLC, and options to purchase 982,500 shares of the Company&#8217;s Class&#160;A common stock exercisable within 60 days of February&#160;15, 2022 held by Dr.&#160;Rothberg. Dr.&#160;Rothberg, the Founder of Legacy Hyperfine and Liminal, is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC and has sole voting and investment control of the Company&#8217;s Class&#160;A common stock and Class&#160;B common stock owned by those entities. Dr.&#160;Rothberg&#8217;s son is the manager of 23rd Century Capital LLC. Dr.&#160;Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of options to purchase 183,296 shares of the Company&#8217;s Class&#160;A common stock exercisable within 60 days of February&#160;15, 2022 held by Dr.&#160;Siddiqui. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of shares of the Company&#8217;s Class&#160;A common stock held by Ms.&#160;Fattori. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See footnotes 1 through 3. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 5,534,000 shares held directly by the HC Sponsor LLC and 1,000,000 shares purchased in the PIPE Investment by entities affiliated with HC Sponsor LLC (such affiliates, the &#8220;HC Affiliates&#8221;). HC Sponsor LLC is managed by its manager, HealthCor Sponsor Investments LLC, which is managed by its manager, HealthCor Group, LLC, which also indirectly manages the HC Affiliates. Arthur Cohen and Joseph Healey are the controlling members of HealthCor Group, LLC. As such, Messrs. Cohen and Healey have voting and investment discretion with respect to the shares held by each of HC Sponsor LLC and the HC Affiliates and may be deemed to have shared beneficial ownership of these shares. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc284543_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SELLING SECURITYHOLDERS </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to the possible resale by the Selling Securityholders of up to 41,775,946 shares of our Class&#160;A common stock and up to 15,055,288 shares of our Class&#160;B common stock. The Selling Securityholders may from time to time offer and sell any or all of the shares of Class&#160;A common stock or the shares of Class&#160;B common stock set forth below pursuant to this prospectus and any accompanying prospectus supplement. When we refer to the &#8220;Selling Securityholders&#8221; in this prospectus, we mean the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the Selling Securityholders&#8217; interest in the shares of Class&#160;A common stock and the shares of Class&#160;B common stock other than through a public sale. We cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such shares of Class&#160;A common stock or shares of Class&#160;B common stock. In addition, the Selling Securityholders may sell, transfer or otherwise dispose of, at any time and from time to time, shares of Class&#160;A common stock and shares of Class&#160;B common stock in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus. For purposes of this table, we have assumed that the Selling Securityholders will have sold all of the securities covered by this prospectus upon the completion of the offering. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table is prepared based on information provided to us by the Selling Securityholders. It sets forth the name and address of the Selling Securityholders, the aggregate number of shares of Class&#160;A common stock and shares of Class&#160;B common stock that the Selling Securityholders may offer pursuant to this prospectus, and the beneficial ownership of the Selling Securityholders both before and after the offering. We have based the percentage ownership prior to this offering on 55,277,061 shares of Class&#160;A common stock and 15,055,288 share of Class&#160;B common stock outstanding, in each case as of February&#160;15, 2022. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the tables have sole voting and sole investment power with respect to all securities that they beneficially own, subject to community property laws where applicable. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Selling Securityholder information for each additional Selling Securityholder, if any, will be set forth by prospectus supplement to the extent required prior to the time of any offer or sale of such Selling Securityholder&#8217;s shares pursuant to this prospectus. Any prospectus supplement may add, update, substitute, or change the information contained in this prospectus, including the identity of each Selling Securityholder and the number of shares registered on its behalf. A Selling Securityholder may sell or otherwise transfer all, some or none of such shares in this offering. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan of Distribution</div></div>.&#8221; </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated, the business address of each of these holders is c/o Hyperfine, Inc., 531 New Whitfield Street, Guilford, Connecticut 06437. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;A&#160;Common<br/>Stock&#160;Beneficially&#160;Owned<br/>Prior to this Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;B<br/>Common Stock<br/>Beneficially Owned<br/>Prior to this Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of&#160;Shares<br/>of&#160;Class&#160;A<br/>Common<br/>Stock<br/>Being<br/>Offered</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of&#160;Shares<br/>of&#160;Class&#160;B<br/>Common<br/>Stock<br/>Being<br/>Offered</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;A<br/>Common Stock<br/>Beneficially&#160;Owned<br/>After the Offered<br/>Shares of Class&#160;A<br/>Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;B<br/>Common Stock<br/>Beneficially&#160;Owned&#160;After<br/>the Offered Shares of<br/>Class&#160;A Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholder</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2012 JMR Trust Common, LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,737</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,737</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">23rd Century Capital LLC <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">4C Holdings I, LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,236,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,236,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,236,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,236,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">4C Holdings V, LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Bonnie E. Gould Rothberg, M.D.<div style="font-size:85%; vertical-align:top;display:inline;;font-size:7.5px">(4)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(5)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,086,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,086,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(6)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,849,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,849,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth A. Whayland<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(7)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,346</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,346</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;A&#160;Common<br/>Stock&#160;Beneficially&#160;Owned<br/>Prior to this Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;B<br/>Common Stock<br/>Beneficially Owned<br/>Prior to this Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of&#160;Shares<br/>of&#160;Class&#160;A<br/>Common<br/>Stock<br/>Being<br/>Offered</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of&#160;Shares<br/>of&#160;Class&#160;B<br/>Common<br/>Stock<br/>Being<br/>Offered</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;A<br/>Common Stock<br/>Beneficially&#160;Owned<br/>After the Offered<br/>Shares of Class&#160;A<br/>Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;B<br/>Common Stock<br/>Beneficially&#160;Owned&#160;After<br/>the Offered Shares of<br/>Class&#160;A Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholder</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth A. Whayland and Gregory T. Mulhern, as Joint Tenants With Right of Survivorship</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,876</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,876</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Khan Siddiqui<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(8)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">290,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Mark Hughes<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(9)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">208,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">163,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Neela Paykel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(10)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">156,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruth Fattori<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(11)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">891</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Scott Huennekens<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(12)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,206,772</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,187,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">YH North America Capital<br/>L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (13)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Yonghua International I<br/>L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (14)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Yonghua International II<br/>L.P. <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(15)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">696,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">696,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">HC Sponsor LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(16)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,534,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,534,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael Weinstein<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(17)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher Wolfgang<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(17)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Taylor Harris<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(17)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jefferies LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(18)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;">CD-Venture</div> GmbH<div style="font-size:85%; vertical-align:top;display:inline;;font-size:7.5px">(19)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,153,529</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,053,529</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deerfield Partners, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (20)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">James H. Dahl<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(21)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ARK Investment Management LLC on behalf of ARK PIPE Fund LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(22)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Eldridge PIPE Holdings, LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(23)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nantahala Capital Partners II Limited Partnership<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nantahala Capital Partners Limited Partnership<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nantahala Capital Partners SI, LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">316,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">NCP QR LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">NCP RFM LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,573</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Silver Creek CS SAV, L.L.C.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,957</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,153</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Blackwell Partners LLC&#8212;<br/>Series A<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(24)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,936</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,559</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">HighCape Partners Hyperfine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Invest,</div> L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(25)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Brookside Capital Trading Fund, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(26)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">599,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor Sanatate Offshore Master Fund, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(16)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">755,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">755,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor Therapeutics Master Fund, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(16)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor Offshore Master Fund, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(16)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Perceptive Life Sciences Master Fund, Ltd.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(27)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Alyeska Master Fund, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(28)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Avidity Capital Fund II LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(29)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Avidity Capital HL Sub Fund III LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(29)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Avidity Master Fund LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(29)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,185,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,185,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;A&#160;Common<br/>Stock&#160;Beneficially&#160;Owned<br/>Prior to this Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;B<br/>Common Stock<br/>Beneficially Owned<br/>Prior to this Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of&#160;Shares<br/>of&#160;Class&#160;A<br/>Common<br/>Stock<br/>Being<br/>Offered</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of&#160;Shares<br/>of&#160;Class&#160;B<br/>Common<br/>Stock<br/>Being<br/>Offered</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;A<br/>Common Stock<br/>Beneficially&#160;Owned<br/>After the Offered<br/>Shares of Class&#160;A<br/>Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;of&#160;Class&#160;B<br/>Common Stock<br/>Beneficially&#160;Owned&#160;After<br/>the Offered Shares of<br/>Class&#160;A Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholder</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">BEMAP Master Fund Ltd<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bespoke Alpha MAC MIM LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">DS Liquid Div RVA MON LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Monashee Managed Account SP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,079</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,079</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Monashee Pure Alpha SPV I LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Monashee Solitario Fund LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,615,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,523,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">SFL SPV I LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(30)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Catalio Nexus Fund III, LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(31)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Glenview Capital Partners, LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(32)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Glenview Institutional Partners, LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(32)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Glenview Capital Master Fund, Ltd.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (32)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">342,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">342,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Glenview Capital Opportunity Fund, LP<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(32)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Glenview Offshore Opportunity Master Fund, Ltd.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (32)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">185,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">185,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45,171,035</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">73.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,055,288</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41,775,946</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,055,288</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,395,089</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denotes less than 1%. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Selling Securityholders may be deemed to beneficially own other shares reported herein. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">***</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;A common stock issuable upon conversion of shares of Class&#160;B common stock is also included in the Number of Shares of Class&#160;A Common Stock Being Offered column immediately preceding. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D., Vice Chairman of the Company and the Founder of Legacy Hyperfine and Liminal, is the sole manager of 2012 JMR Trust Common, LLC and has sole voting and investment control of the shares of Class&#160;A common stock owned by 2012 JMR Trust Common, LLC. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Rothberg&#8217;s son is the manager of 23rd Century Capital LLC. Dr.&#160;Rothberg disclaims beneficial ownership of the shares held by 23rd Century Capital LLC. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents Class&#160;B common stock, or Class&#160;A common stock issuable upon the conversion of Class&#160;B common stock, as the case may be, held by 4C Holdings I, LLC and 4C Holdings V, LLC. Dr.&#160;Rothberg is the sole manager of 4C Holdings I, LLC and 4C Holdings V, LLC. Dr.&#160;Rothberg has sole voting and investment control over the shares. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonnie E. Gould Rothberg, M.D. is the spouse of Dr.&#160;Rothberg. Dr.&#160;Rothberg disclaims beneficial ownership of the shares held by his spouse. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents (i) 104,074 shares of Class&#160;A common stock held by Dr.&#160;Rothberg, and (ii) 982,500 shares of Class&#160;A common stock that are issuable upon exercise of options held by Dr.&#160;Rothberg. Options to purchase 982,500 shares of Class&#160;A common stock held by Dr.&#160;Rothberg are exercisable within 60 days of February&#160;15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 2,849,250 shares of Class A common stock that are issuable upon exercise of options held by Mr. Scott. No options to purchase shares of Class A common stock held by Mr. Scott are exercisable within 60 days of February 15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents (i) 43,079 shares of Class&#160;A common stock held by Ms.&#160;Whayland, and (ii) 52,267 shares of Class&#160;A common stock that are issuable upon exercise of options held by Ms.&#160;Whayland, all of which are exercisable within 60 days of February&#160;15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 474,978 shares of Class&#160;A common stock that are issuable upon exercise of options held by Dr.&#160;Siddiqui. Options to purchase 183,296 shares of Class&#160;A common stock held by Dr.&#160;Siddiqui are exercisable within 60 days of February&#160;15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents (i) 19,615 shares of Class&#160;A common stock held by Mr.&#160;Hughes, and (ii) 189,133 shares of Class&#160;A common stock that are issuable upon exercise of options held by Mr.&#160;Hughes. Options to purchase 62,774 shares of Class&#160;A common stock held by Mr.&#160;Hughes are exercisable within 60 days of February&#160;15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 255,000 shares of Class A common stock that are issuable upon exercise of options held by Ms. Paykel. No options to purchase shares of Class A common stock held by Ms. Paykel are exercisable within 60 days of February 15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 891 shares of the Company&#8217;s Class&#160;A common stock held by Ms.&#160;Fattori and 19,586 shares of Class A common stock that are issuable upon the vesting of restricted stock units held by Ms.&#160;Fattori. No shares of Class&#160;A common stock are issuable upon vesting of restricted stock units held by Ms.&#160;Fattori within 60 days of February&#160;15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(12)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 1,187,186 shares of Class A common stock that are issuable upon exercise of options held by Mr. Huennekens and 19,586 shares of Class A common stock that are issuable upon the vesting of restricted stock units held by Mr. Huennekens. No options to purchase shares of Class A common stock held by Mr.&#160;Huennekens are exercisable within 60 days of February 15, 2022, and no restricted stock units held by Mr.&#160;Huennekens vest within 60 days of February 15, 2022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(13)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Feng Wei is the controlling person of YH North America Capital L.P. and may be deemed to have beneficial ownership of the shares held by YH North America Capital L.P. The registered address of YH North America Capital L.P. is Governors Square, Suite <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">#5-204,</div> 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-1104,</div> Cayman Islands. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(14)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Feng Wei is the controlling person of Yonghua International I L.P. and may be deemed to have beneficial ownership of the shares held by Yonghua International I L.P. The registered address of Yonghua International I L.P. is Governors Square, Suite <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">#5-204,</div> 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-1104,</div> Cayman Islands. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(15)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Feng Wei is the controlling person of Yonghua International II L.P. and may be deemed to have beneficial ownership of the shares held by Yonghua International II L.P. The registered address of Yonghua International II L.P. is Governors Square, Suite <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">#5-204,</div> 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-1104,</div> Cayman Islands. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(16)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HC Sponsor LLC is managed by its manager, HealthCor Sponsor Investments LLC, which is managed by its manager, HealthCor Group, LLC, which also indirectly manages HealthCor Sanatate Offshore Master Fund, L.P., HealthCor Therapeutics Master Fund, L.P. and HealthCor Offshore Master Fund, L.P. (collectively the &#8220;HC Affiliates&#8221;). Arthur Cohen and Joseph Healey are the controlling members of HealthCor Group, LLC. As such, Messrs. Cohen and Healey have voting and investment discretion with respect to the shares held by each of HC Sponsor LLC and the HC Affiliates and may be deemed to have shared beneficial ownership of these shares. HC Sponsor LLC was the sponsor of HealthCor, Mr.&#160;Cohen was Chief Executive Officer and a director of HealthCor and Mr.&#160;Healey was Chairman of HealthCor&#8217;s board of directors. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(17)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael Weinstein, Christopher Wolfgang, and Taylor Harris were directors of HealthCor until the Closing of the Business Combination. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(18)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jefferies LLC was the sole bookrunning manager for HealthCor&#8217;s Initial Public Offering and acted as the lead financial advisor, capital markets advisor and placement agent to HealthCor in connection with the Business Combination and the PIPE Investment. The business address of such holder is 520 Madison Avenue, New York, New York 10022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(19)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Christoph Boehringer and Dirk Wilken are each a Managing Partner of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CD-Venture</div> GmbH and have voting and investment power over the shares held by the entity. The business address of such holder is Bergheimer Str. 45, Heidelberg, Germany BW 69115. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(20)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P. Mr.&#160;James&#160;E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. Each of Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Mr.&#160;Flynn may be deemed to beneficially own the shares of Class&#160;A common stock of the Company beneficially owned by Deerfield Partners, L.P. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">The business address of Mr.&#160;Flynn, Deerfield Mgmt, Deerfield Partners and Deerfield Management is 345 Park Avenue South, New York, New York 10010. </td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(21)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The business address of such holder is 4314 Pablo Oaks Court, Jacksonville, Florida 32224. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(22)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The business address of such holder is 200 Central Avenue, Suite 1850, St. Petersburg, Florida 33701. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(23)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The business address of such holder is 600 Steamboat Road, Suite 200, Greenwich, Connecticut 06830. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(24)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of each of Nantahala Capital Partners II Limited Partnership, Nantahala Capital Partners Limited Partnership, Nantahala Capital Partners SI, LP, NCP QR LP, NCP RFM LP, Silver Creek CS SAV, L.L.C., and Blackwell Partners LLC&#8212;Series A (collectively, the &#8220;Nantahala Securityholders&#8221;) as a General Partner or Investment Manager and would be considered the beneficial owner of such securities. Nantahala Capital Management, LLC may be deemed to beneficially own 7,356 additional shares of Class&#160;A common stock in the Company on behalf of managed funds and/or accounts not listed above as Selling Stockholders. The above shall not be deemed to be an admission by the record owners or the applicable Nantahala Securityholder that they are themselves beneficial owners of these securities for purposes of Section&#160;13(d) of the Exchange Act or any other purpose. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by the Nantahala Securityholders. The business address of such holder is c/o Nantahala Capital Management, LLC, 130 Main Street, 2nd Floor, New Canaan, Connecticut 06844. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(25)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Kevin Rakin and Matt Zuga are each a general partner of HighCape Partners II GP, L.P., a Delaware limited partnership and the sole general partner of HighCape Partners Hyperfine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Invest,</div> L.P. (&#8220;HighCape Partners&#8221;), and have voting and investment control over the shares held by HighCape Partners. The business address of such holders is 452 Fifth Avenue, 21st Floor, New York, New York 10018-2706. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(26)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 599,658 shares held by Brookside Capital Trading Fund, L.P. (&#8220;Brookside&#8221;). In addition, 337,531 shares are held by Bain Capital Public Equity Global Long Equity Fund, L.P. (&#8220;Global Long&#8221;). Voting and investment decisions on behalf of Brookside are made by the members of Bain Capital Public Equity Management II, LLC (&#8220;BC Public Equity Management II&#8221;), which has sole authority and discretion over the investment decisions of Bain Capital Public Equity Management, LLC, which is the general partner of Brookside Capital Investors, L.P., which is the general partner of Brookside. Voting and investment decisions on behalf of Global Long are made by the members numbers of BC Public Equity Management II, which is the general partner of Bain Capital Public Equity Global Long Equity General Partner, LLC, which is the general partner of Global Long. The business address of such holders is 200 Clarendon Street, Boston, Massachusetts 02116. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(27)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perceptive Advisors, LLC serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. Joseph Edelman is the managing member of Perceptive Advisors, LLC, and disclaims beneficial ownership over the shares except to the extent of his pecuniary interest therein. The business address of Perceptive Life Sciences Master Fund, Ltd. is c/o Perceptive Advisors, LLC, 51 Astor Place, 10th Floor, New York, New York 10003. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(28)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P. (&#8220;Alyeska&#8221;), has voting and investment control of the shares held by Alyeska. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr.&#160;Parekh, however, disclaims any beneficial ownership of the shares held by Alyeska. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-1104,</div> Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago, Illinois 60601. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(29)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avidity Master Fund LP (&#8220;Avidity Master&#8221;) is a Cayman exempted limited partnership, Avidity Capital Fund II LP (&#8220;Avidity II&#8221;) is a Delaware limited partnership, and Avidity Capital HL Sub Fund III LLC (&#8220;Avidity III&#8221;, together with Avidity Master and Avidity II, the &#8220;Avidity Affiliates&#8221;). The general partner of each of the Avidity Affiliates is Avidity Capital Partners Fund (GP) LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP) LLC, a Delaware limited liability company. Avidity Partners Management LP, is the investment manager of the Avidity Affiliates. Avidity Partners Management (GP) LLC is the general partner of Avidity Partners Management LP. David Witzke and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Michael Gregory are the managing members of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP) LLC. Each of the entities and individuals referenced in this paragraph may be deemed to beneficially own the shares held by the Avidity Affiliates. Certain affiliates of the Avidity Affiliates, which are not Selling Securityholders, may also own shares. The business address of the Avidity Affiliates is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201. </td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(30)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;), DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), Monashee Managed Account SP (&#8220;MMA&#8221;), Monashee Pure Alpha SPV I LP (&#8220;Pure Alpha&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), and SFL SPV I LLC (&#8220;SFL&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee Management&#8221;). Jeff Muller is Chief Compliance Officer of Monashee Management and has voting and investment control over Monashee Management and, accordingly, may be deemed to have beneficial ownership of the shares held by BEMAP, Bespoke, DS, MMA, Pure Alpha, Solitario, and SFL. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of BEMAP, Bespoke, DS, MMA, Pure Alpha, Solitario, SFL, Monashee Management and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, Massachusetts 02116. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(31)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R. Jacob Vogelstein is the manager of Catalio Nexus Fund III, LP (&#8220;Catalio&#8221;) and has voting and investment control over Catalio, and accordingly, may be deemed to have beneficial ownership of the shares held by Catalio. R. Jacob Vogelstein disclaims beneficial ownership of the shares held by Catalio. The business address of Catalio is 24 W 25th St Ste 200, New York, New York 10010-2704. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(32)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Larry Robbins is founder, portfolio manager and Chief Executive Officer of Glenview Capital Management, LLC, which serves as investment manager to Glenview Capital Partners, L.P., Glenview Institutional Partners, L.P., Glenview Capital Master Fund, Ltd., Glenview Capital Opportunity Fund, L.P., and Glenview Offshore Opportunity Master Fund, Ltd. (the &#8220;Glenview Investment Funds&#8221;). Mr.&#160;Robbins shares voting and dispositive power over the shares held by the Glenview Investment Funds and may be deemed to beneficially own such shares. The business address of the Glenview Investment Funds is 767 Fifth Avenue, 44th Floor, New York, New York 10153. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc284543_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors and Management </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective as of the Closing Date, and in connection with closing of the Business Combination, each the executive officers of HealthCor resigned and were replaced by certain members of the management team of Legacy Hyperfine, and each of the directors of HealthCor resigned and the stockholders elected seven directors to serve on the Company&#8217;s board of directors (the &#8220;Hyperfine Board&#8221;). Accordingly, the following table sets forth certain information concerning our executive officers and directors as of February&#160;15, 2022: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Position</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">President, Chief Executive Officer and Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alok Gupta</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Financial Officer</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Khan Siddiqui, M.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Medical Officer and Chief Strategy Officer</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neela Paykel</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">General Counsel, Chief Compliance Officer and Corporate Secretary</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scott White</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Commercial Officer</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R. Scott Huennekens</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Executive Chairman</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Vice Chairman</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John Dahldorf</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruth Fattori</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maria Sainz</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Daniel J. Wolterman</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive Officers </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dave Scott</div></div></div></div> has served as our President since March 2022 and as our Chief Executive Officer and as a director of the Company since the Closing of the Business Combination in December 2021 and had served as Chief Executive Officer of Legacy Hyperfine since May 2021. Prior to joining the Company, Mr.&#160;Scott led advanced Research and Development innovation teams as an Executive at Apple, Inc.&#8217;s confidential Special Projects Group from October 2019 to May 2021. From 2015 to 2019, Mr.&#160;Scott was the Chief Operating Officer and EVP of Research and Development for Verb Surgical, an independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> company formed by Google and Johnson&#160;&amp; Johnson to develop surgical platforms, including advanced surgical robotics. Mr.&#160;Scott previously served as Divisional VP of Research and Development for Abbott Medical Optics and as VP of Research and Development at OptiMedica, later acquired by Abbott Medical Optics. In addition, Mr.&#160;Scott led Intuitive Surgical&#8217;s advanced imaging technologies team, which designed, developed and brought to market the visualization platform for the da Vinci<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> robotic surgical system. Mr.&#160;Scott has been awarded over 25 patents in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-ray</div> imaging, medical endoscopy and laser surgery applications. Mr.&#160;Scott serves on the Board of Directors at the Alfred Mann Foundation and holds a Bachelor of Science in Aerospace Engineering from the University of Kansas and a Master of Science in Aerospace Engineering from the University of Colorado, Boulder. Mr.&#160;Scott&#8217;s qualifications to serve on the Hyperfine Board include his leadership experience in the medical technology industry, as well as his knowledge of our business. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Alok Gupta</div></div></div></div> has served as our Chief Financial Officer since the Closing of the Business Combination in December 2021 and had served as Chief Financial Officer of Legacy Hyperfine since August 2021. Prior to joining the Company, Mr.&#160;Gupta served as the Chief Financial Officer and Chief Strategy Officer of Halio, Inc., an electrochromic smart glass company providing an intelligent platform for daylight management, from October 2019 to August 2021. From 2014 to 2019, Mr.&#160;Gupta was Managing Director at Mizuho Securities. Mr.&#160;Gupta received a Bachelor of Science degree in Mechanical Engineering from Jiwaji University, a Master of Science </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">degree in Manufacturing Systems Engineering from Oklahoma State University and a Master of Business Administration degree from the University of California, Los Angeles. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Khan Siddiqui, M.D.</div></div></div></div> has served as our Chief Medical Officer and Chief Strategy Officer since the Closing of the Business Combination in December 2021 and had served as Chief Medical Officer and Chief Strategy Officer of Legacy Hyperfine since January 2020. Dr.&#160;Siddiqui also serves on a medical advisory board of 4Catalyzer that provides services to 4Catalyzer companies. Prior to joining the Company, Dr.&#160;Siddiqui founded and served in leadership roles at higi, Inc. as the Chief Executive Officer from 2012 to 2013 and the Chief Medical Officer and Chief Technology Officer from 2013 to 2021. Dr.&#160;Siddiqui received an M.D. degree from Aga Khan University in Karachi, Pakistan and completed a fellowship in imaging informatics at the University of Maryland Medical Center. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Neela Paykel</div></div></div></div> has served as our General Counsel and Corporate Secretary since the Closing of the Business Combination in December 2021, has served as our Chief Compliance Officer since March 2022, and had served as General Counsel of Legacy Hyperfine since May 2021. Prior to joining the Company, Ms.&#160;Paykel served as the deputy general counsel at Waymo, LLC, an autonomous vehicle technology company, from November 2018 to April 2021. From 2016 to 2018, Ms.&#160;Paykel was the Vice President, Legal Affairs and Compliance at Proteus Digital Health. Ms.&#160;Paykel received a Bachelor of Arts in International Business Administration from Illinois Wesleyan University and a Juris Doctor degree from The George Washington University Law School. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scott White</div></div></div></div> has served as our Chief Commercial Officer since the Closing of the Business Combination in December 2021 and had served as Chief Commercial Officer of Legacy Hyperfine since September 2021. Prior to joining the Company, Mr.&#160;White served as the Vice President of Global Sales for Rapid Micro Biosystems, Inc., a newly public biotech company focused on microbiology automation, from 2018 to September 2021. From 2017 to 2018, Mr.&#160;White was the Market President for Compass Surgical Partners, LLC, a private healthcare management firm. Mr.&#160;White also previously served as the Managing Partner for the Florida Market of Surgery Center Development Co., LLC, a private management company for outpatient surgery centers, from 2015 to 2017. Mr.&#160;White received a Bachelor of Science in Business Administration from the University of Florida and a Master in Business Administration from the University of Miami. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">R. Scott Huennekens</div></div></div></div> has served as the Executive Chairman of the Hyperfine Board since the Closing of the Business Combination in December 2021 and had served as the Executive Chairman of Legacy Hyperfine&#8217;s board of directors since April 2021. Mr.&#160;Huennekens also serves as member of the board of directors of Acutus Medical, Inc., Envista Holdings Corporation and NuVasive, Inc., and was previously on the board of REVA Medical, Inc. and ViewRay, Inc. From August 2015 to December 2018, Mr.&#160;Huennekens was the President, Chief Executive Officer and Chairman of the board for Verb Surgical. Prior to joining Verb Surgical in 2015, Mr.&#160;Huennekens was President, Chief Executive Officer and a board member of Volcano Corporation for 13 years. Mr.&#160;Huennekens received a Bachelor of Science degree in Business Administration from the University of Southern California, and a Master of Business Administration degree from Harvard Graduate School of Business. Mr.&#160;Huennekens&#8217; qualifications to serve on the Hyperfine Board include his extensive executive experience in the biomedical technology industry and his significant corporate governance experience. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jonathan M. Rothberg, Ph.D.</div></div></div></div> is the Founder of Legacy Hyperfine and Liminal and has served as Vice Chairman of the Hyperfine Board since the Closing of the Business Combination in December 2021 and had served on the board of directors of Legacy Hyperfine since 2014 and the board of directors of Liminal since 2018. Dr.&#160;Rothberg previously served as Legacy Hyperfine&#8217;s Chief Executive Officer from 2014 to 2021. Dr.&#160;Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation&#8217;s highest honor for technological achievement, by President Obama for inventing and commercializing high-speed DNA sequencing. Dr.&#160;Rothberg is the Founder of the 4Catalyzer medical technology incubator and the Founder and Chairman of its companies: Legacy Hyperfine, Liminal, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, Butterfly </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Network, Inc., AI Therapeutics, Inc. (formerly LAM Therapeutics, Inc.), Tesseract Health, Inc. and Detect, Inc. (formerly Homodeus Inc.). These companies focus on using inflection points in medicine, such as deep learning, next-generation sequencing, and the silicon supply chain, to address global healthcare challenges. Dr.&#160;Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr.&#160;Rothberg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founded</div> and served as Chairman of ClarifI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation. With 454 Life Sciences, Dr.&#160;Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. With 454&#8217;s technology, Dr.&#160;Rothberg sequenced the first individual human genome, and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Prior to 454 Life Sciences, Dr.&#160;Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation from 1993 to 2004. Dr.&#160;Rothberg&#8217;s contributions to the field of genome sequencing include the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-bacterial</div> cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next generation sequencing technologies. Dr.&#160;Rothberg is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal&#8217;s First Gold Medal for Innovation, SXSW Best in Show, Nature Methods First Method of the Year Award, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize, and an Honorary Doctorate of Science from Mount Sinai. Dr.&#160;Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, is a trustee of Carnegie Mellon University and an Adjunct Professor of Genetics at Yale University. Dr.&#160;Rothberg serves as Chairman of the board of directors of Butterfly Network, Inc. (NYSE: BFLY) and Executive Chairman of the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated (Nasdaq: QSI). Dr.&#160;Rothberg has served as Interim Chief Executive Officer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated since February 2022. Dr.&#160;Rothberg received his Ph.D., M.Phil. and M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University. Dr.&#160;Rothberg&#8217;s qualifications to serve on the Hyperfine Board include his significant scientific, executive and board leadership experience in the technology industry, as well as his knowledge of our business as the Founder of Legacy Hyperfine and Liminal. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">John Dahldorf</div></div></div></div> has served on the Hyperfine Board since the Closing of the Business Combination in December 2021. Since 2017, Mr.&#160;Dahldorf serves as the Chief Financial Officer of Santa Cruz Nutritionals. From 2015 to 2017, Mr.&#160;Dahldorf was the Chief Financial Officer of Acutus Medical, Inc. Mr.&#160;Dahldorf received a Bachelor of Finance and Master of Business Administration from Western Illinois University. Mr.&#160;Dahldorf&#8217;s qualifications to serve on the Hyperfine Board include his extensive financial and accounting experience. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ruth Fattori</div></div></div></div> has served on the Hyperfine Board since the Closing of the Business Combination in December 2021 and had served on the board of directors of Legacy Hyperfine since August 2021. Since January 2019, Ms.&#160;Fattori serves as the managing Partner of Pecksland Partners, a consulting firm dedicated to advising board of directors, CEOs and senior executives on human resources issues. Ms.&#160;Fattori also serves as a Senior Advisor at the Boston Consulting Group supporting their CEO Advisory program and People and Organization Practice. From February 2013 through December 2018, Ms.&#160;Fattori served in various roles at PepsiCo, Inc., most recently as Executive Vice President and Chief Human Resources Officer. From 2010 to February 2013, Ms.&#160;Fattori served as Managing Partner of Pecksland Partners, and from 2008 to 2009 she was Executive Vice President and Chief Administrative Officer for MetLife. Earlier, Ms.&#160;Fattori was the Executive Vice President and Chief Human Resources Officer at Motorola. Ms.&#160;Fattori serves on the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated. Ms.&#160;Fattori received a Bachelor of Science in mechanical engineering from Cornell University. Ms.&#160;Fattori&#8217;s qualifications to serve on the Hyperfine Board include her extensive executive and human resources management experience. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maria Sainz</div></div></div></div> has served on the Hyperfine Board since the Closing of the Business Combination in December 2021. Ms.&#160;Sainz also serves as member of the board of directors of ShockWave Medical, Inc., Avanos Medical, Inc. and Atrion Corporation, and was previously on the board of Orthofix Medical Inc., Iridex </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporation and MRI Interventions, Inc. Ms.&#160;Sainz served as the President and CEO of Aegea Medical, a medical device company in the women&#8217;s health space focused on the development of technology for endometrial ablation, from May 2018 through February 2021. Prior to that, she served as the President and CEO of Cardiokinetix, a medical device company, from 2012 until 2017. Ms.&#160;Sainz received a Bachelor of Arts in Linguistics from the University Complutense in Madrid, Spain and a Masters in International Business from the American Graduate School of International Management. Ms.&#160;Sainz&#8217;s qualifications to serve on the Hyperfine Board include her leadership experience in the healthcare industry. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Daniel J. Wolterman</div></div></div></div> has served on the Hyperfine Board since the Closing of the Business Combination in December 2021. Mr.&#160;Wolterman is currently Chief Executive Officer of Wolterman Consulting LLC, a provider of strategic and operational consulting services to healthcare providers and other entities. From January 2018 to May 2019, Mr.&#160;Wolterman served as Chief Executive Officer of ColubrisMX, Inc. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-Cath,</div> Inc., both privately held medical device companies. Mr.&#160;Wolterman previously served as President and Chief Executive Officer of Memorial Hermann Health System, the largest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-for-profit</div></div> health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in May 2016. Mr.&#160;Wolterman has more than 40 years of experience in the healthcare industry and a long history of community involvement. Mr.&#160;Wolterman has served as a member of the board of directors of NuVasive, Inc. since July 2015 and the chairman of the board of directors of NuVasive, Inc. since May 2021. Mr.&#160;Wolterman previously served on the board of directors of Invuity, Inc. and Volcano Corporation. In addition, Mr.&#160;Wolterman was the 2016 Inductee into the Texas Business Hall of Fame. Mr.&#160;Wolterman received a Bachelor of Science degree in business administration and a Master of Business Administration degree from the University of Cincinnati and a Master of Healthcare Administration degree from Xavier University. Mr.&#160;Wolterman&#8217;s qualifications to serve on the Hyperfine Board include his leadership experience in the healthcare industry. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no family relationships between or among any of our directors or executive officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Role of Board in Risk Oversight </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors have extensive involvement in the oversight of risk management related to us and our business and will accomplish this oversight through the regular reporting to the board of directors by the audit committee. The audit committee will represent the board of directors by periodically reviewing our accounting, reporting and financial practices, including the integrity of its financial statements, the surveillance of administrative and financial controls and its compliance with legal and regulatory requirements. Through its regular meetings with management, including the finance, legal, internal audit and information technology functions, the audit committee will review and discuss all significant areas of our business and summarize for the board of directors all areas of risk and the appropriate mitigating factors. In addition, the board of directors will receive periodic detailed operating performance reviews from management. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Controlled Company Exemption </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D. beneficially owns a majority of the voting power of all outstanding shares of our common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules. Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance standards, including the requirements (1)&#160;that a majority of its board of directors consist of independent directors, (2)&#160;that its board of directors have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities and (3)&#160;that director nominees must either be selected, or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. As a result, you may not have the same protections afforded to stockholders of companies that are subject to all of these </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">corporate governance requirements. If we cease to be a &#8220;controlled company&#8221; and our shares continue to be listed on Nasdaq, we will be required to comply with these standards and, depending on the board&#8217;s independence determination with respect to our then-current directors, we may be required to add additional directors to our board in order to achieve such compliance within the applicable transition periods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Composition of the Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business and affairs will be managed under the direction of our board of directors. Our board of directors is declassified and the directors will be elected annually. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Independence of the Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq rules generally require that independent directors must comprise a majority of a listed company&#8217;s board of directors. As a controlled company, we are largely exempt from such requirements. Based upon information requested from and provided by each proposed director concerning his or her background, employment and affiliations, including family relationships, we have determined that John Dahldorf, Maria Sainz, Daniel J. Wolterman, and Ruth Fattori, representing four of our directors, are &#8220;independent&#8221; as that term is defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Committees </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The standing committees of the Hyperfine Board consist of an audit committee, a compensation committee and a nominating and corporate governance committee. Hyperfine Board may from time to time establish other committees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our chief executive officer and other executive officers will regularly report to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors and the audit, the compensation and the nominating and corporate governance committees to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing evaluation of management controls. We believe that the leadership structure of the Hyperfine Board will provide appropriate risk oversight of our activities given the controlling interests held by Jonathan M. Rothberg, Ph.D. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our audit committee consists of John Dahldorf, who serves as the chairperson, Maria Sainz and Daniel&#160;J.&#160;Wolterman. Each member of the audit committee qualifies as an independent director under the Nasdaq Listing Rules and the independence requirements of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> under the Exchange Act. The Hyperfine Board has determined that Mr.&#160;Dahldorf qualifies as an &#8220;audit committee financial expert&#8221; as such term is defined in Item 407(d)(5) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> and possesses financial sophistication, as defined under the rules of Nasdaq. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the audit committee is to prepare the audit committee report required by the SEC to be included in our proxy statement and to assist the board of directors in overseeing and monitoring (1)&#160;the quality and integrity of the financial statements, (2)&#160;compliance with legal and regulatory requirements, (3)&#160;our independent registered public accounting firm&#8217;s qualifications and independence, and (4)&#160;the performance of our independent registered public accounting firm. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors has adopted a written charter for the audit committee which is available on our website at https://hyperfine.io under Investors&#160;&#8212;&#160;Corporate Governance&#160;&#8212;&#160;Documents&#160;&amp; Charters. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our compensation committee consists of Ruth Fattori, who serves as the chairperson, and John Dahldorf. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the compensation committee is to assist the board of directors in discharging its responsibilities relating to (1)&#160;setting our compensation program and compensation of our executive officers and directors, (2)&#160;monitoring our incentive and equity-based compensation plans and (3)&#160;preparing the compensation committee report required to be included in our proxy statement under the rules and regulations of the SEC. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors has adopted a written charter for the compensation committee, which is available on our website at https://hyperfine.io under Investors&#160;&#8212;&#160;Corporate Governance&#160;&#8212;&#160;Documents&#160;&amp; Charters. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nominating and Corporate Governance Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our nominating and corporate governance committee consists of Daniel J. Wolterman, who serves as the chairperson, Ruth Fattori and Maria Sainz. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the nominating and corporate governance committee is to assist the board of directors in discharging its responsibilities relating to (1)&#160;identifying individuals qualified to become new board of directors members, consistent with criteria approved by the board of directors, (2)&#160;reviewing the qualifications of incumbent directors to determine whether to recommend them for reelection and selecting, or recommending that the board of directors select, the director nominees for the next annual meeting of stockholders, (3)&#160;identifying members of the board of directors qualified to fill vacancies on any committee of the board of directors and recommending that the board of directors appoint the identified member or members to the applicable committee, (4)&#160;reviewing and recommending to the board of directors corporate governance principles applicable to us, (5)&#160;overseeing the evaluation of the board of directors, (6)&#160;overseeing the process of succession planning for the Chief Executive Officer and, as warranted, other senior officers of Hyperfine and (7)&#160;handling such other matters that are specifically delegated to the committee by the board of directors from time to time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors has adopted a written charter for the nominating and corporate governance committee which is available on our website at https://hyperfine.io under Investors&#160;&#8212;&#160;Corporate Governance&#160;&#8212;&#160;Documents&#160;&amp; Charters. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Code of Business Conduct and Ethics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have adopted a code of business conduct and ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer, which is available on our website at https://hyperfine.io under Investors&#160;&#8212; Corporate Governance&#160;&#8212;&#160;Documents&#160;&amp; Charters. Our code of business conduct is a &#8220;code of ethics,&#8221; as defined in Item 406(b) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> We will make any legally required disclosures regarding amendments to, or waivers of, provisions of our code of ethics in a Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> within four business days following the date of the amendment or waiver, unless website posting or the issuance of a press release of such amendment or waiver is then permitted by Nasdaq rules. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Governance Guidelines </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our board of directors has adopted corporate governance guidelines that serve as a flexible framework within which our board of directors and our committees operate. These guidelines cover a number of areas including board membership criteria and director qualifications, director responsibilities, board agenda, meetings of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-management</div> directors, committee responsibilities and assignments, board member access to management and independent advisors, director communications with third parties, director compensation, director orientation and continuing education, evaluation of our chief executive officer management succession planning. A copy of our corporate governance guidelines is posted on our website at https://hyperfine.io under Investors&#160;&#8212; Corporate Governance&#160;&#8212;&#160;Documents&#160;&amp; Charters. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXECUTIVE AND DIRECTOR COMPENSATION </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Introduction </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive and Director Compensation of HealthCor </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following disclosure concerns the compensation of HealthCor&#8217;s executive officers and directors from inception (i.e. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">None of HealthCor&#8217;s executive officers or directors have received any cash compensation for services rendered to HealthCor. Since the consummation of HealthCor&#8217;s initial public offering and until the earlier of the consummation of the initial business combination or HealthCor&#8217;s liquidation, HealthCor agreed to reimburse the Sponsor for office space and secretarial and administrative services provided to HealthCor, in an amount up to $10,000 per month. In addition, the Sponsor, executive officers and directors and their respective affiliates were reimbursed for any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses incurred in connection with activities conducted on HealthCor&#8217;s behalf, such as identifying potential target businesses and performing due diligence on suitable business combinations. HealthCor&#8217;s audit committee was responsible for reviewing all payments made by HealthCor to the Sponsor, executive officers and directors and their respective affiliates on a quarterly basis. Any such payments prior to the Business Combination were made using funds held outside of the Trust Account. Other than quarterly audit committee review of such reimbursements, HealthCor did not have any additional controls in place for governing reimbursement payments to its directors and executive officers for their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses incurred on behalf of HealthCor and in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder&#8217;s and consulting fees, was paid by HealthCor to the Sponsor, executive officers and directors or any of their respective affiliates, prior to completion of the Business Combination. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive and Director Compensation of Hyperfine </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This section provides an overview of Hyperfine&#8217;s executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The number of securities and exercise prices, as applicable, described in this section have been adjusted based on the Hyperfine Exchange Ratio or Liminal Exchange Ratio, as applicable, to reflect the number of securities and exercise prices following the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, Hyperfine&#8217;s named executive officers (&#8220;Named Executive Officers&#8221; or &#8220;NEOs&#8221;) were: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott, President and Chief Executive Officer, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Khan Siddiqui, M.D., Chief Medical Officer and Chief Strategy Officer, and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neela Paykel, General Counsel, Chief Compliance Officer and Corporate Secretary. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The objective of our compensation program is to provide a total compensation package to each NEO that will enable us to attract, motivate and retain outstanding individuals, align the interests of our executive team with those of our equity holders, encourage individual and collective contributions to the successful execution of our short- and long-term business strategies and reward NEOs for performance. Prior to the completion of the Business Combination in December 2021, Legacy Hyperfine&#8217;s board of directors historically determined the compensation for the NEOs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For 2021, the compensation program for the NEOs consisted of a base salary and incentive compensation delivered in the form of cash bonuses and time-based stock option awards, each as described below: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Base Salary</div></div>. Base salary is paid to attract and retain qualified talent and is set at a level that is commensurate with the executive&#8217;s duties and authorities, contributions, prior experience and sustained performance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Bonuses</div></div>. Cash bonuses are paid to incentivize the NEOs to achieve annual financial and operating performance metrics and have been paid at the discretion of the board of directors. Other than the CEO, the bonus is approved by the compensation committee. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Compensation Table </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows information concerning the annual compensation for services provided to us by our NEOs for the year ended December&#160;31, 2020 and 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Position</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Option&#160;Awards&#160;&#160;<br/>($)(1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Dave Scott, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">President and Chief Executive Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">252,147</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,848,819</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,100,966</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Khan Siddiqui, M.D., <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Medical Officer and Chief Strategy Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">331,250</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">144,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,195</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">583,445</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">255,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">494,241</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">899,449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Neela Paykel, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Counsel, Chief Compliance Officer and Corporate Secretary</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">233,333</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(9)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,500</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,683</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(10)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount represents the aggregate grant date fair value for option awards computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718. A discussion of our methodology for determining grant date fair value may be found in Note 12 to our audited combined and consolidated financial statements for the year ended December&#160;31, 2021 included in this prospectus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Scott joined Legacy Hyperfine on May&#160;24, 2021. His current annual base salary is $750,000. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Mr.&#160;Scott received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> signing bonus of $1,500,000, with the first installment of $750,000 paid upon his start date and the second installment of $750,000 paid upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> anniversary of his start date, and a $500,000 discretionary bonus with respect to 2021 performance. Dr. Siddiqui received a $50,000 discretionary transaction bonus paid in connection with the consummation of the Business Combination and a $94,000 discretionary bonus with respect to 2021 performance. Ms. Paykel received a one-time signing bonus of $25,000, a $25,000 discretionary transaction bonus paid in connection with the consummation of the Business Combination and a $102,500 discretionary bonus with respect to 2021 performance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Scott was granted options to purchase shares of Legacy Hyperfine common stock in April 2021 with an exercise price per share equal to the fair market value of the common stock on the grant date. 1,899,500 of the shares underlying the options have an exercise price per share of $3.27 and vest, subject to continued service, as to 25% on June&#160;30, 2022, with the remainder vesting in 36 equal monthly installments thereafter, and 949,750 of the shares underlying the options have an exercise price per share of $3.27 and vest, subject to continued service, upon the achievement of performance conditions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Siddiqui joined Legacy Hyperfine as its Chief Medical Officer and Chief Strategy Officer on January&#160;27, 2020. His current annual base salary is $375,000. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Siddiqui was granted options to purchase shares of Legacy Hyperfine common stock in April 2021 with an exercise price per share equal to the fair market value of the common stock on the grant date. The 54,037 shares underlying the options have an exercise price per share of $3.27 and vest, subject to continued service, in 48 monthly installments beginning on January&#160;31, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Siddiqui was granted options to purchase shares of Liminal common stock in May 2021 with an exercise price per share equal to the fair market value of the common stock on the grant date. The 1,796 shares underlying the options have an exercise price per share of $5.24 and vest, subject to continued service, in 48 monthly installments beginning on October&#160;31, 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Siddiqui was granted options to purchase shares of Legacy Hyperfine common stock in January 2020 with an exercise price per share equal to the fair market value of the common stock on the grant date. The </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">235,145 shares underlying the options have an exercise price per share of $3.76 and vest, subject to continued service, as follows: 25% of the shares vested on December&#160;31, 2020, with the remainder vesting in equal monthly installments over the following 36 months. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ms.&#160;Paykel joined Legacy Hyperfine in May 2021. Her current annual base salary is $350,000. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ms.&#160;Paykel was granted options to purchase shares of Legacy Hyperfine common stock in April 2021 with an exercise price per share equal to the fair market value of the common stock on the grant date. The 98,250 shares underlying the options have an exercise price per share of $3.27 and vest, subject to continued service, as to 25% on June&#160;30, 2022, with the remainder vesting in equal monthly installments over the following three years. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Outstanding Equity Awards at 2021 Fiscal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-End</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows information regarding outstanding equity awards held by the NEOs as of December&#160;31, 2021. The number of securities and exercise prices, as applicable, described in this section have been adjusted based on the Hyperfine Exchange Ratio and the Liminal Exchange Ratio, as applicable, to reflect the number of securities and exercise prices following the Business Combination. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option&#160;Awards</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Securities</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Underlying<br/>Unexercised Options</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercisable (#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>Unexercisable<br/>(#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Expiration<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,899,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Khan Siddiqui, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1/27/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,397</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1/27/2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1/27/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,169</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1/27/2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/14/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,507</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/14/2031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/12/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">561</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/12/2031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neela Paykel</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/27/2031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 1,899,500 shares of Class&#160;A common stock granted on April&#160;27, 2021. The shares underlying this option vest, subject to continued service, as follows: 25% of the shares vest on June&#160;30, 2022, with the remainder vesting in equal monthly installments over the following 36 months. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 474,875 shares of Class&#160;A common stock granted on April&#160;27, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1)&#160;the completion of a business combination that results in the operating business of Legacy Hyperfine and Liminal becoming a publicly traded company (a &#8220;SPAC transaction&#8221;) within two years of Mr.&#160;Scott&#8217;s start date and the common stock of the Company achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within two years of the closing of the SPAC transaction; (2)&#160;the completion of the initial public offering of Legacy Hyperfine and Liminal (&#8220;IPO&#8221;) within two years of Mr.&#160;Scott&#8217;s start date and the common stock of the Company achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within two years of the closing of the IPO; or (3)&#160;the closing of a private financing round within two years of Mr.&#160;Scott&#8217;s start date in which $50&#160;million or more is raised and the Company&#8217;s stock price per share equals or exceeds 1.5 times $3.92 (as adjusted). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 474,875 shares of Class&#160;A common stock granted on April&#160;27, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1)&#160;the completion of a SPAC transaction within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2)&#160;the completion of an IPO within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3)&#160;the closing of a </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">private financing round within four years of Mr.&#160;Scott&#8217;s start date in which $50&#160;million or more is raised and the Company&#8217;s stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 104,800 shares of Class&#160;A common stock granted on January&#160;27, 2020. The shares underlying this option vest, subject to continued service, as follows: 25% of the shares vested on December&#160;31, 2020, with the remainder vesting in equal monthly installments over the following 36 months. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 130,345 shares of Class&#160;A common stock granted on January&#160;27, 2020. The shares underlying this option vest, subject to continued service, as follows: 25% of the shares vested on December&#160;31, 2020, with the remainder vesting in equal monthly installments over the following 36 months. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 54,037 shares of Class&#160;A common stock granted on April&#160;14, 2021. The shares underlying this option vest, subject to continued service, in 48 equal monthly installments beginning on January&#160;31, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 1,796 shares of Class&#160;A common stock granted on May&#160;12, 2021. The shares underlying this option vest, subject to continued service, in 48 equal monthly installments beginning on October&#160;31, 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an option to purchase 98,250 shares of Class&#160;A common stock granted on April&#160;27, 2021. The shares underlying this option vest, subject to continued service, as follows: 25% of the shares vest on June&#160;30, 2022, with the remainder vesting in equal monthly installments over the following 36 months. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employment Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Mr.&#160;Scott as Legacy Hyperfine&#8217;s President and Chief Executive Officer on April&#160;25, 2021, an Offer Letter of Employment with Alok Gupta as Legacy Hyperfine&#8217;s Chief Financial Officer on July&#160;17, 2021, an Offer Letter of Employment with Mr.&#160;Hughes on June&#160;7, 2019, an Offer Letter of Employment with Dr.&#160;Siddiqui as Legacy Hyperfine&#8217;s Chief Medical Officer and Chief Strategy Officer on January&#160;4, 2020, an Offer Letter of Employment with Neela Paykel as Legacy Hyperfine&#8217;s General Counsel on April&#160;13, 2021, and an Offer Letter of Employment with Scott White as Legacy Hyperfine&#8217;s Chief Commercial Officer on August&#160;24, 2021, the material terms of which are described below. In addition, each named executive officer has entered into a confidentiality agreement obligating the officer to refrain from disclosing any of our proprietary information received during the course of employment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dave Scott </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Mr.&#160;Scott on April&#160;25, 2021, as amended, to begin employment as Legacy Hyperfine&#8217;s President and Chief Executive Officer on May&#160;24, 2021. Pursuant to the terms of his Offer Letter, Mr.&#160;Scott&#8217;s initial annual base salary was $400,000. Effective December&#160;22, 2021, Mr.&#160;Scott&#8217;s annual base salary is $750,000. Mr.&#160;Scott is eligible to receive a minimum discretionary bonus of $400,000 for 2021 based on the successful completion of the Company&#8217;s initial public offering or a business combination that results in the operating business of the Company becoming a publicly traded company and the attainment of other goals, objectives and performance metrics. Beginning in 2022, Mr.&#160;Scott is eligible to receive an annual discretionary bonus with a target of 100% of Mr.&#160;Scott&#8217;s base salary and a cap of 200% of Mr.&#160;Scott&#8217;s base salary, provided that he is employed with Hyperfine through the scheduled date of payment of such bonus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to his Offer Letter, Mr.&#160;Scott received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> signing bonus of $1,500,000, with the first installment of $750,000 paid upon his start date and the second installment of $750,000 paid upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> anniversary of his start date. If Mr.&#160;Scott is terminated by the Company for cause (as defined in his Offer Letter) or resigns without good reason (as defined in his Offer Letter) prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> anniversary of his start date, Mr.&#160;Scott is required to repay the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sign-on</div> bonus. If Mr.&#160;Scott is terminated by the Company without cause or resigns with good reason, he will not be required to repay the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sign-on</div> bonus. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, pursuant to the Offer Letter, Mr.&#160;Scott was granted 1,899,500 time-based stock options with an exercise price of $3.27 per share, with 25% of the award to vest on June&#160;30, 2022, and the remainder of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options vesting in equal monthly installments over the following 36 months. If Mr.&#160;Scott&#8217;s employment terminates because of his death, such options will vest such that no less than 50% of the shares subject to the award will be vested on the termination date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Scott was also granted 474,875 performance-based stock options with an exercise price of $3.27 per share, which options vest upon the first to occur of: (1)&#160;the completion of a business combination that results in the operating business of Legacy Hyperfine and Liminal becoming a publicly traded company (a &#8220;SPAC transaction&#8221;) within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within two years of the closing of the SPAC transaction; (2)&#160;the completion of the initial public offering of Legacy Hyperfine and Liminal (&#8220;IPO&#8221;) within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within two years of the closing of the IPO; or (3)&#160;the closing of a private financing round (a &#8220;Financing&#8221;) within two years of Mr.&#160;Scott&#8217;s start date in which $50&#160;million or more is raised and the Company&#8217;s stock price per share equals or exceeds 1.5 times $3.92 (as adjusted). In addition, Mr.&#160;Scott was granted 474,875 performance-based stock options with an exercise price of $3.27 per share, which options vest upon the first to occur of: (1)&#160;the completion of a SPAC transaction within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2)&#160;the completion of an IPO within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3)&#160;the closing of a private financing round within four years of Mr.&#160;Scott&#8217;s start date in which $50&#160;million or more is raised and the Company&#8217;s stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). Mr.&#160;Scott&#8217;s Offer Letter provides that, subject to approval by the board of directors, Mr.&#160;Scott will be granted 474,875 performance-based stock options, which options will vest upon the first to occur of: (1)&#160;the completion of a SPAC transaction within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a price per share of $50.00 or more for at least 20 out of 30 consecutive trading days within six years of the closing of the SPAC transaction; (2)&#160;the completion of an IPO within two years of Mr.&#160;Scott&#8217;s start date and the Company&#8217;s common stock achieving a price per share that equals or exceeds 5.0 times $3.92 (as adjusted) within six years of the closing of the IPO; or (3)&#160;the closing of a private financing round within six years of Mr.&#160;Scott&#8217;s start date in which $50&#160;million or more is raised and Hyperfine&#8217;s stock price per share equals or exceeds 5.0 times $3.92 (as adjusted). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the closing of a SPAC transaction or IPO within two years of Mr.&#160;Scott&#8217;s start date, Mr.&#160;Scott will receive a grant of restricted stock units (&#8220;RSUs&#8221;) in the Company with a value of $2,500,000, subject to the approval of the board of directors, Mr.&#160;Scott&#8217;s continued service on the grant date and time-based vesting conditions. In the event a SPAC transaction or IPO had not occurred, Mr.&#160;Scott would have been awarded a transaction bonus of $2,500,000 for a successful financing round of Legacy Hyperfine of $50&#160;million or more within two years of his start date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Offer Letter, if Mr.&#160;Scott&#8217;s employment is terminated without cause or if Mr.&#160;Scott resigns with good reason, Mr.&#160;Scott will receive severance equal to 12 months base salary and target bonus and payment of an amount equal to COBRA premiums for 12 months. He will receive 12 months accelerated vesting of outstanding time-based vesting equity awards, and any vested options, including options with performance-based vesting that have previously vested, will be eligible to be exercised until the earlier of the third anniversary of Mr.&#160;Scott&#8217;s termination of employment or their originally scheduled expiration date. Mr.&#160;Scott will also receive 36 months of accelerated vesting of any outstanding RSUs granted in connection with a SPAC transaction or IPO described above. If a SPAC transaction, IPO or Financing has not occurred and the Company terminates Mr.&#160;Scott&#8217;s employment within 24 months of his start date, Mr.&#160;Scott will receive $2,500,000 in lieu of the RSU grant described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If during the period beginning three months prior to and ending eighteen months following the date of a change in control, the Company terminates Mr.&#160;Scott&#8217;s employment without cause or if he resigns with good </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reason, Mr.&#160;Scott will receive severance equal to two times the sum of his base salary and target bonus, paid as a lump sum, plus payment of an amount equal to COBRA premiums for 24 months. He will receive 100% accelerated vesting for all time-based vesting equity awards and for the award of 474,875 performance-based stock options that includes the performance vesting criteria of a price per share that equals or exceeds 1.5 times $3.92 (as adjusted). The awards subject to such accelerated vesting shall be eligible to be exercised until the earlier of the third anniversary of Mr.&#160;Scott&#8217;s termination of employment or their originally scheduled expiration date. In addition, if a SPAC transaction, IPO or financing round has not occurred and the Company terminates Mr.&#160;Scott&#8217;s employment without cause or Mr.&#160;Scott terminates his employment for good reason during a change in control period and within 36 months of his start date, Mr.&#160;Scott will receive $2,500,000 in lieu of the RSU grant described above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Alok Gupta </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Mr.&#160;Gupta on July&#160;17, 2021 as Legacy Hyperfine&#8217;s Chief Financial Officer. Pursuant to the terms of his Offer Letter, Mr.&#160;Gupta&#8217;s annual base salary was $400,000. Mr.&#160;Gupta is eligible to receive an annual discretionary bonus with a target of 40% of his base salary, to be prorated for calendar year 2021, provided that he is employed with Hyperfine through the scheduled date of payment of such bonus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to his Offer Letter, Mr.&#160;Gupta will receive a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payment of $85,000 to be paid upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> anniversary of his start date to cover the costs of relocation. If Mr.&#160;Gupta resigns without good reason prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> anniversary of his start date, Mr.&#160;Gupta is required to repay the relocation payment. Mr.&#160;Gupta also received a bonus of $25,000 in January 2022 in connection with the completion of the Business Combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Gupta&#8217;s Offer Letter provides that, subject to approval by our board of directors or compensation committee, at the first meeting of the compensation committee following the registration of our equity compensation plan with the SEC after the closing of a SPAC Transaction, Mr.&#160;Gupta will be granted 100,000 RSUs, with 25% of the award to vest on September&#160;30, 2022 and the remainder of the RSUs vesting in equal quarterly installments over the following three years, subject to Mr.&#160;Gupta&#8217;s continued employment on each vesting date. In addition, subject to approval by our board of directors or compensation committee, Mr.&#160;Gupta will be granted 200,000 stock options at the first meeting of the compensation committee following the closing of a SPAC Transaction, with an exercise price equal to the closing price of the stock on such date, with 25% of the award to vest on September&#160;30, 2022, and the remainder of the options vesting in equal monthly installments over the following three years, subject to Mr.&#160;Gupta&#8217;s continued employment on each vesting date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mark Hughes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Mr.&#160;Hughes on June&#160;7, 2019 to begin employment as Legacy Hyperfine&#8217;s Head of Research and Program Management on July&#160;1, 2019. Beginning January&#160;1, 2020, Mr.&#160;Hughes served as Legacy Hyperfine&#8217;s Chief Operating Officer. In March 2022, Mr.&#160;Hughes transitioned from Chief Operating Officer to the position of Vice President, Hardware Engineering and Operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Khan Siddiqui, M.D. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Dr.&#160;Siddiqui as Legacy Hyperfine&#8217;s Chief Medical Officer and Chief Strategy Officer on January&#160;4, 2020. Pursuant to the terms of his Offer Letter, Dr.&#160;Siddiqui&#8217;s annual base salary was $300,000. As of August&#160;1, 2021, Dr.&#160;Siddiqui&#8217;s annual base salary is $375,000. Dr.&#160;Siddiqui is eligible to receive an annual discretionary bonus with a target of 50% of his annual base salary, provided that he is employed with Hyperfine through the scheduled date of payment of such bonus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to his Offer Letter, Dr.&#160;Siddiqui was granted 235,145 stock options with an exercise price of $3.76 per share, with 25% of each award to vest on December&#160;31, 2020, and the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr.&#160;Siddiqui&#8217;s continued employment on each vesting date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Neela Paykel </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Ms.&#160;Paykel on April&#160;13, 2021 as Legacy Hyperfine&#8217;s General Counsel. Pursuant to the terms of her Offer Letter, Ms.&#160;Paykel&#8217;s annual base salary is $350,000. Ms.&#160;Paykel is eligible to receive an annual discretionary bonus with a target of 40% of her base salary, to be prorated for calendar year 2021, provided that she is employed with Hyperfine through the scheduled date of payment of such bonus. Ms.&#160;Paykel also received a bonus of $25,000 in January 2022 in connection with the completion of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to her Offer Letter, Ms.&#160;Paykel received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payment of $25,000 as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sign-on</div> bonus. If Ms.&#160;Paykel voluntarily terminates her employment prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> anniversary of her start date, Ms.&#160;Paykel is required to repay the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sign-on</div> bonus. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to her Offer Letter, Ms.&#160;Paykel was granted 98,250 stock options with an exercise price of $3.27 per share, with 25% of the award to vest on June&#160;30, 2022, and the remainder of the options vesting in equal monthly installments over the following three years, subject to Ms.&#160;Paykel&#8217;s continued employment on each vesting date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scott White </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into an Offer Letter of Employment with Mr.&#160;White on August&#160;24, 2021 to serve as Legacy Hyperfine&#8217;s Chief Commercial Officer starting on September&#160;27, 2021. Pursuant to the terms of his Offer Letter, Mr.&#160;White&#8217;s annual base salary is $325,000. Mr.&#160;White is eligible to receive an annual discretionary bonus with a target of 40% of his base salary, to be prorated for calendar year 2021, provided that he is employed with Hyperfine through the scheduled date of payment of such bonus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to his Offer Letter, Mr.&#160;White received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payment of $25,000 as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sign-on</div> bonus. If Mr.&#160;White voluntarily terminates his employment prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> anniversary of his start date, Mr.&#160;White is required to repay the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sign-on</div> bonus. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;White&#8217;s Offer Letter provides that, subject to approval by the board of directors or compensation committee, at the first meeting of the board of directors or the compensation committee following the registration of Hyperfine&#8217;s equity compensation plan with the Securities and Exchange Commission after the closing of a SPAC Transaction, Mr.&#160;White will be granted 20,000 RSUs, with 25% of the award to vest on September&#160;30, 2022 and the remainder of the RSUs vesting in equal quarterly installments over the following three years, subject to Mr.&#160;White&#8217;s continued employment on each vesting date. In addition, subject to approval by the board of directors or compensation committee, Mr.&#160;White will be granted 40,000 stock options at the first meeting of the board of directors following the closing of a SPAC Transaction, with an exercise price equal to the closing price of the stock on such date, with 25% of the award to vest on September&#160;30, 2022, and the remainder of the options vesting in equal monthly installments over the following three years, subject to Mr.&#160;White&#8217;s continued employment on each vesting date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Benefits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our NEOs participate in employee benefit programs available to its employees generally, including a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-qualified</div> 401(k) plan. Hyperfine did not maintain any executive-specific benefit or perquisite programs in 2021. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Severance Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2021, the board of directors adopted the Hyperfine, Inc. Executive Severance Plan (the &#8220;Severance Plan&#8221;). Current participants in the Severance Plan include all employees with the title of Vice President, including Executive Vice President, Senior Vice President and Vice President. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Severance Plan, if we terminate a participant&#8217;s employment without cause (as defined in the Severance Plan) at any time other than during the twelve (12)&#160;month period following a change in control (as such term is defined in the Severance Plan) (the &#8220;Change in Control Period&#8221;), then the participant is eligible to receive the following benefits: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Severance payable in the form of salary continuation or a lump sum payment. The severance amount is equal to participant&#8217;s then-current base salary times a multiplier determined based on the participant&#8217;s title or role with us. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will pay for company contribution for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;) during the severance period. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Severance Plan, if we terminate a participant&#8217;s employment without cause or a participant resigns for good reason, during the Change in Control Period, then the participant is eligible to receive the following benefits: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Severance payable in a single lump sum. The severance amount is equal to participant&#8217;s then-current base salary and then-current target annual bonus opportunity, times a change in control multiplier determined based on the participant&#8217;s title or role with us. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will pay for company contribution for continuation coverage under COBRA during the severance period. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any outstanding unvested equity awards held by the participant under any then-current outstanding equity incentive plan(s) will become fully vested as of the date the termination of such participant&#8217;s employment becomes effective. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A participant&#8217;s rights to any severance benefits under the Severance Plan are conditioned upon the participant executing and not revoking a valid separation and general release of claims agreement in a form provided by us. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following table shows the total compensation paid or accrued during the fiscal year ended 2021 to each of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors. Directors who are employed by us are not compensated for their service on our board of directors. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fees&#160;Earned<br/>or Paid in<br/>Cash ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Awards<br/>(1)($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Awards&#160;(2)($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R. Scott Huennekens</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,037</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,995</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,437,008</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,995</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,908,126</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,089,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John Dahldorf</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,995</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruth Fattori</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,995</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">181,913</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maria Sainz</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,995</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">181,776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Daniel J. Wolterman</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,995</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">181,913</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount represents the aggregate grant date fair value for stock awards computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718. A discussion of our methodology for determining grant date fair value may be found in Note 12 to our audited combined and consolidated financial statements for the year ended December 31, 2021 included in this prospectus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount represents the aggregate grant date fair value for option awards computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718. A discussion of our methodology for determining grant date fair value may be found in Note 12 to our audited combined and consolidated financial statements for the year ended December 31, 2021 included in this prospectus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Mr.&#160;Huennekens received $81,667 during 2021 pursuant to a Consulting Agreement entered into between Legacy Hyperfine and Mr.&#160;Huennekens on April&#160;25, 2021, and $1,370 pursuant to Hyperfine&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation policy. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The aggregate grant date fair value for this award was determined by multiplying 19,586, the number of shares granted, by $9.19, the closing price of our Class&#160;A common stock on the Nasdaq Global Market on December&#160;23, 2021, the date of the grant. The RSUs were granted pursuant to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation policy and vest in equal annual installments over three years beginning on December&#160;23, 2022, subject to the director&#8217;s continued service through the applicable vesting date. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Huennekens was granted options to purchase shares of Legacy Hyperfine common stock in April 2021 with an exercise price per share equal to the fair market value of the common stock on the grant date. 712,312 of the shares underlying the options have an exercise price of $3.27 per share and vest, subject to continued service, as to 25% on June&#160;30, 2022, with the remainder vesting in 36 equal monthly installments thereafter, and 474,874 of the shares underlying the options have an exercise price of $3.27 per share and vest, subject to continued service, upon the achievement of performance conditions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Rothberg was granted options to purchase shares of Legacy Hyperfine common stock in April 2021 with an exercise price per share equal to the fair market value of the common stock on the grant date. The 982,500 shares underlying the options have an exercise price of $3.27 per share and vested and became exercisable on December&#160;15, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following table shows the aggregate number of shares subject to options and restricted stock units held by each of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors as of December&#160;31, 2021. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Stock&#160;Options<br/>Held at Fiscal<br/>Year-End</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Restricted<br/>Stock&#160;Units<br/>Held&#160;at&#160;Fiscal<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-End</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R. Scott Huennekens</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,187,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonathan M. Rothberg, Ph.D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">982,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John Dahldorf</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruth Fattori</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maria Sainz</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Daniel J. Wolterman</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director Compensation Policy </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;22, 2021, we adopted a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation policy. Pursuant to the policy, the annual retainer for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors is $50,000. Annual retainers for committee membership are as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Position</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retainer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit committee chairperson</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit committee member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation committee chairperson</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation committee member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nominating and corporate governance committee chairperson</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nominating and corporate governance committee member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">These fees are payable in arrears in quarterly installments as soon as practicable following the last business day of each fiscal quarter, provided that the amount of such payment will be prorated for any portion of such quarter that a director is not serving on our board of directors, on such committee or in such position. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> directors are also reimbursed for reasonable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> business expenses incurred in connection with attending meetings of the board and any committee of the board on which they serve and in connection with other business related to the board. Directors may also be reimbursed for reasonable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> business expenses in accordance with our travel and other expense policies, as may be in effect from time to time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we grant to new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors upon their initial election to our board of directors (including any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director whose election to our board of directors was approved at the Special Meeting of Stockholders held on December&#160;21, 2021) a number of RSUs (each RSU relating to one share of our Class&#160;A common stock) having an aggregate fair market value equal to $180,000, determined by dividing (A) $180,000 by (B)&#160;the closing price of our Class&#160;A common stock on Nasdaq on the date of the grant (rounded down to the nearest whole share), on the first business day after the date that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director is first appointed or elected to the board. Each of these grants shall vest in equal annual installments over three years from the date of the grant, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s continued service as a director on the applicable vesting dates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, in connection with each of our annual meetings of stockholders, each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director automatically receives an option to purchase shares of our Class&#160;A common stock having an aggregate grant date fair value of $100,000, valued based on a Black-Scholes valuation method (rounded down to the nearest whole share), each year beginning in 2022 on the first business day after our annual meeting of stockholders. Each of these options has a term of 10 years from the date of the award and vests at the end of the period beginning on the date of each regular annual meeting of stockholders (or the first business day of the third fiscal quarter, as applicable) and ending on the date of the next regular annual meeting of stockholders, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s continued service as a director through the applicable vesting dates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consulting Agreement with Scott Huennekens </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine entered into a Consulting Agreement with Scott Huennekens on April&#160;25, 2021 to provide consulting services to Legacy Hyperfine as the Executive Chairman of Legacy Hyperfine&#8217;s board of directors. Pursuant to the terms of the Consulting Agreement, Mr.&#160;Huennekens is paid $10,000 per month. In addition, Mr.&#160;Huennekens was granted 712,312 stock options with an exercise price of $3.27 per share, with 25% of the award to vest on June&#160;30, 2022, and the remainder of the options vesting in equal monthly installments over the following 36 months, subject to Mr.&#160;Huennekens&#8217; continued service on each vesting date. Mr.&#160;Huennekens was also granted 237,437 performance-based stock options with an exercise price of $3.27 per share, which options vest upon the first to occur of: (1)&#160;the completion of a SPAC transaction within two years of Mr.&#160;Huennekens&#8217; start date and the Company&#8217;s common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2)&#160;the completion of an initial public offering within two years of Mr.&#160;Huennekens&#8217; start date and the Company&#8217;s common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within three years of the closing of the initial public offering; or (3)&#160;the closing of a private financing round within three years of Mr.&#160;Huennekens&#8217; start date in which $50&#160;million or more is raised and Hyperfine&#8217;s stock price per share equals or exceeds 1.5 times $3.92 (as adjusted). In addition, Mr.&#160;Huennekens was granted 237,437 performance-based stock options with an exercise price of $3.27 per share, which options vest upon the first to occur of: (1)&#160;the completion of a SPAC transaction within two years of Mr.&#160;Huennekens&#8217; start date and the Company&#8217;s common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2)&#160;the completion of an initial public offering within two years of Mr.&#160;Huennekens&#8217; start date and the Company&#8217;s common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the initial public offering; or (3)&#160;the closing of a private financing round within four years of Mr.&#160;Huennekens&#8217; start date in which $50&#160;million or more is raised and Hyperfine&#8217;s stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HealthCor Related Person Transactions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;24, 2020, the Sponsor paid $25,000, or approximately $0.006 per share, to cover certain of HealthCor&#8217;s offering and formation costs in consideration of 4,312,500 Class&#160;B ordinary shares, par value $0.0001. On January&#160;29, 2021, HealthCor consummated the sale of 614,000 Private Placement Shares to the Sponsor at a price of $10.00 per share. In December 2020 and January 2021, the Sponsor transferred 35,000 Class&#160;B ordinary shares to each of Dr.&#160;Wolfgang, Mr.&#160;Weinstein and Mr.&#160;Harris, resulting in HealthCor&#8217;s independent directors holding an aggregate of 105,000 Founder Shares. On January&#160;26, 2021, HealthCor effected a share capitalization pursuant to which it issued 862,500 additional Class&#160;B ordinary shares, resulting in its Initial Shareholders holding 5,175,000 Class&#160;B ordinary shares. Up to 675,000 Founder Shares were subject to forfeiture by the Sponsor depending on the extent to which the underwriters&#8217; exercised their over-allotment option in connection with HealthCor&#8217;s IPO. As a result of the underwriters&#8217; election to fully exercise their over-allotment option, these Founder Shares were no longer subject to forfeiture. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Sponsor purchased, pursuant to a written agreement, an aggregate of 614,000 Private Placement Shares for a purchase price of $10.00 per share in a private placement that occurred with the closing of the IPO. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the completion of the Business Combination, HealthCor maintained its executive offices at 55&#160;Hudson Yards, 28th Floor, New York, NY 10001. The cost for HealthCor&#8217;s use of this space was included in the up to $10,000 per month fee HealthCor paid to the Sponsor for office space, administrative and support services. Upon completion of the Business Combination, HealthCor ceased paying these monthly fees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;23, 2020, HealthCor issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to the Sponsor, pursuant to which HealthCor could borrow up to an aggregate principal amount of $300,000. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;March&#160;31, 2021 and (ii)&#160;the completion of the IPO. The balance of the Promissory Note was repaid in February 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the IPO, HealthCor entered into a registration and shareholder rights agreement (the &#8220;Registration and Shareholder Rights Agreement&#8221;) pursuant to which the Sponsor was entitled to certain registration rights with respect to the Private Placement Shares, the shares issuable upon conversion of working capital loans (if any) and the Class&#160;A ordinary shares issuable upon exercise of the foregoing and upon conversion of the Founder Shares, and, upon consummation of an initial business combination, to nominate three individuals for appointment to HealthCor&#8217;s board of directors, as long as the Sponsor holds any securities covered by the registration and shareholder rights agreement. The Registration and Shareholder Rights Agreement was replaced by the Registration Rights Agreements entered into by and among the Company, the Sponsor, and certain affiliates of the Sponsor, certain Legacy Hyperfine equityholders, certain Liminal equityholders, and certain other parties at the Closing as described below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine and Liminal </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liminal Series A Reclassification </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April&#160;1, 2021, the outstanding capital stock of Liminal was reclassified into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> preferred stock, all of which was held by 4Bionics. The Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock is entitled to 10 votes per share and the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> preferred stock is entitled to 1 vote per share. On April&#160;2, 2021, 4Bionics distributed its shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> preferred stock to its members. In connection with the distribution, Jonathan M. Rothberg, Ph.D. received a cash payment from 4Bionics of $480,000 for prior services provided to Liminal, and as of the date hereof, Dr.&#160;Rothberg had received 38,239,355&#160;shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock and 766,353 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> preferred stock with an aggregate estimated value, as of April&#160;2, 2021, of $43,296,336. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease Arrangements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We occupy office space at 351 New Whitfield Street, Guilford, Connecticut, residential space at 485 Old Whitfield Street, Guilford, Connecticut, and office space at 3000 El Camino Real, Suite 100, Palo Alto, California. Legacy Hyperfine and Liminal previously occupied office space at 251 West 30th Street, New York, New York. The residential space at 485 Old Whitfield Street, Guilford, Connecticut is leased by 4Catalyzer Corporation, or 4Catalyzer, from Oceanco, LLC, of which Jonathan M. Rothberg Children&#8217;s Trust dated April&#160;24, 1997 is the sole owner and Michael Rothberg, who is a sibling of Jonathan M. Rothberg, Ph.D., the Founder of Legacy Hyperfine and Liminal and Vice Chairman of our board of directors, is the trustee of such trust. We have the right to rent rooms at 485 Old Whitfield Street from 4Catalyzer for $125 per employee per&#160;day. The office space at 351 New Whitfield Street, Guilford, Connecticut is leased from an unrelated landlord by 4Catalyzer. 4Catalyzer subleases space to us at 351 New Whitfield Street, where we occupy such portions of the space as 4Catalyzer may designate from time to time on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> basis, and we pay our pro rata share of expenses paid by 4Catalyzer for such space under the master lease. The office space at 3000 El Camino Real is leased from an unrelated landlord by 4Catalyzer. In connection with the Business Combination Agreement, 4Catalyzer granted us a license to use such portions of the office space at 3000 El Camino Real as 4Catalyzer may designate from time to time. The office space at 251 West 30th Street, New York, New York was leased from an unrelated landlord by 4Catalyzer. We paid 4Catalyzer on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> basis for use of the space in 485 Old Whitfield Street and 351 New Whitfield Street, but no rental or lease agreements are effective. Under these arrangements, Legacy Hyperfine and Liminal paid $7,155, $9,990, and $20,025 for the years ended December&#160;31, 2019, 2020, and 2021, respectively, related to 485 Old Whitfield Street; $100,245, $102,838, and $129,344 for the same time periods, respectively, related to 351 New Whitfield Street; $95,922, $100,969, and $99,854 for the same time periods, respectively, related to Suite 100 at 3000 El Camino Real; and $10,854, $1,950, and $0 for the same time periods, respectively, related to 251 West 30th Street, New York, New&#160;York. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated Technology Services Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;11, 2020, Legacy Hyperfine and Liminal entered into an Amended and Restated Technology Services Agreement (the &#8220;ARTSA&#8221;) by and among 4Catalyzer, Legacy Hyperfine, Liminal and other participant companies controlled by the Rothbergs, including Butterfly Network, Inc., AI Therapeutics, Inc., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, 4Bionics, Tesseract Health, Inc. and Homodeus Inc. Under the ARTSA, Legacy Hyperfine, Liminal and the other participant companies agreed to share certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which means any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant, such as software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists, subject to certain restrictions on use, with the other participant companies. The ARTSA provides that ownership of each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technology shared by 4Catalyzer, Legacy Hyperfine, Liminal or another participant company will remain with the company that originally shared the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technology. The ARTSA also provides for 4Catalyzer to perform certain services to Legacy Hyperfine, Liminal and each other participant company, such as general administration, facilities, information technology, financing, legal, human resources and other services. The ARTSA also provides for the participant companies to provide other services to each other. The fees due to 4Catalyzer or the other participants for such services are allocated to Legacy Hyperfine, Liminal and the participant companies based on the total&#160;costs and expenses for the relative amount of services and resources used by the participant company, except for services with respect to intellectual property, which are based on a negotiated cost plus methodology. The ARTSA provides that all inventions of 4Catalyzer, Legacy Hyperfine, Liminal or the other participants made in the course of providing such services will be owned by the receiving participant and that the receiving participant will grant to the participant company providing the services a royalty-free, perpetual, limited, worldwide, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license to use such inventions only in the core business field of the participating company. The ARTSA has an initial term of five years from the date of the ARTSA and provides that the ARTSA will be automatically extended for additional, consecutive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> renewal terms. Each participating company, including Legacy Hyperfine and Liminal, has the right to terminate the ARTSA at any time upon 30 days&#8217; prior notice and 4Catalyzer has the right to terminate the ARTSA at any time upon 90 days&#8217; prior notice. The Company paid an </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">aggregate of $3,074,195, $2,343,681, and $2,281,792 during the years ended December&#160;31, 2019, 2020, and 2021, respectively, for services under the ARTSA. The Company received an aggregate of $324,404, $363,619, and $11,685 during the years ended December&#160;31, 2019, 2020, and 2021, respectively, for services under the ARTSA. On July&#160;7, 2021, Legacy Hyperfine, Liminal and 4Catalyzer entered into First Addendums to the ARTSA, pursuant to which Legacy Hyperfine and Liminal each terminated its participation under the ARTSA immediately prior to the Closing. Legacy Hyperfine and Liminal each entered into a Master Services Agreement (the &#8220;Master Services Agreements&#8221;) with 4Catalyzer effective as of July&#160;7, 2021 pursuant to which Legacy Hyperfine and Liminal may engage 4Catalyzer to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Technology and Services Exchange Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Legacy Hyperfine and Liminal have entered into Technology and Services Exchange Agreements (each, a &#8220;TSEA&#8221; and collectively, the &#8220;TSEA&#8221;) with other participant companies controlled by the Rothbergs. A TSEA by and among Butterfly Network, Inc., AI Therapeutics, Inc., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, 4Bionics, Tesseract Health, Inc., Detect, Inc. (f/k/a Homodeus Inc.), Legacy Hyperfine and Liminal was signed in November 2020; a TSEA by and among <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, AI Therapeutics, Inc., 4Bionics, Tesseract Health, Inc., Detect, Inc., Legacy Hyperfine and Liminal was signed in February 2021 (and which Protein Evolution, Inc. joined in August 2021); and a TSEA by and among Legacy Hyperfine, Liminal, AI Therapeutics, Inc., Tesseract Health, Inc. and Detect, Inc. was signed in July 2021 and became effective upon the Closing. Under the TSEA, Legacy Hyperfine, Liminal and the other participant companies may, in their discretion, permit the use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which include any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant, such as software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists, by other participant companies. The TSEA provides that ownership of each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technology shared by Legacy Hyperfine, Liminal or another participant company will remain with the company that originally shared the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technology. In addition, any participant company (including Legacy Hyperfine and Liminal) may, in its discretion, permit its personnel to be engaged by another participant company to perform professional, technical or consulting services for such participant. Unless otherwise agreed to by Legacy Hyperfine, Liminal and the other participant company, all rights, title and interest in and to any inventions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">works-of-authorship,</div></div> idea, data or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> invented, made, created or developed by the personnel (employees, contractors or consultants) in the course of conducting services for a participant company (&#8220;Created IP&#8221;) will be owned by the participant company for which the work was performed, and the recipient participant company grants to the party that had its personnel provide the services that resulted in the creation of the Created IP a royalty-free, perpetual, limited, worldwide, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable</div> (and with respect to software, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensable</div> in object code only) license to utilize the Created IP only in the core business field of the originating participant company, including a license to create and use derivative works based on the Created IP in the originating participant&#8217;s core business field, subject to any agreed upon restrictions. Fees or other compensation payable for services or use of technology under the TSEA will be determined at fair market value and set forth in one or more written work orders to be entered into between the applicable participant companies. As of February&#160;15, 2022, the amount of financial obligations Legacy Hyperfine and Liminal have under the TSEA is approximately $10,568. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investors&#8217; Rights, Voting and Right of First Refusal Agreements with Legacy Hyperfine and Liminal Stockholders </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with Legacy Hyperfine&#8217;s Series D preferred stock financing, Legacy Hyperfine entered into investors&#8217; rights, voting and right of first refusal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-sale</div> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with holders of Legacy Hyperfine&#8217;s preferred stock and certain holders of its common stock. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2021, Liminal entered into investors&#8217; rights, voting and right of first refusal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-sale</div> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">with holders of Liminal&#8217;s preferred stock. In connection with the distribution of Liminal preferred stock by 4Bionics, each recipient of Liminal preferred stock became party to the investors&#8217; rights, voting and right of first refusal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-sale</div> agreements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amended and Restated Registration Rights Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Closing of the Business Combination, the Company, the Sponsor, certain affiliates of the Sponsor, certain stockholders of Legacy Hyperfine, and certain stockholders of Liminal entered into the Registration Rights Agreement, pursuant to which, among other things, the parties to the Registration Rights Agreement agreed, subject to certain exceptions, not to effect any sale or distribution of any equity securities of the Company held by any of them during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period described therein and were granted certain registration rights with respect to their respective shares of the Company&#8217;s common stock, in each case, on the terms and subject to the conditions therein. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advisory Agreement with Jonathan M. Rothberg, Ph.D. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the consummation of the Business Combination Agreement, Legacy Hyperfine and Dr.&#160;Rothberg, the Founder of Legacy Hyperfine and Liminal and a member of the Hyperfine Board, entered into the Advisory Agreement, effective as of the Closing, pursuant to which Dr.&#160;Rothberg will advise the Company&#8217;s Chief Executive Officer and provide guidance to Hyperfine Board. As compensation for Dr.&#160;Rothberg&#8217;s services under the Advisory Agreement, we will pay Dr.&#160;Rothberg a consulting fee of $16,667 per month during the term of the Advisory Agreement. The term of the Advisory Agreement will continue until terminated by us or Dr.&#160;Rothberg. Any of the parties may terminate the Advisory Agreement for any reason upon giving thirty&#160;(30)&#160;days&#8217; advance notice of such termination. In the event of such termination, we will be obligated to pay Dr.&#160;Rothberg any earned but unpaid consulting fee as of the termination date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification Agreements with Officers and Directors and Directors&#8217; and Officers&#8217; Liability Insurance </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with this Business Combination, we entered into indemnification agreements with each of our executive officers and directors. The indemnification agreements and our Bylaws require that we indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, the indemnification agreements and the Bylaws also require us to advance expenses incurred by our directors and officers. We also maintain a general liability insurance policy, which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Policies and Procedures for Related Party Transactions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A &#8220;Related Person Transaction&#8221; is a transaction, arrangement or relationship in which the Company or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds the lesser of (i) $120,000, and (ii)&#160;one percent of the average of the Company&#8217;s total assets at year end for the last two completed fiscal years, and in which any related person had, has or will have a direct or indirect material interest. Transactions involving compensation for services provided to the Company or any of its subsidiaries as an employee, consultant or director will not be considered related person transactions under this policy. A &#8220;Related Person&#8221; is: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any person who is or was an executive officer, director, or director nominee of the Company at any time since the beginning of the Company&#8217;s last fiscal year; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a person who is or was an Immediate Family Member (as defined below) of an executive officer, director, director nominee at any time since the beginning of the Company&#8217;s last fiscal year; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any person who, at the time of the occurrence or existence of the transaction, is the beneficial owner of more than 5% of any class of the Company&#8217;s voting securities (a &#8220;Significant Stockholder&#8221;); or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any person who, at the time of the occurrence or existence of the transaction, is an Immediate Family Member of a Significant Stockholder of the Company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An &#8220;Immediate Family Member&#8221; of a person is any child, stepchild, parent, stepparent, spouse, sibling, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mother-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">father-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">son-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">daughter-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">brother-in-law</div></div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sister-in-law</div></div> of such person, or any other person sharing the household of such person, other than a tenant or employee. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has implemented policies and procedures designed to minimize potential conflicts of interest arising from any dealings it may have with its affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, pursuant to its charter, the audit committee has the responsibility to review related party transactions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the related person transaction policy, the related person in question or, in the case of transactions with a beneficial holder of more than 5% of the Company&#8217;s voting stock, an officer with knowledge of a proposed transaction, will be required to present information regarding the proposed related person transaction to the audit committee (or to another independent body of our board of directors) for review. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To identify related person transactions in advance, we expect to rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related person transactions, our audit committee is expected to take into account the relevant available facts and circumstances, which may include, but are not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the related person&#8217;s interest in the transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the approximate dollar value of the amount involved in the transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the approximate dollar value of the amount of the related person&#8217;s interest in the transaction without regard to the amount of any profit or loss; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether the transaction was undertaken in the ordinary course of business of the Company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to the Company than terms that could have been reached with an unrelated third party; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the purpose of, and the potential benefits to the Company of, the transaction; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any other information regarding the transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The audit committee will approve only those transactions that it determines are fair to the Company and in the Company&#8217;s best interests. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Independence of the Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq rules generally require that independent directors must comprise a majority of a listed company&#8217;s board of directors. As a controlled company, we are largely exempt from such requirements. Based upon information requested from and provided by each proposed director concerning his or her background, employment and affiliations, including family relationships, we have determined that John Dahldorf, Ruth Fattori, Maria Sainz and Daniel J. Wolterman, representing four of our directors, are &#8220;independent&#8221; as that term is defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. FEDERAL INCOME TAX CONSIDERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a discussion of certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of our Hyperfine Class&#160;A common stock and Hyperfine Class&#160;B common stock, which we refer to collectively as our securities. This discussion is limited to certain U.S. federal income tax considerations to beneficial owners of our securities who are initial purchasers of our securities pursuant to this offering and hold our securities as a capital asset within the meaning of Section&#160;1221 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). This discussion assumes that any distributions made by us on our securities and any consideration received by a holder in consideration for the sale or other disposition of our securities will be in U.S. dollars. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This summary is based upon U.S. federal income tax laws as of the date of this prospectus, which is subject to change or differing interpretations, possibly with retroactive effect. This discussion is a summary only and does not describe all of the tax consequences that may be relevant to you in light of your particular circumstances, including but not limited to the alternative minimum tax, the Medicare tax on certain net investment income, U.S. federal gift and estate tax laws, and the different consequences that may apply if you are subject to special rules that apply to certain types of investors, including but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">banks, financial institutions, or financial services entities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">broker-dealers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">governments or agencies or instrumentalities thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulated investment companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">real estate investment trusts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expatriates, former citizens, or former long-term residents of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that actually or constructively own five percent or more (by vote or value) of our securities (except to the limited extent set forth below); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that acquired our securities pursuant to an exercise of employee share options, in connection with employee stock incentive plans or otherwise as compensation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">insurance companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">dealers or traders subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> method of accounting with respect to our securities (except to the limited extent set forth below); </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons for whom our securities constitutes &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons holding our securities shares as part of a &#8220;straddle,&#8221; constructive sale, hedge, conversion or other integrated or similar transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subchapter S corporations, partnerships or entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of such partnerships or pass-through entities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> entities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">controlled foreign corporations (including &#8220;specified foreign corporations&#8221;); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">passive foreign investment companies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a partnership (including an entity or arrangement treated as a partnership or other pass-thru entity for U.S. federal income tax purposes) holds our securities, the tax treatment of a partner, member or other beneficial </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">owner in such partnership will generally depend upon the status of the partner, member or other beneficial owner, the activities of the partnership and certain determinations made at the partner, member or other beneficial owner level. If you are a partner, member or other beneficial owner of a partnership holding our securities, you are urged to consult your tax advisor regarding the tax consequences of the acquisition, ownership and disposition of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations as of the date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> taxation, or any U.S. federal taxes other than income taxes (such as gift and estate taxes). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not sought, and do not expect to seek, a ruling from the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, Treasury Regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. You are urged to consult your tax advisor with respect to the application of U.S. federal tax laws to your particular situation, as well as any tax consequences arising under the laws of any state, local or foreign jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES. EACH PROSPECTIVE INVESTOR IN OUR SECURITIES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY U.S. FEDERAL <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-INCOME,</div> STATE, LOCAL, AND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> TAX LAWS. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This section applies to you if you are a &#8220;U.S. Holder.&#8221; A U.S. Holder is a beneficial owner of our securities who or that is, for U.S. federal income tax purposes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an individual who is a citizen or resident of the United States as determined for United States federal income tax purposes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United&#160;States, any state thereof or the District of Columbia; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a trust, if (i)&#160;a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii)&#160;it has a valid election in effect under Treasury Regulations to be treated as a United States person. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taxation of Distributions</div></div>. If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of our Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in its Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, as applicable. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Any remaining excess will be treated as gain realized on the sale or other disposition of Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, as applicable, and will be treated as described under &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Holders &#8212; Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock or Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock&#8221; </div></div>below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Dividends we pay to a U.S. Holder that is a taxable corporation generally will qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holder may constitute &#8220;qualified dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holders may be subject to tax on such dividend at regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock or Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B common stock</div></div>. Upon a sale or other taxable disposition of our Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in its Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, as applicable. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock so disposed of exceeds one year. Long-term capital gains recognized by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holders may be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, the amount of gain or loss recognized by a U.S. Holder is an amount equal to the difference between (i)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock generally will equal the U.S. Holder&#8217;s acquisition cost of such common stock, less any prior distributions treated as a return of capital. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Optional Conversion and Mandatory Conversion of Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock</div></div>. A U.S. Holder of Hyperfine Class&#160;B common stock is not expected to recognize any income, gain or loss under U.S. federal income tax laws as a result of the optional conversion of such U.S. Holder&#8217;s Hyperfine Class&#160;B common stock into Hyperfine Class&#160;A common stock. It is expected that a U.S. Holder who elects to convert its Hyperfine Class&#160;B common stock into Hyperfine Class&#160;A common stock (i)&#160;would have the same basis in its Hyperfine Class&#160;A common stock as such U.S. Holder had in its Hyperfine Class&#160;B common stock prior to conversion into Hyperfine Class&#160;A common stock, and (ii)&#160;such U.S. Holder&#8217;s holding period in the Hyperfine Class&#160;A common stock would include the U.S. Holder&#8217;s holding period in the Hyperfine Class&#160;B common stock so converted. A mandatory conversion of any U.S. Holder&#8217;s Hyperfine Class&#160;B common stock into Hyperfine Class&#160;A common stock is expected to be treated the same as an optional conversion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Information Reporting and Backup Withholding</div></div>. In general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition of our securities, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holders </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This section applies to you if you are a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-U.S.</div> Holder.&#8221; As used herein, the term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-U.S.</div> Holder&#8221; means a beneficial owner of our securities who or that is for U.S. federal income tax purposes: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> alien individual (other than certain former citizens and residents of the United States subject to U.S. tax as expatriates); </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a foreign corporation; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an estate or trust that is not a U.S. Holder; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of the disposition (as such days are calculated pursuant to Section&#160;7701(b)&#160;(3) of the Code). If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Taxation of Distributions. In general, any distributions we make to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder of shares of our Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN-E).</div></div> Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder&#8217;s adjusted tax basis in its shares of Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock, as applicable, and, to the extent such distribution exceeds the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of our securities, which will be treated as described under <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-U.S.</div> Holders &#8212; Gain on Sale, Taxable Exchange or Other Taxable Disposition of Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock and Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock&#8221;</div></div> below. In addition, if we determine that we are likely to be classified as a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;United States real property holding corporation&#8221; (see <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-U.S.</div> Holders &#8212; Gain on Sale, Taxable Exchange or Other Taxable Disposition of Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock and Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock&#8221;</div></div> below), we generally will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The withholding tax generally does not apply to dividends paid to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder who provides a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;W-8ECI,</div> certifying that the dividends are effectively connected with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder&#8217;s conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to regular U.S. federal income tax as if the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise. A corporate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax&#8221; imposed at a rate of 30% (or a lower applicable treaty rate). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on Sale, Taxable Exchange or Other Taxable Disposition of Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock and Hyperfine Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock</div></div>. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our securities unless: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the gain is effectively connected with the conduct by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder of a trade or business within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder); or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder held our securities, and, in the case where shares of our Hyperfine Class&#160;A common stock or our Hyperfine Class&#160;B common stock are regularly traded on an established </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">securities market, as defined pursuant to applicable Treasury Regulations, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder has owned, directly or constructively, more than 5% of our Hyperfine Class&#160;A common stock or our Hyperfine Class&#160;B common stock at any time within the shorter of the five-year period preceding the disposition or such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder&#8217;s holding period for the shares of our Hyperfine Class&#160;A common stock or our Hyperfine Class&#160;B common stock. There can be no assurance that our Hyperfine Class&#160;A common stock or our Hyperfine Class&#160;B common stock will be treated as regularly traded on an established securities market for this purpose. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless an applicable treaty provides otherwise, gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder were a U.S. resident. Any gains described in the first bullet point above of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder that is treated as a foreign corporation for U.S. federal income tax purposes may also be subject to an additional &#8220;branch profits tax&#8221; imposed at a 30% rate (or lower treaty rate). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the second bullet point above applies to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder, gain recognized by such Holder on the sale, exchange or other disposition of our Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Hyperfine Class&#160;A common stock or Hyperfine Class&#160;B common stock from such holder may be required to withhold U.S. federal income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a United States real property holding corporation if the fair market value of our &#8220;United States real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. We believe we are not currently and do not anticipate becoming a United States real property holding corporation. However, because the determination of whether we are a United States real property holding corporation depends on the fair market value of our U.S. real property interests relative to the fair market value of our other business assets, there can be no assurance that we will not become a United States real property holding corporation in the future. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Information Reporting and Backup Withholding</div></div>. Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our securities. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FATCA Withholding Taxes</div></div>. Provisions commonly referred to as &#8220;FATCA&#8221; generally impose withholding at a rate of 30% on payments of dividends (including constructive dividends) in respect to our securities which are held by or through certain &#8220;foreign financial institutions&#8221; (which is broadly defined for this purpose and in general includes investment vehicles) and certain other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> entities unless various U.S. information reporting and due diligence requirements (generally relating to ownership by United States persons of interests in or accounts with those entities) have been satisfied by, or an exemption applies to, the payee (typically certified by the delivery of a properly completed IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN-E).</div></div> Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Accordingly, the entity through which our securities are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of our securities held by an investor that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30% unless such entity either (1)&#160;certifies to us or the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (2)&#160;provide certain information regarding the entity&#8217;s &#8220;substantial United States owners&#8221; which will in turn be provided to the U.S. Department of Treasury. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Under certain circumstances, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder might be eligible for refunds or credits of such withholding taxes, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder might be required to file a U.S. federal income tax return to claim such refunds or credits. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The withholding provisions described above currently apply to payments of dividends. The U.S. Treasury Department has released proposed Treasury Regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a disposition of our securities. In its preamble to such proposed Treasury Regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final Treasury Regulations are issued. Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our securities. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PLAN OF DISTRIBUTION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are registering the resale by the Selling Securityholders of up to 41,775,946 shares of our Class&#160;A common stock and up to 15,055,288 shares of our Class&#160;B common stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Selling Securityholders may offer and sell, from time to time, their respective shares of Class&#160;A common stock and Class&#160;B common stock covered by this prospectus. The Selling Securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The Selling Securityholders may sell their securities by one or more of, or a combination of, the following methods: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> distribution in accordance with the rules of Nasdaq; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">through trading plans entered into by a Selling Securityholder pursuant to Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b5-1</div> under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">short sales; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distribution to employees, members, limited partners or stockholders of the Selling Securityholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by pledge to secured debts and other obligations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delayed delivery arrangements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to or through underwriters or agents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on an exchange or other similar offerings through sales agents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in privately negotiated transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in options transactions; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through a combination of any of the above methods of sale, as described below, or any other method permitted pursuant to applicable law. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any securities that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the securities or otherwise, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with Selling Securityholders. The Selling Securityholders may also sell the securities short and redeliver the securities to close out such short positions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Selling Securityholders may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged securities pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In effecting sales, broker-dealers or agents engaged by the Selling Securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In offering the securities covered by this prospectus, the Selling Securityholders and any broker-dealers who execute sales for the Selling Securityholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the Selling Securityholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. Certain of our stockholders have entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will make copies of this prospectus available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have agreed to indemnify certain of the Selling Securityholders against certain liabilities, including certain liabilities under the Securities Act, the Exchange Act or other federal or state law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have agreed with certain Selling Securityholders pursuant to the Registration Rights Agreement to use our commercially reasonable efforts to keep the registration statement of which this prospectus constitutes a part effective until such time as all securities covered by this prospectus have been sold or otherwise cease to be registrable securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also agreed with the PIPE Investors pursuant to the Subscription Agreements and with Jefferies LLC pursuant to the Letter Agreement to cause the registration statement to remain effective until the earlier of (i)&#160;five years from the effective date of the registration statement, (ii)&#160;the date the Selling Securityholder ceases to hold the shares covered by the registration statement or (iii)&#160;the first date on which the Selling Securityholder can sell all of its shares under Rule 144 of the Securities Act without restriction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated Registration Rights Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, the Company, the Sponsor and certain affiliates of the Sponsor (the &#8220;Sponsor Group Holders&#8221;), and certain security holders of Legacy Hyperfine and Liminal (the &#8220;Hyperfine Holders&#8221;) entered into </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an amended and restated registration rights agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;), pursuant to which, among other things, the Sponsor Group Holders and the Hyperfine Holders were granted certain registration rights with respect to their respective shares of the Company&#8217;s common stock on the terms and subject to the conditions therein. The Sponsor Group Holders and the Hyperfine Holders also agreed not to effect any sale, disposition or distribution of any equity securities of the Company held by any of them (except with respect to shares of the Company&#8217;s Class&#160;A common stock acquired in open market transactions or pursuant to the PIPE Investment) during their respective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods. Each of the Hyperfine Holders agreed to not transfer securities of the Company (subject to certain exceptions described above) for the period ending on the earlier of (a) 180 days after the Closing, subject to certain customary exceptions, and (b)&#160;subsequent to the Closing, (x)&#160;if the last reported sale price of the Company&#8217;s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading days after the Closing or (y)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#8217;s public stockholders having the right to exchange their shares of the Company&#8217;s common stock for cash, securities or other property (the &#8220;Hyperfine Shares <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> Period&#8221;). In addition, each Sponsor Group Holder agreed to not transfer any securities of the Company (subject to certain exceptions described above) for the period ending on the earlier of (a)&#160;one year after the Closing, and (b)&#160;subsequent to the Closing, (x)&#160;if the last reported sale price of the Company&#8217;s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading days commencing at least 180 days after the Closing, or (y)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#8217;s public stockholders having the right to exchange their shares of the Company&#8217;s common stock for cash, securities or other property. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc284543_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL MATTERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has passed upon the validity of the Hyperfine Class&#160;A common stock and Hyperfine Class&#160;B common stock offered by this prospectus and certain other legal matters related to this prospectus. </div></div> <div id="toc284543_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXPERTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The combined and consolidated financial statements of Hyperfine, Inc. as of December&#160;31, 2021 and 2020, and for each of the two years in the period ended December&#160;31, 2021, included in this prospectus have been audited by Deloitte&#160;&amp; Touche LLP, independent registered public accounting firm, as stated in their report appearing herein. Such combined and consolidated financial statements have been so included in reliance upon such report of such firm given upon their authority as experts in accounting and auditing. </div></div> <div id="toc284543_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WHERE YOU CAN FIND MORE INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</div> as amended, including exhibits, under the Securities Act of 1933, as amended, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement and our exhibits. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public on a website maintained by the SEC located at www.sec.gov. We also maintain a website at https://hyperfine.io. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc284543_22a">INDEX TO FINANCIAL STATEMENTS </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Combined and Consolidated Financial Statements as of December&#160;31, 2021 and 2020 and for the years ended December&#160;31, 2021 and 2020 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Page<br/>Number</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin284543_1">Report of Independent Registered Public Accounting Firm (Deloitte &amp; Touche LLP, PCAOB ID 34)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin284543_2">Combined and Consolidated Balance Sheets as of December 31, 2021 and 2020</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin284543_3">Combined and Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2021 and 2020</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin284543_4">Combined and Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2021 and 2020</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin284543_5">Combined and Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin284543_6">Notes to Combined and Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin284543_1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the stockholders and the Board of Directors of Hyperfine, Inc. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying combined and consolidated balance sheets of Hyperfine, Inc. and subsidiaries, (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related combined and consolidated statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the two years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2021, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Deloitte&#160;&amp; Touche LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, New York </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;25, 2022 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2021. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin284543_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED AND CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CURRENT ASSETS:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">188,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, less allowance of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> in 2021 and 2020, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unbilled receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,718</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,357</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">691</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due from related parties</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">197,485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets&#8212;related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:OtherAssetsRelatedPartyNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long term assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202,473</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,526</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CURRENT LIABILITIES:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">948</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred grant funding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:DeferredGrantFundingCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:DeferredGrantFundingCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related parties</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,981</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AccruedExpensesAndOtherCurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AccruedExpensesAndOtherCurrentLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,246</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,294</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMMITMENTS AND CONTINGENCIES (NOTE 16)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONVERTIBLE PREFERRED STOCK</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine convertible preferred stock (Series A, B, C and D): $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0">.0001</ix:nonFraction></ix:nonFraction> par value, aggregate liquidation preference of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">147,651</ix:nonFraction>; <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">129,788,828</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">95,010,858</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STOCKHOLDERS&#8217; EQUITY (DEFICIT):</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0">.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">600,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">130,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">55,277,061</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,576,137</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0">.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,055,288</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">322,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">136,320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity (deficit)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,227</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,054</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202,473</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,526</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these combined and consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin284543_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross margin</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,167</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">477</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,593</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,701</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,014</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,868</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,491</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before provision for income taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss and comprehensive loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per common share attributable to common stockholders, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,690,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,523,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these combined and consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin284543_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share amounts) </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hyperfine Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liminal Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A&#160;Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B&#160;Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity&#160;(Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">67,211,210</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68,646</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,508,415</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,178</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">48,042</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">39,864</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series D convertible preferred stock, net of issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,799,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,640</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment from 4Bionics, LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AdjustmentsToAdditionalPaidInCapitalInvestments" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AdjustmentsToAdditionalPaidInCapitalInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise&#160;of&#160;stock&#160;options</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">67,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based&#160;compensation</div> expense</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance,&#160;December&#160;31,&#160;2020</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">95,010,858</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,286</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,576,137</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,415</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71,469</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,054</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series D convertible preferred stock, net of issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,171,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,461</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment from 4Bionics, LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AdjustmentsToAdditionalPaidInCapitalInvestments" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AdjustmentsToAdditionalPaidInCapitalInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of Liminal Common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:RecapitalizationOfPermanentToTemporaryEquityShares" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:RecapitalizationOfPermanentToTemporaryEquityValues" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,350</ix:nonFraction></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="hypr:ConversionOfLiminalCommonStock" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="hypr:ConversionOfLiminalCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise&#160;of&#160;stock&#160;options</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">565,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of the convertible preferred stock into Class&#160;A and Class&#160;B common stock at the Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">109,182,191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">158,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">57,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,350</ix:nonFraction></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,028,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,055,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">168,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">168,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net equity infusion from the&#160;Business&#160;Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">21,806,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;A common stock to a service provider</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">300,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based&#160;compensation</div> expense</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance,&#160;December&#160;31,&#160;2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">55,277,061</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,055,288</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">322,540</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">136,320</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,227</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these combined and consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin284543_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">289</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-down of inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Write-off</div> of other assets&#8212;related party</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:WriteOffOfOtherAssetsRelatedParty" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">984</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales under sales type leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:SalesTypeLeaseSellingProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments received on net investment in lease</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetInvestmentInLeasePurchase" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetInvestmentInLeasePurchase" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Unbilled receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="hypr:UnbilledReceivables" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Due from related parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets&#8212;related party</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseDueFromOtherRelatedParties" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseDueFromOtherRelatedParties" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidSupplies" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long term assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">377</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred grant funding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,052</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,082</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to related parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">773</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">47,182</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,525</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,711</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,568</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Series D convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock issuance costs related to Series D convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of notes payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of notes payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment from 4Bionics, LLC</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net proceeds from equity infusion from the Business Combination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:ProceedsFromBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">176,767</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,938</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash and cash equivalents and restricted cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">126,874</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,845</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, beginning of year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, end of year</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,160</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,286</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">188,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and restricted cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,160</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,286</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash received from exchange of research and development tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">261</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of noncash information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncash acquisition of fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these combined and consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin284543_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Hyperfine, Inc. (together with its subsidiaries, as applicable, &#8220;Hyperfine&#8221;, the &#8220;Company&#8221;), formerly known as HealthCor Catalio Acquisition Corp. (&#8220;HealthCor&#8221;), was incorporated as a Cayman Islands exempted company on November&#160;18, 2020. The Company&#8217;s legal name became Hyperfine, Inc. in connection with the closing of the Business Combination (the &#8220;Closing&#8221;) on December&#160;22, 2021 (the &#8220;Closing Date&#8221;), as defined and described in Note 3. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>. In connection with the Closing, Hyperfine, Inc., a Delaware corporation (&#8220;Legacy Hyperfine&#8221;), and Liminal Sciences, Inc., a Delaware corporation (&#8220;Liminal&#8221;), merged with and into separate wholly owned subsidiaries of HealthCor and became wholly-owned subsidiaries of the Company, and changed their names to Hyperfine Operations, Inc. and Liminal Operations, Inc., respectively. Liminal subsequently changed its name to Liminal Sciences, Inc. The prior period financial information represents the combined financial results of Legacy Hyperfine and Liminal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is an innovative digital health business with a mission to provide affordable and accessible imaging and monitoring through magnetic resonance imaging (&#8220;MRI&#8221;) to revolutionize healthcare for people around the world. Hyperfine&#8217;s Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Portable Magnetic Resonance (&#8220;MR&#8221;) Imaging System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM </div>produces high-quality images at a lower magnetic field strength than conventional MRI systems, and can be used by healthcare professionals to make effective clinical diagnoses on a patient in a variety of settings where MRI devices have previously been inaccessible. Hyperfine received 510(k) clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in 2020 for its Swoop Portable MR Imaging System, which is commercially available in the United States. In 2021, Hyperfine also obtained a Medical Device License issued by Health Canada and expanded into the Canadian market, and also obtained regulatory authorization in New Zealand and Pakistan. All of the Company&#8217;s revenue to date has been generated from sales of this machine and related services. Additionally, the Company is in the process of developing a device to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasively</div> measure key vital signs in the brain to enable unprecedented access to dramatically improve patient outcomes. The Company is in the early research and development stage of such device and has not generated any revenue to date for it. In addition to Legacy Hyperfine and Liminal, the Company has an indirect wholly-owned subsidiary in the United Kingdom that did not have any significant operations during 2021. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719535"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined and consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All intercompany transactions and balances have been eliminated. </div></div></ix:nonNumeric> <ix:nonNumeric name="hypr:Covid19OutbreakPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719542"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Outbreak </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The recent outbreak of the novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;),</div> which was declared a pandemic by the World Health Organization on March&#160;11, 2020 and declared a National Emergency by the President of the United States on March&#160;13, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts on the Company&#8217;s operating results, financial condition and cash flows. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had, and is expected to continue to have, an adverse impact on the Company&#8217;s operations, particularly as a result of preventive and precautionary measures that the Company, other businesses, and governments are taking. Governmental mandates related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or other infectious diseases, or public </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelection_41719535" continuedAt="TextSelectionAppend_41719535_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719542"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">health crises, have impacted, and the Company expects them to continue to impact, its personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt or delay the Company&#8217;s receipt of instruments, components and supplies from the third parties the Company relies on to, among other things, produce its products. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has also had an adverse effect on the Company&#8217;s ability to attract, recruit, interview and hire at the pace the Company would typically expect to support its rapidly expanding operations. The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions taken to contain or address the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, as well as its economic impacts. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In adjusting to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> market and manufacturing conditions, the Company did not have to materially adjust its existing resource allocation or its factors of production. The Company has not incurred any significant impairment losses in the carrying values of its assets as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and is not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in its combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The estimates of the impact on the Company&#8217;s business may change based on new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or address its impact and the economic impact on local, regional, national and international markets. While the Company is unable to predict the full impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will have on its future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic, and the actions that may be taken by government authorities across the United States and elsewhere, it is not expected to result in any significant changes in costs going forward. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719545"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. At December&#160;31, 2021 and 2020, substantially all the Company&#8217;s cash and cash equivalents were invested at two financial institutions. The Company also maintains balances in various operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. </div></div> <ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant customers are those that represent more than 10% of the Company&#8217;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"></td>
<td style="width: 18%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer E</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer F</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer G</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer H</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_1" continuedAt="TextSelectionAppend_41719535_2"><ix:continuation id="TextSelection_41719545"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes a single exclusive manufacturer for its Swoop MRI scanner. Additionally, the Company purchases raw materials from this manufacturer. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;). Legacy Hyperfine and Liminal represent <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> operating segments. Given the similar qualitative and economic characteristics of the two operating segments, such that both are focused upon the development and commercialization of existing and new products and services, Legacy Hyperfine and Liminal are aggregated into <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> reporting segment. All of the Company&#8217;s long-lived assets are located in the United States. Other than $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2021To12_31_2021_AUsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction> of revenue recognized in Australia, all of the revenues were earned in the United States. Since the Company is aggregated into a single operating segment, all required financial segment information is provided in the combined and consolidated financial statements. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its combined and consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (&#8220;SSP&#8221;) of performance obligations and estimation of variable consideration; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for doubtful accounts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowances with respect to deferred tax assets; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumptions underlying the fair value used in calculation of the stock-based compensation expense. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s combined and consolidated financial statements. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All highly liquid investments purchased with a maturity of three months or less are cash equivalents. As of December&#160;31, 2021 and 2020, cash and cash equivalents consist principally of cash and money market accounts. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash balance represents funds received as part of grant funding and restricted in use to the purpose of the funding. For details, see the Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies&#8212;Grant Funding</div></div> and Note&#160;16. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commitments and Contingencies</div></div>. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">9</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_2" continuedAt="TextSelectionAppend_41719535_3"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are stated as the amount the Company expects to collect. The Company maintains allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. As of December&#160;31, 2021 and 2020, the allowance for doubtful accounts was $<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories primarily consist of finished goods which are produced by the Company&#8217;s third-party contract manufacturers as well as raw materials ordered in advance by the third-party contract manufacturer due to long delivery-lead time and which were billed to the Company. Inventories are stated at the lower of actual cost, determined using the average cost method, or net realizable value. Cost includes an allocation of wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. Net realizable value is based upon an estimated average selling price reduced by the estimated costs of disposal and transportation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation of inventory also requires the Company to estimate excess and obsolete inventory. The Company considers sales forecasts and historical experience to identify excess, close out, or slow-moving items as well as new product development schedules, product obsolescence and product merchantability, including whether older products can be remanufactured into new products, among other factors. The Company reduces the value of inventory for estimated obsolescence or lack of marketability by the difference between the cost of the affected inventory and the net realizable value. </div></div></ix:nonNumeric> <ix:nonNumeric name="hypr:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prepaid Expenses and Other Current Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets include amounts paid in advance for operating expenses as well as monies to be received from the State of Connecticut for research and development tax credits. These research and development tax credits are exchanged for a cash refund and are typically collected within one year from the date the tax return is filed with the state. The credits are recognized as an offset to research and development expenses in the combined and consolidated statements of operations and comprehensive loss in the annual period in which the corresponding expenses were incurred. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719558"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. </div></div> <ix:nonNumeric name="hypr:ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Useful lives of property and equipment are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_LeasedDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">7</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">10</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_3" continuedAt="TextSelectionAppend_41719535_4"><ix:continuation id="TextSelection_41719558"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other property and equipment include furniture and fixtures, software, vehicles, and machinery and equipment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditures for major renewals and improvements are capitalized. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation is eliminated from the balance sheet, and any resulting gains or losses are included in the combined and consolidated statements of operations and comprehensive loss in the period of disposal. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews its long-lived assets for impairment at least annually or when the Company determines a triggering event has occurred. When a triggering event has occurred, each impairment test is based on a comparison of the future expected undiscounted cash flow to the recorded value of the asset. If the recorded value of the asset is less than the undiscounted cash flow, the asset is written down to its estimated fair value. <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> impairments were recorded for the years ended December&#160;31, 2021 and 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capitalized Software Development Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For the costs incurred in developing the firmware embedded in the hardware devices that the Company sells and leases to its customers, the Company applies the principles of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed</div></div> (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20&#8221;).</div> ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20</div> requires that software development costs incurred in conjunction with product development be charged to research and development expense until technological feasibility is established. Thereafter, until the product is released for sale, software development costs must be capitalized and reported at the lower of unamortized cost or net realizable value of the related product. The Company has adopted the &#8220;tested working model&#8221; approach to establishing technological feasibility for its software products. Under this approach, the Company does not consider a product in development to have passed the technological feasibility milestone until the Company has completed a model of the product that contains essentially all the functionality and features of the final product and has tested the model to ensure that it works as expected. The Company&#8217;s hardware device, with the embedded firmware, was released for sale during the fourth quarter of the year ended December&#160;31, 2020, when the Company had completed all of the research and development activity to establish the technological feasibility of the product. As of December&#160;31, 2021 and 2020, the Company had not incurred significant costs between the establishment of technological feasibility and the release of a product for sale; thus, the Company had expensed all software development costs as incurred. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For software developed or acquired for internal use, including software used in the provision of subscription services to the Company&#8217;s customers, the Company applies the principles of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Cost of Computer Software Developed or Obtained for Internal Use</div></div> (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40&#8221;).</div> ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40</div> requires that software development costs incurred before the preliminary project stage be expensed as incurred. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Costs incurred during the preliminary project and post-implementation stages, including training and maintenance, are expensed as incurred. Capitalized costs are amortized on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">project-by-project</div></div> basis using the <ix:nonNumeric name="us-gaap:CapitalizedContractCostAmortizationMethod" contextRef="P01_01_2021To12_31_2021">straight-line method</ix:nonNumeric> over the estimated economic life of the application, which is <ix:nonNumeric name="us-gaap:CapitalizedContractCostAmortizationPeriod" contextRef="PAsOn12_31_2021" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, beginning when the asset is substantially ready for use. As of December&#160;31, 2021 and 2020, the Company did <ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any amount of capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software development costs. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">1</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_4" continuedAt="TextSelectionAppend_41719535_5"> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719562"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Revenue from Contracts with Customers.&#8221;</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is recognized when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following 5 steps: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 1: Identify Contracts with Customers:</div></div> The Company executes signed contracts with its customers for the sale of hardware devices and subscription services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 2: Identify Performance Obligations:</div></div> The Company&#8217;s contracts with customers primarily include two performance obligations, namely the hardware device and subscription services, which include access to the Company&#8217;s hosted cloud-based software applications and hardware maintenance and support on an ongoing basis throughout the subscription period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 3: Determine Transaction Price:</div></div> The Company&#8217;s contracts with customers include variable consideration in the form of discounts and price concessions. The Company estimates variable consideration using the expected value method based on the data available as of the end of each reporting period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 4: Allocate Transaction Price to Performance Obligations:</div></div> The Company allocates transaction price to the performance obligations in a contract with a customer, based on the relative standalone selling prices of the goods and services. The standalone selling prices of the hardware devices and subscription services are determined based on the observable standalone selling prices for which the Company sells the respective goods and services on a standalone basis, including renewals of subscription services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 5: Recognize Revenue as Performance Obligations are Satisfied:</div></div> Each unit of hardware devices is a performance obligation satisfied at a point in time, when control of the good transfers from the Company to the customer, which is usually upon delivery of the good to the customer. For sales of hardware where control of the product transfers to the customer upon shipment, the Company has made an accounting policy election to account for shipping and handling as fulfillment activities rather than a performance obligation. The subscription services are stand-ready obligations that are satisfied over time by providing the customer with ongoing access to the Company&#8217;s resources throughout the subscription period. The Company uses the time elapsed (straight line) measure of progress to recognize revenue as these performance obligations are satisfied evenly over the respective service period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company offers alternative payment structures and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;as-a-service&#8221;</div></div> offerings that are assessed to determine whether an embedded lease arrangement exists. The Company accounts for those contracts as a lease arrangement under the current lease standard if it is determined that the contract contains an identified asset and that the right to direct the use of that asset has transferred to the customer. When a contract includes lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, the Company allocates consideration under the contract to each component based on the relative standalone selling price and subsequently assesses lease classification for each lease component within a contract as a sales-type lease or an operating lease. On commencement of sales-type leases, the Company recognizes revenue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front,</div> and amounts due from the customer under the lease contract are recognized as financing receivables on the combined and consolidated balance sheets. Interest income is recognized as revenue over the term of the lease based on the effective interest method. The Company has elected not to include sales and other taxes collected from the lessee as part of lease revenue. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">2</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_5" continuedAt="TextSelectionAppend_41719535_6"><ix:continuation id="TextSelection_41719562"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All other leases that do not meet the definition of a sales-type lease are classified as operating leases. The underlying asset in an operating lease arrangement is carried at depreciated cost within Property and equipment, net on the combined and consolidated balance sheets. Depreciation is calculated using the straight-line method over the term of the underlying lease contract and is recognized as cost of revenue. The depreciable basis is the original cost of the equipment less the estimated residual value of the equipment at the end of the lease term. The Company recognizes operating lease income to product revenue on a straight-line basis over the lease term. Impairment of equipment under operating leases is assessed on the same basis as other long-lived assets. </div></div> </ix:continuation> <ix:nonNumeric name="hypr:DeferredRevenuePolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue primarily consists of billings or payments received in advance of revenue recognition from subscription services described above and is reduced as the revenue recognition criteria are met. Deferred revenue is classified as current based on expected revenue recognition timing. Specifically, deferred revenue that will be recognized as revenue within the succeeding twelve-month period is recorded as current in the Company&#8217;s combined and consolidated balance sheets. </div></div></ix:nonNumeric> <ix:nonNumeric name="hypr:WarrantiesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warranties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company offers a device warranty to customers for the longer of (a)&#160;twelve (12) months from delivery of the device for devices obtained through a capital purchase, or (b)&#160;the term of the subscription agreement for devices obtained on a subscription basis (subject to continued payment of fees for the subscription service). The Company&#8217;s subscription services include hardware maintenance and support. As noted in the accounting policy for revenue recognition, the Company recognizes revenue for subscription service over time using the time elapsed measure of progress. The costs of hardware maintenance are recognized in costs of revenue as they are incurred. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs consists of production costs for prototype, test and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-production</div> units, lab supplies, consulting and personnel costs, including salaries, stock-based compensation, bonuses, benefit costs and depreciation. Certain research and development grant funding is recognized as a reduction to research and development costs (see Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies&#8212;Grant Funding</div></div>). The Company recognizes these costs as they are incurred. </div></ix:nonNumeric> <ix:nonNumeric name="hypr:GrantFundingPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant Funding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received certain research and development funding through a grant issued by the Bill&#160;&amp; Melinda Gates Foundation (&#8220;BMGF&#8221;). Funding is recorded on the combined and consolidated balance sheet as restricted cash upon receipt. The funding is recognized in the combined and consolidated statements of operations and comprehensive loss as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. Grant funding payments received in advance of research and development expenses incurred are recorded as deferred grant funding as a current liability in the Company&#8217;s combined and consolidated balance sheets. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of Sales </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales consists of product and service costs including personnel cost and benefits including stock-based compensation, product costs, production setup expenses, depreciation and amortization expenses, inventory excess and obsolescence expenses. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">3</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_6" continuedAt="TextSelectionAppend_41719535_7"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="hypr:PatentCostsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent costs have been charged to operations as incurred, as their realization is uncertain. These costs are included in general and administrative expenses in the combined and consolidated statements of operations and comprehensive loss. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses primarily consist of personnel costs and benefits including stock-based compensation, patent and filing fees, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales and Marketing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing costs primarily consist of personnel costs and benefits including stock-based compensation, advertising, promotional, as well as conferences, meetings, and other events. Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising expenses were $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,459</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">437</ix:nonFraction>, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Common Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is calculated by dividing the net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares plus the common equivalent shares of the period, including any dilutive effect from such shares. The Company&#8217;s diluted net loss per common share is the same as basic net loss per common share for all periods presented since the effect of potentially dilutive securities is anti-dilutive. Refer to Note 13. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share</div></div> for further discussion. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has applied the guidance in ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A,</div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities,</div></div> and has therefore classified the Series A, Series B, Series C and Series D Convertible Preferred Stock (&#8220;Convertible Preferred Stock&#8221;) (see Note 10. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock</div></div>) as mezzanine equity. The Convertible Preferred Stock was recorded outside of stockholders&#8217; equity (deficit) because the Convertible Preferred Stock included a redemption provision upon a change of control, which is deemed a liquidation event that is considered outside the Company&#8217;s control. The Convertible Preferred Stock has been recorded at its original issue price, net of issuance costs. The Company did not adjust the carrying value of the Convertible Preferred Stock to the liquidation price associated with a change of control at December&#160;31, 2020 because a change of control of the Company was not considered probable at the reporting date (see Note&#160;10. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock</div></div>). Subsequent adjustments to increase or decrease the carrying values to their respective liquidation prices were made only when it became probable that such a change of control would occur. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">4</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_7" continuedAt="TextSelectionAppend_41719535_8"> <ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The measurement of stock-based compensation expense for all stock-based payment awards, including stock options granted to employees, directors, and consultants, is based on the estimated fair value of the awards on the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes stock-based compensation expense for stock option grants and incentive unit grants with only service conditions on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Generally, stock option grants and incentive unit grants fully vest <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durwordsen">four years</ix:nonNumeric> after the grant date, and stock option grants generally have a term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2021To12_31_2021">10 years</ix:nonNumeric>. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes the effect of forfeiture in compensation costs based on actual forfeitures when they occur. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s stock-based compensation program includes stock option grants to its employees, directors, and consultants. Stock options are granted at exercise prices not less than the estimated fair market value of the Company&#8217;s common stock at the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair values of stock option grants are estimated using a Black-Scholes option-pricing model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, Liminal was a wholly owned subsidiary of 4Bionics, and as such, 4Bionics granted equity awards in the form of incentive units to Liminal employees and nonemployees under 4Bionics&#8217; stock-based compensation program. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#8217;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), Tesseract Health, Inc. and Protein Evolution, Inc. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to the modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. </div></div></ix:nonNumeric> <ix:nonNumeric name="hypr:EarnOutSharesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, as defined in Note 3.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Business Combination</div></div>, to which the Companies&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> equity holders are entitled, fall within the scope of ASC 815,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;) pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and are to be recognized upon achievement of the market price milestone. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares to which certain employees are entitled to fall within the scope of ASC 718, pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">5</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_8" continuedAt="TextSelectionAppend_41719535_9"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="hypr:ResearchAndDevelopmentTaxCreditsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Tax Credits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes research and development tax credits as a reduction of Research and Development expense as earned. For State of Connecticut research and development tax credits, which are exchanged for a cash refund from the State of Connecticut, such exchanged credits are recognized as earned as a reduction of Research and Development expense in the combined and consolidated statements of operations and comprehensive loss. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilizes the asset and liability method of accounting for income taxes, as set forth in ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company has recorded a full valuation allowance as of December&#160;31, 2021 and 2020. Based on the available evidence, the Company believes that it is more likely than not that it will be unable to utilize all of its deferred tax assets in the future. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the provisions of ASC Topic 740, the Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. The Company&#8217;s policy is to recognize any interest and penalties related to income taxes in income tax expense in the combined and consolidated statements of operations and comprehensive loss. The Company&#8217;s open tax years subject to examination by the relevant taxing authorities are <span style="-sec-ix-hidden:hidden41720084">2017 through 2019</span>. As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction name="hypr:UncertainTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="hypr:UncertainTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> uncertain tax positions. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719582"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting pronouncements adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-15,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangibles&#8212;Goodwill and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Other&#8212;Internal-Use</div> Software Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</div></div> The guidance requires certain costs incurred during the application development stage to be capitalized and other costs incurred during the preliminary project and post-implementation stages to be expensed as they are incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. A customer&#8217;s accounting for the hosting component of the arrangement is not affected. This new guidance is effective for the Company for the annual reporting period beginning <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric> and interim periods beginning January&#160;1, 2022. The Company <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:booleantrue">adopted this guidance</ix:nonNumeric> on January&#160;1, 2021 and there was <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:booleantrue">no material effect of adoption on the combined and consolidated financial statements</ix:nonNumeric>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt-Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</div></div>, which simplifies the </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">6</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_9" continuedAt="TextSelectionAppend_41719535_10"><ix:continuation id="TextSelection_41719582" continuedAt="TextSelectionAppend_41719582_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">accounting for convertible instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also requires the application of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for calculating diluted earnings per share and the treasury stock method will be no longer available. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2024, and interim reporting periods within annual reporting periods beginning January&#160;1, 2024, with early adoption permitted. The Company elected to early <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:booleantrue">adopt this accounting pronouncement</ix:nonNumeric> on <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric> and there was <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:booleantrue">no material impact on the Company&#8217;s combined and consolidated financial statements and disclosures</ix:nonNumeric>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying existing guidance. For the Company, this ASU is effective for fiscal years beginning after December&#160;15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:booleantrue">adopted</ix:nonNumeric> this guidance on <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric> and there was <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:booleanfalse">no</ix:nonNumeric> material effect of adoption on the Company&#8217;s combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting pronouncements issued but not yet adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842),</div></div> which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-05</div> issued by FASB, entities that have not yet issued or made available for issuance the financial statements as of June&#160;3, 2020 can defer the new guidance for one year. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2020, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, and interim reporting periods within annual reporting periods beginning January&#160;1, 2023. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#8217;s combined and consolidated financial statements and does not expect it to be material. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221;</div></div> which was subsequently amended in November 2018 through ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-19,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses.&#8221;</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-19</div> further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>. As per the latest ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-02,</div> the FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January&#160;1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719535_10"><ix:continuation id="TextSelectionAppend_41719582_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#8217;s combined and consolidated financial statements and disclosures. </div></div> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719219"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. BUSINESS COMBINATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, Legacy Hyperfine and Liminal merged with and into separate wholly owned subsidiaries of HealthCor and each became a wholly-owned subsidiary of the Company. The Business Combination is accounted for as a reverse recapitalization in accordance with U.S. GAAP primarily due to the fact that Legacy Hyperfine and Liminal stockholders continued to control the Company following the closing of the Business Combination. Under this method of accounting, HealthCor is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Hyperfine and Liminal issuing stock for the net assets of HealthCor, accompanied by a recapitalization. The net assets of HealthCor are stated at historical cost, with no goodwill or other intangible assets recorded. Reported shares and loss per share available to holders of the Company&#8217;s capital stock and equity awards prior to the Business Combination have been retroactively restated reflecting the exchange ratios established pursuant to the Business Combination Agreement dated as of July&#160;7, 2021 (the &#8220;Business Combination Agreement&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Business Combination Agreement, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of Legacy Hyperfine capital stock (other than shares of Legacy Hyperfine Series A preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P07_07_2021To07_07_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.3275</ix:nonFraction> </div>(the &#8220;Hyperfine Exchange Ratio&#8221;), rounded down to the nearest whole number of shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of Legacy Hyperfine Series A preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Hyperfine Exchange Ratio, rounded down to the nearest whole number of shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each share of Liminal capital stock (other than shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to <ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P07_07_2021To07_07_2021_LiminalMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.1796</ix:nonFraction> (the &#8220;Liminal Exchange Ratio&#8221;), rounded down to the nearest whole number of shares; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each share of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Liminal Exchange Ratio, rounded down to the nearest whole number of shares; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each option to purchase shares of Legacy Hyperfine common stock and each option to purchase shares of Liminal common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such option immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelection_41719219" continuedAt="TextSelectionAppend_41719219_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal Exchange Ratio, as applicable, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded up to the nearest whole cent; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Business Combination Agreement, the Company will issue to holders of Legacy Hyperfine and Liminal securities as of immediately prior to the Effective Time, in accordance with their pro rata share, up to <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P07_07_2021To07_07_2021_LiminalMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares of Class&#160;A common stock as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> consideration (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Shares&#8221;), if at any time during the period between the Closing Date and the third anniversary of the Closing Date (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Period&#8221;), (i) the last share price of the Class&#160;A common stock is greater than or equal to $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn07_07_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">15.00</ix:nonFraction> for any <ix:nonFraction name="hypr:BusinessCombinationTransactionThresholdTradingDays" contextRef="P07_07_2021To07_07_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> trading days within any <ix:nonFraction name="hypr:BusinessCombinationTransactionThresholdConsecutiveTradingDays" contextRef="P07_07_2021To07_07_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction> consecutive trading day period, or (ii)&#160;there is a transaction that will result in shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value greater than or equal to $15.00. During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Period, if there is a transaction (other than for stock splits, stock dividends, special cash dividends, reorganizations, recapitalizations or similar transactions affecting the Class&#160;A common stock) that will result in the shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value less than $15.00, then the right to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will terminate. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;21, 2021, HealthCor filed the Certificate of Incorporation (the &#8220;Certificate&#8221;) with the Secretary of State of the State of Delaware, which became effective after the Domestication. As a consequence of filing the Certificate, the Company adopted a dual class structure, comprised of the Company&#8217;s Class&#160;A common stock, which is entitled to <ix:nonFraction name="hypr:NumberOfVotesPerShareEntitledToClassOfCommonStock" contextRef="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote per share, and the Company&#8217;s Class&#160;B common stock, which is entitled to <ix:nonFraction name="hypr:NumberOfVotesPerShareEntitledToClassOfCommonStock" contextRef="P12_12_2021To12_12_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> votes per share. The Company&#8217;s Class&#160;B common stock has the same economic terms as the Company&#8217;s Class&#160;A common stock, but is subject to a &#8220;sunset&#8221; provision if Jonathan M. Rothberg, Ph.D., the founder of Legacy Hyperfine and Liminal, and a Director of the Company (&#8220;Dr.&#160;Rothberg&#8221;), and other permitted holders of the Company&#8217;s Class&#160;B common stock collectively cease to beneficially own at least twenty percent (<ix:nonFraction name="hypr:PercentageNumberOfSharesCeasesToBeneficiallyOwned" contextRef="P12_12_2021To12_12_2021" unitRef="Unit_pure" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction>%) of the number of shares of the Company&#8217;s Class&#160;B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination or recapitalization of the Company&#8217;s Class&#160;B common stock) collectively held by Dr.&#160;Rothberg and permitted transferees of the Company&#8217;s Class&#160;B common stock as of the Effective Time. At the Effective Time, the Company amended the Certificate to change the name of the Company from HealthCor Catalio Acquisition Corp. to &#8220;Hyperfine, Inc.&#8221; (the Certificate, as amended, the &#8220;Amended Certificate&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, HealthCor entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain institutional investors and accredited investors (the &#8220;PIPE Investors&#8221;), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,610,000</ix:nonFraction> shares of HealthCor Class&#160;A common stock at a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">10.00</ix:nonFraction> per share (the &#8220;PIPE Investment&#8221;). </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_41719219_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on December&#160;22, 2021, HealthCor, HC Sponsor LLC (the &#8220;Sponsor&#8221;), Legacy Hyperfine and Liminal entered into a Forfeiture Agreement (the &#8220;Forfeiture Agreement&#8221;), pursuant to which, immediately prior to the Closing, <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> shares of HealthCor&#8217;s Class&#160;B common stock held by the Sponsor were irrevocably forfeited and automatically cancelled (the &#8220;Forfeiture&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of shares of the Company&#8217;s Class&#160;A common stock outstanding immediately following the Closing was <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">54,977,061</ix:nonFraction> comprising: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">29,711,224</ix:nonFraction> shares of Class&#160;A common stock issued to Hyperfine stockholders (other than certain holders of Hyperfine Series A preferred stock); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,459,081</ix:nonFraction> shares of Class&#160;A common stock issued to Liminal stockholders (other than certain holders of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock); </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,610,000</ix:nonFraction> shares of Class&#160;A common stock issued in connection with the Closing to the PIPE Investors pursuant to the PIPE Investment; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,025,000</ix:nonFraction> shares of Class&#160;A common stock issued immediately prior to the Effective Time to the initial shareholders upon conversion of the <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P12_22_2021To12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,025,000</ix:nonFraction> shares of Class&#160;B common stock outstanding immediately prior to the Effective Time (following the issuance of the <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,175,000</ix:nonFraction> shares of Class&#160;B common stock upon the Conversion of the <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P12_22_2021To12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,175,000</ix:nonFraction> Class&#160;B ordinary shares held by the initial shareholders and after reflecting the irrevocable forfeiture by the Sponsor to HealthCor of <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> shares of Class&#160;B common stock for no consideration and automatic cancellation as of immediately prior to the Closing); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">614,000</ix:nonFraction> shares of Class&#160;A common stock issued to the Sponsor; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_ClassAOrdinarySharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,557,756</ix:nonFraction> shares of Class&#160;A common stock issued to the Company&#8217;s public stockholders holding <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_22_2021_ClassAOrdinarySharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,557,756</ix:nonFraction> Class&#160;A ordinary shares outstanding at the Effective Time, after reflecting redemptions of <ix:nonFraction name="hypr:CommonStockSubjectToRedemption" contextRef="P12_22_2021To12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HealthCorCatalioAcquisitionCorpMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,142,244</ix:nonFraction> shares of HealthCor Class&#160;A common stock. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of shares of the Company&#8217;s Class&#160;B common stock outstanding immediately following the Closing was <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_22_2021_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,055,288</ix:nonFraction> shares. Immediately following the Closing, Dr.&#160;Rothberg held approximately <ix:nonFraction name="hypr:PercentageOfCommonStockVotingPower" contextRef="P12_22_2021To12_22_2021_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">84.8</ix:nonFraction>% of the combined voting power of the Company. Accordingly, Dr.&#160;Rothberg and his permitted transferees control the Company, and the Company is a controlled company within the meaning of the Nasdaq listing rules. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net equity infusion from the Business Combination was $<ix:nonFraction name="hypr:ProceedsFromBusinessCombination" contextRef="P12_22_2021To12_22_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,471</ix:nonFraction>, which consists of $<ix:nonFraction name="hypr:ProceedsFromBusinessCombination" contextRef="P12_22_2021To12_22_2021_HealthCorMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">207,448</ix:nonFraction> proceeds from HealthCor, $<ix:nonFraction name="hypr:ProceedsFromBusinessCombination" contextRef="P12_22_2021To12_22_2021_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">126,100</ix:nonFraction> proceeds from the PIPE Investors, net of payments to redeeming HealthCor shareholders of $<ix:nonFraction name="hypr:InterestAndPaymentsToRedeemingCompanyShareholders" contextRef="P12_22_2021To12_22_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">171,437</ix:nonFraction> and payment of transaction costs of $<ix:nonFraction name="hypr:BusinessCombinationPaymentOfTransactionCosts" contextRef="P12_22_2021To12_22_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,640</ix:nonFraction>. Additionally, 300,000 shares of Class&#160;A Common Stock were issued to a service provider in exchange for the services provided in connection with the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2021, in connection with the closing of the Business Combination, the Company prepaid directors and officers insurance policy in the amount of $<ix:nonFraction name="hypr:PrepaidInsurancePolicyInConnectionWithBusinessCombination" contextRef="PAsOn12_22_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,244</ix:nonFraction> and repaid the Liminal Paycheck Protection Program (&#8220;PPP&#8221;) loan in full in the amount of $<ix:nonFraction name="hypr:PaymentOfPaycheckProtectionProgramLoan" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113</ix:nonFraction>. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719644"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. REVENUE RECOGNITION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company disaggregates revenue from contracts with customers by product type. The Company believes that these categories aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719678">The following table summarizes the Company&#8217;s disaggregated revenues:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719678">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pattern of<br/>Recognition</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Point&#160;in&#160;time</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Over time</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,496</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Balances </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract balances represent amounts presented in the combined and consolidated balance sheets when either the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. These contract balances include trade accounts receivable and deferred revenue. Deferred revenue represents consideration received from customers at the beginning of the subscription period for services that are transferred to the customer over the respective subscription period. The accounts receivable balances represent amounts billed to customers for goods and services where the Company has an unconditional right to payment of the amount billed. </div></div> <ix:nonNumeric name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about receivables and deferred revenue from contracts with customers: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unbilled receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a receivable when it has an unconditional right to payment, and payment terms range from <ix:nonNumeric name="hypr:RevenueRecognizeReceivablePaymentTermsRangeMinimum" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durday">20</ix:nonNumeric> days to <ix:nonNumeric name="hypr:RevenueRecognizeReceivablePaymentTermsRangeMaximum" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durmonth">6</ix:nonNumeric> months based on the terms agreed upon with the respective customer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of revenue recognized during the years ended December&#160;31, 2021 and 2020 that was included in the deferred revenue balance at the beginning of the period was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from leasing arrangements is not subject to the revenue standard for contracts with customers and remains separately accounted for under existing lease accounting guidance. The Company records operating lease rental revenue as service revenue on a straight-line basis over the lease term. The Company records revenue from the sale of equipment under sales-type leases as product revenue in an amount equal to the present value of minimum lease payments at the inception of the lease. Sales-type leases also produce financing income, which is included in products net revenue in the combined and consolidated statements of operations and comprehensive loss and is recognized at effective rates of return over the lease term. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719644"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Costs of Obtaining or Fulfilling Contracts </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company incurs incremental costs of obtaining contracts with customers. Incremental costs of obtaining contracts, which include commissions paid as a result of obtaining contracts with customers, are capitalized to the extent that the Company expects to recover such costs. Capitalized costs are amortized in a pattern that is consistent with the Company&#8217;s transfer to the customer of the related goods and services. Such costs are recorded in Other long term assets and were $<ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction> as of December&#160;31, 2021. Capitalized costs were not material for the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction price allocated to remaining performance obligations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 202<ix:nonNumeric name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" format="ixt-sec:duryear">1</ix:nonNumeric> and 2020, the Company had remaining performance obligations amounting to $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,800</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">859</ix:nonFraction>, respectively. The Company expects to recognize approximately <ix:nonFraction name="hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage" contextRef="PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">43</ix:nonFraction>% of its remaining performance obligations as revenue in fiscal year 2022, and an additional <ix:nonFraction name="hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage" contextRef="PAsOn12_31_2021_2023-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">57</ix:nonFraction>% in fiscal year 2023 and thereafter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Judgements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company makes significant judgments applying the guidance related to the determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price of performance obligations and estimation of variable consideration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Practical Expedients and Accounting Policy Elections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a practical expedient, the Company does not adjust transaction price for the effects of a significant financing component in contracts in which the period between when the Company transfers the promised good or service to the customer and when the customer pays for that good or service is a year or less. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has made an accounting policy election to exclude all sales taxes from the transaction price of its contracts with customers. Accordingly, sales taxes collected from customers and remitted to government authorities is not included in revenue and is accounted for as a liability until it has been remitted to the respective government authority. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41720032"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. FAIR VALUE OF FINANCIAL INSTRUMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;1</div></div> &#8212; Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;2</div></div> &#8212; Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41720032"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;3</div></div> &#8212; Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level&#160;3 inputs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of cash and cash equivalents, notes receivable, accounts payable and accrued expenses and other current liabilities approximates their fair values due to the short-term or on demand nature of these instruments. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> </div>transfers between fair value measurement levels during the years ended December&#160;31, 2<ix:nonFraction name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction>21 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,625</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,418</ix:nonFraction> of money market funds included in cash and cash equivalents and restricted cash as of December&#160;31, 2021 and 2020, respectively. These assets were valued using quoted market prices and accordingly were classified as Level&#160;1. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company determines that notes payable as of December&#160;31, 2020 was classified as Level&#160;2 and the relevant fair value approximates its carrying amount since it bore interest at rates that approximate current market rates. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. INVENTORIES </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of inventories are as follows at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,955</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,718</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total inventories</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,310</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,718</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing overhead costs primarily include management&#8217;s best estimate and allocation of the labor costs incurred related to acquiring finished goods from the Company&#8217;s contract manufacturer. Labor costs include wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. The majority of these costs have been written off based on the Company&#8217;s analysis of net realizable value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2021 and 2020, net realizable value inventory adjustments and excess and obsolete inventory charges were $<ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction>, respectively, and were recognized in cost of sales. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. PROPERTY AND EQUIPMENT, NET </div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net, are recorded at historical cost and consist of the following at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">613</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,620</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,753</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,904</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense amounted to $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">726</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">289</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </div></div></div> <ix:nonNumeric name="hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities consist of the following at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted services</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AccruedContractedServicesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AccruedContractedServicesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPAC bonus and other costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:AccruedBonusAndOtherCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,071</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll and related benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:AccruedExpensesAndOtherCurrentLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,115</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:AccruedExpensesAndOtherCurrentLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,264</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. NOTES PAYABLE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the Company received loan proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P08_01_2020To08_31_2020_PayrollProtectionProgramLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,067</ix:nonFraction> under the PPP. The Legacy Hyperfine PPP loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_10_2020_HyperfinePayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">889</ix:nonFraction> was evidenced by a promissory note dated August&#160;10, 2020 and was fully paid off during the fourth quarter of 2020. The Liminal PPP loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_01_2020_LiminalPayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction> is evidenced by a promissory note dated May&#160;1, 2020. The Company used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintaining its payroll levels. The Company accounted for the loan as debt. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the closing of the Business Combination as discussed in Note 3. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>, the Company repaid the Liminal PPP loan in full in December 2021. The Company recognized an insignificant amount of interest expense in the combined and consolidated statements of operations and comprehensive loss related to the loan. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:nonNumeric name="us-gaap:PreferredStockTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719997"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. CONVERTIBLE PREFERRED STOCK </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legacy Hyperfine Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine had issued four series of Convertible Preferred Stock, Series A through Series D. <ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719996">The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine immediately prior to the Business Combination:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_41719996"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/>of Class<br/>Issuance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Price&#160;per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Authorized</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Issued and<br/>Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Proceeds<br/>or<br/>Exchange<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Carrying<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial<br/>Liquidation<br/>Price per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">2014</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">2017</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,625,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,625,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">2017</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,586,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,586,210</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,382</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P07_06_2021To07_06_2021_MinimumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">2020</ix:nonNumeric>-<ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P07_06_2021To07_06_2021_MaximumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">2021</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">2.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">62,577,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,970,981</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P07_06_2021To07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P07_06_2021To07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn07_06_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">129,788,828</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn07_06_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn07_06_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">109,182,191</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P07_06_2021To07_06_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">159,119</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P07_06_2021To07_06_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">372</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn07_06_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158,747</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/>of Class<br/>Issuance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Price&#160;per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Authorized</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Issued and<br/>Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Proceeds<br/>or<br/>Exchange<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Carrying<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial<br/>Liquidation<br/>Price per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">2014</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">2017</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,625,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,625,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">2017</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,586,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,586,210</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,382</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="hypr:TemporaryEquityYearOfClassIssuance" contextRef="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">2.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">62,577,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,799,648</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,640</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">129,788,828</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">95,010,858</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,651</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="hypr:TemporaryEquitySharesIssuanceCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">365</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,286</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The powers, preferences, rights, qualifications, limitations and restrictions of the shares of Convertible Preferred Stock are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends shall accrue to holders of the Convertible Preferred Stock at the rate of <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="P01_01_2020To12_31_2020_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>% of the original issue price for the applicable series of Convertible Preferred Stock, per annum subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization, reclassification and other similar events payable only when, and if, declared by Legacy Hyperfine&#8217;s board of directors. The right to receive dividends on Convertible Preferred Stock is not cumulative, and therefore, if not declared in any year, the right to such dividends shall terminate and shall not carry forward into the next year. There have been <ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> dividends declared to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden41719881">In the event of any liquidation, dissolution or winding up of Legacy Hyperfine, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Legacy Hyperfine&#8217;s assets, or a</span> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div><ix:continuation id="TextSelection_41719997" continuedAt="TextSelectionAppend_41719997_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transaction which the holders of capital stock of Legacy Hyperfine hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Legacy Hyperfine available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1)&#160;the applicable original issue price of such Convertible Preferred Stock, plus any declared and unpaid dividends or (2)&#160;an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Legacy Hyperfine common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of shares of the Convertible Preferred Stock shall be entitled to vote on all matters on which the holders of shares of Legacy Hyperfine common stock shall be entitled to vote. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each holder of record of shares of Series A Convertible Preferred Stock shall be entitled to <ix:nonFraction name="hypr:NumberOfVotesPerShare" contextRef="PAsOn12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> votes per share of Legacy Hyperfine Special-voting common stock into which such Series A Convertible Preferred Stock are convertible, as discussed below under &#8220;Conversion,&#8221; on all matters to be voted on by Legacy Hyperfine&#8217;s stockholders. Each holder of record of shares of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be entitled to <ix:nonFraction name="hypr:NumberOfVotesPerShare" contextRef="PAsOn12_31_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote per share of Legacy Hyperfine common stock into which such Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock are convertible, as discussed below under Conversion, on all matters to be voted on by Legacy Hyperfine&#8217;s stockholders. The holders of Convertible Preferred Stock and the holders of Legacy Hyperfine common stock shall vote together and not as separate classes. There shall be no series voting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P01_01_2021To12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series A Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Legacy Hyperfine Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock.</ix:nonNumeric> <ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P01_01_2021To12_31_2021_SeriesBCAndDConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Legacy Hyperfine common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock.</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the earlier to occur of (i)&#160;election of the Convertible Preferred Stock by (A)&#160;the consent or vote of the majority holders of the Convertible Preferred Stock (voting together as a single class and not as separate series, and on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis), (B) the consent or vote of the majority holders of Series C Convertible Preferred Stock (voting separately as a single class) and (C)&#160;the consent or vote of the majority holders of Series D Convertible Preferred Stock (voting separately as a single class) or (ii)&#160;the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933 covering the offer and sale of shares of Legacy Hyperfine common stock in which the aggregate gross proceeds to Legacy Hyperfine are at least $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction> (1) each share of Series A Convertible Preferred Stock shall </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719997_1" continuedAt="TextSelectionAppend_41719997_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">automatically be converted into shares of Legacy Hyperfine Special-voting common stock on a 1 for 1 basis and (2)&#160;each share of Series B, Series C and Series D Convertible Preferred Stock shall automatically be converted into Legacy Hyperfine common stock on a 1 for 1 basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Business Combination, the Convertible Preferred Stock converted into Class&#160;A and Class&#160;B common stock based on the Business Combination&#8217;s Hyperfine Exchange Ratio of <ix:nonFraction name="hypr:BusinessCombinationExchangeRatio" contextRef="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.3275</ix:nonFraction> of the Company&#8217;s shares for each Legacy Hyperfine share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of the Closing. There are <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of Convertible Preferred Stock outstanding as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liminal Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P04_01_2021To04_01_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">On April 1, 2021 Liminal effected a recapitalization whereby each share of Liminal common stock outstanding was exchanged for shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock and Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> preferred stock. The value ascribed to the preferred stock is equivalent to the total amount of historical equity investments contributed by the common shareholder.</ix:nonNumeric> There were no new investments or changes in control in conjunction with the recapitalization. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The powers, preferences, rights, qualifications, limitations and restrictions of the shares of Liminal Convertible Preferred Stock are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends shall accrue to holders of the Convertible Preferred Stock at the rate of <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>% of the original issue price for the applicable series of Convertible Preferred Stock, per annum subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization, reclassification and other similar events payable only when, and if, declared by Liminal&#8217;s board of directors. The right to receive dividends on Convertible Preferred Stock is not cumulative, and therefore, if not declared in any year, the right to such dividends shall terminate and shall not carry forward into the next year. There have been <ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> dividends declared to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><ix:nonNumeric name="us-gaap:LiquidationBasisOfAccountingLiquidationPlan" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">In the event of any liquidation, dissolution or winding up of Liminal, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Liminal&#8217;s assets, or a transaction which the holders of capital stock of Liminal hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Liminal available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issuance price of $.1287 per share for Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Liminal common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock.</ix:nonNumeric> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of shares of the Convertible Preferred Stock shall be entitled to vote on all matters on which the holders of shares of Liminal common stock shall be entitled to vote. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelectionAppend_41719997_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Each holder of record of shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock shall be entitled to <ix:nonFraction name="hypr:NumberOfVotesPerShare" contextRef="PAsOn12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> votes per share of Liminal Special-voting common stock into which such Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock are convertible, as discussed below under &#8220;Conversion,&#8221; on all matters to be voted on by Liminal&#8217;s stockholders. Each holder of record of shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock shall be entitled to <ix:nonFraction name="hypr:NumberOfVotesPerShare" contextRef="PAsOn12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote per share of Liminal common stock into which such Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock are convertible, as discussed below under Conversion, on all matters to be voted on by Liminal&#8217;s stockholders. The holders of Convertible Preferred Stock and the holders of Liminal common stock shall vote together and not as separate classes. There shall be no series voting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P01_01_2021To12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Liminal Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of Liminal common stock for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock.</ix:nonNumeric> <ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P01_01_2021To12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Liminal common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of common stock for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock.</ix:nonNumeric> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the earlier to occur of (i)&#160;election of the Convertible Preferred Stock by the consent or vote of the majority holders of the Convertible Preferred Stock (voting together as a single class and not as separate series, and on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) or (ii)&#160;the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, covering the offer and sale of shares of Liminal common stock in which the aggregate gross proceeds to Liminal are at least $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction> (1) each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock shall automatically be converted into shares of Liminal Special-voting common stock on a 1 for 1 basis and (2)&#160;each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock shall automatically be converted into Liminal common stock on a 1 for 1 basis. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Business Combination, the Liminal Convertible Preferred Stock converted into Class&#160;A and Class&#160;B common stock based on the Business Combination&#8217;s Liminal Exchange Ratio of <ix:nonFraction name="hypr:BusinessCombinationExchangeRatio" contextRef="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.1796</ix:nonFraction> of the Company&#8217;s shares for each Liminal share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of the Closing. There are <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of Convertible Preferred Stock&#160;outstanding as of December&#160;31, 2021. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719764"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, and 2020, the Company had authorized <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">600,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">130,000,000</ix:nonFraction> shares of Class&#160;A common stock at $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value per share, of which a total of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">55,277,061</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,576,137</ix:nonFraction> shares were outstanding, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, and 2020, the Company had authorized <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> shares of Class&#160;B common stock at $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value per share, of which a total of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,055,288</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> shares were outstanding, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <ix:continuation id="TextSelection_41719764"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of the Company&#8217;s common stock are not entitled to receive dividends unless declared by the Company&#8217;s board of directors. There have been <ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> dividends declared to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of shares of the Company&#8217;s Class&#160;A common stock are entitled to <ix:nonFraction name="hypr:CommonStockNumberOfVotesPerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote per share on all matters on which the Company&#8217;s Class&#160;A common stock shall be entitled to vote. The holders of shares of the Company&#8217;s Class&#160;B common stock are entitled to <ix:nonFraction name="hypr:CommonStockNumberOfVotesPerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> votes per share on all matters on which the Company&#8217;s Class&#160;B common stock shall be entitled to vote. The holders of the Company&#8217;s Class&#160;A common stock and Class&#160;B common stock shall vote together and not as separate classes. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719998"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. EQUITY INCENTIVE PLAN </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hyperfine Inc. 2021 Equity Incentive Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">16,013,762</ix:nonFraction> shares of common stock are reserved for issuance under the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;Hyperfine Plan&#8221;). The Hyperfine Plan is administered by the Company&#8217;s board of directors. The board of directors may grant restricted stock and options to purchase shares either as incentive stock options or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options. The option grants are subject to certain terms and conditions, option periods and conditions, exercise rights and privileges as set forth in the Hyperfine Plan. At December&#160;31, 2021, <ix:nonFraction name="hypr:CommonStockRemainsAvailableForIssuance" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,256,741</ix:nonFraction> common shares remain available for issuance under the Hyperfine Plan. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the Business Combination, Legacy Hyperfine and Liminal were distinct entities with separate equity incentive plans for their employees and nonemployees. Both plans were subsequently adopted and assumed by the Company as a consequence of the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Legacy Hyperfine option from Legacy Hyperfine&#8217;s 2014 Employee, Director and Consultant Equity Incentive Plan as amended on October&#160;9, 2020 (the &#8220;Legacy Hyperfine Plan&#8221;) outstanding immediately prior to the Closing, whether vested or unvested, was converted into an option to purchase shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock subject to such option multiplied by the Hyperfine Exchange Ratio of <ix:nonFraction name="hypr:ExchangeRatio" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.3275</ix:nonFraction>, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Closing divided by <ix:nonFraction name="hypr:ExchangeRatio" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.3275</ix:nonFraction>, rounded up to the nearest whole cent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Liminal option from Liminal&#8217;s 2021 Employee, Director, and Consultant Equity Incentive Plan (the &#8220;Liminal Plan&#8221;) outstanding immediately prior to the Closing, whether vested or unvested, was converted into an option to purchase shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Liminal common stock subject to such option multiplied by the Liminal Exchange Ratio of <ix:nonFraction name="hypr:ExchangeRatio" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LiminalMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.1796</ix:nonFraction>, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Closing divided by <ix:nonFraction name="hypr:ExchangeRatio" contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LiminalMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.1796</ix:nonFraction>, rounded up to the nearest whole cent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each exchanged option will continue to be governed by the same terms and conditions (including vesting and exercisability terms) as were applicable to the corresponding option immediately prior to the Closing. All activity was retroactively restated to reflect the exchange that occurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719998" continuedAt="TextSelectionAppend_41719998_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respect to a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock option activity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each stock option grant carries varying vesting schedules whereby the options become exercisable at the participant&#8217;s sole discretion provided they are an employee, director or consultant of the Company on the applicable vesting date. Each option shall terminate not more than ten years from the date of the grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company granted certain equity awards to the newly hired Chief Executive Officer. These awards include (1)&#160;an option award to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,899,500</ix:nonFraction> shares of Class&#160;A common stock which will vest based on continued service over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durwordsen">four year</ix:nonNumeric> period, (2)&#160;a separate option award to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ShareBasedPaymentArrangementSeparateOptionAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">474,875</ix:nonFraction> shares of Class&#160;A common stock, which will be fully vested upon the occurrence of various service, performance, and market conditions. <ix:nonFraction name="hypr:NumberOfSeparateOptionAwards" contextRef="PAsOn12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis" unitRef="Unit_Option" decimals="INF" scale="0" format="ixt-sec:numwordsen">Two</ix:nonFraction> additional <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsOneMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsTwoMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">474,875</ix:nonFraction></ix:nonFraction> share option awards (<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">949,750</ix:nonFraction> options total) with terms similar to those described above will be granted pursuant to the terms of the offer letter. Certain equity awards were also granted to the Executive Chairman of the Legacy Hyperfine board of directors. The equity compensation included (1)&#160;an option award to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">712,312</ix:nonFraction> shares of Class&#160;A common stock which will vest based on continued service, over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric>, (2)&#160;<ix:nonFraction name="hypr:NumberOfSeparateOptionAwards" contextRef="PAsOn12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_Option" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> separate option awards to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_StockOptionsOneMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">237,437</ix:nonFraction> shares each of Class&#160;A common stock (<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">474,874</ix:nonFraction> shares in total), which will be fully vested upon the occurrence of various certain service, performance, and market conditions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The service condition for these awards is satisfied by providing service to the Company based on the defined service period per the award agreement. The performance-based condition is satisfied upon the occurrence of a special purpose acquisition company (&#8220;SPAC&#8221;) transaction, initial public offering (&#8220;IPO&#8221;), or financing event as defined in the award agreement. The market condition is satisfied by achieving various multiples of a defined price per share. The achievement of the performance condition and the commencement of the related expense recognition event cannot occur until the event is deemed probable, which only occurs once a SPAC transaction, IPO, or financing event has occurred. The performance condition was satisfied as a result of the Business Combination and the Company recognized stock-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,772</ix:nonFraction> in connection with these awards during the year ended December&#160;31, 2021. None of the market conditions have been satisfied and as such, none of the awards are exercisable as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the above, restricted stock units with a value of $<ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction> will be granted to the Chief Executive Officer following the Business Combination and within two years of the Chief Executive Officer&#8217;s start date, subject to continued service and which will vest on a schedule to be agreed upon between the Company and the Chief Executive Officer. These restricted stock units were not yet approved by the Board of Directors and therefore had not yet been granted as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company also granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ServiceAndPerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">258,833</ix:nonFraction> option awards subject to certain service and performance conditions. The service condition required the participant&#8217;s continued employment with the Company through the applicable vesting date, and the performance condition required the consummation of a Sale, IPO, or SPAC transaction as defined in the option award agreement. These awards were forfeited and cancelled prior to the consummation of the Business Combination. As a Sale, IPO, or SPAC transaction did not occur prior to forfeiture, the Company did not record any stock-based compensation expense related to these option <div style="letter-spacing: 0px; top: 0px;;display:inline;">awards</div>. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">30</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_41719998_1" continuedAt="TextSelectionAppend_41719998_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All options granted by the Company during the years ended December&#160;31, 2021 and 2020 were granted with exercise prices equal to the estimated fair value of the Company&#8217;s common stock at the date of grant, as determined by the Company&#8217;s board of directors. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the stock option activity under the Hyperfine Plan is presented in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,903,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.07</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,771,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">565,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">587,047</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,522,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.79</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,052</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,332,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.82</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,785</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,117,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.77</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received cash proceeds from the exercise of stock options of $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction> during the years ended December&#160;31, 2021 and 2020, respectively. The total intrinsic value (the amount by which the stock price exceeds the exercise price of the option on the date of exercise) of the stock options exercised during the years ended December&#160;31, 2021 and 2020, was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,752</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">167</ix:nonFraction>, respectively. The weighted-average grant date fair value of options granted during the year ended December&#160;31, 2021 and 2020, was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.66</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.69</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock option valuation inputs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilized the Black-Scholes option pricing model for determining the estimated fair value for service awards. The Black-Scholes model requires the use of subjective assumptions which determine the fair value of stock-based awards. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719994">The assumptions used to value option grants to employees and nonemployees for the years ended December&#160;31, 2021 and 2020 were as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719994">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.95</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.13</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.40</ix:nonNumeric>&#160;years&#160;-&#160;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">6.17</ix:nonNumeric>&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.8</ix:nonNumeric>&#160;years&#160;-&#160;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">6.0</ix:nonNumeric>&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk free interest rate </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has never declared or paid any cash dividends and does not expect to pay any cash dividends in the foreseeable future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">1</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_41719998_2" continuedAt="TextSelectionAppend_41719998_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For employee awards, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">calculates </div>the expected term using the &#8220;simplified&#8221; method, which is the simple average of the vesting period and the contractual term. The simplified method is applied as the Company does not have sufficient historical data to provide a reasonable basis for an estimate of the expected term. The Company calculates expected term for employee awards that take into account the effects of employee&#8217;s expected exercise and post-vesting employment termination behavior. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As Legacy Hyperfine was privately held from inception through the Closing and all option grants occurred prior to the Closing Date, there was no specific historical or implied volatility information available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, the Company estimates the expected volatility on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the stock-based awards. Point estimates of expected annual equity volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>% for December&#160;31, 2021 and 2020, respectively, were selected in the guideline companies&#8217; historical range. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise price </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price is taken directly from the grant notice issued to employees and nonemployees. </div></div> <ix:nonNumeric name="hypr:ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options granted to the Company&#8217;s employees and nonemployees for the periods presented were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to employee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,534,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">897,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to nonemployee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,236,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">284,816</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock options granted</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,771,237</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,182,056</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Unit and Preferred Stock Award Activity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incentive unit grants typically vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_IncentiveUnitActivityMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">four year</ix:nonNumeric> period provided the holder is an employee, director or consultant of the Company on the applicable vesting date. Upon termination of service, pursuant to the terms of the grant, the participant 1) immediately forfeits any unvested (but issued) incentive units and 2) the Company has the right, but not the obligation, to repurchase at the fair market value on the date of termination, any vested incentive units. The repurchase right is valid for <ix:nonNumeric name="hypr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" contextRef="P01_01_2021To12_31_2021_IncentiveUnitActivityMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">18 months</ix:nonNumeric> commencing with the date of service. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#8217;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), and Tesseract Health. The preferred stock awards are subject to service vesting conditions only. <ix:nonFraction name="hypr:ShareBasedPaymentArrangementPlanModificationIncrementalValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> incremental compensation expense was recognized as a result of the modification. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">2</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_41719998_3" continuedAt="TextSelectionAppend_41719998_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the dissolution of 4Bionics, a portion of total 4Bionics stock-based compensation expense was allocated to Liminal based on the level of service provided by the relevant employees and nonemployees to Liminal over the term of the award. Subsequent to the dissolution of 4Bionics, the Company recognizes the stock-based compensation expense related to the replacement preferred stock awards and no allocation methodology is required. In connection with the Business Combination, all replacement preferred stock awards were accelerated to fully vest. The Company recognized stock-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">578</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> related to the incentive unit awards and replacement preferred stock awards during the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2021, immediately following the Business Combination, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">117,516</ix:nonFraction> restricted stock units (&#8220;RSUs&#8221;) to members of the Company&#8217;s Board of Directors. The RSUs vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three year</ix:nonNumeric> period, contingent on the ongoing service of the Directors. The grant date fair value of the RSUs was measured using the fair value of the underlying Class&#160;A common stock, which was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P12_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.19</ix:nonFraction> per share on the grant date. The total grant date fair value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,080</ix:nonFraction> will be recognized evenly over the <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three year</ix:nonNumeric> period as the service condition is satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the achievement of certain milestones, certain employees are entitled to a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">933,933</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares fall within the scope of ASC 718, pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-out</div> valuation inputs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilized a Monte Carlo Simulation pricing model for determining the estimated fair value for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. The fair value is based on the simulated price of the Company over the maturity date of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. <ix:nonNumeric name="hypr:ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719959">The key assumptions used in the valuation were as follows:</ix:nonNumeric> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719959">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">54.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk free interest rate </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has never declared or paid any cash dividends and does not expect to pay any cash dividends in the foreseeable future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_41719998_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, the expected term is determined to be <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years from the Closing as this is the period over which the market price milestone may be achieved. As there is no dependent vesting period, the shares are exercisable at the point that the market milestone is reached. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As Legacy Hyperfine was privately held from inception through the Closing, there was no specific historical or implied volatility information available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, the Company estimates the expected volatility on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> awards. A point estimate of expected annual equity volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction>% for December&#160;31, 2021 was selected in the guideline companies&#8217; historical range. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s stock-based compensation expense for the periods presented was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales&#8212;Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales&#8212;Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,901</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total unrecognized stock-based compensation expense as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,650</ix:nonFraction>, which will be recognized over the remaining vesting period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">2.66</ix:nonNumeric> years. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41720031"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. NET LOSS PER SHARE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common equivalent shares of the Company, including convertible preferred stock, outstanding stock options, RSUs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common equivalent shares of the Company outstanding would have been anti-dilutive. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41720031"> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the calculation of basic and diluted net loss per share for the Company&#8217;s common stock: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator for Basic and Dilutive EPS&#8212;Loss available to common stockholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,427</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,690,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,523,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic and Dilutive EPS&#8212;Weighted-average common stock</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,690,523</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,523,096</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and dilutive loss per share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.57</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.38</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the Company was in a net loss position for all periods presented, the basic loss per share calculation excludes preferred stock as it does not participate in net losses of the Company. Additionally, net loss per share attributable to Class&#160;A and Class&#160;B common stockholders was the same on a basic and diluted basis, as the inclusion of all common equivalent shares outstanding would have been anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41720028">Anti-dilutive common equivalent shares were as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41720028">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding options to purchase common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,522,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,903,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding Legacy Hyperfine convertible preferred stock (Series A through D)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_OutstandingLegacyHyperfineConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,116,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding RSUs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">117,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive common equivalent shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,639,652</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">33,019,535</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719566"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. INCOME TAXES </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets (liabilities):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonuses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,136</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,788</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets (liabilities)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719566" continuedAt="TextSelectionAppend_41719566_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> income tax expense due to federal and state net operating losses incurred for the years ended December&#160;31, 2021 and 2020. The Company has also not recorded any income tax benefits for its federal and state net operating losses incurred in each period due to uncertainty of realizing the benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States. The effective tax rate for the Company for the years ended December&#160;31, 2021 and 2020 was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction> percent. <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719585">A reconciliation of the income tax expense at the federal statutory tax rate to the Company&#8217;s effective income tax rate follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719585">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">4.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development credit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">3.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write down of federal NOL due to 382 limitation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="hypr:Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write down of federal R&amp;D credits due to 382 limitation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="hypr:Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax adjustment resulting from tax rate change</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">28.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">15.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rate for December&#160;31, 2021 and 2020 differs from the federal statutory tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></ix:nonFraction>% mainly due to the effect of deferred state income tax benefits resulting from state net operating loss carryforwards and the tax benefits related to research and development tax credits. These benefits to the effective tax rate are fully offset by the increase in the Company&#8217;s valuation allowance from the prior year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty of the Company&#8217;s ability to generate sufficient taxable income to realize the deferred tax assets, and therefore has not recognized any benefits from the net operating losses, tax credits and other deferred tax assets. The Company&#8217;s valuation allowance increased $<ix:nonFraction name="hypr:DeferredTaxAssetsValuationAllowanceIncreased" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,348</ix:nonFraction> and $<ix:nonFraction name="hypr:DeferredTaxAssetsValuationAllowanceIncreased" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,729</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_41719566_1" continuedAt="TextSelectionAppend_41719566_2"><ix:nonNumeric name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had the following tax net operating loss carryforwards available to reduce future federal and Connecticut taxable income, and tax credit carryforwards available to offset future federal and Connecticut income taxes: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hyperfine</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Begin to Expire<br/>in</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine tax net operating loss carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-2018</div> NOLs)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:OperatingLossCarryforwardsBeginToExpireYear" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis">2034</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal (post-2017 NOLs)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No&#160;Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:OperatingLossCarryforwardsBeginToExpireYear" contextRef="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2034</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TaxCreditCarryforwardBeginToExpirationYear" contextRef="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">2034</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">752</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut others</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TaxCreditCarryforwardBeginToExpirationYear" contextRef="P01_01_2021To12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal others</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TaxCreditCarryforwardBeginToExpirationYear" contextRef="P01_01_2021To12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liminal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Begin to Expire<br/>in</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal tax net operating loss carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-2018</div> NOLs)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal (post-2017 NOLs)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LiminalMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,304</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No&#160;Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:OperatingLossCarryforwardsBeginToExpireYear" contextRef="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2038</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="hypr:TaxCreditCarryforwardBeginToExpirationYear" contextRef="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">2038</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_LiminalMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">Under Internal Revenue Code Section&#160;382, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">pre-change</div> net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an <ix:nonNumeric name="hypr:OwnershipChangeDescription" contextRef="P01_01_2021To12_31_2021">ownership change occurs when certain shareholders increase their aggregated ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically <ix:nonNumeric name="hypr:OwnershipChangePercentageTestingPeriod" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durwordsen">three years</ix:nonNumeric>).</ix:nonNumeric> The Company performed a Section&#160;382 analysis for Legacy Hyperfine to determine whether an ownership change has occurred. Based on this analysis, Legacy Hyperfine experienced <ix:nonFraction name="hypr:NumberOfConsecutiveOwnershipChanges" contextRef="PAsOn12_31_2021" unitRef="Unit_Ownership" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> consecutive ownership changes, one on <ix:nonNumeric name="hypr:OwnershipChangesDateOne" contextRef="P01_01_2021To12_31_2021" format="ixt:datemonthdayyearen">January 17, 2017</ix:nonNumeric>, and one on <ix:nonNumeric name="hypr:OwnershipChangesDateTwo" contextRef="P01_01_2021To12_31_2021" format="ixt:datemonthdayyearen">May 16, 2017</ix:nonNumeric>. As a result, Legacy Hyperfine&#8217;s net operating loss and tax credit carryforwards as of December&#160;31, 2020 are subject to a Section&#160;382 limitation. The January&#160;17, 2017 ownership change resulted in an annual limitation of $<ix:nonFraction name="hypr:NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" contextRef="PAsOn01_17_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">865</ix:nonFraction> and the May&#160;16, 2017 ownership change resulted in an annual limitation of $<ix:nonFraction name="hypr:NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" contextRef="PAsOn05_16_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,008</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">. The first (earlier) limitation will limit the deduction of pre-change losses and credits arising before the first ownership change. The second (later) ownership change creates another limit to deduction of those pre-change losses and credits. However, the second ownership change does not allow for a &#8220;step-up&#8221; of the first limitation and therefore the pre-January 17, 2017 losses and credits are still subject to the first limitation amount. Due to these limitations, the Company estimates that $</div><ix:nonFraction name="hypr:NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" contextRef="PAsOn01_17_2017_FederalNetOperatingLossMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,125</ix:nonFraction> and $<ix:nonFraction name="hypr:NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" contextRef="PAsOn01_17_2017_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">249</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;of the federal net operating loss and research and development credit carryforwards, respectively, will expire before utilization. Accordingly, Legacy Hyperfine&#8217;s gross deferred tax assets and corresponding valuation allowance have been adjusted to reflect the estimated expirations. In addition, as a result of the Business Combination and any other equity issuances during the year, the Company is currently updating its Section 382 analysis to determine whether any additional ownership changes have occurred through December 31, 2021. This analysis is expected to be completed in <ix:nonNumeric name="hypr:OwnershipChangesAnalysisExpectedToBeCompletedYear" contextRef="P01_01_2021To12_31_2021">2022</ix:nonNumeric>.&#160;</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-37 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_41719566_2"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has adopted the accounting guidance within ASC Topic 740 on uncertainties in income taxes. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the Company did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits. To the extent penalties and interest would be assessed on any underpayment of income tax, the Company&#8217;s policy is that such amounts would be accrued and classified as a component of income tax expense in the combined and consolidated financial statements. To date, the Company has not recorded any such interest or penalties. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files income tax returns in the U.S. federal and various state jurisdictions. As a result of the Company&#8217;s net operating loss carryforwards, the Company&#8217;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company does not currently have any federal or state income tax examinations in progress. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted which included provisions related to net operating loss carryovers and carrybacks, refundable payroll tax credits, deferral of payroll taxes, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The Company has evaluated the relevant provisions of the CARES Act and has not recognized any benefit related to these provisions. Therefore, <ix:nonFraction name="hypr:IncomeTaxEffectsRecognized" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="hypr:IncomeTaxEffectsRecognized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> related income tax effects have been recognized in the financial statements for the years ended December&#160;31, 2021 and 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, as a result of legislation in the state of Connecticut, companies have the opportunity to exchange certain research and development tax credit carryforwards for a cash payment of <ix:nonFraction name="hypr:PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction>% of the research and development tax credit. The research and development expenses that qualify for Connecticut credits are limited to those costs incurred within Connecticut. The Company has elected to participate in the exchange program and, as a result, has recognized net benefits of $<ix:nonFraction name="hypr:ExchangeProgramRecognizedNetBenefits" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">103</ix:nonFraction> and $<ix:nonFraction name="hypr:ExchangeProgramRecognizedNetBenefits" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively, which is included in research and development expenses in the accompanying statements of operations and comprehensive loss. As of December&#160;31, 2021 and 2020, the Company has recorded $<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">196</ix:nonFraction> and $<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">467</ix:nonFraction> of the research and development tax credit receivables in Prepaid expenses and other current assets on the Company&#8217;s combined and consolidated balance sheets, respectively. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41739438"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilizes and subleases office and lab space in Connecticut which is being leased from an unrelated landlord by 4Catalyzer Corporation, (&#8220;4C&#8221;), which is owned by a related party. The Company pays rent to 4C on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> basis, and no lease agreement was entered into between the parties until June 2021. A total of approximately $<ix:nonFraction name="hypr:RelatedPartyTransactionPaymentsForRent" contextRef="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">149</ix:nonFraction> and $<ix:nonFraction name="hypr:RelatedPartyTransactionPaymentsForRent" contextRef="P01_01_2020To12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113</ix:nonFraction> was paid during 2021 and 2020, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to 4Bionics executing a plan of liquidation and dissolution on April&#160;2, 2021, certain expenses incurred at 4Bionics were allocated to its subsidiaries, including Liminal. Expenses that broadly benefited 4Bionics and its subsidiaries were allocated evenly amongst its <ix:nonFraction name="hypr:NumberOfSubsidiaries" contextRef="P01_01_2021To12_31_2021_FourBionicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_Subsidiary" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> subsidiaries. Expenses that were incurred on behalf of the employees of each company were allocated based on each subsidiary&#8217;s relative headcount. Total proceeds allocated to Liminal upon liquidation and dissolution in 2021 were $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2021To12_31_2021_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">101</ix:nonFraction> and total expenses allocated to Liminal in 2020 were $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2020To12_31_2020_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64</ix:nonFraction>. The method used to allocate common expenses of 4Bionics to Liminal is reasonable. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_41739438" continuedAt="TextSelectionAppend_41739438_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2018, the Company entered into a Promissory Note (the &#8220;Note&#8221;) with one of its employees (the &#8220;Borrower&#8221;) in the amount of $<ix:nonFraction name="us-gaap:DueFromEmployeesNoncurrent" contextRef="PAsOn01_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction>. The Note bears interest at a rate equal to <ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="P01_01_2018To01_31_2018" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.68</ix:nonFraction>% per annum. In accordance with the terms of the Note, since the Borrower remained employed with the Company on the maturity date of January&#160;11, 2022, $<ix:nonFraction name="hypr:DueFromEmployeesForgiveness" contextRef="P01_11_2022To01_11_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction> of the then outstanding principal amount and all interest accrued to that date was forgiven and Borrower is no longer required to repay the amount. Interest on the Note was payable annually in cash on the anniversary date of the Note, and as of December&#160;31, 2021 and 2020, interest receivable in the amount of $<ix:nonFraction name="hypr:InterestReceivableRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="hypr:InterestReceivableRelatedPartiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction>, respectively, are included in Prepaid expenses and other current expenses on the combined and consolidated balance sheets, and interest income of $<ix:nonFraction name="us-gaap:InterestIncomeRelatedParty" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestIncomeRelatedParty" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction>, respectively, were recognized as of December&#160;31, 2021 and 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also made payments to 4C to prefund the acquisition of capital assets and these amounts are included in Other assets&#8212;related party on the combined and consolidated balance sheets. Such prepaid advances were $<ix:nonFraction name="hypr:OtherAssetsRelatedPartyNoncurrent" contextRef="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="hypr:OtherAssetsRelatedPartyNoncurrent" contextRef="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,154</ix:nonFraction> as of December&#160;31, 2021 and 2020, respectively. During 2021, the Company wrote off $<ix:nonFraction name="hypr:PrepaidAdvancesUnrecoverable" contextRef="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">983</ix:nonFraction> of such prepaid advances considered to be unrecoverable. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company was a party to an Amended and Restated Technology Services Agreement (the &#8220;ARTSA&#8221;), most recently amended on November&#160;11, 2020, by and among 4C, the Company and other participant companies controlled by the Rothberg family. Under the ARTSA, the Company and the other participant companies agreed to share certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which means any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant and subject to certain restrictions on use. The ARTSA also provided for 4C to perform certain services for the Company and each other participant company such as monthly administrative, management and technical consulting services to the Company which are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> approximately once a quarter. The Company incurred expenses from 4C of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,055</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,160</ix:nonFraction> during the years ended December&#160;31, 2021 and 2020 respectively. The amounts advanced and due from 4C at December&#160;31, 2021 and 2020, related to operating expenses was $<ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,496</ix:nonFraction>, respectively, and is included in Due from related parties on the combined and consolidated balance sheets. There was also $<ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,872</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction> of amounts due to 4C for expenses paid on their behalf. These payables are included in Due to related parties on the combined and consolidated balance sheets. On July&#160;7, 2021, Legacy Hyperfine, Liminal and 4C entered into First Addendums to the ARTSA, pursuant to which Legacy Hyperfine and Liminal each terminated its participation under the ARTSA immediately prior to the Closing. Legacy Hyperfine and Liminal each entered into a Master Services Agreement (the &#8220;Master Services Agreements&#8221;) with 4C effective as of July&#160;7, 2021 pursuant to which Legacy Hyperfine and Liminal may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ARTSA also provided for the participant companies to provide other services to each other. The Company also has transactions with other entities under common ownership, which include payments made to third parties on behalf of the Company. The amounts remaining payable at December&#160;31, 2021 and 2020 are $<ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">110</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">124</ix:nonFraction>, respectively, and are included in the Due to related parties on the combined and consolidated balance sheets. In addition, the Company has transactions with these other entities under common ownership which include payments made by the Company to third parties on behalf of the other entities and the amounts remaining receivable are in the aggregate $<ix:nonFraction name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction> at December&#160;31, 2021 and the amounts remaining payable are in the aggregate $<ix:nonFraction name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30</ix:nonFraction> at December&#160;31, 2020, and are reflected in the Due from related parties on the combined and consolidated balance sheets. All amounts are paid or received throughout the year within 30 days after the end of each month. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="display:inline;">9</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_41739438_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Legacy Hyperfine and Liminal entered into Technology and Services Exchange Agreements (each, a &#8220;TSEA&#8221; and collectively, the &#8220;TSEA&#8221;) with other participant companies controlled by the Rothbergs. A TSEA by and among Butterfly Network, Inc., AI Therapeutics, Inc., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, 4Bionics, Tesseract Health, Inc., Detect, Inc. (f/k/a Homodeus Inc.), Legacy Hyperfine and Liminal was signed in November 2020; a TSEA by and among <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, AI Therapeutics, Inc., 4Bionics, Tesseract Health, Inc., Detect, Inc., Legacy Hyperfine and Liminal was signed in February 2021 (and which Protein Evolution, Inc. joined in August 2021); and a TSEA by and among Legacy Hyperfine, Liminal, AI Therapeutics, Inc., Tesseract Health, Inc. and Detect, Inc. was signed in July 2021 and is effective upon the Closing. Under the TSEA, Legacy Hyperfine, Liminal and other participant companies may, in their discretion, permit the use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which include any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant, such as software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists, by other participant companies. As of December&#160;31, 2021, the Company had transactions with other participant companies and had expenses of $<ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_TechnologyAndServicesExchangeAgreementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction> included in Accounts payable.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_41719218"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. The Company did not make any matching contributions to the 401(k) plan for the years ended December&#160;30, 2021 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During 2020, the Company was awarded a $<ix:nonFraction name="hypr:DeferredGrantFundingCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction> grant from the BMGF for the provision and equipping of <ix:nonFraction name="hypr:NumberOfSites" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_Site" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> sites with the Hyperfine portable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system to enable the performance of a multi-site study focused on optimizing diagnostic image quality (the &#8220;Project&#8221;). During 2021, the Company was awarded an additional $<ix:nonFraction name="hypr:GrantAwarded" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,300</ix:nonFraction> grant from the BMGF, of which $<ix:nonFraction name="hypr:GrantAwardedForProvisionAndEquipping" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction> was received for the provision and equipping of <ix:nonFraction name="hypr:NumberOfSites" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Site" decimals="INF" scale="0" format="ixt:numdotdecimal">5</ix:nonFraction> sites and other related deliverables, of which the remaining $<ix:nonFraction name="hypr:GrantAwardedForOtherRelatedDeliverables" contextRef="P04_01_2002To04_30_2022_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction> is to be received by April 2022. The funds are accounted for as restricted cash with an offset to deferred grant revenue. At December&#160;31, 2021 and 2020, the Company has $<ix:nonFraction name="hypr:DeferredGrantFundingCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,662</ix:nonFraction> and $<ix:nonFraction name="hypr:DeferredGrantFundingCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction>, respectively, on the combined and consolidated balance sheets. Any grant funds, plus any income, that have not been used for, or committed to, the Project must be returned promptly to the BMGF upon expiration of or termination of the agreement. As of December&#160;31, 2021 and 2020, there were no grant fund amounts that were required to be returned under the provisions of the Project. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company does not have any outstanding or ongoing litigation and legal matters where, based on present information, including its assessment of the merits of the particular claims, the Company believes it is reasonably possible that any asserted or unasserted legal claims or proceedings, individually or in aggregate, will have a material adverse effect on its results of operations or financial condition. The ultimate outcome of any legal matter cannot be predicted with certainty. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has indemnification obligations under some agreements that the Company enters into with other parties in the ordinary course of business, including business partners, investors, contractors, and the Company&#8217;s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or threatened third-party claim because of the Company&#8217;s activities or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with certain representations and warranties made </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">40</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. AND SUBSIDIARIES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2021 AND 2020 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(all amounts are in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_41719218"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions due to the Company&#8217;s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the combined and consolidated statements of operations and comprehensive loss in connection with the indemnification provisions have not been material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">The Company agreed to pay $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction><div style="display:inline;">&#160;to a third party service provider upon the receipt by the Companies&#8217; pre-closing equity holders of any Earn-Out Shares (see Note 3. Business Combination). The Company determined the probability of such payment to be not probable thus no liability was recognized.&#160;</div> <br/></div> </ix:continuation> <div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-41 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2pt solid rgb(0, 0, 0); text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0); text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 24pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">HYPERFINE, INC. </div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 41,775,946 Shares of Class&#160;A Common Stock </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 15,055,288 Shares of Class&#160;B Common Stock </div></div></div><div style="font-size: 150pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 150pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">PROSPECTUS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 150pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different information. You should not assume that the information contained or incorporated by reference in this prospectus is accurate as of any date other than the date of this prospectus. We are not making an offer of these securities in any state where the offer is not permitted. </div></div></div><div style="font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 4.5pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc284543_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INFORMATION NOT REQUIRED IN PROSPECTUS </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Expenses of Issuance and Distribution. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the estimated expenses to be borne by the registrant in connection with the issuance and distribution of the securities being registered hereby. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities and Exchange Commission registration fee</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,037.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting fees and expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees and expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial printing and miscellaneous expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification of Directors and Officers. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), permits a corporation to indemnify its directors and officers against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or proceeding brought by third parties. The directors or officers must have acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reason to believe their conduct was unlawful. In a derivative action, an action only by or in the right of the corporation, indemnification may be made only for expenses, including attorney&#8217;s fees, actually and reasonably incurred by directors and officers in connection with the defense or settlement of an action or suit, and only with respect to a matter as to which they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation. No indemnification shall be made if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought determines upon application that the defendant officers or directors are fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability. The certificate of incorporation, as amended, of the registrant provides that the registrant may indemnify its directors, officers, employees or agents to the fullest extent permitted by applicable law and the bylaws, as amended, of the registrant provide that the registrant shall indemnify its directors and officers to the fullest extent permitted by applicable law. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;102(b)(7) of the DGCL permits a corporation to provide in its charter that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (2)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&#160;for payments of unlawful dividends or unlawful stock purchases or redemptions or (4)&#160;for any transaction from which the director derived an improper personal benefit. The current certificate of incorporation, as amended, of the registrant provide for such limitation of liability. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into indemnification agreements with each of our directors and executive officers in which we have agreed to indemnify and hold harmless, and also advance expenses as incurred, to the fullest extent permitted under applicable law, against all expenses, losses and liabilities incurred by the indemnitee or on the indemnitee&#8217;s behalf arising from the fact that such person is or was a director, officer, employee or agent of our company or our subsidiaries. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, our certificate of incorporation, as amended, our bylaws, as amended, any agreement, any vote of stockholders or disinterested directors or otherwise. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain standard policies of insurance that provide coverage (1)&#160;to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (2)&#160;to us with respect to indemnification payments that we may make to such directors and officers. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;15.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Sales of Unregistered Securities. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;24, 2020, HealthCor&#8217;s sponsor, HC Sponsor LLC (the &#8220;Sponsor&#8221;) paid $25,000 to cover certain offering and formation costs of HealthCor in consideration for 4,312,500 HealthCor Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). In December 2020, the Sponsor transferred 35,000 HealthCor Class&#160;B ordinary shares to each of Dr.&#160;Christopher Wolfgang and Mr.&#160;Michael Weinstein for their service as independent directors of HealthCor. In January 2021, the Sponsor transferred 35,000 HealthCor Class&#160;B ordinary shares to Mr.&#160;Taylor Harris for his service as an independent director of HealthCor. On January&#160;26, 2021, HealthCor effected a share capitalization pursuant to which HealthCor issued 862,500 additional HealthCor Class&#160;B ordinary shares, resulting in these shareholders holding 5,175,000 Class&#160;B ordinary shares. Such securities were issued in connection with HealthCor&#8217;s organization pursuant to the exemption from registration contained in Section&#160;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Sponsor and each of these HealthCor directors is an accredited investor for purposes of Rule 501 of Regulation D. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Shares </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of HealthCor&#8217;s Initial Public Offering on January&#160;26, 2021, the Sponsor purchased from HealthCor 614,000 HealthCor Class&#160;A ordinary shares (the &#8220;Private Placement Shares&#8221;) in a private placement at a price of $10.00 per share, for an aggregate purchase price of $6,140,000. Such Private Placement Shares were issued pursuant to the exemption from registration contained in Section&#160;4(a)(2) of the Securities Act. The Sponsor is an accredited investor for purposes of Rule 501 of Regulation D. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2021 (the &#8220;Closing Date&#8221;), HealthCor sold to the PIPE Investors, pursuant to the Subscription Agreements, an aggregate of 12,610,000 shares of Class&#160;A common stock at a price of $10.00 per share for aggregate gross proceeds to HealthCor of $126.1&#160;million in the PIPE Investment. The PIPE Investment closed immediately prior to the Business Combination. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares issued to the PIPE Investors in the PIPE Investment on the Closing Date were issued pursuant to the exemption from registration under Section&#160;4(a)(2) of the Securities Act and/or Regulation D promulgated under the Securities Act. The PIPE Investors are accredited investors for purposes of Rule 501 of Regulation D. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Additional Issuance </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;23, 2021, the Company issued 300,000 shares of Class&#160;A common stock to a service provider in lieu of $3.0&#160;million of cash compensation payable to the service provider. These shares were issued pursuant to and in accordance with the exemption from registration under Section&#160;4(a)(2) of the Securities Act and/or Regulation D promulgated under the Securities Act. The service provider is an accredited investor for purposes of Rule 501 of Regulation D. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits and Financial Statement Schedules. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">(a) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exhibits</div></div>. </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 44%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit <br/>Number</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference&#160;Herein<br/>from Form or<br/>Schedule</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sec File/<br/>Reg.&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;2.1&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921089996/tm2121601d1_ex2-1.htm">Business Combination Agreement, dated as of July&#160;7, 2021, by and among Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.), Optimus Merger Sub I, Inc., Optimus Merger Sub II, Inc., Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Liminal Sciences, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> (Exhibit 2.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7/8/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex3-1.htm">Certificate of Incorporation of Hyperfine, Inc., as amended </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 3.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex3-2.htm">Bylaws of Hyperfine, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 3.2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921120431/tm2121883d12_ex4-2.htm">Specimen Class&#160;A Common Stock Certificate </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div><br/>(Exhibit 4.2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">9/29/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;5.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465922006593/hypr-20220121xex5d1.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div><br/>(Exhibit 5.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">1/24/2022</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-262300</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921089996/tm2121601d1_ex10-1.htm">Form of PIPE Investor Subscription Agreement for institutional investors, dated as of July&#160;7, 2021, by and between Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.) and the subscriber parties thereto </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7/8/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921089996/tm2121601d1_ex10-2.htm">Form of PIPE Investor Subscription Agreement for individual investors, dated as of July&#160;7, 2021, by and between Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.) and the subscriber parties thereto </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7/8/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921090293/tm2121601d3_ex10-1.htm">Transaction Support Agreement, dated as of July&#160;8, 2021, by and among Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.), Dr.&#160;Jonathan&#160;M. Rothberg, and certain supporting stockholders of Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Liminal Sciences, Inc. affiliated with Dr.&#160;Rothberg </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7/8/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921089996/tm2121601d1_ex10-3.htm">Sponsor Letter Agreement, dated as of July&#160;7, 2021, by and among Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.), Hyperfine Operations, Inc. (formerly Hyperfine, Inc.), Liminal Sciences, Inc., HC Sponsor LLC, and the other stockholders party thereto </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.3)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7/8/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit <br/>Number</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference&#160;Herein<br/>from Form or<br/>Schedule</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sec File/<br/>Reg.&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.5+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-5.htm">Advisory Agreement, dated as of December&#160;22, 2021, by and between Hyperfine, Inc. and Dr.&#160;Jonathan&#160;M.&#160;Rothberg </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.5)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.6+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d15.htm">Second Amended and Restated Offer Letter, dated as of April&#160;25, 2021, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and David Scott</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit&#160;10.15)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.7+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d11.htm">Amended and Restated Offer Letter, dated as of August&#160;27, 2021, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Alok Gupta </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.11)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.8+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d12.htm">Offer Letter, dated as of June&#160;7, 2019, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Mark Hughes </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.12)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.9+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d13.htm">Offer Letter, dated as of January&#160;4, 2020, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Khan Siddiqui, M.D. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.13)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.10+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d14.htm">Offer Letter, dated as of April&#160;13, 2021, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Neela Paykel </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.14)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.11+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921120431/tm2121883d12_ex10-20.htm">Offer Letter, dated as of August&#160;24, 2021, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Scott White</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div><br/>(Exhibit 10.20)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">09/29/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.12+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d16.htm">Consulting Agreement, dated as of April&#160;25, 2021, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and R. Scott Huennekens </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.16)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.13+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-13.htm">Hyperfine, Inc. Executive Severance Plan </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.13)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.14</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d17.htm">Technology and Services Exchange Agreement, dated as of November&#160;19, 2020, by and among Butterfly Network, Inc., Hyperfine Operations, Inc. (formerly Hyperfine, Inc.), Liminal Sciences, Inc. and the other participants named therein </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.17)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.15</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d18.htm">Technology and Services Exchange Agreement, dated as of February&#160;17, 2021, by and among <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</span> Incorporated, Hyperfine Operations, Inc. (formerly Hyperfine, Inc.), Liminal Sciences, Inc. and the other participants named therein </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.18)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-4 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 16%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit <br/>Number</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference&#160;Herein<br/>from Form or<br/>Schedule</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sec File/<br/>Reg.&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-16.htm">Technology and Services Exchange Agreement, dated as of July&#160;7, 2021, by and among Hyperfine Operations, Inc. (formerly Hyperfine, Inc.), Liminal Sciences, Inc. and the participants named therein </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.16)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.17@</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d8.htm">License Agreement, dated as of May&#160;29, 2014, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and The General Hospital Corporation, d/b/a Massachusetts General Hospital </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.8)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.18@</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d9.htm">License Agreement, dated as of June&#160;30, 2014, by and between Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and The General Hospital Corporation, d/b/a Massachusetts General Hospital </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit 10.9)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.19@</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921110757/hcaq-20210830xex10d10.htm">Manufacture and Supply Agreement, dated as of October&#160;15, 2018, by and between Hyperfine, Inc. and Benchmark Electronics, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div><br/>(Exhibit&#160;10.10)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">08/30/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-259148</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.20.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d20-1.htm">Hyperfine, Inc. 2021 Equity Incentive Plan </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit&#160;10.20.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.20.2+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d20-2.htm">Form of Stock Option Agreement under 2021 Equity Incentive Plan </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.20.2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.20.3+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d20-3.htm">Form of Restricted Stock Unit Agreement under 2021 Equity Incentive Plan </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.20.3)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.21.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d21-1.htm">Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) 2014 Employee, Director and Consultant Equity Incentive Plan, as amended </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.21.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.21.2+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d21-2.htm">Form of Stock Option Agreement under Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) 2014 Employee, Director and Consultant Equity Incentive Plan, as amended </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.21.2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.22.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d22-1.htm">Liminal Sciences, Inc. 2021 Employee, Director and Consultant Equity Incentive Plan, as amended </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit 10.22.1)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.22.2+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10d22-2.htm">Form of Stock Option Agreement under Liminal Sciences, Inc. 2021 Employee, Director and Consultant Equity Incentive Plan, as amended </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/>(Exhibit&#160;10.22.2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12/28/2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39949</div></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-5 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:43%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:14%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit <br/>Number</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit Description</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporated&#160;by<br/>Reference&#160;Herein<br/>from Form or<br/>Schedule</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Filing<br/>Date</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Sec File/<br/>Reg.&#160;Number</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.23+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-23.htm">Nonemployee Director Compensation Policy </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form <div style="white-space:nowrap;display:inline;">8-K</div><br/>(Exhibit 10.23)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">12/28/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="white-space:nowrap;display:inline;">001-39949</div></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.24+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-24.htm">Form of Indemnification Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form <div style="white-space:nowrap;display:inline;">8-K</div><br/>(Exhibit&#160;10.24)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">12/28/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="white-space:nowrap;display:inline;">001-39949</div></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.25+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921002582/tm2037139d3_ex10-4.htm">Form of Indemnity Agreement of HealthCor</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form S-1<br/>(Exhibit&#160;10.4)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">1/11/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">333-252002</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-25.htm">Amended and Restated Registration Rights Agreement, dated as of December&#160;22, 2021, by and among Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.), HC Sponsor LLC and certain other security holders </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form <div style="white-space:nowrap;display:inline;">8-K</div><br/>(Exhibit 10.25)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">10/28/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="white-space:nowrap;display:inline;">001-39949</div></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.27</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-26.htm">Form of <span style="white-space:nowrap;display:inline;">Lock-up</span> Agreement </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form <div style="white-space:nowrap;display:inline;">8-K</div><br/>(Exhibit 10.26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">12/28/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><div style="white-space:nowrap;display:inline;">001-39949</div></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465921153941/tm2136302d1_ex10-27.htm">Forfeiture Agreement, dated as of December&#160;21, 2021, by and among Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.), HC Sponsor LLC, Hyperfine Operations, Inc. (formerly Hyperfine, Inc.) and Liminal Sciences, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form <div style="white-space:nowrap;display:inline;">8-K</div><br/>(Exhibit 10.27)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">12/28/2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space:nowrap;display:inline;">001-39949</div></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000095017022004670/hypr-ex21_1.htm">List of Subsidiaries </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Form <div style="white-space:nowrap;display:inline;">10-K</div><br/>(Exhibit 21.1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">3/25/2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space:nowrap;display:inline;">001-39949</div></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d284543dex231.htm">Consent of Deloitte&#160;&amp; Touche LLP, independent registered public accounting firm of Hyperfine, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">X</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1833769/000110465922006593/hypr-20220121xex5d1.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii284543_1">Power of Attorney (included on the signature page to the initial registration statement)</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document).</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">X</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">X</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">X</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">X</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit <br/>Number</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference&#160;Herein<br/>from Form or<br/>Schedule</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sec File/<br/>Reg.&#160;Number</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments).</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To be filed by amendment. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8224;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management contract or compensatory plan or arrangement. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">@</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i)&#160;are not material and (ii)&#160;would be competitively harmful if publicly disclosed. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;17.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Undertakings. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided, however</div></div>, that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining any liability under the Securities Act, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining liability under the Securities Act to any purchaser: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iv)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc284543_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective No.&#160;1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the Town of Guilford, State of Connecticut, on March&#160;28, 2022. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HYPERFINE, INC.</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Dave Scott</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dave Scott</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">President and Chief Executive Officer</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No.&#160;1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 35%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Title</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Dave Scott</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">President, Chief Executive Officer and Director (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal Executive Officer</div></div>)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Alok Gupta</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alok Gupta</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Chief Financial Officer<br/>(<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal Financial Officer and Principal Accounting Officer</div></div>)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Executive Chairman</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">R. Scott Huennekens</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Vice Chairman</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Jonathan M. Rothberg, Ph.D.</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">John Dahldorf</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Ruth Fattori</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Maria Sainz</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">March&#160;28, 2022</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Daniel J. Wolterman</td></tr></table><div style="clear: both; max-height: 0pt; text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 10%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">*By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Dave Scott</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dave Scott</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Attorney-in-fact</div></div></div></td></tr></table><div style="clear: both; max-height: 0pt; text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-9 </div></div></div></div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d284543dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-262300</FONT> on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated March&nbsp;25, 2022, relating to the combined and consolidated financial statements of Hyperfine, Inc. We also consent to the reference to us under the heading &#147;Experts&#148; in
such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;28, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>hypr-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-March-2022 [01:02:49] {AM}-->
<schema targetNamespace="http://hyperfine.io/20211231" elementFormDefault="qualified" xmlns:hypr="http://hyperfine.io/20211231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://hyperfine.io/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets" id="CombinedAndConsolidatedBalanceSheets">
<link:definition>1002 - Statement - COMBINED AND CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical" id="CombinedAndConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" id="CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit">
<link:definition>1005 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows" id="CombinedAndConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
<link:definition>1007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/BusinessCombination" id="BusinessCombination">
<link:definition>1009 - Disclosure - BUSINESS COMBINATION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognition" id="RevenueRecognition">
<link:definition>1010 - Disclosure - REVENUE RECOGNITION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
<link:definition>1011 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/Inventories" id="Inventories">
<link:definition>1012 - Disclosure - INVENTORIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1013 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
<link:definition>1014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/NotesPayable" id="NotesPayable">
<link:definition>1015 - Disclosure - NOTES PAYABLE</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/ConvertiblePreferredStock" id="ConvertiblePreferredStock">
<link:definition>1016 - Disclosure - CONVERTIBLE PREFERRED STOCK</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
<link:definition>1017 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlan" id="EquityIncentivePlan">
<link:definition>1018 - Disclosure - EQUITY INCENTIVE PLAN</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1019 - Disclosure - NET LOSS PER SHARE</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1020 - Disclosure - INCOME TAXES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1021 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1022 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognitionTables" id="RevenueRecognitionTables">
<link:definition>1025 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IinventoriesTables" id="IinventoriesTables">
<link:definition>1026 - Disclosure - IINVENTORIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
<link:definition>1028 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/ConvertiblePreferredStockTables" id="ConvertiblePreferredStockTables">
<link:definition>1029 - Disclosure - CONVERTIBLE PREFERRED STOCK (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanTables" id="EquityIncentivePlanTables">
<link:definition>1030 - Disclosure - EQUITY INCENTIVE PLAN (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1031 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1032 - Disclosure - INCOME TAXES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails" id="SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails">
<link:definition>1033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Significant customer, percentage of revenue (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" id="SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
<link:definition>1035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful lives of property and equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails" id="BusinessCombinationAdditionalInformationDetails">
<link:definition>1036 - Disclosure - BUSINESS COMBINATION - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails" id="RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails">
<link:definition>1037 - Disclosure - REVENUE RECOGNITION - Summary of Disaggregated Revenues (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails" id="RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails">
<link:definition>1038 - Disclosure - REVENUE RECOGNITION - Information about Receivables and Deferred Revenue from Contracts with Customers (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails" id="RevenueRecognitionAdditionalInformationDetails">
<link:definition>1039 - Disclosure - REVENUE RECOGNITION - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1" id="RevenueRecognitionAdditionalInformationDetails1">
<link:definition>1040 - Disclosure - REVENUE RECOGNITION - Additional Information (Details1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails" id="FairValueOfFinancialInstrumentsAdditionalInformationDetails">
<link:definition>1041 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails" id="InventoriesSummaryOfInventoriesDetails">
<link:definition>1042 - Disclosure - INVENTORIES - Summary of Inventories (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/InventoriesAdditionalInformationDetails" id="InventoriesAdditionalInformationDetails">
<link:definition>1043 - Disclosure - INVENTORIES - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<link:definition>1044 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and equipment, net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails" id="PropertyAndEquipmentNetAdditionalInformationDetails">
<link:definition>1045 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
<link:definition>1046 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/NotesPayableAdditionalInformationDetails" id="NotesPayableAdditionalInformationDetails">
<link:definition>1047 - Disclosure - NOTES PAYABLE - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails" id="ConvertiblePreferredStockAdditionalInformationDetails">
<link:definition>1048 - Disclosure - CONVERTIBLE PREFERRED STOCK - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails" id="ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails">
<link:definition>1049 - Disclosure - CONVERTIBLE PREFERRED STOCK - Summary of Authorized, Issued and Outstanding Convertible Preferred Stock (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails" id="StockholdersEquityDeficitAdditionalInformationDetails">
<link:definition>1050 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails" id="EquityIncentivePlanAdditionalInformationDetails">
<link:definition>1051 - Disclosure - EQUITY INCENTIVE PLAN - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails" id="EquityIncentivePlanSummaryOfStockOptionActivityDetails">
<link:definition>1052 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails" id="EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails">
<link:definition>1053 - Disclosure - EQUITY INCENTIVE PLAN - Assumptions Used to Value Option Grants to Employees and Nonemployees (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails" id="EquityIncentivePlanSummaryOfStockOptionsGrantedDetails">
<link:definition>1054 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock Options Granted (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails" id="EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails">
<link:definition>1055 - Disclosure - EQUITY INCENTIVE PLAN - Key Assumptions Used in Valuation for Earn-Out Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails" id="EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails">
<link:definition>1056 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock-Based Compensation Expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" id="NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
<link:definition>1057 - Disclosure - NET LOSS PER SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails" id="NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails">
<link:definition>1058 - Disclosure - NET LOSS PER SHARE - Schedule of Anti-dilutive Common Equivalent Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails">
<link:definition>1059 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets (Liabilities) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1060 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" id="IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails">
<link:definition>1061 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails" id="IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails">
<link:definition>1062 - Disclosure - INCOME TAXES - Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>1063 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>1064 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1Alternate" id="RevenueRecognitionAdditionalInformationDetails1Alternate">
<link:definition>1065 - Disclosure - REVENUE RECOGNITION - Additional Information (Details1) Alternate</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="hypr-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="HyperfineConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_HyperfineConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="DeferredGrantFundingCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_DeferredGrantFundingCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_AccruedExpensesAndOtherCurrentLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherAssetsRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_OtherAssetsRelatedPartyNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LiminalConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_LiminalConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfLiminalCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ConversionOfLiminalCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RecapitalizationOfPermanentToTemporaryEquityShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_RecapitalizationOfPermanentToTemporaryEquityShares" substitutionGroup="xbrli:item" />
<element name="RecapitalizationOfPermanentToTemporaryEquityValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_RecapitalizationOfPermanentToTemporaryEquityValues" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ProceedsFromBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnbilledReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_UnbilledReceivables" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WriteOffOfOtherAssetsRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_WriteOffOfOtherAssetsRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Covid19OutbreakPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_Covid19OutbreakPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DeferredRevenuePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_DeferredRevenuePolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_WarrantiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GrantFundingPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_GrantFundingPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_PatentCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EarnOutSharesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_EarnOutSharesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentTaxCreditsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="CustomerDMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerDMember" substitutionGroup="xbrli:item" />
<element name="CustomerEMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerEMember" substitutionGroup="xbrli:item" />
<element name="CustomerFMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerFMember" substitutionGroup="xbrli:item" />
<element name="CustomerGMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerGMember" substitutionGroup="xbrli:item" />
<element name="CustomerHMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerHMember" substitutionGroup="xbrli:item" />
<element name="CustomerAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerAMember" substitutionGroup="xbrli:item" />
<element name="CustomerBMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerBMember" substitutionGroup="xbrli:item" />
<element name="CustomerCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CustomerCMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="UncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_UncertainTaxPositions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="ResearchDevicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ResearchDevicesMember" substitutionGroup="xbrli:item" />
<element name="SalesAndMarketingDevicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SalesAndMarketingDevicesMember" substitutionGroup="xbrli:item" />
<element name="LeasedDevicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_LeasedDevicesMember" substitutionGroup="xbrli:item" />
<element name="TradeShowAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_TradeShowAssetsMember" substitutionGroup="xbrli:item" />
<element name="ClassBOrdinarySharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ClassBOrdinarySharesMember" substitutionGroup="xbrli:item" />
<element name="ClassAOrdinarySharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ClassAOrdinarySharesMember" substitutionGroup="xbrli:item" />
<element name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SeriesA1PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SponsorMember" substitutionGroup="xbrli:item" />
<element name="HealthCorCatalioAcquisitionCorpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_HealthCorCatalioAcquisitionCorpMember" substitutionGroup="xbrli:item" />
<element name="ImmediatelyPriorToEffectiveTimeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ImmediatelyPriorToEffectiveTimeMember" substitutionGroup="xbrli:item" />
<element name="HealthCorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_HealthCorMember" substitutionGroup="xbrli:item" />
<element name="SubscriptionAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SubscriptionAgreementsMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationTransactionThresholdTradingDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_BusinessCombinationTransactionThresholdTradingDays" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationTransactionThresholdConsecutiveTradingDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<element name="NumberOfVotesPerShareEntitledToClassOfCommonStock" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" substitutionGroup="xbrli:item" />
<element name="PercentageNumberOfSharesCeasesToBeneficiallyOwned" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" substitutionGroup="xbrli:item" />
<element name="CommonStockSubjectToRedemption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_CommonStockSubjectToRedemption" substitutionGroup="xbrli:item" />
<element name="PercentageOfCommonStockVotingPower" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_PercentageOfCommonStockVotingPower" substitutionGroup="xbrli:item" />
<element name="PrepaidInsurancePolicyInConnectionWithBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_PaymentOfPaycheckProtectionProgramLoan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InterestAndPaymentsToRedeemingCompanyShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_InterestAndPaymentsToRedeemingCompanyShareholders" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BusinessCombinationPaymentOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_BusinessCombinationPaymentOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegacyHyperfineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_LegacyHyperfineMember" substitutionGroup="xbrli:item" />
<element name="PIPEInvestorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_PIPEInvestorsMember" substitutionGroup="xbrli:item" />
<element name="LiminalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_LiminalMember" substitutionGroup="xbrli:item" />
<element name="RevenueRecognizeReceivablePaymentTermsRangeMinimum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" substitutionGroup="xbrli:item" />
<element name="RevenueRecognizeReceivablePaymentTermsRangeMaximum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" substitutionGroup="xbrli:item" />
<element name="RevenueRemainingPerformanceObligationExpectedTimingPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" substitutionGroup="xbrli:item" />
<element name="AccruedContractedServicesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_AccruedContractedServicesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedBonusAndOtherCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_AccruedBonusAndOtherCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PayrollProtectionProgramLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_PayrollProtectionProgramLoanMember" substitutionGroup="xbrli:item" />
<element name="HyperfinePayrollProtectionProgramLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_HyperfinePayrollProtectionProgramLoanMember" substitutionGroup="xbrli:item" />
<element name="LiminalPayrollProtectionProgramLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_LiminalPayrollProtectionProgramLoanMember" substitutionGroup="xbrli:item" />
<element name="SeriesATwoConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SeriesATwoConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesBCAndDConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_SeriesBCAndDConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_BusinessCombinationExchangeRatio" substitutionGroup="xbrli:item" />
<element name="NumberOfVotesPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_NumberOfVotesPerShare" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityYearOfClassIssuance" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_TemporaryEquityYearOfClassIssuance" substitutionGroup="xbrli:item" />
<element name="TemporaryEquitySharesIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_TemporaryEquitySharesIssuanceCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_CommonStockNumberOfVotesPerShare" substitutionGroup="xbrli:item" />
<element name="HyperfineEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_HyperfineEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="FourBionicsTwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="ExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ExchangeRatio" substitutionGroup="xbrli:item" />
<element name="CommonStockRemainsAvailableForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_CommonStockRemainsAvailableForIssuance" substitutionGroup="xbrli:item" />
<element name="NumberOfSeparateOptionAwards" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_NumberOfSeparateOptionAwards" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" substitutionGroup="xbrli:item" />
<element name="ShareBasedPaymentArrangementPlanModificationIncrementalValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncentiveUnitActivityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_IncentiveUnitActivityMember" substitutionGroup="xbrli:item" />
<element name="IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" substitutionGroup="xbrli:item" />
<element name="EarnOutSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_EarnOutSharesMember" substitutionGroup="xbrli:item" />
<element name="StockOptionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_StockOptionsOneMember" substitutionGroup="xbrli:item" />
<element name="StockOptionsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_StockOptionsTwoMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedPaymentArrangementSeparateOptionAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" substitutionGroup="xbrli:item" />
<element name="ServiceAndPerformanceSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ServiceAndPerformanceSharesMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" substitutionGroup="xbrli:item" />
<element name="OutstandingLegacyHyperfineConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="FederalNetOperatingLossMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_FederalNetOperatingLossMember" substitutionGroup="xbrli:item" />
<element name="FederalAndStateNetOperatingLossesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_FederalAndStateNetOperatingLossesMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsValuationAllowanceIncreased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_DeferredTaxAssetsValuationAllowanceIncreased" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OwnershipChangePercentageTestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_OwnershipChangePercentageTestingPeriod" substitutionGroup="xbrli:item" />
<element name="OwnershipChangeDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_OwnershipChangeDescription" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveOwnershipChanges" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_NumberOfConsecutiveOwnershipChanges" substitutionGroup="xbrli:item" />
<element name="OwnershipChangesDateOne" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_OwnershipChangesDateOne" substitutionGroup="xbrli:item" />
<element name="OwnershipChangesDateTwo" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_OwnershipChangesDateTwo" substitutionGroup="xbrli:item" />
<element name="NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OwnershipChangesAnalysisExpectedToBeCompletedYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" substitutionGroup="xbrli:item" />
<element name="IncomeTaxEffectsRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_IncomeTaxEffectsRecognized" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" substitutionGroup="xbrli:item" />
<element name="ExchangeProgramRecognizedNetBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_ExchangeProgramRecognizedNetBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" substitutionGroup="xbrli:item" />
<element name="Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" substitutionGroup="xbrli:item" />
<element name="HyperfineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_HyperfineMember" substitutionGroup="xbrli:item" />
<element name="FederalOtherMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_FederalOtherMember" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardBeginToExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_TaxCreditCarryforwardBeginToExpirationYear" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsBeginToExpireYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_OperatingLossCarryforwardsBeginToExpireYear" substitutionGroup="xbrli:item" />
<element name="ConnecticutResearchAndDevelopmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ConnecticutResearchAndDevelopmentMember" substitutionGroup="xbrli:item" />
<element name="ConnecticutOthersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_ConnecticutOthersMember" substitutionGroup="xbrli:item" />
<element name="PreTwoThaousandEighteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_PreTwoThaousandEighteenMember" substitutionGroup="xbrli:item" />
<element name="PostTwoThaousandSeventeenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_PostTwoThaousandSeventeenMember" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionPaymentsForRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_RelatedPartyTransactionPaymentsForRent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DueFromEmployeesForgiveness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_DueFromEmployeesForgiveness" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfSubsidiaries" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_NumberOfSubsidiaries" substitutionGroup="xbrli:item" />
<element name="InterestReceivableRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="hypr_InterestReceivableRelatedPartiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaidAdvancesUnrecoverable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_PrepaidAdvancesUnrecoverable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CatalyzerCorporation4Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_CatalyzerCorporation4Member" substitutionGroup="xbrli:item" />
<element name="FourBionicsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_FourBionicsMember" substitutionGroup="xbrli:item" />
<element name="TechnologyAndServicesExchangeAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_TechnologyAndServicesExchangeAgreementMember" substitutionGroup="xbrli:item" />
<element name="AllocationOfExpenseIncurredMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_AllocationOfExpenseIncurredMember" substitutionGroup="xbrli:item" />
<element name="AmendedAndRestatedTechnologyServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="hypr_AmendedAndRestatedTechnologyServicesAgreementMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSites" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_NumberOfSites" substitutionGroup="xbrli:item" />
<element name="GrantAwarded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_GrantAwarded" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GrantAwardedForProvisionAndEquipping" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_GrantAwardedForProvisionAndEquipping" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GrantAwardedForOtherRelatedDeliverables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="hypr_GrantAwardedForOtherRelatedDeliverables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>hypr-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-March-2022 [01:02:49] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedBalanceSheets" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfCashFlows" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#InventoriesSummaryOfInventoriesDetails" roleURI="http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" />
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OtherAssetsRelatedPartyNoncurrent" xlink:label="loc_HYPR_OtherAssetsRelatedPartyNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_HYPR_OtherAssetsRelatedPartyNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredGrantFundingCurrent" xlink:label="loc_HYPR_DeferredGrantFundingCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_HYPR_DeferredGrantFundingCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermNotesPayable" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="25" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingAndMarketingExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="12" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InventoryWriteDown" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_WriteOffOfOtherAssetsRelatedParty" xlink:label="loc_HYPR_WriteOffOfOtherAssetsRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HYPR_WriteOffOfOtherAssetsRelatedParty" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="loc_us-gaap_SalesTypeLeaseSellingProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_SalesTypeLeaseSellingProfitLoss" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentInLeasePurchase" xlink:label="loc_us-gaap_NetInvestmentInLeasePurchase" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetInvestmentInLeasePurchase" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UnbilledReceivables" xlink:label="loc_HYPR_UnbilledReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HYPR_UnbilledReceivables" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ProceedsFromBusinessCombination" xlink:label="loc_HYPR_ProceedsFromBusinessCombination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_HYPR_ProceedsFromBusinessCombination" use="optional" order="31" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents" use="optional" order="33" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="loc_us-gaap_AccruedBonusesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedContractedServicesCurrent" xlink:label="loc_HYPR_AccruedContractedServicesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="loc_HYPR_AccruedContractedServicesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedBonusAndOtherCostsCurrent" xlink:label="loc_HYPR_AccruedBonusAndOtherCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="loc_HYPR_AccruedBonusAndOtherCostsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_HYPR_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" xlink:label="loc_HYPR_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_HYPR_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" xlink:label="loc_HYPR_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_HYPR_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="9" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>hypr-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-March-2022 [01:02:49] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedBalanceSheets" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedBalanceSheetsParenthetical" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfCashFlows" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#BusinessCombinationAdditionalInformationDetails" roleURI="http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails" roleURI="http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionAdditionalInformationDetails" roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionAdditionalInformationDetails1" roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#FairValueOfFinancialInstrumentsAdditionalInformationDetails" roleURI="http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NotesPayableAdditionalInformationDetails" roleURI="http://hyperfine.io/role/NotesPayableAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails" roleURI="http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#StockholdersEquityDeficitAdditionalInformationDetails" roleURI="http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanAdditionalInformationDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanSummaryOfStockOptionActivityDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanSummaryOfStockOptionsGrantedDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails" roleURI="http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://hyperfine.io/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionAdditionalInformationDetails1Alternate" roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1Alternate" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#BusinessCombination" roleURI="http://hyperfine.io/role/BusinessCombination" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognition" roleURI="http://hyperfine.io/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#FairValueOfFinancialInstruments" roleURI="http://hyperfine.io/role/FairValueOfFinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#Inventories" roleURI="http://hyperfine.io/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNet" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NotesPayable" roleURI="http://hyperfine.io/role/NotesPayable" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStock" roleURI="http://hyperfine.io/role/ConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#StockholdersEquityDeficit" roleURI="http://hyperfine.io/role/StockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlan" roleURI="http://hyperfine.io/role/EquityIncentivePlan" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShare" roleURI="http://hyperfine.io/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxes" roleURI="http://hyperfine.io/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RelatedPartyTransactions" roleURI="http://hyperfine.io/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CommitmentsAndContingencies" roleURI="http://hyperfine.io/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IinventoriesTables" roleURI="http://hyperfine.io/role/IinventoriesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetTables" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStockTables" roleURI="http://hyperfine.io/role/ConvertiblePreferredStockTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanTables" roleURI="http://hyperfine.io/role/EquityIncentivePlanTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionTables" roleURI="http://hyperfine.io/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShareTables" roleURI="http://hyperfine.io/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesTables" roleURI="http://hyperfine.io/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails" roleURI="http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#InventoriesAdditionalInformationDetails" roleURI="http://hyperfine.io/role/InventoriesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#InventoriesSummaryOfInventoriesDetails" roleURI="http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CoverPage" roleURI="http://hyperfine.io/role/CoverPage" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_135" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_135" xlink:to="loc_us-gaap_StatementTable_141" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_143" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_143" xlink:to="loc_us-gaap_ClassOfStockDomain_139" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_139_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_143" xlink:to="loc_us-gaap_ClassOfStockDomain_139_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_139" xlink:to="loc_hypr_HyperfineConvertiblePreferredStockMember_146" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_139" xlink:to="loc_us-gaap_CommonClassAMember_150" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_139" xlink:to="loc_us-gaap_CommonClassBMember_155" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_135" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_StockholdersEquityAbstract_140" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_CommonStockValue_147" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_AdditionalPaidInCapital_152" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_159" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_StockholdersEquity_160" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_138" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredGrantFundingCurrent" xlink:label="loc_hypr_DeferredGrantFundingCurrent_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_hypr_DeferredGrantFundingCurrent_149" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_AccountsPayableCurrent_145" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_161" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_157" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities_167" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_LiabilitiesCurrent_169" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_LongTermNotesPayable_153" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_154" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_Liabilities_163" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_CommitmentsAndContingencies_168" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_171" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_135" xlink:to="loc_us-gaap_AssetsAbstract_137" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_148" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_AssetsCurrentAbstract_136" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_144" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_RestrictedCashCurrent_151" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_156" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_AssetsCurrent_173" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_164" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_InventoryNet_166" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_170" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_172" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OtherAssetsRelatedPartyNoncurrent" xlink:label="loc_hypr_OtherAssetsRelatedPartyNoncurrent_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_hypr_OtherAssetsRelatedPartyNoncurrent_158" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_162" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_Assets_165" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_198" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_StatementTable_199" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_199" xlink:to="loc_us-gaap_StatementClassOfStockAxis_196" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_196" xlink:to="loc_us-gaap_ClassOfStockDomain_197" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_197_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_196" xlink:to="loc_us-gaap_ClassOfStockDomain_197_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_197" xlink:to="loc_hypr_HyperfineConvertiblePreferredStockMember_200" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_197" xlink:to="loc_us-gaap_CommonClassAMember_203" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_197" xlink:to="loc_us-gaap_CommonClassBMember_204" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_202" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_205" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_212" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_208" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_210" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockSharesIssued_211" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_206" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_207" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_245" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_RevenuesAbstract_241" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_241" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_StatementTable_242" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_242" xlink:to="loc_srt_ProductOrServiceAxis_243" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_243" xlink:to="loc_srt_ProductsAndServicesDomain_244" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_243" xlink:to="loc_srt_ProductsAndServicesDomain_244_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_244" xlink:to="loc_us-gaap_ProductMember_249" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_244" xlink:to="loc_us-gaap_ServiceMember_252" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_GrossProfit_255" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_246" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_246" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_250" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_OperatingExpensesAbstract_247" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_OperatingExpenses_256" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_253" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_SellingAndMarketingExpense_254" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_251" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_OperatingIncomeLoss_257" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_InvestmentIncomeInterest_258" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_259" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_260" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_261" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_NetIncomeLoss_262" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_263" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_264" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_312" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StatementTable_308" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_308" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_311" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_311" xlink:to="loc_us-gaap_EquityComponentDomain_310" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_310_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_311" xlink:to="loc_us-gaap_EquityComponentDomain_310_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_310" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_314" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_310" xlink:to="loc_us-gaap_RetainedEarningsMember_318" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_310" xlink:to="loc_us-gaap_CommonStockMember_320" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_308" xlink:to="loc_us-gaap_StatementClassOfStockAxis_309" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_309" xlink:to="loc_us-gaap_ClassOfStockDomain_313" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_313_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_309" xlink:to="loc_us-gaap_ClassOfStockDomain_313_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_hypr_HyperfineConvertiblePreferredStockMember_316" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalConvertiblePreferredStockMember" xlink:label="loc_hypr_LiminalConvertiblePreferredStockMember_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_hypr_LiminalConvertiblePreferredStockMember_319" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_us-gaap_CommonClassBMember_323" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_us-gaap_CommonClassAMember_321" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockholdersEquity_315" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_317" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_328" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xlink:label="loc_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments_329" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConversionOfLiminalCommonStock" xlink:label="loc_hypr_ConversionOfLiminalCommonStock_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_ConversionOfLiminalCommonStock_330" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xlink:label="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityShares_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityShares_331" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xlink:label="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityValues_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityValues_332" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_322" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_SharesIssued_324" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_NetIncomeLoss_326" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_327" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_338" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_339" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_341" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_342" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_333" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_334" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_335" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_336" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_405" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_410" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_421" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_423" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ProceedsFromBusinessCombination" xlink:label="loc_hypr_ProceedsFromBusinessCombination_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_hypr_ProceedsFromBusinessCombination_441" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_430" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_434" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_436" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_443" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_401" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xlink:label="loc_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401" xlink:to="loc_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits_411" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_412" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_419" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_426" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_413" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xlink:label="loc_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination_1367313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" xlink:to="loc_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination_1367313" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_StatementTable_404" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_416" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UnbilledReceivables" xlink:label="loc_hypr_UnbilledReceivables_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_hypr_UnbilledReceivables_418" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_424" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_437" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies_440" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_428" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_435" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_442" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_444" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_445" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_446" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_447" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_448" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_ProfitLoss_414" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_415" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_ShareBasedCompensation_422" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_InventoryWriteDown_425" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentInLeasePurchase" xlink:label="loc_us-gaap_NetInvestmentInLeasePurchase_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_NetInvestmentInLeasePurchase_438" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_WriteOffOfOtherAssetsRelatedParty" xlink:label="loc_hypr_WriteOffOfOtherAssetsRelatedParty_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_hypr_WriteOffOfOtherAssetsRelatedParty_427" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="loc_us-gaap_SalesTypeLeaseSellingProfitLoss_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_SalesTypeLeaseSellingProfitLoss_432" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_431" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_417" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_429" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_712" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_712" xlink:to="loc_us-gaap_ConcentrationRiskTable_711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" xlink:to="loc_us-gaap_SalesRevenueNetMember_717" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" xlink:to="loc_us-gaap_AccountsReceivableMember_721" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_srt_MajorCustomersAxis_714" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_714" xlink:to="loc_srt_NameOfMajorCustomerDomain_715" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_715_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_714" xlink:to="loc_srt_NameOfMajorCustomerDomain_715_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerDMember" xlink:label="loc_hypr_CustomerDMember_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerDMember_724" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerEMember" xlink:label="loc_hypr_CustomerEMember_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerEMember_725" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerFMember" xlink:label="loc_hypr_CustomerFMember_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerFMember_726" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerGMember" xlink:label="loc_hypr_CustomerGMember_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerGMember_727" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerHMember" xlink:label="loc_hypr_CustomerHMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerHMember_728" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerAMember" xlink:label="loc_hypr_CustomerAMember_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerAMember_720" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerBMember" xlink:label="loc_hypr_CustomerBMember_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerBMember_722" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerCMember" xlink:label="loc_hypr_CustomerCMember_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerCMember_723" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_716" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_716" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_713" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_713_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_716" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_713_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_713" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_719" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_712" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_718" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_srt_StatementGeographicalAxis_763" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_763" xlink:to="loc_srt_SegmentGeographicalDomain_765" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_765_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_763" xlink:to="loc_srt_SegmentGeographicalDomain_765_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU" xlink:label="loc_country_AU_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_765" xlink:to="loc_country_AU_771" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_774" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" xlink:to="loc_us-gaap_TypeOfAdoptionMember_767" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" xlink:to="loc_us-gaap_TypeOfAdoptionMember_767_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_767" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_776" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201815Member_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_767" xlink:to="loc_us-gaap_AccountingStandardsUpdate201815Member_773" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201912Member_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_767" xlink:to="loc_us-gaap_AccountingStandardsUpdate201912Member_777" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_NumberOfOperatingSegments_772" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_NumberOfReportableSegments_775" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UncertainTaxPositions" xlink:label="loc_hypr_UncertainTaxPositions_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_hypr_UncertainTaxPositions_788" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_778" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_779" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_780" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationMethod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationMethod_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationMethod_781" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_782" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_783" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_AdvertisingExpense_784" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_785" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_786" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_OpenTaxYear_787" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_789" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_790" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_791" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_792" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_819" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_819" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LaboratoryEquipmentMember" xlink:label="loc_hypr_LaboratoryEquipmentMember_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_LaboratoryEquipmentMember_821" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchDevicesMember" xlink:label="loc_hypr_ResearchDevicesMember_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_ResearchDevicesMember_823" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SalesAndMarketingDevicesMember" xlink:label="loc_hypr_SalesAndMarketingDevicesMember_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_SalesAndMarketingDevicesMember_825" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_us-gaap_ComputerEquipmentMember_826" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_830" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LeasedDevicesMember" xlink:label="loc_hypr_LeasedDevicesMember_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_LeasedDevicesMember_829" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TradeShowAssetsMember" xlink:label="loc_hypr_TradeShowAssetsMember_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_TradeShowAssetsMember_828" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_827" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" xlink:to="loc_srt_RangeAxis_814" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_814" xlink:to="loc_srt_RangeMember_815" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_814" xlink:to="loc_srt_RangeMember_815_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MinimumMember_820" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MaximumMember_824" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_819" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_822" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_891" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_900" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_903" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_SharesIssued_914" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_915" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_CommonStockSharesIssued_916" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_917" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationTransactionThresholdTradingDays" xlink:label="loc_hypr_BusinessCombinationTransactionThresholdTradingDays_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_BusinessCombinationTransactionThresholdTradingDays_908" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xlink:label="loc_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays_910" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xlink:label="loc_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock_911" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xlink:label="loc_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned_912" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_913" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockSubjectToRedemption" xlink:label="loc_hypr_CommonStockSubjectToRedemption_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_CommonStockSubjectToRedemption_918" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_897" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_StatementClassOfStockAxis_881" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_881" xlink:to="loc_us-gaap_ClassOfStockDomain_889" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_889_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_881" xlink:to="loc_us-gaap_ClassOfStockDomain_889_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_us-gaap_CommonClassBMember_901" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_us-gaap_CommonClassAMember_895" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ClassBOrdinarySharesMember" xlink:label="loc_hypr_ClassBOrdinarySharesMember_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_hypr_ClassBOrdinarySharesMember_905" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ClassAOrdinarySharesMember" xlink:label="loc_hypr_ClassAOrdinarySharesMember_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_hypr_ClassAOrdinarySharesMember_907" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesA1PreferredStockMember" xlink:label="loc_hypr_SeriesA1PreferredStockMember_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_hypr_SeriesA1PreferredStockMember_909" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_srt_TitleOfIndividualAxis_885" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_885" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_885" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890" xlink:to="loc_srt_DirectorMember_896" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_srt_ConsolidatedEntitiesAxis_886" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_886" xlink:to="loc_srt_ConsolidatedEntitiesDomain_883" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_883_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_886" xlink:to="loc_srt_ConsolidatedEntitiesDomain_883_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SponsorMember" xlink:label="loc_hypr_SponsorMember_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_SponsorMember_899" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HealthCorCatalioAcquisitionCorpMember" xlink:label="loc_hypr_HealthCorCatalioAcquisitionCorpMember_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_HealthCorCatalioAcquisitionCorpMember_902" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ImmediatelyPriorToEffectiveTimeMember" xlink:label="loc_hypr_ImmediatelyPriorToEffectiveTimeMember_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_ImmediatelyPriorToEffectiveTimeMember_893" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HealthCorMember" xlink:label="loc_hypr_HealthCorMember_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_HealthCorMember_906" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_TypeOfArrangementAxis_888" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_888" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_888" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SubscriptionAgreementsMember" xlink:label="loc_hypr_SubscriptionAgreementsMember_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887" xlink:to="loc_hypr_SubscriptionAgreementsMember_894" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_884" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_884" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_884" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LegacyHyperfineMember" xlink:label="loc_hypr_LegacyHyperfineMember_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" xlink:to="loc_hypr_LegacyHyperfineMember_892" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PIPEInvestorsMember" xlink:label="loc_hypr_PIPEInvestorsMember_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" xlink:to="loc_hypr_PIPEInvestorsMember_904" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" xlink:to="loc_hypr_LiminalMember_898" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageOfCommonStockVotingPower" xlink:label="loc_hypr_PercentageOfCommonStockVotingPower_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PercentageOfCommonStockVotingPower_919" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xlink:label="loc_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination_920" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PaymentOfPaycheckProtectionProgramLoan" xlink:label="loc_hypr_PaymentOfPaycheckProtectionProgramLoan_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PaymentOfPaycheckProtectionProgramLoan_921" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xlink:label="loc_hypr_InterestAndPaymentsToRedeemingCompanyShareholders_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_InterestAndPaymentsToRedeemingCompanyShareholders_922" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ProceedsFromBusinessCombination" xlink:label="loc_hypr_ProceedsFromBusinessCombination_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_ProceedsFromBusinessCombination_923" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationPaymentOfTransactionCosts" xlink:label="loc_hypr_BusinessCombinationPaymentOfTransactionCosts_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_BusinessCombinationPaymentOfTransactionCosts_924" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_945" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_945" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_942" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_942" xlink:to="loc_srt_ProductOrServiceAxis_943" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_943" xlink:to="loc_srt_ProductsAndServicesDomain_944" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_944_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_943" xlink:to="loc_srt_ProductsAndServicesDomain_944_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944" xlink:to="loc_us-gaap_ProductMember_947" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944" xlink:to="loc_us-gaap_ServiceMember_949" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_942" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_946" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" xlink:to="loc_us-gaap_TransferredOverTimeMember_950" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_945" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_974" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" xlink:label="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum_976" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" xlink:label="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum_977" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_975" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_978" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaap_CapitalizedContractCostNet_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_CapitalizedContractCostNet_979" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_980" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_991" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_992" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_992" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_994" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:label="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage_995" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_996" use="optional" order="4" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1020" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1017" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1017" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1017" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1021" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1025" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1023" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1026" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1067" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_1078" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_EquipmentMember_1068" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchDevicesMember" xlink:label="loc_hypr_ResearchDevicesMember_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_hypr_ResearchDevicesMember_1070" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SalesAndMarketingDevicesMember" xlink:label="loc_hypr_SalesAndMarketingDevicesMember_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_hypr_SalesAndMarketingDevicesMember_1072" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_ComputerEquipmentMember_1073" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_ConstructionInProgressMember_1074" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_1075" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TradeShowAssetsMember" xlink:label="loc_hypr_TradeShowAssetsMember_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_hypr_TradeShowAssetsMember_1076" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1077" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1069" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1071" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NotesPayableAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1122" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1122" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_1126" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1122" xlink:to="loc_us-gaap_DebtInstrumentTable_1123" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1123" xlink:to="loc_us-gaap_DebtInstrumentAxis_1118" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1119" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1119_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1119_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PayrollProtectionProgramLoanMember" xlink:label="loc_hypr_PayrollProtectionProgramLoanMember_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1119" xlink:to="loc_hypr_PayrollProtectionProgramLoanMember_1124" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1123" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1120" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1120" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1121" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1121_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1120" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1121_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfinePayrollProtectionProgramLoanMember" xlink:label="loc_hypr_HyperfinePayrollProtectionProgramLoanMember_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1121" xlink:to="loc_hypr_HyperfinePayrollProtectionProgramLoanMember_1125" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalPayrollProtectionProgramLoanMember" xlink:label="loc_hypr_LiminalPayrollProtectionProgramLoanMember_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1121" xlink:to="loc_hypr_LiminalPayrollProtectionProgramLoanMember_1128" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1122" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1127" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1167" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1165" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1165" xlink:to="loc_us-gaap_ClassOfStockDomain_1164" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1164_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1165" xlink:to="loc_us-gaap_ClassOfStockDomain_1164_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1171" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalConvertiblePreferredStockMember" xlink:label="loc_hypr_LiminalConvertiblePreferredStockMember_1174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_LiminalConvertiblePreferredStockMember_1174" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1176" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1183" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesATwoConvertiblePreferredStockMember" xlink:label="loc_hypr_SeriesATwoConvertiblePreferredStockMember_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_SeriesATwoConvertiblePreferredStockMember_1188" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesBCAndDConvertiblePreferredStockMember" xlink:label="loc_hypr_SeriesBCAndDConvertiblePreferredStockMember_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_SeriesBCAndDConvertiblePreferredStockMember_1185" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesA1PreferredStockMember" xlink:label="loc_hypr_SeriesA1PreferredStockMember_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_SeriesA1PreferredStockMember_1186" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1162" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1162" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1162" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LegacyHyperfineMember" xlink:label="loc_hypr_LegacyHyperfineMember_1173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169" xlink:to="loc_hypr_LegacyHyperfineMember_1173" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAxis" xlink:label="loc_us-gaap_DividendsAxis_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_DividendsAxis_1168" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DividendsAxis_1168" xlink:to="loc_us-gaap_DividendsDomain_1163" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain_1163_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DividendsAxis_1168" xlink:to="loc_us-gaap_DividendsDomain_1163_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendDeclaredMember" xlink:label="loc_us-gaap_DividendDeclaredMember_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsDomain_1163" xlink:to="loc_us-gaap_DividendDeclaredMember_1170" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_1172" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1175" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationExchangeRatio" xlink:label="loc_hypr_BusinessCombinationExchangeRatio_1181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_hypr_BusinessCombinationExchangeRatio_1181" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1182" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingLiquidationPlan" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingLiquidationPlan_1177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingLiquidationPlan_1177" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfVotesPerShare" xlink:label="loc_hypr_NumberOfVotesPerShare_1178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_hypr_NumberOfVotesPerShare_1178" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1189" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1184" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_PreferredStockConversionBasis_1187" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1221" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquityYearOfClassIssuance" xlink:label="loc_hypr_TemporaryEquityYearOfClassIssuance_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_hypr_TemporaryEquityYearOfClassIssuance_1224" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1219" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1219" xlink:to="loc_us-gaap_ClassOfStockDomain_1220" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1220_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1219" xlink:to="loc_us-gaap_ClassOfStockDomain_1220_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1223" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1226" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1228" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1230" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" xlink:to="loc_srt_RangeAxis_1217" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1217" xlink:to="loc_srt_RangeMember_1218" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1218_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1217" xlink:to="loc_srt_RangeMember_1218_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1218" xlink:to="loc_srt_MinimumMember_1222" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1218" xlink:to="loc_srt_MaximumMember_1227" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1225" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1229" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1236" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1232" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1233" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1231" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquitySharesIssuanceCost" xlink:label="loc_hypr_TemporaryEquitySharesIssuanceCost_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_hypr_TemporaryEquitySharesIssuanceCost_1234" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1235" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1252" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1255" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1255" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1253" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1253" xlink:to="loc_us-gaap_ClassOfStockDomain_1254" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1254_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1253" xlink:to="loc_us-gaap_ClassOfStockDomain_1254_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1254" xlink:to="loc_us-gaap_CommonClassAMember_1257" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1254" xlink:to="loc_us-gaap_CommonClassBMember_1258" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1256" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1259" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1260" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_1261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_DividendsCommonStock_1261" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockNumberOfVotesPerShare" xlink:label="loc_hypr_CommonStockNumberOfVotesPerShare_1262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_hypr_CommonStockNumberOfVotesPerShare_1262" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_PlanNameAxis_1321" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1321" xlink:to="loc_us-gaap_PlanNameDomain_1318" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1318_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1321" xlink:to="loc_us-gaap_PlanNameDomain_1318_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember_1327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1318" xlink:to="loc_hypr_HyperfineEquityIncentivePlanMember_1327" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xlink:label="loc_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1318" xlink:to="loc_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember_1336" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1318" xlink:to="loc_hypr_LiminalMember_1331" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_srt_TitleOfIndividualAxis_1316" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1316" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1316" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" xlink:to="loc_srt_ChiefExecutiveOfficerMember_1330" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_1333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_1333" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1322" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1322" xlink:to="loc_us-gaap_ClassOfStockDomain_1323" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1323_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1322" xlink:to="loc_us-gaap_ClassOfStockDomain_1323_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1323" xlink:to="loc_us-gaap_CommonClassAMember_1329" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_AwardTypeAxis_1324" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1326" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncentiveUnitActivityMember" xlink:label="loc_hypr_IncentiveUnitActivityMember_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_IncentiveUnitActivityMember_1335" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xlink:label="loc_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember_1339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember_1339" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1334" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_EarnOutSharesMember_1341" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_StockOptionsOneMember" xlink:label="loc_hypr_StockOptionsOneMember_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_StockOptionsOneMember_1342" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_StockOptionsTwoMember" xlink:label="loc_hypr_StockOptionsTwoMember_1344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_StockOptionsTwoMember_1344" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xlink:label="loc_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember_1346" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xlink:label="loc_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember_1349" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ServiceAndPerformanceSharesMember" xlink:label="loc_hypr_ServiceAndPerformanceSharesMember_1350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_ServiceAndPerformanceSharesMember_1350" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ExchangeRatio" xlink:label="loc_hypr_ExchangeRatio_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_ExchangeRatio_1337" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1338" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1328" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockRemainsAvailableForIssuance" xlink:label="loc_hypr_CommonStockRemainsAvailableForIssuance_1332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_CommonStockRemainsAvailableForIssuance_1332" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1340" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1351" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1352" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSeparateOptionAwards" xlink:label="loc_hypr_NumberOfSeparateOptionAwards_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_NumberOfSeparateOptionAwards_1343" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1345" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_1347" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1348" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1353" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1364" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService_1354" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xlink:label="loc_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue_1355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue_1355" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1356" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1357" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1359" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1360" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1361" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1362" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1363" use="optional" order="52" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1406" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1411" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1417" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1424" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1425" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1420" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1407" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1412" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1415" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1423" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1426" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1419" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" xlink:to="loc_us-gaap_PlanNameAxis_1405" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1405" xlink:to="loc_us-gaap_PlanNameDomain_1403" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1403_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1405" xlink:to="loc_us-gaap_PlanNameDomain_1403_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember_1409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1403" xlink:to="loc_hypr_HyperfineEquityIncentivePlanMember_1409" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1408" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1414" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1418" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1410" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1413" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1416" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1451" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1455" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1456" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" xlink:to="loc_us-gaap_AwardTypeAxis_1446" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1452" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" xlink:to="loc_srt_RangeAxis_1449" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1449" xlink:to="loc_srt_RangeMember_1450" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1449" xlink:to="loc_srt_RangeMember_1450_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1450" xlink:to="loc_srt_MinimumMember_1453" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1450" xlink:to="loc_srt_MaximumMember_1454" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1457" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1458" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1474" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1480" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1474" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" xlink:to="loc_us-gaap_PlanNameAxis_1476" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1476" xlink:to="loc_us-gaap_PlanNameDomain_1477" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1477_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1476" xlink:to="loc_us-gaap_PlanNameDomain_1477_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember_1481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1477" xlink:to="loc_hypr_HyperfineEquityIncentivePlanMember_1481" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaap_GranteeStatusAxis_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" xlink:to="loc_us-gaap_GranteeStatusAxis_1478" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_1478" xlink:to="loc_us-gaap_GranteeStatusDomain_1473" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain_1473_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_1478" xlink:to="loc_us-gaap_GranteeStatusDomain_1473_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_1473" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1479" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_1473" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1482" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1505" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" xlink:to="loc_us-gaap_AwardTypeAxis_1499" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1499" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1499" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500" xlink:to="loc_hypr_EarnOutSharesMember_1502" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_SharePrice_1501" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1503" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1504" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1506" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1524" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1524" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1530" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1524" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" xlink:to="loc_srt_ProductOrServiceAxis_1526" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1526" xlink:to="loc_srt_ProductsAndServicesDomain_1525" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1526" xlink:to="loc_srt_ProductsAndServicesDomain_1525_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1525" xlink:to="loc_us-gaap_ProductMember_1531" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1525" xlink:to="loc_us-gaap_ServiceMember_1534" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1528" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1528" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1529" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1529_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1528" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1529_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1533" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_CostOfSalesMember_1532" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1535" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_1536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_1536" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1551" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1557" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1558" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_NetIncomeLoss_1555" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_StatementTable_1552" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1552" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1553" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1553" xlink:to="loc_us-gaap_EquityComponentDomain_1550" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1550_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1553" xlink:to="loc_us-gaap_EquityComponentDomain_1550_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1550" xlink:to="loc_us-gaap_CommonStockMember_1554" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1556" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1572" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1572" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1576" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1572" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1577" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember_1578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember_1578" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_us-gaap_RestrictedStockMember_1579" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember_1580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_hypr_EarnOutSharesMember_1580" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1640" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1640" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1641" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1641" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1641" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalNetOperatingLossMember" xlink:label="loc_hypr_FederalNetOperatingLossMember_1650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" xlink:to="loc_hypr_FederalNetOperatingLossMember_1650" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" xlink:to="loc_us-gaap_ResearchMember_1651" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalAndStateNetOperatingLossesMember" xlink:label="loc_hypr_FederalAndStateNetOperatingLossesMember_1647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" xlink:to="loc_hypr_FederalAndStateNetOperatingLossesMember_1647" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1640" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1643" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1643" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1642" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1642_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1643" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1642_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1642" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1646" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1652" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredTaxAssetsValuationAllowanceIncreased" xlink:label="loc_hypr_DeferredTaxAssetsValuationAllowanceIncreased_1653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_DeferredTaxAssetsValuationAllowanceIncreased_1653" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangePercentageTestingPeriod" xlink:label="loc_hypr_OwnershipChangePercentageTestingPeriod_1654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangePercentageTestingPeriod_1654" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1648" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1649" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangeDescription" xlink:label="loc_hypr_OwnershipChangeDescription_1655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangeDescription_1655" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1666" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfConsecutiveOwnershipChanges" xlink:label="loc_hypr_NumberOfConsecutiveOwnershipChanges_1656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_NumberOfConsecutiveOwnershipChanges_1656" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesDateOne" xlink:label="loc_hypr_OwnershipChangesDateOne_1657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangesDateOne_1657" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesDateTwo" xlink:label="loc_hypr_OwnershipChangesDateTwo_1658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangesDateTwo_1658" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xlink:label="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation_1659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation_1659" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xlink:label="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation_1660" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xlink:label="loc_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear_1661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear_1661" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1662" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncomeTaxEffectsRecognized" xlink:label="loc_hypr_IncomeTaxEffectsRecognized_1663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_IncomeTaxEffectsRecognized_1663" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xlink:label="loc_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards_1664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards_1664" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ExchangeProgramRecognizedNetBenefits" xlink:label="loc_hypr_ExchangeProgramRecognizedNetBenefits_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_ExchangeProgramRecognizedNetBenefits_1665" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_dei_LegalEntityAxis_1724" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1724" xlink:to="loc_dei_EntityDomain_1723" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1723_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1724" xlink:to="loc_dei_EntityDomain_1723_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineMember" xlink:label="loc_hypr_HyperfineMember_1732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1723" xlink:to="loc_hypr_HyperfineMember_1732" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_1737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1723" xlink:to="loc_hypr_LiminalMember_1737" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1725" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1725" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1722" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1722_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1725" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1722_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1722" xlink:to="loc_us-gaap_DomesticCountryMember_1731" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1722" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1739" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalOtherMember" xlink:label="loc_hypr_FederalOtherMember_1743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1722" xlink:to="loc_hypr_FederalOtherMember_1743" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1721" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1721" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1721" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" xlink:to="loc_us-gaap_ResearchMember_1734" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConnecticutResearchAndDevelopmentMember" xlink:label="loc_hypr_ConnecticutResearchAndDevelopmentMember_1736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" xlink:to="loc_hypr_ConnecticutResearchAndDevelopmentMember_1736" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConnecticutOthersMember" xlink:label="loc_hypr_ConnecticutOthersMember_1742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" xlink:to="loc_hypr_ConnecticutOthersMember_1742" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_TaxPeriodAxis_1729" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1729" xlink:to="loc_us-gaap_TaxPeriodDomain_1730" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1730_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1729" xlink:to="loc_us-gaap_TaxPeriodDomain_1730_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PreTwoThaousandEighteenMember" xlink:label="loc_hypr_PreTwoThaousandEighteenMember_1735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1730" xlink:to="loc_hypr_PreTwoThaousandEighteenMember_1735" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PostTwoThaousandSeventeenMember" xlink:label="loc_hypr_PostTwoThaousandSeventeenMember_1740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1730" xlink:to="loc_hypr_PostTwoThaousandSeventeenMember_1740" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1733" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TaxCreditCarryforwardBeginToExpirationYear" xlink:label="loc_hypr_TaxCreditCarryforwardBeginToExpirationYear_1744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_hypr_TaxCreditCarryforwardBeginToExpirationYear_1744" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OperatingLossCarryforwardsBeginToExpireYear" xlink:label="loc_hypr_OperatingLossCarryforwardsBeginToExpireYear_1738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_hypr_OperatingLossCarryforwardsBeginToExpireYear_1738" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1741" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1778" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RelatedPartyTransactionPaymentsForRent" xlink:label="loc_hypr_RelatedPartyTransactionPaymentsForRent_1786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_RelatedPartyTransactionPaymentsForRent_1786" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1794" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromEmployeesNoncurrent" xlink:label="loc_us-gaap_DueFromEmployeesNoncurrent_1796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_DueFromEmployeesNoncurrent_1796" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_1797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_1797" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DueFromEmployeesForgiveness" xlink:label="loc_hypr_DueFromEmployeesForgiveness_1798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_DueFromEmployeesForgiveness_1798" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" xlink:to="loc_us-gaap_RelatedPartyDomain_1780" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1780_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" xlink:to="loc_us-gaap_RelatedPartyDomain_1780_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CatalyzerCorporation4Member" xlink:label="loc_hypr_CatalyzerCorporation4Member_1787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_CatalyzerCorporation4Member_1787" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FourBionicsMember" xlink:label="loc_hypr_FourBionicsMember_1792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_FourBionicsMember_1792" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_1793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_LiminalMember_1793" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TechnologyAndServicesExchangeAgreementMember" xlink:label="loc_hypr_TechnologyAndServicesExchangeAgreementMember_1795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_TechnologyAndServicesExchangeAgreementMember_1795" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1781" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1781" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1782" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1782_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1781" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1782_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AllocationOfExpenseIncurredMember" xlink:label="loc_hypr_AllocationOfExpenseIncurredMember_1788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1782" xlink:to="loc_hypr_AllocationOfExpenseIncurredMember_1788" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xlink:label="loc_hypr_AmendedAndRestatedTechnologyServicesAgreementMember_1791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1782" xlink:to="loc_hypr_AmendedAndRestatedTechnologyServicesAgreementMember_1791" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1783" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1783" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1784" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1784_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1783" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1784_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1784" xlink:to="loc_us-gaap_SubsequentEventMember_1789" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSubsidiaries" xlink:label="loc_hypr_NumberOfSubsidiaries_1790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_NumberOfSubsidiaries_1790" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_InterestReceivableRelatedPartiesCurrent" xlink:label="loc_hypr_InterestReceivableRelatedPartiesCurrent_1799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_InterestReceivableRelatedPartiesCurrent_1799" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeRelatedParty" xlink:label="loc_us-gaap_InterestIncomeRelatedParty_1800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_InterestIncomeRelatedParty_1800" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OtherAssetsRelatedPartyNoncurrent" xlink:label="loc_hypr_OtherAssetsRelatedPartyNoncurrent_1801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_OtherAssetsRelatedPartyNoncurrent_1801" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidAdvancesUnrecoverable" xlink:label="loc_hypr_PrepaidAdvancesUnrecoverable_1802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_PrepaidAdvancesUnrecoverable_1802" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1803" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_1804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_1804" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_1805" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1806" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredGrantFundingCurrent" xlink:label="loc_hypr_DeferredGrantFundingCurrent_1827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_DeferredGrantFundingCurrent_1827" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_1826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_1826" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_1826" xlink:to="loc_srt_StatementScenarioAxis_1825" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1825" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1824" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1824_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1825" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1824_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1824" xlink:to="loc_srt_ScenarioForecastMember_1828" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSites" xlink:label="loc_hypr_NumberOfSites_1829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_NumberOfSites_1829" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwarded" xlink:label="loc_hypr_GrantAwarded_1830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_GrantAwarded_1830" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwardedForProvisionAndEquipping" xlink:label="loc_hypr_GrantAwardedForProvisionAndEquipping_1831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_GrantAwardedForProvisionAndEquipping_1831" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwardedForOtherRelatedDeliverables" xlink:label="loc_hypr_GrantAwardedForOtherRelatedDeliverables_1832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_GrantAwardedForOtherRelatedDeliverables_1832" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1834" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1Alternate">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_991" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_992" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:label="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage_995" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_996" use="optional" order="4" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>hypr-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-March-2022 [01:02:49] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_HyperfineConvertiblePreferredStockMember" xml:lang="en-US">Hyperfine Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_HyperfineConvertiblePreferredStockMember" xml:lang="en-US">Hyperfine Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_HyperfineConvertiblePreferredStockMember" xlink:to="lab_hypr_HyperfineConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_HyperfineConvertiblePreferredStockMember" xml:lang="en-US">Hyperfine convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Class A Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Class B Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredGrantFundingCurrent" xlink:label="loc_hypr_DeferredGrantFundingCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_DeferredGrantFundingCurrent" xml:lang="en-US">Deferred Grant Funding Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_DeferredGrantFundingCurrent" xml:lang="en-US">Deferred grant funding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_DeferredGrantFundingCurrent" xlink:to="lab_hypr_DeferredGrantFundingCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_DeferredGrantFundingCurrent" xml:lang="en-US">Represents the carrying amount of deferred grant funding as of balance sheet date, classified as current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_AccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_AccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_hypr_AccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_hypr_AccruedExpensesAndOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_AccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Long term notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Long term deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 16)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Hyperfine convertible preferred stock (Series A, B, C and D): $.0001 par value, aggregate liquidation preference of $0 and $147,651; 0 and 129,788,828 shares authorized; 0 and 95,010,858 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Net Carrying Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, less allowance of $32 and $0 in 2021 and 2020, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xml:lang="en-US">Unbilled Receivables, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xml:lang="en-US">Unbilled receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xml:lang="en-US">Due from Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xml:lang="en-US">Due from related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OtherAssetsRelatedPartyNoncurrent" xlink:label="loc_hypr_OtherAssetsRelatedPartyNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OtherAssetsRelatedPartyNoncurrent" xml:lang="en-US">Other Assets Related Party Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_hypr_OtherAssetsRelatedPartyNoncurrent" xml:lang="en-US">Other assets - related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OtherAssetsRelatedPartyNoncurrent" xml:lang="en-US">Prepaid advances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OtherAssetsRelatedPartyNoncurrent" xlink:to="lab_hypr_OtherAssetsRelatedPartyNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OtherAssetsRelatedPartyNoncurrent" xml:lang="en-US">Other assets related party noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other long term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for doubtful accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Convertible preferred stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Issuance Price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Convertible preferred stock, aggregate liquidation preference</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common shares, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Convertible preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common shares, par value, (per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common shares, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common shares, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Convertible preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Convertible preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Device</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServiceMember" xml:lang="en-US">Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServiceMember" xml:lang="en-US">Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross margin</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xml:lang="en-US">Cost of Goods and Services Sold [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Total cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share attributable to common stockholders, basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and dilutive loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Denominator for Basic and Dilutive EPS - Weighted-average common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalConvertiblePreferredStockMember" xlink:label="loc_hypr_LiminalConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_LiminalConvertiblePreferredStockMember" xml:lang="en-US">Liminal Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_LiminalConvertiblePreferredStockMember" xml:lang="en-US">Liminal Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_LiminalConvertiblePreferredStockMember" xlink:to="lab_hypr_LiminalConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_LiminalConvertiblePreferredStockMember" xml:lang="en-US">Liminal convertible preferred stock .</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series D convertible preferred stock, net of issuance costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary equity stock issued during period shares new issues.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xlink:label="loc_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xml:lang="en-US">Adjustments To Additional Paid In Capital Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xml:lang="en-US">Investment from 4Bionics, LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xlink:to="lab_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xml:lang="en-US">Adjustments to additional paid in capital investments.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConversionOfLiminalCommonStock" xlink:label="loc_hypr_ConversionOfLiminalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ConversionOfLiminalCommonStock" xml:lang="en-US">Conversion of Liminal Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ConversionOfLiminalCommonStock" xlink:to="lab_hypr_ConversionOfLiminalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ConversionOfLiminalCommonStock" xml:lang="en-US">Conversion of Liminal Common stock</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xlink:label="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xml:lang="en-US">Recapitalization Of Permanent To Temporary Equity Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xml:lang="en-US">Conversion of Liminal Common stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xlink:to="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xml:lang="en-US">Recapitalization of permanent to temporary equity shares.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xlink:label="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityValues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xml:lang="en-US">Recapitalization Of Permanent To Temporary Equity Values</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xml:lang="en-US">Conversion of Liminal Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xlink:to="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityValues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xml:lang="en-US">Recapitalization of permanent to temporary equity values.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares held by sponsor , irrevocably forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Series D convertible preferred stock, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Net equity infusion from the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Net equity infusion from the Business Combination (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Class A common stock to a service provider (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Liminal Common stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Cash proceeds from exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xml:lang="en-US">Proceeds from Issuance of Redeemable Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xml:lang="en-US">Proceeds from issuance of Series D convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Stock issuance costs related to Series D convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ProceedsFromBusinessCombination" xlink:label="loc_hypr_ProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ProceedsFromBusinessCombination" xml:lang="en-US">Proceeds From Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ProceedsFromBusinessCombination" xml:lang="en-US">Net proceeds from equity infusion from the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ProceedsFromBusinessCombination" xlink:to="lab_hypr_ProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ProceedsFromBusinessCombination" xml:lang="en-US">Proceeds from business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from issuance of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xml:lang="en-US">Investment from 4Bionics, LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xlink:label="loc_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xml:lang="en-US">Cash Received From Exchange Of Research And Development Tax Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xml:lang="en-US">Cash received from exchange of research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xlink:to="lab_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xml:lang="en-US">Cash received from exchange of research and development tax credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental disclosure of noncash information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Noncash acquisition of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xlink:label="loc_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xml:lang="en-US">Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xml:lang="en-US">Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xlink:to="lab_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xml:lang="en-US">Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UnbilledReceivables" xlink:label="loc_hypr_UnbilledReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_UnbilledReceivables" xml:lang="en-US">Unbilled Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_hypr_UnbilledReceivables" xml:lang="en-US">Unbilled receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_UnbilledReceivables" xlink:to="lab_hypr_UnbilledReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_UnbilledReceivables" xml:lang="en-US">Unbilled receivables</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xml:lang="en-US">Increase (Decrease) Due from Other Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xml:lang="en-US">Other assets - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidSupplies" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidSupplies" xml:lang="en-US">Prepaid inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidSupplies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xml:lang="en-US">Due from related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Deferred grant funding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Due to related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Inventory Write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Write-down of inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Inventory adjustments and excess and obsolete inventory charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentInLeasePurchase" xlink:label="loc_us-gaap_NetInvestmentInLeasePurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetInvestmentInLeasePurchase" xml:lang="en-US">Net Investment in Lease, Purchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetInvestmentInLeasePurchase" xml:lang="en-US">Payments received on net investment in lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentInLeasePurchase" xlink:to="lab_us-gaap_NetInvestmentInLeasePurchase" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_WriteOffOfOtherAssetsRelatedParty" xlink:label="loc_hypr_WriteOffOfOtherAssetsRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_WriteOffOfOtherAssetsRelatedParty" xml:lang="en-US">Write Off Of Other Assets Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_WriteOffOfOtherAssetsRelatedParty" xml:lang="en-US">Write-off of other assets - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_WriteOffOfOtherAssetsRelatedParty" xlink:to="lab_hypr_WriteOffOfOtherAssetsRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_WriteOffOfOtherAssetsRelatedParty" xml:lang="en-US">Write-off of other assets - related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="loc_us-gaap_SalesTypeLeaseSellingProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesTypeLeaseSellingProfitLoss" xml:lang="en-US">Sales-type Lease, Selling Profit (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SalesTypeLeaseSellingProfitLoss" xml:lang="en-US">Sales under sales type leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:to="lab_us-gaap_SalesTypeLeaseSellingProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net increase in cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">BUSINESS COMBINATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">REVENUE RECOGNITION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Long-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">NOTES PAYABLE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Preferred Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockTextBlock" xml:lang="en-US">CONVERTIBLE PREFERRED STOCK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">EQUITY INCENTIVE PLAN</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">NET LOSS PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Covid19OutbreakPolicyTextBlock" xlink:label="loc_hypr_Covid19OutbreakPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_Covid19OutbreakPolicyTextBlock" xml:lang="en-US">Covid 19 Outbreak [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_Covid19OutbreakPolicyTextBlock" xml:lang="en-US">COVID-19 Outbreak</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_Covid19OutbreakPolicyTextBlock" xlink:to="lab_hypr_Covid19OutbreakPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_Covid19OutbreakPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for Covid 19 outbreak.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="loc_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xml:lang="en-US">Prepaid Expenses And Other Current Assets Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="lab_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for prepaid expenses and other current assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xml:lang="en-US">Capitalized Software Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredRevenuePolicyPolicyTextBlock" xlink:label="loc_hypr_DeferredRevenuePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_DeferredRevenuePolicyPolicyTextBlock" xml:lang="en-US">Deferred Revenue Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_DeferredRevenuePolicyPolicyTextBlock" xml:lang="en-US">Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_DeferredRevenuePolicyPolicyTextBlock" xlink:to="lab_hypr_DeferredRevenuePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_DeferredRevenuePolicyPolicyTextBlock" xml:lang="en-US">Represents the Deferred revenue policy.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_WarrantiesPolicyTextBlock" xlink:label="loc_hypr_WarrantiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_WarrantiesPolicyTextBlock" xml:lang="en-US">Warranties Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_WarrantiesPolicyTextBlock" xml:lang="en-US">Warranties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_WarrantiesPolicyTextBlock" xlink:to="lab_hypr_WarrantiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_WarrantiesPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for warranties.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantFundingPolicyTextBlock" xlink:label="loc_hypr_GrantFundingPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_GrantFundingPolicyTextBlock" xml:lang="en-US">Grant Funding Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_GrantFundingPolicyTextBlock" xml:lang="en-US">Grant Funding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_GrantFundingPolicyTextBlock" xlink:to="lab_hypr_GrantFundingPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_GrantFundingPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for grant funding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PatentCostsPolicyTextBlock" xlink:label="loc_hypr_PatentCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PatentCostsPolicyTextBlock" xlink:to="lab_hypr_PatentCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PatentCostsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for patent costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Sales and Marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xml:lang="en-US">Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesPolicyTextBlock" xlink:label="loc_hypr_EarnOutSharesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_EarnOutSharesPolicyTextBlock" xml:lang="en-US">Earn Out Shares Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_EarnOutSharesPolicyTextBlock" xml:lang="en-US">Earn-Out Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_EarnOutSharesPolicyTextBlock" xlink:to="lab_hypr_EarnOutSharesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_EarnOutSharesPolicyTextBlock" xml:lang="en-US">Earn-Out shares.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xlink:label="loc_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xml:lang="en-US">Research And Development Tax Credits Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xml:lang="en-US">Research and Development Tax Credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xlink:to="lab_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for research and development tax credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedule of each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule Of Useful Lives For Property Plant And Equipment Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule of estimated useful lives of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule of useful lives for property, plant and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Summary of Disaggregated Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Information about Receivables and Deferred Revenue from Contracts with Customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="loc_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Accrued Expenses and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:to="lab_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xml:lang="en-US">Tabular disclosure for accrued liabilities and other current liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Temporary Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Summary of Authorized, Issued and Outstanding Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Assumptions Used to Value Option Grants to Employees and Nonemployees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" xlink:label="loc_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" xml:lang="en-US">Schedule Of Stock Options Granted To Employees And Nonemployees Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" xml:lang="en-US">Summary of Stock Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" xlink:to="lab_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" xml:lang="en-US">Schedule of stock options granted to employees and nonemployees.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" xlink:label="loc_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule Of Share Based Payment Award Earn Out Shares Valuation Assumptions Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" xml:lang="en-US">Key Assumptions Used in Valuation for Earn-Out Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" xlink:to="lab_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of share-based payment award, earn-out shares, valuation assumptions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Stock-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Anti-dilutive Common Equivalent Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets (Liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xml:lang="en-US">Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTable" xml:lang="en-US">Concentration Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerDMember" xlink:label="loc_hypr_CustomerDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerDMember" xml:lang="en-US">Customer D [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerDMember" xml:lang="en-US">Customer D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerDMember" xlink:to="lab_hypr_CustomerDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerDMember" xml:lang="en-US">Customer D.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerEMember" xlink:label="loc_hypr_CustomerEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerEMember" xml:lang="en-US">Customer E [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerEMember" xml:lang="en-US">Customer E</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerEMember" xlink:to="lab_hypr_CustomerEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerEMember" xml:lang="en-US">Customer E.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerFMember" xlink:label="loc_hypr_CustomerFMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerFMember" xml:lang="en-US">Customer F [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerFMember" xml:lang="en-US">Customer F</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerFMember" xlink:to="lab_hypr_CustomerFMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerFMember" xml:lang="en-US">Customer F.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerGMember" xlink:label="loc_hypr_CustomerGMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerGMember" xml:lang="en-US">Customer G [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerGMember" xml:lang="en-US">Customer G</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerGMember" xlink:to="lab_hypr_CustomerGMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerGMember" xml:lang="en-US">Customer G.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerHMember" xlink:label="loc_hypr_CustomerHMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerHMember" xml:lang="en-US">Customer H [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerHMember" xml:lang="en-US">Customer H</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerHMember" xlink:to="lab_hypr_CustomerHMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerHMember" xml:lang="en-US">Customer H.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerAMember" xlink:label="loc_hypr_CustomerAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerAMember" xml:lang="en-US">Customer A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerAMember" xml:lang="en-US">Customer A</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerAMember" xlink:to="lab_hypr_CustomerAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerAMember" xml:lang="en-US">Customer A.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerBMember" xlink:label="loc_hypr_CustomerBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerBMember" xml:lang="en-US">Customer B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerBMember" xml:lang="en-US">Customer B</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerBMember" xlink:to="lab_hypr_CustomerBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerBMember" xml:lang="en-US">Customer B.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerCMember" xlink:label="loc_hypr_CustomerCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CustomerCMember" xml:lang="en-US">Customer C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CustomerCMember" xml:lang="en-US">Customer C</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CustomerCMember" xlink:to="lab_hypr_CustomerCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CustomerCMember" xml:lang="en-US">Customer C.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xml:lang="en-US">Concentration Risk [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_hypr_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_hypr_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU" xlink:label="loc_country_AU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_AU" xml:lang="en-US">AUSTRALIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_AU" xml:lang="en-US">Australia</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_hypr_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reporting segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UncertainTaxPositions" xlink:label="loc_hypr_UncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_UncertainTaxPositions" xml:lang="en-US">Uncertain Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_UncertainTaxPositions" xml:lang="en-US">Uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_UncertainTaxPositions" xlink:to="lab_hypr_UncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_UncertainTaxPositions" xml:lang="en-US">Amount of uncertain tax positions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Revenue recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Revenue recognized that was included in the deferred revenue balance at the beginning of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Allowance for doubtful accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationMethod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationMethod" xml:lang="en-US">Capitalized Contract Cost, Amortization Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationMethod" xml:lang="en-US">Capitalized costs, amortization method</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationMethod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationMethod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xml:lang="en-US">Capitalized costs, amortization period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xml:lang="en-US">Capitalized Computer Software, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xml:lang="en-US">Capitalized internal-use software development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US">Stock option grants, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open Tax Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open tax year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in accounting principle, accounting standards update, adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adoption Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in accounting principle, accounting standards update, adoption date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in accounting principle, accounting standards update, immaterial effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xml:lang="en-US">Change in accounting principle, accounting standards update, early adoption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xml:lang="en-US">ASU 2020-06</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201815Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201815Member" xml:lang="en-US">Accounting Standards Update 2018-15 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201815Member" xml:lang="en-US">ASU No. 2018-15</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201815Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201815Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201912Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201912Member" xml:lang="en-US">Accounting Standards Update 2019-12 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201912Member" xml:lang="en-US">ASU 2019-12</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201912Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201912Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LaboratoryEquipmentMember" xlink:label="loc_hypr_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_LaboratoryEquipmentMember" xlink:to="lab_hypr_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_LaboratoryEquipmentMember" xml:lang="en-US">This member stands for laboratory equipment.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchDevicesMember" xlink:label="loc_hypr_ResearchDevicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ResearchDevicesMember" xml:lang="en-US">Research Devices [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ResearchDevicesMember" xml:lang="en-US">Research Devices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ResearchDevicesMember" xlink:to="lab_hypr_ResearchDevicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ResearchDevicesMember" xml:lang="en-US">Research devices.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SalesAndMarketingDevicesMember" xlink:label="loc_hypr_SalesAndMarketingDevicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SalesAndMarketingDevicesMember" xml:lang="en-US">Sales And Marketing Devices [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SalesAndMarketingDevicesMember" xml:lang="en-US">Sales and Marketing Devices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SalesAndMarketingDevicesMember" xlink:to="lab_hypr_SalesAndMarketingDevicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SalesAndMarketingDevicesMember" xml:lang="en-US">Sales and marketing devices.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xml:lang="en-US">Other Capitalized Property Plant and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LeasedDevicesMember" xlink:label="loc_hypr_LeasedDevicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_LeasedDevicesMember" xml:lang="en-US">Leased Devices [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_LeasedDevicesMember" xml:lang="en-US">Leased Devices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_LeasedDevicesMember" xlink:to="lab_hypr_LeasedDevicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_LeasedDevicesMember" xml:lang="en-US">This member stands for leased devices.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TradeShowAssetsMember" xlink:label="loc_hypr_TradeShowAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_TradeShowAssetsMember" xml:lang="en-US">Trade Show Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_TradeShowAssetsMember" xml:lang="en-US">Trade Show Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_TradeShowAssetsMember" xlink:to="lab_hypr_TradeShowAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_TradeShowAssetsMember" xml:lang="en-US">Trade show assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xml:lang="en-US">Tools, Dies and Molds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xml:lang="en-US">Tooling</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:to="lab_us-gaap_ToolsDiesAndMoldsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property Plant And Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule Of Business Acquisitions By Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ClassBOrdinarySharesMember" xlink:label="loc_hypr_ClassBOrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ClassBOrdinarySharesMember" xml:lang="en-US">Class B Ordinary Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ClassBOrdinarySharesMember" xml:lang="en-US">Class B Ordinary Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ClassBOrdinarySharesMember" xlink:to="lab_hypr_ClassBOrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ClassBOrdinarySharesMember" xml:lang="en-US">Class B ordinary shares.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ClassAOrdinarySharesMember" xlink:label="loc_hypr_ClassAOrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ClassAOrdinarySharesMember" xml:lang="en-US">Class A Ordinary Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ClassAOrdinarySharesMember" xml:lang="en-US">Class A Ordinary Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ClassAOrdinarySharesMember" xlink:to="lab_hypr_ClassAOrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ClassAOrdinarySharesMember" xml:lang="en-US">Class A ordinary shares.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesA1PreferredStockMember" xlink:label="loc_hypr_SeriesA1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SeriesA1PreferredStockMember" xml:lang="en-US">Series A-1 preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SeriesA1PreferredStockMember" xml:lang="en-US">Series A-1 Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SeriesA1PreferredStockMember" xlink:to="lab_hypr_SeriesA1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SeriesA1PreferredStockMember" xml:lang="en-US">Series A-1 preferred stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Dr. Rothberg</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SponsorMember" xlink:label="loc_hypr_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SponsorMember" xml:lang="en-US">Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SponsorMember" xlink:to="lab_hypr_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SponsorMember" xml:lang="en-US">Sponsor.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HealthCorCatalioAcquisitionCorpMember" xlink:label="loc_hypr_HealthCorCatalioAcquisitionCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_HealthCorCatalioAcquisitionCorpMember" xml:lang="en-US">Health Cor Catalio Acquisition Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_HealthCorCatalioAcquisitionCorpMember" xml:lang="en-US">HealthCor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_HealthCorCatalioAcquisitionCorpMember" xlink:to="lab_hypr_HealthCorCatalioAcquisitionCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_HealthCorCatalioAcquisitionCorpMember" xml:lang="en-US">HealthCor catalio acquisition corp.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ImmediatelyPriorToEffectiveTimeMember" xlink:label="loc_hypr_ImmediatelyPriorToEffectiveTimeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ImmediatelyPriorToEffectiveTimeMember" xml:lang="en-US">Immediately Prior To Effective Time [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ImmediatelyPriorToEffectiveTimeMember" xml:lang="en-US">Immediately Prior To Effective Time</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ImmediatelyPriorToEffectiveTimeMember" xlink:to="lab_hypr_ImmediatelyPriorToEffectiveTimeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ImmediatelyPriorToEffectiveTimeMember" xml:lang="en-US">Immediately prior to effective time.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HealthCorMember" xlink:label="loc_hypr_HealthCorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_HealthCorMember" xml:lang="en-US">Health Cor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_HealthCorMember" xml:lang="en-US">HealthCor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_HealthCorMember" xlink:to="lab_hypr_HealthCorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_HealthCorMember" xml:lang="en-US">HealthCor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SubscriptionAgreementsMember" xlink:label="loc_hypr_SubscriptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SubscriptionAgreementsMember" xml:lang="en-US">Subscription Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SubscriptionAgreementsMember" xml:lang="en-US">Subscription Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SubscriptionAgreementsMember" xlink:to="lab_hypr_SubscriptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SubscriptionAgreementsMember" xml:lang="en-US">Subscription agreements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business combination, shares issued as earn out consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationTransactionThresholdTradingDays" xlink:label="loc_hypr_BusinessCombinationTransactionThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_BusinessCombinationTransactionThresholdTradingDays" xml:lang="en-US">Business Combination Transaction Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_BusinessCombinationTransactionThresholdTradingDays" xml:lang="en-US">Business combination transaction threshold trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_BusinessCombinationTransactionThresholdTradingDays" xlink:to="lab_hypr_BusinessCombinationTransactionThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_BusinessCombinationTransactionThresholdTradingDays" xml:lang="en-US">Business combination transaction threshold trading days.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xlink:label="loc_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xml:lang="en-US">Business Combination Transaction Threshold Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xml:lang="en-US">Business combination transaction threshold consecutive trading days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xlink:to="lab_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xml:lang="en-US">Business combination transaction threshold consecutive trading days.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xlink:label="loc_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xml:lang="en-US">Number Of Votes Per Share Entitled To Class Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xml:lang="en-US">Number of votes per share entitled to class of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xlink:to="lab_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xml:lang="en-US">Number of votes per share entitled to class of common stock.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xlink:label="loc_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xml:lang="en-US">Percentage Number Of Shares Ceases To Beneficially Owned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xml:lang="en-US">Percentage number of shares ceases to beneficially owned</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xlink:to="lab_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xml:lang="en-US">Percentage number of shares ceases to beneficially owned.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Aggregate number of shares issued in transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockSubjectToRedemption" xlink:label="loc_hypr_CommonStockSubjectToRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CommonStockSubjectToRedemption" xml:lang="en-US">Common Stock Subject To Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CommonStockSubjectToRedemption" xml:lang="en-US">Common stock subject to redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CommonStockSubjectToRedemption" xlink:to="lab_hypr_CommonStockSubjectToRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CommonStockSubjectToRedemption" xml:lang="en-US">Common stock subject to redemption.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stock split, conversion ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageOfCommonStockVotingPower" xlink:label="loc_hypr_PercentageOfCommonStockVotingPower" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PercentageOfCommonStockVotingPower" xml:lang="en-US">Percentage Of Common Stock Voting Power</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PercentageOfCommonStockVotingPower" xml:lang="en-US">Percentage of common stock voting power</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PercentageOfCommonStockVotingPower" xlink:to="lab_hypr_PercentageOfCommonStockVotingPower" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PercentageOfCommonStockVotingPower" xml:lang="en-US">Percentage of common stock voting power.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xlink:label="loc_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xml:lang="en-US">Prepaid Insurance Policy in Connection With Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xml:lang="en-US">Prepaid directors and officers insurance policy in connection with closing of business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xlink:to="lab_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xml:lang="en-US">Prepaid insurance policy in connection with business combination.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PaymentOfPaycheckProtectionProgramLoan" xlink:label="loc_hypr_PaymentOfPaycheckProtectionProgramLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PaymentOfPaycheckProtectionProgramLoan" xml:lang="en-US">Payment Of Paycheck Protection Program Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PaymentOfPaycheckProtectionProgramLoan" xml:lang="en-US">Payment of paycheck protection program loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PaymentOfPaycheckProtectionProgramLoan" xlink:to="lab_hypr_PaymentOfPaycheckProtectionProgramLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PaymentOfPaycheckProtectionProgramLoan" xml:lang="en-US">Payment of paycheck protection program loan.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xlink:label="loc_hypr_InterestAndPaymentsToRedeemingCompanyShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xml:lang="en-US">Interest And Payments To Redeeming Company Shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xml:lang="en-US">Interest and payments to redeeming company shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xlink:to="lab_hypr_InterestAndPaymentsToRedeemingCompanyShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xml:lang="en-US">Interest and payments to redeeming company shareholders.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationPaymentOfTransactionCosts" xlink:label="loc_hypr_BusinessCombinationPaymentOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_BusinessCombinationPaymentOfTransactionCosts" xml:lang="en-US">Business Combination Payment of Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_BusinessCombinationPaymentOfTransactionCosts" xml:lang="en-US">Payment of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_BusinessCombinationPaymentOfTransactionCosts" xlink:to="lab_hypr_BusinessCombinationPaymentOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_BusinessCombinationPaymentOfTransactionCosts" xml:lang="en-US">Business combination payment of transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LegacyHyperfineMember" xlink:label="loc_hypr_LegacyHyperfineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_LegacyHyperfineMember" xml:lang="en-US">Legacy Hyperfine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_LegacyHyperfineMember" xml:lang="en-US">Legacy Hyperfine</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_LegacyHyperfineMember" xlink:to="lab_hypr_LegacyHyperfineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_LegacyHyperfineMember" xml:lang="en-US">Legacy hyperfine.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PIPEInvestorsMember" xlink:label="loc_hypr_PIPEInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PIPEInvestorsMember" xml:lang="en-US">P I P E Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PIPEInvestorsMember" xml:lang="en-US">PIPE Investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PIPEInvestorsMember" xlink:to="lab_hypr_PIPEInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PIPEInvestorsMember" xml:lang="en-US">PIPE investors.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_LiminalMember" xml:lang="en-US">Liminal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_hypr_LiminalMember" xml:lang="en-US">Liminal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_LiminalMember" xlink:to="lab_hypr_LiminalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_LiminalMember" xml:lang="en-US">Liminal.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation Of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation Of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xml:lang="en-US">Timing of Transfer of Good or Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xml:lang="en-US">Timing of Transfer of Good or Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xml:lang="en-US">Transferred at Point in Time [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xml:lang="en-US">Point In Time</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransferredOverTimeMember" xml:lang="en-US">Transferred over Time [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransferredOverTimeMember" xml:lang="en-US">Over Time</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" xlink:label="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" xml:lang="en-US">Payment terms range, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" xlink:to="lab_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" xml:lang="en-US">The minimum payment term agreed upon with the respective customer.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" xlink:label="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" xml:lang="en-US">Payment terms range, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" xlink:to="lab_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" xml:lang="en-US">The maximum payment term agreed upon with the respective customer.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaap_CapitalizedContractCostNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xml:lang="en-US">Capitalized Contract Cost, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xml:lang="en-US">Capitalized contract cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Remaining performance obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:label="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xml:lang="en-US">Remaining performance obligation expected to be recognized, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:to="lab_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xml:lang="en-US">Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xml:lang="en-US">Remaining performance obligation expected to be recognized, duration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair value liabilities transfers, Level 2 to Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="lab_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair value asset transfers, Level 2 to Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Laboratory Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction In Progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leased Devices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued Bonuses, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Bonus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedContractedServicesCurrent" xlink:label="loc_hypr_AccruedContractedServicesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_AccruedContractedServicesCurrent" xml:lang="en-US">Accrued Contracted Services Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_AccruedContractedServicesCurrent" xml:lang="en-US">Contracted services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_AccruedContractedServicesCurrent" xlink:to="lab_hypr_AccruedContractedServicesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_AccruedContractedServicesCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for contracted services.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedBonusAndOtherCostsCurrent" xlink:label="loc_hypr_AccruedBonusAndOtherCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_AccruedBonusAndOtherCostsCurrent" xml:lang="en-US">Accrued Bonus and Other Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_AccruedBonusAndOtherCostsCurrent" xml:lang="en-US">SPAC bonus and other costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_AccruedBonusAndOtherCostsCurrent" xlink:to="lab_hypr_AccruedBonusAndOtherCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_AccruedBonusAndOtherCostsCurrent" xml:lang="en-US">Accrued bonus and other costs current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Legal fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Payroll and related benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Debt Instrument [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PayrollProtectionProgramLoanMember" xlink:label="loc_hypr_PayrollProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PayrollProtectionProgramLoanMember" xml:lang="en-US">Payroll Protection Program Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PayrollProtectionProgramLoanMember" xml:lang="en-US">Payroll Protection Program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PayrollProtectionProgramLoanMember" xlink:to="lab_hypr_PayrollProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PayrollProtectionProgramLoanMember" xml:lang="en-US">Payroll protection program loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfinePayrollProtectionProgramLoanMember" xlink:label="loc_hypr_HyperfinePayrollProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_HyperfinePayrollProtectionProgramLoanMember" xml:lang="en-US">Hyperfine Payroll Protection Program Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_HyperfinePayrollProtectionProgramLoanMember" xml:lang="en-US">Hyperfine PPP loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_HyperfinePayrollProtectionProgramLoanMember" xlink:to="lab_hypr_HyperfinePayrollProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_HyperfinePayrollProtectionProgramLoanMember" xml:lang="en-US">Hyperfine payroll protection program loan.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalPayrollProtectionProgramLoanMember" xlink:label="loc_hypr_LiminalPayrollProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_LiminalPayrollProtectionProgramLoanMember" xml:lang="en-US">Liminal Payroll Protection Program Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_LiminalPayrollProtectionProgramLoanMember" xml:lang="en-US">Liminal PPP loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_LiminalPayrollProtectionProgramLoanMember" xlink:to="lab_hypr_LiminalPayrollProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_LiminalPayrollProtectionProgramLoanMember" xml:lang="en-US">Liminal payroll protection program loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Amount of note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity By Class Of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_us-gaap_SeriesDPreferredStockMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesATwoConvertiblePreferredStockMember" xlink:label="loc_hypr_SeriesATwoConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SeriesATwoConvertiblePreferredStockMember" xml:lang="en-US">Series A-Two Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SeriesATwoConvertiblePreferredStockMember" xml:lang="en-US">Series A-2 Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SeriesATwoConvertiblePreferredStockMember" xlink:to="lab_hypr_SeriesATwoConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SeriesATwoConvertiblePreferredStockMember" xml:lang="en-US">Series A-two convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesBCAndDConvertiblePreferredStockMember" xlink:label="loc_hypr_SeriesBCAndDConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_SeriesBCAndDConvertiblePreferredStockMember" xml:lang="en-US">Series B, C and D Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_SeriesBCAndDConvertiblePreferredStockMember" xml:lang="en-US">Series B, C and D Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_SeriesBCAndDConvertiblePreferredStockMember" xlink:to="lab_hypr_SeriesBCAndDConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_SeriesBCAndDConvertiblePreferredStockMember" xml:lang="en-US">Series B, C and D convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Convertible preferred stock dividend rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xml:lang="en-US">Dividends Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationExchangeRatio" xlink:label="loc_hypr_BusinessCombinationExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_BusinessCombinationExchangeRatio" xml:lang="en-US">Business Combination Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_BusinessCombinationExchangeRatio" xml:lang="en-US">Exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_BusinessCombinationExchangeRatio" xlink:to="lab_hypr_BusinessCombinationExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_BusinessCombinationExchangeRatio" xml:lang="en-US">Business combination, exchange ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingLiquidationPlan" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingLiquidationPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingLiquidationPlan" xml:lang="en-US">Liquidation Basis of Accounting, Liquidation Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingLiquidationPlan" xml:lang="en-US">Liquidation rights, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingLiquidationPlan" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingLiquidationPlan" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfVotesPerShare" xlink:label="loc_hypr_NumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NumberOfVotesPerShare" xml:lang="en-US">Number Of Votes Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_NumberOfVotesPerShare" xml:lang="en-US">Number of votes per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NumberOfVotesPerShare" xlink:to="lab_hypr_NumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NumberOfVotesPerShare" xml:lang="en-US">Number of votes per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Aggregate gross proceeds of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Convertible preferred stock, conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis" xlink:to="lab_us-gaap_PreferredStockConversionBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAxis" xlink:label="loc_us-gaap_DividendsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsAxis" xml:lang="en-US">Dividends [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAxis" xlink:to="lab_us-gaap_DividendsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsDomain" xml:lang="en-US">Dividends [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDomain" xlink:to="lab_us-gaap_DividendsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendDeclaredMember" xlink:label="loc_us-gaap_DividendDeclaredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendDeclaredMember" xml:lang="en-US">Dividend Declared [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendDeclaredMember" xml:lang="en-US">Dividend Declared</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendDeclaredMember" xlink:to="lab_us-gaap_DividendDeclaredMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquityYearOfClassIssuance" xlink:label="loc_hypr_TemporaryEquityYearOfClassIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_TemporaryEquityYearOfClassIssuance" xml:lang="en-US">Temporary Equity Year Of Class Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_TemporaryEquityYearOfClassIssuance" xml:lang="en-US">Year of Class Issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_TemporaryEquityYearOfClassIssuance" xlink:to="lab_hypr_TemporaryEquityYearOfClassIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_TemporaryEquityYearOfClassIssuance" xml:lang="en-US">Temporary equity, year of class issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xml:lang="en-US">Initial Liquidation Price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Total Proceeds or Exchange Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquitySharesIssuanceCost" xlink:label="loc_hypr_TemporaryEquitySharesIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_TemporaryEquitySharesIssuanceCost" xml:lang="en-US">Temporary Equity Shares Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_TemporaryEquitySharesIssuanceCost" xml:lang="en-US">Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_TemporaryEquitySharesIssuanceCost" xlink:to="lab_hypr_TemporaryEquitySharesIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_TemporaryEquitySharesIssuanceCost" xml:lang="en-US">Temporary equity, shares, issuance cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class Of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends declared common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockNumberOfVotesPerShare" xlink:label="loc_hypr_CommonStockNumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CommonStockNumberOfVotesPerShare" xml:lang="en-US">Common Stock Number Of Votes Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CommonStockNumberOfVotesPerShare" xml:lang="en-US">Common shares, votes per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CommonStockNumberOfVotesPerShare" xlink:to="lab_hypr_CommonStockNumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CommonStockNumberOfVotesPerShare" xml:lang="en-US">Common stock number of votes per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_HyperfineEquityIncentivePlanMember" xml:lang="en-US">Hyperfine Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_hypr_HyperfineEquityIncentivePlanMember" xml:lang="en-US">Hyperfine Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_HyperfineEquityIncentivePlanMember" xlink:to="lab_hypr_HyperfineEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_HyperfineEquityIncentivePlanMember" xml:lang="en-US">This member stands for Hyperfine equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xlink:label="loc_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xml:lang="en-US">Four Bionics Two Thousand Nineteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xml:lang="en-US">4Bionics Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xlink:to="lab_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xml:lang="en-US">Four Bionics 2019 Equity Incentive Plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xml:lang="en-US">Executive Chairman</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ExchangeRatio" xlink:label="loc_hypr_ExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ExchangeRatio" xml:lang="en-US">Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ExchangeRatio" xml:lang="en-US">Exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ExchangeRatio" xlink:to="lab_hypr_ExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ExchangeRatio" xml:lang="en-US">Exchange ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Option award to purchase shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock, capital shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockRemainsAvailableForIssuance" xlink:label="loc_hypr_CommonStockRemainsAvailableForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CommonStockRemainsAvailableForIssuance" xml:lang="en-US">Common Stock Remains Available For Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CommonStockRemainsAvailableForIssuance" xml:lang="en-US">Common stock remain available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CommonStockRemainsAvailableForIssuance" xlink:to="lab_hypr_CommonStockRemainsAvailableForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CommonStockRemainsAvailableForIssuance" xml:lang="en-US">Common stock remains available for issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value of stock options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSeparateOptionAwards" xlink:label="loc_hypr_NumberOfSeparateOptionAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NumberOfSeparateOptionAwards" xml:lang="en-US">Number Of Separate Option Awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_NumberOfSeparateOptionAwards" xml:lang="en-US">Number of separate option awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NumberOfSeparateOptionAwards" xlink:to="lab_hypr_NumberOfSeparateOptionAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NumberOfSeparateOptionAwards" xml:lang="en-US">Number of separate option awards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Granted value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected annual equity volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Remaining vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Repurchase Right Valid Period Commencing With Date Of Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xml:lang="en-US">Repurchase right valid period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xlink:to="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award repurchase right valid period commencing with date of service.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xlink:label="loc_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xml:lang="en-US">Share Based Payment Arrangement Plan Modification Incremental Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xml:lang="en-US">Incremental value as a result of the modification of the awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xlink:to="lab_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xml:lang="en-US">Share based payment arrangement plan modification incremental value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Incremental Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xml:lang="en-US">Incremental compensation expense recognized as a result of the modification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Restricted stock units ("RSU") granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Grant date fair value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Total grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US">Total grant date fair value recognized period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Number of shares entitle to certain employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Total unrecognized stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Outstanding Options to Purchase Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncentiveUnitActivityMember" xlink:label="loc_hypr_IncentiveUnitActivityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_IncentiveUnitActivityMember" xml:lang="en-US">Incentive Unit Activity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_IncentiveUnitActivityMember" xml:lang="en-US">Incentive Unit Grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_IncentiveUnitActivityMember" xlink:to="lab_hypr_IncentiveUnitActivityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_IncentiveUnitActivityMember" xml:lang="en-US">Incentive unit activity.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xlink:label="loc_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xml:lang="en-US">Incentive Unit Awards And Replacement Preferred Stock Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xml:lang="en-US">Incentive Unit Awards and Replacement Preferred Stock Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xlink:to="lab_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xml:lang="en-US">Incentive unit awards and replacement preferred stock awards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_EarnOutSharesMember" xml:lang="en-US">Earn Out Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_EarnOutSharesMember" xml:lang="en-US">Earn-Out Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_EarnOutSharesMember" xlink:to="lab_hypr_EarnOutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_EarnOutSharesMember" xml:lang="en-US">Earn-Out Shares.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_StockOptionsOneMember" xlink:label="loc_hypr_StockOptionsOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_StockOptionsOneMember" xml:lang="en-US">Stock Options One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_StockOptionsOneMember" xml:lang="en-US">Stock Options One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_StockOptionsOneMember" xlink:to="lab_hypr_StockOptionsOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_StockOptionsOneMember" xml:lang="en-US">Stock options one.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_StockOptionsTwoMember" xlink:label="loc_hypr_StockOptionsTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_StockOptionsTwoMember" xml:lang="en-US">Stock Options Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_StockOptionsTwoMember" xml:lang="en-US">Stock Options Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_StockOptionsTwoMember" xlink:to="lab_hypr_StockOptionsTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_StockOptionsTwoMember" xml:lang="en-US">Stock options two.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xlink:label="loc_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xml:lang="en-US">Share Based Payment Arrangement Two Separate Option Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xml:lang="en-US">Two Separate Option Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xlink:to="lab_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xml:lang="en-US">Share based payment arrangement two separate option awards.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xlink:label="loc_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xml:lang="en-US">Share Based Payment Arrangement Separate Option Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xml:lang="en-US">Separate Option Award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xlink:to="lab_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xml:lang="en-US">Share based payment arrangement separate option awards.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ServiceAndPerformanceSharesMember" xlink:label="loc_hypr_ServiceAndPerformanceSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ServiceAndPerformanceSharesMember" xml:lang="en-US">Service And Performance Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ServiceAndPerformanceSharesMember" xml:lang="en-US">Service and Performance Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ServiceAndPerformanceSharesMember" xlink:to="lab_hypr_ServiceAndPerformanceSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ServiceAndPerformanceSharesMember" xml:lang="en-US">Service and performance shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value Rollforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xml:lang="en-US">Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:to="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Rollforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xml:lang="en-US">Weighted Average Remaining Contractual Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xlink:to="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk Free interest rate, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk Free interest rate, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaap_GranteeStatusAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GranteeStatusAxis" xml:lang="en-US">Grantee Status [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GranteeStatusAxis" xml:lang="en-US">Grantee Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GranteeStatusDomain" xml:lang="en-US">Grantee Status [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GranteeStatusDomain" xml:lang="en-US">Grantee Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xml:lang="en-US">Employee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xml:lang="en-US">Nonemployee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk Free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost of Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost Of Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xml:lang="en-US">Sales and Marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Numerator for Basic and Dilutive EPS &#8211; Loss available to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Total anti-dilutive common equivalent shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xml:lang="en-US">Outstanding Legacy Hyperfine Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xml:lang="en-US">Outstanding Legacy Hyperfine Convertible Preferred Stock (Series A through D)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xlink:to="lab_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xml:lang="en-US">Outstanding legacy hyperfine convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Outstanding RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets (liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accrued bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalNetOperatingLossMember" xlink:label="loc_hypr_FederalNetOperatingLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_FederalNetOperatingLossMember" xml:lang="en-US">Federal Net Operating Loss [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_FederalNetOperatingLossMember" xml:lang="en-US">Federal Net Operating Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_FederalNetOperatingLossMember" xlink:to="lab_hypr_FederalNetOperatingLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_FederalNetOperatingLossMember" xml:lang="en-US">Federal Net Operating Loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Federal Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalAndStateNetOperatingLossesMember" xlink:label="loc_hypr_FederalAndStateNetOperatingLossesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_FederalAndStateNetOperatingLossesMember" xml:lang="en-US">Federal and state net operating losses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_FederalAndStateNetOperatingLossesMember" xml:lang="en-US">Federal And State Net Operating Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_FederalAndStateNetOperatingLossesMember" xlink:to="lab_hypr_FederalAndStateNetOperatingLossesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_FederalAndStateNetOperatingLossesMember" xml:lang="en-US">Federal and state net operating losses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredTaxAssetsValuationAllowanceIncreased" xlink:label="loc_hypr_DeferredTaxAssetsValuationAllowanceIncreased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_DeferredTaxAssetsValuationAllowanceIncreased" xml:lang="en-US">Deferred Tax Assets Valuation Allowance Increased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_DeferredTaxAssetsValuationAllowanceIncreased" xml:lang="en-US">Deferred tax assets valuation allowance increased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_DeferredTaxAssetsValuationAllowanceIncreased" xlink:to="lab_hypr_DeferredTaxAssetsValuationAllowanceIncreased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_DeferredTaxAssetsValuationAllowanceIncreased" xml:lang="en-US">Deferred tax assets valuation allowance increased.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangePercentageTestingPeriod" xlink:label="loc_hypr_OwnershipChangePercentageTestingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OwnershipChangePercentageTestingPeriod" xml:lang="en-US">Ownership Change percentage testing period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OwnershipChangePercentageTestingPeriod" xml:lang="en-US">Ownership change percentage testing period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OwnershipChangePercentageTestingPeriod" xlink:to="lab_hypr_OwnershipChangePercentageTestingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OwnershipChangePercentageTestingPeriod" xml:lang="en-US">Ownership Change percentage testing period</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangeDescription" xlink:label="loc_hypr_OwnershipChangeDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OwnershipChangeDescription" xml:lang="en-US">Ownership Change description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OwnershipChangeDescription" xml:lang="en-US">Ownership change, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OwnershipChangeDescription" xlink:to="lab_hypr_OwnershipChangeDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OwnershipChangeDescription" xml:lang="en-US">Ownership Change description</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Research and development tax credit receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfConsecutiveOwnershipChanges" xlink:label="loc_hypr_NumberOfConsecutiveOwnershipChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NumberOfConsecutiveOwnershipChanges" xml:lang="en-US">Number of consecutive ownership changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NumberOfConsecutiveOwnershipChanges" xlink:to="lab_hypr_NumberOfConsecutiveOwnershipChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NumberOfConsecutiveOwnershipChanges" xml:lang="en-US">Number of consecutive ownership changes.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesDateOne" xlink:label="loc_hypr_OwnershipChangesDateOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OwnershipChangesDateOne" xml:lang="en-US">Ownership changes Date one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OwnershipChangesDateOne" xml:lang="en-US">Ownership changes date, one</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OwnershipChangesDateOne" xlink:to="lab_hypr_OwnershipChangesDateOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OwnershipChangesDateOne" xml:lang="en-US">Ownership changes Date one</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesDateTwo" xlink:label="loc_hypr_OwnershipChangesDateTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OwnershipChangesDateTwo" xml:lang="en-US">Ownership changes Date two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OwnershipChangesDateTwo" xml:lang="en-US">Ownership changes date, two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OwnershipChangesDateTwo" xlink:to="lab_hypr_OwnershipChangesDateTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OwnershipChangesDateTwo" xml:lang="en-US">Ownership changes Date two</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xlink:label="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xml:lang="en-US">Net Operating Loss And Tax Credit Carry forwards Annual Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xml:lang="en-US">Amount of annual limitation of net operating loss and tax credit carryforwards due to ownership change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xlink:to="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xml:lang="en-US">The amount of annual limitation of net operating loss and tax credit carryforwards due to ownership change, Under Internal Revenue Code Section 382.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xlink:label="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xml:lang="en-US">Net Operating Loss And Tax Credit Carry forwards Will Expire Estimation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xml:lang="en-US">Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xlink:to="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xml:lang="en-US">Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change, under Internal Revenue Code Section 382.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xlink:label="loc_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xml:lang="en-US">Ownership changes analysis expected to be completed year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xml:lang="en-US">Ownership changes analysis expected to be completed year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xlink:to="lab_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xml:lang="en-US">Ownership changes analysis expected to be completed year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncomeTaxEffectsRecognized" xlink:label="loc_hypr_IncomeTaxEffectsRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_IncomeTaxEffectsRecognized" xml:lang="en-US">Income tax Effects Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_IncomeTaxEffectsRecognized" xml:lang="en-US">Income tax effects recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_IncomeTaxEffectsRecognized" xlink:to="lab_hypr_IncomeTaxEffectsRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_IncomeTaxEffectsRecognized" xml:lang="en-US">Income tax effects recognized.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xlink:label="loc_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xml:lang="en-US">Percentage of Cash Payment in Research and Development Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xml:lang="en-US">Percentage of cash payment in research and development tax credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xlink:to="lab_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xml:lang="en-US">Percentage of cash payment in research and development tax credit carryforwards.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ExchangeProgramRecognizedNetBenefits" xlink:label="loc_hypr_ExchangeProgramRecognizedNetBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ExchangeProgramRecognizedNetBenefits" xml:lang="en-US">Exchange program Recognized Net Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ExchangeProgramRecognizedNetBenefits" xml:lang="en-US">Exchange program recognized net benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ExchangeProgramRecognizedNetBenefits" xlink:to="lab_hypr_ExchangeProgramRecognizedNetBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ExchangeProgramRecognizedNetBenefits" xml:lang="en-US">Exchange program recognized net benefits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State taxes, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Federal research and development credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" xlink:label="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" xml:lang="en-US">Write down of federal NOL due to 382 limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" xlink:to="lab_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationWriteDownOfFederalNolDueTo382Limitation</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" xlink:label="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" xml:lang="en-US">Write down of federal R&amp;D credits due to 382 limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" xlink:to="lab_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationWriteDownOfFederalResearchAndDevelopmentCreditsDueTo382Limitation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Deferred tax adjustment resulting from tax rate change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineMember" xlink:label="loc_hypr_HyperfineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_HyperfineMember" xml:lang="en-US">Hyperfine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_HyperfineMember" xml:lang="en-US">Hyperfine</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_HyperfineMember" xlink:to="lab_hypr_HyperfineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_HyperfineMember" xml:lang="en-US">Hyperfine.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalOtherMember" xlink:label="loc_hypr_FederalOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_FederalOtherMember" xml:lang="en-US">Federal Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_FederalOtherMember" xml:lang="en-US">Federal Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_FederalOtherMember" xlink:to="lab_hypr_FederalOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_FederalOtherMember" xml:lang="en-US">Federal other.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Tax net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TaxCreditCarryforwardBeginToExpirationYear" xlink:label="loc_hypr_TaxCreditCarryforwardBeginToExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_TaxCreditCarryforwardBeginToExpirationYear" xml:lang="en-US">Tax Credit Carryforward Begin to Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_TaxCreditCarryforwardBeginToExpirationYear" xml:lang="en-US">Begin to Expire in</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_TaxCreditCarryforwardBeginToExpirationYear" xlink:to="lab_hypr_TaxCreditCarryforwardBeginToExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_TaxCreditCarryforwardBeginToExpirationYear" xml:lang="en-US">Tax credit carryforward begin to expiration year.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OperatingLossCarryforwardsBeginToExpireYear" xlink:label="loc_hypr_OperatingLossCarryforwardsBeginToExpireYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_OperatingLossCarryforwardsBeginToExpireYear" xml:lang="en-US">Operating Loss Carryforwards Begin to Expire Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_OperatingLossCarryforwardsBeginToExpireYear" xml:lang="en-US">Begin to Expire in</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_OperatingLossCarryforwardsBeginToExpireYear" xlink:to="lab_hypr_OperatingLossCarryforwardsBeginToExpireYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_OperatingLossCarryforwardsBeginToExpireYear" xml:lang="en-US">Operating loss carryforwards begin to expire year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConnecticutResearchAndDevelopmentMember" xlink:label="loc_hypr_ConnecticutResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ConnecticutResearchAndDevelopmentMember" xml:lang="en-US">Connecticut Research and Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ConnecticutResearchAndDevelopmentMember" xml:lang="en-US">Connecticut Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ConnecticutResearchAndDevelopmentMember" xlink:to="lab_hypr_ConnecticutResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ConnecticutResearchAndDevelopmentMember" xml:lang="en-US">Connecticut research and development.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConnecticutOthersMember" xlink:label="loc_hypr_ConnecticutOthersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_ConnecticutOthersMember" xml:lang="en-US">Connecticut Others [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_ConnecticutOthersMember" xml:lang="en-US">Connecticut Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_ConnecticutOthersMember" xlink:to="lab_hypr_ConnecticutOthersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_ConnecticutOthersMember" xml:lang="en-US">Connecticut others.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PreTwoThaousandEighteenMember" xlink:label="loc_hypr_PreTwoThaousandEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PreTwoThaousandEighteenMember" xml:lang="en-US">Pre Two Thaousand Eighteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PreTwoThaousandEighteenMember" xml:lang="en-US">Pre-2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PreTwoThaousandEighteenMember" xlink:to="lab_hypr_PreTwoThaousandEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PreTwoThaousandEighteenMember" xml:lang="en-US">Pre two thaousand eighteen.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PostTwoThaousandSeventeenMember" xlink:label="loc_hypr_PostTwoThaousandSeventeenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PostTwoThaousandSeventeenMember" xml:lang="en-US">Post Two Thaousand Seventeen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PostTwoThaousandSeventeenMember" xml:lang="en-US">Post-2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PostTwoThaousandSeventeenMember" xlink:to="lab_hypr_PostTwoThaousandSeventeenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PostTwoThaousandSeventeenMember" xml:lang="en-US">Post two thaousand seventeen.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RelatedPartyTransactionPaymentsForRent" xlink:label="loc_hypr_RelatedPartyTransactionPaymentsForRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_RelatedPartyTransactionPaymentsForRent" xml:lang="en-US">Related Party Transaction Payments For Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_RelatedPartyTransactionPaymentsForRent" xml:lang="en-US">Payments for rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_RelatedPartyTransactionPaymentsForRent" xlink:to="lab_hypr_RelatedPartyTransactionPaymentsForRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_RelatedPartyTransactionPaymentsForRent" xml:lang="en-US">Related party transaction payments for rent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Expenses allocated</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromEmployeesNoncurrent" xlink:label="loc_us-gaap_DueFromEmployeesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromEmployeesNoncurrent" xml:lang="en-US">Due from Employees, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueFromEmployeesNoncurrent" xml:lang="en-US">Promissory Note with one of the employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromEmployeesNoncurrent" xlink:to="lab_us-gaap_DueFromEmployeesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xml:lang="en-US">Related Party Transaction, Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xml:lang="en-US">Interest rate of the Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DueFromEmployeesForgiveness" xlink:label="loc_hypr_DueFromEmployeesForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_DueFromEmployeesForgiveness" xml:lang="en-US">Due From Employees Forgiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_DueFromEmployeesForgiveness" xml:lang="en-US">Promissory Note with one of the employees will be forgiven</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_DueFromEmployeesForgiveness" xlink:to="lab_hypr_DueFromEmployeesForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_DueFromEmployeesForgiveness" xml:lang="en-US">Due from employees forgiveness.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSubsidiaries" xlink:label="loc_hypr_NumberOfSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NumberOfSubsidiaries" xml:lang="en-US">Number Of Subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_NumberOfSubsidiaries" xml:lang="en-US">Number of subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NumberOfSubsidiaries" xlink:to="lab_hypr_NumberOfSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NumberOfSubsidiaries" xml:lang="en-US">Number of subsidiaries.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_InterestReceivableRelatedPartiesCurrent" xlink:label="loc_hypr_InterestReceivableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_InterestReceivableRelatedPartiesCurrent" xml:lang="en-US">Interest Receivable Related Parties Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_InterestReceivableRelatedPartiesCurrent" xml:lang="en-US">Interest receivable from the Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_InterestReceivableRelatedPartiesCurrent" xlink:to="lab_hypr_InterestReceivableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_InterestReceivableRelatedPartiesCurrent" xml:lang="en-US">Interest receivable related parties current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeRelatedParty" xlink:label="loc_us-gaap_InterestIncomeRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeRelatedParty" xml:lang="en-US">Interest Income, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeRelatedParty" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeRelatedParty" xlink:to="lab_us-gaap_InterestIncomeRelatedParty" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidAdvancesUnrecoverable" xlink:label="loc_hypr_PrepaidAdvancesUnrecoverable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_PrepaidAdvancesUnrecoverable" xml:lang="en-US">Prepaid Advances Unrecoverable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_PrepaidAdvancesUnrecoverable" xml:lang="en-US">Prepaid advances unrecoverable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_PrepaidAdvancesUnrecoverable" xlink:to="lab_hypr_PrepaidAdvancesUnrecoverable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_PrepaidAdvancesUnrecoverable" xml:lang="en-US">Prepaid advances unrecoverable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Expenses incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Due to related parties for payments paid on their behalf</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xml:lang="en-US">Accounts Receivable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xml:lang="en-US">Due from related parties for payments made on behalf of the other entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CatalyzerCorporation4Member" xlink:label="loc_hypr_CatalyzerCorporation4Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_CatalyzerCorporation4Member" xml:lang="en-US">Catalyzer Corporation4 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_CatalyzerCorporation4Member" xml:lang="en-US">4C</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_CatalyzerCorporation4Member" xlink:to="lab_hypr_CatalyzerCorporation4Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_CatalyzerCorporation4Member" xml:lang="en-US">Catalyzer corporation 4.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FourBionicsMember" xlink:label="loc_hypr_FourBionicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_FourBionicsMember" xml:lang="en-US">Four Bionics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_FourBionicsMember" xml:lang="en-US">4Bionics</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_FourBionicsMember" xlink:to="lab_hypr_FourBionicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_FourBionicsMember" xml:lang="en-US">Four bionics.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TechnologyAndServicesExchangeAgreementMember" xlink:label="loc_hypr_TechnologyAndServicesExchangeAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_TechnologyAndServicesExchangeAgreementMember" xml:lang="en-US">Technology And Services Exchange Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_TechnologyAndServicesExchangeAgreementMember" xml:lang="en-US">TESA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_TechnologyAndServicesExchangeAgreementMember" xlink:to="lab_hypr_TechnologyAndServicesExchangeAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_TechnologyAndServicesExchangeAgreementMember" xml:lang="en-US">Technology and services exchange agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AllocationOfExpenseIncurredMember" xlink:label="loc_hypr_AllocationOfExpenseIncurredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_AllocationOfExpenseIncurredMember" xml:lang="en-US">Allocation Of Expense Incurred [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_AllocationOfExpenseIncurredMember" xml:lang="en-US">Allocation of Expense Incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_AllocationOfExpenseIncurredMember" xlink:to="lab_hypr_AllocationOfExpenseIncurredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_AllocationOfExpenseIncurredMember" xml:lang="en-US">Allocation of expense incurred.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xlink:label="loc_hypr_AmendedAndRestatedTechnologyServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xml:lang="en-US">Amended And Restated Technology Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xml:lang="en-US">ARTSA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xlink:to="lab_hypr_AmendedAndRestatedTechnologyServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xml:lang="en-US">Amended and restated technology services agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable" xml:lang="en-US">Product Liability Contingency [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable" xml:lang="en-US">Product Liability Contingency [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable" xlink:to="lab_us-gaap_ProductLiabilityContingencyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems" xml:lang="en-US">Product Liability Contingency [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems" xml:lang="en-US">Product Liability Contingency [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems" xlink:to="lab_us-gaap_ProductLiabilityContingencyLineItems" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSites" xlink:label="loc_hypr_NumberOfSites" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_NumberOfSites" xml:lang="en-US">Number Of Sites</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_hypr_NumberOfSites" xml:lang="en-US">Number of sites for equipping Hyperfine portable point-of-care MRI system</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_NumberOfSites" xlink:to="lab_hypr_NumberOfSites" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_NumberOfSites" xml:lang="en-US">The number of sites for equipping Hyperfine portable point-of-care MRI system.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwarded" xlink:label="loc_hypr_GrantAwarded" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_GrantAwarded" xml:lang="en-US">Grant Awarded</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_GrantAwarded" xml:lang="en-US">Grant awarded from the BMGF</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_GrantAwarded" xlink:to="lab_hypr_GrantAwarded" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_GrantAwarded" xml:lang="en-US">The amount of grant awarded.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwardedForProvisionAndEquipping" xlink:label="loc_hypr_GrantAwardedForProvisionAndEquipping" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_GrantAwardedForProvisionAndEquipping" xml:lang="en-US">Grant Awarded For Provision And Equipping</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_GrantAwardedForProvisionAndEquipping" xml:lang="en-US">Grant awarded for provision and equipping</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_GrantAwardedForProvisionAndEquipping" xlink:to="lab_hypr_GrantAwardedForProvisionAndEquipping" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_GrantAwardedForProvisionAndEquipping" xml:lang="en-US">The amount of grant awarded for provision and equipping.</label>
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwardedForOtherRelatedDeliverables" xlink:label="loc_hypr_GrantAwardedForOtherRelatedDeliverables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_hypr_GrantAwardedForOtherRelatedDeliverables" xml:lang="en-US">Grant Awarded For Other Related Deliverables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_hypr_GrantAwardedForOtherRelatedDeliverables" xml:lang="en-US">Grant awarded for other related deliverables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hypr_GrantAwardedForOtherRelatedDeliverables" xlink:to="lab_hypr_GrantAwardedForOtherRelatedDeliverables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_hypr_GrantAwardedForOtherRelatedDeliverables" xml:lang="en-US">Grant awarded for other related deliverables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>hypr-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-March-2022 [01:02:49] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CoverPage" roleURI="http://hyperfine.io/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedBalanceSheets" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedBalanceSheetsParenthetical" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CombinedAndConsolidatedStatementsOfCashFlows" roleURI="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#BusinessCombination" roleURI="http://hyperfine.io/role/BusinessCombination" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognition" roleURI="http://hyperfine.io/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#FairValueOfFinancialInstruments" roleURI="http://hyperfine.io/role/FairValueOfFinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#Inventories" roleURI="http://hyperfine.io/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNet" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NotesPayable" roleURI="http://hyperfine.io/role/NotesPayable" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStock" roleURI="http://hyperfine.io/role/ConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#StockholdersEquityDeficit" roleURI="http://hyperfine.io/role/StockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlan" roleURI="http://hyperfine.io/role/EquityIncentivePlan" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShare" roleURI="http://hyperfine.io/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxes" roleURI="http://hyperfine.io/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RelatedPartyTransactions" roleURI="http://hyperfine.io/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CommitmentsAndContingencies" roleURI="http://hyperfine.io/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionTables" roleURI="http://hyperfine.io/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IinventoriesTables" roleURI="http://hyperfine.io/role/IinventoriesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetTables" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStockTables" roleURI="http://hyperfine.io/role/ConvertiblePreferredStockTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanTables" roleURI="http://hyperfine.io/role/EquityIncentivePlanTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShareTables" roleURI="http://hyperfine.io/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesTables" roleURI="http://hyperfine.io/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#BusinessCombinationAdditionalInformationDetails" roleURI="http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails" roleURI="http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails" roleURI="http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionAdditionalInformationDetails" roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RevenueRecognitionAdditionalInformationDetails1" roleURI="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#FairValueOfFinancialInstrumentsAdditionalInformationDetails" roleURI="http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#InventoriesSummaryOfInventoriesDetails" roleURI="http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#InventoriesAdditionalInformationDetails" roleURI="http://hyperfine.io/role/InventoriesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NotesPayableAdditionalInformationDetails" roleURI="http://hyperfine.io/role/NotesPayableAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails" roleURI="http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#StockholdersEquityDeficitAdditionalInformationDetails" roleURI="http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanAdditionalInformationDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanSummaryOfStockOptionActivityDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanSummaryOfStockOptionsGrantedDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails" roleURI="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails" roleURI="http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails" roleURI="http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="hypr-20211231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://hyperfine.io/role/CommitmentsAndContingenciesDetails" />
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1359875" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1359876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_DocumentType_1359876" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1359877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_AmendmentFlag_1359877" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1359887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_EntityRegistrantName_1359887" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1359888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_EntityCentralIndexKey_1359888" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1359891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_EntityFilerCategory_1359891" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1359892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_EntitySmallBusiness_1359892" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1359893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_EntityEmergingGrowthCompany_1359893" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1359895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_EntityExTransitionPeriod_1359895" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1360630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1359875" xlink:to="loc_dei_AmendmentDescription_1360630" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_134" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_134" xlink:to="loc_us-gaap_StatementTable_141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_143" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_143" xlink:to="loc_us-gaap_ClassOfStockDomain_139" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_139" xlink:to="loc_hypr_HyperfineConvertiblePreferredStockMember_146" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_139" xlink:to="loc_us-gaap_CommonClassAMember_150" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_139" xlink:to="loc_us-gaap_CommonClassBMember_155" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementLineItems_135" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_135" xlink:to="loc_us-gaap_AssetsAbstract_137" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_AssetsCurrentAbstract_136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_144" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_RestrictedCashCurrent_151" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_156" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_164" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_InventoryNet_166" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_170" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_172" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_136" xlink:to="loc_us-gaap_AssetsCurrent_173" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_148" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OtherAssetsRelatedPartyNoncurrent" xlink:label="loc_hypr_OtherAssetsRelatedPartyNoncurrent_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_hypr_OtherAssetsRelatedPartyNoncurrent_158" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_162" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_137" xlink:to="loc_us-gaap_Assets_165" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_135" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_138" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_AccountsPayableCurrent_145" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredGrantFundingCurrent" xlink:label="loc_hypr_DeferredGrantFundingCurrent_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_hypr_DeferredGrantFundingCurrent_149" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_157" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_161" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities_167" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_138" xlink:to="loc_us-gaap_LiabilitiesCurrent_169" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_LongTermNotesPayable_153" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_154" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_Liabilities_163" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_CommitmentsAndContingencies_168" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_171" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_StockholdersEquityAbstract_140" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_CommonStockValue_147" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_AdditionalPaidInCapital_152" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_159" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_140" xlink:to="loc_us-gaap_StockholdersEquity_160" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_142" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_174" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_195" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_195" xlink:to="loc_us-gaap_StatementTable_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_199" xlink:to="loc_us-gaap_StatementClassOfStockAxis_196" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_196" xlink:to="loc_us-gaap_ClassOfStockDomain_197" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_197" xlink:to="loc_hypr_HyperfineConvertiblePreferredStockMember_200" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_197" xlink:to="loc_us-gaap_CommonClassAMember_203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_197" xlink:to="loc_us-gaap_CommonClassBMember_204" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_199" xlink:to="loc_us-gaap_StatementLineItems_198" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_202" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_205" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_206" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_207" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_208" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_210" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockSharesIssued_211" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_212" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_240" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_240" xlink:to="loc_us-gaap_StatementTable_242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_242" xlink:to="loc_srt_ProductOrServiceAxis_243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_243" xlink:to="loc_srt_ProductsAndServicesDomain_244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_244" xlink:to="loc_us-gaap_ProductMember_249" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_244" xlink:to="loc_us-gaap_ServiceMember_252" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_242" xlink:to="loc_us-gaap_StatementLineItems_245" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_RevenuesAbstract_241" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_241" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_246" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_246" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_GrossProfit_255" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_OperatingExpensesAbstract_247" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_251" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_253" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_SellingAndMarketingExpense_254" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_247" xlink:to="loc_us-gaap_OperatingExpenses_256" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_OperatingIncomeLoss_257" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_InvestmentIncomeInterest_258" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_259" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_260" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_261" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_NetIncomeLoss_262" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_263" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_264" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_307" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_307" xlink:to="loc_us-gaap_StatementTable_308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_308" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_311" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_311" xlink:to="loc_us-gaap_EquityComponentDomain_310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_310" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_314" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_310" xlink:to="loc_us-gaap_RetainedEarningsMember_318" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_310" xlink:to="loc_us-gaap_CommonStockMember_320" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_308" xlink:to="loc_us-gaap_StatementClassOfStockAxis_309" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_309" xlink:to="loc_us-gaap_ClassOfStockDomain_313" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_HyperfineConvertiblePreferredStockMember_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_hypr_HyperfineConvertiblePreferredStockMember_316" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalConvertiblePreferredStockMember" xlink:label="loc_hypr_LiminalConvertiblePreferredStockMember_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_hypr_LiminalConvertiblePreferredStockMember_319" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_us-gaap_CommonClassAMember_321" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_313" xlink:to="loc_us-gaap_CommonClassBMember_323" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_308" xlink:to="loc_us-gaap_StatementLineItems_312" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockholdersEquity_315" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_317" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_322" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_SharesIssued_324" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_NetIncomeLoss_326" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_327" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_328" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AdjustmentsToAdditionalPaidInCapitalInvestments" xlink:label="loc_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments_329" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConversionOfLiminalCommonStock" xlink:label="loc_hypr_ConversionOfLiminalCommonStock_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_ConversionOfLiminalCommonStock_330" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RecapitalizationOfPermanentToTemporaryEquityShares" xlink:label="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityShares_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityShares_331" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RecapitalizationOfPermanentToTemporaryEquityValues" xlink:label="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityValues_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_hypr_RecapitalizationOfPermanentToTemporaryEquityValues_332" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_333" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_334" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_335" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_336" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_337" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_338" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_339" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_341" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_342" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_StockholdersEquity_343" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_344" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_SharesIssued_346" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1361266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_312" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1361266" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_399" xlink:to="loc_us-gaap_StatementTable_404" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_404" xlink:to="loc_us-gaap_StatementLineItems_405" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_ProfitLoss_414" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_415" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_ShareBasedCompensation_422" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_InventoryWriteDown_425" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_WriteOffOfOtherAssetsRelatedParty" xlink:label="loc_hypr_WriteOffOfOtherAssetsRelatedParty_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_hypr_WriteOffOfOtherAssetsRelatedParty_427" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="loc_us-gaap_SalesTypeLeaseSellingProfitLoss_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_SalesTypeLeaseSellingProfitLoss_432" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentInLeasePurchase" xlink:label="loc_us-gaap_NetInvestmentInLeasePurchase_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_407" xlink:to="loc_us-gaap_NetInvestmentInLeasePurchase_438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_416" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UnbilledReceivables" xlink:label="loc_hypr_UnbilledReceivables_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_hypr_UnbilledReceivables_418" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_424" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_428" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_435" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_437" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidSupplies_440" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_442" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_444" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_445" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_446" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_447" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_408" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_448" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_431" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_417" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_409" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_410" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_421" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_423" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_430" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_434" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_436" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ProceedsFromBusinessCombination" xlink:label="loc_hypr_ProceedsFromBusinessCombination_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_hypr_ProceedsFromBusinessCombination_441" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_400" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_443" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_429" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_433" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_439" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_412" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_419" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_402" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_426" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_401" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits" xlink:label="loc_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401" xlink:to="loc_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits_411" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_405" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_413" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination" xlink:label="loc_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination_1367313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_403" xlink:to="loc_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination_1367313" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_453" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_459" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_459" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/BusinessCombination">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_465" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_465" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_466" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognition">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_471" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_471" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_472" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/FairValueOfFinancialInstruments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_477" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_478" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/Inventories">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_483" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_483" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_484" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_489" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_490" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_495" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_496" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NotesPayable">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_501" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_501" xlink:to="loc_us-gaap_LongTermDebtTextBlock_502" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/ConvertiblePreferredStock">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_507" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_507" xlink:to="loc_us-gaap_PreferredStockTextBlock_508" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/StockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_513" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_513" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_514" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_519" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_519" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_525" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_525" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_531" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_532" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_537" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_537" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_538" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_543" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_543" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_544" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_583" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_584" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Covid19OutbreakPolicyTextBlock" xlink:label="loc_hypr_Covid19OutbreakPolicyTextBlock_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_Covid19OutbreakPolicyTextBlock_585" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_586" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_587" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_UseOfEstimates_588" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_589" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_590" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_591" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_592" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="loc_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_593" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_594" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_595" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_596" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_597" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredRevenuePolicyPolicyTextBlock" xlink:label="loc_hypr_DeferredRevenuePolicyPolicyTextBlock_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_DeferredRevenuePolicyPolicyTextBlock_598" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_WarrantiesPolicyTextBlock" xlink:label="loc_hypr_WarrantiesPolicyTextBlock_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_WarrantiesPolicyTextBlock_599" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_600" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantFundingPolicyTextBlock" xlink:label="loc_hypr_GrantFundingPolicyTextBlock_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_GrantFundingPolicyTextBlock_601" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_602" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PatentCostsPolicyTextBlock" xlink:label="loc_hypr_PatentCostsPolicyTextBlock_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_PatentCostsPolicyTextBlock_603" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_604" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_605" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_606" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_607" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_608" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesPolicyTextBlock" xlink:label="loc_hypr_EarnOutSharesPolicyTextBlock_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_EarnOutSharesPolicyTextBlock_609" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xlink:label="loc_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock_610" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_611" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_612" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_618" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_618" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_619" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_618" xlink:to="loc_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock_620" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_626" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_626" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_627" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_626" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_628" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IinventoriesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_633" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_633" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_639" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_639" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_645" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="loc_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_645" xlink:to="loc_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_646" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/ConvertiblePreferredStockTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_651" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_651" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_652" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_661" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_661" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_662" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_661" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_663" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock" xlink:label="loc_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_661" xlink:to="loc_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock_664" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock" xlink:label="loc_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_661" xlink:to="loc_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock_665" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_661" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_666" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_672" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_672" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_673" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_672" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_674" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_681" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_681" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_682" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_681" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_683" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_681" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_708" xlink:to="loc_us-gaap_ConcentrationRiskTable_711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_srt_MajorCustomersAxis_714" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_714" xlink:to="loc_srt_NameOfMajorCustomerDomain_715" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerAMember" xlink:label="loc_hypr_CustomerAMember_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerAMember_720" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerBMember" xlink:label="loc_hypr_CustomerBMember_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerBMember_722" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerCMember" xlink:label="loc_hypr_CustomerCMember_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerCMember_723" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerDMember" xlink:label="loc_hypr_CustomerDMember_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerDMember_724" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerEMember" xlink:label="loc_hypr_CustomerEMember_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerEMember_725" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerFMember" xlink:label="loc_hypr_CustomerFMember_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerFMember_726" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerGMember" xlink:label="loc_hypr_CustomerGMember_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerGMember_727" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CustomerHMember" xlink:label="loc_hypr_CustomerHMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_715" xlink:to="loc_hypr_CustomerHMember_728" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_710" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" xlink:to="loc_us-gaap_SalesRevenueNetMember_717" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_709" xlink:to="loc_us-gaap_AccountsReceivableMember_721" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_716" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_716" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_713" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_713" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_719" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_711" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_712" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_712" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_718" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_762" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_762" xlink:to="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_769" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_774" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_768" xlink:to="loc_us-gaap_TypeOfAdoptionMember_767" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201815Member_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_767" xlink:to="loc_us-gaap_AccountingStandardsUpdate201815Member_773" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_767" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_776" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201912Member_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_767" xlink:to="loc_us-gaap_AccountingStandardsUpdate201912Member_777" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_srt_StatementGeographicalAxis_763" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_763" xlink:to="loc_srt_SegmentGeographicalDomain_765" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU" xlink:label="loc_country_AU_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_765" xlink:to="loc_country_AU_771" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesTable_764" xlink:to="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_NumberOfOperatingSegments_772" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_NumberOfReportableSegments_775" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_778" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_779" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_780" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationMethod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationMethod_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationMethod_781" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_782" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_783" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_AdvertisingExpense_784" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_785" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_786" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_OpenTaxYear_787" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_UncertainTaxPositions" xlink:label="loc_hypr_UncertainTaxPositions_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_hypr_UncertainTaxPositions_788" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_789" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_790" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_791" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_SummaryOfSignificantAccountingPoliciesLineItems_766" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_792" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_813" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_813" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LaboratoryEquipmentMember" xlink:label="loc_hypr_LaboratoryEquipmentMember_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_LaboratoryEquipmentMember_821" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchDevicesMember" xlink:label="loc_hypr_ResearchDevicesMember_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_ResearchDevicesMember_823" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SalesAndMarketingDevicesMember" xlink:label="loc_hypr_SalesAndMarketingDevicesMember_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_SalesAndMarketingDevicesMember_825" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_us-gaap_ComputerEquipmentMember_826" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_827" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TradeShowAssetsMember" xlink:label="loc_hypr_TradeShowAssetsMember_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_TradeShowAssetsMember_828" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LeasedDevicesMember" xlink:label="loc_hypr_LeasedDevicesMember_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_hypr_LeasedDevicesMember_829" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_816" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_830" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" xlink:to="loc_srt_RangeAxis_814" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_814" xlink:to="loc_srt_RangeMember_815" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MinimumMember_820" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MaximumMember_824" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_817" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_819" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_819" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_822" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_879" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_879" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_884" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_884" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LegacyHyperfineMember" xlink:label="loc_hypr_LegacyHyperfineMember_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" xlink:to="loc_hypr_LegacyHyperfineMember_892" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" xlink:to="loc_hypr_LiminalMember_898" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PIPEInvestorsMember" xlink:label="loc_hypr_PIPEInvestorsMember_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_882" xlink:to="loc_hypr_PIPEInvestorsMember_904" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_StatementClassOfStockAxis_881" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_881" xlink:to="loc_us-gaap_ClassOfStockDomain_889" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_us-gaap_CommonClassAMember_895" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_us-gaap_CommonClassBMember_901" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ClassBOrdinarySharesMember" xlink:label="loc_hypr_ClassBOrdinarySharesMember_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_hypr_ClassBOrdinarySharesMember_905" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ClassAOrdinarySharesMember" xlink:label="loc_hypr_ClassAOrdinarySharesMember_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_hypr_ClassAOrdinarySharesMember_907" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesA1PreferredStockMember" xlink:label="loc_hypr_SeriesA1PreferredStockMember_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_889" xlink:to="loc_hypr_SeriesA1PreferredStockMember_909" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_TypeOfArrangementAxis_888" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_888" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SubscriptionAgreementsMember" xlink:label="loc_hypr_SubscriptionAgreementsMember_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_887" xlink:to="loc_hypr_SubscriptionAgreementsMember_894" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_srt_ConsolidatedEntitiesAxis_886" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_886" xlink:to="loc_srt_ConsolidatedEntitiesDomain_883" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ImmediatelyPriorToEffectiveTimeMember" xlink:label="loc_hypr_ImmediatelyPriorToEffectiveTimeMember_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_ImmediatelyPriorToEffectiveTimeMember_893" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SponsorMember" xlink:label="loc_hypr_SponsorMember_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_SponsorMember_899" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HealthCorCatalioAcquisitionCorpMember" xlink:label="loc_hypr_HealthCorCatalioAcquisitionCorpMember_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_HealthCorCatalioAcquisitionCorpMember_902" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HealthCorMember" xlink:label="loc_hypr_HealthCorMember_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_883" xlink:to="loc_hypr_HealthCorMember_906" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_srt_TitleOfIndividualAxis_885" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_885" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_890" xlink:to="loc_srt_DirectorMember_896" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_880" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_891" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_897" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_900" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_903" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationTransactionThresholdTradingDays" xlink:label="loc_hypr_BusinessCombinationTransactionThresholdTradingDays_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_BusinessCombinationTransactionThresholdTradingDays_908" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays" xlink:label="loc_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays_910" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock" xlink:label="loc_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock_911" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned" xlink:label="loc_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned_912" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_913" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_SharesIssued_914" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_915" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_CommonStockSharesIssued_916" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_917" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockSubjectToRedemption" xlink:label="loc_hypr_CommonStockSubjectToRedemption_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_CommonStockSubjectToRedemption_918" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageOfCommonStockVotingPower" xlink:label="loc_hypr_PercentageOfCommonStockVotingPower_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PercentageOfCommonStockVotingPower_919" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination" xlink:label="loc_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination_920" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PaymentOfPaycheckProtectionProgramLoan" xlink:label="loc_hypr_PaymentOfPaycheckProtectionProgramLoan_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_PaymentOfPaycheckProtectionProgramLoan_921" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_InterestAndPaymentsToRedeemingCompanyShareholders" xlink:label="loc_hypr_InterestAndPaymentsToRedeemingCompanyShareholders_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_InterestAndPaymentsToRedeemingCompanyShareholders_922" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ProceedsFromBusinessCombination" xlink:label="loc_hypr_ProceedsFromBusinessCombination_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_ProceedsFromBusinessCombination_923" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationPaymentOfTransactionCosts" xlink:label="loc_hypr_BusinessCombinationPaymentOfTransactionCosts_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_891" xlink:to="loc_hypr_BusinessCombinationPaymentOfTransactionCosts_924" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_939" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_939" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_942" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_942" xlink:to="loc_srt_ProductOrServiceAxis_943" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_943" xlink:to="loc_srt_ProductsAndServicesDomain_944" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944" xlink:to="loc_us-gaap_ProductMember_947" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944" xlink:to="loc_us-gaap_ServiceMember_949" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_942" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_940" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_946" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_941" xlink:to="loc_us-gaap_TransferredOverTimeMember_950" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_942" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_945" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_945" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_958" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_958" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_959" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_958" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_960" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_958" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_961" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_958" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_962" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_973" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_973" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_975" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_975" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_974" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum" xlink:label="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum_976" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum" xlink:label="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum_977" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_978" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaap_CapitalizedContractCostNet_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_CapitalizedContractCostNet_979" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_974" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_980" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_990" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_990" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_992" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_992" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_994" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_992" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_991" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:label="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage_995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_991" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_996" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1013" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1013" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1015" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1016" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1020" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1017" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1017" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1018" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1014" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_1023" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1019" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1026" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1033" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1033" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1034" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1033" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1035" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1033" xlink:to="loc_us-gaap_InventoryNet_1036" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/InventoriesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1041" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1041" xlink:to="loc_us-gaap_InventoryWriteDown_1042" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1062" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1062" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1066" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_EquipmentMember_1068" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ResearchDevicesMember" xlink:label="loc_hypr_ResearchDevicesMember_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_hypr_ResearchDevicesMember_1070" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SalesAndMarketingDevicesMember" xlink:label="loc_hypr_SalesAndMarketingDevicesMember_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_hypr_SalesAndMarketingDevicesMember_1072" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_ComputerEquipmentMember_1073" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_ConstructionInProgressMember_1074" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_1075" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TradeShowAssetsMember" xlink:label="loc_hypr_TradeShowAssetsMember_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_hypr_TradeShowAssetsMember_1076" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1077" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1065" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_1078" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1067" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1069" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1064" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1071" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1083" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1083" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1084" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1095" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_us-gaap_AccruedBonusesCurrent_1096" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedContractedServicesCurrent" xlink:label="loc_hypr_AccruedContractedServicesCurrent_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_hypr_AccruedContractedServicesCurrent_1097" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedBonusAndOtherCostsCurrent" xlink:label="loc_hypr_AccruedBonusAndOtherCostsCurrent_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_hypr_AccruedBonusAndOtherCostsCurrent_1098" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1099" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1100" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1101" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1095" xlink:to="loc_hypr_AccruedExpensesAndOtherCurrentLiabilities_1102" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NotesPayableAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1117" xlink:to="loc_us-gaap_DebtInstrumentTable_1123" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1123" xlink:to="loc_us-gaap_DebtInstrumentAxis_1118" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1119" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PayrollProtectionProgramLoanMember" xlink:label="loc_hypr_PayrollProtectionProgramLoanMember_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1119" xlink:to="loc_hypr_PayrollProtectionProgramLoanMember_1124" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1123" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1120" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1120" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1121" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfinePayrollProtectionProgramLoanMember" xlink:label="loc_hypr_HyperfinePayrollProtectionProgramLoanMember_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1121" xlink:to="loc_hypr_HyperfinePayrollProtectionProgramLoanMember_1125" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalPayrollProtectionProgramLoanMember" xlink:label="loc_hypr_LiminalPayrollProtectionProgramLoanMember_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1121" xlink:to="loc_hypr_LiminalPayrollProtectionProgramLoanMember_1128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1123" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1122" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1122" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_1126" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1122" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1127" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_1161" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_1161" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1165" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1165" xlink:to="loc_us-gaap_ClassOfStockDomain_1164" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1171" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalConvertiblePreferredStockMember" xlink:label="loc_hypr_LiminalConvertiblePreferredStockMember_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_LiminalConvertiblePreferredStockMember_1174" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1176" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1183" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesBCAndDConvertiblePreferredStockMember" xlink:label="loc_hypr_SeriesBCAndDConvertiblePreferredStockMember_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_SeriesBCAndDConvertiblePreferredStockMember_1185" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesA1PreferredStockMember" xlink:label="loc_hypr_SeriesA1PreferredStockMember_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_SeriesA1PreferredStockMember_1186" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_SeriesATwoConvertiblePreferredStockMember" xlink:label="loc_hypr_SeriesATwoConvertiblePreferredStockMember_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1164" xlink:to="loc_hypr_SeriesATwoConvertiblePreferredStockMember_1188" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1162" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1162" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LegacyHyperfineMember" xlink:label="loc_hypr_LegacyHyperfineMember_1173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1169" xlink:to="loc_hypr_LegacyHyperfineMember_1173" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAxis" xlink:label="loc_us-gaap_DividendsAxis_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_DividendsAxis_1168" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAxis_1168" xlink:to="loc_us-gaap_DividendsDomain_1163" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendDeclaredMember" xlink:label="loc_us-gaap_DividendDeclaredMember_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsDomain_1163" xlink:to="loc_us-gaap_DividendDeclaredMember_1170" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1166" xlink:to="loc_us-gaap_TemporaryEquityLineItems_1167" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_1172" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1175" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingLiquidationPlan" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingLiquidationPlan_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingLiquidationPlan_1177" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfVotesPerShare" xlink:label="loc_hypr_NumberOfVotesPerShare_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_hypr_NumberOfVotesPerShare_1178" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_BusinessCombinationExchangeRatio" xlink:label="loc_hypr_BusinessCombinationExchangeRatio_1181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_hypr_BusinessCombinationExchangeRatio_1181" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1182" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1184" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_PreferredStockConversionBasis_1187" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1167" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1189" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_1215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_1215" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1219" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1219" xlink:to="loc_us-gaap_ClassOfStockDomain_1220" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1223" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1226" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1228" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1220" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1230" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" xlink:to="loc_srt_RangeAxis_1217" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1217" xlink:to="loc_srt_RangeMember_1218" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1218" xlink:to="loc_srt_MinimumMember_1222" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1218" xlink:to="loc_srt_MaximumMember_1227" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1216" xlink:to="loc_us-gaap_TemporaryEquityLineItems_1221" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquityYearOfClassIssuance" xlink:label="loc_hypr_TemporaryEquityYearOfClassIssuance_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_hypr_TemporaryEquityYearOfClassIssuance_1224" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1225" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1229" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1231" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1232" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1233" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TemporaryEquitySharesIssuanceCost" xlink:label="loc_hypr_TemporaryEquitySharesIssuanceCost_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_hypr_TemporaryEquitySharesIssuanceCost_1234" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1235" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1221" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1236" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1251" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1251" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1255" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1255" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1253" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1253" xlink:to="loc_us-gaap_ClassOfStockDomain_1254" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1254" xlink:to="loc_us-gaap_CommonClassAMember_1257" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1254" xlink:to="loc_us-gaap_CommonClassBMember_1258" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1255" xlink:to="loc_us-gaap_ClassOfStockLineItems_1252" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1256" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1259" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_1261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_us-gaap_DividendsCommonStock_1261" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockNumberOfVotesPerShare" xlink:label="loc_hypr_CommonStockNumberOfVotesPerShare_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1252" xlink:to="loc_hypr_CommonStockNumberOfVotesPerShare_1262" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1315" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1315" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_PlanNameAxis_1321" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1321" xlink:to="loc_us-gaap_PlanNameDomain_1318" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember_1327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1318" xlink:to="loc_hypr_HyperfineEquityIncentivePlanMember_1327" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1318" xlink:to="loc_hypr_LiminalMember_1331" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember" xlink:label="loc_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1318" xlink:to="loc_hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember_1336" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1322" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1322" xlink:to="loc_us-gaap_ClassOfStockDomain_1323" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1323" xlink:to="loc_us-gaap_CommonClassAMember_1329" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_AwardTypeAxis_1324" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1326" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1334" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncentiveUnitActivityMember" xlink:label="loc_hypr_IncentiveUnitActivityMember_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_IncentiveUnitActivityMember_1335" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember" xlink:label="loc_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember_1339" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_EarnOutSharesMember_1341" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_StockOptionsOneMember" xlink:label="loc_hypr_StockOptionsOneMember_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_StockOptionsOneMember_1342" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_StockOptionsTwoMember" xlink:label="loc_hypr_StockOptionsTwoMember_1344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_StockOptionsTwoMember_1344" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember" xlink:label="loc_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember_1346" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember" xlink:label="loc_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember_1349" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ServiceAndPerformanceSharesMember" xlink:label="loc_hypr_ServiceAndPerformanceSharesMember_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1317" xlink:to="loc_hypr_ServiceAndPerformanceSharesMember_1350" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_srt_TitleOfIndividualAxis_1316" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1316" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" xlink:to="loc_srt_ChiefExecutiveOfficerMember_1330" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_1333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1325" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_1333" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1328" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CommonStockRemainsAvailableForIssuance" xlink:label="loc_hypr_CommonStockRemainsAvailableForIssuance_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_CommonStockRemainsAvailableForIssuance_1332" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ExchangeRatio" xlink:label="loc_hypr_ExchangeRatio_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_ExchangeRatio_1337" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1338" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1340" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSeparateOptionAwards" xlink:label="loc_hypr_NumberOfSeparateOptionAwards_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_NumberOfSeparateOptionAwards_1343" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1345" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_1347" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1348" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1351" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1352" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1353" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService_1354" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue" xlink:label="loc_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue_1355" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1356" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1357" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1359" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1360" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1361" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1362" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1363" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1320" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1364" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1397" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1397" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" xlink:to="loc_us-gaap_PlanNameAxis_1405" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1405" xlink:to="loc_us-gaap_PlanNameDomain_1403" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1403" xlink:to="loc_hypr_HyperfineEquityIncentivePlanMember_1409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1406" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1411" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1417" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1420" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1422" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1424" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1425" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1407" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1412" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1415" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1419" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1421" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1423" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1426" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1410" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1413" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward_1404" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1416" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:label="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1399" xlink:to="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1408" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1414" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_1402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1418" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1444" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1444" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" xlink:to="loc_us-gaap_AwardTypeAxis_1446" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1447" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1452" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" xlink:to="loc_srt_RangeAxis_1449" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1449" xlink:to="loc_srt_RangeMember_1450" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1450" xlink:to="loc_srt_MinimumMember_1453" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1450" xlink:to="loc_srt_MaximumMember_1454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1448" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1451" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1455" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1456" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1457" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1458" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1472" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" xlink:to="loc_us-gaap_PlanNameAxis_1476" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1476" xlink:to="loc_us-gaap_PlanNameDomain_1477" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineEquityIncentivePlanMember" xlink:label="loc_hypr_HyperfineEquityIncentivePlanMember_1481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1477" xlink:to="loc_hypr_HyperfineEquityIncentivePlanMember_1481" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaap_GranteeStatusAxis_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" xlink:to="loc_us-gaap_GranteeStatusAxis_1478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaap_GranteeStatusDomain_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_1478" xlink:to="loc_us-gaap_GranteeStatusDomain_1473" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_1473" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_1479" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_1473" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1482" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1474" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1480" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1496" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1496" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" xlink:to="loc_us-gaap_AwardTypeAxis_1499" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1499" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1500" xlink:to="loc_hypr_EarnOutSharesMember_1502" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_SharePrice_1501" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1503" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1504" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1505" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1506" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1523" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1523" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" xlink:to="loc_srt_ProductOrServiceAxis_1526" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1526" xlink:to="loc_srt_ProductsAndServicesDomain_1525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1525" xlink:to="loc_us-gaap_ProductMember_1531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1525" xlink:to="loc_us-gaap_ServiceMember_1534" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1528" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1528" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1529" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_CostOfSalesMember_1532" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1533" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1535" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_1536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1529" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_1536" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1527" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1524" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1524" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1530" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1549" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1549" xlink:to="loc_us-gaap_StatementTable_1552" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1552" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1553" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1553" xlink:to="loc_us-gaap_EquityComponentDomain_1550" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1550" xlink:to="loc_us-gaap_CommonStockMember_1554" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1552" xlink:to="loc_us-gaap_StatementLineItems_1551" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_NetIncomeLoss_1555" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1556" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1557" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1551" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1558" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1571" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1575" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1577" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember" xlink:label="loc_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember_1578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember_1578" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_us-gaap_RestrictedStockMember_1579" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_EarnOutSharesMember" xlink:label="loc_hypr_EarnOutSharesMember_1580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1573" xlink:to="loc_hypr_EarnOutSharesMember_1580" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1574" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1572" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1572" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1576" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1596" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1596" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1598" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1601" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1602" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1603" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1604" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1605" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1606" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1597" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1607" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1639" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1639" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1640" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1641" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1641" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalAndStateNetOperatingLossesMember" xlink:label="loc_hypr_FederalAndStateNetOperatingLossesMember_1647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" xlink:to="loc_hypr_FederalAndStateNetOperatingLossesMember_1647" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalNetOperatingLossMember" xlink:label="loc_hypr_FederalNetOperatingLossMember_1650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" xlink:to="loc_hypr_FederalNetOperatingLossMember_1650" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1644" xlink:to="loc_us-gaap_ResearchMember_1651" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1640" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1643" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1643" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1642" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1642" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1646" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1640" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1648" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1649" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1652" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredTaxAssetsValuationAllowanceIncreased" xlink:label="loc_hypr_DeferredTaxAssetsValuationAllowanceIncreased_1653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_DeferredTaxAssetsValuationAllowanceIncreased_1653" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangePercentageTestingPeriod" xlink:label="loc_hypr_OwnershipChangePercentageTestingPeriod_1654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangePercentageTestingPeriod_1654" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangeDescription" xlink:label="loc_hypr_OwnershipChangeDescription_1655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangeDescription_1655" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfConsecutiveOwnershipChanges" xlink:label="loc_hypr_NumberOfConsecutiveOwnershipChanges_1656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_NumberOfConsecutiveOwnershipChanges_1656" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesDateOne" xlink:label="loc_hypr_OwnershipChangesDateOne_1657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangesDateOne_1657" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesDateTwo" xlink:label="loc_hypr_OwnershipChangesDateTwo_1658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangesDateTwo_1658" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation" xlink:label="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation_1659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation_1659" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation" xlink:label="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation_1660" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear" xlink:label="loc_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear_1661" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1662" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_IncomeTaxEffectsRecognized" xlink:label="loc_hypr_IncomeTaxEffectsRecognized_1663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_IncomeTaxEffectsRecognized_1663" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards" xlink:label="loc_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards_1664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards_1664" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ExchangeProgramRecognizedNetBenefits" xlink:label="loc_hypr_ExchangeProgramRecognizedNetBenefits_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_hypr_ExchangeProgramRecognizedNetBenefits_1665" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1645" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1666" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1681" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1681" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1683" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1685" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1686" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation" xlink:label="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation_1687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation_1687" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation" xlink:label="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation_1688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation_1688" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1689" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1690" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1691" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1682" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1692" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1720" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1720" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1726" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_dei_LegalEntityAxis_1724" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1724" xlink:to="loc_dei_EntityDomain_1723" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_HyperfineMember" xlink:label="loc_hypr_HyperfineMember_1732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1723" xlink:to="loc_hypr_HyperfineMember_1732" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_1737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1723" xlink:to="loc_hypr_LiminalMember_1737" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1725" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1722" xlink:to="loc_us-gaap_DomesticCountryMember_1731" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1722" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1739" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FederalOtherMember" xlink:label="loc_hypr_FederalOtherMember_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1722" xlink:to="loc_hypr_FederalOtherMember_1743" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_TaxPeriodAxis_1729" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1729" xlink:to="loc_us-gaap_TaxPeriodDomain_1730" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PreTwoThaousandEighteenMember" xlink:label="loc_hypr_PreTwoThaousandEighteenMember_1735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1730" xlink:to="loc_hypr_PreTwoThaousandEighteenMember_1735" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PostTwoThaousandSeventeenMember" xlink:label="loc_hypr_PostTwoThaousandSeventeenMember_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1730" xlink:to="loc_hypr_PostTwoThaousandSeventeenMember_1740" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1721" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1721" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" xlink:to="loc_us-gaap_ResearchMember_1734" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConnecticutResearchAndDevelopmentMember" xlink:label="loc_hypr_ConnecticutResearchAndDevelopmentMember_1736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" xlink:to="loc_hypr_ConnecticutResearchAndDevelopmentMember_1736" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_ConnecticutOthersMember" xlink:label="loc_hypr_ConnecticutOthersMember_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1728" xlink:to="loc_hypr_ConnecticutOthersMember_1742" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1726" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1733" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OperatingLossCarryforwardsBeginToExpireYear" xlink:label="loc_hypr_OperatingLossCarryforwardsBeginToExpireYear_1738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_hypr_OperatingLossCarryforwardsBeginToExpireYear_1738" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1741" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TaxCreditCarryforwardBeginToExpirationYear" xlink:label="loc_hypr_TaxCreditCarryforwardBeginToExpirationYear_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1727" xlink:to="loc_hypr_TaxCreditCarryforwardBeginToExpirationYear_1744" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1777" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1777" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1779" xlink:to="loc_us-gaap_RelatedPartyDomain_1780" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_CatalyzerCorporation4Member" xlink:label="loc_hypr_CatalyzerCorporation4Member_1787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_CatalyzerCorporation4Member_1787" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_FourBionicsMember" xlink:label="loc_hypr_FourBionicsMember_1792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_FourBionicsMember_1792" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_LiminalMember" xlink:label="loc_hypr_LiminalMember_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_LiminalMember_1793" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_TechnologyAndServicesExchangeAgreementMember" xlink:label="loc_hypr_TechnologyAndServicesExchangeAgreementMember_1795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1780" xlink:to="loc_hypr_TechnologyAndServicesExchangeAgreementMember_1795" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1781" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1781" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1782" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AllocationOfExpenseIncurredMember" xlink:label="loc_hypr_AllocationOfExpenseIncurredMember_1788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1782" xlink:to="loc_hypr_AllocationOfExpenseIncurredMember_1788" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_AmendedAndRestatedTechnologyServicesAgreementMember" xlink:label="loc_hypr_AmendedAndRestatedTechnologyServicesAgreementMember_1791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1782" xlink:to="loc_hypr_AmendedAndRestatedTechnologyServicesAgreementMember_1791" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1783" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1783" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1784" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1784" xlink:to="loc_us-gaap_SubsequentEventMember_1789" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1785" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1778" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_RelatedPartyTransactionPaymentsForRent" xlink:label="loc_hypr_RelatedPartyTransactionPaymentsForRent_1786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_RelatedPartyTransactionPaymentsForRent_1786" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSubsidiaries" xlink:label="loc_hypr_NumberOfSubsidiaries_1790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_NumberOfSubsidiaries_1790" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1794" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromEmployeesNoncurrent" xlink:label="loc_us-gaap_DueFromEmployeesNoncurrent_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_DueFromEmployeesNoncurrent_1796" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_1797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_1797" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DueFromEmployeesForgiveness" xlink:label="loc_hypr_DueFromEmployeesForgiveness_1798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_DueFromEmployeesForgiveness_1798" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_InterestReceivableRelatedPartiesCurrent" xlink:label="loc_hypr_InterestReceivableRelatedPartiesCurrent_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_InterestReceivableRelatedPartiesCurrent_1799" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeRelatedParty" xlink:label="loc_us-gaap_InterestIncomeRelatedParty_1800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_InterestIncomeRelatedParty_1800" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_OtherAssetsRelatedPartyNoncurrent" xlink:label="loc_hypr_OtherAssetsRelatedPartyNoncurrent_1801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_OtherAssetsRelatedPartyNoncurrent_1801" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_PrepaidAdvancesUnrecoverable" xlink:label="loc_hypr_PrepaidAdvancesUnrecoverable_1802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_hypr_PrepaidAdvancesUnrecoverable_1802" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1803" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_1804" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_1805" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1778" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_1806" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://hyperfine.io/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1822" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1822" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_1826" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_1826" xlink:to="loc_srt_StatementScenarioAxis_1825" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1825" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1824" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1824" xlink:to="loc_srt_ScenarioForecastMember_1828" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_1826" xlink:to="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_DeferredGrantFundingCurrent" xlink:label="loc_hypr_DeferredGrantFundingCurrent_1827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_DeferredGrantFundingCurrent_1827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_NumberOfSites" xlink:label="loc_hypr_NumberOfSites_1829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_NumberOfSites_1829" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwarded" xlink:label="loc_hypr_GrantAwarded_1830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_GrantAwarded_1830" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwardedForProvisionAndEquipping" xlink:label="loc_hypr_GrantAwardedForProvisionAndEquipping_1831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_GrantAwardedForProvisionAndEquipping_1831" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="hypr-20211231.xsd#hypr_GrantAwardedForOtherRelatedDeliverables" xlink:label="loc_hypr_GrantAwardedForOtherRelatedDeliverables_1832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_hypr_GrantAwardedForOtherRelatedDeliverables_1832" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_1823" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1834" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g284543g22s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284543g22s22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1204&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 7P            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &               K   !4P         !
M      $              5,    K                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "?,    !    H
M !0   '@   E@   "=< &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( !0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C
M\T8GE*2%M)7$U.3TI0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @,!            "0H'" 4& P0  @L!_\0 4!   00! @0# @@'"PD)
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MR<7I:VKHJ2?*4J)7+N1#83&K*\--)<ESW9<@QPM25.NKZHEYZJ<==0S.U*E
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M0*27:0R%-K#:XRU,-%*@OH6TXHE[MU\%RMJQ3Y955J3/8T3M2GR"6E+!)FT
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MVT?=W&8'>,>  '( X _E//US&83S%YA='-IMEC-#G]]5*P>2EI./O8Y4WLJ
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M"HF9 BT\ABD\4M&9!Q\T#3:\TJEM.HJ*AWL(24I540=[]!4[%+!6#O0T5BQ
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MN2@#;<K@F2;F#SQ7WQ:*2]9YB<1R!-5.<JW].:%B%8(B/+ANSJV^R%<J,IY
M4$O,I>9<<:'[H&7FUCL>]3X\9=F?\I\GS.FHEU=-34K*@-I4@K:><5MD#W@+
MB]L$KV2J_+*CA[JK)*K-*6B?<S1]:&GJAIE8:>I&4K6$K!44JB$D2)!BX,9*
MF\6'6FEJ:RI8TGQ)]BM@Q(+3CRL@#KB(C#<<.$) 0"H-A9^*$[GL.'%/QOS^
MA9IJ0:94H-TZ&]_8/J,(2 +@A)L/U8Y<YQ&5/LKZ*KZU]]6N6FTO..OD)K:,
M^^M3D!)1)@J $SY>&,L?%UUK/8Z28>KO[E7Y/R]AMMMV^;_#A8<><])@:9>
M L32U Y>I^JYY>>&BO9/T020-=*)CEV](/\ LD];=;],3MRY>)3JIJ[JE3X+
M>Z10FZVTAW#KL['3:>U5ZZVJF63+\@34&.8S[D5,([K2L/26N@*[[6O2/%?.
M-19F:-[(7*=OLEK+A:<;,I0I0 *R09VP0/&3TF@\1_9WT[I#3CF<Y9K!BK=9
MJ*=I;%0\THJ2^ZAH=F&6T$E.XJ4"#9,V ."$5_\ I&V7]6F?N-\:-5^C4?3_
M ,0QDE'NN?2^_%F>(S',><<QS%9\>_T@,N_H6!]AX=K^:-?3<_B3B2>_1J/I
M?=BR'^LG]4_8[PTQ&=1Z'XIQJN;?HM>?T'/_ .&<X[3S'J/CAQ2?.F/ICXIQ
M'>@_\W5+_M'?[]SA2I]]?H?OP^SKY\?H#_#B<5?G*_43]\\)8B%^Z?J^(Q7/
MF"_D[$OZTQ?N+X5:YJ]#\%8LVF?ZVK_NO^>+"5_\49_41]Q/":N9]3\<5L^^
MY^T7\<=M?YBOU5?8>.L<QCGOXN[]*/\ FXYCX<]Q7IBE>H?Z877UT_=''2>0
M]!\,$O*/FM-^Q3_ G&GG\S_YI_PX17R'T/N.))KWS_S?_7CE5_")_5'W3Q&N
M^XCU/WX['N+^FK^+%M-+_P!#T_6)'_+Q(T/N#\=#@=:A^=N?LTXU;#?YVLS^
MJ0OM1Q"T'Z2K/I#XG$KF']G,K^G_ (<3TGU3]!^U7%A/+ZT_$8J7Z_\ R_?C
M3=2/T-O_ *D[]Y/$;G/Z,J_V2L2>1_I1CZ:OX%XPVE_Z"U7U5?WG.(S3OZ&_
M^-?\!P[U!^F'_P!HU\4XU32O^4<V_K"K[>&>DOG&8_7\%8=ZI^;91_=D?QJQ
M/#/YX^@\7+%8QV^.8YB%-9/T;3_2\3^]/%+U7\Q1_?/^X,6O2GSY?]V>^_$B
M4G\0C?5HO_#M\6FE^9Y?_=FOABK5'SFL_;.?$XBFE_G2RO\ HZ/_ 'QXJ^5_
MVKS#]DKXG%GS;^S-!^U/P;Q-[GY@_5/V#BX'WT^G^>*JKD?0_#&,N?Y&MOJ$
MG^Y7PWK?FSW[)S^'#ND^=4W[1'\9Q'6C_P"B37UR9]K/$)I/]%'^\.?Q+Q+Z
ML_2C7[!OX(QTM7_X"O\ ]K*^XGA;4'S='TA\1B0TG[[_ --K[\0NG^#'Z@^[
MQ43[[?T1\1BU#WE>O^,8XQZ*^C_$<?.%#R^M/Q&)%TS_ $C5]3E?:UQ)91\X
1'[,_#$'J#]&J_;M_Q*Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g284543g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284543g23s23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1FD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &8B^938X0DE-! 0      &$< 5H  QLE1QP"   "AH < E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(#(X-#4T,U](>7!E<F9I;F4@+2!0
M;W-T+45F9F5C=&EV92!!;65N9&UE;G0@=&\@ #A"24T$)0      $-^1K8CP
MP9^>#.A&VJ(Q/P4X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :D            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              '    $X0         !
M      $             !.$   '                       $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #P<    !    H
M #D   '@  !JX   #NL &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #D H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M>G;N0XY#Q[3]'V:;G?\ 75UK?J_TAE#<9M#FX[&AC:==
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     /_A0"!H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,#,M
M,C-4,34Z,S4Z-34K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \
M>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X
M;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R
M+3 S+3(S5#$U.C0W.C,V*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C R,BTP,RTR,U0Q-3HT-SHS-BLP-3HS
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N
M,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(S,#<R.#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CY-:6-R;W-O9G0@5V]R9" M(#(X-#4T,U](>7!E<F9I;F4@+2!0;W-T
M+45F9F5C=&EV92!!;65N9&UE;G0@=&\@4RTQ/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT
M(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.D(X,S-&.#(W.3)!045#,3%!-38T13)"
M,34Y-$9#1$8Q/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ
M1&]C=6UE;G1)1#YX;7 N9&ED.D(V,S-&.#(W.3)!045#,3%!-38T13)",34Y
M-$9#1$8Q/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z0C8S,T8X,C<Y,D%!14,Q,4$U-C1%
M,D(Q-3DT1D-$1C$\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D(V,S-&.#(W.3)!045#,3%!-38T13)",34Y-$9#1$8Q/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(R+3 S+3(S5#$U.C0W.C(V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0C<S,T8X,C<Y
M,D%!14,Q,4$U-C1%,D(Q-3DT1D-$1C$\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#,M,C-4,34Z-#<Z
M,S8K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D(X,S-&.#(W.3)!045#,3%!-38T13)",34Y-$9#1$8Q/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(R+3 S+3(S5#$U.C0W.C,V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D(W,S-&.#(W.3)!045#
M,3%!-38T13)",34Y-$9#1$8Q/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D(V,S-&.#(W.3)!045#
M,3%!-38T13)",34Y-$9#1$8Q/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @
M(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z0C8S,T8X
M,C<Y,D%!14,Q,4$U-C1%,D(Q-3DT1D-$1C$\+W-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T
M;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@ S0([ P$1  (1 0,1 ?_$ !\   $#!0$! 0
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MBY\,WZ[=_7G.;4=SW]7OG_T_+U2^Y7#*OU#*#>A4$=<KWM3C9]9S- ]O)0-
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M=\=_^V/_ ,/#Z>LJ?,YBC4\HM>CD'E[]_9C5AX!P0L W"LBVVUY>/IX[;_\
M4X19&U]IXSGMLO8&/#&?"Y6+'?P[>PCCW]8DV?S@U%<S,.8_",/<0.8\.>]=
M,;4/HWP @'[C\.JZHY6(FKY65Y?)]6$I_;&U,(QG&S-@8SC"<]\7*QXSGQ[>
MPECQ\?7X^WW]8\_$L^I(&=S7+;[^_4CS^VW(XV(?1?T<(4G@G##8-_Q++[^T
M%#SKD#A'?V]ME"NZ=G["3G&<9QE-TLF.WAGU9P2QVSC/JSCMVSC&<=L^K%S/
M%^*1MW<_FA9-5,]@^TD\ZW'F1C;R_HCZ+2);^C_"FL40<E 0001^9_UVYX?-
M*Y?\@Z#,:D0MB&C\-I>%NB;?(<LL*4A*L><TXZ24Z19PK'VOI(DZ.[C&>_G]
M\8ZCROIGZ0</DU+GGS"*PU0YD"6-A8M18#K[0U_.<4>+?P1>@O&\N\;<&@X?
M,5(CS7#!ZI+&U,%8K'4,FGGI>,AJ%DX]CN,/+.I<A1T@<J,FM[ $Q423%9=D
MX=9E1,*2TLN!D+PER8/2ZM")++C:)8]QUIN1AUMV/*D>O>B_I?DO2.)HU7U?
M/PJ#-E&;=A=&6%FHO&#S4@,FP(IE)^4/X1?X,.+^@.929G^Z'!,VY7)\2CC9
M=#$%ER^<2BL.8T E2&,<R@LA!#(O7G788\PP=&#!T8,'1@QYU^4:\I5H3R;>
MHF]A;8D2;#<K+\.@ZMU&!EQ6;;L(U";0J1EMR3AQL'5Q*GXB[):YC#\02S(C
ML18A4S-&")^KPC@^;XSF#!EETHE&:=[$<2GJ38U,=]*@@D@[@;XBEE6)=1W)
MV51S8^ _?CX0.4W]4">4@Y'GRCE;V_+X[4.1(DX%4726$UR1"@N*RF.T2OBV
MW+N7GH9SYK\MHN+@.O94]&#PD^B9:]3R'HCP?)H.TA]=F [TN8&I23L2L0.A
M1RH'4?\ *\<U\U*Q.^D>"[5\O.^M^/385QM3O*@^46HAA!VO<W.32R#;N'\)
ML6X;G=!BW,+POS70=S*V (^RK.,85'?'.,*3W0IM2,Y3UHOP#@DJE6X;E *T
MDQQ*AOQM*-C;KSZC$8GF!OM'^4DC;RY=<>S?%W^J).0=S+AM=\O;U+CBYWP4
M7 VU1XD6H? 9*O,CMR+X%KC$".[#?5GO)/ADQOB]79R2'?CN/S(<_#/1ST<R
MA99.%Q2,Q_"YC5.5U="LC%%7P-;==KQR'I3E?2'.1G,\*XMF(3$I+Y&(]@LE
M42T<D:@EJ!I&)!/4;#'O+#VQL"<Q&G1=DW.7$F,M2HTIBYFY#$IB0WAYF0P^
MV04V\R\VM+C3K:E(<0I*T*RE6,]=&W!.#:2!PS(4 :*Y6$ @=12#8_\ >\>8
MY;BO%S+IES^>#+)I=7S$MA@:8&VY@^.%]K9>Q\HQGY?W;OCOZ[6>SWQYV._^
M/X]?Y>L?,\&X4I-<.R7R9>,51'ERZU\]X]"X;GL[($UYJ=MQN9&)L#<[D\_#
MIYXSHV7L;/?&;]=<^'K^51WOCU>Z?^GJB_">&"CZADP+K;+1=?ZN_ERQNKF<
MSH#=O)N2*#-M1/+?RQ=]DC8O^7]V_P#:L]__ -_3/N5PS_$<K_[:+]V#UK,?
MR\O^NW[\9V]D;$RG/>^W7.<>W-J.9SX)SG_P[V]O5U7EX9PT760RFW^8CZUR
M[NV-7*32FM4CMSNV-&OE^O&TWL;8>?'Y>W3U8_VTG/5]/P_PZS9N&Y 61D\M
ML3MV$=; ^"_]^>.JR0UE=6YT@?+8WWZ[=?'&?&QMA>']O=S[YPK/WT'/G_Y=
M[\?E]WOR)LCDP#65@Z["-!RVZ+TN_D^7'6Y.&!R%:&,U0)*@WM[.MWC1>V3L
M5*LXQ?KKCPSVSBTG,9]>,>/:=C]?;UX^;$FR^7!-01C8GX*\]_+;[> QT4&2
MRE*?5H=P?R >GGY].OMO"2_LW9"5=L;!O'CW_P!M9[V=L?\ A_K]?CX>'L[]
M86;C1 Y50*4U0%[6/#]^^^-W+<.R!TWD\N235F)#]&FOG&$US9^RL*5C[(=Y
M]7A_;<?QZU=_#L0QZL=OS>/?K$G9J0*2"=[OII(HUMSZ^?+EC:R_"^&M0;(Y
M4U_F(^F^_=_Z5A,D;2V9A6,8V)>\8\?5;C_K[_OAZOF_3[L6>:86.T<4:V/D
M3MY^?U;8VLOP7A#<^&Y,BQSR\=[C;<+\^$IW:FS\=\XV/?/#MVQ\L+#[<Y_\
MH_-^7V_/CSYK,+>F:4$$C9V (!J]B#>__7IC8@]'^"$C5PK($=X&\M&2:OQ!
M ]O,?(!A'?VQM%*E>;LF_8]??M<;%COVSWQZB/S_ %_DQ<QG<X+K-3[6=I7'
M4\N]MR'VY[$'HYP$KJ/!^';]#E8CR) YKY>&_+H,)#^V=J)2K.-F;!]6<^%S
ML?NS_P"4OI_/\WCBS\3SRFAF\R.8VF<>._/;ET'@.F->'T8]'20#P3AA.W/)
MP>1'^#)Z\Q7R]4=_;FU^W?&S]AX[H[X[72Q^';Q\/[)=9.;XKQ-5&G/YH7S^
M_/UV\<;>5]$O1AB2W >%$@ [Y++D&_(QUR%>>'+5>4_(&DS&Y(G:-IFMM+PM
M<"QD'K- D)3G/[$ZP<5-REM7;MG,=QAU.,YPVXWU5A]+>/Y"77'Q&>4 "X\P
MPFC8 <M+#:QL2-^O,"FY[^"OT$XQEVBG]'\EEF(-3Y!#DYU9A>I7A*J3=&F1
ME-401CUKXL<U:_O!Y%-M<.-5]D(84Y&B,O*R&M#+#?GR) 5Q]2GH\]K"''9
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M]Y\[WQY(V=X[E,V^6SF>SJSQ-3AIY-+<AJ4EK*L18-"P;Y<Y7:V7L?+:<_9
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M<I+D2SK&R(:['#I\V/.@W.>#BU.:,*Q33HR99XDY7+H-;1))F((II4!M()'
MD)92#&&I4,G) Y-KS#8MR2 &I6(]H&U>._3KRZXD*F[*V+NZG[E#[A,S[[3Z
MIK ]<H%EM6$3YNKK8+=CMT5NG&WV<R*S N%DE0J)*I8N1%KQF">Q(4%7-KPD
M@)@FAR^3ER<F5(CE>>./0DC'MXG%S&12S"0HMR]H06! -Z21AX=G#A]P!8)
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MKC2 @E#\"EMDU0*<L4>,J+D)H7"&BR0;.#4/,I,.<P"Q=[W6YZ>.)HXRZ&F
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M>,;.7_P?V\<(K_J3^!GZNLC.? 7^M[AC?RO,_P SZCA&?^Z5^#^K/6!F.?\
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M><?3!Y%KBF:I &S<E[J,>&D=@!T577$*8RIJ3BF?#HI(W8U-.I\Y#%A(CA3
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M?@Q^T?W,>?\ S,L9\?M'BS6(1O<T*KV\SN)BX ]'GSH2X6**'UZT1$ML)KQ
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M:[!(U$^8%[;>67,,K%&D0;?!!))#<A1!&U Z2#?SX<1UKFY\C]!V6 'W*JT
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M#NRB_,7YL/37W#OB;J:TP+QJ[C-H77-S%MRV1MLH^IJ+5K&/:GQ784YJ$:"
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M-"[Y$ T!S&U[;GJ/*.#_ %,SY4J2:0*D5/3 ^$J1AG-DF[B$+"MM^?A/PI;
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M/^VS7_.Q9FL6K_?$,8^; &J]OS9$YQG\O?I"C])F'GIC/_QPX9G*CGPZ$_\
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MD2(+\0 !X 7A1E<WN3Q&:R2>[!E@HO\ ) ,9-#I9)H[DXSIK=G3Z[^7SX_\
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M/A]E<]C'NQ6:7_J/U=)ZGG.G$Y@?'U;*$_3#]'7"CB/"Q_\ I_*'^W<3Y?\
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M!PL=$DD"!&=(:BPH,&$RN1,F2Y+ZD,QXL6.VX_(D/+0TRTA;CBTH3G.% )(
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MO)&A(4-\(1*5ZQ6X&0EP'65L.S!5G.P9&4>D8)RT*PZK'G<23S2*P=7ED<,
M5#!G)!TD C8[BN>)4&E56JI0*\ZWQ*;G[6Y^ K^#GJ%N1]A]V'KS'M'OQ&6E
ML8QJRC]O_$47ZUY_7GK+X+^+<J/\T/[S?NQK<>WXQGOTH_W:8E#K5QD8.C!@
MZ,&&%K_TGR;D^B\W*_E/>O-PO.<)RKY;6/S?.5C"LX3W[>=G"59[>K'?K0XI
M\;_LO#_U#*XS.$_%&_IO$_VCFL8=;2=K204QS<(?7X2RI+S$08FM[)8K2#<
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M:+1+./KQ4A6UA8!')Z U&FB<3(I(:[+9-E9X=!EB*=H71"2I#,C!76P2.ZQ
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M-AL":I5K+,?=IJ$!*M=+'G(:B6@[D: O<YJ0S4"1O,61Z)WJ&;+,@@8E&=&
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ML]Z1)2'>GJ$Y8FQHV2+D$N?>5G8QHG:1S1&BQTK-FCFB5O<%6-#V7S-AXC
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M@3[Y*.EC!LZMZH("S]>B* )?($C .$'*PBQHOA,.8Y2S$R3R-*(A$\DCLRH
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M5W%PO/;)VI,N]:W5(HE,MVP>/.S]H:^=U\*M3]NMO'&Z5NS5-\)<)AT9/IL
MZ*JP:O66$T,-8=R*&EA+HI]1Z-8(X<[V4:HT2R-'%FH8G+LNE,VC*P9%%/I9
MV=;JRQ!Z4K1V2;JRA(KJAL'?Q%#PVO$'K\EB"D6761%[;K@X-2:NU5+/*IU
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MLFJU7G4X;?>HY1JQUJRMWO3QV? 'Q39%NN27ETZU07#-?D&:B2^&(BP[$+5
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M"[,JK0(4T78DE@FE2<*TH7<CD2#ORHD?31YU\N(Z/\_=]!R# :KU*LW6QO\
M)D'JUT:0>BU@(QK\[SUV'QJBR6"&/ALY5I<K%7#"/A3S;HZ*0)JL[L&5B%(%
MR)%X;"59VE9(TR@F+ &1S*.'QYIAI[H"=HS#8V!L+ K"&4WI"DG6%/A6MEYG
MJ0/#K[">^-"<L0V_+*[4PE0)!35:H/RDVE$G$HTI>M[MC95ZU6[K*?F/'0@H
M:C6?5.S/A)!A<1A ^O#)[<5V-8X3C&=F,I)EEU,RLKR%86 ($J=FDHE .X4I
M+'X]YB.:L ]7#&@.0L^1LBMMKV)]E;8X1V_Y2?;-CUK6,Z$TS)J5QW!<.-\C
M3%HV#8:F1$VG1F]]X@=.HV;'#CIDO(2T-D3@%F/2[7AK(N#>*]9IKY10BRU>
M!>BX="KN<Q.'CBCS';+&KJ5GB@,RPZB&U*PYR**[K+0V.(VD8BD6F.G26KX+
M&KJ^?EOT\1CV?CI<1'80ZYZ5U#+:77?,PWZ5Q*$X6YZ-/VJ//5C*O,3X)[^;
MCPQUC_;[<L3XS=&#$5Z8^\-K\;-D?RC6OK)X'^+8?TV=_7LSCH/2C\=3_P!%
MX5^R<CB5.M;'/X.C!BU?W"OP5?5GHPC<C[#[L,76.<8H%3[YQC^P<'U__1=6
M\_\ ',S^E;WXI\.^(Y7]$OUX;?(+;D;0>C=O[MG!'[)"U)K6Z['E@(LY@9(-
M1Z97B%@>%,$9+,B/ =GH@9C-S9##S,93F'G&G$(4G,,$1GGA@5@IED2/402%
MUNJW0W.Q- ;DBABVS:5+<Z%U]OI/(=<<TZSYX5,Y%V;]EZOA]73=81=;$)\B
MG[ %;ZK1]C:\^UB*<#K)C6XETN7V$^5II2/-UQ'K"K2U$GUHI!B$8%AAO(LR
MY%QV7J[&<2M,H#1G+LI@TF1F$K4(@'4B0L%O4I(*D8:LEWJ&G3774-^5$<SY
M#?EXX9VSO*D\<=<%1L&/&V%>()2E5FZ1C5.UY>"D!MFR;O":(6#GM-UQ4X39
M:]:RLQ=EKQ:+".BU!Y(3XL>LC\80N6+A.<E5C4:%6D4K)+&A^]0=N2"S ,K)
M\!EL-S^""<(94! [QNN2D\S6_4;\]L3P2YO\70TF\QB^V@PI.N1]C)VN>2#V
MN"$CQ*:2C![I\36"4 :!VV32"\R,+NL"I$#D^H$'<0['&%R$K;36&2S1$9$+
M'M2@0 J6N2S'J4,60. 2A<*&&ZDBCAVM-^]6F[NQ5<^8%UUKEAQW;D[K.A53
M7NPK$60#U_>T6TBNP6D?::F0#UVF:LONV#9AVJ&*PW95/PJ[0"LJ6')CPDY@
M<B5/1Z=^*R-G,3+2R,\:(7D1D32I5@6>01 :PQ6B[  @D$D"Q8PI90 2:!W%
MW?*^7D.>&1)Y\<38E+:O[^WQR*V]9C=1^UK%Y<L+1NM5P;<;$B53&ZPNY0A@
M*FF0UR+GY@%@ /J!D/:99-H"4@D'Y?4,YVAC[ Z@JN>_'I"NQ5.^7"6[ JJA
MBQ<%0+!&$[1!O?T'V\JO8$$^'7"G)YP\6(A:S!WMR5OTM2KUHM!@DU#L$BL+
M%4FL*NMP0$N$<.[4[2:K%10[9#]8JYHQ91(9E\A.$LQV'5H:,CG"J-V#T[(B
MBUUEI&*("FK6H=@51F&EF!4&\':)9&H6.?.OGJB1S(!L#?EC5!\Z^+5AM8"D
M#MGX;LUFD5N(*'%J5L2OI3)NK\F-1VB\^P5(6-KN;U(AR(]%589@M%TD(PS6
M%%77$(4-D<VJ.YB[J%P2'C;>, R:0CL7$8(,A2P@(U$8-:W5[[=#UY6:H7TO
M&JGGWQ(6$L5B:W&*>#5F55XLN6S7;J]DRFZVQFBU(C28S5:7+V(!LERD1JP%
ML=!CV4!/-R(XZ.27)?:;6X</SI95$#:F#D#4FPC3M'UDL!&R1]]E<J5&YH8.
MT3\X;[#GON5\/$$7RVPU]I^47XR:RJ&V;'\JBUI,:FUSL#8<^HA:==6"5A^Q
MM756*U5"O%BE<A5N;=0+*X\:VUI)?)BA.+ER+Q!K\446=@N@X;FYWA5454FE
MBA$C.A56E<HC, Q948A@C$4Y'=)VM&D5;YD@%JH[@"S1(K;KOM\F'%)YV<>@
M$$B2N]TC52*S8R @9%6$O16PN" ]&U_?#UGM%3B4U%DH@BKB=CUU5RG64;%"
MTQLB*5:#8J82P/C,&1S+-I2(L=*M=HJDM(\2JC%],A9HV":"6??2I LN+J!9
M->-@V-@38%U5B_#K6'I6>7_'2Y;05IJL;-&&-@_&9($V,B"+-D1*L FNQ;@0
MKD"X.!6Z81L<>H3(UJ^3\"P2#+M;=2=8A.BN\K#&RF96+MFB*Q<R24U:=9CU
MZ-6L)V@*:RNG6--WR ZDZ0;/L/A=7RNB#7.M\(5[YH:-U1:;;5MGVR-69U>M
M2*H,ABQ5RNIT[-9UM5=GE\8KU1J14C#=#5JTQRLQN/@FRT!CN'I,J+';G1Q[
MH\EF94#Q1%D*ZRQ*(H!D:)1J=U!U.C*.7>[M$T2%U!HG?PW)Y7T'S^ W)PSQ
MOE"^-TLWL\9-LIB /US9]<U: =8IUU/P]F3MG:P&[9KCNK8M;KA8A>V5U.?(
MGR6ZS&*3(HT5-L,J+'K3@\O-D/#<V%A8(I,RS-HUHK1=C*8F$VIAV1#[=^A9
M O4=.&B5"2+Y$"Z.]@$5MOL>F.O*7=*KL2JU^\T<\-M%0M0J&;KM@#R42QI8
M7/:2]%F1'T>&4.(5V4A>$.M.86R\VV\TXVFFZ-&[1NI5T)5E845(Y@C[>.'@
M@BQN#AS]-PN#HP8.C!@Z,&+'/VMS\!7\'/2-R/L/NPJ\Q[1[\1GI?^]91_WB
MB_6OK+X+^+<K^B']Y\:W'OQOGOTJ_P"[3$G]:N,C!T8,'1@PQ==_>Z_^-%Y_
MCO8NM#BGQO\ LO#_ -0RN,SA'Q-OZ;Q+]HYK#ZSZL^WK/QIX:P>YU@^;M5;#
M'19(]1R P7<!,.4V].KA$R$@607"+,)5Y\.1/ E!Y:*VYC"G8,V-(3CS'4YR
MXJZJK,I57#%&((5@K%25/(T00:Y'8X2P21>XYCPO<8='G)_=8_/CV>O\W3+'
MB,+@\Y/[K'Y\=%CG8KQO!@\Y/[K'Y\=+@P95CMGQQ^?'\_18\<&&Y7K?6K4Y
M8F*\<&F'ZE8I-3LS0^2B0L'98<$<3E!"6$9SF,18'EQDQV,YV<0Q.C+SCLXG
MI2K*%+ J'74A/)EU%0RGJ"RD6.H(YC" @W70T?;C6LUZJ--S!3:+&&!+*),*
M%LD9S,>22Q7@1&SG,CXJE_")OQ37Q!(O/Q%:=5&@PWGW<)0G&5 #,"5!8+6H
MCDH9@H)/(62 +JR0!N<+8\>?+SPE5G:NO;D8F *Q;P9PN/<,L$( V5B0_"D5
MY-:4:C2L)QYK$D:BXUA<N.[E+[:#<!66_-=SE*M&Z:=:E=2ZEU"M2V1J'BI(
M(!\0>>$!!Y$'ZO;X8D'SD_NL?GQTVQXX7#) ['I%IG?%U;M(,],PY:&LM")[
M)!"7:39E4VW1U/QE.1T2JW:FW:\9BK=Q(@%V7X+[27F'4I<RLIIE*_!V8$'O
M*&78@;,IU ]5((L&\%CQ\?HV/S'8X>WG)_=8_/CZ?J\>FV#R.#!YR?W6/SXZ
M,&&&'VAK^PWJV:T!6X$6O=$B!YUSJX^<W*+5B/8(V)H7)J.SY^![I*&MN9%C
M2%(DN1'F97HL1WV7''M'(JH[(RI)?9L00' L$K?, @BQM8(NP<(&!) ()',#
MI[?#V8?O3,+@Z,&#HP8.C!@Z,&**]6?HS]71@Q!FKOO7F_CYM;^5*X]<GD?P
M#_TSB/[0S6.OXY\>C_T9P/\ 8O#\/;6GWK)_&"Y_QTL/7<9_XR?T.5_58<<!
MPSXI_:,Y^MS8?V<=\9QGU9\,]4\:&.7+YPPXX[)(EC5HHI1)XY:#UO+V*K[%
MV=0;+/*6JJ5.CVR _8Z'<JV<S4K;5J)3A-KH29Z:-9FZV)DG:Z0FQ$2>K,><
MS,(58Y:55551HXI$4([R(0LJ. Z/([(]:U+&F -8:45C9 )-V>IL '<;\@/F
MP@SN!/% C=XE]F:M==)P##E@A5W%\V4WJZ*=D4)>K9YEC2[5Q1J!HJ6UVXNG
M'""*/B6> YQ!,NSFT(\UZ\0S:1=BLH"%=)/90F73VG:A>W,?;Z1)WU':;-N*
MWPAC0FR-S75JV  VNKH 75XU:]Y/[B?66"C(_6YB9DS@(@A*LNU-OW,D[%K5
M+V'KJN#6BMOOIPG$#U^C;5O=7!AH<M@4($FF8P^''P% J%C<0S;@!I=E#* L
M<2 AI(Y6)"1J&+211NS$%B5%FB001H+(7F03N>8! Z[4"1MT.&3R3X"TW<P0
M2SKL\G3]N@PZ'69EQC8V47(2J#KFM;&JM8J,1VF[@U6?%(A"MIW&-(F1;.J)
M9(9:2(O@FX!5H'-/RW$98)"[@S@ZV[-NR"EY)(Y6<K)#*AMXT:M*D$6C*1>$
M>,,*!"\MZ)- $ ;$'8$U_P![G$'Q9U,.TGHW1),><-T_CT-U;#UU,<LQ^O6*
M%.U#7XE:JIJ4:IQ*O37Y+PN._"/#O2I!6$:3+!3(F:#)2QST#9J9Y\QF-0#Y
MDR&2E!!$C:F4*RD+1HJP[P(#!@:PH1=*J186JW/,#GM7[O+&_IWBYH_0D\L3
MU;49P*:6$CJXETI<[U<T *D'DRYHBC4>/=[+8XVO-?"IDZ5*&:_H;-<I<"0[
MZ:("9<0VI"3YF?, "9]05S)01$U2$49'T*ID<@ %WU.:HFL*$538%;5UY> '
M(#V89@S@UQ>#SS9"#K>5A1LJ.+X@2[]LHD K<@;L@%M]N'KVLDKA+KFL 4W9
ME8KUR.UG7(NK5VRF PYVPBRC45IE,ASV;8*.V(TJRVJ1JS!HC"3(P0-*PB8H
MK2%V532D8:(T!L#>P;LFJ(.UDA18W J^N'.3XE<?#$S8D\CKUF3+VQ5MKTK8
M#N;%;6_E#6-X)JB-IBW$,GFVQZ+6FD5?#LD2B!-%?%:<@I(O,J=F2P9K,!8T
M$K:8GBDCV6U>'5V1!TWW [ 7MN;L[X=H7<Z1O=^=[GZ<1Z=\GUQ,LME*VDYK
M@W/G&,7[,@6YMG<C=-AR-IT8WK?9) %KYC8#5$K1>]4^Q&1MI-5VN"RQJ5-R
M<G37C[$8HS*.(YU5TB<_X/O=G"93V4@ECN8QF4B.159%+E5H * *PWLH_P T
M;70L@"QI- &K(-$U9ZX?EXXBZ V)+*%++3":#Q8S6+ [:JQ?MC42Y#C-/JDR
MC B%;N=&MM<M-3?;IQ$C627R7+AVSX4A/'GT$X\R0AR),WF8PJK*="JZZ'6.
M2,K(XD8-'(C(UN PU*2" 00<*40\U\-Q8.W+<$'IXX0 O!KBO7;$,L834\,;
MD2*%"HU6CV:[8UG(^(Z8G70<T7U&JRJU8?N RB(14X5Z.TXC=& :$0&SZ64X
M3A[9[-LK*TUZF+%S'%VHN0RE1/H[94,A+F,2!+)[N#0MV 1M6Q(!]H!HGS(O
M#NTMQ9TAQ\)V@UJJL&PQ>Y J95[ 2/["V/L&;)K.NW;2[1*[$D[$MMK=#@JB
MBZ6.#7Q 94 >+$S(P6+';$B0\* R?-SYE469PRQL[HJI'&H>33VC5&J L^A2
MQ-EB+.]G L:I>D<P ;).PNAOT%D >&.>6/)I<:XU[.'HH,_$I)O7P"F-4"+?
M=IL(J)&G[.@[3I1[5EL:V$BP:;B4BPP&9%,JNIW*8#J<W*R5=:&/.O-.3_=+
M,E$4E"T<DCZS!!;B2(0NDRF+3.&0$,90Y8$AKNR@B0$T-B -.]"B2"-[!L]*
MKF*.%XKY-3AF8K2*A+U?8F:XN':QY4:*W5O8$BV0+I?;#M$_"OT@)LL?+V+%
M<V);+-<1+%[D6)JMGCA.?6TB7I;N5"\4SR.9%G&O4K!FAR[Z&1!&IC#Q,L51
M@)]["C2 *H# 8HS0T\MMBPYF]Z(O??>\207X7\;C+)AN7K^6RZ;.1K/-("+U
ML2OF6K'!W$1Y 0C8DZ M@TU7RD/;Y6?<XDT!/&/QI+^!C"T F6!;<(SF: H2
MDC1H 949=(A&7"E64@@1*$W!V%_"WPNA/S1O[>A)'TD_]@,*/'GCQ#TA(W%9
M2!R!:]A;VVH4VGL*T"ZLQ3!TN<L*%JU>#BJ\R5.J'CP59KPUN2XZ8FOF[-+L
MMKDYCS+%*BLKF<TV8$"45BRT(AA0N7*KJ9V):ELL[L12@*H51>FR*@74=K<V
MQ H':AMOT O?<V>N$2O\(>+]6?GR NL41USK=KZZM(D6Z^$HX,OJK8"=J:^'
MT^(3M$R+1Z96-AI5;(.NJ:R"U\Z5?EKF5B2S,EM/$F=S4JA7F:@KJ:5%+"1.
MS<R%5!D=D 4R2%I-( U5MA0BKR%<O':MQ7A[!CJ['AC&/=U5P[!T8,17IC[P
MVOQLV1_*-:^LG@?XMA_39W]>S..@]*/QU/\ T7A7[)R.)4ZUL<_@Z,&+5_<*
M_!5]6>C"-R/L/NQ <?5E%VSJNA!+\'?-#!* M@@1V#1X&IDM!COMQ92I->)B
MI3Z6D2'L9BR'W8;OGXR]'<4A&4W<X[)G<R5-'M'%T#M?F#BEPX Y'*V+J(?7
MA9Y$ZD1OW0VY='NF\5IG;VL+SK5VQ9%(.X!HNE<(5]1905R<,;+)'IGYE9&K
M(P$3<-?!U3(R7,NIKY>4P9B', %C#+'* &*DF-M0 8 D$\KHUS&XQ<9=2E>5
M@B\>>9'R60NVU:\0+[<=-D+%8R>HBX,33>*=)IV@XA+39:X%@D^_:"(W*WB]
MIS; F\&0=HF&[<-E.5^,$B5]ZOS@[)1>DG%6B=##',B*N8#%\V[S_P 95%?L
M\P(XS$%[-2@"&FMB3J($78[$'03W*I J]RZU+9!)LV?9X86)GDS_ (-5*P I
M.T:9KZ0&HS]>(L4_CK2:C2'[1!W]6>1=/L-;UW0+#20-6 U^Z5U0HI65.FC5
MLK<M"2]W1969=F)-^ZKDL9(VDU2,P,F8EED"OEVRSJTD@9G;0P96H*K @)I-
M!>Q6@!0H#8* +#:K '*STNNNYPV(ODE*-")[=D0K5K<:QLG[)LH:?$\8=4#]
MO#2>W+VQ?K0JY;N2XY?[Z%$SOC(-3A#$ZGO0Z^10/MY2[J%C)$=S<8F*Y>UE
M9H#"=)S4I@(@C[.,) :CC)7X;=\DV4"6;.Q!U[@:]5G2+[W.SS(\!=<L=H<L
MN+D/E+4 55F7&334!8VV(R9D8&T>5(3M3C_MG0[ZE1WB@K#>0T;:;UD:QZ9>
M)SX5H6O,5N<N?$IY3-ME'+J@<EH6W8BNQFCF % _",8!/0<N=A[IK %D5?+S
M%8A2R<$+&G9=HW3JK>TC6^U#EXL%@&G9^LP]Y!!:I=./G'70UNJZZP4L8QDF
M5>5QOJ=ZKMH7/BL!#$Q\03KEE"HEQRDR9\&+L)LNLL)":E$C1L7CEFE1@X4F
MOO[JZUWAR((!#3'WM0:C9(L6!852*L=%%>'GL,,JU>39*7 !9->G.0YXEJN3
M+WK=*?79NMZPBU ]Q<A-5;-U9>;Y9KF')!8MM!,1-P[&L(2B#:G38T(S8&67
MSLL2'#CX+UXIV;I*N519E]74N)'*-%EY$D2,1D,48]FBM+K;9; #,Q*=E>Q8
ME>\0"!8+*038JQN2!7SX5SO"W9=_Y ;2,638<8!QYM!CBQ8I](A5<22L6Q3'
M'=,*QB/@]O\ CB*5U^/9N@,&H_#4)/NV$1%;A@YE:<<*3YZ)GHHLO%HB+9I&
MS>F1F8)&N85%^!I(D:@U$D!36I7L#"M&6)!-(0H*@"S5FKZ;GSOH1A+KODW)
M\)C4P^U;[)VP9Q[^P+5]$Q$ZX"@7JMJ/1F[=4[EC4^WRX!][-YMMG5IFC5.=
M?,,UR(-&C5$XE,=)3BJB W$]I^SRXC.9[=ISVCMKEGR\D!=!I&A5$TK!+))8
MJ7(TT@BW4ER0M4* V#:@#X\@/8/,VPM@^2>3LG:FT]@V??<N?!V,!Y1UB.W-
MUI&*;"#5_E'0K=22=>E;,)7F6[/J^KTVEM6L:L$K-2 # PJ.(-P3A)3=EB2Q
M<7:"**-,LH,<N4F)$I"%\HP96$8BV:2B)&9G8FB"-EP&$,22Q-AQN.C[,-CY
M;;#SO$JDN ^PEG;)L"N<CF:OM;8+%^!;'M3&FQ96O&JAM6C:-J]Z'5NG%[S*
MS5[$V<T:'M-,L,JP6(<!R;(@S]9N<1B-*Q']TE^]J^5#QPF-X4[9E*O#)-(C
M,XC.L??F5D"@D!2"IO#NS-L=7><MJ-<PP ( O;8#QWOIMB1-7\&*SJ=>N8]:
MN1)0/6>_B>[00N8'0](<A2M RM!CJ9+)Y*Y<?^+1+S)MRQKCJ?FR(^(*Q;*7
M<S$P29YY0X9%MX! :+  #,G,ZE!O\IBH%U5$DF\ C"U1.S:O_I"U\PYX7YO#
M^',Y!FM]9O4Q,DU8[98%5GY/,J8CKM6A*!HMR-@K\;I6YB'&HC=C2[F G+SQ
M-8M2&D1$S7V^N,,LF6$8I E-J-GLYIIP* Y$RE39_)'C6#LQKUV=[V\B #_=
M!VQ -4\G+;-;KJ!?6G(9NO6W7434,BCG#>H85G@0[%0..4+C!<I=A!*OXE)V
MOW_7H4$0A H9 $5IEI@/$&+4=&3G@Z;+\264.LN6#)(9>T03,A(DG.80*P0T
MT<C,"VZNA *AE#8:(B*IJJJ[O@-.^^]CV&^IQWIHK4@W1>J:=JP67)6%BK09
M:9=A+MPV"1\V8*S[!8CDJ*.9CCH*RY\L2()'0&&H(YN2B#"0F-';QU0GE,\K
MRD!2Y%*MTJJH55!))-* +))/,G$BC2H%W7,^).Y/RGIB7.HL.P=&#!T8,'1@
MQ8Y^UN?@*_@YZ1N1]A]V%7F/:/?B,]+_ -ZRC_O%%^M?67P7\6Y7]$/[SXUN
M/?C?/?I5_P!VF)/ZU<9&#HP8.C!A@T#TGR;DX:SC"\V:]X2K*?/PE6;M8L)5
ME.%(RI.,^.4X4GOC';SL=^_6AQ3XW_9>'_J&5QF<(^)M_3>)?M'-8TM6A=J@
MJ]-A[=V!5-CV5PS-DP3M/UQ,U@,B@W6(B8(EZOSK]L5Z7.B/MS'I!G!R,W-1
M*992)AYB*=DTY&B9@8HWB4* 5>02DMO;!@B4#T6B1XFQC2%CF0=^8%;=+W._
MGM[,>;&R>)>V=B\F+R8+UNSHTO=N1@FZGY=9VAFD*L5&#<"#&JQ[I1-2NH&W
MOC8V\&J^,4!>;2_(F18AV0->K,=XFC4BSL,64BC6NVCR[Q /"LH5GS\<QT]H
MK("8 XU5>Y6[.(BA+,2+!<&P2IH1%>G@:&^UFZVQR1;M!;STZ,XYBKI4=^["
M$;&3PB&;7H8;DE+E7+9?((-KKF=(Y(#6;39MSB1\&81'9U$NS./72J:UO<(.
M' 1#DID?,3 L)F<M,V=(.7C94SKY>1LLBI'$SY80!4CB)#7KTTC/&"6TFB,,
MT.!&#J;X 8:]["MJ/,"MAU'EB1 O#WEP[5=DFSL+9J[-!UQI,1JJM+Y%$5V)
MG7T?D?N*X[>T9"MT?8WP"-M5[C*5H&EY&VSA./'F&\19(/9*H<(E8XS&SF1U
MPB,1:>VF>9_5AI9SEH8XIQ'H4]D<R)9EA M%)#1[A2[0^Y).P '>!)!9BRWR
M^#0!^GKAR.<9>8#M9Q]C<'L35]4V3MZ^:FF:GO.[QEBNNC>'NWZSJ"+:[7\J
M1FQ+Z$E7RC7G7VQ[7KD%3+Y:I]1#;?R#KA**R-DCX+/6<C=3".5XX(I.UC@*
MI/G(6F*H0R1NL;QR1H[:%#/$'8'F5TOMIL#40 6^#'L/.R*)&]5RZ88W]:9S
M4CW3DF5>=Y &"%E-71Z/,B[IUI7=8;1TW)Y*ZYNH+4FK5C-C1=FTF^3..H6Q
M:N"G+N#UC7]>$I)N$(NCPVTR#K;QF\E4'=RZA5C%'+LTL<H@E5Y)"8]$B"9E
M8A3(7-,8[0831("2"QW-65 TV*4 'PL[U\^.A];<=MWA^&?-NAU'6=UT_?-L
M;#VO<='42Y;:KMGN\,68U_01]0'D=BUV^WH2$(22E=GA83#UY(0ZPTU%AI+.
M 8D,B[%+F<N^;X>\DD<T<$$4>89(&1"PDF9AV;1QEP ZEF"=_<U=@*JL$DH%
M2S%@+%BU4;$$@<J]NYYWB#=N<>>4^Z;Q8]T3^.VSP)G.U]OR]55$IN/43=NU
M[7+WP5%:F 6N4NM;ODT47 C;O"-*)B:_:+ <AKEYL,(3/@RRDKJ2/,Y2"'L%
MFC<-EX5E98)=$C)G^V=#KC5R>PY-I"G2$U<L(49FU413'39W%QT#M8H-5T3U
M/B,(MRXY\T*E!V?/K?'PUM[-SB;DAQ*BG;M# P%V*]GN%;-5V(5BRMQZ\38)
ME4&:WVU8(P5ZWUF::R D5F98 #-QA3)SVS'#YFA!E[)8507V3DZ(SF3V*5&^
MD2&2,:BM*#9!*D833*NN@#JL78&YKO>=;UR)//$9[$XG<TAU/TM6M$:JY4#(
MNMJC7IH<O?-X:5?V)]E9G<!JU;'/WIX5S&=U]3QEG!9&NU.+00.WW)@"0S02
M4C6P0.[!,O@S>0+SR9DY?[X[_>XH'2-8QERD2Q_Q0NQUMWS(T7>':$.S%@C)
M)2A=6U66<V;-G8ML/"K.GN[<L28&X?<HJ6+ME;IVK-BB*/%VYR-L-PJU>W=5
M*Y.WG0[SS>H.WQD"A&XNVVYE;GW?CXT5JS3EQGZTF-D@=IK5GF5V):(MA/L;
M.Y21P\CH\AARJ1R/ 3V+IPTP%I 8K98<SI-*'UZ5DTM5!=#J!0ZL6WY@RAJ
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MFFF&9C3S=E.5# E^($C' 12?5;AK:VC6=.T58Y#$0UK%,X2-^TTA"07BUBZ
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M'-.Y9E9XW5%RVC+PN'EI-!1WD<ZF9.[&=BUG"]H>K!:J@=RYU,"!O=[=+YT
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M=YHXUS8D$,+*DZ/$D3L).T+N@D:-32/&TRHI5F1M("L6=K( I8I1+#8V6JB
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M5&R+_4=ER;K!V%BR#**U:J\(HT%B(*K@=EBSB!M6L,"VAICTYTN1A;U9VA:
M=CD*G5E[&=Y7CC>/3H"]KH)=V!-%&9E(:P"1AK&K4=3[<F0!003Y6>0NKVH
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MI\DLC:,5@0$860)*DKG/"8T@C\*?<DNON&;S';P9B20ROEGC:(/>E1&XD5
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M)(KS]G/DV3WE-8E3ENS[-Q]O<.ADG-T"*-<A]OH9%Z[W#15J@:XM]8CUEPK
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MB-FAJ]#76:],&V"97ER1BB[1IX2Q1)EC&K4T,C%8W!\6%/I(%(=SJVP\.":
M;G1-"@0 2#N:J^OOK"+LORB59UOR/^P+(U/>30B%:ZIKL_M$:MA=:#["O5-=
MNE7KZFFXS\93#L!8R&6=GF19T=)+Q)<6LE V'"F)(N'22Y8YA9(P>SDE$3&G
M:.*01N19!L4S *K JOP@Q"EK2A7"$$60-5&MP#X>!\?GWPS:9Y2<K;@%;2_Q
MEO +8^SZUH&Y:3U],O\ KZ6UL"M<B8&QR-2(%K?#(."*(^$A:DOA"TP"S$R7
M%'PPV Z39DTD+$?+PPQM)69B>.!\RD\H20=FV6,:L%0@-(&,J:2-(W;504M@
M$M@=TVP4J+!)#60?(=T[GPN]\2'J[F!8L\7*KO?:-.>:L-IY1$-!R:D.E"(T
MFL(L_-DMQ>I^"<R!/-!9TNG#I8*7:)0DE+A')0HF\*DI;FQG$13Y-5S1R\#Z
M@,LDX=@1J)RBYEZ% C4=04$ BQJZG"J]J2W=[[+5\N^5 OKT!/7<X;%\\H^,
MHI89A_2-WGT=&ZMF:;N.T/C<5 HE+E:VV9&UI+*%3TEC(F%((R'I-C;'64E5
MA[ (;/0FPRC"&1;[X^&R2#:6(.88YDBLF1TEB:4%5ZA0H5@NIPS#N59 9!X'
MX14FCL00*\-[VWHT:.$DGY3!B% V'9HG&_;A*@5R19X&OKLC$ <*V>6I>VP6
MG+ (B/%FH(ZN2YMC,OSJFY-*SXA02'(?*&142JX@M\'#3KCC.9A$KM&KQG43
M&)(S*')4,&"H.\!361I#"R$$H(+:2 +HGK3:3[-ZV\_(X[EUEN 7L&63J\T0
M:K.QJD,!O[ JDL%;5!:V7+Q$R'0X;8)*L!*??D0'\/17BE/GDHF<M8=<3'0\
MUA5%XR@5[5D<L(V#J2P6C90,70$&QK5;'G8$@8&QU'/8[?+5'Y,3!U'A<6.?
MM;GX"OX.>D;D?8?=A5YCVCWXC/2_]ZRC_O%%^M?67P7\6Y7]$/[SXUN/?C?/
M?I5_W:8D_K5QD8.C!@Z,&&)KS.,5U_OGMWM%Y_CO8NM#BGQO^R\/_4,KC,X1
M\4;^F\2_:.:P^<*PKOYN<9SCZ?#/L[]9^-/')LKF+J\%LS86L+A@Q7C-.V55
M]65[$('8[D0V#9K)I6%O-UBO5^F C9EKXGISA:205)C98;8 D)JY#;.4)ZMK
MDIWACFC4.DD3S'O*IC1)_5[8NRC>0J  23>PYX89%!()((.GD39TZZ%7^3O\
MF-Z)S2XU$8T&>-V;%*"Y]<J5L0;&5FZD*_""7NJS;Q3WC5AA5R0$K\^Q5* ^
M>&!#LX<;>@.0G/B["B8U$MK9+-*#JC"TSI3-&"3&XC?2ID#,JN0I8 K=T=CA
M=:]#?L!(W%\P*Y;X2<\[^*;<FKPY.W!T"3<Q%#L%?04K5V%8D MH&' .O#4]
M1&M14 Q-R*-J:KQ ZL;$(Q?-),/*&N-RU.]0SG>J$G0TBM3(::%=4H%,=90<
M](/ASVPG:(:[W/36Q_+^#TVOSQOE.;?&,))+Q#.T8HB2&@3"C[1.KWB#F<.@
M[ K^JY$ZO9E5IE-KBXV#:ZU6&GJQDNW*GG12XJWHDUB2MJY/-.%*1:@S*EJT
M9IFC>0!AKM"4C=N]5!3>^#M%',GE?P6JKT\ZKF?;UY8V3W-#C55BM8!VG9L6
MKF[=\!4&#V2M70$32R4NJM=B9AJ"5KL.35QQ>Y-O!!!*S-B(!1Z/)E#Y,F!%
MD2FQ<GFG5FCA+JI(+*R,-0C[4J"'IF5.\RJ2RC8@$@84NH(!(!/('GSTV1S
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M=QH[M';3MRP:5JM(KPH5[:\?/#%;X-<26H5?&M:*I38ZL%3!H9 0R13">G6
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MLVS.@ BEP@$A0N0F6S3Q*A0]^= G:!]2E93((TUPQR3.KOK[1\_ID MS6C+
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MA)E+9?("=1$(X/6CV31M)())2W;T'5 @HS? /:%"3IQ'J-?"D()-MI (.D$
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M+),X ND9L8?!DO1\1T+E\FBKEXV6?/$QY>02KH;U81.YUR&V"M5L 0H(&HL
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MQK<>_&^>_2K_ +M,2?UJXR,'1@P=&##%UW][K_XT7G^.]BZT.*?&_P"R\/\
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M7A( M6Q1\T70IY$R9^Q6YLV[Q*_4@<X;9Y]<DFA5'L$ZKC!\6*,9&=<MZP4
M$<7WE9="EQ%G9$A;6]*&E6-"[$%0RJ74,6P\ZUU5?,]XW==RV%#>AOL-^@-'
M'47$DSRRO>TM5P=I;BV:;UL#H&X[?@NSJM6NQVS90G9M+KE"'WM^]ZSKUF<;
MB@C%M=&+&A-=D;<+'"3ZX<B)%D$"]3-KDTR\YB@B68S0IH,W:M&K0RM(\?9R
M%*9@H-F7225NRH#D+E@"Q*Z20=-7N!1L;]? \N=DX9-RY <A8W*'>H;75TWC
M>S.MM[0*V*T.$U(+*ZE<TKGC+4;W;"CFP'*-'1F]0;D5^&5J#/VF.G2['. 5
M50%\79U2L2KE<L<GEWDC@198'9LP96$QS S+QHO9]L.YI2F(C 5-3:BP *:G
MU-3,=+5I"[:2!9U:39W.UF^5=<<NZMV'RPV\?KK.W[?OV11M><@N#^RX%A@Z
M^MJ9D:;=7=] -K5F<3.\6-+RSE6KI87K)%GC"-?/!Z/.-2,_*]<-3CT"Y/%D
MH%)ACRXDER>?ATF5""4:$Q.BI/+H=H];(Q=7:O@],,4R,=]5!T8;$58<$&QN
M!W2;&UC#QT_LGGE'O7'VKOFK-K:KCZ9QMCAM8Q>/)Q57O52.5(5)W21+R*UJ
MZ-3Z.9KI7%K%.Q2=\H.:$D+6YT*HF62;0ZP19B'AICS#H@D)ES&J1LRFJ(AP
M(0HDD,CHRL""$DUC7NA&'J7! )(.D$ *18HWJH5?CN">9QM&(_+(UJ34J=K[
M3Y*62$=H/D\N1=_)-:[KL6Q4&_2.0<2/N"O!1M/U*U-;%5^L-B[(;J)44?.A
MGJY',$',P996-,0>HK//V,.50(_$<O$#(Q65!EV[!V+RD%BX(1U*(Q>A9TX:
M0^E>\Y)$9(H;$,M\EVKF;)Y;WCZ&\>K'CW\,>/O^?KGO;BSBO1@P=&#!T8,4
M5ZL_1GZNC!B#-7?>O-_'S:W\J5QZY/(_@'_IG$?VAFL=?QSX]'_HS@?[%X?A
M[:T^]9/XP7/^.EAZ[C/_ !D_H<K^JPXX#AGQ3^T9S];FP_O5Z^J>-#%F76\9
MPG*TX5G&<X3G/CG&/7G&/7G&/;GHP8M].SC'G9=;PGOG&<Y6G&,9QW[XSGOV
MQG';/?&?5V\>BZV^V_+Y^GCTP8KZ5OMW\]/;PQW[^'=7;S<?3GOCMCV]\=O7
MTEC[?;Y_#K@Q3+[.,9SZ5O&,=\9SE6,8QG&,YSC.>_AG&,=\XSX]O'MT7TZ_
M;Y.F#"%$LPZ8=+UUM!-! '"#$9[TD$<A!EQ3JR3<# RR3![%=-RT*$R_C,>%
M*D)X-*H"S48>@L*5-!9WVKESLV*U6-B*L?;;!A>],UWPGTB/.SZD^=CSL^WP
MQZ\^&/9CI<&#+S6/.[N(QYN>RNZL8\W/_"[Y^U_+VZ/G^8_8_)A+'B-N?EBY
M*DJ^YSC/AW\/=[_HZ,+B[HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!
MB*],?>&U^-FR/Y1K7UD\#_%L/Z;._KV9QT'I1^.I_P"B\*_9.1Q*G6MCG\'1
M@Q:O[A7X*OJST81N1]A]V&+K'[P*G^\<#_1=6\_\<S/Z5O?BGP[XCE?T2_7A
M^=5,7<'1@P=&#!T8,'1@P=&#!T8,'1@P=&#!T8,'1@P=&#!T8,'1@P=&#!T8
M,'1@P=&#!T8,6.?M;GX"OX.>D;D?8?=A5YCVCWXC/2_]ZRC_ +Q1?K7UE\%_
M%N5_1#^\^-;CWXWSWZ5?]VF)/ZU<9&#HP8.C!ABZ[^]U_P#&B\_QWL76AQ3X
MW_9>'_J&5QF<(^)M_3>)?M'-8?76?C3Q'U]VA2M:)K*KB76,S<;*S3JPQ&$&
MS<PS9Y 4Y88X:)! #B<SX2^(K9F2PIUA#+KD3$-MQ<Z5$C/N1&DUZ!?9KK<V
M %74JV22!\)E'CN.APA8"@3N30'4G<\A[#AW"2\,R-'E8>9*8Q.!$)1FIX\@
M((MQ9T=N2QB>'+1H1<7+PTZC$D>4@PY\)[SXTV+'DM.-(:=B1U!JO,>_Y,+A
MMS-C4X??Z]J^8;99O%KJ%ROE?!YBSUY(5/7YJB5VWEL$6XJQ,? <ULNDP50I
M<Z.1FJ-X>'0Y<<>5>@NT.4,FDZ RH6\'=69%KF2RHY'DN$U"ZL71/R T3\AY
MX>>7FL9[9<1C/;.>V58QGMCMWSG&?'&,=\=\Y\/GZ;A<4P^SGMV=1GOWQCLK
M&>^<9[9QCW]LYQC/;U9\,]'GT\<'U\O/%?3-8PK.7$=D9SA6?.QV3G'K\[/?
MLGMW]O;H^WU^[!B_&<*QC*<XSC/JSC/?&?GQGVX^?H^VXKWX,5Z,&#HP8.C!
MA"$5BN )E@(@P0@1/MA=L_:)HT=$@R[$<:$C039@Y(C--.E";84,)$HFS5/R
M4#1@^$ES$:'';;4LS!0SLP0$(&8D(I);2H/P5U$FAM9)ZX/D OG0J_/V^>%W
MI,&#HP8.C!@Z,&#HP8.C!@Z,&**]6?HS]71@Q!FKOO7F_CYM;^5*X]<GD?P#
M_P!,XC^T,UCK^.?'H_\ 1G _V+P_#VUI]ZR?Q@N?\=+#UW&?^,G]#E?U6''
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MJ  C[_(Q%U@$; (+I0.\.H*WIH[[6;(.^PWK;$'<>O)37@$=UA$W-JVDF:2
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M!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&+'/VMS\!7\'/2-R/L/NPJ\Q[1[\1GI?\
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MZ<>O+4D:7BN(7XXRO#B._GMKQB]Q"WEAG [DV4RN@W=M!!'EI 3ON)(6-;$
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M^]H9GUY_NV7C/ACYF_5\W5=N,3 _@H]C7-^I \>F+"^BV2-7F,UN+YQ>!/\
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MZ:W"(1_A9=P?S.@O\V_IVQ9CXM*YHQ1_(6\#XD^&-C&\"F<8S\1P?'_E3_\
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'GF3XG'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g284543g26s26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284543g26s26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CL4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9J            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %1   "V          !
M      $              M@   %1                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   %1     %)G:'1L;VYG   "V     9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !40    !29VAT;&]N9P   M@    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     #D\    !    H
M $H   '@  "*P   #C, &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $H H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M4K<BFEC;K';MVK .3_4:C*)CNH:Z#5-N<?HCYG1/#P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% (&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0'_P  1" "S 8(# 1$  A$! Q$!_\0 'P   0,% 0$!
M      8'" (#! 4) 0H+_\0 8A   00! P(#! 0(!0T*"@L  0(#! 4&  <1
M$B$($S$4(D%1"15A<187(S*!D:&Q"E.2P=$D)3-"4E978I?&TM?P)C0W1':"
MAZ*WUAA&5(:3E):RQ_$G-39RA+;"U-7AY/_$ !T! 0 " P$! 0$
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MPOJ^(0RIXF4KNW&:279#G8CW66BISCGU40$I]5$:C**TO>^OO2,:I@22#<6
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MX4I/<I!/S(!TA  !Z #[AQ^[2$!2D^H!^\ _OTA  !Z #[@!^[2$! /J ?O
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M7*3"QRD5,9#J&([LE\+EALLE0:;40')C8*@4H2M1"1K?WDE4Q##$]IB2B<@
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MV%+9A3H\IQ/YHZN6'5]222>#TI/<<@'D:YDR5\I3.A5ZH(/B!41F%:LH.WU
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M8H+/*>HOM.*5VX!4LA2@.5)'/*O*S/@?XMQ*$%''5!10 OLR ZF.8L)9&P#
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M:YVQG>46WDE;4IYI[S&G7$*?W4VA)22"2Y2"2^YN12@?RBIEI-W/?&ALMI?
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MQ^/'RY^ST[:HS+#!K6KJ[GO.P\WBJCV?!^7WTU:-#M$$_BKV^*>>!BE0D?\
M-8*"/LXZ1]O?OQVUD_4L?[G\??[F.1C!0&[JOO0N;;^Z.7.92DE)^)"03V[<
MDC]@U));?4#\>_O&D+]*^%8OMCJ"QZ<=P?O4H?NU)#> /B'B)QS)&F4D CJ*
M][PHJ&P-=-CN!9"5.%MX'T+:B"#]A23Z\<>OIVUHXN2)DM>[9@P%#8TN79[W
M&P,;.!GF4N6_TDL35VKZ?D6M\77\*^PG)8_B,\,FX\A$AS#[W:;)<;JY "E1
MV;W'<E%G;1N2%(1(EUU_6.@<H\QJ,L]1+84CU'P',EY,9+.7YB4E=;U"@*<C
MRO=HZV++@J%>RP-=CH+[^&D<C,.<8W(P.A^J<F:4).(Y% +:(\D-PYMI0UM>
M]8QX=1$LY==>8#8,094&.$U7UXU;-MMVE='-BZ_[6>I?U"H#N'JP8'IW-=[O
M'%)4":!W(9]'-JM7R -&81&#Q89)0V>9U4&M>?DV5/'?=OG_ *PDS&T.S5L.
M,1W67)4N+'M7FV7+&Z3$6E"[*?(;=0D-(0WEPRR%&:D%*/J )8:T\*5JY/,Q
MM8<J:K$,SUT-".1:FHT+/'Z-'T(F#Y1M[]&#X2J7+HST2VG8'/R]B+)4HOLT
M6=93>9IC"74J!+?5CM]6.(:[%EIQ#)2E2"!\.X_,1/X[CIR#V3,-K7:@W#'Q
M;1X[6'*E20HAE.:7'*M&M3QY1U1N:"IR*(B%<P(EC%3)B3/9YL=J2R9,%]N7
M#>+3J5(\R-*99D,JXZFWFFW$$+0E0Y@)34%C6HI0QGAL'/#QLL[(7+7MIA"I
M"UQ75.G&:DJ+D%+:8:S_ %-QS&0RRAH !*6VFT  ('%_G3?]:O&*Y$^_?HT6
M)'AOV/E./NO[7X,MR3(1+D*.,5/Y:4CS2'W![/PM:U/++I4"'@>ET+2$A+YT
MW19[Z^_Y&L,HY\JFG2,M?A^V=<>1)=VZPYR0VW$92ZYCU:M268-?]50V6^MA
M0;9CUW]1MM( :$<):Z.E"0(,V<[B:H=-.C,T,B>9[_?L1<5L'M"ZG'$/[>XA
M(;Q%$EO&6W<?KEHHTS77GY?U<%LJ]G+[TF4X2D\!4J2>"7G"JH7,<J*R2??N
MFT"@'^3^7\XPE>'#8Y;CCIVNPCK>:6RZH8[6CK87$D05QU#R.DQEQ9<II<?C
MRE><M93YBEK5?YLS_4?)_%GB,@[J>C>>IW8Z0H+79S;.ZLY%S:85C<^VE1(T
M*182JB$],>CPFG6(;:WW&BL^S,O.,L$D^4V0E 2$HZ0FS1]*R+^>^]J_O$Y0
M;\N5@W=XZ"$^SX>MFXZVI#.U^$(DQ)1F0GACM87(LA33,?SHZ_(ZF7$1XT>.
MV6^@-,M(0V$I2 !G3C_W%;=PW8A^L,@W/5ZQJ\8\,>S&*,Y%&@8+3/0\HR)C
M++B):IDWD5=W$:=9A/PXMQ(FQJR/ 9??17P:UJ-"A!YTQV$%Q7,?-FF\PGWU
M/MMH! &^]_PT:K+_  E[!YI5RZ>SVRQN/%G16H,F32QW<;LW*]$AF28*;?'W
M:VV9CO*8:;E--36TRF4J8DI=8<6VH9LS_5K5Z:;@..EMFAE#-Y]_@[4>,FS\
M+6RUG*QF8Y@E)!>Q#(JG*J84Z7J)M-W0J0[429R:9V FU;@NMLOM0K43(!=C
MQW%Q2IE"A*ITQ:0E50X)V<!@U2>E!SM$A(%OMZWC9WKL>RWAVUJH#@$_&ZW*
M\@O/) /L]3.B-T%=&ED?V-%K927)$)M:DE[ZAEJ2A:8OF#'$P^I8!)/4>YY^
M&D(O:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0C7V,CV:)(>(Y"$J6>#P>
M$)"SQ]O;@?;J0'(&Y:(- 32@)K:@UC48Y&+-0TI?47WDF2^MSD+4]*<5)>ZN
M.3V<=6$COPCI3\-0KLDB[%J-NV[><515*3O4^R+\VN.<<Y_I(<^-5@./X'%?
M*96762Y<X(=(/U52%IXLKZ>%!N3.<C)//*5AKI5V!(^;_P!2,>J1PE.%1_\
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M[QYO%?U3^%,0")^/EJ!<$>@WL[7 /(1(O%\7W&890C)::+UIY(EM6$#K<'
M*F6WE@D^A*5A(X)XX&O18/@F+1D*W+72QNS$/K2]Z,S1\^X[\:?"20M<C%(F
MA1*@E).89G KHQ\'%HU&93(\*UPTSC[,FOS>H6^EQ*BIQ ;E(/LZ4)67RLK"
M&_)ZTN+(0@^]SKUO"L&O#K4%LFX;:X8[]W31H^1?%/'\!Q7#RY>%_0L*!+&@
M4E0>EV#-;QKIM]MNMQ9V&X7&Q^WQZ%BM!N*NZ;3.:D3;M34N=$L+>M:B-(,9
MADPFY3$=]]Y+K<A\.!I*6N#Z;"R\DQ9>X?E5T[D4+DA._41X3'8I.*+)04@
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MSHL5F&WSY<=ZR>LK-UMOJD6#A<*$44K+5B?^(?U:)!<7&YJ[1M$[$[5A"?\
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M#XZ2)BYY2*T.4%M:9M@+$7!I2/Q1\:?".-X)Q*8C#X:;.EA\IE?,4'#,[I2
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M4A24]G*57(-Q6PN*MHPUYQJ39+K<FK,Z7YVKH2Q'0;-<H[W;B]D>6<=5$/\
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M+<::EF2IMV._'DQW%LM^8P^TM2$%92,"T*0<J@QV<'T)B7??O!'K#R!M []
MYX]#[W'ZR1^D:K$Q;>C-/(*%I)!(/91[<>G )*0/@4\ $<@@CMI"&,%4S@V[
MU,]5@Q:W<UBUA7%:T F*]DM! ;L:V^0TDAMJ9+HHEI7V[X27;!,6D4^"Y""U
M(0^I4CD\N+!Y/('H._I^;\-(1>TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0< ^
MHYTA%E;#3G=: 2/0_$?=\!S\1QP?CJ"^A(.XARTVC17D1@ULY"$A+BH[B@H
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M?FTRJ4SNP51VJ_-F?;QC&52UFLM+@"N4@BAY-S I7K5X\&\%6\!DLI3+W6M
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M\I)K+B9.C*F,5<25%I[.0S97DF/"FQZ& E,8/2+E^+,]H9@%A#BXT6<^%+3
MD<;4_A4W#D!18%(6]&KT-V%ZZ4UC:PV"QV,5ED!("J=HL7);D]QI5P7K1_=M
M_%-M,^Y&3"F64M;RBZ@>PL0&DQF41752GY]E)@UD5*T2V4".]*%@AYU*%0T$
MH!T9LTX8/GSHJI1"LP?9P:$"I<B_.._(^#>-3BD_-DD$!P5 LYL0231ZZ,0=
M8E'A?BQP>Z7":QJLO[UZ1:1ZJ&N,Y6/0I*Y<6Z>\WSJR=:*8\I-%+48S[2)G
ML[T*:8WL4E+YY&)X]AP"E*,QL0FIU-A8^C1L8SX,QV$EIF3URF+D*20 /I!#
M/8Y@SBE-:C<Y3XH<K<1:Q,4VTO);\>9;U<">E+]M%=M*N!D;SL>3'K(Q?C+4
M_50$1?,_)3%3'(S+OM;26'.!B>/8F80,+A)_9^I00L@A5JA/*K.1XQT,#\)X
M4)E3L1Q'#)2HETJF2P6!%\RG9U%WW+B';A6V166R]Y:Y2)R;=^JM2\B952J4
ML)*"$M,0I,"!)3'0A:?+<?CGKX6I,A]/*D^K^'YJYTS"+GI,N<J:ET3!E([0
M()!8BGGUCQ_'</(PF*G2L/,1-0D#*M"DK27!89DD@UT=Q;K!5()(''8'CD#C
M@#CX\?'C[_3MW.OL(ET2&+E)) Z@ 6/BPTI'E5XHA:I:RK*E((=V?85J-J1D
MI9!Y  Y "@3W//KR"/M! U< Z ]&-'Y:?SJ\:AG9E%Z)(54T#BSDGF&$;&.C
MR@%<E/8<K!4D<GGXI(/(/;L>.?7G4UIN#][,7\&C34$J(S2S-2Q=(<O>S?Z3
M6G-X5-18VJY4:)%D.NNOO-L,,E1<\Q:UA*4@'WU=1[=BH\'COQVPSC+E2U3)
MF5*4 ERP% ]RP+^AI&D<.B?-2B6&*E !#.=+L";/H&8UUCGO]/EX]<S\"WA2
MP7:K:.WDXWO)XA5VV/1LIKG0Q8XCAV/QJ][-;VK="2]'MICEO"H:R6A33L15
M@_/8>2]#;!\Q\.X"5QCBLZ?.94F0OYS$$YP"6&H(9+][F/6I0<%AD2Y8 [&5
M20"H@$.20 "+FIZ6CXAMMO#5:;GT,G<#,<V7CK=T]86+#E@$65M:]#SCLR[G
MR;2R@,QX\AQNP=:?G3$R; Q)JX_48SZM?5)J\/A)0&'ELP#!";:6 TN;<V,:
M9GU[([^=_P""S7M00W6>X-G/ARS_ !F[QS+IT.?#EM7N%9QC,N92SZ^PJY@X
M6UY;C4^GN*RPCA$MEQ2%L2&B$E;9[ZXP\K'AIR $J<$+%*Z5#AVMNU1%D3%+
M<D5 %G:MC<FVSN/$?HY?0B^/&^\=_@YILKW"=8?W<VNO'MK]S9C?EH.06M/6
MUTVJRU;"$(3'<R2HG1I4QI(+2;1FQ+'$=30/Q[XDX6GAG$ERD B676@,R0Y8
M@%F(# MH"!:.O(65I8L6%37>FO7K>.L=G5XW"@7TB2BNB0Y3$R7?.I;:B!]K
MV);4N7/>:#:W'/8V?+<E2%K<0RRA(<2VTD)X$9^GL1$E6S/@^6WD5\^WA;R*
MJ"PQD=W-R^2'JF/($7+:V78SY=TAR&_&1*KKNILG743(C!KWH,I+;<<)SB;/
M   5E"0 P47  Y<J,\8SEW+O4!@:T[]J._>3"APC:7PF8]:8_EF$JVYKK&A\
MZUI9=7D40I@JR%2*E^8(R+4LE=G(::K_ #I#*E.S([4=)]H82VBI,Y3DA9>M
MB0[5:F@BX*0+Z4<^K]_L-#\V.[^V%(RP9NX>$Q6UO0XR79.44S:2[.M%TD5)
M/MBB@R+E"JEM;@"%V250@KVD*;%"E5RE7_I(^T05I%U)#;J'YC,B;J8#,N)-
M$SFF)N6<-I;\J$WD%6N3';9E&$^7VTROR2F9*5,NMJ_*MN#\HA">^F1=\JFW
MRG6VFL2""'!!#M0O;I"VK;6KNH4>RI[*!;5TMOS8L^MF1Y\*2UU%/F1Y45QU
MAYOJ2I/6VXI/4".>0=5((H0QV,3&?I"#2$&D(-(0:0AH,Y_X1-G/^4N5_P#9
M_>Z0AU](1D:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@/'Q_;I"$;:H1
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M1]"0=60I25 RE9%BZGJ]DO73F"]:184J 7;6VM;68;CO#QBU>"XJY9_62**
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M20H CGX$<'58B*M(0:0@TA!I"&@SG_A$V<_Y2Y7_ -G][I"'7TA%Y2@@%2N
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MP4\EG8/9W.AWT[W'='W<[);)[>^'W:W#-G=JL>@XK@& 8_"QS&:2O;"6HL&
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MP+!=3$:A17K)+V.M>RUTBSNI]J[&9BB"E4DL^=:R8C+"G/+6XESR$CKKG,"
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MWEC3NF,)*I>0HO\ V0Q8<%AB7%JK1;,:2I#L=3JH:ID9:G1!F(DJF5;3JNJ
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M$V  J !T:WAT$:N*2H*2)4M+!(=DAG<@LU#8=:,+F%3"P>WL74,U]/8V;KA
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5A!I"#2$&D(-(0:0@TA!I"#2$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g284543g27s27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284543g27s27.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )J"^F(@X0DE-! 0      &$< 5H  QLE1QP"   "AH < E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(#(X-#4T,U](>7!E<F9I;F4@+2!0
M;W-T+45F9F5C=&EV92!!;65N9&UE;G0@=&\@ #A"24T$)0      $-^1K8CP
MP9^>#.A&VJ(Q/P4X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8Z            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              $_   "[@         !
M      $              NX   $_                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     '"     !    H
M $0   '@  !_@   ' 0 &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@               0  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 !!0$! 0             ! @,$!08'" G_Q !'$0 ! @0$ P8$! 4"! 8
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MIBV@LI293;D9A"^E) 4$-N+3R>0.>!ZDZW_"$),J<MG6D^$\F<D5;3;]]+Q
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MS=[_ &T&Y_A/IFL;%AL^[)J+^M0[(546%E)G0[QIIHN>ZH<E?^C2DA/2POS
M@K)01R0=96'XDBG?YB21<FEW<^=][N:BS,X4);9,H(!8@=.;&NXN-"YA&F+L
M;O2K-YAS;K,G5P J(XMNBL^CSFW%I=(<\A33O*T*Z2VI2%^J"4D'6Z.-P61)
M !!0-:EQL[U:[;QCH_,!10$@Y%%+Y6HDY278!RVA8:Z,LW:*QFT%F7\^VUS=
M$3W"6VEXU$U(:>7'*$J4TJ(20"K@*[CN3QSQSJ\3/3-7FDK$L, Q5L;L^W3Y
M#:2"I*66@DER#E!%69Z<BU1?UYCD69M)F35QZ^;6M%YX18\WSVWTI4XOI4LN
MML@@@)*OD'2>P]>-60L(#JFYQ9B2:D]03_AHN=_DJ964%G="2[ :97WUY:1A
MZO(GGUEQPE;A(44^8GCCZ$<G^'MZ\]^/OJXD=X4E))3LY\@6U_:D/S0- A-1
M3P(!85L0?K5GTC>L=MW')<I?0!PEL@E94.>KUY20GT'KW^O?Z:O8;"KFS""7
M2"7&VH-B3<FAVJ;Q;5C):"2I*7H[A-GV '+:G.$ [H[]X1B6X^:U5U)LEBNM
M?,>36UDF4PMUR,RX$*D,+0WRE+R@I(/)/!5U%/.JL=V8QDXYI2V0XM6@%18V
M(:G,NT;S!=I)(E.)2' H0E/06=_,U>IT')+3?6ERV$ZK$XUF XYY:56%<Y&#
M2#RE;K:75DGOV'')Y[C[G1XK@<_" #O&":E+DN_B(!8DW>FM(W?#N(2\>9DP
MXE*.\2?!D0P"1D()RT!9R"Q<V+0Y'[*J=9,[DYY5KDN*@SL5;M7V%=7#DUN=
M%;0Z$+7TMD(6I'*$CGU5^-LA/Y<A@0XS%R7(H][,6+#J-8Y?B<B5)X@#+7G*
MPHDN*,QJP9W.@T;G#[RVT*0A/"@>""E*U @\^G90'/' Y) _$:Q$C*@9:5ZW
M+:O%AJOJWL:PT3O+N5OAM1XD]_',2W-RW(,?V]\/N![J8?MQEB,>D82O,,KW
M*O,/GQK9ZFQ>LRJ7CT*KCQID>O9R5B6S)8)58K0\ORLV0F6N6$E(,PDC,200
M"@L0'9@H.7$"0 2= [#:_P -'=XX1FOM3]ZJ'=3/MK$8CM9<-XQ)1CD?+4UV
M5U-909#5[HX-MSDUYF%-*RI[(&<4C(RN;:PU/Q<>0L5Q=B7-W C//NYLKAH6
M$DS$AZD$AQY"@WN2VFUDSDC0UHW,.3H.5/A";L=]H5XO)%72Q6L\P^1)_I)Q
M6!?YA8T*)^/2L2OO$!N;A#T>B:B2*YBMAHQ_'ZEB#=6,FR6]%0R"^B:ZY+7G
M_P +PW]R; U+ 5J'=^0O#\PFX2K5GY <KEZ 5!UI"A<*]I_O/&H*><[@.+VC
M\:)1,SJ2V5=KSW,7LG&;27,PQ01YD*$]A&&G'H+%\I4&:_Y(L.JSC+89#F+.
MX;*23EFI8BC*! +"EB[]-]HD+*AF'A#M5MB^[VI;Z:CD?M@M_,8VZL[.UPC:
MA>>)Q[ ,\IHL>MRN+B\W%LNV?A[I6=(_.MLMKVV+ZN2\[!B2UVB/?06!7T=Q
M,+D$6I7"U35* FH&5KD.35^EMJ:Q4ZM]3H 35J%B#9S2CU.VZ9_XKO$Y?^!#
M>O=K;O,WZ#=I7BSK,&V[G.5%3+;I,4N\XQ6NBXTW'FU4B/(A(@V<NN5/EQW)
M90XI[SPXE!12O!IEXN5(=)?,Y)=) 23>QH^VVD H_'4;$GX@7TJ0\(MV\]H-
MXUMW\_R.RCY)N+'P_*=T=@Z_#MM<+J-O*#,HN+S\1W^JL\IZ6VS+&IL$6&49
MGM>S8L/V\A:8Z&(C<-UEF4XTO<3^'X-,E'=*0)C.HJ545#AB0[#E9ZBD2Y;<
MV+:&VQY'6Y+4:%^^!/Q3^(O>)O=29:YG$W"MZ/PT8GN)AN.7U7"KDU>XMGE&
MYS*<3S:355U$ZK)ZIJCH,.S8UZ8]6U<55I/K&V8LAEUW38R5ATK")20CQ-2I
MUK=1:EB79A=XAU$4=Q2PJ:#F+O\ 6ACA^%>V;W]W'L5L4>PE#2581574V_R>
M/DT*HH<$GY5CFS%OF-\3(877Q,0WMLLF7>QGWF'W-OL.DVL9"#.39MW!PS#*
M2%KQ*4J(?(% FSY:FA;0V-&B?&*@^>WMJUJW:K/&4W8]I+XJ+S;C=Y_!Z'#,
M?F[6[;VN7NY7C%3:6TS<.SQ_?V7M; D;8?'[/X%#QK,ZVM1*@2;IFUD1$S9;
M2Y'0(5H">'X8%&6;G$Q64N1X#E).9C3Y%KM6'5SI8$,XI];4+G_ZC2,H\=7B
MWS;+=N\SK,PK-OL>D8+M#<9)M3CF+M?$861Y1XH7]J\IQ3)+#)$V;Z,EJ:6I
MDT]L&VZZ&);[\BJBAE#%JNH\+PZRI*YN1.89%$CJ[EK EA5R*AVBE4S('()%
MJ7)9WZ&A9GJVE>I9;[6G?S$,-E9I7;/8'F<!57C5_*KL:CY:[8X/(SBXS3#<
M8V[S9OXFH)S=.7U6+_$UPX\1AJJL;5YZMAB-$?=(X1A HA.*2[T\0=5 ='I4
MAKECN\09X+#0#SZ#ISITA4NRGC5WDWU\-V4;I6^'UVV]C_2CBVSL)V+#G*>H
M+8SL>QC<G()+-V\ZQ.@8[ED^ZAT<IM/NLR-6MONI= <YP\9AD8=92A68"KG5
M[,U?6C,7+N7?)V+.S[<VK1K5!)Z1H6:[S;K6UUN<QLWXBJN=AV/W^-4U]D.?
MY?MMB"ZF[KLDLG\LJ<(G0L+R&16US57#:Q+XCD6+7,:;=K6Y5S%%F0\BE,I)
M0AP,RA9R".9;6HH3TUBK,7=R0:\P&<,&V8&]+F+[Q >)_<*-LWX?LHV\S+(,
M#LLGH+V]OS=N8D]?29%'0P9D./?65E2JI[02);[D]W'*2IILAR^L=95CJ:\K
M %V5A4**@I26 !<G0C0CWVWBDS@DL026J0?N]_.-_P!^O%)O3M'O-C%IB+5-
M?[=#9K:V_P NPRWI)[=Q:7.?;QQ\$=GXN] D1G:NY1%NH#IAV?OT,L12P8B9
M:TN.42<&9JYB<X 00U0+D[BMO7:'?IJX+_$_=?7SY6U[3?<VN\YS(:7:SX<O
M"\LS+XU7KR"+7T=E'VZO\NQS;.Y>G6DE"\[AVU(*^]CL>6N3'ELIC5D"66P[
M>5@ A*E*704N'N XMJ=8"<%$) ()WY&OKY7OJ=HQSQU[^7XV]LKFFVGI\;W
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M>W2.W/IVX[?R^GIJRI2F+EP4F@ %*B]:TOSC+)(>MRU.9;F[.=*QO$.3YB4
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M:0@TA!I"#2$&D(-(0:0@TA!I"#2$4EN%*@D 'D ]_P 21I")QU?UNG^1)_Q
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M\24A2@0DJ(#@-8EPX8!S9X^J)'$^%<*P\N0CA\A,J4GN@HA !4!F"?%E#EP
M$U)L6M=X_9Y#MG/3E6%9<I-C46$1B084>?%;?4MUU'0^AX,-3626>E3+B2%
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M8$#4FE]7L+7(K&TEME2%!@PNXTI04#WY.:QW*)*!J90\XJ_W0DDCN ._T^Y
M'T'H3^-** J%2#04%6W;D'H7ZQ6%.I*?[G+7?*&KN;,/.]83CX@=^X>Q.W*[
MQIH3LPR!]%)A%&CEU^QO92DMI<\D *6Q$2HN*/!:+HC)4K]Z.G-X9P+&X[&R
M\2M+X5"PO$$U D)(,QZC^DV:G(1H.-\3G8- D22RUJ"'!-,SO2MF ORU#[/X
M/O#?*P6(YO'NX/VDWHSE'QF=-M2W*5BZ+!*GOAL OATQY'0\$2'&TI0T.F.P
MWPV77<_M5Q_"H6GA_!R/X7+>6E*"R53@  3EH').KLW(C)[/\*65)Q,U(49A
M"CF=R2:N[L?*CFK&% [C[XMXL\]$B)8<,7AM3KR^?G1QYC;37'9*>1S\QZN>
M>2"$CQ7C/%)\B>6+!W</:A-W+AZ&S4CU?AG!<//"?"*E-V<.^AO8C2HM%AA>
M[L;-X+T@MH0_%>#4I">$H2M20MMP)/)Z5H"^#QV( )'5VO\ #N)'B$LRU*)[
ML$FMR- +Z>W(B,7B^ '#)K(!99)\2="20P)/(/6]3MT&+F/NK@4DJ*$GL4GL
M0>P[ I X (/;GN._.LQ +7_J+5).@O[L79JT>-3FS*!(%0/9ZBER>?[=+I,V
MC3$A)=4E0(!22GYN_'Y]N>P!X]>_KQ<RA04:@I!4"0:-K3+4@5Y'9HV,HY0H
MAF J&N/7G]UBVW'VWQ/>3&)5'=QF4S6VG'*6Y;0KXC4SP@^[NQ76NE\(#W0M
M;25?3E/ &LSA':.=A)Z9$PMAE$)F@ETD6S6(H;:'6-1C>$R\8B9B)0'YB6DF
M5E2YNV]V=]3UCB/A_P!T\EK\@O\ 8#=20H9UAK(71V<KD+RC&BOJ9E,*("I+
MT>,Y%Y6E3B_* 607$*&NBX]PB3BL&G'X<)4E0SYD@ #2M214,:;DL'$8' Y\
MW#XON,13*69R"U+.&#'8EO:%B8HXW(LYST9I"2:UIE4@=*G)/F.!P^4_T_.R
MD CJ'(2K@#N=<-A4GNE5- 34DV(9[AS7>A-3'58Q??3DLS4J-"-RP?9MZZ-&
MO9ODT>M-75S$M^3/5,8C%:U*4EQIGSO=4M*Y0^V^A#@<:7V7RH*'"B#JL82*
M7KYW85IK1O2I:-SP_#@.3497/.E#Y!F)&VE V![-#"8>WOCP\56,UT5<*O@U
MTHUT0J)9CP)5U"L6&6$* Z&T>]*2@ _*GC@D< ;GAP'Y=?(#X<C\MQI'$<>3
MDXA*_P!25DU8_J'5M"7OMOZ#D#E:?_>!_3OK( 8 ;!HUD- ^W2C7<[V7_BN3
M1![SX^(TTJ=Y*5+4*6-E5'(N@OI'/E*KVW4N_P!5*%*4HD I/2=ES_Z[A@"'
M[P TT5+WU+>F^UB>Q010,#\7!/F&?2D?/=\-J$R-OMPD"6Y%_P#.7%7W78\>
M1+DI:C./N2$,1(TN!)EN-)05O-19;2TLD.N%Q@+2/;5_I6:W&CZDZL1UN.58
MU$\@J!UHUR*=+OI3YQWJJVI1DNV+V(Y;D[M78YW!QVQKW8]1/>B4S<2T$:G-
MZY86TE:'[VR*H#$:*[Y;029+*5(2\-:TS6FI!L?M@]+?'<B* >H:KFAW^]!I
MR;^I,<NZK=BGQ"$%+RBNW IZ2N]U2IXJMVLBBQ(+D4IY>45RPTI@L]#G(!0M
M/98S<499P.+"V<2%4+58$C0@G1JGRB\@S"3E=@ VE0?1C[;B/K8;:U6Y[. 8
M2S-R''T2V<2QIF4V_B\YUYN4W2P424NN#(D];OO =+CA;05*5P4\IUX//[GO
MIC"G>+9C_J.P/K8Z4C/E"<150%$T*:BFIS@DC<ZOY;JNNW$((&28TD_<8G-^
MGK_^DP/^&K0[EZ@^I^@^,5J&(8LH>0)/IFB":S<;C_UDQQ7KRH8I._O_ /.4
M^GYZ$R= ?,JI%'_%6!#'4IM_^H_&-5RRGW$:H+58R;'WC[LHMMHQF:GEWMT]
M75?/IX"N.3T* ^Q!(%J=.P<J03/0<H8DEM'Y%GMRV,7</A\><4DR<44EZ!(8
MZ ,HK-NAY"M/,IXI&L@B[YYHG)WW)-\Q*@.RY+/+3,CI@0G(3\5" KR&41FX
MR$(!XZF5+)^8I'Q?^+TW 8GM DR?Z%::EP;Z ?&INT?J3_X;<'-E?ARM?%,5
M^80O&>"4I05Y%.8ER2P# O6M8JX9N':XK/BSD-L6#EOA]F)@DI2'%.L+ME-J
M\Q* M*TCA*5\\IZBLA2NE2>3P/&%8?%)09'>$R6S,[!U6\)K2UND=EQS@B>.
M3L3AF_)2\/B\/,DH!*<Q:4 2V7PG4 $:1R?(;VQM:ZM<?<+2;(V%A+::2VPT
M[+-O8!"_+:;0GY4A+:1_5 /2!U$:T7:'B_?+0DR52PI05F 84S #](N2_4["
MG3]FN%H25E4X3ORV64 HO_2DE3E2B+'2]'H\.I^S0BY,]CF4FIG18,=.5UWN
M:YD"1/:4I$)SWLMMHG0^E)4EA3O0L@CM]3Q](?@DO/ALQ)RYR]#4!^=#<$7=
M]H^+?_%692N(24R@GO):638D9<H +A[$ES9B]:P\BJMW'Z049-C82>H]L6F]
M^25?]HQZ$D?7GU U]'?R?]7O]/O>/BI8Q9_2L#_Z.*M1PO3XP"KW)('.48]Z
M<_\ JG-/T_\ XE'^6JOY(JWN3[/\HMMC/[A_L_\ ]1 U>XHY_P#.C'^H#Z8G
M.[GU'89-_</7\]4'NRHG^DM1CY_;Q4V);]0SW)RBUAJ_W>$%^-6KW;;VXSI[
MXY32Z-O"I#<B-753M=,4IR='$A:0[+GK0VB,IXNJ#R>4!2>.">.)_$+\N>S^
M),OPJ[F=F&I9(VJSDCZF/6/P/$\?B!P<8U258;\S+/B#!ZBQ)8V9C<TVAES9
MEZN+-U%LY*TQ(ZQ9REI0\U%;BLI!"D/PNJ5YR'&0D-J*$O,J(4I8)"OCK@B\
M-+QN*7,;(%K4LN<HJ;@.2<Q K;=A'Z7]L.\3,PG\/ [HRDH44LQ44IH'8,[*
MKM2.GR[3 ,RAWS;-?4RY,1"YCZ8D>8]->C,H679#<E=?'<2\V4 ,D+<3R%*Z
MCR0-E,F<,Q*IY:7<J\*:MN#HS7-P]!2-#+/&N"G#8A!GA$TH025)0AB0$I*$
MDYC?1[!Q1]=\'HG+\16%&D4^AE4JX7)05%;PJO<9"S[P6^%J0'!&2H+<2GJ2
MD#A13QD?A]AT_P =E"1FRF8H@I507_4+G1G--W:,'\;IF$F=@S/Q(3^<*1E"
MF"LP6DM6KNJH:PJ2\>E/'(>X(I:[HR/'FVRP2TV[BTYYQ+1/4VEQQ.1H#B@V
M4CJ"4@\ \#T/VSA @8:2)@(F=TG,=R$Z_P"7.P-(_+3'39Z\9B%$!S.F49ZO
M3TVIS85C,*C;AI/;)L92./KB,X=_YY/^6LD"415[[MMO&"I>(#,PZH_<_;1$
MP]QE#A.3XPH^O"L3F <?F<G//VX'/KI_)_U<ZGZ?2("L4J@(?F@ >N;Z1@;^
MLW3<I[5$/(\=7)<@2DQDHQF:V#(+#B64A9OW4H)<Z>%E*P">>E7'&KT@X839
M9F.4=XG,Y8A.8$GT&MMF-</%)XCW4TRYB"LRU9 )9!S96#,2U2'9SJQ:GRZM
MXJ?;^]\=NZ5"[06,"@=W)S6+;UV62@])9OX[TH7$J>[+?C]<==\B5-9ANR%J
M\AQ#20L>OO$B9@3@<)W!!1W<MK54 D&CTK>^[5C$X?\ FS(E_G3_ #<RBHD%
MPDJH.98BK;0IJ^V]L*&LD+BMP)E7&JD&LFT&/KKVX\B.J/)CQ73&GUSL^$Y2
MPI:X%/%5)2].F-RD1/._>KL3 5*) %22;O4^]&H'-P':)61F)34!2F)+N#9K
M:$49[;&$5>)N$FOAXXS-2&9T>QMF8K3*EK;:KU)B//QV0.IE*(K[\9ORV0I+
M<SWY"2 TIO62/^5*!T632E"; ==:G72+LG*;,5/YL]";&N]/*/:)_LT%#N2S
M[/NTE,VL*NH[#>S-I&/(LZ>3/0N(S$IXL]4-Y%M";3'^,,SU% :'[Y;AXZB2
MKR;M7W(XJL*#^!)I0CFX>]6MI8$QFH1B5#^66%:,[BMP2-^;>T>BCX=N.T.L
MY1C7  ''[*S3QSQ_^\@!_D?QY/&N9>2="D;NH_+X#YQ<*<6D.9B3RRVZG-\K
MQ,(FXJQP,HQGD]@!B4WDD]AP1D_([_AJ/Y'^H]'^8^41FQ-LP<ZY00":7*Z<
M]HIKJMR0DES),<*?3A>,3^.3Z'YLB^GX#G\1JK-(_M]O\Q;,K&#_ -Q/DD__
M -GH](::]H?7;F,8)D3E]:55CCRLDQSRV*^O>@+#:6Y7>4CSY2TQO>Q#X2Y(
M<;Z@"D)('/CGXRRL*OL[,,O*)A2"H6+G*%#?</J]0]_J3_POY1VI4.(U\?\
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M%;@++<>=+4^IH+5)+47H"G7"E/8>Q*4\Q 0^5*219AH&%03H&-;AZ15W$Y"
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M3Y*&^G@) UX/Q=OXAB6H.]7[J/WK[QM<+64.FNI=BVG5N;DF'2CZ_P D_P"
MUK(R(:(]I?8IA7&U2P2?W&0(3\BBD*\VN'/9/ 4"4I4200"?QXZ+@DA4X+R4
M.9B1?3H=:?M738H@XU.9CEED@,X<%K5T-6KY&$*X9D@*5)45J45 ]N5#I/U(
M]02/H!S]QVUN_P"'K=0=1-:OKNSD["NG4Q1(Q9 .8OE40Q(L%$ 5Z "EM!"D
M:ZW=75R.E!ZC$6$I 4 LJ XYX']_;OZ_74+X;,5+$M!4E:YLME)OE?Q!P7 9
MZ$UM4TC)F8Y$LF8$@M+6R@'(410BA-[4U!AMFNER/$1X]FZ*9'=FX1X;L<B6
M"H#C:A$>RN>M)9);6GRN&9RO-4>%*6W6!@'I0$CL\7-5P/@$V6Y3,GX-<K-7
M.2L&H4DDO0!W;>T<[PE*N*8^=WR<Z05?K\>7*:L%VJX-6+.SPY]E&;WE+"?E
MMRW061YX0"2"I'HE:$GI/0$^@Y2I0Y3P3SKYZ5C9LK"*PQ"N\3BN\)KF8*)H
MJQ>WZG9S41Z]PC!24)0%-E3<$)8!W< \K;%J /",\SRAMV-8YCE%A!KXOFOR
M0_;V#==51(S'"Y%A:2I ;;CPVT)!;*3(=?=_W>.PZXL <CQ.9/Q\PRI:59R6
M>N;36C,12M6'-NA/$9&! R!)RNP!#4\O]5XP'ADWPVIW#RG(J/&-R,]RPP_=
M$6UCB&%Q*K":AEU;B6I0L[>WB65A&X"U"483*W&TJ6TGA11KI^RW!9TJ4M2T
MK)(JZ:EP;W)K<DO?>.;X_P!H#BDH!DI)8 *8$B@9G! T+AF-!H O6JH57>-V
M.98-G\;(,9IYLN'/>N69#;C3T!T-R8Q9CLORBL*<2L+80ZD-?O>2CYM;7%)7
MAUK0);5)'A%":<V=CI<FM08TG#ES)Q>9G;0%1H+T#C?0-0](V#&F[E_(I=$X
MZW7V-6%N629;RQ'9;2 XS*;6$*$B)-3P8CJ0D+;)*QR%=.N[U>;Q**$U!JSZ
M%)U+"H#&FD;N2B:9BD)SJ"@V5Z,YWVT+:ZPJ##85[)K??DMLR?(6MN4W D-R
M7X10HJ0IYAD(>9ZD@+844\*24J0HIU0G"R\5.24SLB0<Q*%90P!+%B*48ACT
M>+LQ:L&H HR*704:A%7(&@)+,]7)NZ5?%AA>2-7>T^]&W]5,GYIB&9T^.VT6
MLC.KE6F.W<A,14:0EA"UJCQBV([I65):3(*EI0VA2AW_ &8Q\J=@<1@,6K/*
M0E82N80H,_\ J>X(9G8.:&W.<2DSY:Q/E)*%*7F*D@)4QM4 &^AN=WHMLNNX
M>S2B%$+C"6DQ784>3YK\2*EMGWDALJ*EN-O DH0A2N2M7202=<9CUIE32B4R
M$$_T@)!J;A+7;6FNQCI\)+5,2E2R5'*DL7+. K7=M+5>.";KY)56UY0,1&I+
MK\*\8>@^>6CRJ0UY,E84TOE*FD.\=+@!22KD<\G6EQ2<Y!2[$AOO6HJPJ\=/
M@DD!;W"--01UL6J_I'!?!BGGVB7B?=6?WKN'T:SQ_64IBA"E\C^JYP%D$\]2
MED\$G708"6$X9=*DIV=F+UKL[6CSWCZGXA+43F "PY<T\--*#U%QS>V:_P")
MZ??M]O\ Z:R$I#6!J0[;$QK#\A[@/'(O$!LYC6_FS6Z.S67,J7C&YV#Y!AER
M60@NMQ;NND0UO-I6I*2XRXXP\UW!#K0)4D'J&5A)ZL)B9.)EDI7*F)6Z24J.
M4U\0K44BA:0M*D[AGCY@/C-\$GBH]F_NID^!Y7 RZNPU^SE)Q+="A:LHV(YM
M1QW7TU5BW/C<PV+)44@RZF4[[Y!6^IL!;:TG7M'"N.83'85)4N6E:FS)*DE8
M+<PX)8@W\[G5S<,JN89JEB*-<!^7/X&D<)Q[Q4[DUE;6UMA%H,MN:@.LX[DN
M15PM<GHU2"E"16SB_P":EQA7"HR"@I:=Z5)Z5]/.>%X,@S3W:B@N5,"S<V.O
M32U8M=U346!<$N6TU-FKRA\_V'7LE=UO$%O]BOB]\0>'7..;,8%>MYQC3>65
M<B'/W4S!I9ET[\6%/;8D.X]7RA'M'[-UHQI;D=,.)YR%K>/'=I^/R!AU83"S
M )BBRC)44*"2*N4Y79Z DA[4<QF826ZBXH !XFYBQ??9Z6HT>_RO;"$NIX'1
MU H[<)()4?E05*Z0!PGGDE7 )/8:\P#NHER22:EZ1GLUF;EO5^NE1&0Z4_V1
M^@U,(@4(X/RI'X\#M_=I",38P1+B2V%#Y'V5I"@1RD$$)4#]/ZIX'T_NM3Y<
MN;+4B:D+2H$$*2%"QT+@TY=!2+F'694]"PP"5)-KUJ"W76G2&,O'IX7,GN;9
MW<S$ZE^QM(,8L9#6Q&^9<V#%:_W.?&;'"7ULLI]W=0@EU;(0@ I2!KYH_%/L
M--QBYF/P$E(FY@L"2EE90DN2$,*[;AS45^V?P'_%# <,0C@O$)X3A9BB9:9B
MPF6)V9JH6&S GPK(<$L-X:D:R2VJ4LP7H5>V_!COP$BPJ6E3&VGPZ'F'R\M+
MW/[Y:2E7<$'D%*N3\]KG\:P2^X3@YAF2W29IE$+-34K8J+!VJ;L[Q]D85/">
M-J7B<-Q(?S\JW$\!0RY68I-4@@4H.49[&,3S/=*[JZ#&Z5,Z6WTQF6ZNN,>#
M$:=DJD.NSEQVULQF^75.><\L%2N"E*@HJUN.&\)XEQZ9+DS\$2 H+"U2GJ"4
MU)#D/,IFL1<%C&IXYQ_@O8W!XN<KB$A"RDJ5+[Y 6J8$@BE7!"2& WJ\>COP
MB;$1]I,&I:5*0^_%0J7.F]'EIG6\HE4AU /"E--<^6T%#@(2D#C@I3]>?AYV
M93P7 )>6):LJ79"4YEEBJU2-"=="S1^9_P"+/;=?:_C6(G9U9$32$)SJ("4D
ML*,"7)-*;O4PN-M 2@ I (YY' ^Y_P M>F1Y Y-R\5-0PV'I")5< *) /8\]
MAW''<'\]3".-[IX1'S+'+"K<:#S4N#*A2(ZP5)?B/MJ0\A23QU]25E(X!(44
MDC@<C0]H.'(XC@)LDH"W0L9"E)"@0 0RJ>7GUZ;LKQE7!>*X?'!:TJDS$+04
MD!EI)(+Z;$TI<VCSK;T>'/=?9F\R$XE GV^&VJW?+F5\5<MR)'=4ZE4.7%:0
M\\T]'"PV7DM%MYI:0I1\M0'R3VE['\4X=B<4K!84IE3%%A*ED.G,4LI*0SI?
M85=M#'Z)]@/Q,[.]J\'A$<5Q4B1B)" Z9LQ",RT@>)R/$7&KM32R;,/I-QE6
M#T#$L>R%^?8-""\Q%J)RR4+)04N<1>AD=E!:^4#Z$  $<-A.#]H!B%(3AL0
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M:.)FK5-69BB2HER34F[O]TI=HRS:BI )]3S_ '$C5R*(GTA%H[)0VM25+2
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MSX[ZD6#!A")]3"&'_;"R0P_LJPMJ2XF6[DZ4NLQGI*&0A$!0\Y32%%OMR.5
M ?<'@:Z[LVDSI,X)(02RG+:BUS[AG (M&JF358?'A8+A2<M" 7)]#2C GH=6
MR-J6BJYJ&V''77C8,NG_ '>0IM#+:FUKY)840> K^HKO].W Z?AB%X;$3%*4
ME0)8=#0\CMI;F\43IDS).E%8=2BIVH':E]-:LVEXZCF$^.NNLZ^*)*4RFG8
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M,*=6LJ*H\5')"%=:E(2=;8=KL<)*T39RE&8D@L0&+6M:H&P;:,B5V7D)6%!
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M*)8@OH:E[^0+TK[0H_5F+L0/8'\CI"+)UXJ:4CI5RI/\:2D)'ISP3_I]=-0
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M,\YDS$NL)9JV#:T<L=F<O=HZ-/WMJ\P8$Y=GD*8'28S:)@]Y2TZ5)*^I"I_
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MNS4VX6\:<JW&W4R=UIR:^[90(%1:2U*9FTZ(/2WYC"X[[?SI24]( <;(Y"T
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M/B2I+R5!Q(0E8;3MN&8+BLJ:E6)FNA*@X*B?"""0 "U1N-XY?B^/[/SY,Q.
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M68Q;*=.RJOIY?NEFGWC$VXE?4660&*]95D>LC%NMZ8Q5,<:6LY?YS!)H,("
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M -+!8NQ :W+?K%2.,<42^>>L@BC$5(:M;EJ/6Y\L[']BI/C-@)\0TH\=^O\
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M@C[CC2$6;C!2>6RHE1^;J5U <>G'/)^I_P _II"(F..CJY47.!R >!SVY'8
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ML\81&VFXZ*VB@JWCR)R95VZYUG;G%<-2[D%:Z6@*&7%15IC08J %D3JYEF>
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M0B:3MWN"^WE[;.ZU]#7?OLNX\ZC&L1=5A#;;P==CU@<JUHMVWV?]W*KP374
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ME2K9$F:@,I6VXE:U** +5UTC+_L5G*;UBQ.X]NNH;QQ50_COP#'?=9=Q[GY
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M&-XBM6#L-/H?=BUR':IUNY;D-!41Q=TW)>"%%UEUMP A#SI\*Z??[[]45%K
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M_(^X_4:G.G?V/TA!R/N/U&F8&QKI0W](1'3Q_P"GWA!IX_\ 3[P@T\?^GWA
M2!ZD#\]';]1')GA$.1]Q^NF8&@(?1P81'3Q_Z3T=_*$4B\@>I_P_UU29B1=Q
MU;ZPB<+2H @^O_/KZ:JSIW]C")N0?0\Z.3^EN;O"#D#U/&CD?J9N3WA$.1]Q
M^HTSIW]C](0<C[C]1IG3O['Z0@Y'W'ZC3.G?V/TA!R/N/U&F=._L?I"#D?<?
MJ-,R3J/.GQA!R/N/U&IS)W'K"#D?<?J-1G3O['Z0@Y'W'ZC3.G?V/TA$=57A
M!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA#2GM2?%-G/A^V^Q*AV\L5TF5;@
M3YK2;EL=;U?5U;3;D\QDA2>AYSWAI'7RHM_, GN%#?<$P<O$3"N8'2DM5N6_
MSC0<6Q\W#E$J664K4.SN0!R<N[[;/#&.&^+GQ 7&"WD"QS#*)DIFASR8SE:<
MRM6+Q=C^SF0RX3+,5N0I)3"?B-*@],?DO!'"%G5/:##IP\P3)82F62D4%@
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M(</2]ZN/>"C>+-<EM[G!,NLI-U\/K6[2ML)BR[,2PW[JTXT^\I:O.(6\ GD
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MV!,G?#+>]I552%3'([34U4O'9<EP.!(-4]&G-K<2^@:L'AZ@4I)2,R\H\6K
M[ U< :/%WO$FC*T =K'GRU.@INW*:[VE>SR9S--:8_N6]D:I<:)(J<>Q27<I
M@2[:[RC'L?JY\OJALHN;>XQBRK6F&@[&3+3%2]+;1(2XBX>&+%04@;YB?5F
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MP?I6,T$&Q^_O772+P*21SR._?UU5"#D?<?J-(1;2%A()4KE"@0 !SPHCA/)
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MA+C2??I\]WJ*@$E26V4*4'E)/05%8Y\_QO'>(]HEXF7AIV0(F3 @"F5*5G*
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M37 RV9$V<_)F/+3UOOK42H\Y.Q$_$K7,GS"I2BY"G)%FL&&@IRK:+H1E42&
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M>L'W$)6X9CTAQMMYI(2$I*"$*3VSI<\RTE 44@@N>2@02XJ"SU#M<,8Q%L5
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M% @LUJ-6U:DU/M"^;42%1G?(+B72RLMK2$A*5A/4D#D<@JXZ.ZN#SPH\$ZM
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M$/VIWBAQN;M12>&2+"VHM9D&QN6KNYQJQN[MRLFIEQ$3GEY-#15.>]1F)/\
MU:+#U"7'DH*M7$\,EJ!)QS5HV3X,*;LWP:U,QRW2429A#5&4D$^3T^SHZ(,$
M]BQX_L+191JSPKQJXVN(9)32W_VLQU^(_)G53S,"*ZPS/]X$?WGR>ITON+0
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M/4GC3\LG^Y/J?K$_G2W_ "C[\V^R[7U(.#LDS9Q4E>V^4A0X)DQ*N3$D%('
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MY[G5N-@D$7)Z._W]^5QI%4&D(-(0:0@TA!I"#2$6KL5E9Y*5 D=)Z2K@I (
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G0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g284543g28s28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284543g28s28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1+*4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8Z            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              "L   "D          !
M  $              I    "L                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   "L     %)G:'1L;VYG   "D     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    K     !29VAT;&]N9P   I     #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     "+<    !    H    "H
M  '@  !.P   ")L &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( "H H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&3-"P1HD)38Y4G*RL]'2X2<H-#=$1D=38G-T@I8U.$-F=G>&DI.4HZ2V_]H
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M;IY]>G[[?;AH)]I<!':_<RH(WOD^WG_Q9I_3UN;#S^5\(O93AL2&&'9.H16
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MWPLO@P8,&)$DV;!]%H%_0%0O]XV_?=H ]I8=<_C=N91>HZTR<J 'T RS "0
M1T )'2V_W)[\#Z\UF_)#V0Y:W%9LRS,;S3P\>ND)>>;(-:HL@F[C@G16&_<F
MT"W?I(*DA1)[0R&Y4N(.6YR<JO1Z$_ 0Z,P"2"J5&J:$K2N*XVL%2$+"2-KD
M>AQJZ7E^JT6H2$NO!^4K4\Y("=+#NM1*BV--S<V)OOMM;IC8V6(4J"W1,T.%
MTR*;(2\RU[L2PL=X4K1KZE2]92C?^<KIL<9MQAH68.+68'LU5693XG<4UMY3
M;RC'?4([*&FV5:DK*EH0E*1=70"Y/7&M:]G:O-\*:;PX5+D2Z%!J<J:J,M]3
MC,:25V4MA"E!/F=]-C8$]-X>$^2Z?6JG"$+,D2ER92@8Z9KA;:;6A"BI2EV(
M2!;J2;*MMZ8YQ'KZE9RS/7IM39G4;A-!DTFE.MN>\0JA7Y:.Y9]W=20%**W%
M+ LDI2S<#;=.B5(=F2I$M]14[)><>62;DJ<6I9/3U4?7IAP2]BN4H\&>= @_
M\I&1MOEEZ;;S'D;]1ZX]P%SZG[SB?@PF+VRU_P"+(YQP!_R+YH_R37E^_3#,
M+1"ZB344K!2#-D%%^NG6NY'PN /2WSQN/+,.0XJ'(0V4I!4I#R2$JU(%U$$]
M0+>(6VO]N*YM"BN?)$M)<DK=;?:4G]&LN&PN2+#<WOMN ;'>UK6Y 4PZRZ\Z
M9R-+2$]V"PM+?5-QOM9/Q-OF<?*?4VXL=YN2P'4/ H4#U(2J]E)!!"=]B;7V
MZ^=]8KD6(U%1'2['1WX?2ZTK9"MP6RV22IL$F^YN//RQ6F5'=J" AY3PJ"5%
MQV[1;2=-E:FAN GJ=[['TOBC;A4X3$1I:=3,0F0[.93;O6-=W&[$VN4$I3>V
M_0XR>J,*BT&KS&XD./ ?2TJ%9)*C%<2LMN.*/U70D!-KD7'KCE=M\/9IIZDC
MZM7IZ=6H*O\ URGKZ&QZ;[6-S?#WIR JU<EG*>57!/ #AEUZ7^BM.WOYD[;>
M1OCL?!@P8,&#%'*/0>?Z,V^ =03]P%[?##-IV^[JF>UZYSG-)*F^)[NE(WU?
MUI#%C8'S)VWW%L)LY2S)+RO6H-7CV6AI:4RHRKEN3$<($B.M-TDI=;)20"#Z
M$'?"G'"[,<++].I<_,LV5F/@-F&05R:5"E=]+RI/<0%+:<BE:>X:2M24-E;A
M#@2HW)!QTCG3A)ENH929S)P_?B2Z1)CB=34&0A;[,1P!:"^RA2^[<0V4A842
M;D;^9QSAT<C/9;1!6[6)>=8LM9;IX8:=@OZ4+((4I06TVD6UKTV'B.-#9EXJ
M9S@+S9D80X,2F52:@/1V6TN2'@Q(44A,H;J+8'B2+C8CITV%PURAF*O3Z53*
M:Z1(>=B2H;3A4A*E.  W(238BZ;6\1(!N"1A;_A[S/9XY+>$&8<ZYX&5*O4?
MH]5,J93RY5:/&9K<BK5.%(8A/TUW^MY<A,9U0<2X2M.M(LDWMCS+\U'$>FEA
MS+]$J4R9FWB%5)N>>,E0<=2$RZM-?,BB4)"D+5JBT:.ZX\E!0VKWF8\E6K0D
M!/ZLO:(R%$$AQQ!7J!24@D*45 [@@G?:]^N'BGL RD]DCR;:2#;A_4@?A^M=
M=V.%C\&#!@Q*=-DD6O>_V?O^^U\- WM+NW; <QYWW<RG\]\L4SJ!\_P^&$6<
MEU:=E]^GUJE2'8M0ITT38DEM1#C;[3A4!:Q 3LD@>I-]KX6$X79+9XN\):YQ
M^X39VH5,XGY;F1!Q+X/U26F+4,WH90[(5F++49(7[UWJ(_<3(=V[.O I391M
MF0R=1,]Y6HV;J)6'9&>*VFIKS!P_=CJC2LJ"E:6&GBRE))9F..N.-$WU!(Z;
M8N#LC-,2D1,E0\HM/AYV-'F3C#><EM/&.$$)T@E*E*)(!3<D=+XUKQ#H='A9
MC=C279DYQEEB*Y")>94S-]W39"FQI4-*[#2023??IC$,L\.ZQF"NTVE(9<TR
MYXCMQ74K1'CEQ7A]X=*?T9(/5:NMS?&V..4?(O!N/.R-DZ-3ZYQ"DQX\.5^3
MWDSH-$D/!*Y4U4MMT^-O0M"B1I!5N,)K\4\V,LTBE</Z6['=9IA5-KLZ*045
M2MOK<4^Z5!1UH:2L-I-ANFUL:$6K2E2B;  DFXZ6O<W_ '^W;#@A[%$[WW!G
MG/<!!2>)61K6.Q"<OSD7'4$$B_W'KMCW)8,&$QNV6(3V9'.0H]!P7S./B+M-
M],,Q](2EU<EY 4>]DO$$VV!><";B]_7;<;C?:^-DPE/0VV7.]66V39ML+^LM
MP .)*1?:P\AZ>N)BV'%MNS&W>X9"E#NM5M*Q>W722;]38[^>,==>4'%&Y#HN
M4J!\^BB?AN/*_EMBD]Y<W"E:B3?<[G<W'R(V&]ONQ6">ITM)4 D-@@ $6\74
MG;J"=S?;J+VQ<X"U60M*P%)+J4Z38@N I&J^UKD7/H3OC*:8T]WAE/[Q4LZ7
M%.$=VNZK6!N20"+GX=?C>:[-6<NSJ<RH/LI"%H7WH4$H5J<TMBP&E!64BYO8
M=,<PTELG,< !84?RU$45$_WDI&I(N-RD$ ;6-O3#W]R!$'DLY3^NW +ADGT!
M(RI3M][$CH<=D8,&#!@P8H):23?RLD?:5I2/CU-]K[89ONWQ:#W:^\YJ2DD'
MB>\OH#I'NT,@G>WF#>]Q;TOA*\"PL.@V&-I<-N*%6R!.6@VJ>79Z#&K-!EZG
M8DR.OPDI2;]TZW<+;=19:%)!OYXZ_P H\3G:)&;GY%K$B?E>4;3\MS'OT].4
MK<L,-N*25M)0LI!1>X1N!87[!Y?>(W+=)SBB3GNO5;*ZA0<P.AUN(^II5853
M9'Y.CD(CN*"%2NZ;4H)L+W38;XY85*R],XC2JD]5$2J7[W5'V9#JBFZ5^\.L
M&RD)4I3A* L*0DH)^6,^X<<RD/A)F^%F2#2VLXU)$9YJ+3%EPLPWFEJ3&60E
M*0>Z44K W22@7(!L-><;>8W.>?JG+SUQ3S,:C7&EO/96RFA87#I+BKF&I3+8
M4RW[L@(W7=2K:3YX3IJM1D5:H2ZC*6IR1+?=?=6LDJ4IQQ2]R?(7L.E@+; #
M&)5H^*&A9 :<>TK)(ZV)'7H+#K;[>N'BGL 1I[)+DZ/4'(=2 MOUS57+7_I]
M,+*8,&#!B2^H)1N+W*4CIL5$"^_XV\NF]L-!/M+R2.U]YD5@$I;<REJ4-R;Y
M:IJ+?>DW)(Z[;[81.I#*FHC84!<:UV)'\^Y3Y6N+C;RZ;VOC+LMYKS#E*<BH
MY?J\VDRVR%!V$\MI14E04G44E(4+I&R@<=5Y1YD9LZ="FUNHNY?S5'*$#-E/
M2I+TQ*=(0U.CMCNW4#NT=X2G])N5^5^W.!O.;F3ACQ7REQ S+3,M<2*-3:_%
MK%8IL@->[5J-';"$,R(R1WC)T7)'=^)2E"^U\7WB7S#9$XM<8J_Q+DY&9RU
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E$N+]4?X+/^1Q68,&#!@P8^'JGY_T''W%GJ/\JS_A?Z.*C'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g284543g29s29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284543g29s29.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1U*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '2Z^=' X0DE-! 0      &$< 5H  QLE1QP"   "AH < E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(#(X-#4T,U](>7!E<F9I;F4@+2!0
M;W-T+45F9F5C=&EV92!!;65N9&UE;G0@=&\@ #A"24T$)0      $-^1K8CP
MP9^>#.A&VJ(Q/P4X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9             IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              $C   !G          !
M      $              9P   $C                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $JT    !    H
M '$   '@  #3X   $I$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( '$ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MZ7HK>P/\:O2;WEF7AWX[QINK<RYFAV_3W4V?^!(6%5H]RF'T@L?&^M_U<R(
MS64N=VR ZG7]W=>UC'?YZUJ+:;F-MI>VRMWT7L<'-/P<U%3_ /_1[3ZQ=3&*
M+6P2UC0^P"3[&M-SYC\US6+Q;)RK\NVW+O=NNR'FU[CW+CN7M'UHM9]ERJ28
M#ZR'@:$@M+?='T]K5X@26L],_2;+3\BD8['NO$M*;G2"UO4L<.U:'-GYZKTQ
MN0VIHVL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"111814R<8$CD0H60J&QP20S4F+1X1<T<G.2\/$8)35#4W2"HK/2_\0 '0$
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M)Y 4GF=7-N&9V:?OZS@BWW_@8S>EX+%=# Q70P,5T,#%=# Q70P,5T,#%=#
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MHJLJ+8ULO*8:\<D:C1=1FZ<S-JLAJ*JUVZ2X]:K_ /%4U(GR/Q$5)K<B09(
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M%RD=S_&/*G7RD^I(.,CCL1^@_P #T04"6G7M'K@<AZ??IC%:?>2M8*\[<DC
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MUP1]ZG[M@B2DAR]M -QU()TW<[-ANUFDS8%-,^*\I_Y92G)#+H WH!_B;%I
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MOC-U'C5^O7W<)JMQR:_)C5EVA1ZJI\+$UBCK;I$%3*D[DIC"*RP&$IRE+8P
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MKU9[]?X#FDHH4ZE%8%-1#H![.[N1H"#?KCBGBU=?-UUT\S34:R J6)8AV9@
M;EI+&V^)2RV1&=(*U.()RA9SA84?3R" K XR,!7YB.>NFY6NFO224*< !PFS
M3H(8L1K8SCD2TK166*J% E7EYMY ]NIT'?&9$>QMPGCOG/8_4CO]>W?C(YZ4
MI(>]BXZ;CLQ^NH&'00I/F$"'^_INV\..,^2,@8*<9'L?I_S]NQ^PBD,3N-[1
M]F>MCA0U-FC5H^=M=7!9X"RS(R=IX4H %*N H$#W[# QGMV_DVJ"[[.-1ZC]
MWZMA"R\2P:&LX>&^D2[=!9JC8'X^RJM4EL-UF$@K>:R-E3BH1DH*T@%,A(W*
M;7]MF"%=-* 4 E4C0'[T^6&C3#%28)T#RVC::,T;RV(TQ7G8SB?,0MA2"6EH
M=)"TJ"P"A04,EP$XP><G(^G45!":YT3REI)'6QN'ZVVNPKF+>9F@A@W70M_B
M<$2FR92T-[&).%CT@L.#=GL4Y2<@Y[@D=CQTHUQS 0W, [F=])]IC<8=0CF#
MD,X@EVU8EK#374X>\-<]M/,5\;02K*5 )P!GU<#@*[=P#V'2:F:0@Q,'T]/U
M(C#@RM58\HE[7B[V/I[Z86TNR&P#L>.4I5L4A2AA78@<DGZ<YQ[].IK)4!($
M.\G9Q8?4MMAH\Z8)9NVFW[:[8<$"IDH\Q"GD)0"E24[DNI<R?2M."05G&S .
M04D9!Z<^(BW,/OJSG[VPVZGDN)<L'+L_8.\?)YQ^>9\=[6YS4SXG.JJXTM%0
MIFD%+LW3" VYEYK- I$:J5Z*ML)V%,JNU>HLOG84I"05'*  TLI59E,=#&GS
M$VN&G#R2IAM?T>S2]GTF[ZQOLKRG;2DZI:=MOO6U FQ:;=5$ILP3:GI[4:BI
M3+#E0IR@EQRAON%UIFIH\R$XPE3:GVW4)"BIH2%.$L>4]+MO^N)F7<I)!?F'
M(LF.9!?F2_\ :[#8Q&APPYFME7K<JIP9L-]=O,NM1J=,I\A<B1&7 !2S6(Q0
M3(AOLD.!$>0A<)27 VH;/47:E>L@ !3 F( (N6D:D]=;8NL_FJ9X?1RB"!3I
M%-2FASY%B>8$N7"B1):+86YE@V34+,N6NQ;FG2:E5(SKF9S;4:9)?4A]R3!?
M3!6X[(CH7AS=_"]02E6Y)P(KE2N8JF[G?II$/:^N*!"U+A4C4/H9O%W#D=W&
M!#0])*36J(S^!AB0Y+EL%,!L&=-;6EOR9KRFHD/YSY=P#S&&@5.I<2<K)4"5
MT4I6%%0"F+ZFY.VFX;U+8;JJ4'""P%H! (&Y<N-+6-S@2ZV:-WOHC>,6CW'2
MJC;LJ= I]=H[TQB13Y<JAU%M9BU!E!<$J,H84SE02L[=RDIR$A:0*-85:7DJ
M),*!/E)2!8N+-IA2*O-27260I"WYTD \T<K'6W5M\,6@T&.]4$/NJ_A1&W9:
ME%.4I4E.62K*1M"GUH45X]1 2HXQB84JSJE5*JDJJAASL 3\@#T<&T7Q#6NE
MEPA%) 2D<W* #<ES<&0-SW@G!'H=)7 B5)YJ8\7_ )R#\Q'CLH\V7"$8N-(.
M 1Y272?4"0%)]76YX31'])30*RDU0H$K) ( !! LUX?=N]+G*ZJ]7X?*" "6
M*8$L'<.Y!MT?48QKF7,9MF+0Z@YYIFOFL.-*:2EYO8[(*!+5E1*AYA#8' 2<
M) R08O'ZM1.56@U5*:F0/,6) N&(!81+N[M,*R&4I4*WQ44D(4N"0)*29!>P
M/HSP0P(DC\,_0>5KSXW= --V(3<J#4K[H4NH%384I%,IDI57K1(! 2@4BFS\
MJ(VH7L4K ZPE%)Y)'F)G0@-^X:+_ "Q>A2AJSA^^FLVG;TQ^JE28[$5*&&$)
M0U'BLQF$C V,LI"$-@#C"$)0!]  !P!T_A#O]<1C\2E7--APHZWB8\B!.<>C
M%YQKSDH(;<"R@@J2&G%@I.1CU=QU?<!32J5*G,T, X!;6 ;2TN+W>R%U33$
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M??1SAJ5.D/Q7 W)0IIY(4%M/-N1WTJ PI*D.I"MR3P=@4/?..A:^K3-NK':
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M)D+33FTEZDK;=J'D16VGVFS'J:@A$AQZ0\HL-I,4E94['EN-6(@,1NXOJ^$
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MX8OBL@"74K:"D[DFEU).[;GO*8./K[?MQSGK1^&C_P"9$N4):=>8VZ_>F$5
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MM^,?PYJ9#-U\QD\L%*)*BA*"6!))4%,/*"VCMK&/6'@'\4\M6R=+(<=JM60
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M"\&JKS63*TQ_44RHZD!2 7Z$7O)MCCGC+B>3S?\ 4!/*>1*TA@'<(,ZV:&#
M N;8E!X?JQ4*A9\%V6N1-J;[DARH%"-\EQY^2^^9JF&U.^4VZMY8;4ZI&$$^
MD #KT;6RM/+(2A+)"4N\!U0X=PY;0?Y\_9VLGXRR[ J  '4AV#EA^N)018E8
M=:2?E'F@,[E.J0T!C@'U*R01R0 1[X[]5"UT0HNH.78 ;GT8_P"-(6%.$EI8
M29!UU?1@#!OTPX(+3L=LN2Y*4)23N2RE;RMO]H$("2DXY! 5]0%8ZC5% OR
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M'Y1-X.6V_27CN0FHO6\U5FI;7F( #KT%B>\IR-(4AMLN37O+W%:ST,%Z_>^
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MT+=2&<@:^+ 8J+#W\%*DK#IP2DCE/'MC.>.V?J2>>I""2R522"!N1$1WW.C
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MEN!2G%+2.#C@ D XP 1_=WSU74J]=U/4A1)!:1L9W&_^="::*?*4U%)*0"1
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M"F,UN#(6F,ZIM"E8W[B<@$<%/Y2D$<CM[G'/3*_@J2[O#MJY$-)L_P!<$P:
MK:VLWTU8-;Y8(<&1.?;+=6:9FM* 3O1MWH2>_H!RH9QD@$CCJ H ?E+$$N]B
M=2]W$G:#HV 00+BQ<?KKMT&@OB^Q1C3W52Z6]M2I0*XBR2A:>24I!]SD8XR/
MMC'1*K!:0E8<@-S:B &#.XOZ6P087!&LR[=&CH\:6)Q51$>06?+:2BHI*WVE
M*64J8=0WZEE(.5-K"4I=0=OF(RG(&#TE!8DDNEP"!+AW8=0[#NPPVI3DI >X
M?8'MH'[#3 HN.\JG04QY]6AQ9U":EL4^NNQVBW+HTAY0")+S*2IJ1!7YC>Z0
MVC<@$J4K /5C3HH6602A925(GRK ZEE)BX<[L1 "$D.Y>P+2S;Z/TMA8KU#H
MLRA/5%IE*@^TER(^RM*X[S3J''@\V4I&4%I!4%9SG.3[=,H6M=;X+LWY@6Y@
MQ #RWYC]ZA:4C4MT;[L)$6M@$R;<B3&T/Q%Y"TA2E,D$[0 "5#G<,#![8^WM
M.J94AD\H ,*)@AWD 6(NQ<%KWPA@&,EVN(W/41/[A\-N19,12@IM"F70<^<@
M+;43[E1& ?KD8X]AGJ*O)%)=/FV+ '9N[0-,**TAON]KMZ-A8A42H0$I\QI4
MY@JS@DE13R#MR5 D>PQGW[@]5]3)K2Y#DR;>K']Y?!I(4Q@RQ[/VT:-"?DZZ
M91Z?*X;'D/$D^4\DI!)4?2"1P1P!D=^_/4!7,E10I*G! <6W=XC=AK&%D &"
MX[_>^WTP^(%LI0 3'&TD$E.U8.!_9P"3G'<X'8G@]&""[2Q8]#;!$@7('K@@
MTB&S&*$!I()4G/8\;DCL!@'GI0DCN.O^<).IT ,6>[OTV]]L/!!YQ[8[?R_Y
M]%A6+H."#]#GH8&%VACUR#_NH']ZCT,#$?-=>:Q0\\_Z%-[_ />1.K[@#M7(
MT"/_ )*'ZX2O\I]/J, MQ.5'L.0?VVC/MUHW.YQ'1^4>OU.+"F$<>G=^HSCZ
M_P _\NE\SV+;B/U(^[Z869M^NW5_3H,84F&DH'ISP<CGWYR/N/Y=AR.C?F$:
M'=H^K?L[:8(#F=B(#OV^_P"1B*'B.E.TJS*L6E-M(,=9><=&XMLH0IQ91C..
M!DG(/N3U9Y8M0K+5_9368Z EU=F8]&G 0RJU*F7=:T &/^0 ZW.Q[-C\_P!H
MFD[GC/\ &9J+3JG=DVWX5;K]V5I5?1345F4S$H]09I4&$W&<F1 K*5QHL<&0
ME#>T$I6<#K"'+CB7%%TA42E*E&5$@ !@Q+*Z&!OZWARRJ3J+$ .&)T802+_1
MF@-C;C=7P6;7TKT)NS42C4"^]6[I:MJ>_$0ZRQ)DT]]2$M)5%M6D(<4V^@.B
M1\P\_4%-H;6K8V$E74O.\'I\,RF;K*'Q2:*N3X;J4((! 4$LY!(,XD<,"<WF
MZ-&H$A)J@**C=+QI=MV>0YP3O"5IK<VF^GUO4"I(<2:5$99?#V0]&<:;2E3!
M00D@(6A;>%)1M &$@DI'D?C^5SO_ %+.9A>76KXE59"4()4 2R0S79C=\>Q?
M#&:HTN&Y;(HS-!%.A20D_$J  P]@"?S&2PZQ>=E&?:5-<\H.D.)04!M*W$^;
MD9&$)4K*C[ <=L')Q&RV0SN82 G)YAV%Z1%]V)V)@$6UQ;5<[DDJ4^<RSI9*
M@*H+GH&D0;D$/W&)/V#1]09BV1"MJK&,I25B4:?+4R02!R0SL&0"22G=VP>X
M*JW >*I4GERZT M)2H!BY9RD!V;KMKB#6XUP5*2DYBB3L%),#_W1L\C1KXFW
M8UHUFGN(G2?FH;B4H\Q :=;2M7"L*2O;G&  "D@CCJTRO!^*466NFH\H"F2E
M1@%[\O1M[G=\KQ'BG"JU-=--5!*DJ2Y4' 4.5PY)#7D>[8(=;IL2JMJ8D1,O
M;  ^X@#)P/?.>_T_3@CI>;R5:K%2C5!;5!;3NT;P6],0>'YK+9=C3S-(A)MS
MCTZ'8M&Y; LJ=B1O+6VTEM:]J\;4DC)^A*1SC@  D_0]^JH\/S:R4TJ%6(<I
M4!#BX<L^_P!2V+NIQ[*$ ?'2S,0I: _3\S;[8!5<T,JU:=6BG4B74?.*TN-1
M8SJ]P<."D$H"05;L#) !YS@$F5PWP_Q&IG$+IT5IJ<R2HE*PDAPS'E*K#407
M8,QPK_Q-D$96M0KYBFI 2L\@4@GE4"3!6(8]P+$Z;&- (-T4?3>C6_>U,-.K
M5$+M,C%UV,IR92HZ_P#W=)=;8<<#3GD%+"DDJ)2TG)SD#TUX>H9JCPY(KEBD
M)W&AL& TZ-M,>6_%^>R>:XRK^E20GS<S@$$O,A9W>1JQD8DI39#8:::6IML-
M*!W,G81G)PL'!<)SD*2<#![9P9M0**E%C(,%IM:[>HEYQF79PHFX,6-W>)VZ
M,1A;<"W]WRLU.T$99;2D.J!'YB@JW Y_*, *R#SD=-) 2?-3+O!)) V#R(&O
M=V; (YBX5Z 3&K7+>^V@Q;+<II.[>ZE2$DY5O0I0['&T$<<9R1WST9*5$,E/
MR:VLAK:#0N8P""UR6<EP1]1/KBVNN+AM)WK4A*=Q7(4M*2R$ *)4HGL1D>_<
MG@CH_P"G"C9S#) =S\M=!;1YP$@%O+H[EP'^?V\:8B]KKK-7J'3;?=M62PR:
M[<E/AUNH*2TXN':J''%U%,8!1/S=1"6:?'D+"$,-KE*\P';OT'!^"HKU:OQ4
MM\*F5A"B1S5 '$"&%R)T+1@$)2Q)3YB!!W,O[<M@&WG#KI<^2+1HD.I2C=3T
MB"N@U9^-!<8_$HZV%_(.S(J"M36 VEHS%-D"0A)*@GDPZJ:-/-51&72%"K3%
M18/(I_,E)@%Q9#@L3VQ)IY6JH.EB)<L1Z'RG:1L>F,6QZY<,&6C36KB2(=+D
M/+CJ?;6754:IQW6H"/-4E 68CA6EUP>DE0P<#EZO0RG(,]16DJ*$^4$.*B%#
MF@/^9H!EAO>-F*-2FDND'S: L001<);T$&7Q[GV]7;$FA+P=D4QY:@P[LWMI
M:6K>/X@QPD**>,D$$8(!ZETZ^7S],E)"5I2.8. HD18 [ SH>H&*_F6D_#(C
M2(EC!&Q(<86X\Z+-9W<(7@Y' YQWP"<$\C'OR1WQTVNB 0&<18]=?:Y'[X0?
MB"!;JYM(:.G\8S&OR[21A/*.3V]\G!P<_3.<G].HRT4S_:0;$D=# F0^^F'D
M%2=K'YM'\W?%](9P0L$KQ^8'!]\8Q@C&1SCV]^.HM3*4ZDJ0"^IB6;8@^V@F
M,2 M# D$'5@X&SO>UL+M+J,EH!+;N6TG\CBCC/< <$D  ]\'C&#U5UN'K27I
MLTNDE7,_3RL??^ &4Y <#5K6P1J94*>]Y>[^#(. I*UY1N/8I40G/U'I!3_?
MU!5373(=!N)TZ[-I?YC!$003<7 [?;:Z6PXD*5R04X).U23N!3^X'.00?N#T
MDI>P(9X+R/WT;I?<!Q<AF$VG;^8O[7DJSG)'V[#I#$7#84X-B^'#0E JD#_=
M;/\ C_QZ&!B/FNO_ ,9H?_V4W_\ I$ZON 6S'_:C_P"1PE?Y3Z?48""DJ)R
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M?=L$:W)+;OS"_P @V-_FX/=0'O\ 8CL.W'WAEM"_7]I,8,A0)"ARD:'_  ,
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MO"R4)37S&125,2.9(N1<:,(<O:YQD4>I42%'CM1*F)(4G<4[PI84?["D@\.
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M.Q&;[-;3_&&PQ6:I0'$?+..I:]*@ 26C@A0W GT\G! R%8_82>6G400H.IB
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MU,FJW3<=2 5\U6JO79R'ILB9)=6MU:BX$@K 9 ;2A(<XEGEYY5%:$I"4$%0
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MEJ7/^445Q:% >&V/*KDIU:%1S)2E2H;84MV2TU(>:2M* !5YC*5:#+IJ+.[
M VN_,#)D@/#Z!@':6<2I)*_.HE@IW?F,, 0.X,PUW91J&N5PZ51X=L,H_K#=
M=SOLTNF062E37STAKF4XL*2IJ' (4_)<"1N90Z"L* VS,IFUTP*9!YEA^8P
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MK/OR)'MY].OSQ+-0$,\18-8VB_7Y8]K\&-\3N:@S9144D*4BHS'#D_FP%49
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MB'%#"2K)7]%#WB5/&W! IZ%+.H.X0D/L".< @6TW;&IR'X7>,**0G-9GA55
M2$\JLQ6JLW_$F@DI)U(+WG>=&@VCUQ:>S*O4J\BF0W*Q A,FFTVHNU1F+(BN
M2%NJ;FNP8"W&EI>2$),9)1A0).<]8WQ%QZGQA=-5,+ I@@%:0DD=0Z@Y #]L
?=8\'>%,SX>16&850>HE( HJ6MB')',H)+3&O4Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650373000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Hyperfine, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001833769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">On January&#160;24, 2022, the registrant filed a Registration Statement on Form S-1 (Registration No.&#160;333-262300), which was subsequently declared effective by the U.S. Securities and Exchange Commission on February&#160;1, 2022 (the &#8220;Registration Statement&#8221;).  This post-effective amendment is being filed to update the Registration Statement to include information contained in the registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 and certain other information in such Registration Statement.  No additional securities are being registered under this post-effective amendment and all applicable registration and filing fees were paid at the time of the original filing of the Registration Statement. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808647208840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMBINED AND CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 188,498<span></span>
</td>
<td class="nump">$ 62,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">2,662<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowance of $32 and $0 in 2021 and 2020, respectively</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,310<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">197,485<span></span>
</td>
<td class="nump">68,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OtherAssetsRelatedPartyNoncurrent', window );">Other assets - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long term assets</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">202,473<span></span>
</td>
<td class="nump">71,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,248<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">2,662<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,115<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,736<span></span>
</td>
<td class="nump">4,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long term deferred revenue</a></td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,246<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Hyperfine convertible preferred stock (Series A, B, C and D): $.0001 par value, aggregate liquidation preference of $0 and $147,651; 0 and 129,788,828 shares authorized; 0 and 95,010,858 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">322,540<span></span>
</td>
<td class="nump">10,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(136,320)<span></span>
</td>
<td class="num">(71,469)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">186,227<span></span>
</td>
<td class="num">(61,054)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="nump">202,473<span></span>
</td>
<td class="nump">71,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_HyperfineConvertiblePreferredStockMember', window );">Hyperfine Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Hyperfine convertible preferred stock (Series A, B, C and D): $.0001 par value, aggregate liquidation preference of $0 and $147,651; 0 and 129,788,828 shares authorized; 0 and 95,010,858 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying amount of deferred grant funding as of balance sheet date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OtherAssetsRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other assets related party noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OtherAssetsRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_HyperfineConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_HyperfineConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646859624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,788,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_HyperfineConvertiblePreferredStockMember', window );">Hyperfine Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, aggregate liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 147,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">129,788,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">55,277,061<span></span>
</td>
<td class="nump">1,576,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">55,277,061<span></span>
</td>
<td class="nump">1,576,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">15,055,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">15,055,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_HyperfineConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_HyperfineConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808645635992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total sales</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of sales</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="num">(1,167)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">25,842<span></span>
</td>
<td class="nump">14,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,497<span></span>
</td>
<td class="nump">5,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">63,701<span></span>
</td>
<td class="nump">23,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(64,868)<span></span>
</td>
<td class="num">(23,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(64,851)<span></span>
</td>
<td class="num">(23,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (64,851)<span></span>
</td>
<td class="num">$ (23,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (17.57)<span></span>
</td>
<td class="num">$ (15.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">3,690,523<span></span>
</td>
<td class="nump">1,523,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total sales</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of sales</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total sales</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of sales</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808644725016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Hyperfine Convertible Preferred Stock</div></th>
<th class="th"><div>Liminal Convertible Preferred Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class B Common Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (39,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,178<span></span>
</td>
<td class="num">$ (48,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,211,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,508,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series D convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series D convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,799,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments', window );">Investment from 4Bionics, LLC</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (61,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,415<span></span>
</td>
<td class="num">(71,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">95,010,858<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 128,286<span></span>
</td>
<td class="nump">$ 128,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series D convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series D convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,171,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments', window );">Investment from 4Bionics, LLC</a></td>
<td class="nump">3,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ConversionOfLiminalCommonStock', window );">Conversion of Liminal Common stock</a></td>
<td class="num">(9,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RecapitalizationOfPermanentToTemporaryEquityShares', window );">Conversion of Liminal Common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RecapitalizationOfPermanentToTemporaryEquityValues', window );">Conversion of Liminal Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Liminal Common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination</a></td>
<td class="nump">168,097<span></span>
</td>
<td class="num">$ (158,747)<span></span>
</td>
<td class="num">$ (9,350)<span></span>
</td>
<td class="nump">168,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,182,191)<span></span>
</td>
<td class="num">(57,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,028,815<span></span>
</td>
<td class="nump">15,055,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Net equity infusion from the Business Combination</a></td>
<td class="nump">141,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Net equity infusion from the Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,806,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A common stock to a service provider (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 186,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,277,061<span></span>
</td>
<td class="nump">15,055,288<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,540<span></span>
</td>
<td class="num">$ (136,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_AdjustmentsToAdditionalPaidInCapitalInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_AdjustmentsToAdditionalPaidInCapitalInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ConversionOfLiminalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Liminal Common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ConversionOfLiminalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_RecapitalizationOfPermanentToTemporaryEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization of permanent to temporary equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_RecapitalizationOfPermanentToTemporaryEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_RecapitalizationOfPermanentToTemporaryEquityValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization of permanent to temporary equity values.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_RecapitalizationOfPermanentToTemporaryEquityValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646971496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (64,851)<span></span>
</td>
<td class="num">$ (23,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,901<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-down of inventory</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_WriteOffOfOtherAssetsRelatedParty', window );">Write-off of other assets - related party</a></td>
<td class="nump">984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseSellingProfitLoss', window );">Sales under sales type leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetInvestmentInLeasePurchase', window );">Payments received on net investment in lease</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(379)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_UnbilledReceivables', window );">Unbilled receivables</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,667)<span></span>
</td>
<td class="num">(1,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(666)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Due from related parties</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="num">(782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties', window );">Other assets - related party</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Prepaid inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long term assets</a></td>
<td class="num">(1,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,436<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred grant funding</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,851<span></span>
</td>
<td class="nump">773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(47,182)<span></span>
</td>
<td class="num">(21,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(2,711)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,711)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock', window );">Proceeds from issuance of Series D convertible preferred stock</a></td>
<td class="nump">30,468<span></span>
</td>
<td class="nump">59,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs related to Series D convertible preferred stock</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Investment from 4Bionics, LLC</a></td>
<td class="nump">3,516<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ProceedsFromBusinessCombination', window );">Net proceeds from equity infusion from the Business Combination</a></td>
<td class="nump">141,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">176,767<span></span>
</td>
<td class="nump">60,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents and restricted cash</a></td>
<td class="nump">126,874<span></span>
</td>
<td class="nump">37,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">64,286<span></span>
</td>
<td class="nump">26,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">191,160<span></span>
</td>
<td class="nump">64,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">188,498<span></span>
</td>
<td class="nump">62,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">2,662<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">191,160<span></span>
</td>
<td class="nump">64,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits', window );">Cash received from exchange of research and development tax credits</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Noncash acquisition of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination', window );">Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from exchange of research and development tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ProceedsFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ProceedsFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_UnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_UnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_WriteOffOfOtherAssetsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of other assets - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_WriteOffOfOtherAssetsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables due from related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentInLeasePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of net investment in sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentInLeasePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stock that is classified as callable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseSellingProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of profit (loss) recognized at commencement from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseSellingProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650315192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Hyperfine, Inc. (together with its subsidiaries, as applicable, &#8220;Hyperfine&#8221;, the &#8220;Company&#8221;), formerly known as HealthCor Catalio Acquisition Corp. (&#8220;HealthCor&#8221;), was incorporated as a Cayman Islands exempted company on November&#160;18, 2020. The Company&#8217;s legal name became Hyperfine, Inc. in connection with the closing of the Business Combination (the &#8220;Closing&#8221;) on December&#160;22, 2021 (the &#8220;Closing Date&#8221;), as defined and described in Note 3. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>. In connection with the Closing, Hyperfine, Inc., a Delaware corporation (&#8220;Legacy Hyperfine&#8221;), and Liminal Sciences, Inc., a Delaware corporation (&#8220;Liminal&#8221;), merged with and into separate wholly owned subsidiaries of HealthCor and became wholly-owned subsidiaries of the Company, and changed their names to Hyperfine Operations, Inc. and Liminal Operations, Inc., respectively. Liminal subsequently changed its name to Liminal Sciences, Inc. The prior period financial information represents the combined financial results of Legacy Hyperfine and Liminal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is an innovative digital health business with a mission to provide affordable and accessible imaging and monitoring through magnetic resonance imaging (&#8220;MRI&#8221;) to revolutionize healthcare for people around the world. Hyperfine&#8217;s Swoop<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Portable Magnetic Resonance (&#8220;MR&#8221;) Imaging System<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM </div>produces high-quality images at a lower magnetic field strength than conventional MRI systems, and can be used by healthcare professionals to make effective clinical diagnoses on a patient in a variety of settings where MRI devices have previously been inaccessible. Hyperfine received 510(k) clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in 2020 for its Swoop Portable MR Imaging System, which is commercially available in the United States. In 2021, Hyperfine also obtained a Medical Device License issued by Health Canada and expanded into the Canadian market, and also obtained regulatory authorization in New Zealand and Pakistan. All of the Company&#8217;s revenue to date has been generated from sales of this machine and related services. Additionally, the Company is in the process of developing a device to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasively</div> measure key vital signs in the brain to enable unprecedented access to dramatically improve patient outcomes. The Company is in the early research and development stage of such device and has not generated any revenue to date for it. In addition to Legacy Hyperfine and Liminal, the Company has an indirect wholly-owned subsidiary in the United Kingdom that did not have any significant operations during 2021. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650312408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined and consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All intercompany transactions and balances have been eliminated. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Outbreak </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The recent outbreak of the novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;),</div> which was declared a pandemic by the World Health Organization on March&#160;11, 2020 and declared a National Emergency by the President of the United States on March&#160;13, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts on the Company&#8217;s operating results, financial condition and cash flows. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had, and is expected to continue to have, an adverse impact on the Company&#8217;s operations, particularly as a result of preventive and precautionary measures that the Company, other businesses, and governments are taking. Governmental mandates related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or other infectious diseases, or public </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">health crises, have impacted, and the Company expects them to continue to impact, its personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt or delay the Company&#8217;s receipt of instruments, components and supplies from the third parties the Company relies on to, among other things, produce its products. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has also had an adverse effect on the Company&#8217;s ability to attract, recruit, interview and hire at the pace the Company would typically expect to support its rapidly expanding operations. The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions taken to contain or address the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, as well as its economic impacts. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In adjusting to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> market and manufacturing conditions, the Company did not have to materially adjust its existing resource allocation or its factors of production. The Company has not incurred any significant impairment losses in the carrying values of its assets as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and is not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in its combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The estimates of the impact on the Company&#8217;s business may change based on new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or address its impact and the economic impact on local, regional, national and international markets. While the Company is unable to predict the full impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will have on its future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic, and the actions that may be taken by government authorities across the United States and elsewhere, it is not expected to result in any significant changes in costs going forward. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. At December&#160;31, 2021 and 2020, substantially all the Company&#8217;s cash and cash equivalents were invested at two financial institutions. The Company also maintains balances in various operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant customers are those that represent more than 10% of the Company&#8217;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer E</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer F</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer G</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer H</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes a single exclusive manufacturer for its Swoop MRI scanner. Additionally, the Company purchases raw materials from this manufacturer. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;). Legacy Hyperfine and Liminal represent two operating segments. Given the similar qualitative and economic characteristics of the two operating segments, such that both are focused upon the development and commercialization of existing and new products and services, Legacy Hyperfine and Liminal are aggregated into one reporting segment. All of the Company&#8217;s long-lived assets are located in the United States. Other than $78 of revenue recognized in Australia, all of the revenues were earned in the United States. Since the Company is aggregated into a single operating segment, all required financial segment information is provided in the combined and consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its combined and consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (&#8220;SSP&#8221;) of performance obligations and estimation of variable consideration; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for doubtful accounts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowances with respect to deferred tax assets; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumptions underlying the fair value used in calculation of the stock-based compensation expense. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s combined and consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All highly liquid investments purchased with a maturity of three months or less are cash equivalents. As of December&#160;31, 2021 and 2020, cash and cash equivalents consist principally of cash and money market accounts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash balance represents funds received as part of grant funding and restricted in use to the purpose of the funding. For details, see the Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies&#8212;Grant Funding</div></div> and Note&#160;16. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commitments and Contingencies</div></div>. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are stated as the amount the Company expects to collect. The Company maintains allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. As of December&#160;31, 2021 and 2020, the allowance for doubtful accounts was $32 and $0, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories primarily consist of finished goods which are produced by the Company&#8217;s third-party contract manufacturers as well as raw materials ordered in advance by the third-party contract manufacturer due to long delivery-lead time and which were billed to the Company. Inventories are stated at the lower of actual cost, determined using the average cost method, or net realizable value. Cost includes an allocation of wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. Net realizable value is based upon an estimated average selling price reduced by the estimated costs of disposal and transportation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation of inventory also requires the Company to estimate excess and obsolete inventory. The Company considers sales forecasts and historical experience to identify excess, close out, or slow-moving items as well as new product development schedules, product obsolescence and product merchantability, including whether older products can be remanufactured into new products, among other factors. The Company reduces the value of inventory for estimated obsolescence or lack of marketability by the difference between the cost of the affected inventory and the net realizable value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prepaid Expenses and Other Current Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets include amounts paid in advance for operating expenses as well as monies to be received from the State of Connecticut for research and development tax credits. These research and development tax credits are exchanged for a cash refund and are typically collected within one year from the date the tax return is filed with the state. The credits are recognized as an offset to research and development expenses in the combined and consolidated statements of operations and comprehensive loss in the annual period in which the corresponding expenses were incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Useful lives of property and equipment are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other property and equipment include furniture and fixtures, software, vehicles, and machinery and equipment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditures for major renewals and improvements are capitalized. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation is eliminated from the balance sheet, and any resulting gains or losses are included in the combined and consolidated statements of operations and comprehensive loss in the period of disposal. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews its long-lived assets for impairment at least annually or when the Company determines a triggering event has occurred. When a triggering event has occurred, each impairment test is based on a comparison of the future expected undiscounted cash flow to the recorded value of the asset. If the recorded value of the asset is less than the undiscounted cash flow, the asset is written down to its estimated fair value. No impairments were recorded for the years ended December&#160;31, 2021 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capitalized Software Development Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For the costs incurred in developing the firmware embedded in the hardware devices that the Company sells and leases to its customers, the Company applies the principles of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed</div></div> (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20&#8221;).</div> ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20</div> requires that software development costs incurred in conjunction with product development be charged to research and development expense until technological feasibility is established. Thereafter, until the product is released for sale, software development costs must be capitalized and reported at the lower of unamortized cost or net realizable value of the related product. The Company has adopted the &#8220;tested working model&#8221; approach to establishing technological feasibility for its software products. Under this approach, the Company does not consider a product in development to have passed the technological feasibility milestone until the Company has completed a model of the product that contains essentially all the functionality and features of the final product and has tested the model to ensure that it works as expected. The Company&#8217;s hardware device, with the embedded firmware, was released for sale during the fourth quarter of the year ended December&#160;31, 2020, when the Company had completed all of the research and development activity to establish the technological feasibility of the product. As of December&#160;31, 2021 and 2020, the Company had not incurred significant costs between the establishment of technological feasibility and the release of a product for sale; thus, the Company had expensed all software development costs as incurred. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For software developed or acquired for internal use, including software used in the provision of subscription services to the Company&#8217;s customers, the Company applies the principles of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Cost of Computer Software Developed or Obtained for Internal Use</div></div> (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40&#8221;).</div> ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40</div> requires that software development costs incurred before the preliminary project stage be expensed as incurred. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Costs incurred during the preliminary project and post-implementation stages, including training and maintenance, are expensed as incurred. Capitalized costs are amortized on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">project-by-project</div></div> basis using the straight-line method over the estimated economic life of the application, which is three years, beginning when the asset is substantially ready for use. As of December&#160;31, 2021 and 2020, the Company did not have any amount of capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software development costs. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Revenue from Contracts with Customers.&#8221;</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is recognized when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following 5 steps: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 1: Identify Contracts with Customers:</div></div> The Company executes signed contracts with its customers for the sale of hardware devices and subscription services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 2: Identify Performance Obligations:</div></div> The Company&#8217;s contracts with customers primarily include two performance obligations, namely the hardware device and subscription services, which include access to the Company&#8217;s hosted cloud-based software applications and hardware maintenance and support on an ongoing basis throughout the subscription period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 3: Determine Transaction Price:</div></div> The Company&#8217;s contracts with customers include variable consideration in the form of discounts and price concessions. The Company estimates variable consideration using the expected value method based on the data available as of the end of each reporting period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 4: Allocate Transaction Price to Performance Obligations:</div></div> The Company allocates transaction price to the performance obligations in a contract with a customer, based on the relative standalone selling prices of the goods and services. The standalone selling prices of the hardware devices and subscription services are determined based on the observable standalone selling prices for which the Company sells the respective goods and services on a standalone basis, including renewals of subscription services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 5: Recognize Revenue as Performance Obligations are Satisfied:</div></div> Each unit of hardware devices is a performance obligation satisfied at a point in time, when control of the good transfers from the Company to the customer, which is usually upon delivery of the good to the customer. For sales of hardware where control of the product transfers to the customer upon shipment, the Company has made an accounting policy election to account for shipping and handling as fulfillment activities rather than a performance obligation. The subscription services are stand-ready obligations that are satisfied over time by providing the customer with ongoing access to the Company&#8217;s resources throughout the subscription period. The Company uses the time elapsed (straight line) measure of progress to recognize revenue as these performance obligations are satisfied evenly over the respective service period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company offers alternative payment structures and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;as-a-service&#8221;</div></div> offerings that are assessed to determine whether an embedded lease arrangement exists. The Company accounts for those contracts as a lease arrangement under the current lease standard if it is determined that the contract contains an identified asset and that the right to direct the use of that asset has transferred to the customer. When a contract includes lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, the Company allocates consideration under the contract to each component based on the relative standalone selling price and subsequently assesses lease classification for each lease component within a contract as a sales-type lease or an operating lease. On commencement of sales-type leases, the Company recognizes revenue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front,</div> and amounts due from the customer under the lease contract are recognized as financing receivables on the combined and consolidated balance sheets. Interest income is recognized as revenue over the term of the lease based on the effective interest method. The Company has elected not to include sales and other taxes collected from the lessee as part of lease revenue. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All other leases that do not meet the definition of a sales-type lease are classified as operating leases. The underlying asset in an operating lease arrangement is carried at depreciated cost within Property and equipment, net on the combined and consolidated balance sheets. Depreciation is calculated using the straight-line method over the term of the underlying lease contract and is recognized as cost of revenue. The depreciable basis is the original cost of the equipment less the estimated residual value of the equipment at the end of the lease term. The Company recognizes operating lease income to product revenue on a straight-line basis over the lease term. Impairment of equipment under operating leases is assessed on the same basis as other long-lived assets. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue primarily consists of billings or payments received in advance of revenue recognition from subscription services described above and is reduced as the revenue recognition criteria are met. Deferred revenue is classified as current based on expected revenue recognition timing. Specifically, deferred revenue that will be recognized as revenue within the succeeding twelve-month period is recorded as current in the Company&#8217;s combined and consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warranties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company offers a device warranty to customers for the longer of (a)&#160;twelve (12) months from delivery of the device for devices obtained through a capital purchase, or (b)&#160;the term of the subscription agreement for devices obtained on a subscription basis (subject to continued payment of fees for the subscription service). The Company&#8217;s subscription services include hardware maintenance and support. As noted in the accounting policy for revenue recognition, the Company recognizes revenue for subscription service over time using the time elapsed measure of progress. The costs of hardware maintenance are recognized in costs of revenue as they are incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs consists of production costs for prototype, test and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-production</div> units, lab supplies, consulting and personnel costs, including salaries, stock-based compensation, bonuses, benefit costs and depreciation. Certain research and development grant funding is recognized as a reduction to research and development costs (see Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies&#8212;Grant Funding</div></div>). The Company recognizes these costs as they are incurred. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant Funding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received certain research and development funding through a grant issued by the Bill&#160;&amp; Melinda Gates Foundation (&#8220;BMGF&#8221;). Funding is recorded on the combined and consolidated balance sheet as restricted cash upon receipt. The funding is recognized in the combined and consolidated statements of operations and comprehensive loss as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. Grant funding payments received in advance of research and development expenses incurred are recorded as deferred grant funding as a current liability in the Company&#8217;s combined and consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of Sales </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales consists of product and service costs including personnel cost and benefits including stock-based compensation, product costs, production setup expenses, depreciation and amortization expenses, inventory excess and obsolescence expenses. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent costs have been charged to operations as incurred, as their realization is uncertain. These costs are included in general and administrative expenses in the combined and consolidated statements of operations and comprehensive loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses primarily consist of personnel costs and benefits including stock-based compensation, patent and filing fees, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales and Marketing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing costs primarily consist of personnel costs and benefits including stock-based compensation, advertising, promotional, as well as conferences, meetings, and other events. Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising expenses were $2,459 and $437, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Common Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is calculated by dividing the net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares plus the common equivalent shares of the period, including any dilutive effect from such shares. The Company&#8217;s diluted net loss per common share is the same as basic net loss per common share for all periods presented since the effect of potentially dilutive securities is anti-dilutive. Refer to Note 13. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share</div></div> for further discussion. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has applied the guidance in ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A,</div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities,</div></div> and has therefore classified the Series A, Series B, Series C and Series D Convertible Preferred Stock (&#8220;Convertible Preferred Stock&#8221;) (see Note 10. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock</div></div>) as mezzanine equity. The Convertible Preferred Stock was recorded outside of stockholders&#8217; equity (deficit) because the Convertible Preferred Stock included a redemption provision upon a change of control, which is deemed a liquidation event that is considered outside the Company&#8217;s control. The Convertible Preferred Stock has been recorded at its original issue price, net of issuance costs. The Company did not adjust the carrying value of the Convertible Preferred Stock to the liquidation price associated with a change of control at December&#160;31, 2020 because a change of control of the Company was not considered probable at the reporting date (see Note&#160;10. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock</div></div>). Subsequent adjustments to increase or decrease the carrying values to their respective liquidation prices were made only when it became probable that such a change of control would occur. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The measurement of stock-based compensation expense for all stock-based payment awards, including stock options granted to employees, directors, and consultants, is based on the estimated fair value of the awards on the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes stock-based compensation expense for stock option grants and incentive unit grants with only service conditions on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Generally, stock option grants and incentive unit grants fully vest four years after the grant date, and stock option grants generally have a term of 10 years. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes the effect of forfeiture in compensation costs based on actual forfeitures when they occur. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s stock-based compensation program includes stock option grants to its employees, directors, and consultants. Stock options are granted at exercise prices not less than the estimated fair market value of the Company&#8217;s common stock at the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair values of stock option grants are estimated using a Black-Scholes option-pricing model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, Liminal was a wholly owned subsidiary of 4Bionics, and as such, 4Bionics granted equity awards in the form of incentive units to Liminal employees and nonemployees under 4Bionics&#8217; stock-based compensation program. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#8217;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), Tesseract Health, Inc. and Protein Evolution, Inc. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to the modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, as defined in Note 3.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Business Combination</div></div>, to which the Companies&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> equity holders are entitled, fall within the scope of ASC 815,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;) pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and are to be recognized upon achievement of the market price milestone. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares to which certain employees are entitled to fall within the scope of ASC 718, pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Tax Credits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes research and development tax credits as a reduction of Research and Development expense as earned. For State of Connecticut research and development tax credits, which are exchanged for a cash refund from the State of Connecticut, such exchanged credits are recognized as earned as a reduction of Research and Development expense in the combined and consolidated statements of operations and comprehensive loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilizes the asset and liability method of accounting for income taxes, as set forth in ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company has recorded a full valuation allowance as of December&#160;31, 2021 and 2020. Based on the available evidence, the Company believes that it is more likely than not that it will be unable to utilize all of its deferred tax assets in the future. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the provisions of ASC Topic 740, the Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. The Company&#8217;s policy is to recognize any interest and penalties related to income taxes in income tax expense in the combined and consolidated statements of operations and comprehensive loss. The Company&#8217;s open tax years subject to examination by the relevant taxing authorities are <span style="-sec-ix-hidden:hidden41720084">2017 through 2019</span>. As of December&#160;31, 2021 and 2020, the Company had no uncertain tax positions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting pronouncements adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-15,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangibles&#8212;Goodwill and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Other&#8212;Internal-Use</div> Software Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</div></div> The guidance requires certain costs incurred during the application development stage to be capitalized and other costs incurred during the preliminary project and post-implementation stages to be expensed as they are incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. A customer&#8217;s accounting for the hosting component of the arrangement is not affected. This new guidance is effective for the Company for the annual reporting period beginning January 1, 2021 and interim periods beginning January&#160;1, 2022. The Company adopted this guidance on January&#160;1, 2021 and there was no material effect of adoption on the combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt-Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</div></div>, which simplifies the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">accounting for convertible instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also requires the application of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for calculating diluted earnings per share and the treasury stock method will be no longer available. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2024, and interim reporting periods within annual reporting periods beginning January&#160;1, 2024, with early adoption permitted. The Company elected to early adopt this accounting pronouncement on January 1, 2021 and there was no material impact on the Company&#8217;s combined and consolidated financial statements and disclosures. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying existing guidance. For the Company, this ASU is effective for fiscal years beginning after December&#160;15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2021 and there was no material effect of adoption on the Company&#8217;s combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting pronouncements issued but not yet adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842),</div></div> which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-05</div> issued by FASB, entities that have not yet issued or made available for issuance the financial statements as of June&#160;3, 2020 can defer the new guidance for one year. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2020, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, and interim reporting periods within annual reporting periods beginning January&#160;1, 2023. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#8217;s combined and consolidated financial statements and does not expect it to be material. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221;</div></div> which was subsequently amended in November 2018 through ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-19,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses.&#8221;</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-19</div> further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>. As per the latest ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-02,</div> the FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January&#160;1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#8217;s combined and consolidated financial statements and disclosures. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650580008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. BUSINESS COMBINATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, Legacy Hyperfine and Liminal merged with and into separate wholly owned subsidiaries of HealthCor and each became a wholly-owned subsidiary of the Company. The Business Combination is accounted for as a reverse recapitalization in accordance with U.S. GAAP primarily due to the fact that Legacy Hyperfine and Liminal stockholders continued to control the Company following the closing of the Business Combination. Under this method of accounting, HealthCor is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Hyperfine and Liminal issuing stock for the net assets of HealthCor, accompanied by a recapitalization. The net assets of HealthCor are stated at historical cost, with no goodwill or other intangible assets recorded. Reported shares and loss per share available to holders of the Company&#8217;s capital stock and equity awards prior to the Business Combination have been retroactively restated reflecting the exchange ratios established pursuant to the Business Combination Agreement dated as of July&#160;7, 2021 (the &#8220;Business Combination Agreement&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Business Combination Agreement, at the effective time of the Business Combination (the &#8220;Effective Time&#8221;): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of Legacy Hyperfine capital stock (other than shares of Legacy Hyperfine Series A preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to <div style="letter-spacing: 0px; top: 0px;;display:inline;">0.3275 </div>(the &#8220;Hyperfine Exchange Ratio&#8221;), rounded down to the nearest whole number of shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of Legacy Hyperfine Series A preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Hyperfine Exchange Ratio, rounded down to the nearest whole number of shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each share of Liminal capital stock (other than shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;A common stock equal to 0.1796 (the &#8220;Liminal Exchange Ratio&#8221;), rounded down to the nearest whole number of shares; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each share of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#8217;s Class&#160;B common stock equal to the Liminal Exchange Ratio, rounded down to the nearest whole number of shares; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each option to purchase shares of Legacy Hyperfine common stock and each option to purchase shares of Liminal common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such option immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the </div></div> </td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal Exchange Ratio, as applicable, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded up to the nearest whole cent; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Business Combination Agreement, the Company will issue to holders of Legacy Hyperfine and Liminal securities as of immediately prior to the Effective Time, in accordance with their pro rata share, up to 10,000,000 shares of Class&#160;A common stock as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> consideration (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Shares&#8221;), if at any time during the period between the Closing Date and the third anniversary of the Closing Date (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Period&#8221;), (i) the last share price of the Class&#160;A common stock is greater than or equal to $15.00 for any 20 trading days within any 30 consecutive trading day period, or (ii)&#160;there is a transaction that will result in shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value greater than or equal to $15.00. During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Period, if there is a transaction (other than for stock splits, stock dividends, special cash dividends, reorganizations, recapitalizations or similar transactions affecting the Class&#160;A common stock) that will result in the shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value less than $15.00, then the right to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will terminate. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;21, 2021, HealthCor filed the Certificate of Incorporation (the &#8220;Certificate&#8221;) with the Secretary of State of the State of Delaware, which became effective after the Domestication. As a consequence of filing the Certificate, the Company adopted a dual class structure, comprised of the Company&#8217;s Class&#160;A common stock, which is entitled to one vote per share, and the Company&#8217;s Class&#160;B common stock, which is entitled to 20 votes per share. The Company&#8217;s Class&#160;B common stock has the same economic terms as the Company&#8217;s Class&#160;A common stock, but is subject to a &#8220;sunset&#8221; provision if Jonathan M. Rothberg, Ph.D., the founder of Legacy Hyperfine and Liminal, and a Director of the Company (&#8220;Dr.&#160;Rothberg&#8221;), and other permitted holders of the Company&#8217;s Class&#160;B common stock collectively cease to beneficially own at least twenty percent (20%) of the number of shares of the Company&#8217;s Class&#160;B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination or recapitalization of the Company&#8217;s Class&#160;B common stock) collectively held by Dr.&#160;Rothberg and permitted transferees of the Company&#8217;s Class&#160;B common stock as of the Effective Time. At the Effective Time, the Company amended the Certificate to change the name of the Company from HealthCor Catalio Acquisition Corp. to &#8220;Hyperfine, Inc.&#8221; (the Certificate, as amended, the &#8220;Amended Certificate&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, HealthCor entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain institutional investors and accredited investors (the &#8220;PIPE Investors&#8221;), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of 12,610,000 shares of HealthCor Class&#160;A common stock at a purchase price of $10.00 per share (the &#8220;PIPE Investment&#8221;). </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on December&#160;22, 2021, HealthCor, HC Sponsor LLC (the &#8220;Sponsor&#8221;), Legacy Hyperfine and Liminal entered into a Forfeiture Agreement (the &#8220;Forfeiture Agreement&#8221;), pursuant to which, immediately prior to the Closing, 150,000 shares of HealthCor&#8217;s Class&#160;B common stock held by the Sponsor were irrevocably forfeited and automatically cancelled (the &#8220;Forfeiture&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of shares of the Company&#8217;s Class&#160;A common stock outstanding immediately following the Closing was 54,977,061 comprising: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29,711,224 shares of Class&#160;A common stock issued to Hyperfine stockholders (other than certain holders of Hyperfine Series A preferred stock); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">3,459,081 shares of Class&#160;A common stock issued to Liminal stockholders (other than certain holders of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock); </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12,610,000 shares of Class&#160;A common stock issued in connection with the Closing to the PIPE Investors pursuant to the PIPE Investment; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,025,000 shares of Class&#160;A common stock issued immediately prior to the Effective Time to the initial shareholders upon conversion of the 5,025,000 shares of Class&#160;B common stock outstanding immediately prior to the Effective Time (following the issuance of the 5,175,000 shares of Class&#160;B common stock upon the Conversion of the 5,175,000 Class&#160;B ordinary shares held by the initial shareholders and after reflecting the irrevocable forfeiture by the Sponsor to HealthCor of 150,000 shares of Class&#160;B common stock for no consideration and automatic cancellation as of immediately prior to the Closing); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">614,000 shares of Class&#160;A common stock issued to the Sponsor; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3,557,756 shares of Class&#160;A common stock issued to the Company&#8217;s public stockholders holding 3,557,756 Class&#160;A ordinary shares outstanding at the Effective Time, after reflecting redemptions of 17,142,244 shares of HealthCor Class&#160;A common stock. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of shares of the Company&#8217;s Class&#160;B common stock outstanding immediately following the Closing was 15,055,288 shares. Immediately following the Closing, Dr.&#160;Rothberg held approximately 84.8% of the combined voting power of the Company. Accordingly, Dr.&#160;Rothberg and his permitted transferees control the Company, and the Company is a controlled company within the meaning of the Nasdaq listing rules. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net equity infusion from the Business Combination was $141,471, which consists of $207,448 proceeds from HealthCor, $126,100 proceeds from the PIPE Investors, net of payments to redeeming HealthCor shareholders of $171,437 and payment of transaction costs of $20,640. Additionally, 300,000 shares of Class&#160;A Common Stock were issued to a service provider in exchange for the services provided in connection with the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2021, in connection with the closing of the Business Combination, the Company prepaid directors and officers insurance policy in the amount of $1,244 and repaid the Liminal Paycheck Protection Program (&#8220;PPP&#8221;) loan in full in the amount of $113. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646658440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. REVENUE RECOGNITION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company disaggregates revenue from contracts with customers by product type. The Company believes that these categories aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. The following table summarizes the Company&#8217;s disaggregated revenues: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pattern of<br/>Recognition</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Point&#160;in&#160;time</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Over time</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,496</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">294</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Balances </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract balances represent amounts presented in the combined and consolidated balance sheets when either the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. These contract balances include trade accounts receivable and deferred revenue. Deferred revenue represents consideration received from customers at the beginning of the subscription period for services that are transferred to the customer over the respective subscription period. The accounts receivable balances represent amounts billed to customers for goods and services where the Company has an unconditional right to payment of the amount billed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about receivables and deferred revenue from contracts with customers: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unbilled receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a receivable when it has an unconditional right to payment, and payment terms range from 20 days to 6 months based on the terms agreed upon with the respective customer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of revenue recognized during the years ended December&#160;31, 2021 and 2020 that was included in the deferred revenue balance at the beginning of the period was $158 and $0, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from leasing arrangements is not subject to the revenue standard for contracts with customers and remains separately accounted for under existing lease accounting guidance. The Company records operating lease rental revenue as service revenue on a straight-line basis over the lease term. The Company records revenue from the sale of equipment under sales-type leases as product revenue in an amount equal to the present value of minimum lease payments at the inception of the lease. Sales-type leases also produce financing income, which is included in products net revenue in the combined and consolidated statements of operations and comprehensive loss and is recognized at effective rates of return over the lease term. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Costs of Obtaining or Fulfilling Contracts </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company incurs incremental costs of obtaining contracts with customers. Incremental costs of obtaining contracts, which include commissions paid as a result of obtaining contracts with customers, are capitalized to the extent that the Company expects to recover such costs. Capitalized costs are amortized in a pattern that is consistent with the Company&#8217;s transfer to the customer of the related goods and services. Such costs are recorded in Other long term assets and were $158 as of December&#160;31, 2021. Capitalized costs were not material for the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction price allocated to remaining performance obligations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the Company had remaining performance obligations amounting to $2,800 and $859, respectively. The Company expects to recognize approximately 43% of its remaining performance obligations as revenue in fiscal year 2022, and an additional 57% in fiscal year 2023 and thereafter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Judgements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company makes significant judgments applying the guidance related to the determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price of performance obligations and estimation of variable consideration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Practical Expedients and Accounting Policy Elections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a practical expedient, the Company does not adjust transaction price for the effects of a significant financing component in contracts in which the period between when the Company transfers the promised good or service to the customer and when the customer pays for that good or service is a year or less. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has made an accounting policy election to exclude all sales taxes from the transaction price of its contracts with customers. Accordingly, sales taxes collected from customers and remitted to government authorities is not included in revenue and is accounted for as a liability until it has been remitted to the respective government authority. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646618264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. FAIR VALUE OF FINANCIAL INSTRUMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;1</div></div> &#8212; Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;2</div></div> &#8212; Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;3</div></div> &#8212; Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level&#160;3 inputs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of cash and cash equivalents, notes receivable, accounts payable and accrued expenses and other current liabilities approximates their fair values due to the short-term or on demand nature of these instruments. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <div style="letter-spacing: 0px; top: 0px;;display:inline;">no </div>transfers between fair value measurement levels during the years ended December&#160;31, 2021 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had $48,625 and $58,418 of money market funds included in cash and cash equivalents and restricted cash as of December&#160;31, 2021 and 2020, respectively. These assets were valued using quoted market prices and accordingly were classified as Level&#160;1. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company determines that notes payable as of December&#160;31, 2020 was classified as Level&#160;2 and the relevant fair value approximates its carrying amount since it bore interest at rates that approximate current market rates. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650302632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. INVENTORIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of inventories are as follows at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,955</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,718</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total inventories</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,310</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,718</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing overhead costs primarily include management&#8217;s best estimate and allocation of the labor costs incurred related to acquiring finished goods from the Company&#8217;s contract manufacturer. Labor costs include wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. The majority of these costs have been written off based on the Company&#8217;s analysis of net realizable value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2021 and 2020, net realizable value inventory adjustments and excess and obsolete inventory charges were $75 and $213, respectively, and were recognized in cost of sales. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646507576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. PROPERTY AND EQUIPMENT, NET </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net, are recorded at historical cost and consist of the following at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">572</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">486</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">575</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">341</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,620</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(716</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,753</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,904</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense amounted to $726 and $289 for the years ended December&#160;31, 2021 and 2020, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646686328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities consist of the following at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted services</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPAC bonus and other costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">452</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll and related benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,115</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,264</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646635240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. NOTES PAYABLE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the Company received loan proceeds of $1,067 under the PPP. The Legacy Hyperfine PPP loan in the amount of $889 was evidenced by a promissory note dated August&#160;10, 2020 and was fully paid off during the fourth quarter of 2020. The Liminal PPP loan in the amount of $178 is evidenced by a promissory note dated May&#160;1, 2020. The Company used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintaining its payroll levels. The Company accounted for the loan as debt. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the closing of the Business Combination as discussed in Note 3. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>, the Company repaid the Liminal PPP loan in full in December 2021. The Company recognized an insignificant amount of interest expense in the combined and consolidated statements of operations and comprehensive loss related to the loan. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646714456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">CONVERTIBLE PREFERRED STOCK</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. CONVERTIBLE PREFERRED STOCK </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legacy Hyperfine Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legacy Hyperfine had issued four series of Convertible Preferred Stock, Series A through Series D. The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine immediately prior to the Business Combination: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/>of Class<br/>Issuance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Price&#160;per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Authorized</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Issued and<br/>Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Proceeds<br/>or<br/>Exchange<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Carrying<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial<br/>Liquidation<br/>Price per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2014</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">998</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,382</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,577,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,970,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,101</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">129,788,828</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109,182,191</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159,119</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">372</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">158,747</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/>of Class<br/>Issuance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Price&#160;per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Authorized</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Issued and<br/>Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Proceeds<br/>or<br/>Exchange<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Carrying<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial<br/>Liquidation<br/>Price per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2014</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">998</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,382</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,577,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,799,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,640</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">129,788,828</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">95,010,858</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,651</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">365</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,286</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The powers, preferences, rights, qualifications, limitations and restrictions of the shares of Convertible Preferred Stock are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends shall accrue to holders of the Convertible Preferred Stock at the rate of 8% of the original issue price for the applicable series of Convertible Preferred Stock, per annum subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization, reclassification and other similar events payable only when, and if, declared by Legacy Hyperfine&#8217;s board of directors. The right to receive dividends on Convertible Preferred Stock is not cumulative, and therefore, if not declared in any year, the right to such dividends shall terminate and shall not carry forward into the next year. There have been no dividends declared to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden41719881">In the event of any liquidation, dissolution or winding up of Legacy Hyperfine, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Legacy Hyperfine&#8217;s assets, or a</span> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transaction which the holders of capital stock of Legacy Hyperfine hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Legacy Hyperfine available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1)&#160;the applicable original issue price of such Convertible Preferred Stock, plus any declared and unpaid dividends or (2)&#160;an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Legacy Hyperfine common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of shares of the Convertible Preferred Stock shall be entitled to vote on all matters on which the holders of shares of Legacy Hyperfine common stock shall be entitled to vote. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each holder of record of shares of Series A Convertible Preferred Stock shall be entitled to ten votes per share of Legacy Hyperfine Special-voting common stock into which such Series A Convertible Preferred Stock are convertible, as discussed below under &#8220;Conversion,&#8221; on all matters to be voted on by Legacy Hyperfine&#8217;s stockholders. Each holder of record of shares of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be entitled to one vote per share of Legacy Hyperfine common stock into which such Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock are convertible, as discussed below under Conversion, on all matters to be voted on by Legacy Hyperfine&#8217;s stockholders. The holders of Convertible Preferred Stock and the holders of Legacy Hyperfine common stock shall vote together and not as separate classes. There shall be no series voting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of Series A Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Legacy Hyperfine Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Legacy Hyperfine common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the earlier to occur of (i)&#160;election of the Convertible Preferred Stock by (A)&#160;the consent or vote of the majority holders of the Convertible Preferred Stock (voting together as a single class and not as separate series, and on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis), (B) the consent or vote of the majority holders of Series C Convertible Preferred Stock (voting separately as a single class) and (C)&#160;the consent or vote of the majority holders of Series D Convertible Preferred Stock (voting separately as a single class) or (ii)&#160;the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933 covering the offer and sale of shares of Legacy Hyperfine common stock in which the aggregate gross proceeds to Legacy Hyperfine are at least $80,000 (1) each share of Series A Convertible Preferred Stock shall </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">automatically be converted into shares of Legacy Hyperfine Special-voting common stock on a 1 for 1 basis and (2)&#160;each share of Series B, Series C and Series D Convertible Preferred Stock shall automatically be converted into Legacy Hyperfine common stock on a 1 for 1 basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Business Combination, the Convertible Preferred Stock converted into Class&#160;A and Class&#160;B common stock based on the Business Combination&#8217;s Hyperfine Exchange Ratio of 0.3275 of the Company&#8217;s shares for each Legacy Hyperfine share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of the Closing. There are no shares of Convertible Preferred Stock outstanding as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liminal Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April 1, 2021 Liminal effected a recapitalization whereby each share of Liminal common stock outstanding was exchanged for shares of Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preferred stock and Liminal Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> preferred stock. The value ascribed to the preferred stock is equivalent to the total amount of historical equity investments contributed by the common shareholder. There were no new investments or changes in control in conjunction with the recapitalization. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The powers, preferences, rights, qualifications, limitations and restrictions of the shares of Liminal Convertible Preferred Stock are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends shall accrue to holders of the Convertible Preferred Stock at the rate of 8% of the original issue price for the applicable series of Convertible Preferred Stock, per annum subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization, reclassification and other similar events payable only when, and if, declared by Liminal&#8217;s board of directors. The right to receive dividends on Convertible Preferred Stock is not cumulative, and therefore, if not declared in any year, the right to such dividends shall terminate and shall not carry forward into the next year. There have been no dividends declared to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event of any liquidation, dissolution or winding up of Liminal, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Liminal&#8217;s assets, or a transaction which the holders of capital stock of Liminal hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Liminal available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issuance price of $.1287 per share for Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Liminal common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of shares of the Convertible Preferred Stock shall be entitled to vote on all matters on which the holders of shares of Liminal common stock shall be entitled to vote. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Each holder of record of shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock shall be entitled to ten votes per share of Liminal Special-voting common stock into which such Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock are convertible, as discussed below under &#8220;Conversion,&#8221; on all matters to be voted on by Liminal&#8217;s stockholders. Each holder of record of shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock shall be entitled to one vote per share of Liminal common stock into which such Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock are convertible, as discussed below under Conversion, on all matters to be voted on by Liminal&#8217;s stockholders. The holders of Convertible Preferred Stock and the holders of Liminal common stock shall vote together and not as separate classes. There shall be no series voting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Liminal Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of Liminal common stock for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock. Each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Liminal common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of common stock for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the earlier to occur of (i)&#160;election of the Convertible Preferred Stock by the consent or vote of the majority holders of the Convertible Preferred Stock (voting together as a single class and not as separate series, and on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) or (ii)&#160;the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, covering the offer and sale of shares of Liminal common stock in which the aggregate gross proceeds to Liminal are at least $80,000 (1) each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Convertible Preferred Stock shall automatically be converted into shares of Liminal Special-voting common stock on a 1 for 1 basis and (2)&#160;each share of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Convertible Preferred Stock shall automatically be converted into Liminal common stock on a 1 for 1 basis. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Business Combination, the Liminal Convertible Preferred Stock converted into Class&#160;A and Class&#160;B common stock based on the Business Combination&#8217;s Liminal Exchange Ratio of 0.1796 of the Company&#8217;s shares for each Liminal share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of the Closing. There are no shares of Convertible Preferred Stock&#160;outstanding as of December&#160;31, 2021. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650303192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, and 2020, the Company had authorized 600,000,000 and 130,000,000 shares of Class&#160;A common stock at $0.0001 par value per share, of which a total of 55,277,061 shares and 1,576,137 shares were outstanding, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, and 2020, the Company had authorized 27,000,000 and 0 shares of Class&#160;B common stock at $0.0001 par value per share, of which a total of 15,055,288 shares and 0 shares were outstanding, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of the Company&#8217;s common stock are not entitled to receive dividends unless declared by the Company&#8217;s board of directors. There have been no dividends declared to date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of shares of the Company&#8217;s Class&#160;A common stock are entitled to one vote per share on all matters on which the Company&#8217;s Class&#160;A common stock shall be entitled to vote. The holders of shares of the Company&#8217;s Class&#160;B common stock are entitled to 20 votes per share on all matters on which the Company&#8217;s Class&#160;B common stock shall be entitled to vote. The holders of the Company&#8217;s Class&#160;A common stock and Class&#160;B common stock shall vote together and not as separate classes. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646637832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY INCENTIVE PLAN</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. EQUITY INCENTIVE PLAN </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hyperfine Inc. 2021 Equity Incentive Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A total of 16,013,762 shares of common stock are reserved for issuance under the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;Hyperfine Plan&#8221;). The Hyperfine Plan is administered by the Company&#8217;s board of directors. The board of directors may grant restricted stock and options to purchase shares either as incentive stock options or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options. The option grants are subject to certain terms and conditions, option periods and conditions, exercise rights and privileges as set forth in the Hyperfine Plan. At December&#160;31, 2021, 8,256,741 common shares remain available for issuance under the Hyperfine Plan. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the Business Combination, Legacy Hyperfine and Liminal were distinct entities with separate equity incentive plans for their employees and nonemployees. Both plans were subsequently adopted and assumed by the Company as a consequence of the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Legacy Hyperfine option from Legacy Hyperfine&#8217;s 2014 Employee, Director and Consultant Equity Incentive Plan as amended on October&#160;9, 2020 (the &#8220;Legacy Hyperfine Plan&#8221;) outstanding immediately prior to the Closing, whether vested or unvested, was converted into an option to purchase shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock subject to such option multiplied by the Hyperfine Exchange Ratio of 0.3275, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Closing divided by 0.3275, rounded up to the nearest whole cent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Liminal option from Liminal&#8217;s 2021 Employee, Director, and Consultant Equity Incentive Plan (the &#8220;Liminal Plan&#8221;) outstanding immediately prior to the Closing, whether vested or unvested, was converted into an option to purchase shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Liminal common stock subject to such option multiplied by the Liminal Exchange Ratio of 0.1796, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Closing divided by 0.1796, rounded up to the nearest whole cent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each exchanged option will continue to be governed by the same terms and conditions (including vesting and exercisability terms) as were applicable to the corresponding option immediately prior to the Closing. All activity was retroactively restated to reflect the exchange that occurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respect to a number of shares of the Company&#8217;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock option activity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each stock option grant carries varying vesting schedules whereby the options become exercisable at the participant&#8217;s sole discretion provided they are an employee, director or consultant of the Company on the applicable vesting date. Each option shall terminate not more than ten years from the date of the grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company granted certain equity awards to the newly hired Chief Executive Officer. These awards include (1)&#160;an option award to purchase 1,899,500 shares of Class&#160;A common stock which will vest based on continued service over a four year period, (2)&#160;a separate option award to purchase 474,875 shares of Class&#160;A common stock, which will be fully vested upon the occurrence of various service, performance, and market conditions. Two additional 474,875 share option awards (949,750 options total) with terms similar to those described above will be granted pursuant to the terms of the offer letter. Certain equity awards were also granted to the Executive Chairman of the Legacy Hyperfine board of directors. The equity compensation included (1)&#160;an option award to purchase 712,312 shares of Class&#160;A common stock which will vest based on continued service, over four years, (2)&#160;two separate option awards to purchase 237,437 shares each of Class&#160;A common stock (474,874 shares in total), which will be fully vested upon the occurrence of various certain service, performance, and market conditions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The service condition for these awards is satisfied by providing service to the Company based on the defined service period per the award agreement. The performance-based condition is satisfied upon the occurrence of a special purpose acquisition company (&#8220;SPAC&#8221;) transaction, initial public offering (&#8220;IPO&#8221;), or financing event as defined in the award agreement. The market condition is satisfied by achieving various multiples of a defined price per share. The achievement of the performance condition and the commencement of the related expense recognition event cannot occur until the event is deemed probable, which only occurs once a SPAC transaction, IPO, or financing event has occurred. The performance condition was satisfied as a result of the Business Combination and the Company recognized stock-based compensation expense of $1,772 in connection with these awards during the year ended December&#160;31, 2021. None of the market conditions have been satisfied and as such, none of the awards are exercisable as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the above, restricted stock units with a value of $2,500 will be granted to the Chief Executive Officer following the Business Combination and within two years of the Chief Executive Officer&#8217;s start date, subject to continued service and which will vest on a schedule to be agreed upon between the Company and the Chief Executive Officer. These restricted stock units were not yet approved by the Board of Directors and therefore had not yet been granted as of December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company also granted 258,833 option awards subject to certain service and performance conditions. The service condition required the participant&#8217;s continued employment with the Company through the applicable vesting date, and the performance condition required the consummation of a Sale, IPO, or SPAC transaction as defined in the option award agreement. These awards were forfeited and cancelled prior to the consummation of the Business Combination. As a Sale, IPO, or SPAC transaction did not occur prior to forfeiture, the Company did not record any stock-based compensation expense related to these option <div style="letter-spacing: 0px; top: 0px;;display:inline;">awards</div>. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All options granted by the Company during the years ended December&#160;31, 2021 and 2020 were granted with exercise prices equal to the estimated fair value of the Company&#8217;s common stock at the date of grant, as determined by the Company&#8217;s board of directors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the stock option activity under the Hyperfine Plan is presented in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,903,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,771,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(565,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(587,047</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,522,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,052</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,332,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,785</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,117,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,445</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received cash proceeds from the exercise of stock options of $1,497 and $120 during the years ended December&#160;31, 2021 and 2020, respectively. The total intrinsic value (the amount by which the stock price exceeds the exercise price of the option on the date of exercise) of the stock options exercised during the years ended December&#160;31, 2021 and 2020, was $2,752 and $167, respectively. The weighted-average grant date fair value of options granted during the year ended December&#160;31, 2021 and 2020, was $0.66 and $0.69, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock option valuation inputs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilized the Black-Scholes option pricing model for determining the estimated fair value for service awards. The Black-Scholes model requires the use of subjective assumptions which determine the fair value of stock-based awards. The assumptions used to value option grants to employees and nonemployees for the years ended December&#160;31, 2021 and 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.95%&#160;-&#160;1.13%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.5%&#160;-&#160;1.7%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.40&#160;years&#160;-&#160;6.17&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.8&#160;years&#160;-&#160;6.0&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk free interest rate </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has never declared or paid any cash dividends and does not expect to pay any cash dividends in the foreseeable future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For employee awards, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">calculates </div>the expected term using the &#8220;simplified&#8221; method, which is the simple average of the vesting period and the contractual term. The simplified method is applied as the Company does not have sufficient historical data to provide a reasonable basis for an estimate of the expected term. The Company calculates expected term for employee awards that take into account the effects of employee&#8217;s expected exercise and post-vesting employment termination behavior. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As Legacy Hyperfine was privately held from inception through the Closing and all option grants occurred prior to the Closing Date, there was no specific historical or implied volatility information available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, the Company estimates the expected volatility on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the stock-based awards. Point estimates of expected annual equity volatility of 70% and 60% for December&#160;31, 2021 and 2020, respectively, were selected in the guideline companies&#8217; historical range. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise price </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price is taken directly from the grant notice issued to employees and nonemployees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options granted to the Company&#8217;s employees and nonemployees for the periods presented were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to employee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,534,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">897,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to nonemployee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,236,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">284,816</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock options granted</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,771,237</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,182,056</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Unit and Preferred Stock Award Activity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incentive unit grants typically vest over a four year period provided the holder is an employee, director or consultant of the Company on the applicable vesting date. Upon termination of service, pursuant to the terms of the grant, the participant 1) immediately forfeits any unvested (but issued) incentive units and 2) the Company has the right, but not the obligation, to repurchase at the fair market value on the date of termination, any vested incentive units. The repurchase right is valid for 18 months commencing with the date of service. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#8217;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), and Tesseract Health. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. No incremental compensation expense was recognized as a result of the modification. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the dissolution of 4Bionics, a portion of total 4Bionics stock-based compensation expense was allocated to Liminal based on the level of service provided by the relevant employees and nonemployees to Liminal over the term of the award. Subsequent to the dissolution of 4Bionics, the Company recognizes the stock-based compensation expense related to the replacement preferred stock awards and no allocation methodology is required. In connection with the Business Combination, all replacement preferred stock awards were accelerated to fully vest. The Company recognized stock-based compensation expense of $578 and $0 related to the incentive unit awards and replacement preferred stock awards during the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2021, immediately following the Business Combination, the Company granted 117,516 restricted stock units (&#8220;RSUs&#8221;) to members of the Company&#8217;s Board of Directors. The RSUs vest over a three year period, contingent on the ongoing service of the Directors. The grant date fair value of the RSUs was measured using the fair value of the underlying Class&#160;A common stock, which was $9.19 per share on the grant date. The total grant date fair value of $1,080 will be recognized evenly over the three year period as the service condition is satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the achievement of certain milestones, certain employees are entitled to a total of 933,933 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares fall within the scope of ASC 718, pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-out</div> valuation inputs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilized a Monte Carlo Simulation pricing model for determining the estimated fair value for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. The fair value is based on the simulated price of the Company over the maturity date of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. The key assumptions used in the valuation were as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.96</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk free interest rate </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has never declared or paid any cash dividends and does not expect to pay any cash dividends in the foreseeable future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, the expected term is determined to be 3 years from the Closing as this is the period over which the market price milestone may be achieved. As there is no dependent vesting period, the shares are exercisable at the point that the market milestone is reached. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As Legacy Hyperfine was privately held from inception through the Closing, there was no specific historical or implied volatility information available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, the Company estimates the expected volatility on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> awards. A point estimate of expected annual equity volatility of 55% for December&#160;31, 2021 was selected in the guideline companies&#8217; historical range. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s stock-based compensation expense for the periods presented was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales&#8212;Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales&#8212;Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">864</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,901</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,117</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total unrecognized stock-based compensation expense as of December&#160;31, 2021 was $13,650, which will be recognized over the remaining vesting period of 2.66 years. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646656616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. NET LOSS PER SHARE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common equivalent shares of the Company, including convertible preferred stock, outstanding stock options, RSUs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common equivalent shares of the Company outstanding would have been anti-dilutive. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the calculation of basic and diluted net loss per share for the Company&#8217;s common stock: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(64,851</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator for Basic and Dilutive EPS&#8212;Loss available to common stockholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(64,851</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(23,427</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,690,523</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,523,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic and Dilutive EPS&#8212;Weighted-average common stock</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,690,523</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,523,096</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and dilutive loss per share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17.57</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15.38</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the Company was in a net loss position for all periods presented, the basic loss per share calculation excludes preferred stock as it does not participate in net losses of the Company. Additionally, net loss per share attributable to Class&#160;A and Class&#160;B common stockholders was the same on a basic and diluted basis, as the inclusion of all common equivalent shares outstanding would have been anti-dilutive. Anti-dilutive common equivalent shares were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding options to purchase common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,522,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,903,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding Legacy Hyperfine convertible preferred stock (Series A through D)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,116,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding RSUs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive common equivalent shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,639,652</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,019,535</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650312408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. INCOME TAXES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets (liabilities):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">949</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonuses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">857</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,136</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,788</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets (liabilities)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had no income tax expense due to federal and state net operating losses incurred for the years ended December&#160;31, 2021 and 2020. The Company has also not recorded any income tax benefits for its federal and state net operating losses incurred in each period due to uncertainty of realizing the benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States. The effective tax rate for the Company for the years ended December&#160;31, 2021 and 2020 was zero percent. A reconciliation of the income tax expense at the federal statutory tax rate to the Company&#8217;s effective income tax rate follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development credit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write down of federal NOL due to 382 limitation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write down of federal R&amp;D credits due to 382 limitation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax adjustment resulting from tax rate change</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rate for December&#160;31, 2021 and 2020 differs from the federal statutory tax rate of 21% mainly due to the effect of deferred state income tax benefits resulting from state net operating loss carryforwards and the tax benefits related to research and development tax credits. These benefits to the effective tax rate are fully offset by the increase in the Company&#8217;s valuation allowance from the prior year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty of the Company&#8217;s ability to generate sufficient taxable income to realize the deferred tax assets, and therefore has not recognized any benefits from the net operating losses, tax credits and other deferred tax assets. The Company&#8217;s valuation allowance increased $18,348 and $3,729 for the years ended December&#160;31, 2021 and 2020, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had the following tax net operating loss carryforwards available to reduce future federal and Connecticut taxable income, and tax credit carryforwards available to offset future federal and Connecticut income taxes: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hyperfine</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Begin to Expire<br/>in</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine tax net operating loss carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-2018</div> NOLs)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal (post-2017 NOLs)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No&#160;Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">752</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut others</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal others</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liminal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Begin to Expire<br/>in</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal tax net operating loss carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-2018</div> NOLs)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal (post-2017 NOLs)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No&#160;Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">Under Internal Revenue Code Section&#160;382, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">pre-change</div> net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an ownership change occurs when certain shareholders increase their aggregated ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). The Company performed a Section&#160;382 analysis for Legacy Hyperfine to determine whether an ownership change has occurred. Based on this analysis, Legacy Hyperfine experienced two consecutive ownership changes, one on January 17, 2017, and one on May 16, 2017. As a result, Legacy Hyperfine&#8217;s net operating loss and tax credit carryforwards as of December&#160;31, 2020 are subject to a Section&#160;382 limitation. The January&#160;17, 2017 ownership change resulted in an annual limitation of $865 and the May&#160;16, 2017 ownership change resulted in an annual limitation of $3,008<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">. The first (earlier) limitation will limit the deduction of pre-change losses and credits arising before the first ownership change. The second (later) ownership change creates another limit to deduction of those pre-change losses and credits. However, the second ownership change does not allow for a &#8220;step-up&#8221; of the first limitation and therefore the pre-January 17, 2017 losses and credits are still subject to the first limitation amount. Due to these limitations, the Company estimates that $</div>3,125 and $249<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;of the federal net operating loss and research and development credit carryforwards, respectively, will expire before utilization. Accordingly, Legacy Hyperfine&#8217;s gross deferred tax assets and corresponding valuation allowance have been adjusted to reflect the estimated expirations. In addition, as a result of the Business Combination and any other equity issuances during the year, the Company is currently updating its Section 382 analysis to determine whether any additional ownership changes have occurred through December 31, 2021. This analysis is expected to be completed in 2022.&#160;</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has adopted the accounting guidance within ASC Topic 740 on uncertainties in income taxes. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the Company did not have any unrecognized tax benefits. To the extent penalties and interest would be assessed on any underpayment of income tax, the Company&#8217;s policy is that such amounts would be accrued and classified as a component of income tax expense in the combined and consolidated financial statements. To date, the Company has not recorded any such interest or penalties. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files income tax returns in the U.S. federal and various state jurisdictions. As a result of the Company&#8217;s net operating loss carryforwards, the Company&#8217;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company does not currently have any federal or state income tax examinations in progress. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted which included provisions related to net operating loss carryovers and carrybacks, refundable payroll tax credits, deferral of payroll taxes, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The Company has evaluated the relevant provisions of the CARES Act and has not recognized any benefit related to these provisions. Therefore, no related income tax effects have been recognized in the financial statements for the years ended December&#160;31, 2021 and 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, as a result of legislation in the state of Connecticut, companies have the opportunity to exchange certain research and development tax credit carryforwards for a cash payment of 65% of the research and development tax credit. The research and development expenses that qualify for Connecticut credits are limited to those costs incurred within Connecticut. The Company has elected to participate in the exchange program and, as a result, has recognized net benefits of $103 and $131 for the years ended December&#160;31, 2021 and 2020, respectively, which is included in research and development expenses in the accompanying statements of operations and comprehensive loss. As of December&#160;31, 2021 and 2020, the Company has recorded $196 and $467 of the research and development tax credit receivables in Prepaid expenses and other current assets on the Company&#8217;s combined and consolidated balance sheets, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646667448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilizes and subleases office and lab space in Connecticut which is being leased from an unrelated landlord by 4Catalyzer Corporation, (&#8220;4C&#8221;), which is owned by a related party. The Company pays rent to 4C on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> basis, and no lease agreement was entered into between the parties until June 2021. A total of approximately $149 and $113 was paid during 2021 and 2020, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to 4Bionics executing a plan of liquidation and dissolution on April&#160;2, 2021, certain expenses incurred at 4Bionics were allocated to its subsidiaries, including Liminal. Expenses that broadly benefited 4Bionics and its subsidiaries were allocated evenly amongst its three subsidiaries. Expenses that were incurred on behalf of the employees of each company were allocated based on each subsidiary&#8217;s relative headcount. Total proceeds allocated to Liminal upon liquidation and dissolution in 2021 were $101 and total expenses allocated to Liminal in 2020 were $64. The method used to allocate common expenses of 4Bionics to Liminal is reasonable. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2018, the Company entered into a Promissory Note (the &#8220;Note&#8221;) with one of its employees (the &#8220;Borrower&#8221;) in the amount of $90. The Note bears interest at a rate equal to 1.68% per annum. In accordance with the terms of the Note, since the Borrower remained employed with the Company on the maturity date of January&#160;11, 2022, $90 of the then outstanding principal amount and all interest accrued to that date was forgiven and Borrower is no longer required to repay the amount. Interest on the Note was payable annually in cash on the anniversary date of the Note, and as of December&#160;31, 2021 and 2020, interest receivable in the amount of $0 and $2, respectively, are included in Prepaid expenses and other current expenses on the combined and consolidated balance sheets, and interest income of $0 and $2, respectively, were recognized as of December&#160;31, 2021 and 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also made payments to 4C to prefund the acquisition of capital assets and these amounts are included in Other assets&#8212;related party on the combined and consolidated balance sheets. Such prepaid advances were $0 and $1,154 as of December&#160;31, 2021 and 2020, respectively. During 2021, the Company wrote off $983 of such prepaid advances considered to be unrecoverable. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company was a party to an Amended and Restated Technology Services Agreement (the &#8220;ARTSA&#8221;), most recently amended on November&#160;11, 2020, by and among 4C, the Company and other participant companies controlled by the Rothberg family. Under the ARTSA, the Company and the other participant companies agreed to share certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which means any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant and subject to certain restrictions on use. The ARTSA also provided for 4C to perform certain services for the Company and each other participant company such as monthly administrative, management and technical consulting services to the Company which are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> approximately once a quarter. The Company incurred expenses from 4C of $4,055 and $2,160 during the years ended December&#160;31, 2021 and 2020 respectively. The amounts advanced and due from 4C at December&#160;31, 2021 and 2020, related to operating expenses was $0 and $1,496, respectively, and is included in Due from related parties on the combined and consolidated balance sheets. There was also $1,872 and $11 of amounts due to 4C for expenses paid on their behalf. These payables are included in Due to related parties on the combined and consolidated balance sheets. On July&#160;7, 2021, Legacy Hyperfine, Liminal and 4C entered into First Addendums to the ARTSA, pursuant to which Legacy Hyperfine and Liminal each terminated its participation under the ARTSA immediately prior to the Closing. Legacy Hyperfine and Liminal each entered into a Master Services Agreement (the &#8220;Master Services Agreements&#8221;) with 4C effective as of July&#160;7, 2021 pursuant to which Legacy Hyperfine and Liminal may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ARTSA also provided for the participant companies to provide other services to each other. The Company also has transactions with other entities under common ownership, which include payments made to third parties on behalf of the Company. The amounts remaining payable at December&#160;31, 2021 and 2020 are $110 and $124, respectively, and are included in the Due to related parties on the combined and consolidated balance sheets. In addition, the Company has transactions with these other entities under common ownership which include payments made by the Company to third parties on behalf of the other entities and the amounts remaining receivable are in the aggregate $14 at December&#160;31, 2021 and the amounts remaining payable are in the aggregate $30 at December&#160;31, 2020, and are reflected in the Due from related parties on the combined and consolidated balance sheets. All amounts are paid or received throughout the year within 30 days after the end of each month. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Legacy Hyperfine and Liminal entered into Technology and Services Exchange Agreements (each, a &#8220;TSEA&#8221; and collectively, the &#8220;TSEA&#8221;) with other participant companies controlled by the Rothbergs. A TSEA by and among Butterfly Network, Inc., AI Therapeutics, Inc., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, 4Bionics, Tesseract Health, Inc., Detect, Inc. (f/k/a Homodeus Inc.), Legacy Hyperfine and Liminal was signed in November 2020; a TSEA by and among <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Quantum-Si</div> Incorporated, AI Therapeutics, Inc., 4Bionics, Tesseract Health, Inc., Detect, Inc., Legacy Hyperfine and Liminal was signed in February 2021 (and which Protein Evolution, Inc. joined in August 2021); and a TSEA by and among Legacy Hyperfine, Liminal, AI Therapeutics, Inc., Tesseract Health, Inc. and Detect, Inc. was signed in July 2021 and is effective upon the Closing. Under the TSEA, Legacy Hyperfine, Liminal and other participant companies may, in their discretion, permit the use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> technologies, which include any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant, such as software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists, by other participant companies. As of December&#160;31, 2021, the Company had transactions with other participant companies and had expenses of $11 included in Accounts payable.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646668568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. The Company did not make any matching contributions to the 401(k) plan for the years ended December&#160;30, 2021 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During 2020, the Company was awarded a $1,610 grant from the BMGF for the provision and equipping of 20 sites with the Hyperfine portable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-care</div></div> MRI system to enable the performance of a multi-site study focused on optimizing diagnostic image quality (the &#8220;Project&#8221;). During 2021, the Company was awarded an additional $3,300 grant from the BMGF, of which $2,500 was received for the provision and equipping of 5 sites and other related deliverables, of which the remaining $800 is to be received by April 2022. The funds are accounted for as restricted cash with an offset to deferred grant revenue. At December&#160;31, 2021 and 2020, the Company has $2,662 and $1,610, respectively, on the combined and consolidated balance sheets. Any grant funds, plus any income, that have not been used for, or committed to, the Project must be returned promptly to the BMGF upon expiration of or termination of the agreement. As of December&#160;31, 2021 and 2020, there were no grant fund amounts that were required to be returned under the provisions of the Project. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company does not have any outstanding or ongoing litigation and legal matters where, based on present information, including its assessment of the merits of the particular claims, the Company believes it is reasonably possible that any asserted or unasserted legal claims or proceedings, individually or in aggregate, will have a material adverse effect on its results of operations or financial condition. The ultimate outcome of any legal matter cannot be predicted with certainty. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has indemnification obligations under some agreements that the Company enters into with other parties in the ordinary course of business, including business partners, investors, contractors, and the Company&#8217;s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or threatened third-party claim because of the Company&#8217;s activities or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with certain representations and warranties made </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions due to the Company&#8217;s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the combined and consolidated statements of operations and comprehensive loss in connection with the indemnification provisions have not been material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">The Company agreed to pay $1,000<div style="display:inline;">&#160;to a third party service provider upon the receipt by the Companies&#8217; pre-closing equity holders of any Earn-Out Shares (see Note 3. Business Combination). The Company determined the probability of such payment to be not probable thus no liability was recognized.&#160;</div> <br/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808644781336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying combined and consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All intercompany transactions and balances have been eliminated. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_Covid19OutbreakPolicyTextBlock', window );">COVID-19 Outbreak</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Outbreak </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The recent outbreak of the novel coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;),</div> which was declared a pandemic by the World Health Organization on March&#160;11, 2020 and declared a National Emergency by the President of the United States on March&#160;13, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts on the Company&#8217;s operating results, financial condition and cash flows. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had, and is expected to continue to have, an adverse impact on the Company&#8217;s operations, particularly as a result of preventive and precautionary measures that the Company, other businesses, and governments are taking. Governmental mandates related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or other infectious diseases, or public </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">health crises, have impacted, and the Company expects them to continue to impact, its personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt or delay the Company&#8217;s receipt of instruments, components and supplies from the third parties the Company relies on to, among other things, produce its products. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has also had an adverse effect on the Company&#8217;s ability to attract, recruit, interview and hire at the pace the Company would typically expect to support its rapidly expanding operations. The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions taken to contain or address the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, as well as its economic impacts. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In adjusting to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> market and manufacturing conditions, the Company did not have to materially adjust its existing resource allocation or its factors of production. The Company has not incurred any significant impairment losses in the carrying values of its assets as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and is not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in its combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The estimates of the impact on the Company&#8217;s business may change based on new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or address its impact and the economic impact on local, regional, national and international markets. While the Company is unable to predict the full impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will have on its future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic, and the actions that may be taken by government authorities across the United States and elsewhere, it is not expected to result in any significant changes in costs going forward. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. At December&#160;31, 2021 and 2020, substantially all the Company&#8217;s cash and cash equivalents were invested at two financial institutions. The Company also maintains balances in various operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant customers are those that represent more than 10% of the Company&#8217;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer E</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer F</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer G</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer H</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes a single exclusive manufacturer for its Swoop MRI scanner. Additionally, the Company purchases raw materials from this manufacturer. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;). Legacy Hyperfine and Liminal represent two operating segments. Given the similar qualitative and economic characteristics of the two operating segments, such that both are focused upon the development and commercialization of existing and new products and services, Legacy Hyperfine and Liminal are aggregated into one reporting segment. All of the Company&#8217;s long-lived assets are located in the United States. Other than $78 of revenue recognized in Australia, all of the revenues were earned in the United States. Since the Company is aggregated into a single operating segment, all required financial segment information is provided in the combined and consolidated financial statements. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its combined and consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (&#8220;SSP&#8221;) of performance obligations and estimation of variable consideration; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for doubtful accounts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowances with respect to deferred tax assets; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumptions underlying the fair value used in calculation of the stock-based compensation expense. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s combined and consolidated financial statements. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All highly liquid investments purchased with a maturity of three months or less are cash equivalents. As of December&#160;31, 2021 and 2020, cash and cash equivalents consist principally of cash and money market accounts. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash balance represents funds received as part of grant funding and restricted in use to the purpose of the funding. For details, see the Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies&#8212;Grant Funding</div></div> and Note&#160;16. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commitments and Contingencies</div></div>. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are stated as the amount the Company expects to collect. The Company maintains allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. As of December&#160;31, 2021 and 2020, the allowance for doubtful accounts was $32 and $0, respectively. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories primarily consist of finished goods which are produced by the Company&#8217;s third-party contract manufacturers as well as raw materials ordered in advance by the third-party contract manufacturer due to long delivery-lead time and which were billed to the Company. Inventories are stated at the lower of actual cost, determined using the average cost method, or net realizable value. Cost includes an allocation of wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. Net realizable value is based upon an estimated average selling price reduced by the estimated costs of disposal and transportation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation of inventory also requires the Company to estimate excess and obsolete inventory. The Company considers sales forecasts and historical experience to identify excess, close out, or slow-moving items as well as new product development schedules, product obsolescence and product merchantability, including whether older products can be remanufactured into new products, among other factors. The Company reduces the value of inventory for estimated obsolescence or lack of marketability by the difference between the cost of the affected inventory and the net realizable value. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prepaid Expenses and Other Current Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets include amounts paid in advance for operating expenses as well as monies to be received from the State of Connecticut for research and development tax credits. These research and development tax credits are exchanged for a cash refund and are typically collected within one year from the date the tax return is filed with the state. The credits are recognized as an offset to research and development expenses in the combined and consolidated statements of operations and comprehensive loss in the annual period in which the corresponding expenses were incurred. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Useful lives of property and equipment are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other property and equipment include furniture and fixtures, software, vehicles, and machinery and equipment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditures for major renewals and improvements are capitalized. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation is eliminated from the balance sheet, and any resulting gains or losses are included in the combined and consolidated statements of operations and comprehensive loss in the period of disposal. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews its long-lived assets for impairment at least annually or when the Company determines a triggering event has occurred. When a triggering event has occurred, each impairment test is based on a comparison of the future expected undiscounted cash flow to the recorded value of the asset. If the recorded value of the asset is less than the undiscounted cash flow, the asset is written down to its estimated fair value. No impairments were recorded for the years ended December&#160;31, 2021 and 2020. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software Development Costs</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capitalized Software Development Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For the costs incurred in developing the firmware embedded in the hardware devices that the Company sells and leases to its customers, the Company applies the principles of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed</div></div> (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20&#8221;).</div> ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">985-20</div> requires that software development costs incurred in conjunction with product development be charged to research and development expense until technological feasibility is established. Thereafter, until the product is released for sale, software development costs must be capitalized and reported at the lower of unamortized cost or net realizable value of the related product. The Company has adopted the &#8220;tested working model&#8221; approach to establishing technological feasibility for its software products. Under this approach, the Company does not consider a product in development to have passed the technological feasibility milestone until the Company has completed a model of the product that contains essentially all the functionality and features of the final product and has tested the model to ensure that it works as expected. The Company&#8217;s hardware device, with the embedded firmware, was released for sale during the fourth quarter of the year ended December&#160;31, 2020, when the Company had completed all of the research and development activity to establish the technological feasibility of the product. As of December&#160;31, 2021 and 2020, the Company had not incurred significant costs between the establishment of technological feasibility and the release of a product for sale; thus, the Company had expensed all software development costs as incurred. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For software developed or acquired for internal use, including software used in the provision of subscription services to the Company&#8217;s customers, the Company applies the principles of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Cost of Computer Software Developed or Obtained for Internal Use</div></div> (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40&#8221;).</div> ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40</div> requires that software development costs incurred before the preliminary project stage be expensed as incurred. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Costs incurred during the preliminary project and post-implementation stages, including training and maintenance, are expensed as incurred. Capitalized costs are amortized on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">project-by-project</div></div> basis using the straight-line method over the estimated economic life of the application, which is three years, beginning when the asset is substantially ready for use. As of December&#160;31, 2021 and 2020, the Company did not have any amount of capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software development costs. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Revenue from Contracts with Customers.&#8221;</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is recognized when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following 5 steps: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 1: Identify Contracts with Customers:</div></div> The Company executes signed contracts with its customers for the sale of hardware devices and subscription services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 2: Identify Performance Obligations:</div></div> The Company&#8217;s contracts with customers primarily include two performance obligations, namely the hardware device and subscription services, which include access to the Company&#8217;s hosted cloud-based software applications and hardware maintenance and support on an ongoing basis throughout the subscription period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 3: Determine Transaction Price:</div></div> The Company&#8217;s contracts with customers include variable consideration in the form of discounts and price concessions. The Company estimates variable consideration using the expected value method based on the data available as of the end of each reporting period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 4: Allocate Transaction Price to Performance Obligations:</div></div> The Company allocates transaction price to the performance obligations in a contract with a customer, based on the relative standalone selling prices of the goods and services. The standalone selling prices of the hardware devices and subscription services are determined based on the observable standalone selling prices for which the Company sells the respective goods and services on a standalone basis, including renewals of subscription services. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Step 5: Recognize Revenue as Performance Obligations are Satisfied:</div></div> Each unit of hardware devices is a performance obligation satisfied at a point in time, when control of the good transfers from the Company to the customer, which is usually upon delivery of the good to the customer. For sales of hardware where control of the product transfers to the customer upon shipment, the Company has made an accounting policy election to account for shipping and handling as fulfillment activities rather than a performance obligation. The subscription services are stand-ready obligations that are satisfied over time by providing the customer with ongoing access to the Company&#8217;s resources throughout the subscription period. The Company uses the time elapsed (straight line) measure of progress to recognize revenue as these performance obligations are satisfied evenly over the respective service period. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company offers alternative payment structures and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;as-a-service&#8221;</div></div> offerings that are assessed to determine whether an embedded lease arrangement exists. The Company accounts for those contracts as a lease arrangement under the current lease standard if it is determined that the contract contains an identified asset and that the right to direct the use of that asset has transferred to the customer. When a contract includes lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, the Company allocates consideration under the contract to each component based on the relative standalone selling price and subsequently assesses lease classification for each lease component within a contract as a sales-type lease or an operating lease. On commencement of sales-type leases, the Company recognizes revenue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front,</div> and amounts due from the customer under the lease contract are recognized as financing receivables on the combined and consolidated balance sheets. Interest income is recognized as revenue over the term of the lease based on the effective interest method. The Company has elected not to include sales and other taxes collected from the lessee as part of lease revenue. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All other leases that do not meet the definition of a sales-type lease are classified as operating leases. The underlying asset in an operating lease arrangement is carried at depreciated cost within Property and equipment, net on the combined and consolidated balance sheets. Depreciation is calculated using the straight-line method over the term of the underlying lease contract and is recognized as cost of revenue. The depreciable basis is the original cost of the equipment less the estimated residual value of the equipment at the end of the lease term. The Company recognizes operating lease income to product revenue on a straight-line basis over the lease term. Impairment of equipment under operating leases is assessed on the same basis as other long-lived assets. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_DeferredRevenuePolicyPolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue primarily consists of billings or payments received in advance of revenue recognition from subscription services described above and is reduced as the revenue recognition criteria are met. Deferred revenue is classified as current based on expected revenue recognition timing. Specifically, deferred revenue that will be recognized as revenue within the succeeding twelve-month period is recorded as current in the Company&#8217;s combined and consolidated balance sheets. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_WarrantiesPolicyTextBlock', window );">Warranties</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warranties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company offers a device warranty to customers for the longer of (a)&#160;twelve (12) months from delivery of the device for devices obtained through a capital purchase, or (b)&#160;the term of the subscription agreement for devices obtained on a subscription basis (subject to continued payment of fees for the subscription service). The Company&#8217;s subscription services include hardware maintenance and support. As noted in the accounting policy for revenue recognition, the Company recognizes revenue for subscription service over time using the time elapsed measure of progress. The costs of hardware maintenance are recognized in costs of revenue as they are incurred. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs consists of production costs for prototype, test and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-production</div> units, lab supplies, consulting and personnel costs, including salaries, stock-based compensation, bonuses, benefit costs and depreciation. Certain research and development grant funding is recognized as a reduction to research and development costs (see Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies&#8212;Grant Funding</div></div>). The Company recognizes these costs as they are incurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_GrantFundingPolicyTextBlock', window );">Grant Funding</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant Funding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received certain research and development funding through a grant issued by the Bill&#160;&amp; Melinda Gates Foundation (&#8220;BMGF&#8221;). Funding is recorded on the combined and consolidated balance sheet as restricted cash upon receipt. The funding is recognized in the combined and consolidated statements of operations and comprehensive loss as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. Grant funding payments received in advance of research and development expenses incurred are recorded as deferred grant funding as a current liability in the Company&#8217;s combined and consolidated balance sheets. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of Sales </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales consists of product and service costs including personnel cost and benefits including stock-based compensation, product costs, production setup expenses, depreciation and amortization expenses, inventory excess and obsolescence expenses. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent costs have been charged to operations as incurred, as their realization is uncertain. These costs are included in general and administrative expenses in the combined and consolidated statements of operations and comprehensive loss. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses primarily consist of personnel costs and benefits including stock-based compensation, patent and filing fees, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Sales and Marketing</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales and Marketing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing costs primarily consist of personnel costs and benefits including stock-based compensation, advertising, promotional, as well as conferences, meetings, and other events. Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising expenses were $2,459 and $437, respectively. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Common Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is calculated by dividing the net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares plus the common equivalent shares of the period, including any dilutive effect from such shares. The Company&#8217;s diluted net loss per common share is the same as basic net loss per common share for all periods presented since the effect of potentially dilutive securities is anti-dilutive. Refer to Note 13. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share</div></div> for further discussion. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has applied the guidance in ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A,</div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities,</div></div> and has therefore classified the Series A, Series B, Series C and Series D Convertible Preferred Stock (&#8220;Convertible Preferred Stock&#8221;) (see Note 10. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock</div></div>) as mezzanine equity. The Convertible Preferred Stock was recorded outside of stockholders&#8217; equity (deficit) because the Convertible Preferred Stock included a redemption provision upon a change of control, which is deemed a liquidation event that is considered outside the Company&#8217;s control. The Convertible Preferred Stock has been recorded at its original issue price, net of issuance costs. The Company did not adjust the carrying value of the Convertible Preferred Stock to the liquidation price associated with a change of control at December&#160;31, 2020 because a change of control of the Company was not considered probable at the reporting date (see Note&#160;10. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock</div></div>). Subsequent adjustments to increase or decrease the carrying values to their respective liquidation prices were made only when it became probable that such a change of control would occur. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The measurement of stock-based compensation expense for all stock-based payment awards, including stock options granted to employees, directors, and consultants, is based on the estimated fair value of the awards on the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes stock-based compensation expense for stock option grants and incentive unit grants with only service conditions on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Generally, stock option grants and incentive unit grants fully vest four years after the grant date, and stock option grants generally have a term of 10 years. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes the effect of forfeiture in compensation costs based on actual forfeitures when they occur. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s stock-based compensation program includes stock option grants to its employees, directors, and consultants. Stock options are granted at exercise prices not less than the estimated fair market value of the Company&#8217;s common stock at the date of grant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair values of stock option grants are estimated using a Black-Scholes option-pricing model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, Liminal was a wholly owned subsidiary of 4Bionics, and as such, 4Bionics granted equity awards in the form of incentive units to Liminal employees and nonemployees under 4Bionics&#8217; stock-based compensation program. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#8217;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), Tesseract Health, Inc. and Protein Evolution, Inc. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to the modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_EarnOutSharesPolicyTextBlock', window );">Earn-Out Shares</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, as defined in Note 3.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Business Combination</div></div>, to which the Companies&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> equity holders are entitled, fall within the scope of ASC 815,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;) pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and are to be recognized upon achievement of the market price milestone. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares to which certain employees are entitled to fall within the scope of ASC 718, pursuant to which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock', window );">Research and Development Tax Credits</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Tax Credits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes research and development tax credits as a reduction of Research and Development expense as earned. For State of Connecticut research and development tax credits, which are exchanged for a cash refund from the State of Connecticut, such exchanged credits are recognized as earned as a reduction of Research and Development expense in the combined and consolidated statements of operations and comprehensive loss. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company utilizes the asset and liability method of accounting for income taxes, as set forth in ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company has recorded a full valuation allowance as of December&#160;31, 2021 and 2020. Based on the available evidence, the Company believes that it is more likely than not that it will be unable to utilize all of its deferred tax assets in the future. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the provisions of ASC Topic 740, the Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. The Company&#8217;s policy is to recognize any interest and penalties related to income taxes in income tax expense in the combined and consolidated statements of operations and comprehensive loss. The Company&#8217;s open tax years subject to examination by the relevant taxing authorities are <span style="-sec-ix-hidden:hidden41720084">2017 through 2019</span>. As of December&#160;31, 2021 and 2020, the Company had no uncertain tax positions. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting pronouncements adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-15,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangibles&#8212;Goodwill and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Other&#8212;Internal-Use</div> Software Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</div></div> The guidance requires certain costs incurred during the application development stage to be capitalized and other costs incurred during the preliminary project and post-implementation stages to be expensed as they are incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. A customer&#8217;s accounting for the hosting component of the arrangement is not affected. This new guidance is effective for the Company for the annual reporting period beginning January 1, 2021 and interim periods beginning January&#160;1, 2022. The Company adopted this guidance on January&#160;1, 2021 and there was no material effect of adoption on the combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt-Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</div></div>, which simplifies the </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">accounting for convertible instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also requires the application of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for calculating diluted earnings per share and the treasury stock method will be no longer available. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2024, and interim reporting periods within annual reporting periods beginning January&#160;1, 2024, with early adoption permitted. The Company elected to early adopt this accounting pronouncement on January 1, 2021 and there was no material impact on the Company&#8217;s combined and consolidated financial statements and disclosures. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying existing guidance. For the Company, this ASU is effective for fiscal years beginning after December&#160;15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2021 and there was no material effect of adoption on the Company&#8217;s combined and consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting pronouncements issued but not yet adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842),</div></div> which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-05</div> issued by FASB, entities that have not yet issued or made available for issuance the financial statements as of June&#160;3, 2020 can defer the new guidance for one year. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2020, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, and interim reporting periods within annual reporting periods beginning January&#160;1, 2023. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#8217;s combined and consolidated financial statements and does not expect it to be material. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#8221;</div></div> which was subsequently amended in November 2018 through ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-19,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses.&#8221;</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-19</div> further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>. As per the latest ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-02,</div> the FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January&#160;1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#8217;s combined and consolidated financial statements and disclosures. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_Covid19OutbreakPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Covid 19 outbreak.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_Covid19OutbreakPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_DeferredRevenuePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Deferred revenue policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_DeferredRevenuePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_EarnOutSharesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earn-Out shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_EarnOutSharesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_GrantFundingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_GrantFundingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and development tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_WarrantiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_WarrantiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467743&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808649604904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant customers are those that represent more than 10% of the Company&#8217;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;year&#160;ended<br/>December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer B</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer C</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer E</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer F</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer G</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer H</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives of property and equipment</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Useful lives of property and equipment are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;useful&#160;life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of useful lives for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646613960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregated Revenues</a></td>
<td class="text">The following table summarizes the Company&#8217;s disaggregated revenues:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pattern of<br/>Recognition</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Point&#160;in&#160;time</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Over time</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,496</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">294</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Information about Receivables and Deferred Revenue from Contracts with Customers</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about receivables and deferred revenue from contracts with customers: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unbilled receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646660584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IINVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of inventories are as follows at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,955</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,718</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total inventories</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,310</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,718</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646618824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net, are recorded at historical cost and consist of the following at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">572</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">486</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">575</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">341</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tooling</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade show assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leased devices</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,620</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(716</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,753</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,904</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646699720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock', window );">Schedule Of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities consist of the following at December 31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted services</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPAC bonus and other costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">452</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll and related benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,115</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,264</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646703032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Authorized, Issued and Outstanding Convertible Preferred Stock</a></td>
<td class="text">The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine immediately prior to the Business Combination: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 27%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/>of Class<br/>Issuance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Price&#160;per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Authorized</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Issued and<br/>Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Proceeds<br/>or<br/>Exchange<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Carrying<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial<br/>Liquidation<br/>Price per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2014</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">998</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,382</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,577,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,970,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,101</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">129,788,828</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109,182,191</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">159,119</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">372</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">158,747</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/>of Class<br/>Issuance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Price&#160;per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Authorized</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Issued and<br/>Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Proceeds<br/>or<br/>Exchange<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance<br/>Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Carrying<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial<br/>Liquidation<br/>Price per<br/>share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2014</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">998</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,586,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,382</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,577,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,799,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,640</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">129,788,828</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">95,010,858</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,651</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">365</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,286</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808649649960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the stock option activity under the Hyperfine Plan is presented in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,903,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,771,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(565,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(587,047</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,522,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,052</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,332,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,785</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,117,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,445</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Option Grants to Employees and Nonemployees</a></td>
<td class="text">The assumptions used to value option grants to employees and nonemployees for the years ended December&#160;31, 2021 and 2020 were as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.95%&#160;-&#160;1.13%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.5%&#160;-&#160;1.7%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.40&#160;years&#160;-&#160;6.17&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.8&#160;years&#160;-&#160;6.0&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock', window );">Summary of Stock Options Granted</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options granted to the Company&#8217;s employees and nonemployees for the periods presented were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to employee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,534,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">897,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to nonemployee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,236,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">284,816</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock options granted</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,771,237</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,182,056</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock', window );">Key Assumptions Used in Valuation for Earn-Out Shares</a></td>
<td class="text">The key assumptions used in the valuation were as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.96</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s stock-based compensation expense for the periods presented was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales&#8212;Device</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales&#8212;Service</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">864</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,901</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,117</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of share-based payment award, earn-out shares, valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of stock options granted to employees and nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646538280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the calculation of basic and diluted net loss per share for the Company&#8217;s common stock: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(64,851</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator for Basic and Dilutive EPS&#8212;Loss available to common stockholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(64,851</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(23,427</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,690,523</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,523,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic and Dilutive EPS&#8212;Weighted-average common stock</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,690,523</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,523,096</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and dilutive loss per share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(17.57</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(15.38</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Common Equivalent Shares</a></td>
<td class="text">Anti-dilutive common equivalent shares were as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding options to purchase common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,522,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,903,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding Legacy Hyperfine convertible preferred stock (Series A through D)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,116,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding RSUs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive common equivalent shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,639,652</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,019,535</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808652461480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets (liabilities):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">949</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonuses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">857</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,136</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17,788</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets (liabilities)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate</a></td>
<td class="text">A reconciliation of the income tax expense at the federal statutory tax rate to the Company&#8217;s effective income tax rate follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development credit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write down of federal NOL due to 382 limitation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write down of federal R&amp;D credits due to 382 limitation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax adjustment resulting from tax rate change</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had the following tax net operating loss carryforwards available to reduce future federal and Connecticut taxable income, and tax credit carryforwards available to offset future federal and Connecticut income taxes: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hyperfine</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Begin to Expire<br/>in</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyperfine tax net operating loss carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-2018</div> NOLs)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal (post-2017 NOLs)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No&#160;Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">752</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut others</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal others</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liminal</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Begin to Expire<br/>in</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liminal tax net operating loss carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-2018</div> NOLs)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal (post-2017 NOLs)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No&#160;Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Connecticut research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">No Expiration</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643499112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Significant customer, percentage of revenue (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerAMember', window );">Customer A | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerAMember', window );">Customer A | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerBMember', window );">Customer B | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerCMember', window );">Customer C | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerCMember', window );">Customer C | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerDMember', window );">Customer D | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerDMember', window );">Customer D | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerEMember', window );">Customer E | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerEMember', window );">Customer E | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerFMember', window );">Customer F | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerFMember', window );">Customer F | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerGMember', window );">Customer G | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerGMember', window );">Customer G | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerHMember', window );">Customer H | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hypr_CustomerHMember', window );">Customer H | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hypr_CustomerHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hypr_CustomerHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643582520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 158,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationMethod', window );">Capitalized costs, amortization method</a></td>
<td class="text">straight-line method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized costs, amortization period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 2,459,000<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Stock option grants, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2017 2018 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member', window );">ASU No. 2018-15</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized internal-use software development costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_UncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_UncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of method used for amortizing cost capitalized in obtaining or fulfilling contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123877278&amp;loc=SL120174030-210619<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650373720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful lives of property and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_ResearchDevicesMember', window );">Research Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_SalesAndMarketingDevicesMember', window );">Sales and Marketing Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tooling</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_TradeShowAssetsMember', window );">Trade Show Assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_LeasedDevicesMember', window );">Leased Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember', window );">Other | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember', window );">Other | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_ResearchDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_ResearchDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_SalesAndMarketingDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_SalesAndMarketingDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_TradeShowAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_TradeShowAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_LeasedDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_LeasedDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643045592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 07, 2021 </div>
<div>Day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned', window );">Percentage number of shares ceases to beneficially owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination', window );">Prepaid directors and officers insurance policy in connection with closing of business combination | $</a></td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PaymentOfPaycheckProtectionProgramLoan', window );">Payment of paycheck protection program loan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_InterestAndPaymentsToRedeemingCompanyShareholders', window );">Interest and payments to redeeming company shareholders | $</a></td>
<td class="nump">171,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ProceedsFromBusinessCombination', window );">Net proceeds from equity infusion from the Business Combination | $</a></td>
<td class="nump">141,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_BusinessCombinationPaymentOfTransactionCosts', window );">Payment of transaction costs | $</a></td>
<td class="nump">$ 20,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Dr. Rothberg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">15,055,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PercentageOfCommonStockVotingPower', window );">Percentage of common stock voting power</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=hypr_HealthCorMember', window );">HealthCor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ProceedsFromBusinessCombination', window );">Net proceeds from equity infusion from the Business Combination | $</a></td>
<td class="nump">$ 207,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_BusinessCombinationTransactionThresholdTradingDays', window );">Business combination transaction threshold trading days | Day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays', window );">Business combination transaction threshold consecutive trading days. | Day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock', window );">Number of votes per share entitled to class of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">54,977,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,277,061<span></span>
</td>
<td class="nump">1,576,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,277,061<span></span>
</td>
<td class="nump">1,576,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Immediately Prior To Effective Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">5,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | HealthCor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_CommonStockSubjectToRedemption', window );">Common stock subject to redemption</a></td>
<td class="nump">17,142,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock', window );">Number of votes per share entitled to class of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares held by sponsor , irrevocably forfeited</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,055,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,055,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="nump">5,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock | Immediately Prior To Effective Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_ClassBOrdinarySharesMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares held by sponsor , irrevocably forfeited</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_ClassAOrdinarySharesMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">3,557,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember', window );">Legacy Hyperfine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember', window );">Legacy Hyperfine | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">29,711,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember', window );">Legacy Hyperfine | Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">3,459,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_LiminalMember', window );">Liminal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination, shares issued as earn out consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_PIPEInvestorsMember', window );">PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ProceedsFromBusinessCombination', window );">Net proceeds from equity infusion from the Business Combination | $</a></td>
<td class="nump">$ 126,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_PIPEInvestorsMember', window );">PIPE Investors | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">12,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_BusinessCombinationPaymentOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination payment of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_BusinessCombinationPaymentOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination transaction threshold consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_BusinessCombinationTransactionThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination transaction threshold trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_BusinessCombinationTransactionThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_CommonStockSubjectToRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock subject to redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_CommonStockSubjectToRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_InterestAndPaymentsToRedeemingCompanyShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and payments to redeeming company shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_InterestAndPaymentsToRedeemingCompanyShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share entitled to class of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PaymentOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PaymentOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage number of shares ceases to beneficially owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PercentageOfCommonStockVotingPower">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock voting power.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PercentageOfCommonStockVotingPower</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid insurance policy in connection with business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ProceedsFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ProceedsFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=hypr_HealthCorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=hypr_HealthCorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=hypr_ImmediatelyPriorToEffectiveTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=hypr_ImmediatelyPriorToEffectiveTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=hypr_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=hypr_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=hypr_HealthCorCatalioAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=hypr_HealthCorCatalioAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hypr_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hypr_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_ClassBOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_ClassBOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_ClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_ClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hypr_LiminalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hypr_LiminalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hypr_PIPEInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hypr_PIPEInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808645661288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Summary of Disaggregated Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Device | Point In Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service | Over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646797592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Information about Receivables and Deferred Revenue from Contracts with Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 553<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long term deferred revenue</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808644528440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum', window );">Payment terms range, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum', window );">Payment terms range, maximum</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was included in the deferred revenue balance at the beginning of the period</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract cost</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum payment term agreed upon with the respective customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum payment term agreed upon with the respective customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808649505384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Additional Information (Details1)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage', window );">Remaining performance obligation expected to be recognized, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation expected to be recognized, duration</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage', window );">Remaining performance obligation expected to be recognized, percentage</a></td>
<td class="nump">57.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808645683896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value asset transfers, Level 2 to Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities transfers, Level 2 to Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 48,625<span></span>
</td>
<td class="nump">$ 58,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808644780008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Summary of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">$ 1,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 4,310<span></span>
</td>
<td class="nump">$ 1,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808652454600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory adjustments and excess and obsolete inventory charges</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643486984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Schedule of Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,163<span></span>
</td>
<td class="nump">$ 2,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(1,410)<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_ResearchDevicesMember', window );">Research Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_SalesAndMarketingDevicesMember', window );">Sales and Marketing Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tooling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_TradeShowAssetsMember', window );">Trade Show Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leased Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_ResearchDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_ResearchDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_SalesAndMarketingDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_SalesAndMarketingDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_TradeShowAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hypr_TradeShowAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808652478856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643488520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus</a></td>
<td class="nump">$ 3,421<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_AccruedContractedServicesCurrent', window );">Contracted services</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_AccruedBonusAndOtherCostsCurrent', window );">SPAC bonus and other costs</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,115<span></span>
</td>
<td class="nump">$ 1,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_AccruedBonusAndOtherCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued bonus and other costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_AccruedBonusAndOtherCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_AccruedContractedServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contracted services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_AccruedContractedServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646911688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=hypr_HyperfinePayrollProtectionProgramLoanMember', window );">Hyperfine PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=hypr_LiminalPayrollProtectionProgramLoanMember', window );">Liminal PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hypr_PayrollProtectionProgramLoanMember', window );">Payroll Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="nump">$ 1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=hypr_HyperfinePayrollProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=hypr_HyperfinePayrollProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=hypr_LiminalPayrollProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=hypr_LiminalPayrollProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hypr_PayrollProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hypr_PayrollProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643140968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED STOCK - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingLiquidationPlan', window );">Liquidation rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event of any liquidation, dissolution or winding up of Legacy Hyperfine, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Legacy Hyperfine&#8217;s assets, or a transaction which the holders of capital stock of Legacy Hyperfine hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Legacy Hyperfine available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issue price of such Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Legacy Hyperfine common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
<td class="nump">109,182,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,788,828<span></span>
</td>
<td class="nump">129,788,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember', window );">Dividend Declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember', window );">Legacy Hyperfine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Convertible preferred stock dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_BusinessCombinationExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_LiminalConvertiblePreferredStockMember', window );">Liminal Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Convertible preferred stock dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingLiquidationPlan', window );">Liquidation rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event of any liquidation, dissolution or winding up of Liminal, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Liminal&#8217;s assets, or a transaction which the holders of capital stock of Liminal hold less than 50% of the voting securities) (each a &#8220;Liquidation Event&#8221;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Liminal available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issuance price of $.1287 per share for Series A-1 and Series A-2 Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Liminal common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_BusinessCombinationExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible preferred stock, conversion basis</a></td>
<td class="text">On April 1, 2021 Liminal effected a recapitalization whereby each share of Liminal common stock outstanding was exchanged for shares of Liminal Series A-1 preferred stock and Liminal Series A-2 preferred stock. The value ascribed to the preferred stock is equivalent to the total amount of historical equity investments contributed by the common shareholder.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_LiminalConvertiblePreferredStockMember', window );">Liminal Convertible Preferred Stock | Dividend Declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible preferred stock, conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Legacy Hyperfine Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,799,648<span></span>
</td>
<td class="nump">41,970,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,577,618<span></span>
</td>
<td class="nump">62,577,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesBCAndDConvertiblePreferredStockMember', window );">Series B, C and D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible preferred stock, conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Legacy Hyperfine common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesA1PreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible preferred stock, conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A-1 Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Liminal Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of Liminal common stock for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesATwoConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible preferred stock, conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A-2 Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Liminal common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of common stock for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_BusinessCombinationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination, exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_BusinessCombinationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingLiquidationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the plan of liquidation. Includes, but is not limited to, the manner by which assets are expected to be disposed of and other items expected to be sold that had not been previously recognized as assets, the manner by which liabilities are expected to be settled, and the expected date by which liquidation is expected to be complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686388-199418<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingLiquidationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hypr_LegacyHyperfineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_LiminalConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_LiminalConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesBCAndDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_SeriesBCAndDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hypr_SeriesATwoConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hypr_SeriesATwoConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643145304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED STOCK - Summary of Authorized, Issued and Outstanding Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">129,788,828<span></span>
</td>
<td class="nump">129,788,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">109,182,191<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">109,182,191<span></span>
</td>
<td class="nump">95,010,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total Proceeds or Exchange Value</a></td>
<td class="nump">$ 159,119<span></span>
</td>
<td class="nump">$ 128,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquitySharesIssuanceCost', window );">Issuance Costs</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="nump">$ 158,747<span></span>
</td>
<td class="nump">$ 128,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityYearOfClassIssuance', window );">Year of Class Issuance</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">2014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Issuance Price per share</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total Proceeds or Exchange Value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquitySharesIssuanceCost', window );">Issuance Costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="nump">$ 998<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Initial Liquidation Price per share</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityYearOfClassIssuance', window );">Year of Class Issuance</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Issuance Price per share</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">10,625,000<span></span>
</td>
<td class="nump">10,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">10,625,000<span></span>
</td>
<td class="nump">10,625,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">10,625,000<span></span>
</td>
<td class="nump">10,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total Proceeds or Exchange Value</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquitySharesIssuanceCost', window );">Issuance Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Initial Liquidation Price per share</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityYearOfClassIssuance', window );">Year of Class Issuance</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Issuance Price per share</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">31,586,210<span></span>
</td>
<td class="nump">31,586,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">31,586,210<span></span>
</td>
<td class="nump">31,586,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">31,586,210<span></span>
</td>
<td class="nump">31,586,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total Proceeds or Exchange Value</a></td>
<td class="nump">$ 59,382<span></span>
</td>
<td class="nump">$ 59,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquitySharesIssuanceCost', window );">Issuance Costs</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="nump">$ 59,148<span></span>
</td>
<td class="nump">$ 59,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Initial Liquidation Price per share</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityYearOfClassIssuance', window );">Year of Class Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Issuance Price per share</a></td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">62,577,618<span></span>
</td>
<td class="nump">62,577,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">41,970,981<span></span>
</td>
<td class="nump">27,799,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">41,970,981<span></span>
</td>
<td class="nump">27,799,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total Proceeds or Exchange Value</a></td>
<td class="nump">$ 90,237<span></span>
</td>
<td class="nump">$ 59,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquitySharesIssuanceCost', window );">Issuance Costs</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="nump">$ 90,101<span></span>
</td>
<td class="nump">$ 59,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Initial Liquidation Price per share</a></td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityYearOfClassIssuance', window );">Year of Class Issuance</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TemporaryEquityYearOfClassIssuance', window );">Year of Class Issuance</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_TemporaryEquitySharesIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, shares, issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_TemporaryEquitySharesIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_TemporaryEquityYearOfClassIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, year of class issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_TemporaryEquityYearOfClassIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646715560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared common stock | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">55,277,061<span></span>
</td>
<td class="nump">54,977,061<span></span>
</td>
<td class="nump">1,576,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">15,055,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | Vote</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643794872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Option </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Option </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,901,000<span></span>
</td>
<td class="nump">$ 1,117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue', window );">Incremental value as a result of the modification of the awards | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation expense recognized as a result of the modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 13,650,000<span></span>
</td>
<td class="nump">$ 13,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfSeparateOptionAwards', window );">Number of separate option awards | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,772,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annual equity volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units ("RSU") granted</a></td>
<td class="nump">117,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total grant date fair value | $</a></td>
<td class="nump">$ 1,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Total grant date fair value recognized period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Granted value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=hypr_IncentiveUnitActivityMember', window );">Incentive Unit Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService', window );">Repurchase right valid period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember', window );">Incentive Unit Awards and Replacement Preferred Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annual equity volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=hypr_EarnOutSharesMember', window );">Earn-Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annual equity volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares entitle to certain employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=hypr_StockOptionsOneMember', window );">Stock Options One | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=hypr_StockOptionsTwoMember', window );">Stock Options Two | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember', window );">Two Separate Option Awards | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfSeparateOptionAwards', window );">Number of separate option awards | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,899,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value per share | $ / shares</a></td>
<td class="nump">$ 9.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Stock Options One | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Separate Option Award | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember', window );">Hyperfine Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">16,013,762<span></span>
</td>
<td class="nump">16,013,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_CommonStockRemainsAvailableForIssuance', window );">Common stock remain available for issuance</a></td>
<td class="nump">8,256,741<span></span>
</td>
<td class="nump">8,256,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,771,237<span></span>
</td>
<td class="nump">1,182,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,752,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annual equity volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember', window );">Hyperfine Plan | Service and Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option award to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember', window );">Hyperfine Plan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_LiminalMember', window );">Liminal | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember', window );">4Bionics Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 578,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_CommonStockRemainsAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock remains available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_CommonStockRemainsAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NumberOfSeparateOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of separate option awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NumberOfSeparateOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, award repurchase right valid period commencing with date of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment arrangement plan modification incremental value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_IncentiveUnitActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_IncentiveUnitActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_StockOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_StockOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_StockOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_StockOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_ServiceAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_ServiceAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hypr_LiminalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hypr_LiminalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643004936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN - Summary of Stock Option Activity (Details) - Hyperfine Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding</a></td>
<td class="nump">1,903,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">6,771,237<span></span>
</td>
<td class="nump">1,182,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(565,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(587,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding</a></td>
<td class="nump">7,522,136<span></span>
</td>
<td class="nump">1,903,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">2,332,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="nump">7,117,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">3.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="nump">3.21<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">2.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest</a></td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">7 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">8 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 30,052<span></span>
</td>
<td class="nump">$ 2,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">9,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 28,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646933704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN - Assumptions Used to Value Option Grants to Employees and Nonemployees (Details) - Stock Option Grants<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free interest rate, minimum</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free interest rate, maximum</a></td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808650403720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN - Summary of Stock Options Granted (Details) - Hyperfine Plan - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">6,771,237<span></span>
</td>
<td class="nump">1,182,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">3,534,844<span></span>
</td>
<td class="nump">897,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">3,236,393<span></span>
</td>
<td class="nump">284,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hypr_HyperfineEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808644542968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN - Key Assumptions Used in Valuation for Earn-Out Shares (Details) - Earn-Out Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price</a></td>
<td class="nump">$ 10.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free interest rate</a></td>
<td class="nump">0.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">54.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=hypr_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=hypr_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643096024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,901<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,482<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Device | Cost Of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service | Cost Of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808647427800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (64,851)<span></span>
</td>
<td class="num">$ (23,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Numerator for Basic and Dilutive EPS &#8211; Loss available to common stockholders</a></td>
<td class="num">$ (64,851)<span></span>
</td>
<td class="num">$ (23,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for Basic and Dilutive EPS - Weighted-average common stock</a></td>
<td class="nump">3,690,523<span></span>
</td>
<td class="nump">1,523,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and dilutive loss per share</a></td>
<td class="num">$ (17.57)<span></span>
</td>
<td class="num">$ (15.38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for Basic and Dilutive EPS - Weighted-average common stock</a></td>
<td class="nump">3,690,523<span></span>
</td>
<td class="nump">1,523,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646917160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Anti-dilutive Common Equivalent Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive common equivalent shares</a></td>
<td class="nump">17,639,652<span></span>
</td>
<td class="nump">33,019,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive common equivalent shares</a></td>
<td class="nump">7,522,136<span></span>
</td>
<td class="nump">1,903,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember', window );">Outstanding Legacy Hyperfine Convertible Preferred Stock (Series A through D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive common equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,116,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive common equivalent shares</a></td>
<td class="nump">117,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hypr_EarnOutSharesMember', window );">Earn-Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive common equivalent shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hypr_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=hypr_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646975944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="nump">$ 14,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">3,429<span></span>
</td>
<td class="nump">2,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets (liabilities)</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued bonuses</a></td>
<td class="nump">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">36,136<span></span>
</td>
<td class="nump">17,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (36,136)<span></span>
</td>
<td class="num">$ (17,788)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808647235976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Ownership</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 16, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 17, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_DeferredTaxAssetsValuationAllowanceIncreased', window );">Deferred tax assets valuation allowance increased</a></td>
<td class="nump">$ 18,348,000<span></span>
</td>
<td class="nump">$ 3,729,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OwnershipChangePercentageTestingPeriod', window );">Ownership change percentage testing period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OwnershipChangeDescription', window );">Ownership change, description</a></td>
<td class="text">ownership change occurs when certain shareholders increase their aggregated ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfConsecutiveOwnershipChanges', window );">Number of consecutive ownership changes | Ownership</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OwnershipChangesDateOne', window );">Ownership changes date, one</a></td>
<td class="text">Jan. 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OwnershipChangesDateTwo', window );">Ownership changes date, two</a></td>
<td class="text">May 16,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation', window );">Amount of annual limitation of net operating loss and tax credit carryforwards due to ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,008,000<span></span>
</td>
<td class="nump">$ 865,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear', window );">Ownership changes analysis expected to be completed year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_IncomeTaxEffectsRecognized', window );">Income tax effects recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards', window );">Percentage of cash payment in research and development tax credit</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit receivables</a></td>
<td class="nump">$ 196,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_ExchangeProgramRecognizedNetBenefits', window );">Exchange program recognized net benefits</a></td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=hypr_FederalAndStateNetOperatingLossesMember', window );">Federal And State Net Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=hypr_FederalNetOperatingLossMember', window );">Federal Net Operating Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation', window );">Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Federal Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation', window );">Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_DeferredTaxAssetsValuationAllowanceIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowance increased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_DeferredTaxAssetsValuationAllowanceIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_ExchangeProgramRecognizedNetBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange program recognized net benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_ExchangeProgramRecognizedNetBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_IncomeTaxEffectsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax effects recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_IncomeTaxEffectsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of annual limitation of net operating loss and tax credit carryforwards due to ownership change, Under Internal Revenue Code Section 382.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change, under Internal Revenue Code Section 382.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NumberOfConsecutiveOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive ownership changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NumberOfConsecutiveOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OwnershipChangeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership Change description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OwnershipChangeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OwnershipChangePercentageTestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership Change percentage testing period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OwnershipChangePercentageTestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership changes analysis expected to be completed year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OwnershipChangesDateOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership changes Date one</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OwnershipChangesDateOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OwnershipChangesDateTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership changes Date two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OwnershipChangesDateTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash payment in research and development tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=hypr_FederalAndStateNetOperatingLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=hypr_FederalAndStateNetOperatingLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=hypr_FederalNetOperatingLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=hypr_FederalNetOperatingLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808646973384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation', window );">Write down of federal NOL due to 382 limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation', window );">Write down of federal R&amp;D credits due to 382 limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred tax adjustment resulting from tax rate change</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="num">(5.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(28.10%)<span></span>
</td>
<td class="num">(15.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>EffectiveIncomeTaxRateReconciliationWriteDownOfFederalNolDueTo382Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>EffectiveIncomeTaxRateReconciliationWriteDownOfFederalResearchAndDevelopmentCreditsDueTo382Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643757608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | Federal Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 2,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TaxCreditCarryforwardBeginToExpirationYear', window );">Begin to Expire in</a></td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | Connecticut Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | Connecticut Others</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TaxCreditCarryforwardBeginToExpirationYear', window );">Begin to Expire in</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | Federal | Pre-2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax net operating loss carryforward</a></td>
<td class="nump">$ 12,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OperatingLossCarryforwardsBeginToExpireYear', window );">Begin to Expire in</a></td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | Federal | Post-2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax net operating loss carryforward</a></td>
<td class="nump">$ 91,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax net operating loss carryforward</a></td>
<td class="nump">$ 72,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OperatingLossCarryforwardsBeginToExpireYear', window );">Begin to Expire in</a></td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_HyperfineMember', window );">Hyperfine | Federal Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TaxCreditCarryforwardBeginToExpirationYear', window );">Begin to Expire in</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_LiminalMember', window );">Liminal | Federal Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_TaxCreditCarryforwardBeginToExpirationYear', window );">Begin to Expire in</a></td>
<td class="text">2038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_LiminalMember', window );">Liminal | Connecticut Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_LiminalMember', window );">Liminal | Federal | Post-2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax net operating loss carryforward</a></td>
<td class="nump">12,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hypr_LiminalMember', window );">Liminal | States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax net operating loss carryforward</a></td>
<td class="nump">$ 12,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OperatingLossCarryforwardsBeginToExpireYear', window );">Begin to Expire in</a></td>
<td class="text">2038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OperatingLossCarryforwardsBeginToExpireYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards begin to expire year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OperatingLossCarryforwardsBeginToExpireYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_TaxCreditCarryforwardBeginToExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward begin to expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_TaxCreditCarryforwardBeginToExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=hypr_HyperfineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=hypr_HyperfineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=hypr_ConnecticutResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=hypr_ConnecticutResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=hypr_ConnecticutOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=hypr_ConnecticutOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=hypr_PreTwoThaousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=hypr_PreTwoThaousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=hypr_PostTwoThaousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=hypr_PostTwoThaousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=hypr_FederalOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=hypr_FederalOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=hypr_LiminalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=hypr_LiminalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643533080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromEmployeesNoncurrent', window );">Promissory Note with one of the employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate of the Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_InterestReceivableRelatedPartiesCurrent', window );">Interest receivable from the Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeRelatedParty', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OtherAssetsRelatedPartyNoncurrent', window );">Prepaid advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_DueFromEmployeesForgiveness', window );">Promissory Note with one of the employees will be forgiven</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=hypr_AmendedAndRestatedTechnologyServicesAgreementMember', window );">ARTSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Due to related parties for payments paid on their behalf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Due from related parties for payments made on behalf of the other entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_CatalyzerCorporation4Member', window );">4C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_RelatedPartyTransactionPaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_OtherAssetsRelatedPartyNoncurrent', window );">Prepaid advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_PrepaidAdvancesUnrecoverable', window );">Prepaid advances unrecoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Due to related parties for payments paid on their behalf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,872<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_FourBionicsMember', window );">4Bionics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfSubsidiaries', window );">Number of subsidiaries | Subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_LiminalMember', window );">Liminal | Allocation of Expense Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_TechnologyAndServicesExchangeAgreementMember', window );">TESA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Due to related parties for payments paid on their behalf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_DueFromEmployeesForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from employees forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_DueFromEmployeesForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_InterestReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest receivable related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_InterestReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_OtherAssetsRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other assets related party noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_OtherAssetsRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_PrepaidAdvancesUnrecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid advances unrecoverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_PrepaidAdvancesUnrecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_RelatedPartyTransactionPaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction payments for rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_RelatedPartyTransactionPaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromEmployeesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an Entity employee, not to include stockholders or officers, which are usually due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromEmployeesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest-bearing assets owed to the entity by related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=hypr_AmendedAndRestatedTechnologyServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=hypr_AmendedAndRestatedTechnologyServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_CatalyzerCorporation4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_CatalyzerCorporation4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_FourBionicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_FourBionicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_LiminalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_LiminalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=hypr_AllocationOfExpenseIncurredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=hypr_AllocationOfExpenseIncurredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_TechnologyAndServicesExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hypr_TechnologyAndServicesExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139808643382984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">241 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Site</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Site</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">$ 2,662<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_NumberOfSites', window );">Number of sites for equipping Hyperfine portable point-of-care MRI system | Site</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_GrantAwarded', window );">Grant awarded from the BMGF</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_GrantAwardedForProvisionAndEquipping', window );">Grant awarded for provision and equipping</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses allocated</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hypr_GrantAwardedForOtherRelatedDeliverables', window );">Grant awarded for other related deliverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying amount of deferred grant funding as of balance sheet date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_GrantAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant awarded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_GrantAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_GrantAwardedForOtherRelatedDeliverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant awarded for other related deliverables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_GrantAwardedForOtherRelatedDeliverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_GrantAwardedForProvisionAndEquipping">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant awarded for provision and equipping.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_GrantAwardedForProvisionAndEquipping</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hypr_NumberOfSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of sites for equipping Hyperfine portable point-of-care MRI system.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hypr_NumberOfSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hypr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>d284543dposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:hypr="http://hyperfine.io/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hypr-20211231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_07_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2021-07-07</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="P01_01_2018To01_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="P12_12_2021To12_12_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <startDate>2021-12-12</startDate>
            <endDate>2021-12-12</endDate>
        </period>
    </context>
    <context id="PAsOn01_17_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2017-01-17</instant>
        </period>
    </context>
    <context id="PAsOn05_16_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2017-05-16</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:ResearchDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:SalesAndMarketingDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:TradeShowAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LeasedDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:LeasedDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hypr:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:FederalAndStateNetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:CatalyzerCorporation4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FourBionicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:FourBionicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">hypr:PreTwoThaousandEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LiminalMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:LiminalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hypr:AllocationOfExpenseIncurredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:ConnecticutOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">hypr:FederalOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ShareBasedPaymentArrangementSeparateOptionAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:ShareBasedPaymentArrangementSeparateOptionAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsTwoMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_StockOptionsOneMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:StockOptionsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ServiceAndPerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:ServiceAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsOneMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:StockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IncentiveUnitActivityMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:IncentiveUnitActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:FourBionicsTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:SeriesATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesBCAndDConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:SeriesBCAndDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:LegacyHyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:TradeShowAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:SalesAndMarketingDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:ResearchDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">hypr:PreTwoThaousandEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">hypr:PostTwoThaousandSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LiminalMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">hypr:PostTwoThaousandSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendDeclaredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_2023-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:ConnecticutResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:ConnecticutOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">hypr:FederalOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:HyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_LiminalMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:ConnecticutResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:SeriesATwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">hypr:ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:CatalyzerCorporation4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TechnologyAndServicesExchangeAgreementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:TechnologyAndServicesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hypr:AmendedAndRestatedTechnologyServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hypr:ResearchDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendDeclaredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:CatalyzerCorporation4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hypr:AmendedAndRestatedTechnologyServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P07_07_2021To07_07_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:LegacyHyperfineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2021To07_07_2021_LiminalMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2021To07_07_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-07-07</endDate>
        </period>
    </context>
    <context id="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-12</startDate>
            <endDate>2021-12-12</endDate>
        </period>
    </context>
    <context id="P12_12_2021To12_12_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-12</startDate>
            <endDate>2021-12-12</endDate>
        </period>
    </context>
    <context id="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hypr:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-12</startDate>
            <endDate>2021-12-12</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hypr:CustomerHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OutstandingLegacyHyperfineConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hypr:OutstandingLegacyHyperfineConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:FederalAndStateNetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:CatalyzerCorporation4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:HyperfineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hypr:AllocationOfExpenseIncurredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hypr:LiminalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hypr:FourBionicsTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hypr:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-12</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:ClassBOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:LegacyHyperfineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:LegacyHyperfineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:PIPEInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">hypr:ImmediatelyPriorToEffectiveTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">hypr:ImmediatelyPriorToEffectiveTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">hypr:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="PAsOn12_22_2021_ClassAOrdinarySharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:ClassAOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:ClassBOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HealthCorCatalioAcquisitionCorpMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">hypr:HealthCorCatalioAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021_HealthCorMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">hypr:HealthCorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2021To12_22_2021_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hypr:PIPEInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="P01_11_2022To01_11_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-11</startDate>
            <endDate>2022-01-11</endDate>
        </period>
    </context>
    <context id="P04_01_2002To04_30_2022_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2002-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn01_17_2017_FederalNetOperatingLossMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">hypr:FederalNetOperatingLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2017_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-17</instant>
        </period>
    </context>
    <context id="P04_01_2021To04_01_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:LiminalConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="P08_01_2020To08_31_2020_PayrollProtectionProgramLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hypr:PayrollProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_10_2020_HyperfinePayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">hypr:HyperfinePayrollProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="PAsOn05_01_2020_LiminalPayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">hypr:LiminalPayrollProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021_MaximumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021_MinimumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="P07_06_2021To07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hypr:HyperfineConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833769</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Segment">
        <measure>hypr:Segment</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Site">
        <measure>hypr:Site</measure>
    </unit>
    <unit id="Unit_Subsidiary">
        <measure>hypr:Subsidiary</measure>
    </unit>
    <unit id="Unit_Vote">
        <measure>hypr:Vote</measure>
    </unit>
    <unit id="Unit_Option">
        <measure>hypr:Option</measure>
    </unit>
    <unit id="Unit_Ownership">
        <measure>hypr:Ownership</measure>
    </unit>
    <us-gaap:LiquidationBasisOfAccountingLiquidationPlan contextRef="P01_01_2021To12_31_2021" id="hidden41719881">In the event of any liquidation, dissolution or winding up of Legacy Hyperfine, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Legacy Hyperfine&#x2019;s assets, or a transaction which the holders of capital stock of Legacy Hyperfine hold less than 50% of the voting securities) (each a &#x201c;Liquidation Event&#x201d;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Legacy Hyperfine available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issue price of such Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Legacy Hyperfine common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock.</us-gaap:LiquidationBasisOfAccountingLiquidationPlan>
    <us-gaap:OpenTaxYear contextRef="P01_01_2021To12_31_2021" id="hidden41720084">2017 2018 2019</us-gaap:OpenTaxYear>
    <dei:DocumentType contextRef="P01_01_2021To12_31_2021" id="hidden41773682">POS AM</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2021To12_31_2021">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2021To12_31_2021">0001833769</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="P01_01_2021To12_31_2021">Hyperfine, Inc.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory contextRef="P01_01_2021To12_31_2021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2021To12_31_2021">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2021To12_31_2021">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2021To12_31_2021">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="P01_01_2021To12_31_2021">On January&#160;24, 2022, the registrant filed a Registration Statement on Form S-1 (Registration No.&#160;333-262300), which was subsequently declared effective by the U.S. Securities and Exchange Commission on February&#160;1, 2022 (the &#x201c;Registration Statement&#x201d;).  This post-effective amendment is being filed to update the Registration Statement to include information contained in the registrant&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 and certain other information in such Registration Statement.  No additional securities are being registered under this post-effective amendment and all applicable registration and filing fees were paid at the time of the original filing of the Registration Statement. </dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">188498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">62676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2662000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1610000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">553000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">174000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">91000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4310000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1718000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1357000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">691000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1465000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">197485000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">68334000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3753000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1904000</us-gaap:PropertyPlantAndEquipmentNet>
    <hypr:OtherAssetsRelatedPartyNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1244000</hypr:OtherAssetsRelatedPartyNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1235000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202473000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">71526000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2248000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">948000</us-gaap:AccountsPayableCurrent>
    <hypr:DeferredGrantFundingCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2662000</hypr:DeferredGrantFundingCurrent>
    <hypr:DeferredGrantFundingCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1610000</hypr:DeferredGrantFundingCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1981000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">136000</us-gaap:DueToRelatedPartiesCurrent>
    <hypr:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8115000</hypr:AccruedExpensesAndOtherCurrentLiabilities>
    <hypr:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1264000</hypr:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15736000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4116000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:LongTermNotesPayable>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16246000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4294000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">147651000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">129788828</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">95010858</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">95010858</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">128286000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">55277061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">55277061</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1576137</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1576137</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15055288</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15055288</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">322540000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10415000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-136320000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-71469000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">186227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-61054000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202473000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">71526000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">781000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">94000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">2058000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">763000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">605000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2663000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">771000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1167000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-477000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25842000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14593000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27497000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5921000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10362000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2500000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">63701000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23014000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64868000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23491000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">70000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-17.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">3690523</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">1523096</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">67211210</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">68646000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1508415</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-48042000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-39864000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:NetIncomeLoss>
    <hypr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27799648</hypr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59640000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <hypr:AdjustmentsToAdditionalPaidInCapitalInvestments
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</hypr:AdjustmentsToAdditionalPaidInCapitalInvestments>
    <hypr:AdjustmentsToAdditionalPaidInCapitalInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1000000</hypr:AdjustmentsToAdditionalPaidInCapitalInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">67722</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">120000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">120000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1117000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1117000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">95010858</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">128286000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1576137</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-71469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-61054000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:NetIncomeLoss>
    <hypr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">14171333</hypr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">30461000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <hypr:AdjustmentsToAdditionalPaidInCapitalInvestments
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3516000</hypr:AdjustmentsToAdditionalPaidInCapitalInvestments>
    <hypr:AdjustmentsToAdditionalPaidInCapitalInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3516000</hypr:AdjustmentsToAdditionalPaidInCapitalInvestments>
    <hypr:RecapitalizationOfPermanentToTemporaryEquityShares
      contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">57500000</hypr:RecapitalizationOfPermanentToTemporaryEquityShares>
    <hypr:RecapitalizationOfPermanentToTemporaryEquityValues
      contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">9350000</hypr:RecapitalizationOfPermanentToTemporaryEquityValues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">-180</us-gaap:ConversionOfStockSharesConverted1>
    <hypr:ConversionOfLiminalCommonStock
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-9350000</hypr:ConversionOfLiminalCommonStock>
    <hypr:ConversionOfLiminalCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-9350000</hypr:ConversionOfLiminalCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">565533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">-109182191</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_HyperfineConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-158747000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">-57500000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-9350000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">31028815</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">15055288</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">168092000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">168097000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">21806756</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">141469000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">141471000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">55277061</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">15055288</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">322540000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-136320000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">186227000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">726000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">289000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6901000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1117000</us-gaap:ShareBasedCompensation>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:InventoryWriteDown>
    <hypr:WriteOffOfOtherAssetsRelatedParty
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">984000</hypr:WriteOffOfOtherAssetsRelatedParty>
    <us-gaap:SalesTypeLeaseSellingProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46000</us-gaap:SalesTypeLeaseSellingProfitLoss>
    <us-gaap:NetInvestmentInLeasePurchase
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:NetInvestmentInLeasePurchase>
    <us-gaap:NetInvestmentInLeasePurchase
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:NetInvestmentInLeasePurchase>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">379000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">174000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <hypr:UnbilledReceivables
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">91000</hypr:UnbilledReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2667000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1931000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">666000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-146000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1451000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">782000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-260000</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-226000</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-651000</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1201000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1436000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-377000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1052000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1610000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1082000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1845000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6851000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">773000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-47182000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-21525000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2711000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1568000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-2711000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1568000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">120000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">30468000</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">59769000</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">129000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1067000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">889000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3516000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <hypr:ProceedsFromBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">141471000</hypr:ProceedsFromBusinessCombination>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">176767000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">60938000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">126874000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">37845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64286000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">26441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">191160000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64286000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">188498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">62676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1610000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">191160000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64286000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <hypr:CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">374000</hypr:CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits>
    <hypr:CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">261000</hypr:CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">136000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <hypr:IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3000000</hypr:IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Hyperfine, Inc. (together with its subsidiaries, as applicable, &#x201c;Hyperfine&#x201d;, the &#x201c;Company&#x201d;), formerly known as HealthCor Catalio Acquisition Corp. (&#x201c;HealthCor&#x201d;), was incorporated as a Cayman Islands exempted company on November&#160;18, 2020. The Company&#x2019;s legal name became Hyperfine, Inc. in connection with the closing of the Business Combination (the &#x201c;Closing&#x201d;) on December&#160;22, 2021 (the &#x201c;Closing Date&#x201d;), as defined and described in Note 3. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;. In connection with the Closing, Hyperfine, Inc., a Delaware corporation (&#x201c;Legacy Hyperfine&#x201d;), and Liminal Sciences, Inc., a Delaware corporation (&#x201c;Liminal&#x201d;), merged with and into separate wholly owned subsidiaries of HealthCor and became wholly-owned subsidiaries of the Company, and changed their names to Hyperfine Operations, Inc. and Liminal Operations, Inc., respectively. Liminal subsequently changed its name to Liminal Sciences, Inc. The prior period financial information represents the combined financial results of Legacy Hyperfine and Liminal. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is an innovative digital health business with a mission to provide affordable and accessible imaging and monitoring through magnetic resonance imaging (&#x201c;MRI&#x201d;) to revolutionize healthcare for people around the world. Hyperfine&#x2019;s Swoop&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; Portable Magnetic Resonance (&#x201c;MR&#x201d;) Imaging System&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;TM &lt;/div&gt;produces high-quality images at a lower magnetic field strength than conventional MRI systems, and can be used by healthcare professionals to make effective clinical diagnoses on a patient in a variety of settings where MRI devices have previously been inaccessible. Hyperfine received 510(k) clearance from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in 2020 for its Swoop Portable MR Imaging System, which is commercially available in the United States. In 2021, Hyperfine also obtained a Medical Device License issued by Health Canada and expanded into the Canadian market, and also obtained regulatory authorization in New Zealand and Pakistan. All of the Company&#x2019;s revenue to date has been generated from sales of this machine and related services. Additionally, the Company is in the process of developing a device to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-invasively&lt;/div&gt; measure key vital signs in the brain to enable unprecedented access to dramatically improve patient outcomes. The Company is in the early research and development stage of such device and has not generated any revenue to date for it. In addition to Legacy Hyperfine and Liminal, the Company has an indirect wholly-owned subsidiary in the United Kingdom that did not have any significant operations during 2021. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined and consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; Outbreak &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The recent outbreak of the novel coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;),&lt;/div&gt; which was declared a pandemic by the World Health Organization on March&#160;11, 2020 and declared a National Emergency by the President of the United States on March&#160;13, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts on the Company&#x2019;s operating results, financial condition and cash flows. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had, and is expected to continue to have, an adverse impact on the Company&#x2019;s operations, particularly as a result of preventive and precautionary measures that the Company, other businesses, and governments are taking. Governmental mandates related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; or other infectious diseases, or public &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;health crises, have impacted, and the Company expects them to continue to impact, its personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt or delay the Company&#x2019;s receipt of instruments, components and supplies from the third parties the Company relies on to, among other things, produce its products. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has also had an adverse effect on the Company&#x2019;s ability to attract, recruit, interview and hire at the pace the Company would typically expect to support its rapidly expanding operations. The full extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and the actions taken to contain or address the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, as well as its economic impacts. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In adjusting to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; market and manufacturing conditions, the Company did not have to materially adjust its existing resource allocation or its factors of production. The Company has not incurred any significant impairment losses in the carrying values of its assets as a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and is not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in its combined and consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The estimates of the impact on the Company&#x2019;s business may change based on new information that may emerge concerning &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and the actions to contain it or address its impact and the economic impact on local, regional, national and international markets. While the Company is unable to predict the full impact that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic will have on its future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic, and the actions that may be taken by government authorities across the United States and elsewhere, it is not expected to result in any significant changes in costs going forward. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. At December&#160;31, 2021 and 2020, substantially all the Company&#x2019;s cash and cash equivalents were invested at two financial institutions. The Company also maintains balances in various operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant customers are those that represent more than 10% of the Company&#x2019;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 27%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;year&#160;ended&lt;br/&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;year&#160;ended&lt;br/&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer A&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer B&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer C&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer E&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer F&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer G&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer H&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes a single exclusive manufacturer for its Swoop MRI scanner. Additionally, the Company purchases raw materials from this manufacturer. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer (&#x201c;CEO&#x201d;). Legacy Hyperfine and Liminal represent two operating segments. Given the similar qualitative and economic characteristics of the two operating segments, such that both are focused upon the development and commercialization of existing and new products and services, Legacy Hyperfine and Liminal are aggregated into one reporting segment. All of the Company&#x2019;s long-lived assets are located in the United States. Other than $78 of revenue recognized in Australia, all of the revenues were earned in the United States. Since the Company is aggregated into a single operating segment, all required financial segment information is provided in the combined and consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its combined and consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (&#x201c;SSP&#x201d;) of performance obligations and estimation of variable consideration; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for doubtful accounts; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowances with respect to deferred tax assets; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assumptions underlying the fair value used in calculation of the stock-based compensation expense. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s combined and consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All highly liquid investments purchased with a maturity of three months or less are cash equivalents. As of December&#160;31, 2021 and 2020, cash and cash equivalents consist principally of cash and money market accounts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Restricted cash balance represents funds received as part of grant funding and restricted in use to the purpose of the funding. For details, see the Note 2. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of Significant Accounting Policies&#x2014;Grant Funding&lt;/div&gt;&lt;/div&gt; and Note&#160;16. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are stated as the amount the Company expects to collect. The Company maintains allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. As of December&#160;31, 2021 and 2020, the allowance for doubtful accounts was $32 and $0, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories primarily consist of finished goods which are produced by the Company&#x2019;s third-party contract manufacturers as well as raw materials ordered in advance by the third-party contract manufacturer due to long delivery-lead time and which were billed to the Company. Inventories are stated at the lower of actual cost, determined using the average cost method, or net realizable value. Cost includes an allocation of wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. Net realizable value is based upon an estimated average selling price reduced by the estimated costs of disposal and transportation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The valuation of inventory also requires the Company to estimate excess and obsolete inventory. The Company considers sales forecasts and historical experience to identify excess, close out, or slow-moving items as well as new product development schedules, product obsolescence and product merchantability, including whether older products can be remanufactured into new products, among other factors. The Company reduces the value of inventory for estimated obsolescence or lack of marketability by the difference between the cost of the affected inventory and the net realizable value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Prepaid Expenses and Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other current assets include amounts paid in advance for operating expenses as well as monies to be received from the State of Connecticut for research and development tax credits. These research and development tax credits are exchanged for a cash refund and are typically collected within one year from the date the tax return is filed with the state. The credits are recognized as an offset to research and development expenses in the combined and consolidated statements of operations and comprehensive loss in the annual period in which the corresponding expenses were incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Useful lives of property and equipment are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tooling&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade show assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leased devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other property and equipment include furniture and fixtures, software, vehicles, and machinery and equipment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenditures for major renewals and improvements are capitalized. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation is eliminated from the balance sheet, and any resulting gains or losses are included in the combined and consolidated statements of operations and comprehensive loss in the period of disposal. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews its long-lived assets for impairment at least annually or when the Company determines a triggering event has occurred. When a triggering event has occurred, each impairment test is based on a comparison of the future expected undiscounted cash flow to the recorded value of the asset. If the recorded value of the asset is less than the undiscounted cash flow, the asset is written down to its estimated fair value. No impairments were recorded for the years ended December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capitalized Software Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;For the costs incurred in developing the firmware embedded in the hardware devices that the Company sells and leases to its customers, the Company applies the principles of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;985-20,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;985-20&#x201d;).&lt;/div&gt; ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;985-20&lt;/div&gt; requires that software development costs incurred in conjunction with product development be charged to research and development expense until technological feasibility is established. Thereafter, until the product is released for sale, software development costs must be capitalized and reported at the lower of unamortized cost or net realizable value of the related product. The Company has adopted the &#x201c;tested working model&#x201d; approach to establishing technological feasibility for its software products. Under this approach, the Company does not consider a product in development to have passed the technological feasibility milestone until the Company has completed a model of the product that contains essentially all the functionality and features of the final product and has tested the model to ensure that it works as expected. The Company&#x2019;s hardware device, with the embedded firmware, was released for sale during the fourth quarter of the year ended December&#160;31, 2020, when the Company had completed all of the research and development activity to establish the technological feasibility of the product. As of December&#160;31, 2021 and 2020, the Company had not incurred significant costs between the establishment of technological feasibility and the release of a product for sale; thus, the Company had expensed all software development costs as incurred. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For software developed or acquired for internal use, including software used in the provision of subscription services to the Company&#x2019;s customers, the Company applies the principles of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for the Cost of Computer Software Developed or Obtained for Internal Use&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40&#x201d;).&lt;/div&gt; ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40&lt;/div&gt; requires that software development costs incurred before the preliminary project stage be expensed as incurred. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Costs incurred during the preliminary project and post-implementation stages, including training and maintenance, are expensed as incurred. Capitalized costs are amortized on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;project-by-project&lt;/div&gt;&lt;/div&gt; basis using the straight-line method over the estimated economic life of the application, which is three years, beginning when the asset is substantially ready for use. As of December&#160;31, 2021 and 2020, the Company did not have any amount of capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;internal-use&lt;/div&gt; software development costs. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Revenue from Contracts with Customers.&#x201d;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is recognized when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following 5 steps: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 1: Identify Contracts with Customers:&lt;/div&gt;&lt;/div&gt; The Company executes signed contracts with its customers for the sale of hardware devices and subscription services. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 2: Identify Performance Obligations:&lt;/div&gt;&lt;/div&gt; The Company&#x2019;s contracts with customers primarily include two performance obligations, namely the hardware device and subscription services, which include access to the Company&#x2019;s hosted cloud-based software applications and hardware maintenance and support on an ongoing basis throughout the subscription period. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 3: Determine Transaction Price:&lt;/div&gt;&lt;/div&gt; The Company&#x2019;s contracts with customers include variable consideration in the form of discounts and price concessions. The Company estimates variable consideration using the expected value method based on the data available as of the end of each reporting period. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 4: Allocate Transaction Price to Performance Obligations:&lt;/div&gt;&lt;/div&gt; The Company allocates transaction price to the performance obligations in a contract with a customer, based on the relative standalone selling prices of the goods and services. The standalone selling prices of the hardware devices and subscription services are determined based on the observable standalone selling prices for which the Company sells the respective goods and services on a standalone basis, including renewals of subscription services. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 5: Recognize Revenue as Performance Obligations are Satisfied:&lt;/div&gt;&lt;/div&gt; Each unit of hardware devices is a performance obligation satisfied at a point in time, when control of the good transfers from the Company to the customer, which is usually upon delivery of the good to the customer. For sales of hardware where control of the product transfers to the customer upon shipment, the Company has made an accounting policy election to account for shipping and handling as fulfillment activities rather than a performance obligation. The subscription services are stand-ready obligations that are satisfied over time by providing the customer with ongoing access to the Company&#x2019;s resources throughout the subscription period. The Company uses the time elapsed (straight line) measure of progress to recognize revenue as these performance obligations are satisfied evenly over the respective service period. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company offers alternative payment structures and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;as-a-service&#x201d;&lt;/div&gt;&lt;/div&gt; offerings that are assessed to determine whether an embedded lease arrangement exists. The Company accounts for those contracts as a lease arrangement under the current lease standard if it is determined that the contract contains an identified asset and that the right to direct the use of that asset has transferred to the customer. When a contract includes lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, the Company allocates consideration under the contract to each component based on the relative standalone selling price and subsequently assesses lease classification for each lease component within a contract as a sales-type lease or an operating lease. On commencement of sales-type leases, the Company recognizes revenue &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front,&lt;/div&gt; and amounts due from the customer under the lease contract are recognized as financing receivables on the combined and consolidated balance sheets. Interest income is recognized as revenue over the term of the lease based on the effective interest method. The Company has elected not to include sales and other taxes collected from the lessee as part of lease revenue. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All other leases that do not meet the definition of a sales-type lease are classified as operating leases. The underlying asset in an operating lease arrangement is carried at depreciated cost within Property and equipment, net on the combined and consolidated balance sheets. Depreciation is calculated using the straight-line method over the term of the underlying lease contract and is recognized as cost of revenue. The depreciable basis is the original cost of the equipment less the estimated residual value of the equipment at the end of the lease term. The Company recognizes operating lease income to product revenue on a straight-line basis over the lease term. Impairment of equipment under operating leases is assessed on the same basis as other long-lived assets. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue primarily consists of billings or payments received in advance of revenue recognition from subscription services described above and is reduced as the revenue recognition criteria are met. Deferred revenue is classified as current based on expected revenue recognition timing. Specifically, deferred revenue that will be recognized as revenue within the succeeding twelve-month period is recorded as current in the Company&#x2019;s combined and consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warranties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company offers a device warranty to customers for the longer of (a)&#160;twelve (12) months from delivery of the device for devices obtained through a capital purchase, or (b)&#160;the term of the subscription agreement for devices obtained on a subscription basis (subject to continued payment of fees for the subscription service). The Company&#x2019;s subscription services include hardware maintenance and support. As noted in the accounting policy for revenue recognition, the Company recognizes revenue for subscription service over time using the time elapsed measure of progress. The costs of hardware maintenance are recognized in costs of revenue as they are incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs consists of production costs for prototype, test and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-production&lt;/div&gt; units, lab supplies, consulting and personnel costs, including salaries, stock-based compensation, bonuses, benefit costs and depreciation. Certain research and development grant funding is recognized as a reduction to research and development costs (see Note 2. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of Significant Accounting Policies&#x2014;Grant Funding&lt;/div&gt;&lt;/div&gt;). The Company recognizes these costs as they are incurred. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Grant Funding &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received certain research and development funding through a grant issued by the Bill&#160;&amp;amp; Melinda Gates Foundation (&#x201c;BMGF&#x201d;). Funding is recorded on the combined and consolidated balance sheet as restricted cash upon receipt. The funding is recognized in the combined and consolidated statements of operations and comprehensive loss as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. Grant funding payments received in advance of research and development expenses incurred are recorded as deferred grant funding as a current liability in the Company&#x2019;s combined and consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cost of Sales &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales consists of product and service costs including personnel cost and benefits including stock-based compensation, product costs, production setup expenses, depreciation and amortization expenses, inventory excess and obsolescence expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent costs have been charged to operations as incurred, as their realization is uncertain. These costs are included in general and administrative expenses in the combined and consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;General and Administrative &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses primarily consist of personnel costs and benefits including stock-based compensation, patent and filing fees, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales and Marketing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing costs primarily consist of personnel costs and benefits including stock-based compensation, advertising, promotional, as well as conferences, meetings, and other events. Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising expenses were $2,459 and $437, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per common share is calculated by dividing the net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares plus the common equivalent shares of the period, including any dilutive effect from such shares. The Company&#x2019;s diluted net loss per common share is the same as basic net loss per common share for all periods presented since the effect of potentially dilutive securities is anti-dilutive. Refer to Note 13. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt; for further discussion. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has applied the guidance in ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99-3A,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities,&lt;/div&gt;&lt;/div&gt; and has therefore classified the Series A, Series B, Series C and Series D Convertible Preferred Stock (&#x201c;Convertible Preferred Stock&#x201d;) (see Note 10. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;) as mezzanine equity. The Convertible Preferred Stock was recorded outside of stockholders&#x2019; equity (deficit) because the Convertible Preferred Stock included a redemption provision upon a change of control, which is deemed a liquidation event that is considered outside the Company&#x2019;s control. The Convertible Preferred Stock has been recorded at its original issue price, net of issuance costs. The Company did not adjust the carrying value of the Convertible Preferred Stock to the liquidation price associated with a change of control at December&#160;31, 2020 because a change of control of the Company was not considered probable at the reporting date (see Note&#160;10. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;). Subsequent adjustments to increase or decrease the carrying values to their respective liquidation prices were made only when it became probable that such a change of control would occur. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The measurement of stock-based compensation expense for all stock-based payment awards, including stock options granted to employees, directors, and consultants, is based on the estimated fair value of the awards on the date of grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes stock-based compensation expense for stock option grants and incentive unit grants with only service conditions on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Generally, stock option grants and incentive unit grants fully vest four years after the grant date, and stock option grants generally have a term of 10 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes the effect of forfeiture in compensation costs based on actual forfeitures when they occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s stock-based compensation program includes stock option grants to its employees, directors, and consultants. Stock options are granted at exercise prices not less than the estimated fair market value of the Company&#x2019;s common stock at the date of grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair values of stock option grants are estimated using a Black-Scholes option-pricing model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2020, Liminal was a wholly owned subsidiary of 4Bionics, and as such, 4Bionics granted equity awards in the form of incentive units to Liminal employees and nonemployees under 4Bionics&#x2019; stock-based compensation program. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#x2019;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), Tesseract Health, Inc. and Protein Evolution, Inc. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to the modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares, as defined in Note 3.&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Business Combination&lt;/div&gt;&lt;/div&gt;, to which the Companies&#x2019; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-closing&lt;/div&gt; equity holders are entitled, fall within the scope of ASC 815,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 815&#x201d;) pursuant to which such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are equity classified and are to be recognized upon achievement of the market price milestone. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares to which certain employees are entitled to fall within the scope of ASC 718, pursuant to which such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Tax Credits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes research and development tax credits as a reduction of Research and Development expense as earned. For State of Connecticut research and development tax credits, which are exchanged for a cash refund from the State of Connecticut, such exchanged credits are recognized as earned as a reduction of Research and Development expense in the combined and consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company utilizes the asset and liability method of accounting for income taxes, as set forth in ASC Topic&#160;740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company has recorded a full valuation allowance as of December&#160;31, 2021 and 2020. Based on the available evidence, the Company believes that it is more likely than not that it will be unable to utilize all of its deferred tax assets in the future. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the provisions of ASC Topic 740, the Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. The Company&#x2019;s policy is to recognize any interest and penalties related to income taxes in income tax expense in the combined and consolidated statements of operations and comprehensive loss. The Company&#x2019;s open tax years subject to examination by the relevant taxing authorities are &lt;span style="-sec-ix-hidden:hidden41720084"&gt;2017 through 2019&lt;/span&gt;. As of December&#160;31, 2021 and 2020, the Company had no uncertain tax positions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting pronouncements adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-15,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangibles&#x2014;Goodwill and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&#x2014;Internal-Use&lt;/div&gt; Software Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&lt;/div&gt;&lt;/div&gt; The guidance requires certain costs incurred during the application development stage to be capitalized and other costs incurred during the preliminary project and post-implementation stages to be expensed as they are incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. A customer&#x2019;s accounting for the hosting component of the arrangement is not affected. This new guidance is effective for the Company for the annual reporting period beginning January 1, 2021 and interim periods beginning January&#160;1, 2022. The Company adopted this guidance on January&#160;1, 2021 and there was no material effect of adoption on the combined and consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt-Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Subtopic&#160;470-20)&lt;/div&gt; and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/div&gt;&lt;/div&gt;, which simplifies the &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;accounting for convertible instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; also requires the application of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; method for calculating diluted earnings per share and the treasury stock method will be no longer available. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2024, and interim reporting periods within annual reporting periods beginning January&#160;1, 2024, with early adoption permitted. The Company elected to early adopt this accounting pronouncement on January 1, 2021 and there was no material impact on the Company&#x2019;s combined and consolidated financial statements and disclosures. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&lt;/div&gt;&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying existing guidance. For the Company, this ASU is effective for fiscal years beginning after December&#160;15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2021 and there was no material effect of adoption on the Company&#x2019;s combined and consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting pronouncements issued but not yet adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic 842),&lt;/div&gt;&lt;/div&gt; which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-05&lt;/div&gt; issued by FASB, entities that have not yet issued or made available for issuance the financial statements as of June&#160;3, 2020 can defer the new guidance for one year. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2020, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, and interim reporting periods within annual reporting periods beginning January&#160;1, 2023. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#x2019;s combined and consolidated financial statements and does not expect it to be material. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#x201d;&lt;/div&gt;&lt;/div&gt; which was subsequently amended in November 2018 through ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-19,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses.&#x201d;&lt;/div&gt;&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-19&lt;/div&gt; further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;. As per the latest ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-02,&lt;/div&gt; the FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January&#160;1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#x2019;s combined and consolidated financial statements and disclosures. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying combined and consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <hypr:Covid19OutbreakPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; Outbreak &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The recent outbreak of the novel coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;),&lt;/div&gt; which was declared a pandemic by the World Health Organization on March&#160;11, 2020 and declared a National Emergency by the President of the United States on March&#160;13, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts on the Company&#x2019;s operating results, financial condition and cash flows. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had, and is expected to continue to have, an adverse impact on the Company&#x2019;s operations, particularly as a result of preventive and precautionary measures that the Company, other businesses, and governments are taking. Governmental mandates related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; or other infectious diseases, or public &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;health crises, have impacted, and the Company expects them to continue to impact, its personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt or delay the Company&#x2019;s receipt of instruments, components and supplies from the third parties the Company relies on to, among other things, produce its products. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has also had an adverse effect on the Company&#x2019;s ability to attract, recruit, interview and hire at the pace the Company would typically expect to support its rapidly expanding operations. The full extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and the actions taken to contain or address the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, as well as its economic impacts. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In adjusting to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; market and manufacturing conditions, the Company did not have to materially adjust its existing resource allocation or its factors of production. The Company has not incurred any significant impairment losses in the carrying values of its assets as a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and is not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in its combined and consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The estimates of the impact on the Company&#x2019;s business may change based on new information that may emerge concerning &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and the actions to contain it or address its impact and the economic impact on local, regional, national and international markets. While the Company is unable to predict the full impact that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic will have on its future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic, and the actions that may be taken by government authorities across the United States and elsewhere, it is not expected to result in any significant changes in costs going forward. &lt;/div&gt; </hypr:Covid19OutbreakPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. At December&#160;31, 2021 and 2020, substantially all the Company&#x2019;s cash and cash equivalents were invested at two financial institutions. The Company also maintains balances in various operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant customers are those that represent more than 10% of the Company&#x2019;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 27%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;year&#160;ended&lt;br/&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;year&#160;ended&lt;br/&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer A&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer B&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer C&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer E&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer F&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer G&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer H&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes a single exclusive manufacturer for its Swoop MRI scanner. Additionally, the Company purchases raw materials from this manufacturer. &lt;/div&gt;&lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant customers are those that represent more than 10% of the Company&#x2019;s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 27%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;year&#160;ended&lt;br/&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;year&#160;ended&lt;br/&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer A&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer B&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer C&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer E&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer F&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer G&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer H&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerDMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerEMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerFMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerGMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerHMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer (&#x201c;CEO&#x201d;). Legacy Hyperfine and Liminal represent two operating segments. Given the similar qualitative and economic characteristics of the two operating segments, such that both are focused upon the development and commercialization of existing and new products and services, Legacy Hyperfine and Liminal are aggregated into one reporting segment. All of the Company&#x2019;s long-lived assets are located in the United States. Other than $78 of revenue recognized in Australia, all of the revenues were earned in the United States. Since the Company is aggregated into a single operating segment, all required financial segment information is provided in the combined and consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2021To12_31_2021_AUsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its combined and consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (&#x201c;SSP&#x201d;) of performance obligations and estimation of variable consideration; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for doubtful accounts; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowances with respect to deferred tax assets; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assumptions underlying the fair value used in calculation of the stock-based compensation expense. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s combined and consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All highly liquid investments purchased with a maturity of three months or less are cash equivalents. As of December&#160;31, 2021 and 2020, cash and cash equivalents consist principally of cash and money market accounts. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Restricted cash balance represents funds received as part of grant funding and restricted in use to the purpose of the funding. For details, see the Note 2. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of Significant Accounting Policies&#x2014;Grant Funding&lt;/div&gt;&lt;/div&gt; and Note&#160;16. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are stated as the amount the Company expects to collect. The Company maintains allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. As of December&#160;31, 2021 and 2020, the allowance for doubtful accounts was $32 and $0, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories primarily consist of finished goods which are produced by the Company&#x2019;s third-party contract manufacturers as well as raw materials ordered in advance by the third-party contract manufacturer due to long delivery-lead time and which were billed to the Company. Inventories are stated at the lower of actual cost, determined using the average cost method, or net realizable value. Cost includes an allocation of wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. Net realizable value is based upon an estimated average selling price reduced by the estimated costs of disposal and transportation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The valuation of inventory also requires the Company to estimate excess and obsolete inventory. The Company considers sales forecasts and historical experience to identify excess, close out, or slow-moving items as well as new product development schedules, product obsolescence and product merchantability, including whether older products can be remanufactured into new products, among other factors. The Company reduces the value of inventory for estimated obsolescence or lack of marketability by the difference between the cost of the affected inventory and the net realizable value. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <hypr:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Prepaid Expenses and Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other current assets include amounts paid in advance for operating expenses as well as monies to be received from the State of Connecticut for research and development tax credits. These research and development tax credits are exchanged for a cash refund and are typically collected within one year from the date the tax return is filed with the state. The credits are recognized as an offset to research and development expenses in the combined and consolidated statements of operations and comprehensive loss in the annual period in which the corresponding expenses were incurred. &lt;/div&gt;&lt;/div&gt;</hypr:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Useful lives of property and equipment are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tooling&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade show assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leased devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other property and equipment include furniture and fixtures, software, vehicles, and machinery and equipment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenditures for major renewals and improvements are capitalized. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation is eliminated from the balance sheet, and any resulting gains or losses are included in the combined and consolidated statements of operations and comprehensive loss in the period of disposal. &lt;/div&gt;&lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <hypr:ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Useful lives of property and equipment are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;useful&#160;life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tooling&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade show assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leased devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </hypr:ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_LeasedDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews its long-lived assets for impairment at least annually or when the Company determines a triggering event has occurred. When a triggering event has occurred, each impairment test is based on a comparison of the future expected undiscounted cash flow to the recorded value of the asset. If the recorded value of the asset is less than the undiscounted cash flow, the asset is written down to its estimated fair value. No impairments were recorded for the years ended December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capitalized Software Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;For the costs incurred in developing the firmware embedded in the hardware devices that the Company sells and leases to its customers, the Company applies the principles of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;985-20,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;985-20&#x201d;).&lt;/div&gt; ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;985-20&lt;/div&gt; requires that software development costs incurred in conjunction with product development be charged to research and development expense until technological feasibility is established. Thereafter, until the product is released for sale, software development costs must be capitalized and reported at the lower of unamortized cost or net realizable value of the related product. The Company has adopted the &#x201c;tested working model&#x201d; approach to establishing technological feasibility for its software products. Under this approach, the Company does not consider a product in development to have passed the technological feasibility milestone until the Company has completed a model of the product that contains essentially all the functionality and features of the final product and has tested the model to ensure that it works as expected. The Company&#x2019;s hardware device, with the embedded firmware, was released for sale during the fourth quarter of the year ended December&#160;31, 2020, when the Company had completed all of the research and development activity to establish the technological feasibility of the product. As of December&#160;31, 2021 and 2020, the Company had not incurred significant costs between the establishment of technological feasibility and the release of a product for sale; thus, the Company had expensed all software development costs as incurred. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For software developed or acquired for internal use, including software used in the provision of subscription services to the Company&#x2019;s customers, the Company applies the principles of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for the Cost of Computer Software Developed or Obtained for Internal Use&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40&#x201d;).&lt;/div&gt; ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40&lt;/div&gt; requires that software development costs incurred before the preliminary project stage be expensed as incurred. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Costs incurred during the preliminary project and post-implementation stages, including training and maintenance, are expensed as incurred. Capitalized costs are amortized on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;project-by-project&lt;/div&gt;&lt;/div&gt; basis using the straight-line method over the estimated economic life of the application, which is three years, beginning when the asset is substantially ready for use. As of December&#160;31, 2021 and 2020, the Company did not have any amount of capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;internal-use&lt;/div&gt; software development costs. &lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:CapitalizedContractCostAmortizationMethod contextRef="P01_01_2021To12_31_2021">straight-line method</us-gaap:CapitalizedContractCostAmortizationMethod>
    <us-gaap:CapitalizedContractCostAmortizationPeriod contextRef="PAsOn12_31_2021">P3Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Revenue from Contracts with Customers.&#x201d;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is recognized when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following 5 steps: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 1: Identify Contracts with Customers:&lt;/div&gt;&lt;/div&gt; The Company executes signed contracts with its customers for the sale of hardware devices and subscription services. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 2: Identify Performance Obligations:&lt;/div&gt;&lt;/div&gt; The Company&#x2019;s contracts with customers primarily include two performance obligations, namely the hardware device and subscription services, which include access to the Company&#x2019;s hosted cloud-based software applications and hardware maintenance and support on an ongoing basis throughout the subscription period. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 3: Determine Transaction Price:&lt;/div&gt;&lt;/div&gt; The Company&#x2019;s contracts with customers include variable consideration in the form of discounts and price concessions. The Company estimates variable consideration using the expected value method based on the data available as of the end of each reporting period. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 4: Allocate Transaction Price to Performance Obligations:&lt;/div&gt;&lt;/div&gt; The Company allocates transaction price to the performance obligations in a contract with a customer, based on the relative standalone selling prices of the goods and services. The standalone selling prices of the hardware devices and subscription services are determined based on the observable standalone selling prices for which the Company sells the respective goods and services on a standalone basis, including renewals of subscription services. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Step 5: Recognize Revenue as Performance Obligations are Satisfied:&lt;/div&gt;&lt;/div&gt; Each unit of hardware devices is a performance obligation satisfied at a point in time, when control of the good transfers from the Company to the customer, which is usually upon delivery of the good to the customer. For sales of hardware where control of the product transfers to the customer upon shipment, the Company has made an accounting policy election to account for shipping and handling as fulfillment activities rather than a performance obligation. The subscription services are stand-ready obligations that are satisfied over time by providing the customer with ongoing access to the Company&#x2019;s resources throughout the subscription period. The Company uses the time elapsed (straight line) measure of progress to recognize revenue as these performance obligations are satisfied evenly over the respective service period. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company offers alternative payment structures and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;as-a-service&#x201d;&lt;/div&gt;&lt;/div&gt; offerings that are assessed to determine whether an embedded lease arrangement exists. The Company accounts for those contracts as a lease arrangement under the current lease standard if it is determined that the contract contains an identified asset and that the right to direct the use of that asset has transferred to the customer. When a contract includes lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, the Company allocates consideration under the contract to each component based on the relative standalone selling price and subsequently assesses lease classification for each lease component within a contract as a sales-type lease or an operating lease. On commencement of sales-type leases, the Company recognizes revenue &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front,&lt;/div&gt; and amounts due from the customer under the lease contract are recognized as financing receivables on the combined and consolidated balance sheets. Interest income is recognized as revenue over the term of the lease based on the effective interest method. The Company has elected not to include sales and other taxes collected from the lessee as part of lease revenue. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All other leases that do not meet the definition of a sales-type lease are classified as operating leases. The underlying asset in an operating lease arrangement is carried at depreciated cost within Property and equipment, net on the combined and consolidated balance sheets. Depreciation is calculated using the straight-line method over the term of the underlying lease contract and is recognized as cost of revenue. The depreciable basis is the original cost of the equipment less the estimated residual value of the equipment at the end of the lease term. The Company recognizes operating lease income to product revenue on a straight-line basis over the lease term. Impairment of equipment under operating leases is assessed on the same basis as other long-lived assets. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <hypr:DeferredRevenuePolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue primarily consists of billings or payments received in advance of revenue recognition from subscription services described above and is reduced as the revenue recognition criteria are met. Deferred revenue is classified as current based on expected revenue recognition timing. Specifically, deferred revenue that will be recognized as revenue within the succeeding twelve-month period is recorded as current in the Company&#x2019;s combined and consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;</hypr:DeferredRevenuePolicyPolicyTextBlock>
    <hypr:WarrantiesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warranties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company offers a device warranty to customers for the longer of (a)&#160;twelve (12) months from delivery of the device for devices obtained through a capital purchase, or (b)&#160;the term of the subscription agreement for devices obtained on a subscription basis (subject to continued payment of fees for the subscription service). The Company&#x2019;s subscription services include hardware maintenance and support. As noted in the accounting policy for revenue recognition, the Company recognizes revenue for subscription service over time using the time elapsed measure of progress. The costs of hardware maintenance are recognized in costs of revenue as they are incurred. &lt;/div&gt;&lt;/div&gt;</hypr:WarrantiesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs consists of production costs for prototype, test and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-production&lt;/div&gt; units, lab supplies, consulting and personnel costs, including salaries, stock-based compensation, bonuses, benefit costs and depreciation. Certain research and development grant funding is recognized as a reduction to research and development costs (see Note 2. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of Significant Accounting Policies&#x2014;Grant Funding&lt;/div&gt;&lt;/div&gt;). The Company recognizes these costs as they are incurred. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <hypr:GrantFundingPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Grant Funding &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received certain research and development funding through a grant issued by the Bill&#160;&amp;amp; Melinda Gates Foundation (&#x201c;BMGF&#x201d;). Funding is recorded on the combined and consolidated balance sheet as restricted cash upon receipt. The funding is recognized in the combined and consolidated statements of operations and comprehensive loss as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. Grant funding payments received in advance of research and development expenses incurred are recorded as deferred grant funding as a current liability in the Company&#x2019;s combined and consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;</hypr:GrantFundingPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cost of Sales &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales consists of product and service costs including personnel cost and benefits including stock-based compensation, product costs, production setup expenses, depreciation and amortization expenses, inventory excess and obsolescence expenses. &lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <hypr:PatentCostsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent costs have been charged to operations as incurred, as their realization is uncertain. These costs are included in general and administrative expenses in the combined and consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt;</hypr:PatentCostsPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;General and Administrative &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses primarily consist of personnel costs and benefits including stock-based compensation, patent and filing fees, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. &lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales and Marketing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing costs primarily consist of personnel costs and benefits including stock-based compensation, advertising, promotional, as well as conferences, meetings, and other events. Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising expenses were $2,459 and $437, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2459000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">437000</us-gaap:AdvertisingExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per common share is calculated by dividing the net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares plus the common equivalent shares of the period, including any dilutive effect from such shares. The Company&#x2019;s diluted net loss per common share is the same as basic net loss per common share for all periods presented since the effect of potentially dilutive securities is anti-dilutive. Refer to Note 13. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt; for further discussion. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has applied the guidance in ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99-3A,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities,&lt;/div&gt;&lt;/div&gt; and has therefore classified the Series A, Series B, Series C and Series D Convertible Preferred Stock (&#x201c;Convertible Preferred Stock&#x201d;) (see Note 10. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;) as mezzanine equity. The Convertible Preferred Stock was recorded outside of stockholders&#x2019; equity (deficit) because the Convertible Preferred Stock included a redemption provision upon a change of control, which is deemed a liquidation event that is considered outside the Company&#x2019;s control. The Convertible Preferred Stock has been recorded at its original issue price, net of issuance costs. The Company did not adjust the carrying value of the Convertible Preferred Stock to the liquidation price associated with a change of control at December&#160;31, 2020 because a change of control of the Company was not considered probable at the reporting date (see Note&#160;10. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;). Subsequent adjustments to increase or decrease the carrying values to their respective liquidation prices were made only when it became probable that such a change of control would occur. &lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The measurement of stock-based compensation expense for all stock-based payment awards, including stock options granted to employees, directors, and consultants, is based on the estimated fair value of the awards on the date of grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes stock-based compensation expense for stock option grants and incentive unit grants with only service conditions on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Generally, stock option grants and incentive unit grants fully vest four years after the grant date, and stock option grants generally have a term of 10 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes the effect of forfeiture in compensation costs based on actual forfeitures when they occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s stock-based compensation program includes stock option grants to its employees, directors, and consultants. Stock options are granted at exercise prices not less than the estimated fair market value of the Company&#x2019;s common stock at the date of grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair values of stock option grants are estimated using a Black-Scholes option-pricing model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2020, Liminal was a wholly owned subsidiary of 4Bionics, and as such, 4Bionics granted equity awards in the form of incentive units to Liminal employees and nonemployees under 4Bionics&#x2019; stock-based compensation program. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#x2019;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), Tesseract Health, Inc. and Protein Evolution, Inc. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to the modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. &lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2021To12_31_2021">10 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <hypr:EarnOutSharesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares, as defined in Note 3.&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Business Combination&lt;/div&gt;&lt;/div&gt;, to which the Companies&#x2019; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-closing&lt;/div&gt; equity holders are entitled, fall within the scope of ASC 815,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 815&#x201d;) pursuant to which such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are equity classified and are to be recognized upon achievement of the market price milestone. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares to which certain employees are entitled to fall within the scope of ASC 718, pursuant to which such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. &lt;/div&gt;</hypr:EarnOutSharesPolicyTextBlock>
    <hypr:ResearchAndDevelopmentTaxCreditsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Tax Credits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes research and development tax credits as a reduction of Research and Development expense as earned. For State of Connecticut research and development tax credits, which are exchanged for a cash refund from the State of Connecticut, such exchanged credits are recognized as earned as a reduction of Research and Development expense in the combined and consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt;</hypr:ResearchAndDevelopmentTaxCreditsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company utilizes the asset and liability method of accounting for income taxes, as set forth in ASC Topic&#160;740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company has recorded a full valuation allowance as of December&#160;31, 2021 and 2020. Based on the available evidence, the Company believes that it is more likely than not that it will be unable to utilize all of its deferred tax assets in the future. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the provisions of ASC Topic 740, the Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. The Company&#x2019;s policy is to recognize any interest and penalties related to income taxes in income tax expense in the combined and consolidated statements of operations and comprehensive loss. The Company&#x2019;s open tax years subject to examination by the relevant taxing authorities are &lt;span style="-sec-ix-hidden:hidden41720084"&gt;2017 through 2019&lt;/span&gt;. As of December&#160;31, 2021 and 2020, the Company had no uncertain tax positions. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <hypr:UncertainTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD">0</hypr:UncertainTaxPositions>
    <hypr:UncertainTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</hypr:UncertainTaxPositions>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting pronouncements adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-15,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangibles&#x2014;Goodwill and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&#x2014;Internal-Use&lt;/div&gt; Software Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&lt;/div&gt;&lt;/div&gt; The guidance requires certain costs incurred during the application development stage to be capitalized and other costs incurred during the preliminary project and post-implementation stages to be expensed as they are incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. A customer&#x2019;s accounting for the hosting component of the arrangement is not affected. This new guidance is effective for the Company for the annual reporting period beginning January 1, 2021 and interim periods beginning January&#160;1, 2022. The Company adopted this guidance on January&#160;1, 2021 and there was no material effect of adoption on the combined and consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt-Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Subtopic&#160;470-20)&lt;/div&gt; and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/div&gt;&lt;/div&gt;, which simplifies the &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;accounting for convertible instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; also requires the application of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; method for calculating diluted earnings per share and the treasury stock method will be no longer available. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2024, and interim reporting periods within annual reporting periods beginning January&#160;1, 2024, with early adoption permitted. The Company elected to early adopt this accounting pronouncement on January 1, 2021 and there was no material impact on the Company&#x2019;s combined and consolidated financial statements and disclosures. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&lt;/div&gt;&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies U.S. GAAP for other areas of Topic 740 by clarifying existing guidance. For the Company, this ASU is effective for fiscal years beginning after December&#160;15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2021 and there was no material effect of adoption on the Company&#x2019;s combined and consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting pronouncements issued but not yet adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic 842),&lt;/div&gt;&lt;/div&gt; which outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-05&lt;/div&gt; issued by FASB, entities that have not yet issued or made available for issuance the financial statements as of June&#160;3, 2020 can defer the new guidance for one year. For public entities, this guidance is effective for annual reporting periods beginning January&#160;1, 2020, including interim periods within that annual reporting period. For the Company, this guidance is effective for annual reporting periods beginning January&#160;1, 2022, and interim reporting periods within annual reporting periods beginning January&#160;1, 2023. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#x2019;s combined and consolidated financial statements and does not expect it to be material. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&#x201d;&lt;/div&gt;&lt;/div&gt; which was subsequently amended in November 2018 through ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-19,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses.&#x201d;&lt;/div&gt;&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-19&lt;/div&gt; further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;. As per the latest ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-02,&lt;/div&gt; the FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January&#160;1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company is in the process of evaluating the impact that the adoption of this pronouncement will have on the Company&#x2019;s combined and consolidated financial statements and disclosures. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201815MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect contextRef="PAsOn12_31_2021_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption contextRef="PAsOn12_31_2021_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. BUSINESS COMBINATION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the Closing, Legacy Hyperfine and Liminal merged with and into separate wholly owned subsidiaries of HealthCor and each became a wholly-owned subsidiary of the Company. The Business Combination is accounted for as a reverse recapitalization in accordance with U.S. GAAP primarily due to the fact that Legacy Hyperfine and Liminal stockholders continued to control the Company following the closing of the Business Combination. Under this method of accounting, HealthCor is treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Hyperfine and Liminal issuing stock for the net assets of HealthCor, accompanied by a recapitalization. The net assets of HealthCor are stated at historical cost, with no goodwill or other intangible assets recorded. Reported shares and loss per share available to holders of the Company&#x2019;s capital stock and equity awards prior to the Business Combination have been retroactively restated reflecting the exchange ratios established pursuant to the Business Combination Agreement dated as of July&#160;7, 2021 (the &#x201c;Business Combination Agreement&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Business Combination Agreement, at the effective time of the Business Combination (the &#x201c;Effective Time&#x201d;): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each share of Legacy Hyperfine capital stock (other than shares of Legacy Hyperfine Series A preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#x2019;s Class&#160;A common stock equal to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.3275 &lt;/div&gt;(the &#x201c;Hyperfine Exchange Ratio&#x201d;), rounded down to the nearest whole number of shares; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each share of Legacy Hyperfine Series A preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#x2019;s Class&#160;B common stock equal to the Hyperfine Exchange Ratio, rounded down to the nearest whole number of shares; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;each share of Liminal capital stock (other than shares of Liminal Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; preferred stock) that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#x2019;s Class&#160;A common stock equal to 0.1796 (the &#x201c;Liminal Exchange Ratio&#x201d;), rounded down to the nearest whole number of shares; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;each share of Liminal Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; preferred stock that was issued and outstanding as of immediately prior to the Effective Time was automatically cancelled and extinguished and converted into the right to receive a number of shares of the Company&#x2019;s Class&#160;B common stock equal to the Liminal Exchange Ratio, rounded down to the nearest whole number of shares; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each option to purchase shares of Legacy Hyperfine common stock and each option to purchase shares of Liminal common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company&#x2019;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such option immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liminal Exchange Ratio, as applicable, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded up to the nearest whole cent; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company&#x2019;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the Business Combination Agreement, the Company will issue to holders of Legacy Hyperfine and Liminal securities as of immediately prior to the Effective Time, in accordance with their pro rata share, up to 10,000,000 shares of Class&#160;A common stock as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earn-out&lt;/div&gt; consideration (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Earn-Out&lt;/div&gt; Shares&#x201d;), if at any time during the period between the Closing Date and the third anniversary of the Closing Date (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Earn-Out&lt;/div&gt; Period&#x201d;), (i) the last share price of the Class&#160;A common stock is greater than or equal to $15.00 for any 20 trading days within any 30 consecutive trading day period, or (ii)&#160;there is a transaction that will result in shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value greater than or equal to $15.00. During the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Period, if there is a transaction (other than for stock splits, stock dividends, special cash dividends, reorganizations, recapitalizations or similar transactions affecting the Class&#160;A common stock) that will result in the shares of Class&#160;A common stock being converted or exchanged into the right to receive cash or other consideration having a value less than $15.00, then the right to receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares will terminate. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;21, 2021, HealthCor filed the Certificate of Incorporation (the &#x201c;Certificate&#x201d;) with the Secretary of State of the State of Delaware, which became effective after the Domestication. As a consequence of filing the Certificate, the Company adopted a dual class structure, comprised of the Company&#x2019;s Class&#160;A common stock, which is entitled to one vote per share, and the Company&#x2019;s Class&#160;B common stock, which is entitled to 20 votes per share. The Company&#x2019;s Class&#160;B common stock has the same economic terms as the Company&#x2019;s Class&#160;A common stock, but is subject to a &#x201c;sunset&#x201d; provision if Jonathan M. Rothberg, Ph.D., the founder of Legacy Hyperfine and Liminal, and a Director of the Company (&#x201c;Dr.&#160;Rothberg&#x201d;), and other permitted holders of the Company&#x2019;s Class&#160;B common stock collectively cease to beneficially own at least twenty percent (20%) of the number of shares of the Company&#x2019;s Class&#160;B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination or recapitalization of the Company&#x2019;s Class&#160;B common stock) collectively held by Dr.&#160;Rothberg and permitted transferees of the Company&#x2019;s Class&#160;B common stock as of the Effective Time. At the Effective Time, the Company amended the Certificate to change the name of the Company from HealthCor Catalio Acquisition Corp. to &#x201c;Hyperfine, Inc.&#x201d; (the Certificate, as amended, the &#x201c;Amended Certificate&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the Business Combination Agreement, HealthCor entered into subscription agreements (the &#x201c;Subscription Agreements&#x201d;) with certain institutional investors and accredited investors (the &#x201c;PIPE Investors&#x201d;), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of 12,610,000 shares of HealthCor Class&#160;A common stock at a purchase price of $10.00 per share (the &#x201c;PIPE Investment&#x201d;). &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, on December&#160;22, 2021, HealthCor, HC Sponsor LLC (the &#x201c;Sponsor&#x201d;), Legacy Hyperfine and Liminal entered into a Forfeiture Agreement (the &#x201c;Forfeiture Agreement&#x201d;), pursuant to which, immediately prior to the Closing, 150,000 shares of HealthCor&#x2019;s Class&#160;B common stock held by the Sponsor were irrevocably forfeited and automatically cancelled (the &#x201c;Forfeiture&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total number of shares of the Company&#x2019;s Class&#160;A common stock outstanding immediately following the Closing was 54,977,061 comprising: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,711,224 shares of Class&#160;A common stock issued to Hyperfine stockholders (other than certain holders of Hyperfine Series A preferred stock); &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;3,459,081 shares of Class&#160;A common stock issued to Liminal stockholders (other than certain holders of Liminal Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; preferred stock); &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,610,000 shares of Class&#160;A common stock issued in connection with the Closing to the PIPE Investors pursuant to the PIPE Investment; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,025,000 shares of Class&#160;A common stock issued immediately prior to the Effective Time to the initial shareholders upon conversion of the 5,025,000 shares of Class&#160;B common stock outstanding immediately prior to the Effective Time (following the issuance of the 5,175,000 shares of Class&#160;B common stock upon the Conversion of the 5,175,000 Class&#160;B ordinary shares held by the initial shareholders and after reflecting the irrevocable forfeiture by the Sponsor to HealthCor of 150,000 shares of Class&#160;B common stock for no consideration and automatic cancellation as of immediately prior to the Closing); &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;614,000 shares of Class&#160;A common stock issued to the Sponsor; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,557,756 shares of Class&#160;A common stock issued to the Company&#x2019;s public stockholders holding 3,557,756 Class&#160;A ordinary shares outstanding at the Effective Time, after reflecting redemptions of 17,142,244 shares of HealthCor Class&#160;A common stock. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total number of shares of the Company&#x2019;s Class&#160;B common stock outstanding immediately following the Closing was 15,055,288 shares. Immediately following the Closing, Dr.&#160;Rothberg held approximately 84.8% of the combined voting power of the Company. Accordingly, Dr.&#160;Rothberg and his permitted transferees control the Company, and the Company is a controlled company within the meaning of the Nasdaq listing rules. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net equity infusion from the Business Combination was $141,471, which consists of $207,448 proceeds from HealthCor, $126,100 proceeds from the PIPE Investors, net of payments to redeeming HealthCor shareholders of $171,437 and payment of transaction costs of $20,640. Additionally, 300,000 shares of Class&#160;A Common Stock were issued to a service provider in exchange for the services provided in connection with the Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2021, in connection with the closing of the Business Combination, the Company prepaid directors and officers insurance policy in the amount of $1,244 and repaid the Liminal Paycheck Protection Program (&#x201c;PPP&#x201d;) loan in full in the amount of $113. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P07_07_2021To07_07_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      unitRef="Unit_pure">0.3275</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P07_07_2021To07_07_2021_LiminalMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      unitRef="Unit_pure">0.1796</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P07_07_2021To07_07_2021_LiminalMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn07_07_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.00</us-gaap:SharesIssuedPricePerShare>
    <hypr:BusinessCombinationTransactionThresholdTradingDays
      contextRef="P07_07_2021To07_07_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_Day">20</hypr:BusinessCombinationTransactionThresholdTradingDays>
    <hypr:BusinessCombinationTransactionThresholdConsecutiveTradingDays
      contextRef="P07_07_2021To07_07_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_Day">30</hypr:BusinessCombinationTransactionThresholdConsecutiveTradingDays>
    <hypr:NumberOfVotesPerShareEntitledToClassOfCommonStock
      contextRef="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1</hypr:NumberOfVotesPerShareEntitledToClassOfCommonStock>
    <hypr:NumberOfVotesPerShareEntitledToClassOfCommonStock
      contextRef="P12_12_2021To12_12_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">20</hypr:NumberOfVotesPerShareEntitledToClassOfCommonStock>
    <hypr:PercentageNumberOfSharesCeasesToBeneficiallyOwned
      contextRef="P12_12_2021To12_12_2021"
      decimals="2"
      unitRef="Unit_pure">-0.20</hypr:PercentageNumberOfSharesCeasesToBeneficiallyOwned>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_12_2021To12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">12610000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_12_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementsMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">150000</us-gaap:SharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">54977061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">29711224</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3459081</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">12610000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5025000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P12_22_2021To12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5025000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_ImmediatelyPriorToEffectiveTimeMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5175000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P12_22_2021To12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5175000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_22_2021_ClassBOrdinarySharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">150000</us-gaap:SharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_shares">614000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_ClassAOrdinarySharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3557756</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_22_2021_ClassAOrdinarySharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3557756</us-gaap:CommonStockSharesIssued>
    <hypr:CommonStockSubjectToRedemption
      contextRef="P12_22_2021To12_22_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HealthCorCatalioAcquisitionCorpMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_shares">17142244</hypr:CommonStockSubjectToRedemption>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_22_2021_DirectorMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_shares">15055288</us-gaap:CommonStockSharesOutstanding>
    <hypr:PercentageOfCommonStockVotingPower
      contextRef="P12_22_2021To12_22_2021_DirectorMembersrtTitleOfIndividualAxis"
      decimals="3"
      unitRef="Unit_pure">0.848</hypr:PercentageOfCommonStockVotingPower>
    <hypr:ProceedsFromBusinessCombination
      contextRef="P12_22_2021To12_22_2021"
      decimals="-3"
      unitRef="Unit_USD">141471000</hypr:ProceedsFromBusinessCombination>
    <hypr:ProceedsFromBusinessCombination
      contextRef="P12_22_2021To12_22_2021_HealthCorMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">207448000</hypr:ProceedsFromBusinessCombination>
    <hypr:ProceedsFromBusinessCombination
      contextRef="P12_22_2021To12_22_2021_PIPEInvestorsMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">126100000</hypr:ProceedsFromBusinessCombination>
    <hypr:InterestAndPaymentsToRedeemingCompanyShareholders
      contextRef="P12_22_2021To12_22_2021"
      decimals="-3"
      unitRef="Unit_USD">171437000</hypr:InterestAndPaymentsToRedeemingCompanyShareholders>
    <hypr:BusinessCombinationPaymentOfTransactionCosts
      contextRef="P12_22_2021To12_22_2021"
      decimals="-3"
      unitRef="Unit_USD">20640000</hypr:BusinessCombinationPaymentOfTransactionCosts>
    <hypr:PrepaidInsurancePolicyInConnectionWithBusinessCombination
      contextRef="PAsOn12_22_2021"
      decimals="-3"
      unitRef="Unit_USD">1244000</hypr:PrepaidInsurancePolicyInConnectionWithBusinessCombination>
    <hypr:PaymentOfPaycheckProtectionProgramLoan
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">113000</hypr:PaymentOfPaycheckProtectionProgramLoan>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. REVENUE RECOGNITION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company disaggregates revenue from contracts with customers by product type. The Company believes that these categories aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. The following table summarizes the Company&#x2019;s disaggregated revenues: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pattern of&lt;br/&gt;Recognition&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Device&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Point&#160;in&#160;time&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Over time&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,496&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;294&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract Balances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract balances represent amounts presented in the combined and consolidated balance sheets when either the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. These contract balances include trade accounts receivable and deferred revenue. Deferred revenue represents consideration received from customers at the beginning of the subscription period for services that are transferred to the customer over the respective subscription period. The accounts receivable balances represent amounts billed to customers for goods and services where the Company has an unconditional right to payment of the amount billed. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides information about receivables and deferred revenue from contracts with customers: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unbilled receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;158&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes a receivable when it has an unconditional right to payment, and payment terms range from 20 days to 6 months based on the terms agreed upon with the respective customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amount of revenue recognized during the years ended December&#160;31, 2021 and 2020 that was included in the deferred revenue balance at the beginning of the period was $158 and $0, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from leasing arrangements is not subject to the revenue standard for contracts with customers and remains separately accounted for under existing lease accounting guidance. The Company records operating lease rental revenue as service revenue on a straight-line basis over the lease term. The Company records revenue from the sale of equipment under sales-type leases as product revenue in an amount equal to the present value of minimum lease payments at the inception of the lease. Sales-type leases also produce financing income, which is included in products net revenue in the combined and consolidated statements of operations and comprehensive loss and is recognized at effective rates of return over the lease term. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Costs of Obtaining or Fulfilling Contracts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company incurs incremental costs of obtaining contracts with customers. Incremental costs of obtaining contracts, which include commissions paid as a result of obtaining contracts with customers, are capitalized to the extent that the Company expects to recover such costs. Capitalized costs are amortized in a pattern that is consistent with the Company&#x2019;s transfer to the customer of the related goods and services. Such costs are recorded in Other long term assets and were $158 as of December&#160;31, 2021. Capitalized costs were not material for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Transaction price allocated to remaining performance obligations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, the Company had remaining performance obligations amounting to $2,800 and $859, respectively. The Company expects to recognize approximately 43% of its remaining performance obligations as revenue in fiscal year 2022, and an additional 57% in fiscal year 2023 and thereafter. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Judgements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company makes significant judgments applying the guidance related to the determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price of performance obligations and estimation of variable consideration. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Practical Expedients and Accounting Policy Elections &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a practical expedient, the Company does not adjust transaction price for the effects of a significant financing component in contracts in which the period between when the Company transfers the promised good or service to the customer and when the customer pays for that good or service is a year or less. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has made an accounting policy election to exclude all sales taxes from the transaction price of its contracts with customers. Accordingly, sales taxes collected from customers and remitted to government authorities is not included in revenue and is accounted for as a liability until it has been remitted to the respective government authority. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2021To12_31_2021">The following table summarizes the Company&#x2019;s disaggregated revenues:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pattern of&lt;br/&gt;Recognition&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Device&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Point&#160;in&#160;time&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Over time&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,496&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;294&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">781000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">94000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides information about receivables and deferred revenue from contracts with customers: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unbilled receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;158&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">553000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">174000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">91000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <hypr:RevenueRecognizeReceivablePaymentTermsRangeMinimum contextRef="P01_01_2021To12_31_2021">P20D</hypr:RevenueRecognizeReceivablePaymentTermsRangeMinimum>
    <hypr:RevenueRecognizeReceivablePaymentTermsRangeMaximum contextRef="P01_01_2021To12_31_2021">P6M</hypr:RevenueRecognizeReceivablePaymentTermsRangeMaximum>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">859000</us-gaap:RevenueRemainingPerformanceObligation>
    <hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage
      contextRef="PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"
      decimals="2"
      unitRef="Unit_pure">0.43</hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage>
    <hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage
      contextRef="PAsOn12_31_2021_2023-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"
      decimals="2"
      unitRef="Unit_pure">0.57</hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. FAIR VALUE OF FINANCIAL INSTRUMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;1&lt;/div&gt;&lt;/div&gt; &#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;2&lt;/div&gt;&lt;/div&gt; &#x2014; Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;3&lt;/div&gt;&lt;/div&gt; &#x2014; Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level&#160;3 inputs. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value of cash and cash equivalents, notes receivable, accounts payable and accrued expenses and other current liabilities approximates their fair values due to the short-term or on demand nature of these instruments. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;no &lt;/div&gt;transfers between fair value measurement levels during the years ended December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had $48,625 and $58,418 of money market funds included in cash and cash equivalents and restricted cash as of December&#160;31, 2021 and 2020, respectively. These assets were valued using quoted market prices and accordingly were classified as Level&#160;1. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines that notes payable as of December&#160;31, 2020 was classified as Level&#160;2 and the relevant fair value approximates its carrying amount since it bore interest at rates that approximate current market rates. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">48625000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">58418000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. INVENTORIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of inventories are as follows at December 31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,718&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,310&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,718&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing overhead costs primarily include management&#x2019;s best estimate and allocation of the labor costs incurred related to acquiring finished goods from the Company&#x2019;s contract manufacturer. Labor costs include wages, taxes and benefits for employees involved in warehousing, logistics coordination, material sourcing, and production planning activities. The majority of these costs have been written off based on the Company&#x2019;s analysis of net realizable value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December&#160;31, 2021 and 2020, net realizable value inventory adjustments and excess and obsolete inventory charges were $75 and $213, respectively, and were recognized in cost of sales. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of inventories are as follows at December 31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,718&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,310&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,718&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2355000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1955000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1718000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4310000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1718000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. PROPERTY AND EQUIPMENT, NET &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net, are recorded at historical cost and consist of the following at December 31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;341&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;613&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tooling&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade show assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leased devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,620&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,753&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,904&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization expense amounted to $726 and $289 for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net, are recorded at historical cost and consist of the following at December 31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;341&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;613&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tooling&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade show assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leased devices&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,620&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,753&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,904&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">989000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1422000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ResearchDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">486000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_SalesAndMarketingDevicesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">669000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">385000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">341000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">302000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ToolsDiesAndMoldsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">270000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_TradeShowAssetsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">127000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">176000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2620000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1410000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">716000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3753000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1904000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">726000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">289000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses and other current liabilities consist of the following at December 31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonus&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted services&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SPAC bonus and other costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,071&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;452&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll and related benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,115&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,264&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses and other current liabilities consist of the following at December 31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonus&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted services&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SPAC bonus and other costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,071&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;452&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll and related benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,115&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,264&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3421000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">501000</us-gaap:AccruedBonusesCurrent>
    <hypr:AccruedContractedServicesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2711000</hypr:AccruedContractedServicesCurrent>
    <hypr:AccruedContractedServicesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">456000</hypr:AccruedContractedServicesCurrent>
    <hypr:AccruedBonusAndOtherCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1071000</hypr:AccruedBonusAndOtherCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">452000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">282000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">441000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <hypr:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8115000</hypr:AccruedExpensesAndOtherCurrentLiabilities>
    <hypr:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1264000</hypr:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LongTermDebtTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. NOTES PAYABLE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the Company received loan proceeds of $1,067 under the PPP. The Legacy Hyperfine PPP loan in the amount of $889 was evidenced by a promissory note dated August&#160;10, 2020 and was fully paid off during the fourth quarter of 2020. The Liminal PPP loan in the amount of $178 is evidenced by a promissory note dated May&#160;1, 2020. The Company used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintaining its payroll levels. The Company accounted for the loan as debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the closing of the Business Combination as discussed in Note 3. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;, the Company repaid the Liminal PPP loan in full in December 2021. The Company recognized an insignificant amount of interest expense in the combined and consolidated statements of operations and comprehensive loss related to the loan. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P08_01_2020To08_31_2020_PayrollProtectionProgramLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1067000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_10_2020_HyperfinePayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">889000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_01_2020_LiminalPayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PreferredStockTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. CONVERTIBLE PREFERRED STOCK &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legacy Hyperfine Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legacy Hyperfine had issued four series of Convertible Preferred Stock, Series A through Series D. The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine immediately prior to the Business Combination: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 27%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt;of Class&lt;br/&gt;Issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Price&#160;per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Authorized&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt;Proceeds&lt;br/&gt;or&lt;br/&gt;Exchange&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial&lt;br/&gt;Liquidation&lt;br/&gt;Price per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2014&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,577,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,970,981&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;129,788,828&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;109,182,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;159,119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;372&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;158,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 26%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt;of Class&lt;br/&gt;Issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Price&#160;per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Authorized&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt;Proceeds&lt;br/&gt;or&lt;br/&gt;Exchange&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial&lt;br/&gt;Liquidation&lt;br/&gt;Price per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2014&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,577,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,799,648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,640&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;129,788,828&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;95,010,858&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,651&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;365&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The powers, preferences, rights, qualifications, limitations and restrictions of the shares of Convertible Preferred Stock are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividends shall accrue to holders of the Convertible Preferred Stock at the rate of 8% of the original issue price for the applicable series of Convertible Preferred Stock, per annum subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization, reclassification and other similar events payable only when, and if, declared by Legacy Hyperfine&#x2019;s board of directors. The right to receive dividends on Convertible Preferred Stock is not cumulative, and therefore, if not declared in any year, the right to such dividends shall terminate and shall not carry forward into the next year. There have been no dividends declared to date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden41719881"&gt;In the event of any liquidation, dissolution or winding up of Legacy Hyperfine, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Legacy Hyperfine&#x2019;s assets, or a&lt;/span&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;transaction which the holders of capital stock of Legacy Hyperfine hold less than 50% of the voting securities) (each a &#x201c;Liquidation Event&#x201d;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Legacy Hyperfine available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1)&#160;the applicable original issue price of such Convertible Preferred Stock, plus any declared and unpaid dividends or (2)&#160;an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Legacy Hyperfine common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The holders of shares of the Convertible Preferred Stock shall be entitled to vote on all matters on which the holders of shares of Legacy Hyperfine common stock shall be entitled to vote. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each holder of record of shares of Series A Convertible Preferred Stock shall be entitled to ten votes per share of Legacy Hyperfine Special-voting common stock into which such Series A Convertible Preferred Stock are convertible, as discussed below under &#x201c;Conversion,&#x201d; on all matters to be voted on by Legacy Hyperfine&#x2019;s stockholders. Each holder of record of shares of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be entitled to one vote per share of Legacy Hyperfine common stock into which such Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock are convertible, as discussed below under Conversion, on all matters to be voted on by Legacy Hyperfine&#x2019;s stockholders. The holders of Convertible Preferred Stock and the holders of Legacy Hyperfine common stock shall vote together and not as separate classes. There shall be no series voting. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each share of Series A Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Legacy Hyperfine Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Legacy Hyperfine common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon the earlier to occur of (i)&#160;election of the Convertible Preferred Stock by (A)&#160;the consent or vote of the majority holders of the Convertible Preferred Stock (voting together as a single class and not as separate series, and on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis), (B) the consent or vote of the majority holders of Series C Convertible Preferred Stock (voting separately as a single class) and (C)&#160;the consent or vote of the majority holders of Series D Convertible Preferred Stock (voting separately as a single class) or (ii)&#160;the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933 covering the offer and sale of shares of Legacy Hyperfine common stock in which the aggregate gross proceeds to Legacy Hyperfine are at least $80,000 (1) each share of Series A Convertible Preferred Stock shall &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;automatically be converted into shares of Legacy Hyperfine Special-voting common stock on a 1 for 1 basis and (2)&#160;each share of Series B, Series C and Series D Convertible Preferred Stock shall automatically be converted into Legacy Hyperfine common stock on a 1 for 1 basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the closing of the Business Combination, the Convertible Preferred Stock converted into Class&#160;A and Class&#160;B common stock based on the Business Combination&#x2019;s Hyperfine Exchange Ratio of 0.3275 of the Company&#x2019;s shares for each Legacy Hyperfine share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of the Closing. There are no shares of Convertible Preferred Stock outstanding as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liminal Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On April 1, 2021 Liminal effected a recapitalization whereby each share of Liminal common stock outstanding was exchanged for shares of Liminal Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; preferred stock and Liminal Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; preferred stock. The value ascribed to the preferred stock is equivalent to the total amount of historical equity investments contributed by the common shareholder. There were no new investments or changes in control in conjunction with the recapitalization. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The powers, preferences, rights, qualifications, limitations and restrictions of the shares of Liminal Convertible Preferred Stock are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividends shall accrue to holders of the Convertible Preferred Stock at the rate of 8% of the original issue price for the applicable series of Convertible Preferred Stock, per annum subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization, reclassification and other similar events payable only when, and if, declared by Liminal&#x2019;s board of directors. The right to receive dividends on Convertible Preferred Stock is not cumulative, and therefore, if not declared in any year, the right to such dividends shall terminate and shall not carry forward into the next year. There have been no dividends declared to date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In the event of any liquidation, dissolution or winding up of Liminal, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Liminal&#x2019;s assets, or a transaction which the holders of capital stock of Liminal hold less than 50% of the voting securities) (each a &#x201c;Liquidation Event&#x201d;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Liminal available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issuance price of $.1287 per share for Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Liminal common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The holders of shares of the Convertible Preferred Stock shall be entitled to vote on all matters on which the holders of shares of Liminal common stock shall be entitled to vote. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Each holder of record of shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; Convertible Preferred Stock shall be entitled to ten votes per share of Liminal Special-voting common stock into which such Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; Convertible Preferred Stock are convertible, as discussed below under &#x201c;Conversion,&#x201d; on all matters to be voted on by Liminal&#x2019;s stockholders. Each holder of record of shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Convertible Preferred Stock shall be entitled to one vote per share of Liminal common stock into which such Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Convertible Preferred Stock are convertible, as discussed below under Conversion, on all matters to be voted on by Liminal&#x2019;s stockholders. The holders of Convertible Preferred Stock and the holders of Liminal common stock shall vote together and not as separate classes. There shall be no series voting. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Each share of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Liminal Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of Liminal common stock for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock. Each share of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Liminal common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of common stock for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon the earlier to occur of (i)&#160;election of the Convertible Preferred Stock by the consent or vote of the majority holders of the Convertible Preferred Stock (voting together as a single class and not as separate series, and on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis) or (ii)&#160;the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, covering the offer and sale of shares of Liminal common stock in which the aggregate gross proceeds to Liminal are at least $80,000 (1) each share of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; Convertible Preferred Stock shall automatically be converted into shares of Liminal Special-voting common stock on a 1 for 1 basis and (2)&#160;each share of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Convertible Preferred Stock shall automatically be converted into Liminal common stock on a 1 for 1 basis. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the closing of the Business Combination, the Liminal Convertible Preferred Stock converted into Class&#160;A and Class&#160;B common stock based on the Business Combination&#x2019;s Liminal Exchange Ratio of 0.1796 of the Company&#x2019;s shares for each Liminal share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of the Closing. There are no shares of Convertible Preferred Stock&#160;outstanding as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; </us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P01_01_2021To12_31_2021">The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine immediately prior to the Business Combination: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 27%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt;of Class&lt;br/&gt;Issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Price&#160;per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Authorized&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt;Proceeds&lt;br/&gt;or&lt;br/&gt;Exchange&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial&lt;br/&gt;Liquidation&lt;br/&gt;Price per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2014&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,577,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,970,981&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;129,788,828&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;109,182,191&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;159,119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;372&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;158,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of Legacy Hyperfine as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 26%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt;of Class&lt;br/&gt;Issuance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Price&#160;per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Authorized&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt;Proceeds&lt;br/&gt;or&lt;br/&gt;Exchange&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&lt;br/&gt;Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial&lt;br/&gt;Liquidation&lt;br/&gt;Price per&lt;br/&gt;share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2014&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,625,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,586,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,577,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,799,648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59,640&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;129,788,828&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;95,010,858&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,651&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;365&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">2014</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P07_06_2021To07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">998000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn07_06_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.80</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">2017</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.80</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10625000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10625000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10625000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">8500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P07_06_2021To07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">8500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn07_06_2021_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.80</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">2017</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.88</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31586210</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31586210</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31586210</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59382000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P07_06_2021To07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">234000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59148000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn07_06_2021_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.88</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P07_06_2021To07_06_2021_MinimumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">2020</hypr:TemporaryEquityYearOfClassIssuance>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P07_06_2021To07_06_2021_MaximumMembersrtRangeAxis_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">2021</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">2.15</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">62577618</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">41970981</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">41970981</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P07_06_2021To07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">90237000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P07_06_2021To07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">136000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">90101000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn07_06_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.15</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn07_06_2021"
      decimals="INF"
      unitRef="Unit_shares">129788828</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn07_06_2021"
      decimals="INF"
      unitRef="Unit_shares">109182191</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn07_06_2021"
      decimals="INF"
      unitRef="Unit_shares">109182191</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P07_06_2021To07_06_2021"
      decimals="-3"
      unitRef="Unit_USD">159119000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P07_06_2021To07_06_2021"
      decimals="-3"
      unitRef="Unit_USD">372000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn07_06_2021"
      decimals="-3"
      unitRef="Unit_USD">158747000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">2014</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P01_01_2020To12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">998000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2020_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.80</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">2017</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.80</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10625000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10625000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10625000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">8500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P01_01_2020To12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">8500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.80</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">2017</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.88</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31586210</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31586210</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31586210</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59382000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P01_01_2020To12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">234000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59148000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.88</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <hypr:TemporaryEquityYearOfClassIssuance contextRef="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">2020</hypr:TemporaryEquityYearOfClassIssuance>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">2.15</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">62577618</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27799648</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27799648</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59769000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P01_01_2020To12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">129000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">59640000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2020_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.15</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">129788828</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">95010858</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">95010858</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">128651000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <hypr:TemporaryEquitySharesIssuanceCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">365000</hypr:TemporaryEquitySharesIssuanceCost>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">128286000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="P01_01_2020To12_31_2020_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <hypr:NumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_Vote">10</hypr:NumberOfVotesPerShare>
    <hypr:NumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_Vote">1</hypr:NumberOfVotesPerShare>
    <us-gaap:PreferredStockConversionBasis contextRef="P01_01_2021To12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series A Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Legacy Hyperfine Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:PreferredStockConversionBasis contextRef="P01_01_2021To12_31_2021_SeriesBCAndDConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Legacy Hyperfine common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional common shares for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021_LegacyHyperfineMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <hypr:BusinessCombinationExchangeRatio
      contextRef="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_pure">0.3275</hypr:BusinessCombinationExchangeRatio>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockConversionBasis contextRef="P04_01_2021To04_01_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">On April 1, 2021 Liminal effected a recapitalization whereby each share of Liminal common stock outstanding was exchanged for shares of Liminal Series A-1 preferred stock and Liminal Series A-2 preferred stock. The value ascribed to the preferred stock is equivalent to the total amount of historical equity investments contributed by the common shareholder.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:LiquidationBasisOfAccountingLiquidationPlan contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">In the event of any liquidation, dissolution or winding up of Liminal, whether voluntary or involuntary or a deemed liquidation event (which includes a merger, the sale of all of Liminal&#x2019;s assets, or a transaction which the holders of capital stock of Liminal hold less than 50% of the voting securities) (each a &#x201c;Liquidation Event&#x201d;), the holders of the Convertible Preferred Stock are entitled to be paid out of the assets of Liminal available for distribution to stockholders, pari passu, at a liquidation price per share equal to the greater of: (1) the applicable original issuance price of $.1287 per share for Series A-1 and Series A-2 Convertible Preferred Stock, plus any declared and unpaid dividends or (2) an amount that would have been payable had all the shares of the Convertible Preferred Stock been converted into Liminal common stock. These payments will be made to or set aside prior to the holders of shares of any other class or series of capital stock that is not, by its terms, senior to the Convertible Preferred Stock.</us-gaap:LiquidationBasisOfAccountingLiquidationPlan>
    <hypr:NumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_Vote">10</hypr:NumberOfVotesPerShare>
    <hypr:NumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_Vote">1</hypr:NumberOfVotesPerShare>
    <us-gaap:PreferredStockConversionBasis contextRef="P01_01_2021To12_31_2021_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series A-1 Convertible Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into shares of Liminal Special-voting common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of Liminal common stock for no consideration or consideration less than the conversion price of the Series A Convertible Preferred Stock.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:PreferredStockConversionBasis contextRef="P01_01_2021To12_31_2021_SeriesATwoConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">Each share of Series A-2 Convertible Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into shares of Liminal common stock on a 1 to 1 conversion rate subject to customary anti-dilution adjustments and upon the issuance of additional shares of common stock for no consideration or consideration less than the conversion price of the respective series of Convertible Preferred Stock, which is equal to the original issuance price for each series of Convertible Preferred Stock.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <hypr:BusinessCombinationExchangeRatio
      contextRef="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_pure">0.1796</hypr:BusinessCombinationExchangeRatio>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_LiminalConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. STOCKHOLDERS&#x2019; EQUITY (DEFICIT) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, and 2020, the Company had authorized 600,000,000 and 130,000,000 shares of Class&#160;A common stock at $0.0001 par value per share, of which a total of 55,277,061 shares and 1,576,137 shares were outstanding, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, and 2020, the Company had authorized 27,000,000 and 0 shares of Class&#160;B common stock at $0.0001 par value per share, of which a total of 15,055,288 shares and 0 shares were outstanding, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of the Company&#x2019;s common stock are not entitled to receive dividends unless declared by the Company&#x2019;s board of directors. There have been no dividends declared to date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The holders of shares of the Company&#x2019;s Class&#160;A common stock are entitled to one vote per share on all matters on which the Company&#x2019;s Class&#160;A common stock shall be entitled to vote. The holders of shares of the Company&#x2019;s Class&#160;B common stock are entitled to 20 votes per share on all matters on which the Company&#x2019;s Class&#160;B common stock shall be entitled to vote. The holders of the Company&#x2019;s Class&#160;A common stock and Class&#160;B common stock shall vote together and not as separate classes. &lt;/div&gt;&lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">55277061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1576137</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15055288</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:DividendsCommonStock>
    <hypr:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_Vote">1</hypr:CommonStockNumberOfVotesPerShare>
    <hypr:CommonStockNumberOfVotesPerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_Vote">20</hypr:CommonStockNumberOfVotesPerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. EQUITY INCENTIVE PLAN &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Hyperfine Inc. 2021 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;A total of 16,013,762 shares of common stock are reserved for issuance under the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;Hyperfine Plan&#x201d;). The Hyperfine Plan is administered by the Company&#x2019;s board of directors. The board of directors may grant restricted stock and options to purchase shares either as incentive stock options or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; stock options. The option grants are subject to certain terms and conditions, option periods and conditions, exercise rights and privileges as set forth in the Hyperfine Plan. At December&#160;31, 2021, 8,256,741 common shares remain available for issuance under the Hyperfine Plan. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the Business Combination, Legacy Hyperfine and Liminal were distinct entities with separate equity incentive plans for their employees and nonemployees. Both plans were subsequently adopted and assumed by the Company as a consequence of the Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each Legacy Hyperfine option from Legacy Hyperfine&#x2019;s 2014 Employee, Director and Consultant Equity Incentive Plan as amended on October&#160;9, 2020 (the &#x201c;Legacy Hyperfine Plan&#x201d;) outstanding immediately prior to the Closing, whether vested or unvested, was converted into an option to purchase shares of the Company&#x2019;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock subject to such option multiplied by the Hyperfine Exchange Ratio of 0.3275, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Closing divided by 0.3275, rounded up to the nearest whole cent. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each Liminal option from Liminal&#x2019;s 2021 Employee, Director, and Consultant Equity Incentive Plan (the &#x201c;Liminal Plan&#x201d;) outstanding immediately prior to the Closing, whether vested or unvested, was converted into an option to purchase shares of the Company&#x2019;s Class&#160;A common stock equal to the number of shares of Liminal common stock subject to such option multiplied by the Liminal Exchange Ratio of 0.1796, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Closing divided by 0.1796, rounded up to the nearest whole cent. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each exchanged option will continue to be governed by the same terms and conditions (including vesting and exercisability terms) as were applicable to the corresponding option immediately prior to the Closing. All activity was retroactively restated to reflect the exchange that occurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, each Legacy Hyperfine restricted stock unit and each Liminal restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;respect to a number of shares of the Company&#x2019;s Class&#160;A common stock equal to the number of shares of Legacy Hyperfine common stock or Liminal common stock subject to such Legacy Hyperfine restricted stock unit or Liminal restricted stock unit immediately prior to the Effective Time multiplied by the Hyperfine Exchange Ratio or the Liminal Exchange Ratio, as applicable, rounded down to the nearest whole share. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock option activity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each stock option grant carries varying vesting schedules whereby the options become exercisable at the participant&#x2019;s sole discretion provided they are an employee, director or consultant of the Company on the applicable vesting date. Each option shall terminate not more than ten years from the date of the grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, the Company granted certain equity awards to the newly hired Chief Executive Officer. These awards include (1)&#160;an option award to purchase 1,899,500 shares of Class&#160;A common stock which will vest based on continued service over a four year period, (2)&#160;a separate option award to purchase 474,875 shares of Class&#160;A common stock, which will be fully vested upon the occurrence of various service, performance, and market conditions. Two additional 474,875 share option awards (949,750 options total) with terms similar to those described above will be granted pursuant to the terms of the offer letter. Certain equity awards were also granted to the Executive Chairman of the Legacy Hyperfine board of directors. The equity compensation included (1)&#160;an option award to purchase 712,312 shares of Class&#160;A common stock which will vest based on continued service, over four years, (2)&#160;two separate option awards to purchase 237,437 shares each of Class&#160;A common stock (474,874 shares in total), which will be fully vested upon the occurrence of various certain service, performance, and market conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The service condition for these awards is satisfied by providing service to the Company based on the defined service period per the award agreement. The performance-based condition is satisfied upon the occurrence of a special purpose acquisition company (&#x201c;SPAC&#x201d;) transaction, initial public offering (&#x201c;IPO&#x201d;), or financing event as defined in the award agreement. The market condition is satisfied by achieving various multiples of a defined price per share. The achievement of the performance condition and the commencement of the related expense recognition event cannot occur until the event is deemed probable, which only occurs once a SPAC transaction, IPO, or financing event has occurred. The performance condition was satisfied as a result of the Business Combination and the Company recognized stock-based compensation expense of $1,772 in connection with these awards during the year ended December&#160;31, 2021. None of the market conditions have been satisfied and as such, none of the awards are exercisable as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to the above, restricted stock units with a value of $2,500 will be granted to the Chief Executive Officer following the Business Combination and within two years of the Chief Executive Officer&#x2019;s start date, subject to continued service and which will vest on a schedule to be agreed upon between the Company and the Chief Executive Officer. These restricted stock units were not yet approved by the Board of Directors and therefore had not yet been granted as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, the Company also granted 258,833 option awards subject to certain service and performance conditions. The service condition required the participant&#x2019;s continued employment with the Company through the applicable vesting date, and the performance condition required the consummation of a Sale, IPO, or SPAC transaction as defined in the option award agreement. These awards were forfeited and cancelled prior to the consummation of the Business Combination. As a Sale, IPO, or SPAC transaction did not occur prior to forfeiture, the Company did not record any stock-based compensation expense related to these option &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;awards&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All options granted by the Company during the years ended December&#160;31, 2021 and 2020 were granted with exercise prices equal to the estimated fair value of the Company&#x2019;s common stock at the date of grant, as determined by the Company&#x2019;s board of directors. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the stock option activity under the Hyperfine Plan is presented in the table below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,903,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,771,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(565,533&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(587,047&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,522,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,052&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options exercisable at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,332,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,785&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,117,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,445&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received cash proceeds from the exercise of stock options of $1,497 and $120 during the years ended December&#160;31, 2021 and 2020, respectively. The total intrinsic value (the amount by which the stock price exceeds the exercise price of the option on the date of exercise) of the stock options exercised during the years ended December&#160;31, 2021 and 2020, was $2,752 and $167, respectively. The weighted-average grant date fair value of options granted during the year ended December&#160;31, 2021 and 2020, was $0.66 and $0.69, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock option valuation inputs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilized the Black-Scholes option pricing model for determining the estimated fair value for service awards. The Black-Scholes model requires the use of subjective assumptions which determine the fair value of stock-based awards. The assumptions used to value option grants to employees and nonemployees for the years ended December&#160;31, 2021 and 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk Free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.95%&#160;-&#160;1.13%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.5%&#160;-&#160;1.7%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.40&#160;years&#160;-&#160;6.17&#160;years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.8&#160;years&#160;-&#160;6.0&#160;years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk free interest rate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The risk free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected dividend yield &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has never declared or paid any cash dividends and does not expect to pay any cash dividends in the foreseeable future. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected term &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For employee awards, the Company &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;calculates &lt;/div&gt;the expected term using the &#x201c;simplified&#x201d; method, which is the simple average of the vesting period and the contractual term. The simplified method is applied as the Company does not have sufficient historical data to provide a reasonable basis for an estimate of the expected term. The Company calculates expected term for employee awards that take into account the effects of employee&#x2019;s expected exercise and post-vesting employment termination behavior. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As Legacy Hyperfine was privately held from inception through the Closing and all option grants occurred prior to the Closing Date, there was no specific historical or implied volatility information available. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, the Company estimates the expected volatility on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the stock-based awards. Point estimates of expected annual equity volatility of 70% and 60% for December&#160;31, 2021 and 2020, respectively, were selected in the guideline companies&#x2019; historical range. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Exercise price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price is taken directly from the grant notice issued to employees and nonemployees. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock options granted to the Company&#x2019;s employees and nonemployees for the periods presented were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to employee&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,534,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;897,240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to nonemployee&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,236,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;284,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock options granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,771,237&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,182,056&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Incentive Unit and Preferred Stock Award Activity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Incentive unit grants typically vest over a four year period provided the holder is an employee, director or consultant of the Company on the applicable vesting date. Upon termination of service, pursuant to the terms of the grant, the participant 1) immediately forfeits any unvested (but issued) incentive units and 2) the Company has the right, but not the obligation, to repurchase at the fair market value on the date of termination, any vested incentive units. The repurchase right is valid for 18 months commencing with the date of service. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;2, 2021, 4Bionics executed a plan of liquidation and dissolution and its ownership in Liminal was distributed to its members and to the holders of incentive units. Immediately subsequent to the dissolution, all outstanding unvested incentive unit awards under 4Bionic&#x2019;s 2019 Equity Incentive Plan were replaced with preferred stock awards indexed to and settled in the preferred stock of the former 4Bionics subsidiaries Liminal, Detect, Inc. (f/k/a Homodeus Inc.), and Tesseract Health. The preferred stock awards are subject to service vesting conditions only. No incremental value was provided to participants as a result of the modification of the awards as the modification date fair value of the incentive unit awards was equal to modification date fair value of the stock underlying the restricted stock awards. Moreover, the remaining vesting period before and after modification was unchanged. No incremental compensation expense was recognized as a result of the modification. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the dissolution of 4Bionics, a portion of total 4Bionics stock-based compensation expense was allocated to Liminal based on the level of service provided by the relevant employees and nonemployees to Liminal over the term of the award. Subsequent to the dissolution of 4Bionics, the Company recognizes the stock-based compensation expense related to the replacement preferred stock awards and no allocation methodology is required. In connection with the Business Combination, all replacement preferred stock awards were accelerated to fully vest. The Company recognized stock-based compensation expense of $578 and $0 related to the incentive unit awards and replacement preferred stock awards during the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2021, immediately following the Business Combination, the Company granted 117,516 restricted stock units (&#x201c;RSUs&#x201d;) to members of the Company&#x2019;s Board of Directors. The RSUs vest over a three year period, contingent on the ongoing service of the Directors. The grant date fair value of the RSUs was measured using the fair value of the underlying Class&#160;A common stock, which was $9.19 per share on the grant date. The total grant date fair value of $1,080 will be recognized evenly over the three year period as the service condition is satisfied. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Subject to the achievement of certain milestones, certain employees are entitled to a total of 933,933 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares. These &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares fall within the scope of ASC 718, pursuant to which such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are equity classified and their grant date fair value will be recognized as compensation expense over the vesting period. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-out&lt;/div&gt; valuation inputs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company utilized a Monte Carlo Simulation pricing model for determining the estimated fair value for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares. The fair value is based on the simulated price of the Company over the maturity date of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares. The key assumptions used in the valuation were as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 88%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk Free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk free interest rate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The risk free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected dividend yield &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has never declared or paid any cash dividends and does not expect to pay any cash dividends in the foreseeable future. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected term &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares, the expected term is determined to be 3 years from the Closing as this is the period over which the market price milestone may be achieved. As there is no dependent vesting period, the shares are exercisable at the point that the market milestone is reached. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As Legacy Hyperfine was privately held from inception through the Closing, there was no specific historical or implied volatility information available. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Accordingly, the Company estimates the expected volatility on the historical stock volatility of a group of similar companies that are publicly traded over a period equivalent to the expected term of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earn-out&lt;/div&gt; awards. A point estimate of expected annual equity volatility of 55% for December&#160;31, 2021 was selected in the guideline companies&#x2019; historical range. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s stock-based compensation expense for the periods presented was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales&#x2014;Device&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales&#x2014;Service&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;864&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,901&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total unrecognized stock-based compensation expense as of December&#160;31, 2021 was $13,650, which will be recognized over the remaining vesting period of 2.66 years. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">16013762</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <hypr:CommonStockRemainsAvailableForIssuance
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">8256741</hypr:CommonStockRemainsAvailableForIssuance>
    <hypr:ExchangeRatio
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.3275</hypr:ExchangeRatio>
    <hypr:ExchangeRatio
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.3275</hypr:ExchangeRatio>
    <hypr:ExchangeRatio
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LiminalMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.1796</hypr:ExchangeRatio>
    <hypr:ExchangeRatio
      contextRef="P01_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_LiminalMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.1796</hypr:ExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1899500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ShareBasedPaymentArrangementSeparateOptionAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">474875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <hypr:NumberOfSeparateOptionAwards
      contextRef="PAsOn12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_Option">2</hypr:NumberOfSeparateOptionAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsOneMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">474875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_StockOptionsTwoMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">474875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_shares">949750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">712312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <hypr:NumberOfSeparateOptionAwards
      contextRef="PAsOn12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_Option">2</hypr:NumberOfSeparateOptionAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_StockOptionsOneMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">237437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_shares">474874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1772000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="P01_01_2021To12_31_2021_ChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2500000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ServiceAndPerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">258833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the stock option activity under the Hyperfine Plan is presented in the table below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,903,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,771,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(565,533&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(587,047&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,522,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,052&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options exercisable at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,332,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,785&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,117,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,445&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1903479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">P7Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6771237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">565533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">587047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">7522136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">30052000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2332624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">P7Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">9785000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">7117220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">28445000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">120000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2752000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">167000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021">The assumptions used to value option grants to employees and nonemployees for the years ended December&#160;31, 2021 and 2020 were as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk Free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.95%&#160;-&#160;1.13%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.5%&#160;-&#160;1.7%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.40&#160;years&#160;-&#160;6.17&#160;years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.8&#160;years&#160;-&#160;6.0&#160;years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <hypr:ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock options granted to the Company&#x2019;s employees and nonemployees for the periods presented were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to employee&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,534,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;897,240&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to nonemployee&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,236,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;284,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock options granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,771,237&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,182,056&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </hypr:ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis"
      decimals="INF"
      unitRef="Unit_shares">3534844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis"
      decimals="INF"
      unitRef="Unit_shares">897240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis"
      decimals="INF"
      unitRef="Unit_shares">3236393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis"
      decimals="INF"
      unitRef="Unit_shares">284816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6771237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1182056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_IncentiveUnitActivityMemberusgaapAwardTypeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <hypr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService contextRef="P01_01_2021To12_31_2021_IncentiveUnitActivityMemberusgaapAwardTypeAxis">P18M</hypr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService>
    <hypr:ShareBasedPaymentArrangementPlanModificationIncrementalValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</hypr:ShareBasedPaymentArrangementPlanModificationIncrementalValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">578000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_FourBionicsTwoThousandNineteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">117516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P12_01_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="P12_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">933933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <hypr:ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021">The key assumptions used in the valuation were as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 88%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk Free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </hypr:ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.92</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s stock-based compensation expense for the periods presented was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales&#x2014;Device&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales&#x2014;Service&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;864&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales and marketing&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,901&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,117&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis_ServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1327000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">864000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">5482000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">231000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">68000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1117000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13650000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13. NET LOSS PER SHARE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common equivalent shares of the Company, including convertible preferred stock, outstanding stock options, RSUs and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common equivalent shares of the Company outstanding would have been anti-dilutive. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the calculation of basic and diluted net loss per share for the Company&#x2019;s common stock: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(64,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator for Basic and Dilutive EPS&#x2014;Loss available to common stockholders&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(64,851&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(23,427&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,690,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,523,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic and Dilutive EPS&#x2014;Weighted-average common stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,690,523&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,523,096&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and dilutive loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17.57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15.38&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since the Company was in a net loss position for all periods presented, the basic loss per share calculation excludes preferred stock as it does not participate in net losses of the Company. Additionally, net loss per share attributable to Class&#160;A and Class&#160;B common stockholders was the same on a basic and diluted basis, as the inclusion of all common equivalent shares outstanding would have been anti-dilutive. Anti-dilutive common equivalent shares were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding options to purchase common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,522,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,903,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding Legacy Hyperfine convertible preferred stock (Series A through D)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,116,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding RSUs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total anti-dilutive common equivalent shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,639,652&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;33,019,535&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the calculation of basic and diluted net loss per share for the Company&#x2019;s common stock: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(64,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator for Basic and Dilutive EPS&#x2014;Loss available to common stockholders&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(64,851&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(23,427&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,690,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,523,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic and Dilutive EPS&#x2014;Weighted-average common stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,690,523&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,523,096&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and dilutive loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17.57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(15.38&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64851000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-23427000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">3690523</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1523096</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">3690523</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">1523096</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-17.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">Anti-dilutive common equivalent shares were as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding options to purchase common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,522,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,903,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding Legacy Hyperfine convertible preferred stock (Series A through D)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,116,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding RSUs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total anti-dilutive common equivalent shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,639,652&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;33,019,535&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">7522136</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">1903479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_OutstandingLegacyHyperfineConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">31116056</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">117516</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">17639652</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">33019535</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14. INCOME TAXES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities) are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax assets (liabilities):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,512&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;522&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,136&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,788&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(36,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets (liabilities)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had no income tax expense due to federal and state net operating losses incurred for the years ended December&#160;31, 2021 and 2020. The Company has also not recorded any income tax benefits for its federal and state net operating losses incurred in each period due to uncertainty of realizing the benefit from those items. All of the Company&#x2019;s losses before income taxes were generated in the United States. The effective tax rate for the Company for the years ended December&#160;31, 2021 and 2020 was zero percent. A reconciliation of the income tax expense at the federal statutory tax rate to the Company&#x2019;s effective income tax rate follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal research and development credit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write down of federal NOL due to 382 limitation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write down of federal R&amp;amp;D credits due to 382 limitation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax adjustment resulting from tax rate change&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(28.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s effective tax rate for December&#160;31, 2021 and 2020 differs from the federal statutory tax rate of 21% mainly due to the effect of deferred state income tax benefits resulting from state net operating loss carryforwards and the tax benefits related to research and development tax credits. These benefits to the effective tax rate are fully offset by the increase in the Company&#x2019;s valuation allowance from the prior year. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty of the Company&#x2019;s ability to generate sufficient taxable income to realize the deferred tax assets, and therefore has not recognized any benefits from the net operating losses, tax credits and other deferred tax assets. The Company&#x2019;s valuation allowance increased $18,348 and $3,729 for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had the following tax net operating loss carryforwards available to reduce future federal and Connecticut taxable income, and tax credit carryforwards available to offset future federal and Connecticut income taxes: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hyperfine&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Begin to Expire&lt;br/&gt;in&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hyperfine tax net operating loss carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-2018&lt;/div&gt; NOLs)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal (post-2017 NOLs)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No&#160;Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Connecticut research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;752&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Connecticut others&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal others&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liminal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Begin to Expire&lt;br/&gt;in&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liminal tax net operating loss carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-2018&lt;/div&gt; NOLs)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal (post-2017 NOLs)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,304&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No&#160;Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Connecticut research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;Under Internal Revenue Code Section&#160;382, if a corporation undergoes an &#x201c;ownership change,&#x201d; the corporation&#x2019;s ability to use its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;pre-change&lt;/div&gt; net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an ownership change occurs when certain shareholders increase their aggregated ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). The Company performed a Section&#160;382 analysis for Legacy Hyperfine to determine whether an ownership change has occurred. Based on this analysis, Legacy Hyperfine experienced two consecutive ownership changes, one on January 17, 2017, and one on May 16, 2017. As a result, Legacy Hyperfine&#x2019;s net operating loss and tax credit carryforwards as of December&#160;31, 2020 are subject to a Section&#160;382 limitation. The January&#160;17, 2017 ownership change resulted in an annual limitation of $865 and the May&#160;16, 2017 ownership change resulted in an annual limitation of $3,008&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The first (earlier) limitation will limit the deduction of pre-change losses and credits arising before the first ownership change. The second (later) ownership change creates another limit to deduction of those pre-change losses and credits. However, the second ownership change does not allow for a &#x201c;step-up&#x201d; of the first limitation and therefore the pre-January 17, 2017 losses and credits are still subject to the first limitation amount. Due to these limitations, the Company estimates that $&lt;/div&gt;3,125 and $249&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;of the federal net operating loss and research and development credit carryforwards, respectively, will expire before utilization. Accordingly, Legacy Hyperfine&#x2019;s gross deferred tax assets and corresponding valuation allowance have been adjusted to reflect the estimated expirations. In addition, as a result of the Business Combination and any other equity issuances during the year, the Company is currently updating its Section 382 analysis to determine whether any additional ownership changes have occurred through December 31, 2021. This analysis is expected to be completed in 2022.&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has adopted the accounting guidance within ASC Topic 740 on uncertainties in income taxes. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, the Company did not have any unrecognized tax benefits. To the extent penalties and interest would be assessed on any underpayment of income tax, the Company&#x2019;s policy is that such amounts would be accrued and classified as a component of income tax expense in the combined and consolidated financial statements. To date, the Company has not recorded any such interest or penalties. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company files income tax returns in the U.S. federal and various state jurisdictions. As a result of the Company&#x2019;s net operating loss carryforwards, the Company&#x2019;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company does not currently have any federal or state income tax examinations in progress. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted which included provisions related to net operating loss carryovers and carrybacks, refundable payroll tax credits, deferral of payroll taxes, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The Company has evaluated the relevant provisions of the CARES Act and has not recognized any benefit related to these provisions. Therefore, no related income tax effects have been recognized in the financial statements for the years ended December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, as a result of legislation in the state of Connecticut, companies have the opportunity to exchange certain research and development tax credit carryforwards for a cash payment of 65% of the research and development tax credit. The research and development expenses that qualify for Connecticut credits are limited to those costs incurred within Connecticut. The Company has elected to participate in the exchange program and, as a result, has recognized net benefits of $103 and $131 for the years ended December&#160;31, 2021 and 2020, respectively, which is included in research and development expenses in the accompanying statements of operations and comprehensive loss. As of December&#160;31, 2021 and 2020, the Company has recorded $196 and $467 of the research and development tax credit receivables in Prepaid expenses and other current assets on the Company&#x2019;s combined and consolidated balance sheets, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities) are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax assets (liabilities):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,512&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;522&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,136&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,788&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(36,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets (liabilities)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">29300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14512000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3429000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2238000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">117000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1634000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">522000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">949000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">421000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">857000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">90000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">36136000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17788000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">36136000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17788000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_FederalAndStateNetOperatingLossesMemberusgaapTaxCreditCarryforwardAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">A reconciliation of the income tax expense at the federal statutory tax rate to the Company&#x2019;s effective income tax rate follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal research and development credit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write down of federal NOL due to 382 limitation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write down of federal R&amp;amp;D credits due to 382 limitation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax adjustment resulting from tax rate change&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(28.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <hypr:Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.028</hypr:Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation>
    <hypr:Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.011</hypr:Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.055</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.281</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.159</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <hypr:DeferredTaxAssetsValuationAllowanceIncreased
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18348000</hypr:DeferredTaxAssetsValuationAllowanceIncreased>
    <hypr:DeferredTaxAssetsValuationAllowanceIncreased
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3729000</hypr:DeferredTaxAssetsValuationAllowanceIncreased>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had the following tax net operating loss carryforwards available to reduce future federal and Connecticut taxable income, and tax credit carryforwards available to offset future federal and Connecticut income taxes: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Hyperfine&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Begin to Expire&lt;br/&gt;in&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hyperfine tax net operating loss carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-2018&lt;/div&gt; NOLs)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal (post-2017 NOLs)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No&#160;Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Connecticut research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;752&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Connecticut others&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal others&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liminal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Begin to Expire&lt;br/&gt;in&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liminal tax net operating loss carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-2018&lt;/div&gt; NOLs)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal (post-2017 NOLs)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,304&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No&#160;Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Connecticut research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;No Expiration&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis"
      decimals="-3"
      unitRef="Unit_USD">12084000</us-gaap:OperatingLossCarryforwards>
    <hypr:OperatingLossCarryforwardsBeginToExpireYear contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PreTwoThaousandEighteenMemberusgaapTaxPeriodAxis">2034</hypr:OperatingLossCarryforwardsBeginToExpireYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis"
      decimals="-3"
      unitRef="Unit_USD">91306000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">72621000</us-gaap:OperatingLossCarryforwards>
    <hypr:OperatingLossCarryforwardsBeginToExpireYear contextRef="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2034</hypr:OperatingLossCarryforwardsBeginToExpireYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">2338000</us-gaap:TaxCreditCarryforwardAmount>
    <hypr:TaxCreditCarryforwardBeginToExpirationYear contextRef="P01_01_2021To12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">2034</hypr:TaxCreditCarryforwardBeginToExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">752000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:TaxCreditCarryforwardAmount>
    <hypr:TaxCreditCarryforwardBeginToExpirationYear contextRef="P01_01_2021To12_31_2021_ConnecticutOthersMemberusgaapTaxCreditCarryforwardAxis_HyperfineMemberdeiLegalEntityAxis">2022</hypr:TaxCreditCarryforwardBeginToExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:TaxCreditCarryforwardAmount>
    <hypr:TaxCreditCarryforwardBeginToExpirationYear contextRef="P01_01_2021To12_31_2021_FederalOtherMemberusgaapIncomeTaxAuthorityAxis_HyperfineMemberdeiLegalEntityAxis">2022</hypr:TaxCreditCarryforwardBeginToExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LiminalMemberdeiLegalEntityAxis_PostTwoThaousandSeventeenMemberusgaapTaxPeriodAxis"
      decimals="-3"
      unitRef="Unit_USD">12304000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">12300000</us-gaap:OperatingLossCarryforwards>
    <hypr:OperatingLossCarryforwardsBeginToExpireYear contextRef="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2038</hypr:OperatingLossCarryforwardsBeginToExpireYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">449000</us-gaap:TaxCreditCarryforwardAmount>
    <hypr:TaxCreditCarryforwardBeginToExpirationYear contextRef="P01_01_2021To12_31_2021_LiminalMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">2038</hypr:TaxCreditCarryforwardBeginToExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_ConnecticutResearchAndDevelopmentMemberusgaapTaxCreditCarryforwardAxis_LiminalMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">49000</us-gaap:TaxCreditCarryforwardAmount>
    <hypr:OwnershipChangeDescription contextRef="P01_01_2021To12_31_2021">ownership change occurs when certain shareholders increase their aggregated ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years).</hypr:OwnershipChangeDescription>
    <hypr:OwnershipChangePercentageTestingPeriod contextRef="P01_01_2021To12_31_2021">P3Y</hypr:OwnershipChangePercentageTestingPeriod>
    <hypr:NumberOfConsecutiveOwnershipChanges
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_Ownership">2</hypr:NumberOfConsecutiveOwnershipChanges>
    <hypr:OwnershipChangesDateOne contextRef="P01_01_2021To12_31_2021">2017-01-17</hypr:OwnershipChangesDateOne>
    <hypr:OwnershipChangesDateTwo contextRef="P01_01_2021To12_31_2021">2017-05-16</hypr:OwnershipChangesDateTwo>
    <hypr:NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation
      contextRef="PAsOn01_17_2017"
      decimals="-3"
      unitRef="Unit_USD">865000</hypr:NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation>
    <hypr:NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation
      contextRef="PAsOn05_16_2017"
      decimals="-3"
      unitRef="Unit_USD">3008000</hypr:NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation>
    <hypr:NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation
      contextRef="PAsOn01_17_2017_FederalNetOperatingLossMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">3125000</hypr:NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation>
    <hypr:NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation
      contextRef="PAsOn01_17_2017_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-3"
      unitRef="Unit_USD">249000</hypr:NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation>
    <hypr:OwnershipChangesAnalysisExpectedToBeCompletedYear contextRef="P01_01_2021To12_31_2021">2022</hypr:OwnershipChangesAnalysisExpectedToBeCompletedYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <hypr:IncomeTaxEffectsRecognized
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">0</hypr:IncomeTaxEffectsRecognized>
    <hypr:IncomeTaxEffectsRecognized
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD">0</hypr:IncomeTaxEffectsRecognized>
    <hypr:PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.65</hypr:PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards>
    <hypr:ExchangeProgramRecognizedNetBenefits
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">103000</hypr:ExchangeProgramRecognizedNetBenefits>
    <hypr:ExchangeProgramRecognizedNetBenefits
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">131000</hypr:ExchangeProgramRecognizedNetBenefits>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">467000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company utilizes and subleases office and lab space in Connecticut which is being leased from an unrelated landlord by 4Catalyzer Corporation, (&#x201c;4C&#x201d;), which is owned by a related party. The Company pays rent to 4C on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;month-to-month&lt;/div&gt;&lt;/div&gt; basis, and no lease agreement was entered into between the parties until June 2021. A total of approximately $149 and $113 was paid during 2021 and 2020, respectively. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to 4Bionics executing a plan of liquidation and dissolution on April&#160;2, 2021, certain expenses incurred at 4Bionics were allocated to its subsidiaries, including Liminal. Expenses that broadly benefited 4Bionics and its subsidiaries were allocated evenly amongst its three subsidiaries. Expenses that were incurred on behalf of the employees of each company were allocated based on each subsidiary&#x2019;s relative headcount. Total proceeds allocated to Liminal upon liquidation and dissolution in 2021 were $101 and total expenses allocated to Liminal in 2020 were $64. The method used to allocate common expenses of 4Bionics to Liminal is reasonable. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2018, the Company entered into a Promissory Note (the &#x201c;Note&#x201d;) with one of its employees (the &#x201c;Borrower&#x201d;) in the amount of $90. The Note bears interest at a rate equal to 1.68% per annum. In accordance with the terms of the Note, since the Borrower remained employed with the Company on the maturity date of January&#160;11, 2022, $90 of the then outstanding principal amount and all interest accrued to that date was forgiven and Borrower is no longer required to repay the amount. Interest on the Note was payable annually in cash on the anniversary date of the Note, and as of December&#160;31, 2021 and 2020, interest receivable in the amount of $0 and $2, respectively, are included in Prepaid expenses and other current expenses on the combined and consolidated balance sheets, and interest income of $0 and $2, respectively, were recognized as of December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company also made payments to 4C to prefund the acquisition of capital assets and these amounts are included in Other assets&#x2014;related party on the combined and consolidated balance sheets. Such prepaid advances were $0 and $1,154 as of December&#160;31, 2021 and 2020, respectively. During 2021, the Company wrote off $983 of such prepaid advances considered to be unrecoverable. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company was a party to an Amended and Restated Technology Services Agreement (the &#x201c;ARTSA&#x201d;), most recently amended on November&#160;11, 2020, by and among 4C, the Company and other participant companies controlled by the Rothberg family. Under the ARTSA, the Company and the other participant companies agreed to share certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-core&lt;/div&gt; technologies, which means any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant and subject to certain restrictions on use. The ARTSA also provided for 4C to perform certain services for the Company and each other participant company such as monthly administrative, management and technical consulting services to the Company which are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; approximately once a quarter. The Company incurred expenses from 4C of $4,055 and $2,160 during the years ended December&#160;31, 2021 and 2020 respectively. The amounts advanced and due from 4C at December&#160;31, 2021 and 2020, related to operating expenses was $0 and $1,496, respectively, and is included in Due from related parties on the combined and consolidated balance sheets. There was also $1,872 and $11 of amounts due to 4C for expenses paid on their behalf. These payables are included in Due to related parties on the combined and consolidated balance sheets. On July&#160;7, 2021, Legacy Hyperfine, Liminal and 4C entered into First Addendums to the ARTSA, pursuant to which Legacy Hyperfine and Liminal each terminated its participation under the ARTSA immediately prior to the Closing. Legacy Hyperfine and Liminal each entered into a Master Services Agreement (the &#x201c;Master Services Agreements&#x201d;) with 4C effective as of July&#160;7, 2021 pursuant to which Legacy Hyperfine and Liminal may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The ARTSA also provided for the participant companies to provide other services to each other. The Company also has transactions with other entities under common ownership, which include payments made to third parties on behalf of the Company. The amounts remaining payable at December&#160;31, 2021 and 2020 are $110 and $124, respectively, and are included in the Due to related parties on the combined and consolidated balance sheets. In addition, the Company has transactions with these other entities under common ownership which include payments made by the Company to third parties on behalf of the other entities and the amounts remaining receivable are in the aggregate $14 at December&#160;31, 2021 and the amounts remaining payable are in the aggregate $30 at December&#160;31, 2020, and are reflected in the Due from related parties on the combined and consolidated balance sheets. All amounts are paid or received throughout the year within 30 days after the end of each month. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Legacy Hyperfine and Liminal entered into Technology and Services Exchange Agreements (each, a &#x201c;TSEA&#x201d; and collectively, the &#x201c;TSEA&#x201d;) with other participant companies controlled by the Rothbergs. A TSEA by and among Butterfly Network, Inc., AI Therapeutics, Inc., &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quantum-Si&lt;/div&gt; Incorporated, 4Bionics, Tesseract Health, Inc., Detect, Inc. (f/k/a Homodeus Inc.), Legacy Hyperfine and Liminal was signed in November 2020; a TSEA by and among &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quantum-Si&lt;/div&gt; Incorporated, AI Therapeutics, Inc., 4Bionics, Tesseract Health, Inc., Detect, Inc., Legacy Hyperfine and Liminal was signed in February 2021 (and which Protein Evolution, Inc. joined in August 2021); and a TSEA by and among Legacy Hyperfine, Liminal, AI Therapeutics, Inc., Tesseract Health, Inc. and Detect, Inc. was signed in July 2021 and is effective upon the Closing. Under the TSEA, Legacy Hyperfine, Liminal and other participant companies may, in their discretion, permit the use of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-core&lt;/div&gt; technologies, which include any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant, such as software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists, by other participant companies. As of December&#160;31, 2021, the Company had transactions with other participant companies and had expenses of $11 included in Accounts payable.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <hypr:RelatedPartyTransactionPaymentsForRent
      contextRef="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">149000</hypr:RelatedPartyTransactionPaymentsForRent>
    <hypr:RelatedPartyTransactionPaymentsForRent
      contextRef="P01_01_2020To12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">113000</hypr:RelatedPartyTransactionPaymentsForRent>
    <hypr:NumberOfSubsidiaries
      contextRef="P01_01_2021To12_31_2021_FourBionicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_Subsidiary">3</hypr:NumberOfSubsidiaries>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2021To12_31_2021_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">101000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2020To12_31_2020_AllocationOfExpenseIncurredMemberusgaapRelatedPartyTransactionAxis_LiminalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">64000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueFromEmployeesNoncurrent
      contextRef="PAsOn01_31_2018"
      decimals="-3"
      unitRef="Unit_USD">90000</us-gaap:DueFromEmployeesNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="P01_01_2018To01_31_2018"
      decimals="4"
      unitRef="Unit_pure">0.0168</us-gaap:RelatedPartyTransactionRate>
    <hypr:DueFromEmployeesForgiveness
      contextRef="P01_11_2022To01_11_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">90000</hypr:DueFromEmployeesForgiveness>
    <hypr:InterestReceivableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</hypr:InterestReceivableRelatedPartiesCurrent>
    <hypr:InterestReceivableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2000</hypr:InterestReceivableRelatedPartiesCurrent>
    <us-gaap:InterestIncomeRelatedParty
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestIncomeRelatedParty>
    <us-gaap:InterestIncomeRelatedParty
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:InterestIncomeRelatedParty>
    <hypr:OtherAssetsRelatedPartyNoncurrent
      contextRef="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</hypr:OtherAssetsRelatedPartyNoncurrent>
    <hypr:OtherAssetsRelatedPartyNoncurrent
      contextRef="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1154000</hypr:OtherAssetsRelatedPartyNoncurrent>
    <hypr:PrepaidAdvancesUnrecoverable
      contextRef="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">983000</hypr:PrepaidAdvancesUnrecoverable>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">4055000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">2160000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1496000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1872000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_CatalyzerCorporation4MemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">110000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">124000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_AmendedAndRestatedTechnologyServicesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_TechnologyAndServicesExchangeAgreementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. The Company did not make any matching contributions to the 401(k) plan for the years ended December&#160;30, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During 2020, the Company was awarded a $1,610 grant from the BMGF for the provision and equipping of 20 sites with the Hyperfine portable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;point-of-care&lt;/div&gt;&lt;/div&gt; MRI system to enable the performance of a multi-site study focused on optimizing diagnostic image quality (the &#x201c;Project&#x201d;). During 2021, the Company was awarded an additional $3,300 grant from the BMGF, of which $2,500 was received for the provision and equipping of 5 sites and other related deliverables, of which the remaining $800 is to be received by April 2022. The funds are accounted for as restricted cash with an offset to deferred grant revenue. At December&#160;31, 2021 and 2020, the Company has $2,662 and $1,610, respectively, on the combined and consolidated balance sheets. Any grant funds, plus any income, that have not been used for, or committed to, the Project must be returned promptly to the BMGF upon expiration of or termination of the agreement. As of December&#160;31, 2021 and 2020, there were no grant fund amounts that were required to be returned under the provisions of the Project. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company does not have any outstanding or ongoing litigation and legal matters where, based on present information, including its assessment of the merits of the particular claims, the Company believes it is reasonably possible that any asserted or unasserted legal claims or proceedings, individually or in aggregate, will have a material adverse effect on its results of operations or financial condition. The ultimate outcome of any legal matter cannot be predicted with certainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company has indemnification obligations under some agreements that the Company enters into with other parties in the ordinary course of business, including business partners, investors, contractors, and the Company&#x2019;s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or threatened third-party claim because of the Company&#x2019;s activities or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compliance&lt;/div&gt; with certain representations and warranties made &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions due to the Company&#x2019;s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the combined and consolidated statements of operations and comprehensive loss in connection with the indemnification provisions have not been material. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;The Company agreed to pay $1,000&lt;div style="display:inline;"&gt;&#160;to a third party service provider upon the receipt by the Companies&#x2019; pre-closing equity holders of any Earn-Out Shares (see Note 3. Business Combination). The Company determined the probability of such payment to be not probable thus no liability was recognized.&#160;&lt;/div&gt; &lt;br/&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <hypr:DeferredGrantFundingCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1610000</hypr:DeferredGrantFundingCurrent>
    <hypr:NumberOfSites
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_Site">20</hypr:NumberOfSites>
    <hypr:GrantAwarded
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3300000</hypr:GrantAwarded>
    <hypr:GrantAwardedForProvisionAndEquipping
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2500000</hypr:GrantAwardedForProvisionAndEquipping>
    <hypr:NumberOfSites
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_Site">5</hypr:NumberOfSites>
    <hypr:GrantAwardedForOtherRelatedDeliverables
      contextRef="P04_01_2002To04_30_2022_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-3"
      unitRef="Unit_USD">800000</hypr:GrantAwardedForOtherRelatedDeliverables>
    <hypr:DeferredGrantFundingCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2662000</hypr:DeferredGrantFundingCurrent>
    <hypr:DeferredGrantFundingCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1610000</hypr:DeferredGrantFundingCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPK53I[%.[@X]E"V%$;::LEA) #ZN 3(^10&P@M^[+CY$J;"B#45.*A$@>A&
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M+N-QQ$I.,KI87<MOYTDA9ONHIX3@!0U#+=:"$@JDHI!>L4R:$B3LALHPG79
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M.!#^*YK,S5P[TS26Y-<.,$.<D&2. D?2WMQ'XRC$4SM*+07HOS_9,?&+9#E
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MD>X_\>Y/.-WF'PSO*.<TR0_7)!!](@.(WU>4\N>3[!ODX4/[V7]02P,$%
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MHXO_H1OO(_>[\*/@<'^HT6P8H -SS27_X*A 5Z)A;;H2)&=MMZF5N11&HNV
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M8P2FN6L:PU$=YGM*CF^+\,FIYFB\ ^]OB+O;&OZ TX4__A=02P,$%     @
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M/1O'+<;Y2"C[?JK)A"408XAJZ*!S/OH^9"-2?!7Q28Y?)!*XSQ,(\R#&P!8
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M=%M=7^DI9_)BL,4E))TMV(R7\7Z[N/^=U0T7,(_I7(^)$6U',RFWC?F>@(C
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M+\V7P?V _3B;S5FN)0*.A"!Q(1CD(Q:6,#!^<'M8/W# Z%<($^-<%@'C,BO
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M;66?[\,GB.Y;J'+GFF <L0>2(7L?\*".@NJRXC"-2JK65L3^M7!B/4!-4!Z
M463^=]! JX,G'%9DXJO0D31UT'L6O@#4U">R=DU A*NZ**M$.>WCBVCD>0*
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M(0$H%M%L_78I\1!;RHVLZ@\V=0QT]XD-EM!3[ G@C3@\X%[PA-]NTMB-:BK
MPWV)4^MR*"S6PRVA&2X?4+WG,A?'-A-2 2RY0U0RU^@FK*Q#A5(W(?:'A&[L
MBFU\>]"3OE8 EZ8P@2^VP13MC#_G%/9U/AN^]Y@ OMKWI6G<^YH';Y;RS9*=
MA;[X8:];[3Z+WL2O@9OM\9OJ[]HM>70M:(&CD]'YV2#>/=J'8&OY-CBW :&3
M?U>$1#O>@/<+:T/[P JZC\77_P502P,$%     @ $H%\5'QIX5/%!   =@H
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MH_$.=%YI[9X-'^ X[4>_ %!+ P04    "  2@7Q4NNLW(R0#  #2!@  &0
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MX[*ECPY:#B!_;4C]:/ !TV=L^P]02P,$%     @ $H%\5*TW5/W9"0  42@
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M=M.[FKN):-JRSC5+@+.1&=K>E!HAO4VJ25_6V\.ZXUE-/)=16[!M&UQ02%E
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MF_@)Z9R<17&+E;L+W<YT^(-X+7J=7O\'_&N_C'] #+31PYRH8(]MK)*YZ/Z
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M(56#3:0"MF0"C]F&(VDOZ(=C,1D-3OZD4'-"&XRN[<_MX,^$-(;!8!**L(]
M1-MX=^$HH(TF(@S]5LPQ:;P2HV#:[1$;=%)GIY7I2P#2@=L6)LWU^L%HV-V]
M!^@M7V6H@V4&%@_IB(@#9$>T_2CTPOO9+8K,)?^XF-H%95J87^!63ZO?+U^:
MG^W6P\V/GW^5^3)&)9BH!:9V.^/AJ>E)N"]%MN$?\<ZRHLC6_'&E8.XY#<#[
M1985[@MM4/VJ^_W? %!+ P04    "  2@7Q403H1B&X$  "<"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6RE5M]OXC@0?N]?,>).IZV40G[PHW0I
M$K2<>E*W1:6[^W"Z!Y,,Q*H39VVGM/_]C9U 0[>P#_M L&//-]^,OYEXM)'J
M2:>(!EXRD>O+5FI,<='IZ#C%C.FV+#"GE954&3,T5>N.+A2RQ!EEHA/Z?K^3
M,9ZWQB/W;J[&(UD:P7.<*]!EEC'U.D4A-Y>MH+5]\<#7J;$O.N-1P=:X0/.U
MF"N:=78H"<\PUUSFH'!UV9H$%].NW>\V?..XT8TQV$B64C[9R3_)9<NWA%!@
M;"P"H[]GO$(A+!#1^%%CMG8NK6%SO$7_V\5.L2R9QBLIOO/$I)>M\Q8DN&*E
M, ]R<X-U/#V+%TNAW1,VU=[(;T%<:B.SVI@89#RO_ME+G8>&P?DA@[ V"!WO
MRI%C><T,&X^4W("RNPG-#ERHSIK(\=P>RL(H6N5D9\9WLT>XO5\L8#Y[@,7-
MY&$VZAC"M:N=N,:85ACA 8P@A"\R-ZF&69Y@L@_0(4([5N&6U30\BGB-<1NB
MP(/0#X,C>-$NRLCA10?P9DSE/%]KF*."1<H4PK^3I3:*1/'?$?SN#K_K\+N_
ME<7C&$'4AI]Q8,HTCR&G\A12:R@H .T"X!IBF16EP026KY#P9YY0C&!2?-M.
M"W:^<>+$Y(P]HZ):@[S,EH0D5Q68MB-"RZA.2'+QDYU;PRORP/)7H'+6AN7.
M05*JK1]BPV72AFLN'(]?TUP333+&U8K*$HP$)L36,_XH^3,3F)L&JP8+#W@>
MB]*1B&5.H1B^%,2""AF5(@>.N[?'M@ZGL#U >_"P^*J!EL!*XNR^-/!(#E92
M4'=R4;$:41,-[;S'3,2E8*Z)$*&E.Q +D1R.FKIED_E??YR'P>"SWLOQQ8E5
MMY6X?W)79G0P1JJ+DSM"N[5H?\*G?M<[[P5P:L=AY'7# 9R^[75>ICLZ[A"H
MQ<%LOG .P\\.ASTS+EQ8E.XF@52*!-5A1]>82VHY%:VKRG#ATAEY_:'O]<((
M OOT_&&_N?O7Q+Z_%^2>^#Z"G^ZGW<*]RSE1#P;MWJ"*(NBUHW,:+D@SN*?E
M#=,D)&"-<Y.:N^.UO*T@*UWKK0XP\1Q"=?3OW#;E@2]6GZC?2Q*L2P.)I*5<
M&B@823?F!3-HJ6R)_*3X-DR2Q%$C5J3_#Y3&C%%\69KM 5\)1NL3EZEJ//WP
MT&T6K"?-,@3[>?Q V/8-U4R]TQ6?KJO@>-DVZF\C2Y% 2N<,2T3RDQM^MCU"
MBJ\Y/8RX01NJK@M5-TOGON&L+G.;AZ)4<4J?ZWUE#4A/H1=$?5+6T">A#X9[
M +>X9O$KW+Q2@E?4H(_U&?BT()F@3;9)E2S7*5R?0BUP^_4*@K[G]_I[#ES_
M"0+B$?2W>T]VO2CP/=]WO]W:HS1,[&?M<)H(MQ\-O7XOA(C*)AAZO:CWT?>M
MT[@Q4#=9NWN1;4]E;JK+P^[M[NHUJ6X<;]NK>]L7IM:<<BYP1:9^>]!K@:KN
M0M7$R,+=/Y;2T&W&#5.Z/J*R&VA]):793JR#W85T_#]02P,$%     @ $H%\
M5.;7C^[C"P  \B$  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULI5I;
M;]LZ$G[WKR"\Z4$"J(XEVXF3I@'<--UVT1N:GG,66.P#+5$V6TE422J.^^MW
M9DC)LB,GS18H:ILBY_+-G<K%2NGO9BF$97=Y5IB7_:6UY?GQL8F7(N=FH$I1
MP)-4Z9Q;^*D7QZ;4@B=T*,^.H^'PY#CGLNA?7M#:9WUYH2J;R4)\ULQ4><[U
M^I7(U.IE/^S7"U_D8FEQX?CRHN0+<2/LG^5G#;^.&RJ)S$5AI"J8%NG+_BP\
M?S7&_;3A+RE6IO6=H29SI;[CCW?)R_X0!1*9B"U2X/!Q*ZY$EB$A$..'I]EO
M6.+!]O>:^AO2'729<R.N5/:W3.SR97_:9XE(>979+VKU5GA])D@O5IFA_]G*
M[1V-^BRNC%6Y/PP2Y+)PG_S.X] Z,!WN.1#Y Q')[1B1E*^YY9<76JV8QMU
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M@873+^A.:_"(>FG4@U/P",;O.]W"W+!3KD3N:^*M#&.7<I5KQU7+6"G(.6=
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M>O7%5"U01(.R#"JK2TWT NE6$QV04U0&-KY8:C475T'> 7EI,F@_R:^ R&C
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M"P*P^/=&O)/=$G&'L=LM$WNE )N<MP#946 8"7>Y(WBQ[W_MQ"\.1R;N"I7
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M+G5*E--?83*.Q5#C_FJHZPHG7#.CHK^VYF@MZ)I.=GE T5//$*+U3OEW.S8
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M+%EPG;.ZQ>O>BFV\+I5^>6&4;BT(M*$;@8DON,C(?(>H8OQJ.)[LZ(LG00_
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MJ$^R6N"YKT+-H>O1Z,7I8R9^_P7$-OW:T<S4M5G1QZ62X EC W@_-Z;V7W"
M\/M7O_PO4$L#!!0    ( !*!?%1/;LD9M ,  (4)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;,U6W6_J-A1_YZ\XRG2G3;IK2(#;JPZ0 BV]2/U
MA6Z:ICV8Y$"L)G:N[<#EO]^Q$VC6 NKC'@BVS_?'S\?]K50O.D4T\"//A!YX
MJ3'%E>_K.,6<Z0M9H"#*2JJ<&=JJM:\+A2QQ0GGFA^WV%S]G7'C#OCN;J6%?
MEB;C F<*=)GG3.U&F,GMP N\_<$37Z?&'OC#?L'6.$?S7,P4[?R#EH3G*#27
M A2N!EX47(UZEM\Q_,%QJQMKL)$LI7RQFVDR\-K6(<PP-E8#H[\-CC'+K")R
MXWNMTSN8M(+-]5[[Q,5.L2R9QK',_N2)20?>5P\27+$R,T]R^PWK>)R#L<RT
M^\*VYFU[$)?:R+P6)@]R+JI_]J/.PT<$PEH@='Y7AIR7U\RP85_)+2C+3=KL
MPH7JI,DY+FQ1YD81E9.<&<Z?[^^CI[_@<0+SZ>W#=#(=1P\+B,;CQ^>'Q?3A
M%F:/=]/Q]&8.ORS8,D/]:]\W9-B*^W%M9%09"4\8"4*XE\*D&FY$@LE_%?CD
M\<'M<._V*#RK\1KC"^@$GR%LA\$9?9U#&CI.7^>$OBB.92D,%VN8R8S''#7\
M'2VU4=0V_YPQT#T8Z#H#W5-Y)C0E988@5X L3D'SM> K'C-AZCJC^DQMOD%1
M(C -# I4,0I#V+!21AJ6[1F(+!)8*ZEI5?FNB18CW]@BG98_*7*LJF=#LM?%
ME2Y8C ./[@.-:H/><'XD++*G$$PJM?TR0U:= +'DTE&8@*#]R7F9(HQE7C"Q
M^_FGKV%P^;M^&[E49P)?LHR)F+CHOG+** E<)E6^*"O[]-=\4-U\"3/$6?F$
MR040X/^?58(M*B>WDAG=I_JJ]53[$KUG;DWJ'.R043P6>G#D*')9(41AOD3E
M4/7^J#6NHX<(",Z?( SHTZY^K\01].KCL/N6-H;N7L[^NDW:-73L\5&=-^#L
MU>?0ZS2)$]C+=(.W@K>.%M2.0"=L$K_M#4'XI5Z<@7GO //>QV&N#:>Q01DN
M-:[*##*:/RZQA:*AJLS.M0=^+WE!8\X<0^!9:\<1^/PA8PZ2S3Z:'6>[>1_$
M"EMW;"D5,U+M&JP]ZD5-;46P27##+0A[K3G+:AC0S']!=\.^4BW22T/5:&I9
M2+J!B:W36BB66(A2#9C62,W=:=TAS>"DH>.1VIE:]+?+H_7S&Z.1RKYV#P -
M#BO5E#R<'MX8435:7]FK!\H]4VLN-&2X(M'VQ2451U5#O]H86;A!NY2&>LPM
M4WHGH;(,1%]):?8;:^#P\AK^"U!+ P04    "  2@7Q4,XVL%P<#  #U!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R-56UOVC 0_LZO.&73M$E3
M\P*,E@%2"VRKM+4(VNW#M \F.1)KB9W9!MK]^IV=$,I&T;XD?KE[[KGG[/-@
M*]5/G2$:>"ARH8=>9DS9]WT=9U@P?29+%+2SDJI@AJ8J]76ID"7.J<C]* C>
M^07CPAL-W-I,C09R;7(N<*9 KXN"J<<KS.5VZ(7>;F'.T\S8!7\T*%F*"S3W
MY4S1S&]0$EZ@T%P*4+@:>I=A_ZIK[9W!5XY;_60,-I.EE#_MY#H9>H$EA#G&
MQB(P^FUPC'EN@8C&KQK3:T):QZ?C'?H'ESOELF0:QS+_QA.3#;US#Q)<L75N
MYG+[">M\',%8YMI]85O;!A[$:VUD43L3@X*+ZL\>:AW^QR&J'2+'NPKD6$Z8
M8:.!DEM0UIK0[,"EZKR)'!>V* NC:)>3GQG-IU^G-_=3F$_'MQ]OKN^N;V_@
M]1U;YJC?#'Q#$:R=']=H5Q5:] Q:&,$7*4RF82H23 X!?*+6\(MV_*ZBDX@3
MC,^@';Z%*(C"$WCM)M^VPVL_ER]N4*P15DH6,":NBLX%:6XR&#NU4<'WRZ5V
MZS].!.PT 3LN8.>9@(OJM(-<P81KEJ8*4V8P@9J)/J;R:<B[C/C+G.X3%RD8
M6ZSZ4O'?J,'0]E@6)1./KUZ<1V'OO8;D(+2J0_=;,V8,*F'968'M)VA-<,-C
MA)GDP@ 78.@6PDOHA5WZTFUO+5 YB]L-J>5V>^<A7'1:=]*P? =/QN';SL4[
MZW31.2%EMY&R>S+O:U$U(7>;E]1A2,,8^<:=5F B@0FN4*F]N(=EUH=U/JK\
M20:V0_9UR6(<>M0"-<F WM%RE$IN>$*L^#^<U5^<DQUG]91S?,@YWG'NM_9U
MNHQCN19DLH<DK;O=ME6^UVG=BR7/<X>\#WD1@CL5T?O6Y._(O78 8?>\]5G:
M1% 5_Y+KAL'.'XZ5U'_2BHAOZAJN!D>TZDK-:M/3+ZM6MC>O'H0O3*5<:,AQ
M1:[!68]JHZHF6TV,+%UC6TI#XKAA1N\2*FM ^RLIS6YB S0OW>@/4$L#!!0
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MWY;T&*%V#G1?*&5WA@O0/F_C_U!+ P04    "  2@7Q4::R>*"8#  !3!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q]55%OXS8,?O>O('S#T )!
M;<N.G71)@+3-L .NO5R:VS ,>U!L)A9J2SE)OESWZT?9B=L"U[Q8HD1^'TF1
M].2@]),I$2W\J"MIIGYI[?XZ"$Q>8LW-E=JCI)NMTC6W).I=8/8:>=$:U57
MPC -:BZD/YNT9TL]FZC&5D+B4H-IZIKKYQNLU&'J1_[I8"5VI74'P6RRYSM\
M1/MUO]0D!3U*(6J41B@)&K=3?QY=WR1.OU7X4^#!O-J#BV2CU),3/A93/W0.
M886Y=0B<EN]XBU7E@,B-;T=,OZ=TAJ_W)_3?V]@IE@TW>*NJOT1ARZD_\J'
M+6\JNU*'/_ 8S]#AY:HR[1<.G6Y"C'ECK*J/QB370G8K_W',PRN#4?B. 3L:
ML-;OCJCU\HY;/IMH=0#MM G-;=I06VMR3DCW*(]6TZT@.SM;KCXO%ZOUWS!_
MN(/%EZ\?E_>+A_4 'A9KN%CS387F<A)88G+Z07Y$O>E0V3NH$8-[)6UI8"$+
M+-X"!.1B[R<[^7G#SB+>87X%<30 %K+H#%[<QQVW>/%[<6NJ:VV?!["LN+3
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M]_AC(;0SP/6M4O:DN #G7Y7)7U!+ P04    "  2@7Q42Z\# TD%  !T#0
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MRE17L&J_A+XT6FF*CZEB49MJ52;A=2/3G*[>PP@/*:ZA&T0#BO#(IX0/1P<
M][AAZ0O<O5!XUT25M"O*E"ZZ[EBCE%3Y+=AI@K(@<C,J>2F:30ZW9] EVEQ
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M'M_\,>+1\)VERJP(."0@:@+Y!@$F,']A6:9S[$P[;DUM13R!8@:&M&^1]K0
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M[0?%-\U/RA9<*5XUEVN6PH+2#\#W2\[5XP?]*[7]#R4O_P]02P,$%     @
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MQJ)U-829+MXKH7>)QJEX,7N<W2QG:#%+;K_<S!_FMS?H(YJSYGQ8HU/=?+2
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M&5Q<&D:R'"'E1HO<=>&ET*:GNV5FIBY(:V#N5T+H[<8&J.?X\#=02P,$%
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M?=]]W]WY'%=<O,D"0*'WDC(Y=@JEMK>N*],"2BP'? M,G^1<E%AI4VQ<N16
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MAGF#D<:+>N9K0_&M'9LU5WH([;+0SR0(XZ#/<\[5P3"3V#Z\R5]02P,$%
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M(C<LL<V!L@&XOY+2["=6H&N<V2]02P,$%     @ $H%\5'4&<]@;!   J1(
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M\Y]Q)IB\&\D\,9A,OTWNI_._P/!I#.[_>'Z8?+U_FM^ I_LY^ QFLFO"+":
M+L"$R=YAX@W@- 3D1Q:MY:\I;D J>^WCF @<Q?R3S'F>C<''#Y_ !Q"E8+ZB
M&9<)O&<*J38?TPQ*95]VRM )96,2W (;W@!D(=B2/CH_W3I.-R6C"A2J0*&B
MGGT*U'[ZDQBG @PEA/L]!/#WHXP&#X(D_!_-6'8UEEV,U?G56#742T9Y*\E=
M.:<HES^XFX$#7;MG;@YY-8.0FZ/9M"CM5$H[6J6/A/,[, R"+,EB+$@H'R%I
M)T&$=P^IU(\3RD3T;W&A3?MN /= UF?8@59-?$N4!]UV\4XEWOE?F&5'MPEU
M&A)LSZE#;@9!W^JTZW0KG:X>,GZA# O*WE3+:;K,J\IZ5^_H;C56][(=W6UP
M]+M^C74SQO%0.VJ_TNEK=4X))Y@%*S FFR@@7#-U:"F+M:X.&AX8.KPLZK+>
M4<]V$*K!;HGJ=$\\@%"9*D1:L3,<$UXH_8K9*Q%1NCP'O3)2:%\?O3)#J'?#
M]Z-OVIKK^B>@*EN#>E\;T62="<+.<@NH7 BZUV>IS EZ%V;IM=B!4^_B9I#=
M=4X 5^8&]>XVHBD7+-LM3!_2?*FT9*0N\[BX<B3H7QT[4EZ%K,MB+^L=$>W
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M4R,)XRF6JLLWMMAQP+$1I=3V'*=EIYADUJ!GWLWYH,=R24D&<XY$GJ:8OXZ
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M((R!_IYRG5,U,0[JUFW\%U!+ P04    "  2@7Q4*;(,4P0)  "U+P  &0
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M.>7/Z%_O802ZYR1B_S;@NR6^*_&]/?CO*< &RJ^9B"K6AD!C?D93<:_.16;
M^QCQ!4%D26*.DAG"\3,*]2* 3AE+PERNF&2PW^. QG.4IV+T>S+'_C/ZZ3DE
MV0R0VVBU(("7H27,B;DP!$RB\<8E!I%)1(+J0H4$%ZL%]1<PP0]ST N&1B2;
MDZPMI60X)%+(,*Q;_:]_&3AV_RW,8HP(R\BU>(9CAE6B4^@":I&$ <F8@/%Q
M2CG$#$2O_[D.5PY&(6$,IN(8=:T?Q# !LTRXL 8C?IY![!%VB2X(AC4P$M(X
MUMNJQR9"1WG??GO9WI9#7(Z2>$DR3J>@Z ,D89)E8*<G*1EL403S*0_A%D_0
ME* 4TP !H:RG*\5K=<!+R %8X$)F$%[E&9TJMP*6U+V0I0VP&84_C.5MA#GH
M4G54FE$?5@8?RZA!Y$L.Q@,,(< <Z(_#HV3V!EW8ETJH- VI+Y=.8,]2D9]@
M4^6D@ )I60XF,^@.(H4YDYLS('Z(Q0,<!RB/I04"NJ0!B0,F/'[A7,(SA*,$
M=IQP& ?VR\&!"[PD8#0"*N!G*<X"!W(OR;TE4T 3/T@(7PV FS0&W7?,[2=1
M!,:2=KU"'Q>$"6\] VF#?U84%@7W13@@PG(@-?@-O =:"*/ =6'/RO;0 @HS
M)#+*P!2,J>D9)36[6:I/&8H3WD;39T1A=?!/!$YF)*XL9%#XRI"WO#)O><8T
M4X5/2WBF?+O6+.>,8YE>ZJA!+="3"XB":GDS[%JV->@.KCO+:M[?'6A;0QM2
MP] N1VXHT2V5Z)ZL!,[Y G;Y;R2HTZ&[*YHS[ \& V=;B28C-Y3HE4KTC$J,
MBUA!XR*0#-[MEYC]L[#>H,0?-)*9H8<B<G]'K^KLJV"Z%:M9]=8:EBL/S7R[
M%=<&96Q+%W'66<QE5\I$VRCV[1P2\1PR,23D!#)$FB4^(8%*$)7,M,>.HP*^
M:LB!I?[5V]/6!9+M- ZBK41C4ET72+9['N/J5&8?G<M*)D(9&+^VP#5C#ZXL
MZP>3E#I7V>9D-?GJ0ZTR)T(2FM0Z60$,J]%RY3K][AX7ZPQCFU/,Z<E^5*S0
M.QS)MDY2=O] [1S)VN/(':B3E3TXSP[42<DV9Z53=N#H /:A'>CH-.=8+]VK
M'$ \L5E1_O^#>Q2UZ(NU)L4>_AX[DD+T;Z\1P;%?Z45>7=G.H%_!%6(^J?KZ
M]K4M^X[RTOF^NY;")?\GS8JCZR?'7#\=)L\"8),\[?ZP5\]23N4 J7E]="1Y
M%BLT($]'EU6.^9SHY-YG5"S01"I=BCDGM)5JL\LS\BGLUKHSPKL#^!]B= M;
M/$3%&689,60V([Z((XPR4NQB^ALN,CG)"&Q?F755"JFDOXWRN^)(M,(,D6+?
M!3+IZ"!:3ZZDH6W>%XEE9YBS/4Q&-UKB,!>I&:AXJC*WB*IM1(A$2*D4!@O6
M*P;Q1,1KD:9 L@7D;_"Y+VRBJAT@4L*XRAW@ I7= 10L(@#6^@O=5,(PAJRN
M=QUSO7MJRU/ -V]Y'%T/.^9ZN$'A"5+]-XVYHXM>YSRMN:/+7>=EFO.1T[@[
M=W0E[)BKU?5./[*H=W4QZYZG9W<UY[AFSODYCZ:R8!$E'.BD"Y#?D7AI4GNV
M;]><==7;U-4,Y)Z;@<;N+@,YW:U@4N=<349NZE%Y57)FRAJ[NY2U3XT&(S?5
MT!SGGI?C1@?P)QLTU22@!#/X^K$LS45J3U+5>,TJU:"JVZ$&Y#0"RIF)FEP\
M#42FAI%E_;U^"R E::OZM$* V^?K3RGQ*0Y?%^W.)JM"'8ULP5AVU4"B(88U
MIK\"<XN'ZGVM"&D,/<SK@!:-(PY^S=<$)LOU-%%]9U56K-^U5AF-2>*.$[&N
M*) SO.Y%-V_HUDUQ8BEDV8:(^TV<86)/5[.G:V;/8J7QL7E4<Z';.T\>U8SG
MFH]YCLJC_=T\NB=N-2^Z9EY\B30ZV,TJ_?YPV/.V7Q?4C/3L8=\:#O;IH2G6
M/?JPJ6D:'>X(UW.Z_7[/WE&CP<C-]T^:P#WSV5&QP^_::"2C^MBM[FE"]^RS
M;'5/,[5W E,WH88#^+74<&<^\BA&C<P'1_H,Q>@'L;@Z?7AQOCE$,/^;C )X
M*9%?>U5.88S^+ X[V>;QVK[S,R&KZGN;H!O?+.LZSS/7>96F^,B0KKS%]LX3
MTIJ(/3,1'\->7LW+XCUEIZ>)VCOA)4ZCW&+&KR\[S3[\,PK/]9'*MU-O[@JW
M(<VW5(!ZNFKSS%5;LQ-UTU*Z,//.\W[.TR639RZ9C@KBW=)GW^<JNN;IFFN>
MDV/X /Z>&#:Z\ ^D]-H3US\K5L\6H]\!I7<J7SR+#]K_@3-8BH&",]A7UE4?
M""Q3WXBK"YZD\B/H:<+!#?+G@F PC!@ SV<)1%%Q(;ZK+K_4O_D/4$L#!!0
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M0Z?[#J&!#KW?I6/@^*\!<A!4-)_KFY^1U1BXL&[NR,TG?&@/XXL.XXOJ>NY
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M@(J(5Y@VJ&3#@@/P5T$ ^RG?Y8!6(AL3'(!/ 0+8C_@HZEY!&42R04$!J,?
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M?C)@I@SD\Q&50HJ!6J#\".G]!U!+ P04    "  2@7Q4-XUP"@L)  !T-0
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MW/X!<PELICB;VY>1'K/7*RL*X*8# ;<#X'9P<'\LDQ9-F:G3I#0MY'9'RCA
M:0<'H[[CT<&9<3;CWU\D'>"D,Q 5Z]1V1G 5V[\3T6.@?RO" ;(Z.!COQ%8:
M2;/+:3(@0A;GM,>>'53W.9AW@%H'1^U>7ER4RIJG,Z+]CGE83M^M%',AY78-
ME\TP!P"LSD"DK0-X=7#\':5H>FQZ7H\P<8"H#D[4:R[3]U_6JAP2=!8 F,Y
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MDBH,3<8*2\KG!67<01EA^,$RN1)PF44T>NW 4O%72< O23C'1H\7-.R#@TX
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M.\QTM5KUP9-<B#6)S=H&IJO]\;6=D*1\1+L/2+P0V[GW^-Q[HH/=WW/Q(A,
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ME9 6\%"D2I[2(HWO$UY*8I1]6Y$%+<2.-G)'E5SO [FN!S>\4(F$:1%C_);
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M@127M,K5@F^OL2$4&KR$Y])^P[99ZSF05%+QH@G6&12LK'_I0R/$08 F^G*
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M#NP9)14/$C</7K!)3 H3KLW+(H)QNZ&,246H!/\0.K1+8100>R;-+&#%BFM
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M5#=0*(R!_IYPKIXG)D#3DDU_ 5!+ P04    "  2@7Q4TT7QFQT#   6$@
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNVT 4A>&M"%R
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M9VN7?QP_///6U-TAGPU_NYJ] 5!+ 0(4 Q0    ( !*!?%0'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ $H%\5&<Y%@GN    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ $H%\5)E<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  2@7Q4
MFT]\_C0$  #F"P  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ $H%\5'%W%R_?!@  OAL  !@
M     ("!=PP  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M !*!?%0/.;M3Z@,  ( 0   8              " @8P3  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  2@7Q4\DS3#A$%  "=$P  &
M            @(&L%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ $H%\5*6U6$JL!@  =!\  !@              ("!\QP  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !*!?%2$.)[-6@@  /<B
M   8              " @=4C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  2@7Q4Y,PO[+(#  #\!P  &               @(%E+
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ $H%\5&%RL*FF
M'0  $5H  !@              ("!33   'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( !*!?%2+M@ZAP L  %HH   8              "
M@2E.  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  2@7Q4
MTL*?&EL(   X%@  &0              @($?6@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( !*!?%1\:>%3Q00  '8*   9
M      " @;%B  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ $H%\5/-XRM.U P  J@<  !D              ("!K6<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  2@7Q4C<'BLET#  #Q!@
M&0              @(&9:P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( !*!?%0][:F>P0(  /D%   9              " @2UO  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ $H%\5+KK-R,D
M P  T@8  !D              ("!)7(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  2@7Q4K3=4_=D)  !1*   &0
M@(& =0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !*!
M?%2CTU0:A@,  %H)   9              " @9!_  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ $H%\5*CABFUZ$@  X3T  !D
M         ("!38,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  2@7Q403H1B&X$  "<"@  &0              @('^E0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !*!?%3FUX_NXPL  /(A
M   9              " @:.:  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ $H%\5"%8=#J@!P  @A,  !D              ("!O:8
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  2@7Q4,'@I
MY^\%   S#0  &0              @(&4K@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( !*!?%1REC\-QQ\   MK   9
M  " @;JT  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M$H%\5$]NR1FT P  A0D  !D              ("!N-0  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  2@7Q4,XVL%P<#  #U!@  &0
M            @(&CV   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( !*!?%2NU^5^6 (  .H$   9              " @>';  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ $H%\5&FLGB@F P
M4P8  !D              ("!<-X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  2@7Q4=1,Y*M<"  #<!0  &0              @('-
MX0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !*!?%38
MHWVLD ,  +8(   9              " @=OD  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ $H%\5$NO P-)!0  = T  !D
M     ("!HN@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M"  2@7Q4>PA?'[(#  !H"   &0              @($B[@  >&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !*!?%1^OJDL7 4  "$.   9
M              " @0OR  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!
M A0#%     @ $H%\5%V.==R(!   K!T  !D              ("!GO<  'AL
M+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  2@7Q49=SHGE,%
M  !@&   &0              @(%=_   >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;%!+ 0(4 Q0    ( !*!?%0MPI&Y;0,  *P/   9              "
M@><! 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ $H%\
M5,YK^:P'"   -"D  !D              ("!BP4! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  2@7Q4$%PFP_X"  "'"@  &0
M        @(')#0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( !*!?%0SR0\$A0(  %L&   9              " @?X0 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ $H%\5)^)J4W_ @  TP<
M !D              ("!NA,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  2@7Q4+O<%>GT"  !1!P  &0              @('P%@$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !*!?%0+$HPW
MK (  /L&   9              " @:09 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ $H%\5#0B0M!( @  A 4  !D
M ("!AQP! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  2
M@7Q4DVLW35H"  !$!0  &0              @($&'P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !*!?%1U!G/8&P0  *D2   9
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M970T."YX;6Q02P$"% ,4    "  2@7Q4*1;MXH(&  !F)0  &0
M    @($J. $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M !*!?%2O'H58B ,  ) ,   9              " @>,^ 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ $H%\5#>-< H+"0  =#4  !D
M             ("!HD(! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  2@7Q4ZO&;^(L$   ,$0  &0              @('D2P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !*!?%0#")6>00,
M (@+   9              " @:90 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ $H%\5- ''(G7 @  =0@  !D              ("!
M'E0! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  2@7Q4
M!#'OS<,"  #Z!@  &0              @($L5P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( !*!?%1:%-;%<@,  *P-   9
M      " @29: 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ $H%\5-:MZ.@' P  ?@@  !D              ("!SUT! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  2@7Q4(TZ;_68#   ;#
M&0              @($-80$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( !*!?%1"GQ8,2 ,  .X)   9              " @:ID 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ $H%\5(M/F@Z^
M!0  "Q<  !D              ("!*6@! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  2@7Q4&'NW ;4#  "^#   &0
M@($>;@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !*!
M?%1/?P*O6 0  'X6   9              " @0IR 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ $H%\5.!F('7F!   *Q4  !D
M         ("!F78! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M    "  2@7Q4ZV9X]UH#  ">"0  &0              @(&V>P$ >&PO=V]R
M:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( !*!?%331?&;'0,  !82
M   -              "  4=_ 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !( $@ KQ,  "J- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>262</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - COMBINED AND CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets</Role>
      <ShortName>COMBINED AND CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows</Role>
      <ShortName>COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/BusinessCombination</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RevenueRecognition</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/FairValueOfFinancialInstruments</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://hyperfine.io/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - CONVERTIBLE PREFERRED STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/ConvertiblePreferredStock</Role>
      <ShortName>CONVERTIBLE PREFERRED STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/StockholdersEquityDeficit</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - EQUITY INCENTIVE PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlan</Role>
      <ShortName>EQUITY INCENTIVE PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RevenueRecognitionTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/RevenueRecognition</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - IINVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IinventoriesTables</Role>
      <ShortName>IINVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/PropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - CONVERTIBLE PREFERRED STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/ConvertiblePreferredStockTables</Role>
      <ShortName>CONVERTIBLE PREFERRED STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/ConvertiblePreferredStock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - EQUITY INCENTIVE PLAN (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanTables</Role>
      <ShortName>EQUITY INCENTIVE PLAN (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/EquityIncentivePlan</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hyperfine.io/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Significant customer, percentage of revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Significant customer, percentage of revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful lives of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful lives of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - BUSINESS COMBINATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>BUSINESS COMBINATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - REVENUE RECOGNITION - Summary of Disaggregated Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails</Role>
      <ShortName>REVENUE RECOGNITION - Summary of Disaggregated Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - REVENUE RECOGNITION - Information about Receivables and Deferred Revenue from Contracts with Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails</Role>
      <ShortName>REVENUE RECOGNITION - Information about Receivables and Deferred Revenue from Contracts with Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - REVENUE RECOGNITION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>REVENUE RECOGNITION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - REVENUE RECOGNITION - Additional Information (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1</Role>
      <ShortName>REVENUE RECOGNITION - Additional Information (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - INVENTORIES - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails</Role>
      <ShortName>INVENTORIES - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - INVENTORIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/InventoriesAdditionalInformationDetails</Role>
      <ShortName>INVENTORIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Schedule of Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - NOTES PAYABLE - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://hyperfine.io/role/NotesPayableAdditionalInformationDetails</Role>
      <ShortName>NOTES PAYABLE - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - CONVERTIBLE PREFERRED STOCK - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED STOCK - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - CONVERTIBLE PREFERRED STOCK - Summary of Authorized, Issued and Outstanding Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED STOCK - Summary of Authorized, Issued and Outstanding Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hyperfine.io/role/StockholdersEquityDeficit</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - EQUITY INCENTIVE PLAN - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - EQUITY INCENTIVE PLAN - Assumptions Used to Value Option Grants to Employees and Nonemployees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN - Assumptions Used to Value Option Grants to Employees and Nonemployees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN - Summary of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - EQUITY INCENTIVE PLAN - Key Assumptions Used in Valuation for Earn-Out Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN - Key Assumptions Used in Valuation for Earn-Out Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - NET LOSS PER SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - NET LOSS PER SHARE - Schedule of Anti-dilutive Common Equivalent Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Anti-dilutive Common Equivalent Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - INCOME TAXES - Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d284543dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hyperfine.io/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hyperfine.io/role/CommitmentsAndContingencies</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" original="d284543dposam.htm">d284543dposam.htm</File>
    <File>d284543dex231.htm</File>
    <File>hypr-20211231.xsd</File>
    <File>hypr-20211231_cal.xml</File>
    <File>hypr-20211231_def.xml</File>
    <File>hypr-20211231_lab.xml</File>
    <File>hypr-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g284543g22s22.jpg</File>
    <File>g284543g23s23.jpg</File>
    <File>g284543g26s26.jpg</File>
    <File>g284543g27s27.jpg</File>
    <File>g284543g28s28.jpg</File>
    <File>g284543g29s29.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="702">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d284543dposam.htm": {
   "axisCustom": 0,
   "axisStandard": 34,
   "contextCount": 262,
   "dts": {
    "calculationLink": {
     "local": [
      "hypr-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hypr-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d284543dposam.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hypr-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hypr-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hypr-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 592,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 5
   },
   "keyCustom": 76,
   "keyStandard": 268,
   "memberCustom": 55,
   "memberStandard": 51,
   "nsprefix": "hypr",
   "nsuri": "http://hyperfine.io/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://hyperfine.io/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - REVENUE RECOGNITION",
     "role": "http://hyperfine.io/role/RevenueRecognition",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "role": "http://hyperfine.io/role/FairValueOfFinancialInstruments",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - INVENTORIES",
     "role": "http://hyperfine.io/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://hyperfine.io/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - NOTES PAYABLE",
     "role": "http://hyperfine.io/role/NotesPayable",
     "shortName": "NOTES PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - CONVERTIBLE PREFERRED STOCK",
     "role": "http://hyperfine.io/role/ConvertiblePreferredStock",
     "shortName": "CONVERTIBLE PREFERRED STOCK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://hyperfine.io/role/StockholdersEquityDeficit",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - EQUITY INCENTIVE PLAN",
     "role": "http://hyperfine.io/role/EquityIncentivePlan",
     "shortName": "EQUITY INCENTIVE PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - NET LOSS PER SHARE",
     "role": "http://hyperfine.io/role/NetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - COMBINED AND CONSOLIDATED BALANCE SHEETS",
     "role": "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
     "shortName": "COMBINED AND CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - INCOME TAXES",
     "role": "http://hyperfine.io/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://hyperfine.io/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://hyperfine.io/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - REVENUE RECOGNITION (Tables)",
     "role": "http://hyperfine.io/role/RevenueRecognitionTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - IINVENTORIES (Tables)",
     "role": "http://hyperfine.io/role/IinventoriesTables",
     "shortName": "IINVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://hyperfine.io/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - CONVERTIBLE PREFERRED STOCK (Tables)",
     "role": "http://hyperfine.io/role/ConvertiblePreferredStockTables",
     "shortName": "CONVERTIBLE PREFERRED STOCK (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
     "shortName": "COMBINED AND CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - EQUITY INCENTIVE PLAN (Tables)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanTables",
     "shortName": "EQUITY INCENTIVE PLAN (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - NET LOSS PER SHARE (Tables)",
     "role": "http://hyperfine.io/role/NetLossPerShareTables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://hyperfine.io/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Significant customer, percentage of revenue (Details)",
     "role": "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Significant customer, percentage of revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "role": "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "hypr:ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful lives of property and equipment (Details)",
     "role": "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful lives of property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "hypr:ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn07_07_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - BUSINESS COMBINATION - Additional Information (Details)",
     "role": "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
     "shortName": "BUSINESS COMBINATION - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn07_07_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - REVENUE RECOGNITION - Summary of Disaggregated Revenues (Details)",
     "role": "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails",
     "shortName": "REVENUE RECOGNITION - Summary of Disaggregated Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - REVENUE RECOGNITION - Information about Receivables and Deferred Revenue from Contracts with Customers (Details)",
     "role": "http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails",
     "shortName": "REVENUE RECOGNITION - Information about Receivables and Deferred Revenue from Contracts with Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hypr:RevenueRecognizeReceivablePaymentTermsRangeMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - REVENUE RECOGNITION - Additional Information (Details)",
     "role": "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails",
     "shortName": "REVENUE RECOGNITION - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "hypr:RevenueRecognizeReceivablePaymentTermsRangeMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "COMBINED AND CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - REVENUE RECOGNITION - Additional Information (Details1)",
     "role": "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1",
     "shortName": "REVENUE RECOGNITION - Additional Information (Details1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021_2022-01-01TypedMemberusgaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "hypr:RevenueRemainingPerformanceObligationExpectedTimingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "role": "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - INVENTORIES - Summary of Inventories (Details)",
     "role": "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails",
     "shortName": "INVENTORIES - Summary of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - INVENTORIES - Additional Information (Details)",
     "role": "http://hyperfine.io/role/InventoriesAdditionalInformationDetails",
     "shortName": "INVENTORIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and equipment, net (Details)",
     "role": "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Schedule of Property and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional Information (Details)",
     "role": "http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "hypr:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - NOTES PAYABLE - Additional Information (Details)",
     "role": "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails",
     "shortName": "NOTES PAYABLE - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn08_10_2020_HyperfinePayrollProtectionProgramLoanMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - CONVERTIBLE PREFERRED STOCK - Additional Information (Details)",
     "role": "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "CONVERTIBLE PREFERRED STOCK - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn07_06_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - CONVERTIBLE PREFERRED STOCK - Summary of Authorized, Issued and Outstanding Convertible Preferred Stock (Details)",
     "role": "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
     "shortName": "CONVERTIBLE PREFERRED STOCK - Summary of Authorized, Issued and Outstanding Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn07_06_2021",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Additional Information (Details)",
     "role": "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - EQUITY INCENTIVE PLAN - Additional Information (Details)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
     "shortName": "EQUITY INCENTIVE PLAN - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "lang": null,
      "name": "hypr:ShareBasedPaymentArrangementPlanModificationIncrementalValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2020_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock Option Activity (Details)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
     "shortName": "EQUITY INCENTIVE PLAN - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - EQUITY INCENTIVE PLAN - Assumptions Used to Value Option Grants to Employees and Nonemployees (Details)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
     "shortName": "EQUITY INCENTIVE PLAN - Assumptions Used to Value Option Grants to Employees and Nonemployees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock Options Granted (Details)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails",
     "shortName": "EQUITY INCENTIVE PLAN - Summary of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "hypr:ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_HyperfineEquityIncentivePlanMemberusgaapPlanNameAxis_ShareBasedPaymentArrangementEmployeeMemberusgaapGranteeStatusAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - EQUITY INCENTIVE PLAN - Key Assumptions Used in Valuation for Earn-Out Shares (Details)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails",
     "shortName": "EQUITY INCENTIVE PLAN - Key Assumptions Used in Valuation for Earn-Out Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021_EarnOutSharesMemberusgaapAwardTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - EQUITY INCENTIVE PLAN - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "EQUITY INCENTIVE PLAN - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - NET LOSS PER SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - NET LOSS PER SHARE - Schedule of Anti-dilutive Common Equivalent Shares (Details)",
     "role": "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails",
     "shortName": "NET LOSS PER SHARE - Schedule of Anti-dilutive Common Equivalent Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "INCOME TAXES - Schedule of Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
     "shortName": "COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "role": "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate (Details)",
     "role": "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - INCOME TAXES - Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward (Details)",
     "role": "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails",
     "shortName": "INCOME TAXES - Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021_HyperfineMemberdeiLegalEntityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)",
     "role": "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn01_31_2018",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DueFromEmployeesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "hypr:DeferredGrantFundingCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://hyperfine.io/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "lang": null,
      "name": "hypr:NumberOfSites",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Site",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "role": "http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - BUSINESS COMBINATION",
     "role": "http://hyperfine.io/role/BusinessCombination",
     "shortName": "BUSINESS COMBINATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284543dposam.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 111,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hypr_AccruedBonusAndOtherCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "hypr_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued bonus and other costs current.",
        "label": "Accrued Bonus and Other Costs Current",
        "terseLabel": "SPAC bonus and other costs"
       }
      }
     },
     "localname": "AccruedBonusAndOtherCostsCurrent",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_AccruedContractedServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "hypr_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contracted services.",
        "label": "Accrued Contracted Services Current",
        "terseLabel": "Contracted services"
       }
      }
     },
     "localname": "AccruedContractedServicesCurrent",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_AdjustmentsToAdditionalPaidInCapitalInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital investments.",
        "label": "Adjustments To Additional Paid In Capital Investments",
        "terseLabel": "Investment from 4Bionics, LLC"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalInvestments",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_AllocationOfExpenseIncurredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of expense incurred.",
        "label": "Allocation Of Expense Incurred [Member]",
        "terseLabel": "Allocation of Expense Incurred"
       }
      }
     },
     "localname": "AllocationOfExpenseIncurredMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_AmendedAndRestatedTechnologyServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated technology services agreement.",
        "label": "Amended And Restated Technology Services Agreement [Member]",
        "terseLabel": "ARTSA"
       }
      }
     },
     "localname": "AmendedAndRestatedTechnologyServicesAgreementMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_BusinessCombinationExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, exchange ratio.",
        "label": "Business Combination Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "BusinessCombinationExchangeRatio",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "hypr_BusinessCombinationPaymentOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination payment of transaction costs.",
        "label": "Business Combination Payment of Transaction Costs",
        "terseLabel": "Payment of transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationPaymentOfTransactionCosts",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_BusinessCombinationTransactionThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination transaction threshold consecutive trading days.",
        "label": "Business Combination Transaction Threshold Consecutive Trading Days",
        "terseLabel": "Business combination transaction threshold consecutive trading days."
       }
      }
     },
     "localname": "BusinessCombinationTransactionThresholdConsecutiveTradingDays",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_BusinessCombinationTransactionThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination transaction threshold trading days.",
        "label": "Business Combination Transaction Threshold Trading Days",
        "terseLabel": "Business combination transaction threshold trading days"
       }
      }
     },
     "localname": "BusinessCombinationTransactionThresholdTradingDays",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from exchange of research and development tax credits.",
        "label": "Cash Received From Exchange Of Research And Development Tax Credits",
        "terseLabel": "Cash received from exchange of research and development tax credits"
       }
      }
     },
     "localname": "CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_CatalyzerCorporation4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catalyzer corporation 4.",
        "label": "Catalyzer Corporation4 [Member]",
        "terseLabel": "4C"
       }
      }
     },
     "localname": "CatalyzerCorporation4Member",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ClassAOrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A ordinary shares.",
        "label": "Class A Ordinary Shares [Member]",
        "terseLabel": "Class A Ordinary Shares"
       }
      }
     },
     "localname": "ClassAOrdinarySharesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ClassBOrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B ordinary shares.",
        "label": "Class B Ordinary Shares [Member]",
        "terseLabel": "Class B Ordinary Shares"
       }
      }
     },
     "localname": "ClassBOrdinarySharesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock number of votes per share.",
        "label": "Common Stock Number Of Votes Per Share",
        "terseLabel": "Common shares, votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_CommonStockRemainsAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock remains available for issuance.",
        "label": "Common Stock Remains Available For Issuance",
        "terseLabel": "Common stock remain available for issuance"
       }
      }
     },
     "localname": "CommonStockRemainsAvailableForIssuance",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hypr_CommonStockSubjectToRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock subject to redemption.",
        "label": "Common Stock Subject To Redemption",
        "terseLabel": "Common stock subject to redemption"
       }
      }
     },
     "localname": "CommonStockSubjectToRedemption",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "hypr_ConnecticutOthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Connecticut others.",
        "label": "Connecticut Others [Member]",
        "terseLabel": "Connecticut Others"
       }
      }
     },
     "localname": "ConnecticutOthersMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ConnecticutResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Connecticut research and development.",
        "label": "Connecticut Research and Development [Member]",
        "terseLabel": "Connecticut Research and Development"
       }
      }
     },
     "localname": "ConnecticutResearchAndDevelopmentMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ConversionOfLiminalCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Liminal Common stock",
        "label": "Conversion of Liminal Common stock"
       }
      }
     },
     "localname": "ConversionOfLiminalCommonStock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_Covid19OutbreakPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Covid 19 outbreak.",
        "label": "Covid 19 Outbreak [Policy Text Block]",
        "terseLabel": "COVID-19 Outbreak"
       }
      }
     },
     "localname": "Covid19OutbreakPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C.",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer D.",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer E.",
        "label": "Customer E [Member]",
        "terseLabel": "Customer E"
       }
      }
     },
     "localname": "CustomerEMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer F.",
        "label": "Customer F [Member]",
        "terseLabel": "Customer F"
       }
      }
     },
     "localname": "CustomerFMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer G.",
        "label": "Customer G [Member]",
        "terseLabel": "Customer G"
       }
      }
     },
     "localname": "CustomerGMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_CustomerHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer H.",
        "label": "Customer H [Member]",
        "terseLabel": "Customer H"
       }
      }
     },
     "localname": "CustomerHMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying amount of deferred grant funding as of balance sheet date, classified as current.",
        "label": "Deferred Grant Funding Current",
        "terseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_DeferredRevenuePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Deferred revenue policy.",
        "label": "Deferred Revenue Policy [Policy Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenuePolicyPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_DeferredTaxAssetsValuationAllowanceIncreased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowance increased.",
        "label": "Deferred Tax Assets Valuation Allowance Increased",
        "terseLabel": "Deferred tax assets valuation allowance increased"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceIncreased",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_DueFromEmployeesForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from employees forgiveness.",
        "label": "Due From Employees Forgiveness",
        "terseLabel": "Promissory Note with one of the employees will be forgiven"
       }
      }
     },
     "localname": "DueFromEmployeesForgiveness",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_EarnOutSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earn-Out Shares.",
        "label": "Earn Out Shares [Member]",
        "terseLabel": "Earn-Out Shares"
       }
      }
     },
     "localname": "EarnOutSharesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_EarnOutSharesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earn-Out shares.",
        "label": "Earn Out Shares Policy [Text Block]",
        "terseLabel": "Earn-Out Shares"
       }
      }
     },
     "localname": "EarnOutSharesPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EffectiveIncomeTaxRateReconciliationWriteDownOfFederalNolDueTo382Limitation",
        "label": "Write down of federal NOL due to 382 limitation"
       }
      }
     },
     "localname": "Effectiveincometaxratereconciliationwritedownoffederalnoldueto382Limitation",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hypr_Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EffectiveIncomeTaxRateReconciliationWriteDownOfFederalResearchAndDevelopmentCreditsDueTo382Limitation",
        "label": "Write down of federal R&amp;D credits due to 382 limitation"
       }
      }
     },
     "localname": "Effectiveincometaxratereconciliationwritedownoffederalresearchanddevelopmentcreditsdueto382Limitation",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hypr_ExchangeProgramRecognizedNetBenefits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange program recognized net benefits.",
        "label": "Exchange program Recognized Net Benefits",
        "terseLabel": "Exchange program recognized net benefits"
       }
      }
     },
     "localname": "ExchangeProgramRecognizedNetBenefits",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_ExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "ExchangeRatio",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "hypr_FederalAndStateNetOperatingLossesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and state net operating losses.",
        "label": "Federal and state net operating losses [Member]",
        "terseLabel": "Federal And State Net Operating Losses"
       }
      }
     },
     "localname": "FederalAndStateNetOperatingLossesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_FederalNetOperatingLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Net Operating Loss.",
        "label": "Federal Net Operating Loss [Member]",
        "terseLabel": "Federal Net Operating Loss"
       }
      }
     },
     "localname": "FederalNetOperatingLossMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_FederalOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal other.",
        "label": "Federal Other [Member]",
        "terseLabel": "Federal Other"
       }
      }
     },
     "localname": "FederalOtherMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_FourBionicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four bionics.",
        "label": "Four Bionics [Member]",
        "terseLabel": "4Bionics"
       }
      }
     },
     "localname": "FourBionicsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_FourBionicsTwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Bionics 2019 Equity Incentive Plan.",
        "label": "Four Bionics Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "4Bionics Plan"
       }
      }
     },
     "localname": "FourBionicsTwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_GrantAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant awarded.",
        "label": "Grant Awarded",
        "terseLabel": "Grant awarded from the BMGF"
       }
      }
     },
     "localname": "GrantAwarded",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_GrantAwardedForOtherRelatedDeliverables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant awarded for other related deliverables.",
        "label": "Grant Awarded For Other Related Deliverables",
        "terseLabel": "Grant awarded for other related deliverables"
       }
      }
     },
     "localname": "GrantAwardedForOtherRelatedDeliverables",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_GrantAwardedForProvisionAndEquipping": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant awarded for provision and equipping.",
        "label": "Grant Awarded For Provision And Equipping",
        "terseLabel": "Grant awarded for provision and equipping"
       }
      }
     },
     "localname": "GrantAwardedForProvisionAndEquipping",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_GrantFundingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant funding.",
        "label": "Grant Funding Policy [Text Block]",
        "terseLabel": "Grant Funding"
       }
      }
     },
     "localname": "GrantFundingPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_HealthCorCatalioAcquisitionCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCor catalio acquisition corp.",
        "label": "Health Cor Catalio Acquisition Corp [Member]",
        "terseLabel": "HealthCor"
       }
      }
     },
     "localname": "HealthCorCatalioAcquisitionCorpMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_HealthCorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCor.",
        "label": "Health Cor [Member]",
        "terseLabel": "HealthCor"
       }
      }
     },
     "localname": "HealthCorMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_HyperfineConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hyperfine convertible preferred stock.",
        "label": "Hyperfine Convertible Preferred Stock [Member]",
        "terseLabel": "Hyperfine Convertible Preferred Stock"
       }
      }
     },
     "localname": "HyperfineConvertiblePreferredStockMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_HyperfineEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Hyperfine equity incentive plan.",
        "label": "Hyperfine Equity Incentive Plan [Member]",
        "verboseLabel": "Hyperfine Plan"
       }
      }
     },
     "localname": "HyperfineEquityIncentivePlanMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_HyperfineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hyperfine.",
        "label": "Hyperfine [Member]",
        "terseLabel": "Hyperfine"
       }
      }
     },
     "localname": "HyperfineMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_HyperfinePayrollProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hyperfine payroll protection program loan.",
        "label": "Hyperfine Payroll Protection Program Loan [Member]",
        "terseLabel": "Hyperfine PPP loan"
       }
      }
     },
     "localname": "HyperfinePayrollProtectionProgramLoanMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ImmediatelyPriorToEffectiveTimeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immediately prior to effective time.",
        "label": "Immediately Prior To Effective Time [Member]",
        "terseLabel": "Immediately Prior To Effective Time"
       }
      }
     },
     "localname": "ImmediatelyPriorToEffectiveTimeMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_IncentiveUnitActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive unit activity.",
        "label": "Incentive Unit Activity [Member]",
        "terseLabel": "Incentive Unit Grants"
       }
      }
     },
     "localname": "IncentiveUnitActivityMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive unit awards and replacement preferred stock awards.",
        "label": "Incentive Unit Awards And Replacement Preferred Stock Awards [Member]",
        "terseLabel": "Incentive Unit Awards and Replacement Preferred Stock Awards"
       }
      }
     },
     "localname": "IncentiveUnitAwardsAndReplacementPreferredStockAwardsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_IncomeTaxEffectsRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax effects recognized.",
        "label": "Income tax Effects Recognized",
        "terseLabel": "Income tax effects recognized"
       }
      }
     },
     "localname": "IncomeTaxEffectsRecognized",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_InterestAndPaymentsToRedeemingCompanyShareholders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and payments to redeeming company shareholders.",
        "label": "Interest And Payments To Redeeming Company Shareholders",
        "terseLabel": "Interest and payments to redeeming company shareholders"
       }
      }
     },
     "localname": "InterestAndPaymentsToRedeemingCompanyShareholders",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_InterestReceivableRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest receivable related parties current.",
        "label": "Interest Receivable Related Parties Current",
        "terseLabel": "Interest receivable from the Note"
       }
      }
     },
     "localname": "InterestReceivableRelatedPartiesCurrent",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination.",
        "label": "Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination",
        "terseLabel": "Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination"
       }
      }
     },
     "localname": "IssuanceOfClassACommonStockToAServiceProviderInExchangeForTheServiceProvidedInConnectionWithTheBusinessCombination",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_LeasedDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for leased devices.",
        "label": "Leased Devices [Member]",
        "terseLabel": "Leased Devices"
       }
      }
     },
     "localname": "LeasedDevicesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_LegacyHyperfineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy hyperfine.",
        "label": "Legacy Hyperfine [Member]",
        "terseLabel": "Legacy Hyperfine"
       }
      }
     },
     "localname": "LegacyHyperfineMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_LiminalConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liminal convertible preferred stock .",
        "label": "Liminal Convertible Preferred Stock [Member]",
        "terseLabel": "Liminal Convertible Preferred Stock"
       }
      }
     },
     "localname": "LiminalConvertiblePreferredStockMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_LiminalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liminal.",
        "label": "Liminal [Member]",
        "verboseLabel": "Liminal"
       }
      }
     },
     "localname": "LiminalMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails",
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_LiminalPayrollProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liminal payroll protection program loan.",
        "label": "Liminal Payroll Protection Program Loan [Member]",
        "terseLabel": "Liminal PPP loan"
       }
      }
     },
     "localname": "LiminalPayrollProtectionProgramLoanMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of annual limitation of net operating loss and tax credit carryforwards due to ownership change, Under Internal Revenue Code Section 382.",
        "label": "Net Operating Loss And Tax Credit Carry forwards Annual Limitation",
        "terseLabel": "Amount of annual limitation of net operating loss and tax credit carryforwards due to ownership change"
       }
      }
     },
     "localname": "NetOperatingLossAndTaxCreditCarryForwardsAnnualLimitation",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change, under Internal Revenue Code Section 382.",
        "label": "Net Operating Loss And Tax Credit Carry forwards Will Expire Estimation",
        "terseLabel": "Amount of estimated net operating loss and tax credit carryforwards will expire before utilization due to ownership change"
       }
      }
     },
     "localname": "NetOperatingLossAndTaxCreditCarryForwardsWillExpireEstimation",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_NumberOfConsecutiveOwnershipChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive ownership changes.",
        "label": "Number of consecutive ownership changes"
       }
      }
     },
     "localname": "NumberOfConsecutiveOwnershipChanges",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_NumberOfSeparateOptionAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of separate option awards.",
        "label": "Number Of Separate Option Awards",
        "terseLabel": "Number of separate option awards"
       }
      }
     },
     "localname": "NumberOfSeparateOptionAwards",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_NumberOfSites": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of sites for equipping Hyperfine portable point-of-care MRI system.",
        "label": "Number Of Sites",
        "verboseLabel": "Number of sites for equipping Hyperfine portable point-of-care MRI system"
       }
      }
     },
     "localname": "NumberOfSites",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of subsidiaries.",
        "label": "Number Of Subsidiaries",
        "terseLabel": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share.",
        "label": "Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "hypr_NumberOfVotesPerShareEntitledToClassOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share entitled to class of common stock.",
        "label": "Number Of Votes Per Share Entitled To Class Of Common Stock",
        "terseLabel": "Number of votes per share entitled to class of common stock"
       }
      }
     },
     "localname": "NumberOfVotesPerShareEntitledToClassOfCommonStock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "hypr_OperatingLossCarryforwardsBeginToExpireYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards begin to expire year.",
        "label": "Operating Loss Carryforwards Begin to Expire Year",
        "terseLabel": "Begin to Expire in"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeginToExpireYear",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "hypr_OtherAssetsRelatedPartyNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets related party noncurrent.",
        "label": "Other Assets Related Party Noncurrent",
        "terseLabel": "Prepaid advances",
        "verboseLabel": "Other assets - related party"
       }
      }
     },
     "localname": "OtherAssetsRelatedPartyNoncurrent",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_OutstandingLegacyHyperfineConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding legacy hyperfine convertible preferred stock.",
        "label": "Outstanding Legacy Hyperfine Convertible Preferred Stock [Member]",
        "terseLabel": "Outstanding Legacy Hyperfine Convertible Preferred Stock (Series A through D)"
       }
      }
     },
     "localname": "OutstandingLegacyHyperfineConvertiblePreferredStockMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_OwnershipChangeDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership Change description",
        "label": "Ownership Change description",
        "terseLabel": "Ownership change, description"
       }
      }
     },
     "localname": "OwnershipChangeDescription",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hypr_OwnershipChangePercentageTestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership Change percentage testing period",
        "label": "Ownership Change percentage testing period",
        "terseLabel": "Ownership change percentage testing period"
       }
      }
     },
     "localname": "OwnershipChangePercentageTestingPeriod",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hypr_OwnershipChangesAnalysisExpectedToBeCompletedYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership changes analysis expected to be completed year.",
        "label": "Ownership changes analysis expected to be completed year",
        "terseLabel": "Ownership changes analysis expected to be completed year"
       }
      }
     },
     "localname": "OwnershipChangesAnalysisExpectedToBeCompletedYear",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "hypr_OwnershipChangesDateOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership changes Date one",
        "label": "Ownership changes Date one",
        "terseLabel": "Ownership changes date, one"
       }
      }
     },
     "localname": "OwnershipChangesDateOne",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "hypr_OwnershipChangesDateTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership changes Date two",
        "label": "Ownership changes Date two",
        "terseLabel": "Ownership changes date, two"
       }
      }
     },
     "localname": "OwnershipChangesDateTwo",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "hypr_PIPEInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PIPE investors.",
        "label": "P I P E Investors [Member]",
        "terseLabel": "PIPE Investors"
       }
      }
     },
     "localname": "PIPEInvestorsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_PaymentOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of paycheck protection program loan.",
        "label": "Payment Of Paycheck Protection Program Loan",
        "terseLabel": "Payment of paycheck protection program loan"
       }
      }
     },
     "localname": "PaymentOfPaycheckProtectionProgramLoan",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_PayrollProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll protection program loan.",
        "label": "Payroll Protection Program Loan [Member]",
        "terseLabel": "Payroll Protection Program"
       }
      }
     },
     "localname": "PayrollProtectionProgramLoanMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_PercentageNumberOfSharesCeasesToBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage number of shares ceases to beneficially owned.",
        "label": "Percentage Number Of Shares Ceases To Beneficially Owned",
        "terseLabel": "Percentage number of shares ceases to beneficially owned"
       }
      }
     },
     "localname": "PercentageNumberOfSharesCeasesToBeneficiallyOwned",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hypr_PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cash payment in research and development tax credit carryforwards.",
        "label": "Percentage of Cash Payment in Research and Development Tax Credit Carryforwards",
        "terseLabel": "Percentage of cash payment in research and development tax credit"
       }
      }
     },
     "localname": "PercentageOfCashPaymentInResearchAndDevelopmentTaxCreditCarryforwards",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hypr_PercentageOfCommonStockVotingPower": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock voting power.",
        "label": "Percentage Of Common Stock Voting Power",
        "terseLabel": "Percentage of common stock voting power"
       }
      }
     },
     "localname": "PercentageOfCommonStockVotingPower",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "hypr_PostTwoThaousandSeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post two thaousand seventeen.",
        "label": "Post Two Thaousand Seventeen [Member]",
        "terseLabel": "Post-2017"
       }
      }
     },
     "localname": "PostTwoThaousandSeventeenMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_PreTwoThaousandEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre two thaousand eighteen.",
        "label": "Pre Two Thaousand Eighteen [Member]",
        "terseLabel": "Pre-2018"
       }
      }
     },
     "localname": "PreTwoThaousandEighteenMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_PrepaidAdvancesUnrecoverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid advances unrecoverable.",
        "label": "Prepaid Advances Unrecoverable",
        "terseLabel": "Prepaid advances unrecoverable"
       }
      }
     },
     "localname": "PrepaidAdvancesUnrecoverable",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets Policy [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_PrepaidInsurancePolicyInConnectionWithBusinessCombination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid insurance policy in connection with business combination.",
        "label": "Prepaid Insurance Policy in Connection With Business Combination",
        "terseLabel": "Prepaid directors and officers insurance policy in connection with closing of business combination"
       }
      }
     },
     "localname": "PrepaidInsurancePolicyInConnectionWithBusinessCombination",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_ProceedsFromBusinessCombination": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from business combination.",
        "label": "Proceeds From Business Combination",
        "terseLabel": "Net proceeds from equity infusion from the Business Combination"
       }
      }
     },
     "localname": "ProceedsFromBusinessCombination",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_RecapitalizationOfPermanentToTemporaryEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization of permanent to temporary equity shares.",
        "label": "Recapitalization Of Permanent To Temporary Equity Shares",
        "terseLabel": "Conversion of Liminal Common stock (in shares)"
       }
      }
     },
     "localname": "RecapitalizationOfPermanentToTemporaryEquityShares",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "hypr_RecapitalizationOfPermanentToTemporaryEquityValues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization of permanent to temporary equity values.",
        "label": "Recapitalization Of Permanent To Temporary Equity Values",
        "terseLabel": "Conversion of Liminal Common stock"
       }
      }
     },
     "localname": "RecapitalizationOfPermanentToTemporaryEquityValues",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_RelatedPartyTransactionPaymentsForRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction payments for rent.",
        "label": "Related Party Transaction Payments For Rent",
        "terseLabel": "Payments for rent"
       }
      }
     },
     "localname": "RelatedPartyTransactionPaymentsForRent",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_ResearchAndDevelopmentTaxCreditsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for research and development tax credits.",
        "label": "Research And Development Tax Credits Policy [Text Block]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditsPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_ResearchDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research devices.",
        "label": "Research Devices [Member]",
        "terseLabel": "Research Devices"
       }
      }
     },
     "localname": "ResearchDevicesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_RevenueRecognizeReceivablePaymentTermsRangeMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum payment term agreed upon with the respective customer.",
        "label": "Payment terms range, maximum"
       }
      }
     },
     "localname": "RevenueRecognizeReceivablePaymentTermsRangeMaximum",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hypr_RevenueRecognizeReceivablePaymentTermsRangeMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum payment term agreed upon with the respective customer.",
        "label": "Payment terms range, minimum"
       }
      }
     },
     "localname": "RevenueRecognizeReceivablePaymentTermsRangeMinimum",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hypr_RevenueRemainingPerformanceObligationExpectedTimingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Remaining performance obligation expected to be recognized, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingPercentage",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "hypr_SalesAndMarketingDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing devices.",
        "label": "Sales And Marketing Devices [Member]",
        "terseLabel": "Sales and Marketing Devices"
       }
      }
     },
     "localname": "SalesAndMarketingDevicesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for accrued liabilities and other current liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]",
        "terseLabel": "Schedule Of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share-based payment award, earn-out shares, valuation assumptions.",
        "label": "Schedule Of Share Based Payment Award Earn Out Shares Valuation Assumptions Table [Text Block]",
        "terseLabel": "Key Assumptions Used in Valuation for Earn-Out Shares"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEarnOutSharesValuationAssumptionsTableTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of stock options granted to employees and nonemployees.",
        "label": "Schedule Of Stock Options Granted To Employees And Nonemployees Table [Text Block]",
        "terseLabel": "Summary of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsGrantedToEmployeesAndNonemployeesTableTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of useful lives for property, plant and equipment.",
        "label": "Schedule Of Useful Lives For Property Plant And Equipment Table [Text Block]",
        "terseLabel": "Schedule of estimated useful lives of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesForPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 preferred stock",
        "label": "Series A-1 preferred stock",
        "terseLabel": "Series A-1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_SeriesATwoConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-two convertible preferred stock.",
        "label": "Series A-Two Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesATwoConvertiblePreferredStockMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_SeriesBCAndDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B, C and D convertible preferred stock.",
        "label": "Series B, C and D Convertible Preferred Stock [Member]",
        "terseLabel": "Series B, C and D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBCAndDConvertiblePreferredStockMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ServiceAndPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service and performance shares.",
        "label": "Service And Performance Shares [Member]",
        "terseLabel": "Service and Performance Shares"
       }
      }
     },
     "localname": "ServiceAndPerformanceSharesMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, award repurchase right valid period commencing with date of service.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Repurchase Right Valid Period Commencing With Date Of Service",
        "terseLabel": "Repurchase right valid period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRepurchaseRightValidPeriodCommencingWithDateOfService",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value Rollforward",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hypr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Rollforward",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermRollforward",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hypr_ShareBasedPaymentArrangementPlanModificationIncrementalValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment arrangement plan modification incremental value.",
        "label": "Share Based Payment Arrangement Plan Modification Incremental Value",
        "terseLabel": "Incremental value as a result of the modification of the awards"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationIncrementalValue",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_ShareBasedPaymentArrangementSeparateOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment arrangement separate option awards.",
        "label": "Share Based Payment Arrangement Separate Option Awards [Member]",
        "terseLabel": "Separate Option Award"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementSeparateOptionAwardsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment arrangement two separate option awards.",
        "label": "Share Based Payment Arrangement Two Separate Option Awards [Member]",
        "terseLabel": "Two Separate Option Awards"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTwoSeparateOptionAwardsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor.",
        "label": "Sponsor [Member]",
        "terseLabel": "Sponsor"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_StockOptionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options one.",
        "label": "Stock Options One [Member]",
        "terseLabel": "Stock Options One"
       }
      }
     },
     "localname": "StockOptionsOneMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_StockOptionsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options two.",
        "label": "Stock Options Two [Member]",
        "terseLabel": "Stock Options Two"
       }
      }
     },
     "localname": "StockOptionsTwoMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_SubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription agreements.",
        "label": "Subscription Agreements [Member]",
        "terseLabel": "Subscription Agreements"
       }
      }
     },
     "localname": "SubscriptionAgreementsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hypr_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "hypr_TaxCreditCarryforwardBeginToExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward begin to expiration year.",
        "label": "Tax Credit Carryforward Begin to Expiration Year",
        "terseLabel": "Begin to Expire in"
       }
      }
     },
     "localname": "TaxCreditCarryforwardBeginToExpirationYear",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "hypr_TechnologyAndServicesExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology and services exchange agreement.",
        "label": "Technology And Services Exchange Agreement [Member]",
        "terseLabel": "TESA"
       }
      }
     },
     "localname": "TechnologyAndServicesExchangeAgreementMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_TemporaryEquitySharesIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, shares, issuance cost.",
        "label": "Temporary Equity Shares Issuance Cost",
        "terseLabel": "Issuance Costs"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssuanceCost",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series D convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "hypr_TemporaryEquityYearOfClassIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, year of class issuance.",
        "label": "Temporary Equity Year Of Class Issuance",
        "terseLabel": "Year of Class Issuance"
       }
      }
     },
     "localname": "TemporaryEquityYearOfClassIssuance",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "hypr_TradeShowAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade show assets.",
        "label": "Trade Show Assets [Member]",
        "terseLabel": "Trade Show Assets"
       }
      }
     },
     "localname": "TradeShowAssetsMember",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "hypr_UnbilledReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled receivables",
        "label": "Unbilled Receivables",
        "negatedLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivables",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_UncertainTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of uncertain tax positions.",
        "label": "Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositions",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "hypr_WarrantiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warranties.",
        "label": "Warranties Policy [Text Block]",
        "terseLabel": "Warranties"
       }
      }
     },
     "localname": "WarrantiesPolicyTextBlock",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "hypr_WriteOffOfOtherAssetsRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of other assets - related party.",
        "label": "Write Off Of Other Assets Related Party",
        "terseLabel": "Write-off of other assets - related party"
       }
      }
     },
     "localname": "WriteOffOfOtherAssetsRelatedParty",
     "nsuri": "http://hyperfine.io/20211231",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Executive Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r110",
      "r250",
      "r255",
      "r261",
      "r455",
      "r456",
      "r459",
      "r460",
      "r519",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r110",
      "r250",
      "r255",
      "r261",
      "r455",
      "r456",
      "r459",
      "r460",
      "r519",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Dr. Rothberg"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r188",
      "r338",
      "r344",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r266",
      "r293",
      "r362",
      "r365",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r581",
      "r585",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r266",
      "r293",
      "r362",
      "r365",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r581",
      "r585",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r188",
      "r338",
      "r344",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r185",
      "r338",
      "r342",
      "r538",
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r185",
      "r338",
      "r342",
      "r538",
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r266",
      "r293",
      "r351",
      "r362",
      "r365",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r581",
      "r585",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r266",
      "r293",
      "r351",
      "r362",
      "r365",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r581",
      "r585",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r123",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r123",
      "r128",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r186",
      "r187",
      "r338",
      "r343",
      "r583",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r338",
      "r343",
      "r583",
      "r599",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r123",
      "r128",
      "r240",
      "r363",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r189",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201815Member": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update 2018-15 [Member]",
        "terseLabel": "ASU No. 2018-15"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201815Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r54",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r54",
      "r109",
      "r514",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Due to related parties for payments paid on their behalf"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r10",
      "r34",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, less allowance of $32 and $0 in 2021 and 2020, respectively",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r64",
      "r109",
      "r513",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Due from related parties for payments made on behalf of the other entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r56"
     ],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "hypr_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r56"
     ],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "hypr_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r230"
     ],
     "calculation": {
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r35",
      "r407",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r404",
      "r405",
      "r406",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r116",
      "r117",
      "r118",
      "r119",
      "r128",
      "r198",
      "r199",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r249",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r436",
      "r437",
      "r438",
      "r439",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r509",
      "r539",
      "r540",
      "r541",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r367",
      "r370",
      "r410",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r370",
      "r395",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r40",
      "r193",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total anti-dilutive common equivalent shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r168",
      "r177",
      "r183",
      "r201",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r455",
      "r459",
      "r485",
      "r520",
      "r522",
      "r556",
      "r570"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r67",
      "r106",
      "r201",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r455",
      "r459",
      "r485",
      "r520",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r371",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r361",
      "r364",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business combination, shares issued as earn out consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "BUSINESS COMBINATION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Noncash acquisition of fixed assets"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Capitalized internal-use software development costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationMethod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of method used for amortizing cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost, Amortization Method",
        "terseLabel": "Capitalized costs, amortization method"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized costs, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Capitalized contract cost"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r48",
      "r95"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r19",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r19",
      "r96",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r90",
      "r95",
      "r100"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r90",
      "r495"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r112",
      "r113",
      "r115",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r249",
      "r400",
      "r401",
      "r402",
      "r436",
      "r464",
      "r465",
      "r466",
      "r486",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r507",
      "r509",
      "r539",
      "r540",
      "r586",
      "r587",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r112",
      "r113",
      "r122",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r249",
      "r400",
      "r401",
      "r402",
      "r436",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r486",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r507",
      "r509",
      "r539",
      "r540",
      "r586",
      "r587",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r4",
      "r115",
      "r199",
      "r202",
      "r205",
      "r208",
      "r249",
      "r403",
      "r437",
      "r464",
      "r467",
      "r470",
      "r487",
      "r488",
      "r491",
      "r492",
      "r494",
      "r507",
      "r541",
      "r586",
      "r587",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r116",
      "r127",
      "r200",
      "r210",
      "r407",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r103",
      "r106",
      "r131",
      "r132",
      "r133",
      "r136",
      "r138",
      "r146",
      "r147",
      "r148",
      "r201",
      "r250",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r291",
      "r292",
      "r296",
      "r300",
      "r485",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r59",
      "r239",
      "r561",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r247",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value, (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r188",
      "r482",
      "r483",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r188",
      "r482",
      "r483",
      "r598",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r188",
      "r482",
      "r483",
      "r598",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r151",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r156",
      "r157",
      "r188",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r158",
      "r482",
      "r484",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r188",
      "r482",
      "r483",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction In Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Information about Receivables and Deferred Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r317",
      "r318",
      "r339"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r317",
      "r318",
      "r339"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Revenue recognized that was included in the deferred revenue balance at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of Liminal Common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r291",
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r79",
      "r538"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Total cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold [Abstract]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost Of Sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r155",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r105",
      "r110",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r505",
      "r557",
      "r559",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r263",
      "r281",
      "r282",
      "r504",
      "r505",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Amount of note payable"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r58",
      "r105",
      "r110",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r58",
      "r105",
      "r110",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r308",
      "r311",
      "r312",
      "r313",
      "r503",
      "r504",
      "r505",
      "r506",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r431",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r166"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
      "http://hyperfine.io/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails",
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r338",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails",
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Disaggregated Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY INCENTIVE PLAN"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendDeclaredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.",
        "label": "Dividend Declared [Member]",
        "terseLabel": "Dividend Declared"
       }
      }
     },
     "localname": "DividendDeclaredMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.",
        "label": "Dividends [Axis]"
       }
      }
     },
     "localname": "DividendsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r314",
      "r566"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared common stock"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.",
        "label": "Dividends [Domain]"
       }
      }
     },
     "localname": "DividendsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r24",
      "r26",
      "r558",
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromEmployeesNoncurrent": {
     "auth_ref": [
      "r20",
      "r33",
      "r513",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from an Entity employee, not to include stockholders or officers, which are usually due after 1 year (or 1 business cycle).",
        "label": "Due from Employees, Noncurrent",
        "terseLabel": "Promissory Note with one of the employees"
       }
      }
     },
     "localname": "DueFromEmployeesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r11",
      "r20",
      "r32",
      "r109",
      "r253",
      "r255",
      "r256",
      "r260",
      "r261",
      "r262",
      "r513"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r54",
      "r109",
      "r253",
      "r255",
      "r256",
      "r260",
      "r261",
      "r262",
      "r513"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share attributable to common stockholders, basic and diluted",
        "verboseLabel": "Basic and dilutive loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r107",
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Deferred tax adjustment resulting from tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r420",
      "r443"
     ],
     "calculation": {
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfReconciliationOfAnticipatedIncomeTaxExpenseBenefitComputedByStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "hypr_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option Grants",
        "verboseLabel": "Outstanding Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r71",
      "r72",
      "r73",
      "r112",
      "r113",
      "r114",
      "r117",
      "r124",
      "r126",
      "r145",
      "r209",
      "r307",
      "r314",
      "r404",
      "r405",
      "r406",
      "r438",
      "r439",
      "r473",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r588",
      "r589",
      "r590",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value asset transfers, Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r476",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r272",
      "r281",
      "r282",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r477",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r272",
      "r352",
      "r353",
      "r358",
      "r360",
      "r477",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value liabilities transfers, Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r272",
      "r281",
      "r282",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r366",
      "r368",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r78",
      "r106",
      "r168",
      "r176",
      "r179",
      "r182",
      "r184",
      "r201",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r485"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r93",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r168",
      "r176",
      "r179",
      "r182",
      "r184",
      "r554",
      "r562",
      "r564",
      "r578"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r232",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r421",
      "r424",
      "r430",
      "r441",
      "r444",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r125",
      "r126",
      "r167",
      "r419",
      "r442",
      "r445",
      "r579"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r417",
      "r418",
      "r424",
      "r425",
      "r429",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Research and development tax credit receivables"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseDueFromOtherRelatedParties": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables due from related parties classified as other.",
        "label": "Increase (Decrease) Due from Other Related Parties",
        "negatedLabel": "Other assets - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseDueFromOtherRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Due from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r92",
      "r535"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "negatedLabel": "Prepaid inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest-bearing assets owed to the entity by related party.",
        "label": "Interest Income, Related Party",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r41",
      "r219"
     ],
     "calculation": {
      "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r9",
      "r65",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r66",
      "r101",
      "r143",
      "r216",
      "r218",
      "r220",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r42",
      "r219"
     ],
     "calculation": {
      "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/InventoriesSummaryOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-down of inventory",
        "verboseLabel": "Inventory adjustments and excess and obsolete inventory charges"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
      "http://hyperfine.io/role/InventoriesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r81",
      "r165"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leased Devices"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r55",
      "r106",
      "r178",
      "r201",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r456",
      "r459",
      "r460",
      "r485",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r106",
      "r201",
      "r485",
      "r522",
      "r560",
      "r574"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r57",
      "r106",
      "r201",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r456",
      "r459",
      "r460",
      "r485",
      "r520",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiquidationBasisOfAccountingLiquidationPlan": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the plan of liquidation. Includes, but is not limited to, the manner by which assets are expected to be disposed of and other items expected to be sold that had not been previously recognized as assets, the manner by which liabilities are expected to be settled, and the expected date by which liquidation is expected to be complete.",
        "label": "Liquidation Basis of Accounting, Liquidation Plan",
        "terseLabel": "Liquidation rights, description"
       }
      }
     },
     "localname": "LiquidationBasisOfAccountingLiquidationPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "NOTES PAYABLE"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Long term notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r58",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/FairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r90",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r68",
      "r69",
      "r73",
      "r75",
      "r94",
      "r106",
      "r116",
      "r120",
      "r121",
      "r122",
      "r123",
      "r125",
      "r126",
      "r134",
      "r168",
      "r176",
      "r179",
      "r182",
      "r184",
      "r201",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r475",
      "r485",
      "r563",
      "r577"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r129",
      "r130",
      "r135",
      "r138",
      "r168",
      "r176",
      "r179",
      "r182",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Numerator for Basic and Dilutive EPS \u2013 Loss available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentInLeasePurchase": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase from purchase of net investment in sales-type and direct financing leases.",
        "label": "Net Investment in Lease, Purchase",
        "terseLabel": "Payments received on net investment in lease"
       }
      }
     },
     "localname": "NetInvestmentInLeasePurchase",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash information:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reporting segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r168",
      "r176",
      "r179",
      "r182",
      "r184"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Tax net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r7",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/OrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r56"
     ],
     "calculation": {
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "hypr_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.",
        "label": "Other Capitalized Property Plant and Equipment [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Stock issuance costs related to Series D convertible preferred stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r371",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConversionBasis": {
     "auth_ref": [
      "r30",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.",
        "label": "Preferred Stock, Conversion Basis",
        "terseLabel": "Convertible preferred stock, conversion basis"
       }
      }
     },
     "localname": "PreferredStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Convertible preferred stock dividend rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "CONVERTIBLE PREFERRED STOCK"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r12",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Investment from 4Bionics, LLC"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate gross proceeds of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "verboseLabel": "Total Proceeds or Exchange Value"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stock that is classified as callable.",
        "label": "Proceeds from Issuance of Redeemable Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series D convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from issuance of notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
      "http://hyperfine.io/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r84",
      "r399"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Cash proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Liability Contingency [Line Items]",
        "terseLabel": "Product Liability Contingency [Line Items]"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "auth_ref": [
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.",
        "label": "Product Liability Contingency [Table]",
        "terseLabel": "Product Liability Contingency [Table]"
       }
      }
     },
     "localname": "ProductLiabilityContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Device"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r68",
      "r69",
      "r73",
      "r89",
      "r106",
      "r116",
      "r125",
      "r126",
      "r168",
      "r176",
      "r179",
      "r182",
      "r184",
      "r201",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r454",
      "r457",
      "r458",
      "r461",
      "r462",
      "r475",
      "r485",
      "r564"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r51",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r50",
      "r229"
     ],
     "calculation": {
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r21",
      "r22",
      "r231",
      "r522",
      "r565",
      "r575"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r231",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r21",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r21",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r77",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r192",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r359",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r512",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Expenses allocated"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CommitmentsAndContingenciesDetails",
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r359",
      "r512",
      "r513",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses incurred"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Interest rate of the Note"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r359",
      "r512",
      "r516",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r510",
      "r511",
      "r513",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayment of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r415",
      "r537",
      "r619"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r224",
      "r227",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software Development Costs"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Federal Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r19",
      "r95",
      "r100",
      "r555",
      "r572"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r8",
      "r19",
      "r100"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Outstanding RSUs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r314",
      "r407",
      "r522",
      "r573",
      "r592",
      "r597"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r112",
      "r113",
      "r114",
      "r117",
      "r124",
      "r126",
      "r209",
      "r404",
      "r405",
      "r406",
      "r438",
      "r439",
      "r473",
      "r588",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r163",
      "r164",
      "r175",
      "r180",
      "r181",
      "r185",
      "r186",
      "r188",
      "r337",
      "r338",
      "r538"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Total sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r341",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation expected to be recognized, duration"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Aggregate number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r156",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesSignificantCustomerPercentageOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesTypeLeaseSellingProfitLoss": {
     "auth_ref": [
      "r144",
      "r508"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of profit (loss) recognized at commencement from sales-type lease.",
        "label": "Sales-type Lease, Selling Profit (Loss)",
        "negatedLabel": "Sales under sales type leases"
       }
      }
     },
     "localname": "SalesTypeLeaseSellingProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareScheduleOfAntiDilutiveCommonEquivalentSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Common Equivalent Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Anticipated Income Tax Expense Benefit Computed by Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r370",
      "r394",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r370",
      "r394",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r17",
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IinventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r51",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r514",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r371",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r376",
      "r383",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Value Option Grants to Employees and Nonemployees"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r60",
      "r103",
      "r146",
      "r147",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r300",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r158",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A",
        "verboseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock",
        "verboseLabel": "Series D"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockBasedCompensationExpenseDetails",
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Total grant date fair value recognized period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units (\"RSU\") granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected annual equity volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk Free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk Free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk Free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Stock options granted",
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Option award to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r378",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding",
        "periodStartLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding",
        "periodStartLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental compensation expense recognized as a result of the modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares entitle to certain employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Stock option grants, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r369",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r368",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r366",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r389",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term (years)",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAssumptionsUsedToValueOptionGrantsToEmployeesAndNonemployeesDetails",
      "http://hyperfine.io/role/EquityIncentivePlanKeyAssumptionsUsedInValuationForEarnOutSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Shares held by sponsor , irrevocably forfeited"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software Development Costs"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "States"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r103",
      "r106",
      "r131",
      "r132",
      "r133",
      "r136",
      "r138",
      "r146",
      "r147",
      "r148",
      "r201",
      "r250",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r291",
      "r292",
      "r296",
      "r300",
      "r307",
      "r485",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails",
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://hyperfine.io/role/StockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r63",
      "r71",
      "r72",
      "r73",
      "r112",
      "r113",
      "r114",
      "r117",
      "r124",
      "r126",
      "r145",
      "r209",
      "r307",
      "r314",
      "r404",
      "r405",
      "r406",
      "r438",
      "r439",
      "r473",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r588",
      "r589",
      "r590",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r145",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Granted value"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r30",
      "r31",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Net equity infusion from the Business Combination (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r62",
      "r274",
      "r307",
      "r308",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r307",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class A common stock to a service provider (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r307",
      "r314",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/EquityIncentivePlanSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r63",
      "r307",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Net equity infusion from the Business Combination"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r63",
      "r307",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r307",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r37",
      "r38",
      "r106",
      "r194",
      "r201",
      "r485",
      "r522"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY (DEFICIT):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r27",
      "r28",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r502",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r502",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r502",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Tax Net Operating Loss Carryforward and Tax Credit Carryforward"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails",
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesScheduleOfTaxNetOperatingLossCarryforwardAndTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r18",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r250",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262"
     ],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Hyperfine convertible preferred stock (Series A, B, C and D): $.0001 par value, aggregate liquidation preference of $0 and $147,651; 0 and 129,788,828 shares authorized; 0 and 95,010,858 shares issued and outstanding at December 31, 2021 and 2020, respectively",
        "verboseLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Convertible preferred stock, aggregate liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference Per Share",
        "verboseLabel": "Initial Liquidation Price per share"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value",
        "verboseLabel": "Issuance Price per share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued",
        "verboseLabel": "Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheetsParenthetical",
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://hyperfine.io/role/ConvertiblePreferredStockAdditionalInformationDetails",
      "http://hyperfine.io/role/ConvertiblePreferredStockSummaryOfAuthorizedIssuedAndOutstandingConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series D convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r18",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Summary of Authorized, Issued and Outstanding Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/ConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r338",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r338",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools, Dies and Molds [Member]",
        "terseLabel": "Tooling"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred at point in time.",
        "label": "Transferred at Point in Time [Member]",
        "terseLabel": "Point In Time"
       }
      }
     },
     "localname": "TransferredAtPointInTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "Over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/RevenueRecognitionSummaryOfDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r116",
      "r117",
      "r118",
      "r119",
      "r128",
      "r198",
      "r199",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r249",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r436",
      "r437",
      "r438",
      "r439",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r509",
      "r539",
      "r540",
      "r541",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedBalanceSheets",
      "http://hyperfine.io/role/RevenueRecognitionInformationAboutReceivablesAndDeferredRevenueFromContractsWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r416",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r153",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted",
        "verboseLabel": "Denominator for Basic and Dilutive EPS - Weighted-average common stock"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hyperfine.io/role/CombinedAndConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://hyperfine.io/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467743&loc=d3e20905-112640"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=77885760&loc=SL35686388-199418"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r622": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001193125-22-086634-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-086634-xbrl.zip
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M*3-DEYUEMI'5V>5FE*>=^ -02P,$%     @ $H%\5#@D0?I=T00 -!LT !$
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M@W<P!U=3KW[.H<IIX1[I^]KGMY7Q=>!'H#4X;V/1@8U>1;S+09IZ3IM6QB+
M4T"D[#EQZ'2X,V3"<\(D-H^KC9?N@=TRX3.<%Q@,L1I'HJ/0"G/1WO5:*C!M
M). ?*9.*PV+82QY10R!5>#/@6/9I27\E #R8 Q?0BS@<+A&LX)/SIO96+6HX
M](5+KPXCT1,!# >B2KB>"E8K$P#9C+W#DOQ$$G%ZW/49_L "STD"@@#PG0#2
M]R1B_$W]+?SFL 'R"B(L=N["!!#89[<<@,9A"VQ$R^DSCVB): LW,Q<>: I7
M#8 O10![GP"W&PX& "R"ZYYST^<2L34:  (E,!&\%- W (& D(-5 ]X >[ +
M! I\UO#,D4>V0 1#2%P&H)!2/1X)7D+-M'TA00K%%:<S<@2\'? S "1+'N1>
M-&/#>[^\*\BIV6+K<LB#&W;_.V?1F%B"D^'#P9QB"43_D0/_?,!_/LZU %"E
M/IV$;H(@)E%=?/O1_N&'^IQO-\?&G&]MP"L]?.VISWISOB*.$C[W"UK(]:,F
MO"%B_EG@\?M_\=&<+ZJ")OMA?__H<!**[XHG$6$==#<NO_R"!_@G2<HO3.^0
MROPI!JC^NB/%8.CCR4[?]2-\.RK]NT:_W[N7H%V^TY,85>#1T_P!FNH>'/MF
M".JO,U0.4F_A$2#KF 35>?9B,X76@F=;!C!).$16X'+2!IG?L)C;NGD^H#S>
M?2R@X!$1B.T"$YQ^CP43/,+][8&0R_S'0@@><1-_W1CNW9BXHX\R3"+Z1-;]
M)RU=Z12Y:LC+("=5G2^.'D4*V2C]B&I(++H"M2.4GKS4Y&F>_:LHF,<?AOG>
ME<X/<!*AE[V._ SQ%[(*:W6PE-*Y]"_I1.F3[PK;>WBWU57<;76!NYUR<J[*
MKF%G47P"6O478_M7TWUGOV5K];*Q!1B97YX'HVH.1JM#&04851\!H^H"881<
M4SWZ _ZW4O13D!'5(_C?PF0$[O9PQ7=[N+C=UA3=USZLX&YK'Y17<*$2L?;A
M)ES!7>>Y7>U[/FX?A]'S)&)*^P"CU>.#\5,CSPD/G!J%L<^"$9P4\+_T9-5_
MKRJ,X"2HU><_6;.QSS\U:G_4\-3 2YT5@4U.LAPAU]06>&J\_Z-VN,J[?;];
M6]RI@42_8G0_;C74ZPO9;;93XO95V_4DM]<?P>WUQ7&[T9]K'U<&-CGZ_[AT
MR^J/JRCT$C?^S@<='LDHUI\OHS:/;H7+&_="O@1H-.YY#WVW^K,'[[O'^PJA
MU^=X GY6$1"PUD]3%FO<WX6]_?*N=,H,>-F[U] 4+")5@V,CD5K8VS8AM9G(
M.!SPJ)&B]3O[,XS,UQ+AE YJAH%+5Q3H#+P6\J=Z*)$(PXD?CT=X24,3M)G/
MY35> "?\@L<//';, [<_8-'/E:4H0S8S]IPCK@? -YW<GK..<2"FE%Z&BF<L
M 9EKDF3@A>AX_C1&7MO$63J6 V#M<G&+M]&/(?N784S+7(MEKFDXM_RUO)/K
MV)Y<C]2%'B:GXTTXF5Y(CFP>9RWHY%HJ8UKF>O63R?+7,T^NICVYMD,M?!V;
MJ[E]G+6@DVNIC+F2S+4@BK(GUV;SU[,/)3/!R2P.V[23:S[F.MF$D\ERUBN?
M7,MDS)5DKC56"U_-6_B@J-D\_EH8@[2VZ>1:8^9Z'9NKM7V<M2HGURS&7$GF
M6A!%K<G)9#7#USZY3NW)94^NJ7+F=/LX:U5.KEF,:9EKY4\VRU_+/KF^;M/)
M-1\Y?=V$D\GJA&M^<LUB3,M<KWXR6?YZ[9/KVS:=7&NL%KZ.S?5M^SAK54ZN
M68RYDLRU((JR)]=F\]<YZX2P_S :M?Y*Q!"WE6>-*U6(:80U1>-&X*6#5CP^
M*9=\.<?ZB26F0F*;R.&:2\XBMW_",;U1;BDIE$)AF\B U!N T7<0WASKV6XW
M/<P&QS811C,<#).81UM\6&2J1BDHMHD:;L+0ER="\4;H>ULH'\SH*:#8*FJ(
MF,?;_?"N037'MX\6Z*PHA<(VD<$Y9Y)[VZTPE,!@FTC@NPC$(!FD+I-K%O24
M.^42B]0W54%Z\3?WIL)T^P@G+9?_.! ]T^F8H@960"ZC/.JVBF;9O:79-:79
M/.JVB6;G*9N&:ED@5?>.1GP5BB ^"VX H'EJA<]@U5YVS=C+[M<P]%:_4E>J
M?<^U_G3T3(@\DSAM-;BG5X/+T^KE+8\VA4P75U!N^1Q1A/LV4>@Y@HSYS:SO
M4=KVB+H>Y2FQ'</;<>--[+=TV:4!*TM_*9'-6+6R6^8"P3811=J_"U68>'1&
M%X;BEJ-F4]#WX/,%&ZRN#$H/H.)"">T/;W*;4-X:#/UPQ#E1_.40[X;SF&[<
ML<A;"QU^?*7F^ZD;W"8LM[GOPPF9O]5IW0\!A 6- U@A'/!4;IZ'+L4*K#SJ
M9Z\[4SIFPV";Z.$K#WC$?(!%PX-#$+MA,I2!6T<4<P%BFRC#1 , 1$[X+?=#
M\F1L'5W, 89MHHIF*&/0H#$R8$X:6-^"Z(\CE G(+->CLKVEV!]/@6O;9V&E
M*7!K?7HM%@672=RF/M0%&PFVY GL$7_+VVDG]-8]]7#W3J-PH*)G"'F779P'
M=$]YQ2.:ZWA4/L'*D^=R]TVV>@G,MXGD0 N)(^'&)3XY2W3+V'=._9L$_#91
MWD-N(4M]2Z0^Z[(""CSEGK;,20&ZX/$ES,K0;7,>2ED\@F_8?3/BGHB;+(I&
MW3!"9^#*4].L5=/Q-R<,MHDLFBQF_NAO3&>*AJ%*9CK(D\(U]^&=WA4L<T0W
M?<S%,?)XE/]EY6GC4=M066[3(;--!/*4.ZP_E'3&,,8K-D)(-*((XV[PSXLP
MX%H@YY__"@-B3M99LOH'5]EJ4Y_"8S:_@-MZ>RGWXC3<VEH";EGJ71U'R=I>
M)EMG!"CD81(= Y2$*ZV^A<KY.#RVB1A.P@&7L7";6-L@&DVZY,&V:21Q/P0#
MEZ"6G6EJK,?%.>\QOT4@T/YZ?G,7WO19F$@6>"W1ZX/$+QQX,.L5+7[EZ:D<
M"KE#JQ2"SSB? *"?QB Z<3PM+N!R# _TFIGXVR;F>)C4R9P'LQZO=/Q_)I&0
MGG#'G6Q326CUJ/Y%B>]!UGH NMM$BCK&U1)B&NYKR? 5R+#Q0T9Q>I']E8>]
MB W[ N"RLI2$5^&S5NRJ<_M3X\<V(;(9#@9A0!'UC;E2!&Q,^<($SJR$AER=
MCC'\6.J<19V%0V$#"''1AYREN?EH;GK.E)((>"T<!O!Q]3VM#ZV\B/8MC8]H
M^+Z.QKOLZJA@$/H)YH[-X1R;)GJVUI>V:+$U ^[FE0]B<)O(^6&/A0F(7]^H
MBY=VD$T%S7B.P?:16S,, @X<Z28Q%=.8+Y;G82I=2;J;.]IG"E1>V2>\>=2G
MHZH(QHNXN%A)JEL-CVP^BBT'[VVBMH<\L.M_L"[CS'L.?<^I3&X>J3TFEW]Z
MV;J5I+%G5&^;FWYM!8&%T=:T\G+K0UOS55FSM+40<Z O.-C@W*6TB,MN5[A&
M4P!<W(C8AR_/ D_<"B]1%S"/=_6N).DMR\TZ%\V7 E;3_PR46,I<,&7.C-QM
M\R&+X$$E&TB,K%E,Y5)(;74Y:V8(Z=,P;3EN-L?E#D]Y<Q>N%WO,II>RG5FQ
MOX)$N)*T9=$]%[J/0V"]R^Z)B+@;AY%L]IF(!B9RPZJ@KZ."SL:*I<_%TV?A
M(+T,^'H=I,NBI]7EH+E5A\MMO.9Y&M=L%6EO'M*?ECFK"UT%WA4\'"+D7+YQ
MZ8L/[G(!DL@FQR[;OMVX8WFY[A][-)818<J#/P(1-USX"S:R7F0U$\$S]K=-
M:+[F,0.YZYDR5*5&P,;&)Y?O?IOPGYZ\V]SE8UX@;!-AY$H74,:V2MB^ "!A
MPO8F)VH]<>?;1!Q@)V!)0@#/-HN-N:&PA:11VU9J*-WX]A' <1/;(ECI,!<<
MMH\\&MM$#KG&#-.VODT4\!3WUEBQ;;39Y77[QV;X(Z94%"]NTD9T+#U?U_,$
M^ON8?\6$=Q;H]LW;Y1&9"81MH@9,''%'8WE0B@J.$PG?2-EP 992K$5+J^EK
M5ODP9;O=)G07W<$46 F*VS4?^LPEOBF>VNL89/L(=_BC]K]-9/+X>!E;^^-A
M'7>A6K8M-:-W?[SM!#H?D1POGCIM51P@T(:\#)XC.3>)QI8DB$0 V(3ADY@S
MORP8<_.)E$W"W(/2894Q1^44M 4G_N;>513";/$(+ZUB4.]03E'3VL+=W;1!
MQZ.U4&_G6[\9_4@0K2<=G',F>3_TO;/!, IOB?SE]N)\!CC6$[\W$?-XNQ_>
M-:3DVXA9,F%+H;"F" U#7Y[@94'@?0="W4*4IA5CRD&QGGAMAC!9E%"AP;,
M -&+N-QBY,Z"Q[IB&'M[\LBJ5I^F@&(]\4J]TU$$L>@GQ^::)QPS);:0=U5P
MPTQPK">*3=VQ[<9L*136$Z%6!G_:"-EKVT.L,?)L%[BG%D:U7>"VG<Q#&>?A
MU.:W/+"$ODZ$/AN#ZTGJMG7AZQ3*?J6><:LJ/Q\JFKTATG.5NA4N6D!OG^RT
MO39?CWHW4FZ6-)S?B'C4DGVM)X).,-\" ZFXZ[.QUE_F-YD_T+8Y9VX^$"Q
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MPPA-FY6GIEFK)E$U)PRVB2QL\ZD5:#ZUR@3R%(_<'THZ,XE@'2$D<I7D+\*
M:X&<?_XK#(@YJ<7)ZA]<BW;KS?WB,C"E_H7'0-W2\#-HN+7V!/Q4.FK-242O
MQDF;1[VJU\7TNS %)%24@<>#>/5I[Z&5%YM\;*G%V/!][1@"NT=Y?8 /DFBL
MA?B,!HMEG><V6YO+RY 'X;< V?5XI?+EVN2M&#D_YI;OC^\B$(-DD$:N7N/I
ML_)$N<#[OP??B5&E>:A0P'X>:I:VIM$6NU\CVBK%<WX'"Y!B]MYZYFU4S$ 1
M]8SK<;LTL/+=;Q/^'W?-M'GQ:45[S-[H9/[T,(F. 8S"E3=WX4T_3"0+O L
M$IC5P2:'KSUQY]M$' W/HP[9S+]BPCL+FFPHXJ(EMOF'QTP@;!,U/+ZEK'7Y
M/'RD+.1X>Z5^LJ]%H UY&=A>QTNFC[E?O(0FRT^C31%@!$]<TKW8_/(<:JO;
M3NI+ZZ0^CKGZ<C!'.[B,/!&P:$370^6&\,9@4$4 3-WVFJ+QL>)^;='W<L?Z
MRV#N1$3<C<,H]5K>B-B'L^,L\,2M\!+FKRRZT&,Y;;7X6W%KZXF>Q^M18Y&R
M^8>.$PG?P$PNJ,I2K$5(^_0UJUNOLMUNC&;_,C3V>(HQZ;2U3?-7KB"U*95]
M!KS7D^@>+]BNSJY:9\$MER#2Y;J+M5>S#!^@\!(@;PM]G0T&W!/PJS^Z@M=&
M-V&KVP4%0MSRK%P3Z!7-,)"A+SR,PFCA3M<A'>+%Z0T5L!F0(F*;"^)K3W[S
M>20VD_Q>@ JL6V4ATJ\]1#1%FTMFA0U:"^'Q7KK&=GKI2K>])FC,4$BWAM9=
MOCRY7KB$&\/AS$NXL;'/NH2;AF_K9%\N^ZXT\A^M"GSCS(_[S3"B/$41YDQ%
M3%C<7!5AKHUOC.JPRD1K;R4V$*DI>VV!!-D^[&Z4>_;UO:0K@>IJ[8\:11K6
M;\+L;PK5XG\EL('6+?Q3T"J*/ZU%=<7I:YXRX@4P7L<POMI\87QC8Y^'\0,5
M9UI%C!_\L5_5&'<YZ- B/ WA\&(R3B5XJLJ8$2N+;13?TU9+OY5N<9E(K@+B
M#N:-U:2Q^]6%(!F].\C.1X!<^$?7KAFO65,(O=SHJCWE.U^>CZ=V1!Q[M#!7
M70Z9IKC?9F-OO)3A6F',R%A4H+*_34[]-F>#S0>"):M:\\ODL;'/.W@_9 D>
M\'?:%8R-HM#WKZ(PYE0! /[J16QP'A;3ODYX)SX#HHR2M0B,+UVN4JT?W/!2
MT5_=K7Z8/WT"QBXP?0+07JN.Y8;.B__S,.C%/!H@8-="Z9ZRX&)2Z,L30^XB
MAM!;JR[ND'YO.-R(^JU$[MQ[7RYJW^>X_'FG^=$?U4-SFJ=_3R\&81M2/;(A
MU5R6W1,K62Q&80#E\'!>A2$_]GD*PQ2ZFU;@QM+=B]#=BU7*63&ZLTW67L-4
M63T*L$W6MIT";).U;:< JV-L 06026LQ_[*8+\2)%G#Y?/>$U>5>5I=[25Q:
MK6QS<&GUJ[7$9:V>W?JE%;QJ>%\;1\*-]99^!"*6U^T?>:RN?Y_2F9M<LG94
MJ\]_G;>X<EA3L/WX8&Q+'\_PT*UZP/4K$*;.['HZ06YN <&73L5_"&0OUJQB
M//ML?S$W8]-);<Z4Z,TEM=6O5?E"Z<_+(35;)/>EB^2^#%YMR?SEE\Q_ 4S6
M/EH.?44.K7U<'EXMA[XDARX3D[8]Q2NVIW@9%%OC;YTT\J57D%D:J=FV%:^K
MD5>7AU=[WK^H1KY$3-K#P!X&"R2U)!"*SM"9_\>/]DD.\P/.9!+Q+T*&!_7:
MT2?XU<QB?DJGQ7G*YQS"N)))]>K@SR?,^3MG4<F<21Q]PI^>,.,)&TV9$'YY
MPGR2RAA-W;?Z^0GS?@?T]:>LE'Y[PIQM17PEL^JBQO3S$R8&@OD#Z$\U4L]-
M3^56LBL4?.@B&6!F;Q@]F?HF9\!O3W@08B)+V<QSHZ(XR;NQ33P,7Q&7<8 "
M+OSV%)0E'2D\P:(RJDV[QZ@13YC^W^'T%>-O3YA2M0^=-JGZ]2G3W@4\DGTQ
MG#JS&?# Y._$_2>@@S")7"[5QSYG'@CI7]X!JK_\ O\X,A[Y<."A -UEON@%
MGQSL<L>CSSN% 7?"B_N?G ][[T7PV<D/]WDW_NP,6-03P6XD>OWXD\.2.$R_
MPP'ZJYV'7NIT@>-WNVP@_-$GYW__2L+X,]9BE<X%OW.NPP$+U)=ZI!1_<UC5
M,%M!' X_.=7<%YTPCL.!_HY>*0(\M/&;^[$5^3R&5>S*(7-!JU(C'#WC_>?/
MGI!#GXW@2/)!^1I[EM9SQPD G=#WYAC]I'T^=HT-Z72%SSWG3L1])^YSY\=>
M>\]I<S>)J(R0PP+/:=V[?<PH<?"H%Q)5! ?^]QUSW)WZAXJ#E2 <33B3_T[!
M*I'#LI'Z6#1<\YZ0<41]U)T"C?=!=!%@X?5!>!>QX>/!?1'N_>]_UPZKG_?W
M]W?KA_7]:E7!R)D&L-R>#YZQY]P,CUVS6O"T]>&@W;Z"J%.;F]4Z802R1G^W
MZX9^& %!]#IOJA4'__=V?(@6,35<;/$76L@GAPI@/9-C'['5_7FV6E_7K2Y,
M^-8.Q^%TL"!&?;:\5$M[+-Q^7)S=M$Z<]DWCIM4N$WDO \5%B;M7@F*[U?QQ
M?79S!B!L7)PXK?\TOS4NOK:<YN7W[V?M]MGEQ8N!MKJZH*T^!;2_,=#^@EX<
M!A7G9*^Y!V?S^X./#X!SU4^9!S50M3Y:&"F32O1J25JO_4]1*S444Y#HA\\3
MUA,/+U=8+X\C/JZLQ/[X%,*ZNFS?[+9.3UO-F[-_MYS&]];%"?S_QKFXW'-J
MSLWEZPGQ10'V]/+Z^^)UU5]@9&!FW)7<W17WNWWA@7GT2?WGH'9TM'_XH0[R
M?+?VRSL<_^4!==8>B=/ ?=WZ>M:^N6[<X.%'Z@51Z>8=@UHN!F$T8/X3R+)\
M/KRQ$FZ9OG;2NGZT:6IA60;+FV\M)Z^Y-6^<RU.G]G%_?RX 6R7#*AD&??7Z
MRFH9:FF/9B5Q_RD( _+*"]<)&-X4>EQ\:M'-EG$K!?$%_++CZ&NI:]Y5]8Q+
MLG)VOJ1A/A7G+'#WR$F;O>/+2YT-$PKARIRT3U((W[3NF1L3AIRPZT0I9APF
M'3GD+E[8>HX('!%+Q^VS"*9_:PVH39=MJXC"__-?O\2LXW, N.\/F>?!/+_N
M5'?HLYZ7/D]@\5Y?LRB0JF_<)(H <824%+>U:O5_GN.$USB#27TVE/"M^2O]
MJ;#_'=I35 *R[%=O[%YI_^!_$-+O8J_X,X4^NLPW5*DP4SK4S%0OG\G  B#Q
MK$GAGZAD@P:P8R"=!.:0]?AN)^+LYZX(I/#@>W8;$OG/W#D0U>?/.08M9?'E
MWE^=<)_=,0QOR#/9W"@SM/_0 RNPT_T/!^\W?Y<+]R=\_+!;>W_XL5H_*C,6
MGL<\1VO./&\HSLH)(R>,^SQR_DPB(3U!%4A!2?FE$[W[(@(WC(:AOIK$H5&/
M!>)O^OQV\PGRS54DX'P;.0"KP&.1!TJQEV"&-O,)0!2!!LJ;JR#4##WN@*[<
M >UM"Z!SMG>--_>MP= /1SPBB)SI^$,-D6G (,:#?U#3*+S6]3F+"!Y]5'_N
M4U5/!T<LS^:8N-]?&?/P26$6^^]K-.EO($C!NO ](.*(\_BE3+BEA4N\#CB_
M)L+O@G)9 28/ BS4[":Q4ST\V#]:>XC><)\/^V$ [WA3K^Z_7;QC_^#]A]VC
MVH.1)PL#U='*$M_1D_P'#<^+N)05!TYD/T&3S/E;#,'N\7B%PJ5B@T(G((F;
M'PD:,M-#"\Z'__WO#_7:T6?I#",8+(;,=_@]![(6M^BF !G.I75";+P3PAZ@
MY; [8< &;1?6O?8"_G4 > 4BB])12$(U^X)WG58J8"Y)P$06MD^"[9B?WD+1
MZLBO#TZK(UL=^?5T9+SE!&5X<9HRZ^'9!03M2![=PF%EE6&K#*^>,ORR 3G-
M<(@I.G'XZ64CG#;LJ/PNW#[COG.^YYR"*1[^_;>H."WYE]7DG@;/?X;]P+G:
M0\7#PS!T"\IGD&80_UUQSOFM"%"3Z\._ISR*!!RJ%J)/THO]\%;^')'Z<14.
M>5@!4FU:^GP:-"]!=3L5 0M<P7RG29"QH'P2*(]#24D[WYF4S.TG$IZ73K5>
MJ]76'J)Y@^VP=K0$@^W]07WWL+KVZ;36*IC/*C!9^@?CL6L/AEC-9P8TAL,H
MO!<#C,KP*#2C"[;H8, #E\KAX&<8,0PE]QS)? Z[HO3Y8=(!5?V3\QPH/(ZW
M&A) 'P88O3J,&/IY*&*0=5$4XY)XMXONG]ML)W%?R/3NB4(#I*GSLY<'N_-*
MT'\= 7S6!:5@I.##'9F50.AP]$<H>/$($ X (Q">@IF'?@I$?H>NZ<S/S/$X
M3(X?(@KV%D$2)C 5D_#<,(ED@A''\-QU L@ZJ+UW$@"J0EBN^D+#)5*C' NW
MS]V?-* ;^GYXAXOJA/>ZHH#ZU_G?__YX='#X>;;':F/QEV%%F,(6 &*#.?1'
MZ4IW>?2B4XD%"GL(TTGL'-;?=-Y.15#%&?J<23X-0:1J^K"",N26<Z%VAQE:
MY"SRL0)9QLE3'L.M$/&JX':UH0*!$'T<6/J _S('Q'>\FP$5@!9X"HY$.J6$
MX,XB!$L!6T !GJ6 !5# 6>!A7")W.B,--!CVT[GK<XJ Q1WD4G,(63[, SAR
M7; F8-N '\12A%<)I=\NWLH(PF!7JT:E+Y0#YL.?L/)A&,6(>U :AZ!55!QU
MR "*$!8]IQ>%=W'?_(P5ESCMV>-=$= A)1'S&!94KWZ>MG/ZN?;9#'MPP-3U
MF7%(IGKLE*6:D2)0'+%P&-?JG=VZ!K*F_;3^%'#+7HE2NHI6G4W=H26^7T+"
MS>$RLGAJ'Y8PZ>MG!J5K/$<1HL@T)R;4%R0KEA 7GWN 3IQ'O^+1+VJ\ZM:F
M(%F7!2"A4YBT4$QL@I\FE@+LB34V?MVI[ZSE#*_. P\D:9\BK32!=GHA%AJ=
M)T<;M:T!BW_=$: R@4VI"QD3U;EZ)AXL(9OJ C21'!_K\U)3>S%/?.G4?_@"
MC-U6FHMZ+E5?U$>MF2QSGP]0#JWN.)& &RD?3SF?.F'H<]!SHX3G8%J"1BMA
M5EG"S+&[!5/FPM[XZ,=:VCQ0#RH;8578T:SM*ZVJJ=:S=+9<7 ;=QGI?IEO
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MTXGT#;QCOUK-OT-/DR45$N+\4.8<[J7L4,)&L!9?\ 0?^\?^7E4M&[0I7U,
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MRX\VW1N!8=-LM4ZL)%D'2?+^XPI"QTJ2;98D1SM?3EIXLW-VT4#W+,H48^2
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M_;!2TPX87;Y09Q2K^'!/*/=Z5N30NAGF)*9PFKJ4U1@D0XS?<S?1UQ86K#/
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MMI;_+?];_G]5_I>)ZP*+8WB?U(4A\2Z08AS"),)SWDM /?5 K?+#H<H$Q"A
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M5'LOUO'A*E#*37M=:3H&6:!*&]*]!DB1H >TE.:^Y:\VP)(8L%X 0UTT.<*
M@L\%?$>=$8RJ0:$O [0YX $5M$^]MD'B,"RZERNR2*:/>3E.F42NBG\*G,1*
M)BN9K&3:$,E$%R 8)8@\WXO".Y!(F6<T#994-5;'/1X%CVA6N-I(.GB:NH.#
MQ,-!&/H6RG2VBL,%B3[FAZKSJ<!"I%$<\$CVQ3 G':W$L1+'2IP-DCB8D#<9
MKU&4)SI)70PZ2215I#;*'TS[<ZD]<NAR+\'T02S?DU"H=:(J7=A+&RM&K!C9
M;#&B*A=0JF"NI[#JT1SE.V98IK=,;YE^,YB>W*DF+2;+.:,\ID"B#1)A;D_"
ML_X0$:?+%YW)@2G$*F\9[V6R^QCM^PAZ5EI8:6&EQ>9(BYS7-6("DRX-IQM/
MJHKWM'QO^=[R_>;P?7:9@8G3N*# M4QNF=PR^08QN<G<H !-C+?0=Z41=Z.$
MVIQ5\*-Q%6A3 .]0*^0D#+M=X7*L9_:3CQP^&/KAB'-R(*1=4:W,L#+#RHS-
MD!E44T)R'7\ATERQ]/,ME?"@TBJZM-EX=(8V&D3@)3*.1OA9]W/CNH*(U3*L
MQ+ 28T,DAHI5R#<(H3@)/^SH,"D./X4#X5+-(JLN6.:WS+\QS(\F JH,U$(J
M43$'<,3'(UTEW_*ZY77+ZYO!ZZC48^=S5<_?YSVL.1FS>QV%E&9_:E_"9_K>
MLK]E?\O^"V5_,J[!V%9\B)\6GJ+9O/SWV<EN[:,F:3#L/8X:?*C2M0H%:+.B
MH*:(^#+YW)8@?PW1?V!+D#^J!'G^M9O:#?QFG@+-:;UI$= -H_(GWC+ATQ&9
M-<OR=.>3L2*T*F-"'XN%6LQ8/%@7[1VOI:P>$L%MZ-_".YP@&70X7F4X?R9>
M3S=[H:+,-+!0EWG/.1L,0_B(L=3*7P%TEOBP")9(JIJ<4,B4*HH<AXXGL/R5
M@_%6D<#ZS:;A R9R /+AF-$M44!H^T(5.YX!-IFX?=5S)20_;*Y"KQ>ZB1IT
MQU5B6E?X\%/:R'#N#E8-ZL ";_:I"O/TQ5!A8ZK\V\%RV[3^9(A(Q,LB] 1C
M'HR.*+\5_$YJI&(2'7;:X7\EB#K$K\(++-T+:<8$. ,@_9/3X+ #_*8(!*":
M#(DB9BP-PU54 ?%<L6I71  B&!50>'PWI@+KFKS@CY%JD3=@6-?XKL]5=@V,
MU!C%E0? *CERK9AR9]E;R.-])R3,P>]=/L1:XZ:^=7J#1KO+!][*#"\8@_OZ
MC5D:Q7WG&>4G: Z!Y@[U]Q1^4;>$8UP!(,J%%!C(Y#A$\0SE*V2\HHM63_#*
M0Y7@J<(UK!XDE)L0?1NAHM:L!8&J,C^NO:@&O#K6"7_--U:J ,Y4-7+)J40-
MMOH3,;*<+L$]J6/@WZFR]FBA.F4^#-,4[N3P:]B@<ZK$5)Z:]DQ-\*UKS-!6
M DNGRPVPZ94B!FG( ;XN5N(W= EOI;MP+?-T%C!BGUC9'U$=@ER?!*I*A&72
MPPAOPBOC;(!T?\O4#9AY"?Y(I>D70_F_ATE>1E.K6UQNHH0UL9_J]O# 1+;]
MSZKJ6>^M[OT4W=NX56IP.LO0%QZMM5IQ\']OQR<E)!3FU-_<[^9AL%,&<?AM
M[_W_.+NUO3K\A_[&?U+_S<>C[,%B;Z)]VYOH88'^X_MW;$QT>>K<?&LY5]>7
M[:M6\^;'RC8@>ED-@!H1P9$TP'.F#^CS57=BR=/6.IGAI3MZE';[0&7("P$F
M>(YHJP-$0YK@GI^'FM)HK4ZDYA(HY-AKAPZ[GZIFCU:O*#/5XZY0QD=AS?#G
M7W!H4A=)?!:KBJ*6%?%X9)K TS'N8?B:/_^.]IQCU?12KV:D[JHFUJ.L)WTL
M4W%##)M+=?4*;4J?L2[8M-W$I[9ZS%-O5(LMV*Q95YYQR"FCP'2FSFEO%:.Q
MZ=^^I\V7\(O:T6?IG&3Z+2*K$3!_) 496Z=I*&_37,/3F.NL=\]EZJ8S;S*U
M"+(XX)QUE0*6^Y+?85>C4A _P(,+$F&U#^LMPV[ZW+3C?$FI=3@5:K]Q\LX0
M@P;A+:.P+D_T*!VL3UTB,S.)^(,YVG= K2-!\14>QV;EV,>5/#GH@J%04VHW
M92KK4)F<,!#8MDI_C/L1-0^;48_GC6&"ZS--K&^5N0^&7((TC-4XU#)=W8<*
M#,YPB.N R35=WX61[^TYE\#.[;LP'$[32=]/NXH8P^/G[*&/>P?#>]),CPZT
M9NI<H1C$O7\W&[M.-Y9M*-W/F=YK>R2!YY:QM@\''^IF<68!! A'8H<T'J5K
M494 @++P -DE<0S"%[&!3A3L$XQ=NJ(,92"L?;Q+ 1.^1ZXGH"0X,VY5WS2@
M(<"<(VEGQH4'(^"T2*2R;'+(@Y=W5:\JYDM5&>ZGN6A$LG1A@U3.P!/P>C"7
M)%HT##19$,\@Q_&80C-+<%5/10)S8C%Z1TDM7(G'5;D$<IGE>J-V.$<.R.B6
MVI8M_CIEX1-R)D? X[N)J:&IT4P=8[MH U+?0$.1'I= .::41($&%+1%G&=>
M9"?R=0:C5/(S!RQ52A>M:(R0ET?C@! I86-[CA8MP'QTZA+;DFVM/83&/Z-D
M" F%!Z4(#-="*1]E-L'I]@":1B_'S/W94_!"$)<U@%J-@VD%#N@[]%^#60AP
M045/>T)EKGERDZ$R'CH-+%HKE;8%WP_W4C&;CC4B%HZAP#GA+D<'JW)H8$MY
MU5@^FUEYZCU2@O\$!51ZJC0V<@#YF8"E%;;2IM)--@)(.&?29]@66K>T;L?Z
M/N6$^^P.&?(-?JV7=Q(.T.GITE3I*0!B&913WA,RYNJT1JO X?=\,$1+PM4
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MY]>JE6J5_I\CU^F4SI:@<0'B@UT0!!K9Z'0#@6>NXI:21ZWUUA:^^3)]<YL
MD*FMHJL$/] ^"6+5\9*:P(#R&:*HB>\P5(GP[8?4P>4$;\9-"&?<%Q%J;X%
MCZJ^ YT8_9)[O**59WM\(][JVWW@/75.J7,K7>@T4A R;;]'QA@V^C-R\!^U
M]WM 452I'L!7KSIQQ$C(>VRD(A>I3?G(V:\J+ZN;$ WGAFD@4^I/YGB+5> 3
M>F=A;""9FT4^$ZOIO#D1S$7/'8YORU1KW,1]>D,Z5<]VF>RG"8=C%-MGMZ0W
M.K?,3_A#,-IS3C*R6C@-E"*?"'L*'//6-6)/'T0@NC$W5WU2"DG@X1=PB@HR
MT0$>N>\C'D8]%HB_S2TR9@23%6^^HH0N$'8^B_(+P-Q0DF<:(E,Q][84Y902
MN!)H]_%X(# J/-.A$)1/NVRT*[FF8(77UGABO>KA^DHNV,*9#MC+VI6FM_J@
MO+N)B>R:YZB'3Q/1/_G0#_*4&J+"H DW$L-B*)$L^%+:^3'IB])322U5ITG"
MK#(6<:*#>U42!6;&ZWA->+%0#@/S0_Y-5V=7+>?,_)0="7EM1P5\X$/%T:D%
MBM)DFFJB#SF\W(7=]K#GB8H:J]4KA[5QI2,7QS==_<"8Y]3X30^J?]2J>-QD
MIM:4;>;CK5X_!N6U;C;3UC%88V RTBX-V\MIL4#13:<]!(&'QL5YLTBQZON,
M@&9JM@6&8)@BWN6"\OA38B_,7C9@!JW.0XZU]U-I;P[_6!]#[+4]9$!"Q0M$
MA(D0:.)0'0E<M7;=3?/SE>]S&H7:N[U5O=L[LG=[FWVWM[U9OB3R4G?.N5 U
M.;8Y)R$[UF;:QKX@1SX:4<:HA9\OF/387[FH>CD: ,+3L)7?KTPFVD.E'VSR
M3%MG*L/YG<_870WB/!NO7Y/SZ.G"-U(5/BD4"\D2F8UUF2N8XW&T##HJJWJU
M"]V8B/$.!] $FOCQ8'-J^TZGD/_-LHQO4-24J3()M#WGK)LK_9)6C5&E73#;
MP(6ANNR12=VHY'*HW4("=I0E8&=U$IT[PH$O?G)_O#(2\]"#A]\K!P7W]IQV
M.$C]9&HU$?=54;')<D:ZZ0(EY!'A DFA!]$/[Z9GR-D:JK:&ZE;54'VEHR3+
MN^<L\D<@]%!4^:(+S*HS6$#I=?L!$&]OE&;<Z0S\OI!48)EJU,4.F)G4SS5M
MKJ+*(Z)TTXEX6<4]+-:AB_@17\&8'@^H%XLSX PE)QP'IC4L>4V9VQ?\5AG5
M$H0*^H$P5QM$M&X86>@..6%%VE+/5DQ9,;6N8HI*)3!8UH"\2UIY 35*"R$C
M=E"PF!("6-51N'A% N*%X_V$KKJ9EHQ13:6I^:2JJ7DKC#"A@@7H2,:RUMF
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MX.'Z!YRK>D ^EG+$B/NQGFC%&(7,(8Z_91$+)D9!)W_KZ 75] SO"TLB$JQ
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MW?]69EJ9:67F5LA,H^[E*EFA:!-8N&@\O&K/:5# NVDMGZ;G9(\HB9(7)R1
M"@J;E256EEA9LAFRY"H2+H5W8^_T!"LL4%.L5 7+) -V@L_I8]1 ,,V:(7F$
M;B;L9*NK?12FM3+#R@PK,S9#9DR__\-JJ0-T 64N'3X6-3 ,*3@ ["(=6@33
MQY'HJ$).&)84<)^D3?:.M(\IO$+[PJG2[] S\XN@&S&8)R'A5'",YUQ*A:B%
MG'],^\US6@^(,;8LL\F6AEG5TC ?;&F8C2@-8P]>>_!NXL&+'79U?L*X:5],
M(A 2PU\J3L2&PL-#$Z.!=74_O&QV@93(V:K2XWDL\-RCTL\8"I-K+)[6PM!Y
MZC\"\C903UEZ#SD_>R$>L]@?6W0!IT'LF+.X)-3X)SXXENAJ0FX<CP\HL&;6
M]JPM846:%6F;(=(:DF)?(E6L%4M.HGXO<_&"Z36Q*1HD="5A&(FNAD2J?'04
MBQA=TTM\II+KAZ"+$#XJ69 ,?LBB]JCQ@1L&X4"XID:1E*$KZ+J:[FH\$FW9
M(I(8B=54$BJ(0RN7K%RR<FG!<NEF&:76FY?_/CO9K7TTS:- #G 4 7UF(GBI
MOILN (3R9?)&Y)9%(DQ08*BB'&/BJI)6]!B$Y.4PV@ZJ-EIF8>@Q>2IRE\GP
MO4K!4FX*'8&354V/."A$V(YC#D7)Z%QJ.[H:B:F39BZ)M7?%T<4_9I9CJY37
M8J.R_U1OO>N'=S(KD68EH)6 5@*NIV;V(^@"VB,B[9X?=E W,ZI2*A#,A?%X
MP,D<E1U!9)0*$ZM%61EB9<AFR!!=JC'7&PW@P8$@0!/IA0#0@!*WM-%&"D9>
M8S$=T<8SO2I9.+,J#*1*^^0ODLJ2S;16QY+4:A385J3@M\(<>BN"K BR(FA#
M1-"-Z9T5A$XO81$P.>>J'Q5*E=.3AO(F]? 7YWVM^N;G6X<86A7_B9RK[PTL
M Q:%MU@0L5LHK)C6+2-;C D?OT43KD.E7@..=^-8]SR=496%U=--E'),Y=7=
M=+4J%Q+<B\([&YIG)9>57!LHN528#0J5G$3)_-MX%=\/H[1''U;AUZWNDB"F
M?NM=:I6G4Q*R$CXYM4BE+A14JWQR?*[2=3'%2X4-I]/0Y2 ZX]-W6T%D!9$5
M1 L61+^EH6IYBRJ@DABJ H9J#*KR-7G0PV(<V'EP )R*#?> ]1?N2P^[W5V?
M=;BON2#+-%6"!O/<,X,L$R/.H%C,K*P&+';N@2^&/&"^ZJ],X0M_)H%;\!59
M^6+EBY4OZZKH''/ED\D"?B/^5R(BGO,64?$,$@ET?:;;LN>+%>9L,1^4D:1'
MK5!5$Q^3))6U\@*[+VT?F4FLG)4&DA77U!F96D-@,(H!$*Q,R[-Z*E>"BJ1A
M(7V8NL-5.,,0:Z!Y]#2M'/[.!54-,;6"O.!TP:?:.Y.BABV><Q'2F',A)*XC
M3=7*M@F_I.]**RSI)79&#BIBZLW8< 1L0XI^4'D<4^:<\5C1,9> -!ZHKIU]
M%@T(#Q$?)GH="#!KD5I!;07U9@GJ27<^1H_Z_%X%4ND@4^?'7GO/T<$)L/+
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MM*(A1K6JC3':B!BC91W9TRFV(&-KU?J;SMLWM?0$-,>4EEYR^K&@A-ILN1_
M:BE  @0:EM3(FG.X5$V,.@O%(,= ]F+!LECX*F,\YKD7O5$%.BB &]UM])'N
M_-3EGT?!"CTL$:L$8RJ)<Z9[\6BG_&R&*\XB1:AM>W:?R/05 '9=SIY5[^%1
MP;/0,G$8,/-;.E!G'82/ LJ><Y/'"LIIX:5'=^JK=#'FQ=>AJN$0@S)B@U(J
MM.+A6M!GKZ)6U#%F<H *RRO1)X8X "9>N!4 A]ZN(3 M9R;(##4.W*),T SW
M=?Y3;IM@I(@(H!F2NK/G_,85 FDL=L\.QZ&BIIH.%ATXPYFY+;[#Q &68H5>
M*64"#^<027' ,5T*84<(3I5KM!Y&LWO45PN=QUH3HR):8]2.84@J ">8PGNC
M"J&;>;BC$H)*5ZG+H&+440E7/?@\DIY0E^S4[H(>C4 S2>^F,M+-=!\=JA24
MJ)PC#5B=LC9]@Q0P-0L"1@1(Q"IB0>$5E?'>0S2?=>O MV!+8RE03>[H^ 7-
M-5F6M$&FJ\+0RD67S+2GU_ 3_*8+.P+?F@BX*9!30I9@Q"+L_@P;_N3 ": .
M!.4HQ69MS*30 )HE)@".X $'C"4UL!OZ?GAGX-T57<)Z(# X3+NZR,\)NK8.
M[)AT=YT%@B!\I:CD$N%,5@:<2>HM(M>'FI@Z#F/*^@[PCA:V)E$DW_) !9L!
M4?@<5_^/VE[U2$W1 ;B04P_0_<8MF1?EM<<Q<!'%!$;^ 00BK"KBNB!#=#4H
MX>.53E$RI!W["M%N^HH8Q6BL*16(N8_>&+ AER)#&9"TCXVMI"9!>.$_CJI5
MM=F!@D!Z/<12'QH///4GK#&'Y11!$KM">.:GOQ*P<5&31DGWIIZC&-6K=QQ7
M6D32.^G2&[%2+6 %&6HI$(%U4_0#<+8&B<<[<?XD]Y+(4"\(1[K1BSC?)2I7
MHF+/N>8IYV,=+Q'D'(=3&,QX'!2UYD*;QIN/B;2T@SG=]\;5>&MXK9[A5;.&
MU^887L(#@(1N_</!^X/]/PYVYJ;BQ8=!K8DW^N9;R[D\/6U=GUU\?<@%G7]9
M_=G22DWQ"J&+AJPP=%%1^\H',^;FR_T\$<)8>\PB42!-BTVLE\0F*J0NZ 4'
M1T]9J@HRFX3,_&?1W%&AY9&9TTV!73H2EAU:61"A],:5"K8\0P4Q*HD.G E:
M35B&M^>.?DV?&[M GTTK>G\DF8KS&RC2[=B3H*9X,[]T8'. 7O#K3GUG.:^Q
M+/%4EEC%T_B:4X<L,.$HQ<HI9E>1G:9^."[\4'9N+YWOED>[ED4MB[X@T[4Q
M9E=.9;J0O(5IO$ ;E$HT__7]P\BD&+V)^!"FX<J3F _G5_.KD,$K[;:]\IEN
M V%^E6H5VL>B/0E79U<M.-,PLE_5EJ7"8H61NK9AFDU0T;%$.J\@\R2EP5IS
M#"T+XPJC-(HK'TXW+>C.:?0BKBOB9ND$>NWDH#+%P]0^DF$8:%<O%AM3CEN-
M 7WKGN:B<I5&!@-,UT&N;\Z=)!"J;4XZG_(<F2[U<@S914&:1;2=$Q%EF]!X
M>OOBRLTR0JC*.+6V<JD[![7*T='[RL>#0XVUJ6DG]@BQ1X@BU7%9?OP466ZY
M^R4<K^\KU??O*_4/'RQW6^Z>C[M_**U@&(4NY]Y+\NEON49[H#UQC"_!VU>S
ME%QW&6W 44C[8XPX?5DYGXC:<W[#.R=@FZ$.$AE7;,;>2JJH/S*ZJ5:IBAT$
MIV^, BST&_B]RX>QNO/*O9\-\!9=FDEH XE4:EA!I<.IC$:G]4>ZW8^+/ZE4
M._4<=:=P7";[UKEC!</JG&'GP%F[R=!AQDHH.\26*YB:.JY<QRH4JEZ,]U;1
M0XW-1&R&1A*&U(#0R862 !0&QH[#,(PL^-S76U8WZB"'VCP-UYZ\Z,&_4S0]
M&KQ3YA,Q ,&=' XV-:WV)-];GD(?ZI^=QD#%#Z'TO:9X=8Y_Y((,KY&F9&;Q
MY5%I@@!0#'63B$*A,/ \H99;5B99F;0R,NE&N#\QP7PTZ(3^BXLCDX;X^]5U
MGF>F*4.%X]Q63MV\Z)JZC:YY2G3-*\2K. 51:B3^ UC+K5,MLTAI"C8*-.-E
MBB9A, FITGB@_\_>NS:Y;639HM]OQ/T/C(XY$78$JL:2^^U[)T(MV=.:,VYY
M)/4X[OT&DLDB6B3 !H@J<W[]V6L_,G<"8)4DZU&2\*'=JBH2CWSLW(^UU^+7
MF'B+;^+QQJ_^X)OA<3?<2Z,JX/AM!H"BW_WFWYX_??&_%S\\>OSRV?,7=ZSC
M*7CO:*0CA/CU'OJ-G:)'Q@RT%WT3\1(3:I+^V.RN41U8;&DD%NL _X=3ZU7W
MZG+Q_S4]!7XL- (Y5%,$X7.[C?S;Z,;L5N1T(>X+N^9F(?L30'/&2F9/L0X4
MU#$C_S-'-5D@YN1P4DBYA\R<(B\EG>C<HB(DG2*"LA2E/0D[,[4 ?CP&X-]0
M*,U867;?Y+$1]KZJFYM:-&07?%:A02"DEZSVD< T(6W7RC=Q!*3>'KS7]@YR
M*4TL<15AQ&[03;B%)047ZYY[.B>?>D3>>:+Y0.%$9!%VK,T%U01\]20<KS;.
MMW#%W+=5^O=ZA_*1EFMP9\<'JPTL+&;F@?L\]%WJ'U'?XR;$+F']3=\-?T,#
M%3N)M>"C?WF<HW[YCKCX &.BS2%=(H/@#JH,0S]-1='PY8;5M4AQP!](3$>*
M9#Y?9N/EP>-6=L8]^YH3/]%'_ZMM*!E(WE?/PZY4(0[L\1_B=GX<B78Y#U8>
ML"3HXZY'Z?;'GNA=_[7+=>(MWG#]IOYU-&&<Z-,EL_AN( ,E/!1.)2JUSW!K
M#1E>$+?Q[J_#$5N;U4TB^!ZLRB;ABO)R'[)F\P&_L2E>&U"=3+:U5+!]*U?;
M*EP++4?7=YP2@'PTO9LRQF4TRJ^WF-[#K+SMJ,K82,-"S6A.>D\ZTZL-12RU
M#2_]"GQXMY*5@'9-:O%,#X4_@3^HL+1G=1UV)^L-'TZ1\.[1_>V&@U']V3U>
MFG6L@7_Y_6\O_Y1W>N 6__+PV\O?YK^VT H]#MU"$APYG<ZW0J'R0!\>S$7^
MX2\7CSIA39KZ4B&='TB:,/OUOI=-#>:%5<5'SK\\^/;WE]]F3\5'8!?LA1A9
M,/'EF\#BZA4M&II\.P0Y@TXF%9R$%>L^VFF&QK4U?\8+GE5[[G17MI.X%+2)
MGT7*R,NX-KHG'"P=?;W5QAA)@$]/'MT&[?KN:=!9O]O9>4[C2/\G\O,WW#2F
MWX;]UV=D=V<HS!;3:B,AN58)QO@'?XFPV3 Y 2;<$:NG5Y0AMX_!*LBX<*\.
M)(UW)VG9N?&R3G@M,-$<79?E/\@DD#FYZFNS).+)B+B*]6:AB9-M#P8SF1S[
MLY/4 SYELP%1'EXW"8\R<P3&\Y(.U/A2ZNWD;8:I2B$;*MO-M('IT$Q-?/3O
M-6U?S>N!G;ZJN[YEUN"Q &KT]M:5-);*'>0ALA9+[!6Z"7-*[.21Z &X[[%C
M]@EX9G8U?E@SM+<85_,W"^7/7P9FYK1O[$!BCTM-VNG)_L3W?\"_^=&H[==&
M,9)\>#WX/+,]=Z:2>4A=G;2  OKQ,!72W*51PL+$&'4LKZ/PCVS_L*Z4S5X_
M !N/[!PM!39\J#>)1ZTSR5IE7+'"M^3I6"LQ/;*[AG#[OPJ#Z(8>2GEB+<YQ
M9"3];0R.'^ \Y:FP[;J.4V+[=E3%')FH+K37E1@]B8%>Y["50"]-W%YL3 RQ
MY)#=89%9?!75WT4/3N.A9#[80MH:$?8"\B'%K)%G &-@9=34(BU[KVK%GUBP
M/S&0>4B&$ OBQ/R>O(W1Y;>.#:)H)3T<>14,)4$+_5=8#T:/CAY:2TP**LQ%
M'!72;YB4*(CKCW"W7RG]%W]>/R(J5K@Y!]0XP"68K .D.M&BBR=)RIWT:=:]
M%\/-W>%\.I,'WME0%;9-I.2ZY+[KM&'T8KRDT^:B/R!5@*UBDQ0UMLP737(9
M&I^<4J NIDYH'G9-?17:L4G@XR'ZR<Y!SI1)]8B4#$-^R+I#J[O34+Z7$'A\
MJD7&._7[;S.(XMK'E4Q#C7Q*%T+M-H'? (7*BZR,J(]65'GJW)DG>0[\W-?R
M[P:NS6H79-4+#B!(U.;Z[-DHI,G0 TRVT-BO$2<= M_<<RU+>/2QJ0#&+5VZ
M!X,!2O<<C@C"[6]]FD/9'?6:>(LT;@-)F*31GAF8S'I$#1NV'N@&QM0D*\*S
M=V[NU,S$9F)VZRC*76.P0"J"7]*2ZE&CQ,"KT Z<"&.72L>%2P:-']I%B/S2
MO<K!HPR:%,Y#IN=2J'@/.3(M4YRW"V,SCB(^2II"B[?5I$Q\!K_["O.")[1R
M-,'%1 M>;T8$/]4/7!UMJ1I?87K**64>]9#/WFX91EHV9T@<!HGDT<Y?^*U.
M7E1>QWF?.>F)A/J#;_,$O/[WW==.?GWIY,[*R?LHG'P@!.4[Z>G]L("(G]6\
MJDEO2V137?BXTNP;J^5.!JFP)=V$AY, _32D_::$I +'7K?[*NS V6;WH;V@
M4B9CWV)"V!P$-YE7ZEAY!@[VN3WS6=-IPMMVYE'D=.A?_5[IBRV]8J ]$%26
MW5:38OC/(1ZY*3O"!PP?IN#7CT _48:H-1$?>:<FFT(&Z1O#TIR7F"_BY_VD
MRZ+ NKQI6JXPV5K&[R6^V3GV927V%S]'5*DYX7QV-RC$QSWJ^4>4$D(S^:"#
MY$;3>U]7=A<>1^G&7*4'4[*'NX7-!9&0V#*3TC>L,N>J5[E3I;N>7,97_C5E
M\KJFJ3DI5LHFKX=DD5\.!?G/,9%SU9?D;1Z#,M)I$*2N",T7>UE+KS/%?FI,
M=<7=U#*L+K3[S@)%S<UCCJI-3'S]2,<P-*V*"+KKC.MS=/-)V3]\32E'M78)
M3XUQ;). 0*UUH>6*8U?<+"V-5*&$:QDD42:L1^#2"TLRQHSJ+>Q>0K8E<:%A
M>^WBA:S6TJR&1LY93?2LD*#L)ZZ/2DE5LPOZT%B,2_+N5#H#WI]NFPJYF!6Y
M.4+%]TM8&TNJIX?-=LHRI_=C,.<D7I*MZ'6@&8$%D@"EDTB@C&A*=N:]] [G
M$],@RS#>_B66%$&XT@6I\*KD/4M>[D"#UTOVETP)?4-G/$5Z694\83UY5<MH
MI95445BC:3+W!)J&R+QR-I[Z]5W7#,>-#8U8E^.V;?HK&IVVA5US/'),>[%L
M)#7+A>N:]=F\_F=YM)(/V,PTGH2A2A^Y,8=_';JJE43I^1EM ZTCB+1L;:CP
MN"J!E%4.*BF11<N>/Y<M#-FHD6R90O/RNFG]'M=:?DIK:@HT 0ED_*/25#V(
M?\8X!RUI2 9M<*S LQ.BX?%IIE,QW/9I7SMFK1&GUHT"/["'U]6NMS/<Z>IQ
M-"<7\_;#$D+.4"7#1#_5%^$750.\ZV*7B^]IT\4,^8Z3ZI9IYX%U-E@6H'FL
M>E8NFIC2&IR^,=,R/"9M_*J-&:X8B JP.LUY#)SE66B"D/U<< $B7'$90]*<
MD_[I:Y^S]Y$Q_\/&,\_Z*0 09F^S@ZH;/#V7?-Z=AMD?VX^OL,W[B35AU\RJ
M#U9)$"\P;8AF\G'@/I;L)P &Y?,<G-,$C7=?K44$.,1*'2V/.6[A"5920A,G
M%F+(-YKU?)ZS6A+L0M_Y2;UM&5A9U>[#DX@;-\AM1]P6<_@'\8#46R_$=X]'
M  L2]4=8 :649"6].YCX_WS64KB1OC<2HI^!@NCK"HB^CG[H.Y0/?6OUT+<1
M#YVU0^,:5[)E2^-+>,?.$RHPY STK4,0P#"(MY]R <4P;=":;S\%XY#X;."+
M;J)FH"4Q4N@AO9,'5$@2HD12<,=0[F->G:P2/'NZXG>#0X86"3=?6._%F[5>
MS"9I-DFS2?J0)DD2A9PP%S5TQ-::U5-*G!P?>192%BM_:L$T#[#LUU=!(E_Y
MYV)U0H5X-ARSX9@-QZ=K.)!VM6(<)T"]#Q'_N ;Z4]-U(0)NV:OHEVCP.6A9
M$*TR-TC=;:N#H)<\__JF:KNC17*B[/7PX<)S]*<<K=T_DF:0D<)/]%%N-[\)
MGM8]?6Q/(P(,DG^PV4C-1FHV4I^ND2)7I9-*%,=72-)"7;"M8W)X1?:IH8!J
M]D?FK3YO]4]XJ[O<"F=) [>FM&'57-7(E"!]:EUK\UZ?]_J\US_=O:[U%2>T
M=FB;N@&8685S4RY"&0K\9YL=:KNS%9BMP&P%/F$KP+23_7&EN!L'<D-IXDJ[
M8ML\KRD@X:CJ+6PEE@]X;.VA B?FG@J&M/#&G\W%;"YF<_')F@NT&!I".?6I
MQP94=%$>HH@"8_\8;7@\<;O[A_$6[@VIW!?%*??;UP)*?=E-4?-Y,)\'[^D\
M8"2Q@L:E%//.!7\?/_OOIT\N'OQ)^Q[1,A;VT%?7UN,518_[4S%@MF.IZZSX
MS2!DX/P A$[L,*G]MLA@UZYGJK!N4Z5X2?VT@N14J$V/OK, O)^ZLFOC'FZT
MW<(0R S?CA+D$VGLV3^=[=%LCSX=_S0W@TA2\0"";>CH>6CV^"?8.<AH;7;5
MZIB7WNVW,&!_?]66S 4H9?)MV2D269HL_975W%WMFB70/[%;7GH5.N,D:]JC
M88VMYXDO/6R98D-V@O5J>R4A$*BT;_5=!L6]UV'Q"H0>;,0N&"4 =@3Z?:(8
M?7'3- >P/]3H,ZPZ;0&[JL/1WJ_J7/>P,G>B _4*G"=L=Z.!Q56_[]'O-'X+
M[D4ZUU]C,U0[:"3H2I0=P,9+:"#GA,%LD&>#_*D:9.OZMD1@H7XB^8V)CR#K
MXHK]DK%K(QD[:[ONZS91F0[:MQ,56&R^G28*,_ "&<EPK'#=8;//NS,V'ZA9
M&SVY2NJ(3D[I8XSLR#9ZJI$!-JME<QU&YXYP!&7]-4)SH^TY[KAK7KLWB+G=
M$F,R$_<PAFRZ80O,,N\^A'GG%Q3!%9J7"_E7QB*W++NJ\UQ*B?LUKK0/OT8^
ME@(&>*'1D^7=L-&2<LY#6H\]^3UEQ8);(/<+X6@]%JZ+;Y/5&I+O5=;E[M1)
M.5,B4VR!C7;]R:PQW]--T+YA:QF>IL'P7<A#ADVC:YI>TJX!<>KQIQ\4=1/^
MRBT]BG9;]CW=1_3/<.G>\+;%6W #9/3IY]MI[WWW[ ?2%)\BY#9REM!-)5/?
M_2"^0:OI?>] -E+$=0!(417NQK20MY%G%D.ZA?-$,[%+'G\:\1Y%-LY$>Y-L
MA"-6\X04L/K5YL07LW#1^N53DNP^=2,;[Y^.4EC+B[%"8'U%CG^D <P:7#;%
MXL?G3RF4%-X"&:1W?B[734TC<$T'\'70T[@./1Q1,ECP]?@P<>.JK.9#LLH8
M-)^K%/WN7#@R>*3OTI?^=/G;PR\<8_SAMT9>]U/32N"'L7E!]CCLW\<=__C;
M/SZT6Z))6LD$,]Z33<R.5OOR*ALGIGUX)FV/RF"ZHNFK0#GKFA<P:!]B1I=(
MS"RNF1&B"W7'!Q?/8B1C$JUWMP"%]-:L!7,'B<FP-/9K&@M;VW^_?*&R$Z@;
M"9\6/<Z6M2*@S6*[60ASY <ND7K'$*Q=!W;9-9Z9OB<P&!:O."95'R$Q;TBM
M3\$;C1=3!YHPWI#;IF,.#7Q+YU=J7DIFLCUU%:W_NF.-OC]\IVKT(W*>Y"?)
M UFTH0SV/WB"+/7JE%4EMWP9=>QYYC%;D^<-K3R)^QK[=S&Y;VS39R83XQ?^
M/.&5SVFB.4TTIXD^0 ?M;A=J)?YV#-)?Q>9\_ 1)8C*R9"HNHMOQM2\B)K<B
M$D&5Z_#/WCC1+=E3,34ZQY*&6VN]V@V+OM",F-@"'0X@M;JJ%^E)Y_3T;'=F
MN_-IVQWQ_9C D"/&L?N3\M'.ISNTZ-B%62"_*7[RK.?XR>>5/SH)J*JYI+P8
MF_>['4--\]WJ_'$0<(508MDVY7J<->#TH$N(#7GLWO[62&MV/M70Q&"E$Y6@
M;M?<F$J0I.X0:$N^3\FLLG@!8A-V=:.,5\4;UJ$0Q9K1*PX@-PY8XQ*8D=_1
M<<=SR'^6WWU._YU9V3\J_DG;ZGV&I.I,&DK"2E4"51DKCYGB*YA00&*U; ,'
MO=-,BVFA+,E7"L=I@KL/GDQZF>^N3Z#PTU# ?]%L+G >9%6??3:U'<_GML2!
M07OF?P11P=H39R;2OD^[JHQXN6 =%K'( ;;P-03.+A>/8 =JXV#H4J'/"GO0
MO=%,W-XHNK$\[!$QXC.B^IX=?@]^-R.JWUYFXA.??.]%&"N^EPC(,; 9\]V&
MOR+\4H5%K4.>*21_$>D,;%#3FA66XZ%;!?9_ODP.^ELRQ8,D9JBWXO>[,S=E
M)8I;LI;.\8L<A D7@VI01CU(]WH5PF&!PTM%';()='-\Y\%1*)L/I$<;(?9
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MS!AJFJV9\"D]1'_LD"'0I%=&$G6O@H^/9&-!\;)KZJL+Y!06PF8'OSIGQA/
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MZW+'SV8#NF9SO"E;7>JLA'2EG&.\) \5Z^8M0/Y671ML"^K9?1UUC.2=C*%
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MV0$B[8#Y\<GS>,!D1X?4ZKNC[LDN#)Y-!<N%X5FN:T^*?5!E3VC:CBIKPHI
M5L^<A$_RQG*03(GF;DK=[Y(WW%6O$-R]Z;7-N_:79VAG"YDLL:Z;LMI)N)-,
MI.96%\F.GTMK^HR%2VOVG6>Q]PS2:'M<!2%370W8G*=*8;"NID3 7@"FM"L5
MOOKGUW*[9Q#9#"*;063O\\2 =/H1F4[Y(G:_5!C3+Q"B<P'L'X8]9W95MC/K
ML"('1$D4JVLR2(= WA!HV6=T^6PE9BOQ>5@)DSD?Y"<1B+6L-(C D1RLLFK1
M!$E?5D^!?TT>S'HV![,YF,W!9V(.@ &K&9O'$5"]MO@"W<\2S%3_XV) T^)J
M1H7,V2K,5F&V"I^'52C7^ZI6&E2@30+T%P:J3Q.:3,@*A6O)(2&5N.YW1U6G
MA'6INF5; M\RFXK95,RFXO,P%=J<Q,G@U-Q4++J^8R2@8"*Z;7]<HUDD4;#,
M9(JS'9CMP&=C!Y ;Z*2F*NBV?_:A4QS6.4!QL\DP@@7_Y$&P7.D=H?E'R,79
MCLQV9+8CGXL=Z595UVD7VI3ER#T+U$K7;7DCIH>QQUP/E=Z;':VG->J?H5Y<
MT16."#YF[HS98,P&XW,Q&*M6V^[(&^C"JA=\\TR;\:MH,YJ5;/E5$*3U*>%R
M@,C2MA6QL0MT; ,(-X"K&<'%$DVOW"OED5ZU@,\5[05HF'2F1*Z+6_H?WM'Z
M?O#'UQ_Z&UD2RV:WOKT/7^Z(?\>M\:OZ^MWUJB/M\M5$YQZZ>?:'77,*4MU?
MAT/@U2D8I7)U;%JM]-,XEXP+<_BNME.P'W-.M#*WH;Y"*W-5(V]G;1@1KEGM
MT5A _P!^Z)JUVWT[&OK-!O)(#KP$=H5UV:X-ZI>@3/F<?Y#^E]_?M^VGP#_P
M_W0)CJ>=M(JL?8^SO6G+?MWOM,93[9CZPZ;Y=+GX,:T&20;3?D>#8A7I;@PU
MQH&<0&J93O>5-G8RNKD.5W1BZ4/;VJ*Q6.V:3LM-?6T(4B!AXSH3:)N,Q775
M +38_7GQ5?6U'*I'(_U1P)HBJG7==G16[,HV8F/=JEPVZ\$JIIMW>C%9I-8V
ME!$]'ML^*(=P.$H[5PGK2<]%UX+ @.#'K=$XWI+"UJ\J>^R\"3/N$/Z(?4:Z
M:$#-(;,D]UKV]I"3.'">Z\%;NSEVFQO7^ [3\%5UK7?DRQZEI5HZ%+GC\I8W
MSH8FV7L_$)AHZRNU1V>TX9ZVR)G6**TU,HM1X5H;N7.+GEZN3#:)G/R]].7S
MHES14+>%=4*)7I.7=DE7HL=UXTLCN->Q"ZVB7DL@Z+E_/783V-%&.[9%<Z7@
M,74>_.5HA+LC<*:>78I3&=;1R\,@<O>RZP^,?3[*9!6+5]7JU;)<O4)J->PV
M%VNZNHV C!56 JYT@ F0IGXWPD,.+&D[E8RM,!<UVVJ)CBOX]S21>!])UU8K
M;M[&[FP ,L,/^13XL57&$,^W(O%<%W'TBPA"H<T&&\%/+7/G7FAZ=&//[>7B
M43(*;DR/[J6!GM8^-H'ZV[FE1%'9NN3^AL0%12_;RJ= H"+:@*NVKXX,A\DH
M&:0/X"Z/9>X_^XC]9W^:^\_>IO_L7;I:]VY1P-5:-P?NM*&I6/-FCU8G]A[C
MC*&#:,66G7Y;!P'-QTZFO]A7'C?[)9UYVF)[M)XQ61IHV>@J!>=7&-%J([W'
M3!OACV+RK#(WSQE%>I!V;1Z7=.G(Z0;^%C'M-T%(%I@N^ACT%>P\$?/H_"G7
MFY8H*>1-P<#"ITQ?"]<;.I=JF@):_FOV295SL--<?<6',.[)WU*:!FGH@MF<
M;.72XVL5?P';W8,0 TTJ>^[B%_(I]$GTPHZ]U&?,HPSVL,3]:_,&DZ>;U"1F
MMY*C6?JKL0:N2OR$QV8J&7'$I8ULA0X]=&PQ$<Z&'&YV&G!"<(\T^IUH$-3U
M00$$VXS;XYHN*D6,""'U3&JZRGBW!IU1P8U0[+C(G=3A%1B\36>MY478/\L!
M'1'93:=ZJ<19Y'4)29N"Q&FW7#7ME?*%@9?ANEKWF$ Z0ZNNJ95(S',W',-5
MB_:BY 7RPD56@-G-FN7.)KY(VR'\0B_#^5R>9G'<P%NIG3@_,LRD)9]3_E6M
MW7[8A#7< >]MF2M1Q("H9_(_?5%ZN/YHO7Z@8\"[\O!LA=!A4VD7FGJ=2M2E
MT/@>+LQ.(+&;C)M3TR32/_-ZQ!+R]9#E22(EZ9FTR,_;P&_>,(;7ENFY)6J+
M>K3X>;?ZK<C=0C&$0_^F(T+DUCR_[B0N%,X>$4E$[E*(6(X&%P)&B(T%#]>9
MK>.?,&:9F+YS^B'=\,X)J'N1@'K)5#Y\V"VN^I+K+&&B494K,'?32TT3Y<@R
M<R> ]B.GYNES'"_,633!O'/S6EOTJFUNLF4T)ZE^\V^>T$@I<:1,[REQ>,XM
M<8!%X*8<_"H31"FXT(CG8TBR$BG -(C=<##WEJ #P3V+!R04=G'M!$MOV4>-
M4\:3%,7FR[0.N2NZJUJNMC%/8;+-B0E0&Z,O%]^7[8Z3HLP<R?PN>"".79.G
ML!9NHY2![;H>(?X/S!5=(A>3>O&W92<?6--^K-;*&JJX"DX[L."5Y454\4[.
M-SK 84P1(7,H+-*8,-DW>O#HR.+3&%!F:I$(?]%M(\4>-Z4K=V$\2:[M%4$6
MP1P_] 3:&_Q<)I(>[Q%_U]AE[ W2ZZF;+"QQ/'HZ;G:4,(D@K2E]"G[_^&+,
MYX2P?_)%N%/.>G;3JS$'7>9$[4XQ!<;M,V ':L@A\LX]]_U6,GIAQZ?@5]W7
MEXL7Z4Y8.E>@'>(/-TQ7T-=J>[ *D8Q)5I1\7)R3/F^A=ZN$]U9OQPZOK%7W
M20E']*I"B<:=SCI>01C[BN&[\T8V?@ _KW@FFT^_)WGM"M\8$]NE39C1P1T:
MVM(2QB ,\[ZD3U6Q*W]=X5PWY(_[LY B(-[)XPC>F'@8"WPB64$R+FUNDC*N
M,>;;\*27/,F<HQP=$9S3FJ28F.(\\XT4NU/BF;/'N9U6C%:/"Q'6D?),F&IS
MIF#W)(619K@3U C-SS^ZV??!F:G$IF?\+3<RCL5^^OB<W:KS;M5S)BI6(D.8
MG,[C[[F1?QLW%2TRD*;\#SA A'[ U38HEMIR"F+3&$F"(WD%%PP.PFO.J\H"
M*,&ETGB"M*JN:5E83,:63>'_CM_8$MUD;0.7'_B$X4!/U@3B4]@%!]_+]IC&
M&3F'A8OVI+JE,6VT%IZBY)RWQRPKLPOG5M<TFP1,IIENF6<=R9P38^@V@YOC
M<O&H'GYY(ADC%Y"DD!+/31\/PCD:(M^/YWAVF9_L\9G&A!,CF9T=T"S*DI @
M<H^SHSH*ARE9Z@VJ1D<M7C"C:0HVSEO*',@J%)Q*_6/5$HV3.V,-F6#@_$(I
M'R>=V+3K4_Y0B*21M>0CB'%]FV8EM.JJ3K$Z+;$R:>(Y%<5)2G)BFY5P=+$/
M986H80>3$!2C\B/: VHK\_(Y:DQ,8BM+AJVEZ,$ZRYG<YG//)+F.*K'6L.+
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M0H;2!B19W#SP@GP:4['*Z;9N*3Q-U:<U;3B)(]>!WHT6$,O''+:\%8YDU!7
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MHFV[5FT).<<B\8Z=I%*48[[#([JUO/>@I.6U]%658)NH1%QZL>YC>C-1'/[
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M:Z^UF1GP9O&D^(S#3E5W[&L,JQ;.2&<N6KAP2"+/\@EXC9 5XJY)P1J*<6%
MB!3!77-S>+%XLI);QM7U-LFEQZ=L3;5;<D_H5-PR3E+H$/_6\^$G.5.R#=T+
M?.G)6JY[61Q4*X">O:QR]4[)6,GUO"CVPHN>@9/"-7<M75>C \-+*Y-J<X.
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MGT<4]+S&KO55"&%EDCX_)<XUXKY]<510O5N#2'E61]]V,5PH=UX/*9D'""V
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MFGY"\Q";N!LNN:%Z9%0(4E-1/:.VB#_.3G,L*K:=BNE+60 G*$?[37JI--W
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M@&K:N _H>.5.+G8AG "Y892REI/LPLUV*(B<5)8&;U,.U\BG64Y^TT2[P;2
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M@M?#"Z%._?*+WI 4]"3NQ#N1?/<<RZ.BR>*6N:YV3IF?$O=$25XH.86X\SH
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M5F3TS K:[X\S#$Z*9/#H\%&WA,=1H,X65?5H(MB#*K5KUMM*Y6:0$T]Z/ZX
M MO?NA@T<G#,>(5SDW-TR+YX;RI:VO#&Z-G!M3$IZDFWX-:32>A^.3"$T^$,
MJ[RX:4;>95UT8'H@;P_\;&K&6"::MQ#6+7-?\@E '_N0YTMS.AH*T2K-W^?E
M:5%7I1B\QO'ZT8_<0E+ 6]5*I-4!+8%UYMU<02E8$=+Y=R"16<_V1R]5.Z6:
M@M.:[C&5U=WX-<9,OG(J/Y/W08YAAIZ=-B#S :U&8TMCO11)D_^^[3)V*H:2
MX2TL&1X,)</;6S*\H4714!0FUOW!XS]'=E#$E>GP^<C\6CN6/J87/E'."Z"G
MS&@PQ2*=LO(9YLA!@Y6=-K]: 4E2V\))R5 $92B@@X6[.-D2SA=:9ZC1#^6Q
M^IX-)-6^$C+)J%94)IK,3M!)<2K]I6/PX#%*Q-I2MF$Z,I]B=W!ZI2.[J.3$
MEX;86H_>70B-KLM\OFPDPR<5(G4\/&$A%QG<Q#KR)D,XP9WRX,UQ//_R_H(W
MMIM\M[+J'']27($@\$3XOH482EM-]&6[I0>^DB4D%UKEFQ$Z*CHGT5>H7D\U
M895P7N&1^_?@ ;;+YIMJ6-=__$W>GS86GQ8 7PI][;BJ=SR2"CTB#%+%).NZ
MA$]JU\5ZM<>E+8*C>2[L9%7M\%G:WZ*'/#8,<WWL-%W#[I)0=RD?V0#F']+I
M0SK]AM+IM,>7S&J9UBO0^M7=TF7R/#<PPSR-1BC,S.' W,J-Q47EHES'Z2NY
M8,"1,$^[DDG]UN.+$;K>P\/!<QE*8FR>>V:D'D+BTJAW-082HZHU]/0*,#@4
M?];I#@W1X#Y;ANGRYU$N6XBOK/6\2:=,5DH/0S%JR4[6"?/QB;\!HLNY8AQ\
MP$\N&O<6&H$6GQ!RPZN -=&!N".#M+0JL^>'U*N<%>@F[?D<QX EN149$#($
MK9?&Z^'R<+8V1_*LYA)P!H1L!^-J#A[N/DEFTIG66PYV+@K3F<%'GN[Q%;M6
MDCCN1F A<Z"F:&VKKYHF3P__'+\[N6ATC5'(3L).1?"2>DQG&C@#Y+SR3+ .
MJX(O@_L2H+;-M28/VC*_Z$YGYF[(M^UQK<;VT9RE=$ZOB!%?J1@PD')B21;
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M:!IM47!:2H9Q*AI6M PY+&'2H,87:@5@ LE@->;KE==0!R>4APF3JLBV\RF
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ME=ZE4E:"G/W!@S\+XYG@A1F(/)\'2%7&)?7O-QB9P<@,1N9+,3*O.4E%_U]
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M7M(Z(@UB4A5SN1RS?("M*#@U[&J"I%%&$,ZD<J)!Q;%3=H@+)O8[5BP^DB;
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MWYXWI B0%BG+EELS;P1-23:[)4NMRWAGOVP44 = 684J=%U(HW_]YI.9YU8
M2$KB!:0J8L8MDE6GSB5/WO/)76%QEV1>=SN5WZI>@U]^(X\SQ30AYF46XV)(
M[!^^=-M?NBL*W=U.[->Z\V]1J7N]/?JHS533AKGA:G#]#U_:97YV24YUM[/\
MOV''V4M3!Z@_TSI=F.3\W/V!.PU?VA7N=*7:UEU/V/]F>=A;4].7.:6BIUQ=
M4(4D,*!7W:FSK,J]:<A6%162F6MX)?YS:"YRJ>N_T\U%GCX:FHM\P\U%9#OR
M,J.96%:W52T*VXU\6>^(BUJ"?&%+BHMZ8MR=8=$68[>;7=SYKA;K&,?G"+*$
M)5D2B#*9UX9K<R$#O;><ZBOXS\!M=IW;!#?V%OOF[ #?^#I ]Z_04%\R=QUZ
MW'P%35P?4/]7G.O0>^:>'_#0$V8X]J%7R_T^[!OIH?*U[N_[]_X%&_MHF[IZ
MI1[WNXXU<1/>]IM*T3I+9R;SR(.?Z4H?;NM.WM9+WL.[CX=P;^YAKY!%8$(!
M-457KM&2N[1,3'F:UY7#=/_,KO;##=V9&WJE\O0Z,0&>FX9^NA^7[!HAA__R
M?U[V<FB:&ZR2W;U[<=OO7[/DO,YB]N'&#3?N#KZ_"Y+PR5#(O5/7_Q>+<W^6
MGB*K99%DS-SXTEYY E91G>U-<U-DZDJZ4#>^VHS[W;N2M_W^]0KA)T/=\\Y<
M]&W5S-=^QZ=ITR;-D@0_&=#5(.IW^EY?J:B_ZX7#?/O1I?5^<X!E79WF'+"M
MEK;:=UF=F9K>.]]_]>#UNY.'@Q=KER_T):_JW:YGO5>".NZT%U[4C2[G$'!D
MD*N[>@VO5*[>]9+.>W19.4>"+F:;++MQD4^*%1UXFA?(N1RNXDY>Q4M>LKM>
M<SA<LN&2W1-Y-R0C#5?Q]J_";;]_S?)NR#0:+MGM$_EMO[\3\NX&&H@D#^#U
MN[[.N#?0/'RXC/?]_6N6>#?0[F*X9L,UV_GW=T'F_7 #:4'#91PNX\Z_?[TR
M[X<;2,@9KMEPS7;^_9V0>3>0'S-<QN$R[OS[URSS;B"W9;AFPS7;^?=W0N;=
M0.[*<!F'R[CS[U^SS+N![)7AF@W7;.??WPF9=P/Y*\-E'"[CSK]_S3+O!C)8
MAFLV7+.=?W\G9-Z0PS)<QEVX#+?]_C7+O'N2PP)0C6_KJOVG:\RP"TT5AC9'
M=[C-T<'0YNA+Z/PKCN@+Z>$SD9OQ;P<$_=EDL66\O*6=FZP__BI?Y&5:7#T<
MR&]5N7=2GJ9-?JI@TLG/=9J7R7M3-E7-: 3O3)$"/IPA-HEN9JMD'7=ZV]6V
MK6J^[W>7^KQ[_<.NW>NC!OBA+\VX[M)Z)4SNX EIX8\.#T>)/:_JK*2-2Y<D
MH__,%[2+)'">_I@L%8)_*8T8T@")?S]Y,[6O_^__]?3PX,=GS6<-,.H]?7B8
MG)G:N%<^[K_?3SI5'C9.X*1,@/&.G\Y?R0]/SIL(RM_!H8@3)'^$R/0C^LND
MZ*0)0=>T-=%\.DJ.TS+-\+]S^N H>='5U=*,DI.F3DTQ2OZ>DHHW2OY!(])?
M09<?TOP,OYI4=6V:924S::NDG3.JG9E5] M>3UO1Q8H6T]_4PP.[!J:?G(AF
M9DI#<Z,_9GEM)K@"-'C>-J02XHHT=$5X[765=9,V6E?3YHNNX(T01(^JS-NJ
MQI\<5#2]8 H:MZ:_303X8Y+7DRYOZ]4H6=!M2TNH,$G:+ V/CT>::MJ>I72@
MP2:>^-^FQ8P^T\X7^OAI6N=5U[@3I>&F)FT[VK']Y,/<-.;<,WR03[&=*Z$A
M++]I.OI*HT\W#Y-Y>FH2\^=2=HC^D=>R[HR>:)(Z+1F-9&S:,V-*NB"/?^*9
MD>5ZL)_<"/<X.-PU]M&_X;J;O#'GGX<[]7:U-,R$]+FE[^2"4?Z(FT',<7Z6
M_N=T?F,<QDP[0]C/$\>?N[.-OZRS>KAV&7"!ZIQ&M?<@ 1UFIB6]FIZBBX+[
M*%W!QJ:HSLXY]'!?#[]:7Y4AKD!AA65QS_HO7K+_V6=?C8WFV\7-PBZ_\G,_
M\.1S]O!6IWKX^,Y,]>#'.S/5QS]]R52W>8%NM]_E9S2INU-M,+_.[OJBI0Z-
M[];.\G-[)EWHI[E2VKN^CDLW0C]#@[V!D*Z$D+9U=!MZ^ V4=3V4-?0*'(CJ
MBXGJNGH2_N!"N)^[C,\*%@^?N;7/?(T))OZ/K3;8ER7.]%D7NY(V!Y6OIFKW
MTA_<:"Q>+8K3U\[EZ.,H.3ZB__]ME+QX.TI.7HV2O]/__N,=\+I'R;5G[GP]
MQ=_:WFW# 4^3,Y/6[(7,S&D^,9\;;1B8\/"96V/"7\%>KZ8.>V"O WO]//:*
MWS;=N&G)(,HY#'SEV1=E5>YEIFGKCNPPEX"13JJ../HD9.L#\QX^<W\UZ*O!
M !A8_,#B/Y_%#]QV^,Q.<=NOX*-7 ]]P'_DH>.C -Z^2;[9$NMR,+$WF)BW:
M.5VZ4G(,DX[S(KNBK=,&6L/ 6X?/[ 1OO79-]FJ0/>XC!QXTV:ODR*&/HC6&
M7;V;-%EEQ8MT,L]+XQK7#4QX^,Q=5'"O!JME8*\#>[T4>Q7FF=+WB)DV/&RR
MJ#)3D/:;YBB(XH!;6;5<(-?0!^F)+&W3@<$.G[F_6N[58/G<1S8\^!FN2*M%
M[>5LE9CI-)_D2*8.<AHJKDF4*LR!T0Z?N8N:[-4@,-UO%CH:>.CG\M" 2TJ1
MNOAF!RXY?.;^JJ-7 [-UGWBI\D\BFPXE"\NT;A.+Q3%)&\/@'$\%ZN+Z&K\.
M7';@LL-G=E\7/;B:]G[WB8&>YU8=;/LOL>V%4;H856V:JDQ++F-HZW12IZ5@
MR)BFZ6IC6>S 4H?/W%_%]6 H'5N;RT5:Z\&C06W]8B;<?.J*(BG2Q3@Y2T]Y
M0R_)?/_3(>(.8+1W%XSV< "CO2P8+6[D@/FV^Y!? ^;;@/GV!2-]C=HX8+X-
MF&\#]LV ?3-@O@V$-&"^#91UUREKP'P;B&K ?!L^,WCN+^^Y'U")!L_]3H1/
M&Y/_>PB8#I_9!;;[-0QUP  :&.K-,=2V6]!_,Z-NFH%K#I^YQ\KJ@ LT\-8;
MS(Y.ETLX*K.\:>M\W+$?O)INSC49.._PF3NIKPY(/]N*3MX>?QB8YK9->BXE
MSFOZJ$53*TU7H\<R8TT0!V4_MO!8<0$XE+4!T'WXS'U66@>LGTU*Z\!<S]L@
MCSB9EF57I'62UG6Z"H$EF,$NJFR HQP^<]M,]&O8XX#!,[#'S]R@UZIP0IDD
M&SVMT[83]7/9%4TJ1[D'@+.D,64SX$0.G[G?*N8 PC/PT"OCH<T"CN2Q29%O
M)I"\ _L</G,GE<N=0M1)'BSKZO3A;DQIP'[8[O]%)BC]V)(Z.2[R2;$B2DSS
M N5! R<</G-_%<G#G0+0&?CEP"_OU-4?/K-;_/)K..%.(=H,G/!^<<+_O (0
M&B[NRLO,E'05O^]#!WP>P,O!X89Z+OGR29E@4SCWJ:WHKG%IW2@Y,TE:-%52
M&UHD_E:G[&Z=U 9_;LUD7G+L_\J;#7^B%_?FU=G(MADNP:7*-B\[)![D95F=
MIG:^F3DU1;64/(4T+UND'E1=S?WD39NC77&RK!I>X'[R.Y9@/O%*I?:9'Z9_
M+^O<M&F]HO&G*&MS/>KIO$R-G#!3%/1\QSEAU9*(9I6,5\D, /#<=;DV_^IR
MP7VG(<UB650K8QKD[Y5-5Z ]L_R [+*VJNF'ID.-K,$_JZX%:TL:1I'/I_E$
M0%+&59WBX6 N:7:*?(L&JS!_FDG7FFMJ^9PWDZ*2[#=W%&F#]B$+U)!SKMPI
MIHN]FM7&X-<-R(6VG_X],?8YFGAN-T5^!^C\&7%V_+2?'/FWN=XSVD*A1#J6
M<9YAI$4RK:N%=CVI<#B3JEYBH_ +0.Z'!\H0.HU,(J^S!'F4.0V:=;4^GH=S
MD>]W#1,+?[A_Q :'.,UQ,_.4V3<G$]+V(F&03K=LIC@FOR2>;OSU=IZV--[$
M@$"%8/V8W)HE')5FLPVGZLL0>2+N\'0K=[CAPLXO0XMZE4],V9B0AC;5>5X3
M;_WA\IMW,]M!9#M/B:BX(-AD8%U54L@><<HP+DA5DR#$[9@0[='>T>T8XSZ9
MI@'+UYM4,64RK^=<+WJ?B/(\CF@O6PT^09)B/]EZ"#M/O?QO5^7\V>>P9;R\
M)9XQ67_\Q9^3@DZ #FX#/3-/^D#G]HOPHN37JEEBI.38<CYBN@^R[\;?I<EK
MVOIT,N]H_^G5_AL/-UR.6[LBK\PLG:R27U=$/5,T_HN(-BU)OME=40KV;/5J
M-^7!__Y?3P\/'SU[_<NO_*^#9P_1U 5E-Z? ?J4!5LGAHX/ODP>X/_9I^J4[
M)O<>B\E+S)V^%7_C[QUMP=I'^+=K7QFAMG(I[Q:K4=+169$<HS7B,I,.0/]8
MV]YTP@*L-SW,]ZRJB^P,&HB=+!T QB=5Q&2J%[KK?8:>8J3]8 4ANWC][L2S
MB]4^GXYC/3.%;Z#G.I+I)$>;;OP'=##Z#=;+HV/V&!:3NG*MYAK4)+H45;U'
M#'":M]%M2B>D,2_RR2B9561CB,KDM;@[O3:RPTFW[@2@@TYOD7X2,N*S-7R:
M]G!)AZ'/DJ;>3.I\C%YTI.P4*7&0S$HC)2M+($+*K:<=2W\2P"2Z)TN*R!L?
M-%DG&#.00AU=>U :_6'$CZ;E:GT,5KV$_);$)EHAY:G)F"5,.X:O&87?OX!V
M)R3Z8'?(,D9;5;4!4O3VM**GCP=(T<M"BFX]HJNB 5\;P'>XR!=Y*T!12;[
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MLH%P1^OT%G-?FIE>UX /IRV/9(,(?/NM\X28:>#Z>*F/@ ^/F D+U1U7S<)
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M!9HE*Y8JB7XX9ZR#+6-])O[MAD]OU9%%Y[VB>,,V4DU 9!:)UJJOMU<X%P
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MPS9Y.((<5^=?RUPP,Z1F.^A%3I& %?6=(B EM>I%\]H1'\DWQP-/RN3-I*V
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M[G4'9H$BNZQR<2ID(H80,"&271 @L>W'8HC3<Q,G?2#K?J YW%;JX]1UR9#
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M@X%;#-QBX!;W@UM<@DED!G_@A FGF[2<7IO:R&)MW8W:UL;_I=S(3X _*L,
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MNZ@<-46#0/SYRHD*I16T<47F2"G)%^E,6XUP>U&:!_ "RZI-+2AM8V98#Y#
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MF53LNG$'(4CUSH/JX.$97$[A[Q5B? 1OB. SLCI(5-0^<T4!@C]L:_(#'L.
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MFNRV=\9NQ\E)N FX0ER%(^C9R8/TH="+=$I@OPXK/_BCJ_:I#6O/W=)R'4?
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MZ#1N+WCL]K^85&6UR"?)$>UO3QCI-\3B(O$"SPX)@VE7J)V/=0W96I?5VT[
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MW1Y3=(#%:5@.;"$DM,8\\F>QC>Q\6ARK<\?A0GV]-3D@40OMJ,T&??='24]
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M#$E<0%I+W;*^P6=<: G6*6OCM>W4B1VL2@&+UQYG9PIU4@@,UD)ND[1-8ZY
MMAZ-G4^G6LW@O6PVYZA/\TH<OU5<8EHF)S47L=B3XH5)$9,M:ZQ\>\2/_[A]
M(V@7-(H0M*57C)5J4T9.E&_SO7'0'(Q_,?'-P03&,T#;:B0[5U)[]US"/$,%
M"%%G0NS:2'*DL*@:+CXO1WB](=:&=EYQGX0^4'$4_"$;"D:0-MID4$ II<"3
MO4[BRCQMGS1?]4OZ3U3KO!D#HV>GF<62I+&FLUODJVDUZ9BX-_9!E!Z?O!RV
M0*3.)0#. I97:2'9,!./N;B*9\:]7:1!Z1N&:-L'6(S.#VG@39ZJ/2D(19QQ
MS6T;TK#BF,S1D _VR<4=>1^5$U93IP"+"I;HTP9XQ7>Y=/AF[O(K+H!Y"_N3
MD10W%09_.R7!1]I[=UP'.OX3UIL.!1K,Z)5.M96?]@5T_2JEH&CI]W,@P0L+
M3K1UHR%ET*M9WS(9B@>*]H4[II%(L3LD<$#)<;JBSR4G#=05N*;1,-)DSJ-#
MV_<;231O8Z,)&Y?C. QD@8\&M6OA$2-G+TP]@P 25&:K4XXX1@D%E2RR1N6^
M/$+CT#/HP5J;J%YO3:UTJ#YA+2%S]+"=CWT*MO$K\<W_NH+[&V"R:YOAG7F"
M("2^8 'ZIQ^>DSIWAEG2E^([?<AW^N#[8(02MK[M-^P^^4YQ#D=$FQ/7ZN1-
M"*DA[.%@Y$>A3V^<N^PFJP']#\7CO]*VU9^[X*$ORJY&VG[Z80B_[DQ?E) O
MO#?$.3VC%,?1P=,MC.'%,B_,LED=5WU^X-$3#Q^%Z(F.(017>IT/V+_:V,8:
MNXE=INK>HO]Z26$'14@AA,K43H&^/;*'Z.F)$57WU]DGZ?VT&?"XM=*B6S#I
MUL2.6L:]8<588Q>80U<A.P!8DE)?GTJ%N9O@Z(N8_/Z&;3I<VZ;1.F?&A.S^
M"ZQ2JP[1GZW(.O8B:P21UW3:DU"<(@RNO(GIAT,K8#U@DROXA-%G-6/<ESS+
M4^E 'DS3_3.H9+=J$M-4CY!ZDF1]G9\[3O+& ?&Z(64IEQS)+KP_3O) FX'
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MK_B,<GIF574D\0W+2N*P9-^Y^A:A[5,2Q<CJ:GQ/'-##F2')U!IQQ4J4#=
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MHTT<%6.7^ P95PGT?Q9LD9?NFEC$*/3J-A=4+\,=NC9FL1WPX^K^69N'3=Q
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M.#?%$KR5^7A:K/ZM3S2VMA4V@^!2X\)8'4*,+-9\1-'A8I%&&[-::W%MDLR
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MU'&6_R]]3CSB6?(V_92CDHY7X.N7SL1NS,'/>?VV-LVKC=N^(G +[.)=I'_
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M_F%6R=N W;PVB(E]VV"MOT/D<#4C^"N"-B%#=M%;K9B%@F$8/+RRZ=L]6*@
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M+*OQI->C<EPD<QQY$/PI"'UP7,%/8*&-%U\#M8-"E'6*T*?!%-@$3%N^KQ!
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M$Z:!1Z9B!@!<BNP-GEOW2W%R(^Q1@*(+OP'"$@?CC@SXH//RLLSA-N,2E6_
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MD1^+BG:$7;*C'S%%-\9[@B*+/3<%H^&5->QNYDZO$7BY+/)Z3J40U/&^$)=
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MRIE4Y(;B)S5)BV?H2@B12%-7=+,(J4E;E872\F)@)0.OTKCGF&A]V7_3FRV
M[J]CN><26\DE]CV76 N7J.?<DJVL9S,'*&W=-UHVW^L6_-Q 31O4IT=--X!N
M]=QD5$[#@,K6-=PEH.\!G9UQR$B7#->$ 08)X\0EK)POK[06]^76FW:PYAY5
MJJ;#VWWBNHE[VEHYMA'*K3IP>D+[6>!13OXO$9R;/$HNY@5Y\R3T+7]B=;92
M$+@\&=CVK#11&/TM-J-,L/P"/3%Q;@"/=7#&K21 D%H,\&&6.A:<2/^Y7,!4
MI'$S2Q??K(/7# # ARC2<  $"<:UP52V3DYC+P&\!%@@ 0Z\!%B+!(@JV895
M]FWL4!F[%+^.'O==CGAD4A8$P_*L>3>!DVOZJLXZUT7Q!25)CH^#_;\=:&G2
MRZIE:)H+SE;@V\T8SGUPIZ<2J[8J"2-5\]AUI%3=(Z-4"(/2%#)\AH84D6!-
M':@F4D>ABJV,D.:I_7.4*IQ;)9/Z=O7"B"Y5$,8U; PI X=7+J![ +V$DOTB
M)2E/>6CRNF1T*:KDUSH'$8]QFE"MJ@0,X5[;& *ZSC@0A ]+Y0MA-9*<<'F-
MSX4.+OHP?]1H,/FR#M*_-'0@@F<IE7,]PUV32[:?4PN=2@Q1A/K!+Q$MF%'H
M*<ZVR$WU7#(B+Q(LH;L6K%41?Z$21DRUP%KQA9X\:IL#FI,&@*]+I]EUR/ME
M@H+T:X+T[.M8;HZEB;*L>J[1:<A!?H1$Q>/7=9%E67&MT.OHB.[B$96^0BR0
M=&;-V%2J#G),[7^PF,N:#=[GL<*CJTL7>9H"FEST3*_NPQ"2N-!-ZT5#*5G5
MO!9Q4&/!&?2'FUD0EG?UEI3?9UIUU)N28=!? ZL0>51B2)+U+DW6K/4<*0+Q
MIMIS@F)RP/9X96X9771C):C$0LP4SA6M.VE@IWO8O96C(^?UC.J18;?_R7SZ
MF49&VBF]VH@E[7"L"04,5>-Q$[:>D^DO\V4DS@\W<-6:;&D-(^6IFX^N!S:U
M/!U/;._A?I@=;=1+OT\4=BERI7>PW;/,P5WY:'M"%B%C/=D[H(MQ[*-JW&4D
M-E.D*OE<4FH:)Y'_6"\ (9AJ,C>C!,Y(LN%$TDA[FI#FF8F*^CM%L^A2HJ]P
M!RCI:%.C2O77;0F5B-(I]6YKXNYELPP&HU*0CJU76*ZT1 +ELZ:,H4_3N*K1
MMHKR5=6SW'>$,JO&F+!L-0V2"452[8K&4IFYS/,XF$0<88W;R=3R]X@LF"-J
MYXWJW1$;D9D74I]D4$9IVRS&J>0Y%K)=H#--[IUB378:H?5MYB D:B5-P&HD
M8O4^48@:""<"[#2ZGM3I<]'T^PN2KAFL,9$LBQF8TEC%M[G(2@;P0"W,AB:2
M#"W4_EI&&+JDO+G5NL(YT#(V.![.BEMDW7)>G.^G>&WW+&Q\6COU]4_NS$/Z
M*;P CFAI"U8ZQ..HP$O6Y!'V6]5GYB(3"BG-F]?(/@!71$QDTF8GA0FM1W$:
M36U\I$1<;/6F!%MO='32*47K=18QR:*P]7.Z\FK&$36]$4!"4J@KT*-EO[!"
MT'RP=P:C#;J;T 1,*I9JS#X1[C$3X4Y\(MS&($L\HH:6:KT6I;/F8:'#+9A%
MN!S%XB#29.^H0&_T.7.U,\Q"'Z$/!?DC_KPFD'O9XM)5A0AP(<7BJ]A2@UCG
M<Y6A6WH@"H$/RR!KFGP%5CK-.87,:DB*S/92<M+6_&QAX'8BX*SW3+=Q9(P'
MA%< _AI*Q&OCA%".8=UTS-5G";1/)<N'P0U^GU!_>-HD5='< & VRI@4A]<8
M:+V1T6NIE95P<E*SUZQX!FB\QET[8JW8@8GMECUF)YZ+]O5%=;*4D= 4@99
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M.!.GDN!/"Z,?%"#)FJH0PJYI@8KNHK'0<E;N6ZR==OF*GJ0E<MY8X4/IN.-
M-E,H4Z5$^KW+?%!_+-#@D,HFT;=GOA2^*U&L"NU-<6G25"%#%X@C[/*9-EZB
ML#<(<41OV0*%Y1:.90-.YG@8Y/KU/G8[DA!SCV=E.U=TJGN?MU#BC5$>MXY*
M6F'(B!M^E@GPUZCH#3O;!&GM\D.H'CXKYG&R8E[YK)@GUMIG+6;K>R<CX[/
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M:["X3^QKH1(C*EB@E$#=W:IT2>=,P0KCZPE,=14(URG)PBD>NY2GQ6EE-CS
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M $5N)E"_B I8%7E@QA$!U<'#G6^<H%Q%\4IB6;+S0?!'1MG)1K3)H6CBI/K
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MO\<U<:W@S5$O07L^HY%6M]Y@&MD5C1Q9]O5^T\@)T,A-K.2X%\@8MB '*8T
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MFVAV8O3$8T6.KK^95<Z,F7&<4[LS?L)EG)O@)Q]E"%;XEZ#7@PM"&AB"ICE
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M9WK7MB;#.'MD<2'>3%&&9#5=&9:*K'(@;>.R;?;KRY)M7H=[$T.QE,V,A>4
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MX"LP3>]' ?'7--\)C_8I=6N C)'$4BP'+:YPF25#ZODO&N;9AD> W@I>-@H
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MXEH^?%>>(][K7I]@/R5^A!]H)G"1MS@I<(@L2^7&Q!>FVL]NF#4<M\6&YGM
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M6<LA("L;_R\/(!;-NQ7-+1;-+)H?+YK+XF!-%EUF,06HV#RZ<KQ'?3,B<!@
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M\N+BI4N'N+IXMW#>S_+B'#_?I=^L"; ]*CTN:-!S=.0]9V%<A,E%F(_O''#
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M[H@8ZPKQ6M:[H2]0K?3@_4I:K4RZ1O\MQP(PDS'VE-YT@JX%:DUD.,\_P81
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M6>QTTW6RE")T/LX6W0!ZE).+4^<.OCOS*%2:7)X*WG*-P+F"Q8<1:/-XF[7
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M =!!WJKC_]AJ*%^S9%BR6:7X->2$\>"^V13AS2[F Z?NX&!%S_:F.YM=N.!
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M9^F5E2^S4LM*+2NU%BBUYN(&AI/_D;'3) N7CZ\]N/;@VH.[J>J&@9R(&&I
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MO.;.0./%DS3?6+5W7'W<A!$-&%UO=CJ07V))LU99[P7DKHKZE]ELC04$4C"
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M#\.*7A:D[MLIXO+EQZTX"G<>3[+0<G@Q)-M1+1 T&2:[CK16Z2T<&M'X(*\
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M8<LS=%=@<U^XQ\>;&P*W9O<27:/8M2 =D4L4:R.&#-(:BG0]A.S*O&=,E_O
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M$?DA[@W0$*:/$F0=</U:0T!.K.W@XQ\OR%-@S4!1"3!^@!J@)P@$C%;B,8R
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MZ>-/V)9VR&+QE^>DSJ=2,(Y)29;OC75:;P^'+/1$O_6CDS^:T]JRCS_<XEK
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M! $8/)D"$>1:P )!?G+PM4K  6L+,F V/UO3,9BCS>F[=<S3):F8Z-3!^QV
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M'+;2E.M,)!+QQBS4 #9G?$MG1U+N.\BDV##E-C6=([<TON#FH#D]WM2$FYI
M2A-(N3V0-8&4)I#2!%*^.9#R>)% RI,/,_W*+PQ&NHFC@51;?O?3_J6P=:VE
M:OYI:T;TY;X&<*X7NP4J8,M);"E!V+@))W@Q:$FTMT#C%%\>=@YQ,0B#H@+)
M#X$VNZ=H",A]VCBU-VT4%39+"4X*9)2TE? %2_)*#H7YL51XW=7H5@D9<G&J
M]B5DM4#3/@:325N[%76Y6XR:QT6Z[VS@)ZK-'3);:;[G!L]<!95XHTT5LU[
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M(:GJU!=$_"+:/00C+5LK]'R1.#FS4EB,-K3$3\<[)\BS!!T!?7-8[(Q/J)G
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MO0Z1"O]UU9$MG"SUV);;NYLYHUN:#;O1H/]/1KCDY%[-*9P5^,XQ9?X &*G
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M-#O'2EC\0LT^L"(8%OGR0U6.DKP+5)V,/Y3(IRHC>,I8\[[<6;=Y]J1(FJP
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M.N?QAS"*@T_!?T:OAP<',XI.A/SS0133I6F P)@VU%3NE &I)3N=]PQ(;<J
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M%C\IYFI11,*SLL=FV&*.AU%M/G]L[J/J7Z2ZP!/_66&TT'W!(B78-'%U\LQ
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M#W9C6^3M1R] N*L4VE;EH,_AT@03=)EH8-.[KD]^"M]!, K$% 1+= W%5&7
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M\YM"7A9TZAB63SE4\-6B?R-[:%2<"QO-%6QX--"9X80I,_N-.:ZJS,)4,?A
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MIFED<J3%1GLN 0"AJREF^^/'P,0$TH=)<.I&7] "T<EUR]>[1PL:^^(ZN0)
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MFI0;;Y6^&8)NEO<>N^A<J-V42^\L.TR-;[%GIHQ]1,865ZQAF0?AK1?!47#
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M,09[Y36'.%>+RS"N^6AA+PNQO;QY_C:OM">4X!B!8]T&!9I1?"$IXV\X' ]
M83]01C$JDO1B\??X9$>:A9<$O"2C#XJ5R<,AZ4<#*<&F-$3[F=^[\3UM6["5
MZ27$:1AA'!XN2'(A@-"I!)Y@]9LPPG*X<F88 1A1E!+A0,  #=?EP(7TB!>&
M@CG_'=Q?AKP9LQ "^D"[&]">>Z9ICY"FZ2= GS>4398'J0NQ$S+SZ;AK1<"&
MVNFD*.0&J=66J,+)K<.X--&WN"ZI*?>V%2O(N2"G8T!-L<6E!$BZHE8I@3)X
M7?1/@?'Q2[@MZB>=ZD$0"]H-9#D9[&KZE;W(:M6B"F@;6)W8\I_<0N?795Q;
M(=QO8O_G1?8OV$WU%,Z+QH8;P7T:?"M\TS33KX@6'2/!@9I^WP<=@.QX"[;1
M2MF%JX3GSILM+FN#^^#T9J/+9T]S/+K051/)_4M74=3)@G%-522#JW 1\4_G
MG3BMGYGWACMV,0I[S<""^\U5S,@$+-P<I(,V0_4DBA&Y#KP[H9X;].90J"X5
M:0A>)E$2K($4#/O<;2><<B6U@';)W\2J[<C[/4M_C%0-CMER&(.TW56[K=8J
MOVQPS*6 <L1W;:J:)!R?RR:!@[Y01U3$3 M7B40#CTDAS3$X^T.>\":.[;],
MU@6AJ*$L2%?D$B.A2)?I5)171SUXH*%B&6B+BWIDBCZ>\-TFU?)(92$! X,9
M,R. 6!CAN$R3J]Q1R-KBB%;#*_3<S</5#2Z:N$H==B1&XF,QB3AY@\=Y_5(%
MO]JHI@9J/1^_&Q)D'X!Y3C4N&BM6SR 5/JT4H<N'2IY9FSO3JLODF2HES\AR
M :>0C"%SBV1NT0FQL\PMDKE%A>46+:<-;9%CU#SA'",$,P@B=P*S?"$7?L$S
MZZZU]L.2E]PZ"IHDFR\)->(NX)" L3<EFV.L&4[D0MP,_N\E\@RH1Y6;=#Q-
M83O4SB7&6AWP(9Q9#^-T3T7\6KHG\F2&:-GNA9+\VY)8"_2XBY_WDFGE\S+U
M%#*:G7G !VYJZM$J;$J\7)HA@JSE18:]1ZZ%9V;:;[]FLD'+).?^Y__X!Q\_
M^AAFZ)JW7L@OA)]%P_0Y86A1!T+=?K8=(!;_AM^,>F0@?5*$\G[57.2B[=:8
M=_ 1&C6UF0M?!W^%/R4(\(Y/RDFA6NQG?<'":%_^3!:+IZ_X'>: 4%C&2#.#
M4Y^O5/*U+'_+IJ._X5\G;<&R"!SRQ,2,>L-R#1V-^E?;T)<6>L5@%<'TT;ZK
MM6GG!9MEB0"[-;3<'+ Q,*[U7^^:[S8U+?B<?_P8\S_4507_]V'QD<!Y$=L_
MXA>A/+JV"33Z%%-B0P,\KVJ1F\V"^R!C^!_/SB^_B7,MJ2_F1'VYC 4NX[_H
M1Z;3*O9@\K EZ>^^T,[HPR-J:')Q3V9Q.7XY]$B?;J AO!\"]9L^#T%/EHM=
MM<7NO;PX[ 7,'EK#.UA2/%-'](DB* I<TGTT :XHKE0%E&=M]-<+@2_$UZI9
MOP +L]6%?]KM#QL5!J!RJB<Y,)8^TL5#T7[VA'>;>L2U^QA<4 BGT-$,K%C-
M=#2C_UNS?+"V^#H+>W[A2B<K$ZW>MQN8+ZUDQ0[2)*V9^':E.XA/16?8Q>C+
MM:?UE>F/72NBH5[56^I%YRHE8^[ "Y@S__Q49=8)#G5QG@=Z&JEHQ3/4M\'M
M=VCENRC^%O%5,S-*;G<Y3:+J#%6T0%J38K84$KG,5,];,U6H'\940]0*FZM<
ME/68BW)71DO)*D,'\[O?.K5Z9S&9K.H<4VD1%"J7I%<>1.CL&$9;[RR'P.7*
M.@5JOE*GS4&G%>'D4F^M2N1LGAKLI=KI--1F2EYFU8^/LG*2NQ4K;:'*%LAA
M>ZNTK5JE.6PG:1Q$"9YC+Y+2>?0B?8:GH%\%,OO4-:Q-\ P8BH(E8).9BSSA
M)Q[Y$]*K&AI4^[*MME/2B/9>J ]2@=I)@0KXY]1TJ&;M,@V93>I0)]J+I'3)
M=2BI'>61*!=D@YZY=K2G ^ISF,H:'GL549^Z';5^48!S0*I/NZE/*9QT(@I4
MJ]9=KCTJ%:B3[452ND@%2ASZ*3D'E5ST=ZLS[E>J5B+2D2<#S7[P(,>%.,G-
MRE8N8 OG-LV#B=U3(=B93%,>QZ7M15*ZY/X,>2=TK#CR],SP$_>(E"B2_/AN
MD([:;C;51JO*!NH)AG'N&DE>&H\'2I$38ZBSCR3/P[6V,I*\6XNR660D>0E$
M4/9(\MR$SDZ1Y*VZ6F\OPY@?))1<^J(2QG@+C''=]A'WY*2=#J699V6\4:6A
MV+G,4_JC2MN+I'3)_5'2TY2'ITE %28JM4B/4P$Z>S^B<!4\3DVUU6JJE\WE
MJG'2W#LBZU3<X]2L775/CJ&JZ7%:S52K/$X9J^CFCEW0;4J/4RXB*!]N27J<
M%IFB1"ZG*[73+3@E0GJ<JF5OG\L\I<=)<H;T.%6L%TGIDGN<9 34P?Q2?_":
M\UC\ DOHC43M/*I\*OU313@9.,5[EMX7]![:^%7E J4:C8[:;"[7_I4V8_DX
MJN+>K%;M!/FLFMZLK7FM7$ZN;JTC 3HK(+!"B/BJA%TUN^K%A72"25?'&<Y3
M.L$D9T@G6,5ZD93.SPD&_^*%'?Z15"WSJKY:OA*7PUB=58>-&*A9NC+2W(DR
M<^P18[JKC!U[RBND!N53[;$2KX3IXA<_K5<U'T5KGZ&QW=$)\]+R&NK%U3)&
M#GG/BII'HEY!;O-(L:=W+)>KPO*[J,4#!YCSFH*,X=F>9BI&H+J+FKCOL65>
MXAGKVH*^.YK$JJ-2;5TJ](S,D^ ;_I.HI2JJJ-I6HGIN\.R'M)*K8=@=3&?7
M6;YI[J8USBG\* +\&2(=UUI Q>+\[%C*H).2?Y)ECQR3?GF4!<EI;UXN2YBT
M3?8F_"P?->YHX06D^89(5J)>+).]L 5*M /6@J[3C[<PO<\PN\-OAGV+"5TN
MYQ0?8E/D1-)"]L?>)%TN^+6X4]97RMY1&^MN44@;_PYMK:W5K!7M&2#7C-'R
MXX-XG7'<_\0L<!+/?,]-T")?BER663WU/<.$IG02>->F-OKKXV TL4WH6% *
M]0N4B%-;9R:R'' C=#<EOS5715P/F Z%9TRTXH,N<UY1.=%PR[E<,B?[X(TZ
M#'8*L":UY@M=V'_^-^=417-=?RK$-%>,@A$P>B,IT$FW^4@N^K#C]5[_T83I
MOLD>QNFR(JZ1_A&P32\:TQ#-FR%(A6L3'LRH<C/8Q3.\='<"L6)8/H@>V,W8
MU("9C/;L]XM&IW%U=77!ERU."M\5U]%\YGRUZ!AS\6LVG9GVG %549#"[*,O
M<&VVU/'@1'6P>WC7-.TW]]=E:V[MUA'\VLP:&I"VNV--Y.&)@?$+N@M!H*^F
M/5G,E)<R8J8I:JF2#,;/8ACT.>&6HN$HFN_9@0^*?S/R'0?8B\(W/BFB,&WG
M\N>](BZ$DPL:-;69"U\'?X4_)<CU;K6WO)[B+1>#O&C]G.Y%$+^WBBMWGU/3
M^X3FR'+W%:^NO!B@DQNQY:H5NVIU6?9:!NNM9:DGP_U+^>PPAKXU4%9<3W&P
MC/J)A^/%B)WVSO9&53$&=VA#QQ1G7#%<L#NQ7D^P7%_!K)CZTVS.B[[0:&,:
M>MS IHZ'8(VG6=@S/VE87X2&]<?F!LOZ:CF4X6>^P!_%.A^9AMJ/DM.P46LL
M%R/Z>6OA7LJ(([G5\]GJ2:=:GFS:RLZFU=[II2#ALL.^B(TN(3[*K9T%P8P*
M= ^TM71E;C#SU OJ'% \! 2^%?1%\7!X#:"968M*DPKRX*\2%Q5WNI2&BZ1G
MX*3.'KPT.O43IR C(>>$F76R9XL$F&V$SG=A;_ '7 <4:!CDAI28=NVBOGC3
MQ=>.[L[2;(%3H!0W*[:BU&6ML90\%*.4M.W/>MONKBOLN&V[%=VU^Q!JIUV[
M3KQ)._U\=:57V]0P-LB;G[K&='CKZH^0MB6WTCO23#\!1BJ!H7YY&$L]F6L4
MC^XZ@_A6N@ ?+UV GUMDJ[."#!CT.*,X;U=Y,[R)88D\FIAS(,B/X7&CBN$J
M/(Y4Y--\JPUJRA!4#Q?T)^[ QE"^5^Q*8>,Q-(2X0/BH!S,,6J.8S'.+ME[A
M\#\W;@SBK">:JU@,Y!M*3Q/D/# 5\*-F(+S4G"<'!I3B$;NZ#8.R;$]P*(;T
MSK1YVM."DX'!F<L81:F.?2R.OHGG8D&->\7D=O,*R5TOM6-GKB*BT)0]^&6+
M:1Z&7SY_;,5[7OJ]D;9WDO]9D1A/=L;B5-DT84P],V0@,*;,-VWN4D@M;W,2
M6FI!M&"]_O,G);!86CBKF >[T6ZI2O#/AT_O?MFXB M&F>BE6VL;L(3QY]%H
M"N?A\.YY<'7"JJ*OTBR]=;R3OZFW;93CD;CN]S\?^T^?[^[[JG)W?U-3>O>W
MRN#;]>#N]J[W=-<?;)+8!5)V"XE>1LK>/PR!?,,'9?A[7[EY^'H-1+XE^MX\
MW \>OMS=]H;P!="^=W]SU_NB#(;PQ=?^_?"81*\X._<&RL-G(O+GAR>B_)_]
MWM- Z=_? JUO^S?]K]?]IX4L%WR<LESV)7MA)]!AE;?WFFF*;'101AS&50S;
M=T$Q<57*0Y]Y"D$DDJX">K7XI&N>]B&3DE?%C*#>#"QW/<@+ZGYOKDO=6GRX
M]2XW5;>TC).X:CTG7?\S:/-!@ITP'U72R@,#8)]LB9%FCGP3C-@@3779</7=
M(!OS?_^O;K-9_^0:,!IC;#"=OF@ N1AL85T5*90&S[:DQV#$(DU>6*R(<(OM
M<7N9MCA^C;PN4 JI5Y[1&?4DNL"VM1E\AQF8;H(*H5$S@1X5UQ^/C9$!@E29
M&*YG.^C[(1%"UHYCHX6C: I:W+9%A@W8XP9/8-2L,/$T&':")'QP0<<Q$B8)
M-UY>.&@+K7CM+W(AV(HV&A$N!W5!5CZ!LP1O(7T;G4^QAD-L#I*-MNM]# C*
MWT'?GL(S6+F@>69 #\-VSM9)$-TVG)/0Z+G*%_:BC>9*B!E 0!(SQW@%5C7G
M8&29.L<*,BP\<PWR1#FV_\+186Y,FS8^,AJ>V<DL8'M$B:8Z-H@IOW;B'80V
M(!GE\%XM6T%P -C)H_AVA!=I@R=7R;"XMQ=[TUXUP\3=61#[E@[?J0<"P<&T
M,G.>%/*!0'*3XBA&-^%)C-&78_'$'QF#R,/(L!FELQLP(\T!V8M=&$Q()]2U
M9OXS["K@$A#*F,)MHWM)"X0VYM2_:B:)&GNUJS,M7?[1!KD7FPQ!"(EW-<M"
M\<\(VV)AV*6] <D?\R37*S7:OJ4E7O[H)KE>(]$)OA4.E\K!#%Q2U(&EA?_T
MQ0=M W=XM-?$T1[?KD3P\SNG$V!C9W1$#Y>AUE!S!MW04G3# 08"^1N"^7&4
M*=!O^7.NSQ$Z5D-Q+#)26C#29#YSXB E,3B2?W+0JJ$=7.JZ/4N_C[6_/S;)
M:L)7_10?+@'A!1A@@:+$3_5(O]^,J!)<,,[P*H;:6L1-J1Q.BD0^$8.L2^03
MB7Q290P-B7Q2Q563R"<R9G<]2PU6*3&!?B(C>'/#"/VG8[MN<6Z&[\M#B08:
M*/GQE[D%P :>YOENWG7,6FJ[=:%V+RYD?:G*\>+^7IMR\6+WJJ,V+PJN=":S
M4RIZTL6,<7G8G<1A%_-B'?"\:[8NU=;5,C:5/._*SHX%GW?'8,=F%Y2OQC(R
MOJR;=_CJ:$ ([A$X[>)H99EF9:KFE85@9S)-Z;TZH$Y?QO!NJEJ4?FV7FAUS
M)'WK<![BY?U2,#Q)L=,IC3Z9?\C0/JK@I=KI-, Z60;3S''EJ\*V<J_*O5IP
MA-H^>[6A-KI-M=Y.,]Q.:J]*T[%:!:?/99Z5,1Y+0[%SF>=&R)@BRE.7-JHW
M/!D5//,HJ/'186-&*2/\JH4.9*6'@=-GEIL3$0<U@["NWGR&^\.<4XI<D'&Q
M&4-P%SV(_OF#)XYQ)2@CUF<X=%S68.W68#REH .^P>YUF?7NM['M.U0G<&E[
MB#03D:7'$P0GH#\ 13#_SPJC3U01*&T[F$L$$W!]T\,X:9&!$B3/B-08RAP<
M4<1ID#6'97MKRK<9/A'+FL/L&%YA4E5FON/Z6I3K@L^Y"0 >GJDSTU#"&3-\
MM/%!,:93IAL\UPK(,&8&)CQC74P+.X=IO7_V/1'*_8&2L"*FX'' S0^)64Q$
MQB.IXZJ";V.^(Q7G?@:I2D-7<9@.@T&/X'D6@ 91(4O8!'\Q+ZCJF"SD'9N]
M2L,4@UP8%T]]C+5/@\%E@58-G:*5UX2:[\6P3V&O3]CI']@AYUYH#1[%W?<O
MPYM@]MG#>,#7[_!\W>@J4^ARXB[Q]2@<)L%$)>@OV.U<\MP>+*4W<PR3GYI-
MGE2C*A?7P _&B K'CWQ*"E/@1=J0I@%&ER[R A'%"+:.;?KA9]PU]IO%''=B
MS##SYHN!'&U2!B(\[#G&LR\N]?'9*4<SY2G(=DS(T.9>XON[V'YV_6>7_<>/
M)<#%!J/R=$G?<T$489QDM..3C08YP;Z%DDU,/4P):-8;5PJW,Y7HQ$#+D@?^
MPQXTP6S3.2O-PM.5.S #F#%H^@>?,D[3A54RH[2DQ9>$3$/FC@;DTFP-F+J#
M*8*"J*IRRSR0O"J.K::\'__RUR^:\KN-57=]E[[\H%*?0^8";X.9JOS.--.;
M< FR8KR8>RC*\^*8@RJ_@;2&K:P;W#-K6U1F.M5/L"!KEJ]<R5ZW=<Q')7Z"
MX3KT@V9F+W"^H?#\:JN>) 98]J'$N+>72Y0;T9"$P.;IN\&1:,?/&Q?30#"9
M'<^_8!FGL0DNH,^)@R3Q1$H!>WPFG65Q++ !,%G?SM0,7V7B=',>X D@@AX(
M1F^!"VK*5]MAJ "IXK&IQDM"+X '<%PIGJ$\!O&3' F.T;?@O(!%UU>QRMZJ
MU!I6BK=T8[M>R;AJ%!L>)>%:+F<RT*CL%XM*=V]@J\73*@,T9NF X19OT,X8
M!:XI4>"JA *G)&Y\ Y_EAE4['_)4Y-I9@N1)D+P38F<)DB=!\@X&DM?:!B3O
MXB@@>8?9=8]Q%*:X8P24]L".5]&78CNA.4CA3I&1'P/K66D9 %O:H/ES^S-P
MKR1PS$WVRLR8/RNR6)_GPIB#1]!%N@;R(-8XN<$#KVO"BJTI@W5>F.3,XV[4
MT+QQEU"*4B<.(]9BT W"[T) :ZN\&#2A@%K8%D>O QWV98Z^4@<QCART2N\L
MY&"+<VSD%;Q&T#WFNCCHY\@M"U(A0_<<%V(T DH[P<C'?G"SD 2OB]EZ&PD!
M%/UIO17="_@CW9SN\X:RN60_V[XCUF_X9@^%]+L'LGB,67L$8"Q8U!^C@L.M
MM<$7[4YWV:#&I2Z4*,D E-(193EK;G&_I#N0D&X96%GWG<!91&6C%)#H\,P:
M3*;4GQ90FLX-8^DI\K/QN]=O=,5T5E>N(6.(FX;D]1P"Z 2,EBY[XR=(D!U8
MD$LQV,:P:#Y^Z3X@DN)PHEFI\6L+D@.D19HXC7B 6( XX&GP+7-]GKW"UAH=
MM9V2;;3L .9WG^\%T"R,SQ40LQ_(T2QN;)*WN^&-R;6-$07PXZVX%!:WE=A,
M*2[5<UN:==>/W@0+U*RY5U>%SOR"<E>H;;;U8B/_!UJ;H/ "(3D&V0H//U$9
ME<0I%;&!)8V @Y>?CMT$W)B:*PHG]NB*%,9$W!#@"6.C&\[80^VU?Y'%#<8&
M!S6F'_&Z.81"S+;B-S1+FG@OOLR8[$?#I9\$(!LE$.Z[?>%\_P[+SQ,1TP$2
MU^_AJUKC:GD#1X:G8*2(13C+<"MC)>,<;5G_H O98%DI]6/+-<QA17;2N!IJ
MO9NB=;T98!P\L[A"#Z:8!:=;:$(5*/:>T*!Q#8^)J(LRR[_@]C.0=>&E,EIF
M.&T7 <?/34=,W #D42:XKSG6QP??$P0DYCF.SCF( @K(>S":&+ UR.P $31B
MCJ<98*(;)O"A#9J?&GX7\U& B$,SAL(G,)I"2+;BH(DYP>XH/&R%JK>JGB=0
M'@C/&SB(@G?5:JGP_V6I=!BNHJ/&90?J#8XP$+6Q.G_NR)[1:=8;W"B=1C<9
M,LAU&->'?PXT/N)5'C@T0CV"%U 0E1;@]$T_C5,.$!"4Z8Z@X$1)QF/4TNX;
MI;#,O)!VN)"X(L(%;LW\(YGJ<3>ACUC>Q!+*5Y1 RHWFF+8R,*98^0('B@#&
MR H8 &92&*C.>$QI8 0$H.]ZG.LH7O1P0B+>]6()3I=/AM<TB&R@,(8X8'J8
M@^_@YM)C]4$.-8=,,,[I*G'\5/@C8+ 8=/O^@,YK+F/$-4S[BO/57VP.TB7L
M&DS%*"HQ8OY%@./E/(H3NMN*4>@0P,B7W0H (W>[ZX&1+R5ZL<3!+3=ZL402
M.1UTP$?4"\J! G),U#4BPX)^T',?K+U-T+V=E(UZ[:HI<3S/>:<^&>Y?RF=T
M 1IXE."M#P9!R%V;5X4G)##2]TZ0-WMQK-V$PF)%IXNL%9U %A0 </BS/-Q/
M362$I2*A>U@!2U?F!C-U*3+R+@IW*^A[:)'1RBXR"D !/Y3$D+(@#Q! ##-]
M3[%F'\Y# *RY#G[>O/^?M]G_2-R,0!-9-W[*33 NWKO?6HO.PJI8 ?+@/_S!
M']6:/8\]7[Y*L$<]]ML7M?9!SOTD(M2&3.E3NS0ERWR\9)F?4Q@R8>>L( />
MA 8U/F/!!:F5M0-TCX4;S&^U04T9.A1_.>=&#%[^O%+^&!N/,0A&X %Y,,,$
MAM&YQ3NM,/K.C1OCV%(6PRMND(JFAN&[R(^:H1,8U$AS)R&E>/:&;L.@$'^*
M<RA'))FG/2TX&;/_7<;H7G/L>R"L-_%<Z; BUDOM<X>/:$GX"(F/(/$1*D-9
MB8\@\1$D/L(IQ9"5 _+@2(H\&4C'4-\_'RR&54TQ"<$(#")M>6K"<Y9,GY-R
M[8K<\+%C3WG(KFE3ZB$E^AAD)Q/<)4__H4!>'I7/PWD)%)?'_(9)(/#U'"DI
MDD5TT#NH$8?BABT;:(Y;#7-(DD'P?(G<6"3^#^:,#)?,'F%\SVP#<P,FXJ,8
M0=0W(41H&,][/B'U*;[8<[+%@;N^L!=M-%?"&B,"\--XY4GJ$_1.$(LCH@+M
M/N >Q_9?)G&F5P67XLO I@AZ@'"-"NP#SW;0>XF&O3&=F4:2V(;%-QS!Z;YJ
MAHD<>W XXMYH9#L85&G.DSGW0?: FQ2!L0D()UALHCRG//[(6-$4O%N9$42-
M 8/7',IQT2R#FH8MB9MVYC\#EP+5/4=#P F1."XD"";7O&IF#'@FU4N7^YG
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MBKNXB3_4%K^)%T7&Z6##5&%Z<4_!JFOFW#5<[%O!(V T5V+ _#:(?&#T*7Z
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M(8'C?M5,4>>7Y((&*BDHM:_8/1@HFOYOW\4#B4J^CDW:N4"#8-_I?+!\:];
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M )<K^E-[ON@V8<\>YCUCFQII R/TG4)<B9=%_90,7L;LFKYIB09 6;4D45B
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M@:8WG<-_^[$1#OS8I3 >K*[O)@U[U.QBM&[Q_GL\JB=)>$=S7X ANPRC7<G
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M\+KAR;$EI\8KODZ>6<Z1B4V V5FP*UA6T@9]P..V7407)OF>T:'D2#\0U@&
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M0.7Z#RM\\I/B\8@/."DS_2JSGGC=.BD3_[3#.;&Z0/4CS3^;_P<*WL[)O2Y
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M?U(F.\G2UF\)R\<>6 V<CP  SW4L_PV $8!S]/9H%4"FYHIP!CMJ& )PC]8
M%"<E@.OU8[NC<4 X@(R(B(B8B(R8F(R:E(24FIZ2C(R2GI&6EIZ6EI&:[(1^
MN_PSX9"3DI)3D%-14%#145!0T!V?*.A^F%#_5QP</090$V&#S\?#X03@4N/@
M4>,<O<=6E.2H$T<%&R4!S@G]ED8\  XN/L$90B)B$E*<OPIQL+/_3R$5  <?
M!P\7'Y> \ P1 1Z9!%9(C8?/02-&H&;J1,OI<T/\#%U208TZ%S<]J,-90A(9
M^DJ#D =CMCZUX8*28BBL#>/53#9WU7IR!RU]=LAB&KQ9%_YTV'=F2_M"2E%$
M?6KGR.QV,>"43NF43NF43NF43NF43NF_1$=3JNP>:+2WO(@('"7L=/Q8+NR"
M@(D$.'F+B F+B@ 450*\G5R\P&AV9S!V<ZC$^?G!(TYVB*L2IY64H:BAMP;8
M Z(;A 2;!1F9NP1YN<BY<JHHDR@&R ? O&%@M!-[  P*1\D'*'&>.)?'WA^S
M13C93U307DJ<)YL!=FM#$W8-!!+,+B4L(>0B*B;&+BTM+"8I)2TM=I%=7%1,
M7$04^T]:2$Q27DI:7ER&_3?B5";!GA61KF[R($WMW^"P)27.W^KE[^\O["\A
MC$"ZBXC)R<D=NQ$7%\)J"*$"X6BG "$XBNN'DY]^-,$H%R3DY$T?^W'9";NW
M12MQ<I*P_X%^JQ?,^Q?0/R;PE^=CYUAM>0TD&+NIUL0>RN*BV$!$)83$)<S%
MI.0EI.2EI 1%L3>BBB)_T?PG']CM(7;OJFQB=A*KE+ K%,J.W6BBCJ.6$A87
M%O^#E]]T_^+&$.$*<0O\AU DI>3%_Q3*'S3_Z@/;F*Y.:*?_DI<_ZOY,N,A?
M,OX_;0GO/S3YGUH"*\"VA,2?6P++E#=!(EQ]7<!(9347),+9"<VN"4&A(5 H
M&,DN)BHL)BPFS<YG!8&[(OQ1_(HB?[+XWP[>U>57[-Z^2.A)9W5U$0%#P<<O
MZU'8^,7^'+^KB[S+CX95_I.[$V SL,^?N3\%4(CRSU\0?H2.9?S97.3O]HHB
M_PAV' (:@H:"_R$ -2CZ7P5P7&%YJ!/<78DS0.BW5R&<RO_I3QEF0F+_KD)_
MCN>D0G\-_;@Z;@@DS FM#($YN8-%P-XHMQ/-W[C_VTV.'1"&AO]^[H#!1/[)
M$H76\D/_>TO4\9LC$1 8A?!%NH"U_+!IXOIG5R#POQ@V_^P*J\[UURG-T%!>
M#XY".\&/7SLJ8QG"$(BKO+J4A(2VK+B,G+B:FI:&F)B:E+2DEKBZF)2<I+:&
MIK;8R93P9]._N=5$N/@>-_%O;EVQ;F6TI37%Q67$I,7^O=L_F/[-[8_WG$[0
M_\#]/[CX&XPN=CI!( /_>P/TI-MX.R%1)R]8E3A_)I[S;P;'-B==0=[)Y:0C
MHIS\P*Z*(G_B_6LCR-^;[/]<^;^9_FO__AY@^-\7!#'IGPO"'[3^M9/C*<'?
M"0E6<\?F6/G'@\+O/Z!JF/UIAOXGDW_MVL4#.PF!795%?AK^9/RM8?YQ8OG_
M1HO)BOZ_WF*_+^&G+097=D' C]_Q_S=:#8OCA'WBQ3Z8*;LA$3!V)V]O*,3%
MZ=A*Q _N^MN,Z_TK1=C5[(\+T-^<_%^LK"L8"?GO=- _1/DK3^S_?ZOT?SPF
M_\\+W^F8_#/WK\^;_VKY_/E4\*-;:A]WK/]:.RN>/.?\3R?0OYC^DV?7_\F3
MQ-],_\DSXC]Y5OF7+OZ>[3\D]7]_:_:SK_V+#=I/\=\WS+]$\B>_AV*WH6!E
M2461?V+_VZ!_<$&:VLHDV K_?#?Q3_WZ?Y].04Y!3D%.04Y!3D%.04Y!3D%.
M04Y!3D%.04Y!3D%.04Y!3D%.04Y!3D%.04Y!3D%.04Y!3D%.04Y!3D%.04Y!
M3D%.04Y!3D%.04Y!3D%.04Y!3D%.04Y!3D%.0?Z704A^_]_^8+BK$J<_IXKR
MT3A  X#S']*QD__4!\Z/3W1QX!#BX5#__$17)X - ,#%$M[OG^HC)B$D(CB#
MAP_ )3U6,#GY!A<N/AXN$2$I\?&G%'%^?)^+&D!$PT%,*T:G1L)IZN2#KJFE
M9S@K+HU,XN*6D)22\?6[4=?!R"2KCBJH?[+.PZNI#7(.34G%>F0Y_N07X ^(
M ,)CAT0 '&)<K-B &G#\R2\\ CQ"0N(SA#\ J?$Y  1G: C%U&B/P8C$:^@D
MD3>2.M;IN:2P"+4,C-P2TN@GKZ9XL"B8IV<US7W#ZC:.Q@!D>">?#*,&J !:
M;BM,.PU*6\R +Q6^D6\ 7]#^[/MD 3@Y3*=>K2UR]NQ-*Z^5F[$]L;PR;@/1
M=P>EE4=<J];RE+SBIUP944+\&+-%0L%,[E&>^(F+28^N.9]M0A-HCF=FB+(_
M8RS8X1^*&Y*YX36.IG))FE-FR/6)XGNGYIC3_GB7>_6^<NG"WI>]IH^2N(]O
M'#ZRF!;:7]]GY8L?3]0EX2;8_L[R4%=%Y,'"9$)1\EE.UZ_H12B*Y&S_E^AK
M,DQ6<2'&!7)G*L?&/.8B6SQWTR\8V3L_9-PF\R+SND@G<!=60LW+<TO+]*GO
M/H&N[="$ST@K"[#'(\PV:4BL^.T](MU@F.3NU\\AOGR\>BTTE:0WO.4-'P:"
M97LQV]RRMI.MM*WZ5ZK>#+K!?2X$?-PR>[' W_;DTZ%OD=S<(4?_P2UXLWEA
MQ7DY<QF;&[9@\ 6N\N=D91@K/J-R>U!^%U+3C0Q?/XC3/C!&4-,M)S^_NK3<
MZ7U)R1(P3?MCTF4: Q3O.ADSZ_7V(323GXNA&? ;56EVI@V&KIXKD8B;'M>
M=3&CC:+T;&((2O2>?Z!?IV_8^7168;655^4-S&=I;)%PGJRGM_I@R[DPDJ4#
M-I[-\FT,D(;'LA<,_)0X$;WQ$9LE/L_SX,M/S(&Z[]&]-W?B=7(. J>K<^;@
MLZ.#0ZW$S/%=6K%Z:W;C:!V^A@UGJ2L6Z^]IA]NZ+>KVWXX$N%%JJ7"TW<_8
MO#1V\8SYED\ACY=JIHO<:H'E$X^]87?=..KZJC=4H:_(T^V(:9LW\09ZDQBH
M%+]]Q8E,D93R;4"/I#R/R@Y^_-9HO.0RL.4QKB[WM5SZJ&1**N' ENF-B]WN
MEP.UYK3#M)OSP,F++YVBO <0NA\EE.H+-R#1T^DI8X<[GF3;?>(L#Q.';'VH
MIMI2#$9 #8::_MP(435VN$!&#3OCDO,KCQA9V27R"Z7H]H1R+7BWA%46=+AE
M[_YB!2A+/P8831J>7]E*D$)P@[&^7=YN>8NCW]*LD-$R<DGI7K9JG]A*'G=[
MGN$YW-65$JMW3^Z&T8.@7/U"&O%1]CX71<=U?;HUTV=;T\9A!OQ48<U5'%8
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MT!O$A/'5,TJ\8>J_^<)[J%2I1%$.-ONJC-H<0W*.<,NI-OPF//[EW9ND* E
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M7.SK;UMD]WO7A)&,9!:Z>4G]X5-Q#@/A^N8!=ZTZ(_OTAVP@W2P^PDK[L;9
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MR= W%.@#[ZR@I?8'WWA."+BG^Y]8N'"$BY/+KUGQBO&IT=4S'KI,;.^)@FM
M8!"$/0H"/HL>O:;\IDSX0_F4<RK1<G-B_;]0?RQ/!/1/2\-9\O_,T4,Z_7GY
MP+6'HDSLG?[$(P%!T'80'Y064M-$3_?G!(7_D_TG90)G.,)/&>KB]#-3I#\J
MK_F3?9I=,,31WO-LAB+P@B!0_Z!N]I/]9_4+#DZJ<"@<\8?DDO\P4-'X)3@-
M0Q\..[T2H.#NZ&4("?ECX@BAZ$3^C4OD<#;5_8U_ 7$ZH?V%?3:"+O^P0Q^8
MBFN W_GD9[<8/V8>;*JSTFF#8I^53_4!I'B_)>PQ^I!&WWX& &Z@#Y)% "T
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MPY/*X<&5HYV*4XK]0G[6+=X#=KG5>SW= FWH[)4L%"\'>EK,!TN#DB>?+)P
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M&^)VC'O6U#^ AF3Z^9W$WV/"^/F=1+38YO0SA0!L+&QL/$)\(AP,/!RTE!R
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M5=F'\4(6F<HCE5UF:9X<4]4?*[>#KJ&>5P^0B:._XJ1#%PI"E#*7!YQF_5S
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M?[BQ_##HNDL../8^YX0#,CV))!]"9N& YX5#JG:0W*,O__.:ZEUM5XIQ1H\
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M]@AR(V+U^&-E=/^2MX0EM]V44Z&W@(B  Y%Z"-CTEEGQ;_F O8NQE*)8FR7
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M 5]ZC&X_=:==P %#J: G,]X9!92D;\?T#\/WM04Z<L^D.,T*W67([V""EG
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MK,3>"$*E/L4&@RP/%AS^"]:B-"9BYHT;A,C?FQ(Y:(+3I)7%.0"+<?61S*0
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M@^;IU&D^-/OIZUPZGPRR:?:0/UP]!1]@JXIX.^N"PR_L,JLJ*B5O#L*QZ?K
M<$#I9;B_G/C "\X9/GR-'F10/X6!PY9JO1XJ"$ WL(L5G!G8O569U20'9P;E
M2K5\_.V7J\WM**>\[MB=^)MG5HF [>P'":,,J4R3CB.#HM#IKT?V9-/-4V2:
M4HNH'B4SU31I$?DDH].RA(#I^9A4'MZM=&GNY_$41OF_RC2OT'AUUTC5K0QY
M,RG>*V3)#VCL?K-0H[^@X1Y^M3K,BOCU=P-CX!A3-%._T-S/5COU\U/F#YWD
M$@HJ5BSY; XF(RJ;5L$"FIJDWF-'6;X?\X1CG#_Q%RMHBY8*:8N)6@@/.N=8
MD4SPKE-<Y#T]BJP@XIHLB 8)XV['?0U"0U0C>^,=O.'L^7_O/?0C-L4TSN#9
M\C-/43(@8(G8#1-TUE&3I>14T[O+Q37GLUIJZ-Q],%M,QBJAN4F7<#-6D1![
M2)3"^\@K7']$ED0=)H(W691P4E8%#"6QMD:UM&100]-FR^>P^3)&7J*L5A2#
M/*;*#,0VX&J2+M<JS@5[ S'+H]<2Y]799LMG6U@&C180G2#A^1'0PV4E"Z,F
M'\9U*H8=P8>4-@;H-B6IN_>@Z]01J5$F:C.AO81%).1C(BW&!0!A VE3]HM@
MFYBL+7W>,:E) 1Q _YJ43T27,6YG6\36P^W^;/=J&PZ(9"-YS#UG*^*U\(0#
M+N\<2]<;M"[CEN+H=7@QSAOJ)1/#$)X6_CX)#5_ZCSX;$<$!/RJ,#ZLS+$:I
M'C'I%CFLGMU]GUJS/Z8:=AC'1=Q<5@E)J"X&C/:M7_/;/FE->_RO&#,YWGDV
MA /^1C]C4C%5YBTO&CS1_.LI;H9SANG-RQ=C5*!2=-S>-6W3#6WN4ZGHVE>_
MXYYJD$!^FT<!/[5%1'5Z?B<$'"I#N^DIS?.S#TG*WR]R'W6F3(@^?-!^>*)X
M9ON/$GM?.&D0#@>D49(BK'&MR63X1OPF> 7.N?V]4^"\N7DA[BA1XQ@0=3&#
MP71IXDO:7>_T/,VY0_Q4E']A-C9OUS8),OZTW=\2J <.L&JA=;WW?8YQFY82
M!8A5YGOWA]3._TZ 93*NYXLX2=CL1DLH+_:,;JU?,Q@_:<PH7_-?&E$RC<X/
M%$CX-5L%2/9M_0]DP0$9Y7# 8?[>0;LQ3%JR/%^G[WY0_U&:ZF:Q!K;0P!]M
MY+I9]VF;\AA0#CG"S<M2NU?JOZ][L@['G-!TW?R3^R)NQV,[!;*1;04F%N&
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MO T[,Y<I3QL^XZ>D^X0QKSI@\_8EO5@CWZB\?MP[9A774$ 2 #'I_>LR^C\
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MKU,W$%S%5E\L9;T9&2Q#C$KO;O&,B-% S\G)"NZP#3= [*#U)(H?E.'B/@Y
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MXAGH&Q@^6D^HPY^XX?D6W60K*Y5U</%5>3$C$F*H&5LS0G+<!)0J0P2B;N*
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M$0L3Q"S2#FLS[VK/]$QS@BF&&VT(O\>P415_V5>&,AA4:<42X=^*:RQAZAZ
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M$DQT==8\9W:L@E#-FE;=I!>340R2+H(2+-.X03I?+"BP':6'#%2(UP8P$+M
MC@%&U6111\,$XP&?C5=O?SY53J+^SV?X_J_A_R\NA/?%:OL@KWD>N$SD]?C#
M\AZ0M[&?C6UJ&&3+4(LV&2^F6 O5,>HQ3&&S6UK$,UE-3YV+H5G)H2Y3C' I
MMR8]%\/X 0S%P[@_44@5"&7M:G3!Q#/D,6,'EE='?+^]U&[FS<RU9P&QI+&*
MJZET ; 1(]-H;:GCGVT7A3?R0K&?O([2K_OD<J<T,KVSB!7UBNO-+FLSO,BX
M_+,"3Q>9N,.[YN,]\6K;M+OX;N\_5FHCA!NN^61L F^-P!0.<MGFA2IH_'1!
M,3:CARL*,Z$EC6-CH.P&(WV_H<C5<F'<H^1F?^KO38&< ( 8MH8VU2#_Q>HN
M<B_,5'W>[[A&PDVO^J9*_GKI\X5?&)K3S,@6SI97<6]\Z3U1_F'6?WX$J29X
M%RM[\MXHF*RKTB5F5A/G\#A4^ZHZJ8+T:T),K\2>HD6RCB&GAWY]=BP?X;$<
M.AMCVD):[S/)G"4)Z3I)PI^W#_+=DAR,TMD'I7JJ%7I%Y2JKLM"+4-&+_4#/
MY5P!3^:D9F_B)1]BK<N&'&\"*4.7I/RZ66R1U_-ON'<J[+#)'?:18]I':>-M
MVX7;U&%HE[0A_.7VM^D8B]WZ5YKJ-*@N#2Y^399N[#-NX*9YABH<-IAT"Q<2
M"TE3ZMA"V@/PA$8&52W6U'VG!I(Z1A4B?*1#E$DCS677]]ZVD6SG1Z>;1_Q0
M[:#5]UO16JV=GM M5&4E,G[X]IY1AP"IA]]>ZY?=LB2HRJ*DWBR25]4$WJZX
M7\Q%PQW;A8'WV%216 10,:.%"YCQ%CH_IT:WZ#2]T(P8A SR&%+PN>F[ A>)
MK/!*H-5'G(Q;D!.Y[VS-'5ZW+8!_,ZIZTMN![K6U5,.Z1[_QJA4SMP:>SPEX
M0:JUX[DA#9XWXRY0J+4SB@7H66BU<I'ZR!@WK5LOWXOF!C/>J[Q4-L((6>MQ
MQ2$ ^T$5)OVIL1!+8 28P@/BGC@+7$YA^@G3S8XZC,[>>N'\15CG!6G;N-C8
M[I38K/:C=$3.BJ9VA3=$13Q;&5TJ(-?QBSM$4($XAC\E1V0GU!CLAOO$(AV=
M+;F(#U'=R+N23C).Q*QG*0Q%Q,+5H\R3SU&M]Y,V7TL@@Q3\RG,%R( 1!,M,
MT-9W87<#D4MB.[^4 J02_/6&4V$6?K-.;C-/)OLR.>^YO_P01JB9X9TJ"XQ.
M:Q(NU*S4*[F-[]9B8!4/65\FE&9@=;#S*[6//N\,-AFHOO'%#$JR=P6EU&.W
MD^/'4D6AG'0+9+CM.J[)=\W57<OG(XI'@1S7Y"2A &KP! I)]%&V.V\BR&W#
M(YABB8+VL1Z*T8>A#[^.DM5G"^56MZ;:)[&7\S4S%T^L"-9]SF%OM+362H4H
MV)D@M=@4GUG&7]NAG[ZH5"\6X^:-860VZR2J&J",V1CJ=X\]SFRZU^VS )+4
MMO#+5$ M56B!*+'2JQ/V9)'"=E#N ;+9,+;=!4[U\JXI_P!HR5Y:UIPF-O1T
ML[T:]:XV-I)$"3UFNFS^RN@Q!A%M09 /-ER/XY8U48%U%WQT\@1FD8DQ6ATW
MB&HB,Y/B8D"GVS0#4.PH;&3D">/W*T(-L4V Y)A%[IXF;559&HY-;S)YZ, +
MR<2*XO'C5MLON\(]Y..[KLS.I!X]]S=2&]-)T>-%V[G,LIE\JP);XK;E-9*
M]6<UG*CE5@<N8$D^8^5-NEQ8I#M;.5C$5\T6%?9XG#;)64!! Q>8S'9=3D_D
M262>:9+.RA %E28*P"JB2J=,E:PZ"6FFS5#QJ17&*:E0%MEX[J[&\QCF*CX>
MWFS=M1)?LZ*^= A][>O9=CIL<U@3;\HF*,D-&_D=4 7"FS!0)Q<HL]:SCK/)
M#?!&'W%ERJ]?'J&0+M*]%L>:SX\9!W=&J5C&M,>*F\:'V@)G08/!$11?(KFM
M0TP86K%(<BC" I%-4DCUU@7A[%*#W/LC\G!LR13X;Z75JXCQZ@MC5R$FE3IW
M_"O>U=C;>PZ*Z,2'YU??R$?CDNN*#J:@:"%\.&KS]A,L+C*45'PORU)NF3J@
MPT;/8\4-K@CUH%1_?7Y+78L9[!K_%S'-9$*^P/:ONU0CPV;Z=\I<J\6*^41?
M?+OXKYGNST..;[:MX*XMN25^=782]MMN[R2W?M5D<.!0R(9P+4JV@NU68N@>
MX,_4@X6/](F8&N,@[D_(D:*$(4PPP N\18)YK"AYPWIL49,DEGH9RA?W2EDV
M+#PIWF10=U,<B/(8#6=$VLY!.*2Q/VQJ[!CM'.!6;%7'CQ[LPV[Q\*1"6FS?
ML@B436Y VZ@6K3BOEI^(7N2!RK1DK%M76LY"X3S=N. 1/U5H/M,$4-U_0(_C
MI+E:G\G+E>?E@6>&M$-NH^OF*^R<=3=5RG+&N@,Q9 <PI NLI8-2,%9G%DB_
MB$SX]G8?M?*51_S\?\20^>O<Y6W<Y)-[SJ\*6)M-?":< !E*N32WUV%;#>;=
MMB0<8SID&;5TUY4F<[ZIV_7*C<LI%#1FXEZ^].D/5_\/VMXR* XNVA9LW GN
M[M(X-.[NWC0:W%T:3PCNWKB[NUN"N[L&=R<0$D*^^>Y]=^J]FJIY]:KNS+_]
M]YQ:Y^R]5^VU5^?MJRQ @,5\T3J/9D9&,:05C??$67YHS7X_69,"MP^W+8F=
M$;JDGIV@KU\6FR9'-$+$YKOD9J_6!M&VQ-!"*$(/,'L_F.OOM= X.[%:;:,L
MVA69K><\JHZ&$RHV3FNA99LTHQ.52CLV602;.@]SX==R<G"K[;?0;B6$=@JZ
MVFCIJD/DQYLD*4S8#,T=P)#I6KC-D"V5MK\-I#;\#$B#-"4M%W]JFQ"X,9'S
MHWN9HD54%PD[5J'07E%70\?',%>:7I$+<ON+B]]S ZAF>2(?/O[QU6RGI!$Y
M*^_VZOCWW#MD<L771?&FE*9$51ZE09S]5M%@>CPLI/1-PR0Q$#T)]RD1N'ND
M8>(AG$<3%AJ*YT\ZB7RQ[@E'H*?DYL,>8 _96\VZY7+4D=#$;QO4>PSYZ))J
MN;+O(7+QHL\@:&R&>#5R@^7:-[42",H-Z@[KGFSK!@DI@8ERUCIJKF,5]'X_
MV+["\C9P$-->X&;2HA3)W?+B1\B4MLS&M(@@9TKH]D0CQK5.1/";2Q '%L:>
MVUO[BQ4@?'G=+MQ45:$8EVDWS"=0U=W8W\G%3WB?HJ;;H;/^P'E<9Y!-H6=3
M)&.Z+88-<>+!BP(6#=0&ML(J.*W4U)0]-A.WEP\GH_"LDV<+(@T='E-4M%/0
M#!D3[4L0/$FULK'/,ND$A^-R9%"&V=OC *'!F>U!G3$?$O[T?PXF)R+8*VUQ
M;#?S$7+Y675"UKQ65[_WXV'S'F44)-]SG)FIT2[M/OM).B>&*Y(.*(K3+B4"
MUF4J0;&U8[V\G&$RE/.2,-.JF=Z<"=/6@OS;B0@5-S>!AFHO:7#D$V2N/'PZ
M;\>!B(^MD6W8O?EU'H4^&0T)IAZS=A;)#/FN7UL/-W[:("A)6?3JMW1A9YN*
M0<9&<.UJ45QG+:Q/5'"SEZ80,AC267P_H%K;+ZFMF5*T J>K38L7*5(S%E+Y
M)HJMV *K9&&FSPC1;Q;]K&)M/UIKU?&D$ +J9^,9C,7*WE1:W;-%?^^J3:/4
M/E.SU_=%K+O?KF1B+C$]U)Q5:-G.F_:JP#!=OCFEJR[* )R:HK ++5CTK.D^
M& QP9C(V^UDS<9BU]905LE.9O@GS3W1G55@K)+;3OS1?V-JRA5[I'P3*0  5
MU75&N[7:-+LX@HA^KS[^SDEL_>0F-Y11C86K47/QY?J@38L,\Y<B70I)F^7?
MYG\?!(T+V C\%RZ!&;5@;.D/-"=A1,Z9L=_'^*OHK#MTR^+"58%T&INX82,-
M\?'P=<L5IJ8?M3@1>C+8OO"G:38+R0IA*J0U,6B?RF243C5$N&J\(:R>4$_!
MN2;K7CLF\ACI3E@*#CZKK!6931<?PFDQM+/G5O?Z8R5&$9MACK!Y&PY/HKS2
MHLT:0ZS5F)ECTW,1/#JQI42U<V5AJ(:5U]9-0[IHVEA73@$T&V2^_$I(@;I-
M"SZIHAW"N+Y!(8W4\-P;A2>J-8B;E=5@*HD[]^< FH[E=M>+BEQA:LBVT2H.
M]*+G)I<P.;*&Y L8787PT[AY4A/AO:A>!DDT4["/4POHKEN'7^E"#/.)^YI^
MK<9&5OB+H0]O%W!8ISCQ1RX#.8G9BB-=XG?4)\ 7:V?L_63A=3-9O)_DO[@Z
MH+=W.^W!F;4FRSXUG\*/-!:KU]"I&HPQOR;TVQ_7(LW/-:U6*$=DW86MP6@;
MUO,M.K\9(AANQ7%O5(>IS2;QI4=2#)@>9LT#L_O63*="8T5Q8:C%%!#&4Z]:
M;23O,'FE;ZE\?/ 14OKFRD0^CK\DF5-$R2^B6\I/V$W#]UJB[9*(R1("H5*+
M:[N:UHS0JA3U0N-'!(=U@7JJ!2DMM\B9!A*+. 9VY:UL0C:IUP^R(9NL?(5I
MT=BNE$K7V>')(WSP-K@]Z6D<@.Q%Y7ZH"^$H1Z@_0OB-_)>R./:RC1+2V#?I
M8G,J.]<L5Q<W=B1J\+!S^JZF.1? =FAO533 ? ?.?,)Q+^;[2S^BV195-QG_
M<F4>OTJ1QCP>9I? [_T#C@8TC!8,QJK&R8P#O%-J1<>J4Z%L#G+5MH48&$8K
M6ST\P2*4(0.M7'FHK=B7/H7F;BJ&6IW*Y_%01')^]P=%&%S-,]OLVM@_ ";I
MRW6%Y  .<WJR/W?B4&JRDDGS2 ER87 F.Z'[D 3!DVMBK%1.W>T@+%H':2+%
MSYG1< NLM,S"!(1+F2F-&L^QJ.R!A\8/6YD[ ]&'2-4OT)77"%[!'69VU0C#
MC4T%KPMYS5A?@0TK0WIH2 )&17_*MK29\1)8 _9N$F !JZY7K+^2*%%9' 4*
M]:[GPY,M/$BD?M]/WHQ"!1+QX^UL>5-M,G5Y6_HB+,Q1\2IM4V.D1"-8@9_$
M3^ESFCX88-ICR\RGM+"[-%H&PSJ$%-U^*;_,)AFM\17SS^3 QMU-A+[3JQF!
ML"(KY-0K%=R"#U$T2FW'L46L^\+;0'+[1%9+-WY.=/M[[&L.C>E:<1QF2.==
MWFRW7OA1B2Q/E"UC#>5VL0B\PU61*W7"$R6]=6T@H80R2U:BK(LEHP$,LIZ!
M3\8_'DA>/HF8R$%QK@I@*[Q;IKXSPY]@(\5"Q@4)DHY)XI"IOI%7YJ^Y29@^
M22]OGB.OL_]MND]XC(50XM>89)-[\.=W8O#3/P"*F;^P_M?*X0%ZV#O>NY_+
M(X:KPD* H-OMYB!UB\Q*SMI5\TE(G/"75"S%"H-H"!7!("EP(@EN\_Q+UNQL
M\O#,F&Z6_UB>#$'>,**"_\$7"&N&7)(V8L3:9:>L5S,_\G$L2<=LN:I7L<_+
M;TW:=8KENE\'NL+$MN^9M0?/WKL6Q,8XA72%34AN-8LOH+XW2*R[R&2"*^/2
MR0O^B4,Y_>PZ[A5Z6SM>L'T92;@YQ*(OCO?8!&K6,.;!KE;$;\<Y9;YD;8O7
MCAKB0R<SZ*:3BIX269<9$)DOL*[U'88[\POKE]]!?FM?M9C'.I+"8!*YA1E-
M>CG8-25!M_UDOPQYL\7U/H?6_*QMUT,W?--IK:65V*:1* [UO!TE%?]PO"YI
M#*?;\D!X4C]!(<)(GIVAN?AMA;*;IA4P-7E/ZBPH&8HV1*J%(SIVE9HVL_:N
M\.=EY%XU]X\I%M,3R< 6)JO(<7!\?H,_S4L7+?U(16H\U<6#0*@6\I=MZR6,
MF7C.*_@RJ>/?7U \L,=)3,+KV]9(@8NX*1A4*T52Z!G=P/%J62*I?;R(H4CR
M:KI$RGK!.W!N;[/^?!:QJ5,&A:^KQI4(H:[9-3NN-<+ZSS9CI89!!VJ'ZN0/
MIA6.T[<;((NMXMAAJ+XD>J\4.QO$TVI(P]R345.Q\A,[O1T/[]+$/!FM/VX*
M?S48J4 :AVR8L.0:0).L##\:SVH#P+.G'-U]'#"3+2#%\W\8V4CO:+R[>9BH
M[[<5U'XS&CV9QE"XTA_L),=CU"6OXSQ!-6=S2%ZG.SN%,P?\_I+\DFV]!:^#
MAG+RC'EF;W6-751S]I4JN6%4=\"$L1>^ICB.&$FJ20&_3;K_'65[JM%<6H+2
MO9(Y3PP2;31#>3-I_*.=[;EDP3Q-ZQJ/'8-0N8[MREU*-?S?='S#5$M((&HM
M":G-X;'!(\V<T,";@5(:D?$*#U7MABVWT,69VI191J,[KA5O$"I8E&<1(M]#
M8ZP=B82?&@NJ4F9"G+%^6>E1B[RV6[2'E&%OOKK.VJ881[-X.()'&LMY71LG
M$Q3M^]Z0E"!;MVXZM!-)\OJ1YFVF#/28:P3ZZS@16"FS-:)9O54F>%2@/6[,
M'!E18MQ0S @@#;TVB4#]ZEVG[#HLISB8BZSZ[#L>$=ZHI9-'K)^ K;X9L-MY
MW;71>LJU8\R^G8X_:Q:<R64)UV)2IE"'U+Q@M2FE*4@G='Z<R?B2:QSU82Y#
M'P=4@2VUDHNZW!9LW83;HOC=QK-<X302>U%2R*WI;. D2$R:>-I9X*4P_6-\
MSE1QA_-GMC@C-4<7KR80Q>]H(Y_54#!U<[L/F%U?I@]2[DGHZK*"P9Y$MFVD
M')15+-3MR87C]"!/!,4H.NCNWB/4TU<NC\6E%R$$PZ;HN3$-M:/-X^6%*9>@
M;0Z$;MDT1#6B(<!%NHZK@>],%#K^F^-%.$JIO;OT^G2M5C0TUOKA_81-733B
MY!^_?S"\(11*7S%D"64[A(K[&+"N:3?++)/3L8+#+"OPOKW.D%),@]*CFY?J
MH;%E;4EX-3S!O$3V&TRAAC^7RC X.8L,!8[,-S;PS4WUX^ZO( %@_\_CJAD+
MX)PZY\5(T(<QZR\@7IHXD)Q*$UK#:!=.@U27$&&/!3E%0/C$6F/:/1 /L]?8
MAQD2?M[PV#0V90OFW"QA)^955C?RR7H^7ZUCMD=W8J^$+/M.8)==(,\WO9I^
M9"_!\JJ_CP@\C4Q8)<IU,;;;I@?;&=0KU6!& O6G+KVOUWS:#>PRQ]A7R5)T
MN'>QC-K&V7FZ7IFFI:RZ M2JFK?S*0)+)VUMI![D#-&O@"IT(=;VZ8Z^6CXB
MO(FFMS?X<A$K9,R?L29/@E'F]P69,1\&M 8$505;Q]1;LD(D33:?9XW@UEC7
M=>]?K&_RZY!O<HYZ.CA<NR 1-["5LXE"QIX9RS2Z!$+0,!LP8#EL>C;Y?F<#
M J%+XYW9$BAI,XVO8,)WM-C$>?,]-X1_IA2RAZ'1_<+A3'R!(^QXH\JZFC)=
MJFUF:W^;I;C?EI=982/MN0D12U<E@YB\I/XP3*%6C-0Z)-Q4,L.YTK!P[MMV
MXS]RJ#A?[%6XU%^ V5C(*YVBOOD=[(<"7;$IW@4QPO[+3<9R7-+)ZY[P#\6/
MA(FW#[WH?>-M@0^D%Y_O#!7?#^.>&^L&,%X[V7_3OI^-=5+]<2MX9_L'T*NF
M_.YX1/\_V.31]<^!C7_YS3XGOG"V"57^6TNTW/\#6.'MFCF@QG>[Z%-]273Z
M4/>[]>9*DLS/":5[[4-N.WB8DDCIF2)DT!>.^P3TX_( GY;&$&D(.*1_-IPB
MAB9]4M)QREUI/IM *_1$J>%YV%!3-Z5OPJ- $V%>IP<32\"1;E"T"F]2)NXZ
M%>/RB%+,*]RU>CK:O/JSRSL>/;3_E/96]RG(&W)FV>>&_$%8LF?\;%PU#%D_
M<?/AW^CI!^1A,/(DX+M1N["E99^[0]0EF%5 E$_VN$1F<--BD$)#2P:BX)4U
M J$RL1ZW$MX<X1'A?4J<8RYGFR)H8J/TH17+]B'$K*P"ED$N44^Y0\)\%A9?
MCHQF ZJ6O9! <23FJBQIZ$23I#/CJ:J$^W+.9[P2;)GW,5\)UD?PN"1QC7RT
MBX;]?[JG,Y-J(7 S2INW5R6JD(:&:M):AW#6)2.?85B-%W*),8*A#?W=)%GP
MS6[([ET_,9MD )N0Y#^LA,=KZ8[\=<Q43G@*)4<0DZ[;$ZZ.,'?"C#_K7NFU
M"A>51K"5GDRM>E5K1RHV)1IJ'/\#.)04E,N75TOI_[J8;2HA$UZIZP#Y"M_1
MU5XEOF7ND^*Z-KI !IQ,!Y"-KLOBRA\;84J\6FC%;B-I;*<''1ST8^B;LG^4
M3B9O2XX-^SW47/J.Q6;C2ROKR@=]FCCD>\C#PV^0),_&P<T9\T_(G]??GQJI
M<LT?A;C])]_7)"5$N"TBJ>V=WK N-^OAC+\0]2_2H>1[U2;E[92L1K^@;N00
M,Y6VGNT'EA77=Z=8*>DP=..>V@0 %8,S*0(5Z6I$Z=F4@W-QI-R!>)TS\*C-
M[:&<@T/(B,FH#%X(E9W#FU%W:D/[_[<KTK^0CGVV.Y]?70S#L6UX6\]]_=7^
M%<:>9%*@>/_AG2_Z[\*L5>-1(572.^FW?P"6]W_$VROW6CZ3</[[/7TP'?M\
MQ/Q#^..JQ3C<L 3K>ZGP[YV-SW:4#WEVJX68SYID)"?39YA"1RU*&0+V)>G*
M1QEA:X\O; .CFRODP,>,FG*-).>0]\0HS_J\695M<(EN^-:Y<D&.0';/1C:S
M4QG3B%Q!W7C>S!"A509,7U^[-%9.*_&1%H--"#N)OD7<26<L"P'B(&]E#:^^
M>>D,\"5_1#@=PKQ%?)!*V&-\L:WW67+'%#:/,!U]LA&L+<E/D3&K+[!)X%P=
M)?M24MZ^'5=)01,KP5B D"?->WVZD"1P-<+G0&S9$A+AG;8I8[.\!2T.]*)V
M*U/^KKWEO!W['=5*QCEAUL=Q P#JZ0&8F@DX[6G>,J]!6";>72UMU?;I4%5:
M;M2_>C%<&ZUR65S5[*_%;M]5HHU\^%CJ8KQK0F+ON4% HUQA]2&*&DZJ"K(C
M"]I'SK3!+ )ZT-"6)8(9&!Q)VE(4KD>(&.5S&' 40B?,K/&[3^$0&E;0R+V%
MK!\U0]IV9W!41:X?O=][,$4H;6W&0"!M3[PJD=/VYIKVV'A%A]XP_4*":)F.
M_#'^F!3GRQCK2".EN/W<$/TB+\UI#U+SY-XP(9'M5M<)5G^&1+!GBRP;N=]B
MK4JR?"DK<;C?,#HB%\=YFA0.\@CE%X%_ (%YT@]VNMA+ 8)R:53NNY))LC[.
MXCX\TSR_GV,);F0_QAC5Y*0[YJGT"_SBPDC\0S_<SR8-44@#$DQD%TVJ4OS
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M'Y_UY2J.5M2WVV\\?PYJ&V4A->A<&0^H$YB@;O?1JS Q?;5OHHCL]F\:PI?
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ML>@;92_;2H0ZR<AB:JR?X64[FQ_G+,8V5W"[T\R$?/"3I=KR!M8#K=LH87F
MGM$["Z*W!_KJLZ=UYF,_S5YB?R>%#W?EW':U<0W^GI1 6,M_,O:I+6N3!IJS
M6F #92SA"'\C%TU/&9XX?R3QK*9(@A./J\3B)DHFJ<^@F$M3H3:#I:GJ(RU<
M(F'7&7\RGR(+>6 3[(\66,>0?_68G(9![QA_SQW6?,,J\3?DBN_Y;<!P7+)<
M_1(1>2#%-1X[FC%HM(,_0M9N<$^VHM*CX=)S(5,4RY93"A[;'X\>RN++EK-_
MB9@L9+["PVPYSR$Y3+954HA1PK[.@*<7UCG&E^.,9/.EMUWJ:8AY97@\6< W
M$YL3.<HQ*O3\KNXH0_,\MK+C'?)[V16A2<L'=(-?GA2U"U)X/O516.&$9,RO
M:L5%E#;1_0- <DMHRA8WI+6.,&]825*W((W29 :RM-2*:?.IXK-/9]Z$R?3T
M*GV[/EZL65NIPD3" ^PNL3*0<30#$/3&4^X?^X2[N,;%(TKC'K$G.RPJ;(>V
MP/U*6C<W<<BJPQLC3A305<*XA!J:/WC!TB3Y[337BF1)_ )!<3<<E>[BM'^9
MGG0ELY-X+J\(H_>5M0D:"F:-^<2B!WS(Q[!/$^($(N39JU+1++'W5. DQ7^0
M_*"N(4G[7Z;4"0QJ)14^-<23A GX[O5]'Y^M_U-M$G#\*!GR^2)/\272B?(S
MQ>N/S^=S*&_$40<W]1+/::^#7G]%( &W?/]V1Y+%4W]KL86P21\T;TCGUTZ'
M?TJ0S"\65!_)4HFX?-)U[3%;/"Z@W (OH+370*U$.A/,NR9NEQ-\U]OW1+\&
MUKF\=MBSU>6YQ_<GQZ@=I_='H9A-3Z@Y,CLMN':0@*M$>6QH4X$-62GA)7P@
MAR<9JCG9+&L__GRG/FE[U/C\(QH&+":\:](OEJA,R9RU1IMU!I*\R".!M)R"
MGJ79Y"6;INLM( _"!+L4)L2OP2A&Z]!002Q/T;@6Z(I1KR_Q#\[V=9?$PC8Y
MY>I>YX:K3!-*;&FR%2>;D(V7.O7-F1->'-KD$<)$(]!U_K$V17V>GVDHYDPJ
M'BV\5#TC-]P/&A<Z?G^RR/IV<GXT&AJ!>[T@=L+YK!6G3Q&/3I[4L+>1]UZQ
M<%'E0DJ1VWIK80T,LJ,XJH(M1O291#>CM$%L7OMO^A41W#/GGN>GC8$MKW1*
MT>&F?9F(8!Y+@M>,CZSP8[Q#JFM3#!8DAJ7HY=8 VR=,9:;G&GE2%(V0*06&
MF,TX9#:E<\[U<MQBIS/FL_&&?.M#Y_^G]N#_-?S_3_WD>K3QW5+<RW:3"S$]
MR%0$: 5ET2H3)--3R;/$E0!OD$['?[VO6ZUU9+5U=U)ZE0;)=4FPI;#ILJO[
MI;6E6"&R>I4K(R;(4=([B9^64UE;'O"CB86T7H\3I#^F:HL-S2S[K X]0M0/
MYQOU&)SO93/9!O/CZI\K"H-+$,MXV80HCS6=]('IP\L5\J&KM+E8,=\C@I2N
MB>^P2878M\0\6*-5#"=OJQ*5&9&D@&94DVOR\*O?=.5"K6X,^J5R!-K=NHB#
MX9@MH?2?3$K%RT](-\*<R(VJU1?DOMSV6U7Y<T$WG TY5WD%7-1495?L%<D8
M[P<OO,BY'8YO^KVM,0&S*-E"UH>XZOSPWFC:VZE4%'4+2D_5H88MBTPP&_]@
M\PEVU0_]Y]P3=:JX-57)[@FL@) V*4OGL$IUPXW<C;#VIU+]:.- ?Z7.V2A=
MI_[L,?1^=Q>V4028S=DU1FYI)1$'?ER/^TU9:\KSSM?0F=HAP29I"-(?$ZB.
M2Q6"D<,O>&F59D57BGOWB0R'DME6XH1')3SQD.=NF*^'1>RX-WBA^6Q7R$G-
M.U);*G+G;M+96>S7KN?6P[+C8YPZF7C8$[_X3#N\1WU,P^4VIDUL_9D9="RS
MV!1$M% G5=+RHU?('@VA%I3C$&G+_P35A6&B?:)1&H<C*-3O<G*R7_.^(;1*
M'I$U&N4+3WA3IT5#.ESC#$G.O>7^<"./4%XST?P1S774](? D2FH^TSYB:CT
M*Q?V,HO/,)>Y\;8X-/2I3"YQU%M<8MB(M&&^FY#%9S-,,-]S'OL?0 /%<,H3
M9R&5]<^'"Q)CH="@O&Z;55;MX(+D_L/1E=;ZAF^C]PP4JU54?IY=7KO(7T":
M*<5F>Y:_K=+9)+3[BU;!3R+?QPT[G*BZQ2??$AX9\1[TP^"KQW<QNF_)IL0+
M1#/\M6!V QJS6B-"[208\9/CCA5S8F9=@U+2Q\9ID4Q=O6(3:&S'I1J+D,R9
MTY9JX7A[W7+]G# !=/:@K$A@!U8U@Q-3=%'-B;2@R;ATS%&6R6/]@T2Q?'M%
MHJSUG]Z&K0:K,>P6A/JY7\QJV!0',;+CFM(8:,N\EE04&\VA(6("'^K]6PKK
MY&?\=9R.7X.Z)ZUCC&45+DAOB2E+NZ7JY-D647*1:2AI$S>\)G 0#,QS>OC%
M.@<LKS)P]QYCM<AM/QF5%WI'9PFJ=IMK9#>@LR*HZOV@,;TA=YGP/BZV* D7
M69TVNWHQ8H*X/W0&.EJFB"W</YW9:&+G&3)Z7RJM?K-%]LTOX@XI2KW4WJO:
MHJ7))1&57B'?21F8(M8O,*:,2LAY:-#J_J4_NRE --KJM.4<2S2T_M I]3.2
MR#MXJURH7##Q=7>5/D7C#W;?+_.6TND$(AT:J?@(@C 1=KR)*!.9EMOQP4V;
MZ1@3?MTV1(>V8%Y;<DY[G!4?KA,<*?H>5"$WIVK(%WG]F%9O/7A_+_(?_7]X
M5H,63SXM'_6OM5$U:A.IQ(C&[S3O@JX,A@]LIQ KXBCK/C::DUBB33RFY&<&
MC,AP,]F0YEW0+FUGH]/P:D\M39W@\V#.6+/SSF;$,C9<0=\[2L:SEJR,2E>N
MW<\\R^TAM#$2<$XGE\$%) G 3[IA!Y2]DU]&C2]^/VN*->2 !O&MKJ+5#=G[
M.#=U!?X^""T\ZM)K$E4D[Y#^*$XSG.D5%CR-_'RHQ&W8_"^\P=.UHNA\%$6+
MFU,SV%!Z($URFQ)Y-W+J: 936*"9=[S4JC7O7=DR#N<Y-955D/+6/X I<N--
ML8Q &;  \E:^H>N$95S^Q*S&R+L(QP*A]K2%T.E'RYY]FN=(K>G5C#H=#J>"
MWJ1!>7%C<^N-L76"'?']J/94>]B;0+)LE9.U?R!MV=XMNZ&6!%)N.SVV(8(
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M>/UTAB3G"HRG73CFXQ-#*RK*/Y*'UE#6VBO8H.C44JE)H12+6I#)DW4B5K7
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MM)$SJI''Y#[%X3'SP5I/&O]RO<ZL5*7'R7&Q+!+)U5*IB%P-%BZO\L)&T#/
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M:=@%8PU5.T2?$JOG.]:WZ(?YA3<=?Y.1CIM^+.,>-%V$=3@F2;XZ2BL5J__
M78]YBW^L=?TRA>AX3!<1<4ZW/I[(!VF;CJ28'&8'N]T^+HBZ*D6P4J1\N+(Z
MK/K&QH:=+DB]_3C9%09U11E.8MPZ A(V(:Q%Q^6D#@7W&6_HRIV?2M-3T?#^
M!]W-QW O_<IIJ$J30+=E8\S2P-!WU\^67^#!2(%L>BE02V'KP"3+_.BP>ACN
MQ)?^;EH[=*K/>J8S'41B]D!",J$67 L77KP9<KN_ C1_0$S47KHOX-[,V2O"
MU40$HSC7K$)]G+CVRF#%%MF;RBFJ+4RC_9O>,C_8W+5([X*'-^*A>Y1Y][$6
MK:+A=D:]S0U#GNV^U^C5\U6]Z;TY Y0F-MJL)M=!@MZM85?>*%0"_;4>E%F:
M?I9/*+#"0'\X<VQT&ZW&GK=:9ABI&<]^>$,>07"F4<'N.J0]:! 1TU\TMQ6$
M5)'6"B]T[7Q_/HB6$LR53),?HBS\P),4O"4.,]1 Q9T"'X</RO2;=[+T9 7#
MNR5T,+^3HB0W &RZ;+"J;=NE,TWW;4.J3W4ZGT-<,E:;TV)97>%M2I</IR:&
M-.IQ0CN)3B6S)K#?<W8<\:3K"-+'A4(87/I4)<YR8 G7A=2/0-=( DO=N2S_
M5$+#UB/TB.=#.R$:36<JOW<%H9*=L$EE%- &8A>]0T6?+)-9G>EH'\<%)-F3
M%XB<XP?V]3MBGJAO4-[F)NJX$315Q8;K#EJNL&^EC\8!<.A3G71QG!ER+(DZ
M0*;:;H3CI=9?PSK=OUOV7W/21CW 7>=W/\1WMTZO;552,BJ>6+48E!7/U:&;
M,:,^@$J,#Q/;N(1]5\H$O)JE#E"LFB.RQ%Q:[53Q1=221QP_\://S#Z@K9.I
MX%5KEEPV89B!I6[&\D;C89G"!/ZMIVQIS[:02VJ)_\[_ H+OG'Y1"ZH/,]XW
M2<&FMCN^)2XS-'G=5M#MC7UU%A'"0EL9L1%SI\12V8<S*"<ATD/5# VFNG%;
M^<<G+\H43D*MO' *Z@GJ=,9^S!8,R09O6\3FW+%N(#N3%^KF@\="IEE6U@T3
MD37Y5H@EE$]SJRN4-;A\TW=L,JFJCM5$[Y8/54]ARV^\=K4?=9AVT*?"Q?Y+
M1J<M?#),&S^K]'K[<)-X??)@2W26',JU#\I.6A;75<!BR!FWV")4L4TL0;$X
M6FF:P4$FP@A$!'/ETUPFK^*8,"X(ZDO.TYJA36M]=PY&^D<:+X][#N'9ONZB
M6OB5H\=V>7B,2+?:A/S3@)(T_-KMCZIB,W+M4S:^/XY*_.=HH8"LOJXA0E_^
M;:'4^]F.VFS@0%!U,M=HXBP2:;H\9_;OK7!KGTH!96K<A\1PCR1!=GJ=VTO$
M@9CAW8W"NVY^ZR-'BR>Z7+BJ%$<5G;/G+@+CBK@PIX0F%%'DK-$XW/G&J-K=
MX!R[UZP;H8IM.UCA?I*3^-?7T,GF6%-;I#2%;9LT??D,IK2$KLR)_-^;TTC(
M%2?3'8^3R2/:SIA.*;K16+NM]N!,%28G0,FJU0!J<S@"8 E LZ#W%,XWB##G
MVL.Q!X9#"R/0AS5Y$GK&P"('Q?3K78VDC]H0[K=LP#KRCE)6J]X<).CXH%6)
MQ!XIGJS1^'0HFQ9V.(L<DHN.[4)9WA1'Q^/8\K4>%\A &6>$.?Q!:MG% %]?
M1X;)N[^%'%'\\S713%"[^0.CQT2NA'N&><P: <_+_FBYK@@K]_/,(QMSF+#)
M5V2B<K&4=DY%+E -V9^XY@2RIFR8H0?H)+1K2V$8C+B"GS&:::B?\6GD<-J^
MBJWJ.(&)CQ"1EG'%H3R-N*\A5-2A(MJ@!26>'B5I:POR*(#3A2.#+L%/!2Z1
MJL:D>H+"Y3?_:AH<WW&@T)_8;GVN"#]JP;Q)-/Q9;^AD5*<.;MK/""("!YGS
M9>_?*0O4*H+WP78CYBY#G(K%8A]!ANB/6VP&CPN;:HR2+DP.%JLG.T5DW/BJ
M]#F;SHT.:K+7=174. P,M:'TZ_$?:@@<[FH^DJP4<R'VND_%$OF9<'QMBQ5(
MJ+*,<I?2E=!H@6M8KO@_QGA%2!,0T)YJ68L*U!(*XYG&IW_BPN6;Q4(EG]ST
MX&Q=L_35E..80;?AE#Q(%4OEF-BZWVYRF$8?]+++RLZY7;\>GJ09DNR(Z&&<
M?\3WOS SW%,<<S'W5G(\LXFNI(/!JC4VY+>459H-[SHE"G?7IJH;!OKV*(?G
M#-9'6WV"YL@K4=N5FI@)7!AX*#"#-L4*0P/RL)7#VZESR1/=IJA7>AT, W9T
MO& "]SV!SD+$_FGS57:WXW[<CE@PV@;2NK#MWM7!L*^[.[R% $[J?P&-[Z6_
MB_^!!.U@-TYWG+/W<\;T8\OGR<>O@<<I<;K3%B])YP+M2>1@< [E^\<P92+J
M+%&0%E:KTH&7\8"APKO7H!/I7O0(-*)K\6 T<-.$V=#.0;V\;XY*A1*,$!6=
M2/*^#C1Q!!M?]".7HO@Q'NLH#3BM7?L_3+@]+F2:9ZS^;-+\5'^RPKK6P0,]
MFJM#T=[1>--4D?CJQS)28=S<-1,.P?_&47ZI+0RTPI1V<D'/QG96R)1D VE)
MYE%(%AG:36/D*4#&07S)!R_ZX< TD''XSR+#SXB[;P ,)D+EV\J.#5_]C:1.
MJGN ^Z,7_(LR^PGU"8YJ6 .O*-8&S8G!7RM7 E()U,;B_Q#35RAB,:N)N)5?
MA*9@Y[,334'7-YV=>M*#(-P=M][9#QS='-667\Q.P==FO_,S_//$-D2 ^,/3
M&>6C:1(8$K*WX8I)&DSC*QSLAG:N])RD?FV RG@=+A$1TYK0>MG)/0.?\@6(
M%':@7/>^+)6M!OAWM4B<ZLT&5!BQ+U,8>;GAW:O6^7.-:K'J3K^NMDM#.=HE
M=K1]KD@8+G)=W6JNW%]ELAAZ@[ +=6I>GA$>H,HA'JW&Z!QSD_T3)J4Q XIL
M+>"G9A5F7;#&!^A&ITUMHS'B8 WB(J(RE]OUM;A55*(XD]=31G=^A85)G>AX
M5C=RK%QJ,O9QC93.8UYI^^CE#GN%G_6Y-4+\5F^3PV>OFU8(L83S(JF7S>D(
M\;$B6FR';$%/TC-7F?S*#*ZM2$-70[ZFH;'Z5EP9\U;9VEXRSQ)!ENIFF\QP
MM@LF.N.V"Y9-1ZB3NYD%(09R1!=C<$RF>T#J7)5PY&E/).&?40$X1YK\1F),
M:Q&1-<-(K\2PI0A6BZ@4*!A\/=31I8;HEBH\EV*IU0"D!\)=-KR6$L?3 AS,
M+[!@8/4[&V";N77)/#D/H?80)S&F"5:,+GF4/6H^K/OM4P0V@/0+@D2H'(*O
M0;>6)-/"R<M.A?Z; ]#RI/HZ+J E4-KP;WH&Z>K7XII+V)4^).&/DOU4W]"F
M<1MV62>X&;U<QI:^;M_/N#V6RK!EL"LZY\>96EK45Q,8::B?.&:A23#%KE&R
M:(IFZ->F<(M-(@6*7&470%IT:[W.ZF\O.P09Y#>38YYF,.! $.3NNOA1&,KF
M.NMB.4XVF8&"8Q5/^4&F[X24+'-$P^6PG)6MLPXEY#.^%-?[^BRCB[)]7R8A
MR<:D;!,!X[R#N/EW-V'9MK!,CE8 D7EYE&3\GZ&:27OM7?>*M;42/_I;HV_<
M?6$P K/-$@3X\-6\?M53>=J<.XY*;<29?D0924=JFOC56I&\F28\Q?;D]'$-
M*I,'/V$OFX#H"9]\3$4O/ZAMR((29T439_"/+!=C4>0]>ES7C7!%GM*,.H&!
M':&_*G21^"TX2H^!.-:(H2N"Z3T>:7$ %(-5%P,XCIVO!)TU?+BN;V1J848C
M?[+,S*^Z&_+#3&'%:K22/)=)+Z6&=!TI Y(!B;[&_#91=>-R-,%X\&LYF[2^
MC?W7B(O!P0&A*X.*")AR?/F00OGQ"KFE(HZX-/0F(<XDDXEP2=*)V/_"A%(9
M5FN,/X(7-P/&EK'V+^TT*?WLDK:)[WE)5-S9^XKY%S=HYK_DE[G_C=$1YPLF
MKRL3R3_G@R%_Q"<MI:?A990$$QK"086JJ!\JD36B5YR3# \ZKS)?O 6//XFP
MHU=4C:-3DLMXFMJR5A>CF\?\;C$.?]&+'OMHQKG)#UE]B+/JY*9V;I;L53!@
M[9,&"@HO JY%1E%U&P;?\:4WK8#K*I*#YX%/E^"&[!/%_%BA^M8=X3;ASQ["
MU1#9+5\) ^5U++,A_=<G'SB)Y.5*EXU^SB@Z04MXF#GK?0_^8:+0[-+C28@6
M_>=XFY_TV4XK_,1-.^'C4QSXT2:S&K"Z]HLFZ^AMK]UQ7+CUF'$()S+=%"E;
MWMG+A?=M^_'X;;?"Z5$_DH7B&BD.0%)P%099'FS"##_>H4&R<;#[S>SF$@%)
MK:+,RLZ=)B=]-_2XG\@U!%7IK9U,2U?3V^96I0C--AV8"NX4@C@(PMB&M*04
MGQ'%;8;@=WG0^-NO_P"+;*.,7WZ<):NM[VJ[OODTWX-[.6C$&W,]8$S@@N[/
M)<UEZ+#W$7Q.8;0KV38=U8;9;8_KTBX+C0NM='73R0S\?)LSDNQ#B^QH^ZR>
M#-34$6I4]0CPG03N$]J'X$/\1N(*[1OT$5)#1GXY'7!J0$" 03Q3T8:_L35X
M@>WCNVC-C3][]]N+:Q16># HD^@B&Y<;)G1C6/NA6X=6L]FQ?"^%- '-PX#
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M,R&*JO>:#<@,5&^YTI,KFAU^5$Y/7^8:WMRA2+--&S\:T)'-\#4CB!9R&E+
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MO6GLR;^LNAA06/(^:[/6\UU5^RW<'GC&.>W- MJ2U4X1Q@ )2I#:FB292+X
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M5M#>7P#19R/*A&[0XH.5$!Y'8Z8WR]R[[?170^9D QR\^1N&,NHXDP(,_2N
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MD:G1D9-EP[.YCMN=)J8,S_0> T-ZDTA=)I=%,4P_/S+MQP\A8ASO762+GH*
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MS>43^*SOC5F;:_8K["@R ILB0 F60YU9G6X< S_-  DGY-7Q=-56]3"6="_
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MN_%8X/O_C@/>?!!_L/O/'C&H5DD;$4(<5\.YXBV7U7!CA<$+60IT2E&RFFI
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MF]]]@F':5A"P@8J)P2^P'P:Z,!<7.WTPW,-5Q]K1YIR-"] %P  NYW_L /0
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MH9E2?D\PROMI3.U'C=\3@/GS19!?J6040W@%:(R,43CNZC9=8ZRI65TQ"Q5
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MT$85@R".*F9R/JM;A/>MZ&[-D;36V FA$)1.FGF9?+7,$_,P:S=_G!KVMEA
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M^K1#3/7HT,2S"&0TC$N+6P =JU*E%/MGR@&Y(H"Q5Z)X]OBG-8]O:HNF*,N
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MTL1IIW/=>^MI3C:GRIG,AY99N+.%44.=<TCW872ITJOOWJ1V\H,E8O='5M9
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MT0.-HQV.APA+J&,7/Q!YRJEH) ^!;;B93]3X*E6&/WDRR2PR5,W!)S@9*NV
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ME<XVU*GY0+5JGMMMN:OI+EL9P=>ZQWQM^]EJ-T_!J--G%=_JTQ[<)KNG>AS
M@$>=7'X+((M@JTW<.!LIPKJ>4.SI<ES3#7F((V7US9L& 3SSD 78M]I@V46(
M7[O==17XV3:)J %7-WA\"\]/NO_)JE'<;;LAE(=A>XBWZ:*HGOF\E<(:SWS-
MU1G>-Y#5* I=0]R8MD9"00^\#:RRD.)'[W>R7^[D-4 XWJ?VDYYJ)#3R,?\8
M,@^692\C/2)^DDZK7TZX-*]'J7E=6K(8*F-SZ'S&[%#%Z#HEG. )??'D"=9=
MLDJGF4C;S:#[S]OG@PT#E8P2 # "W[62UPU9E;%*EIQEW?M?5$MDZ>X+=?5L
MK>8=E]6%)1N,+8VW;BRJ9P=[1"GG%5IJ33(<*"FY&>OC1R;TW)/28I4OBV*I
MW2\58S'0YB+U>\;<-.2_F7W4+#]X!PC"\QQYOF7>._!^W?J&,UE92$E,-^RI
MERRS4V68=\[]FU*[9=M.3\K"\_4$M>@+HR;F)5F5\2N(&3PT0HFY",//.VD1
M]7[X,\!-"DTLOA1ZW/9(1T?.P]+86!;F<JF(Q/Q'M&U=2KL6E:'"N0]C;3QY
MS$%3_"F&8T0GA]YN([DYXN\X@*W>B@@E?QY.#6"  >98F"OL"9?>]FR0&7'3
M&RM[_1JI:"?-]Y]'H7B)V@5[S954%/%".8J8<[0&8-%QE "?0\K!8*!A6$P"
M(7'AT)#&6S+ -S=L? 3O7->B4MW>ON:;E2X5<'Q(97&9B*-(;D!7&C/OWCWC
M&!RO+=%U-J,&FI.H*:4$FM4R1:4"WP0&9H)F'F2#9\(-RK8W<L @=>?7PFSZ
M31QMODI*K1W,>J42]:ARLZ,U=YZ8+G[>(E]<'$\DBQ]?E/+5TT! (CO'@09B
M]//DSL/]I5U\ ITFFA!S:UVA' 5#C[,(O\,$O03* 7B]4'**$&E:;Z>U1O(:
M/>(SSVU/$0;_5Q7%: V);J7;(X0X^+'7I6FF%X_S(V[A'AX/([)MJZ=V:UFK
MNV0$27B\$VX8I^C(8]]*'BXK/P8!D4GS1B0X*3LZB8U;!>C]@: ,=ASFW,BV
M5!>322V*B/#]ETZ%5C;9J=3?&G6FNXK++#:N:[5'M2N_.AODJ!9L 4HFC>5Z
M*H+$40H"=% "LI".44\*V@+LN %8>UND^R\7WJHGB9$(".8 06//F0$:>N.
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M=>;U@%AK1$N])[U%C&?&?I8LL-,U_G!BWW@-KR0UO;0,+\[$N2NWONB>F$'
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MF&IF%B ],=]IR4CHQF*MHC<]0*<KQWVV>5QM=F,=HRO2A30@335X78;VS'A
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M[QS*8IAQ,I;EQ@GC0:[6E: A9H9>N;4B*#@@DS/AKEF?K].>>'JJ+/O'OD=
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MO24\]0E(VAA^5[5"0&T)]T/ _S$5(_V?B^Y,JZ&X2%6K70+RH&#;XT] T<3
MKZNL8X1KC1R*Y.'_U-"$O=/3<C^PHREPW\&[7U^'5[=O,M,^ 15@"KR/QFOD
M4<:^9EOGVXT_$Y^ BW.^R\>'.<S@O2[RLPUYGHKF7/RH N7S)KFS;@[?)NQ>
M52ZEW2==:RTQ(42G551<E^1B(!QAAO/U>SZR#Q$@(O+=@E_R.'45[BSEG\&^
M6X2EEO:?<;&TB>!OH2LAN@8C-TPV)MQI5ZN'"7>EIN/Q&&%4\__56"H2D(YX
M4C+VF)(?[YFP10+O'.91PBSQC<=A_3$U63Q\# )5-_G[QC'"XS3P[N[)*_;?
M'.9E5FP$X*V-;$KL/:.<YBCUWU]QZ%>3;N5W6+(5=/ZXE] ##RGAF>6>W/W<
MHX4^QMOX:W+???3M_\(Y9?^:_S+_SB^.SM=]$7:J='>,<#NE].K\3OB?!2OB
MQ,<WF><'XIQM2[)"&0FI#E+R9EUCQT..S8.-,RI;Q^;(WM;)&]D))ZH*<34(
M#ZZ&_;#>\(LR!.$:='N"*(1:V4UP]:2GR*#][896D768$@@="])"QSO$D(%A
M)T>RZ>HW-#@*XQV>:[SSM,?-[WUX'&R>TC6]+:G7QJNP^\'^6"K\EF)277'8
M0,M8H%T;QI]X[Q-!T2.NJZ+-0#3V]X\*(J,&DH,,;&+RVF[OY+.@43H7' V%
MHMP7-%2M)\[6#D$7;L&5F[WF-TT=WU)"\57'Y/RA7/$YO.2F)JQD[CQI\0 *
MX([$)E6.2D$DS@[P)0 7USKZ^8=I*'0-GWXLF]\/7LV]/5K]BY>1DA.TP<'K
M]HRE/J4'/NQ,IRGC6)C %J$"MK<%J-,-'^F],]EZ_-D08R2\C)G0+TWY=M'6
MJWL/R^]"?U6"GC1Q(S34Y',CIF]EA)+@V&%57EDG2(:B,=E(\QK^9$V"U1#Q
ML(M<:<+C,U1KVP[RJO518^!EE9-99!E)&$A>L6L9_'<:';$Y9/^[<'].:Q+.
MO!:+QM9?*PKUM[J1NM%AAV.9RG+I!)B1X">6VURX89R)KRJ,:HGB1P<"/[A4
M=&6>77%EX&-386;<CZE1O=[(^GR,])/_+C)_ 23ZKO90?P)P8W-V12JZ$<M'
M=D%C/=\=6,4*'VV6M334SF).AGS;5,JRPU^MX=A\S;36YCQA27'IG1*D_R0
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M>36GPRDLB'+4R2<3K6V<8V/.3D%*S&0W#&/8B;GXZ#LWWF)S![CE'K^W=O@
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M>[8[G#&)6=7C-,YDN*$=:8Y%+1KRQ3V;E!JP"Z62-ULLT=PG579%+8_!TCC
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M+@+-D5?-02'M6>P*3P#N03\D8T=T#U@/6OWI]2 8JS)4D2=%D!9&\@G(2&M
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MT6?@M=)@;[,J.XGT8+G8ZUCM,C<ICC^$9;Q%KY,#".0W=95\Z-!A4'\%@.1
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MO$G03PJB%B6>A>7^_D2W-07!83ZC)YVT3-35NQGNQ#P.3J*!2]YFQ*:3E9B
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MD9F9P+=1,C(=MQA69?8\.S,NU=#%FG4(!6\V;A'\79YRX']YNR<'\HE- :4
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MY:RS#/S)9]YI@K[M/!"VG=YV0B$[_6UY@!?Z1\#*22]#4G,< *)C2'P(P 6
MOC[Y.DGGB#0P.&"%LC1&FAMM&P/H$.8^6!R8M)@"2&<;Z0"#.CHY0RGODQ83
M-6D-D\H&[4$(M+ QMMTI,B,#*($D!/Q))!L?1KZEZ9$,P@H*!?YGQ.P1B"<E
M 61%:BMZ8@BDL@4ED-K^H<3 ;?YV#-C<_;;;X.WYLN%)#I+:7-MM[V]MZ1V9
M;VW=[;9G ):T7,#;/@=Z!GANMSM)[920X.UE1&9.:B>%^&!"2>TA4EO$/SC
MA]3>WF79 C!HTM+>B:@($>-QB-26W\X(WA9%.B4AFJ0:I?/^J>W^4YM(*MSM
M21G@ L-W,@P5]Y" PM745*$(3*@_ADB4L4)[^*%)UT0#7$ @&DNZC'Z;\PZQ
M;,<62@JR"EQ-145&01;^4Z#^R\%_D;9S^ZWUSGHG9R"._C]YOY/#G2;5'^E$
M(\OZD^=># !MB0# -?HG3Z2<M,I(>6L=^&D^'-OU<HA(#%27DPL-#97UP7C(
M;@?T!_VW O\"_80GNVWN1WB@AM]6.'0[;AZD=1R,AQ("T1[;]_&_%/'_6O'W
M?DBC,%X8/ 9+TK G51GI"D1*-];39_O."O7!_E,2_Y=J?Z%O=4TBUHHO -L!
M68!I@ T@6^P'(*RT )EK*6D$]"-OYM3VP/;*<Q"8_5;W._2;XQ:<N?U&\-DY
M9  #E"W4(Q@?\FULYUPA)]V#& $V@!O@!X0!<=(-1@'8"V@ NH 18 I8 K:
M$^ &> "'@ #2=X90X @0"R0!1X$L(!\X#I0!%4 -T !< -J JT 'T W<!1X
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MFV\87L9C53@OV;(7AU!FHV;:6Z:-JVRG5=<JS"*N4 VH)+8N^ 0^#TZV0IG
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M994 4!2F2,V:H ]<UQ6T=9Q?L;V2[0\.5(3@<,L3TL%RT))0X/BSUJ"-#2M
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MUJ"'!-,SO2MF ORU#[/X/O#?*P6(YO'NX/VDWHSE'QF=-M2W*5BZ+!*GOAL
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MAP'Y=?(#X<C\MQI'$<>3DXA*_P!25DU8_J'5M"7OMOZ#D#E:?_>!_3OK( 8
M;!HUD- ^W2C7<[V7_BN31![SX^(TTJ=Y*5+4*6-E5'(N@OI'/E*KVW4N_P!5
M*%*4HD I/2=ES_Z[A@"'[P TT5+WU+>F^UB>Q010,#\7!/F&?2D?/=\-J$R-
MOMPD"6Y%_P#.7%7W78\>1+DI:C./N2$,1(TN!)EN-)05O-19;2TLD.N%Q@+2
M/;5_I6:W&CZDZL1UN.58U$\@J!UHUR*=+OI3YQWJJVI1DNV+V(Y;D[M78YW!
MQVQKW8]1/>B4S<2T$:G-ZY86TE:'[VR*H#$:*[Y;029+*5(2\-:TS6FI!L?M
M@]+?'<B* >H:KFAW^]!IR;^I,<NZK=BGQ"$%+RBNW IZ2N]U2IXJMVLBBQ(+
MD4IY>45RPTI@L]#G(!0M/98S<499P.+"V<2%4+58$C0@G1JGRB\@S"3E=@ V
ME0?1C[;B/K8;:U6Y[. 82S-R''T2V<2QIF4V_B\YUYN4W2P424NN#(D];OO
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M.*M1PO3XP"KW)('.48]Z<_\ JG-/T_\ XE'^6JOY(JWN3[/\HMMC/[A_L_\
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MEQZ9+DS\$2 H+"U2GJ"4U)#D/,IFL1<%C&IXYQ_@O8W!XN<KB$A"RDJ5+[Y
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M]T?Z:F*&&P]!!Y:!Z(0/^Z/]-4+L.OR,& L /*+:4VDLN$ @@<CCCU Y[))
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M(3XUQ#'+Q^+FXA9)*E.'))"=!7;8!@26O&TEA2 Q)Z/9G^L*H"$<#Y$CL.Q
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MZ$N^6/,42%*[:Z_M;V;Q7$\-@)>"4.Z3+2%/XE*2A+!R#4UJ[E]#:.<X!QS
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M!!"R6?>FI(V<DZ6A[@/-H4DD@<]C]0>?L>>!]3_KJ22D"KE]MW-OO=VC#O\
M>U(E=GQ0E25NCUX)YXY[]NG@CU/8<'^\]JE!3!A>C[7KR:)L'HW-OOK[TC0,
MZP/;K=*B?QK<'#\:SK'Y2%MRJ3+:.LOJIY*QQ\\&UBR8JEIYZFUAKK0KA25!
M0!"4N=)(,J84$%W"B]W^_G$,E3O4>7PK\>MVA*>,>SB\!^%Y"G+L7\*.QU3D
M273(19-8%1O/I>23T.H1)C/1TNIY);4&>I!(4V4D!6L[^,<0,LRC/FA%B$EM
MA<,0-W-=7BDR4/0["IO_ /NIS/+40M*O9K*V*U&AM,PH49EIAF+&;0S%C,I;
M2AAEEAI*6F&$@(2A#2$I"0 !]]=G*IBEDJ5F9WOL^NI_=BT2E"4 L0&:A(TH
MU=AUVZ9Z&Z'$*Z4J2A)"1U(*%$CGGL?5([!)]?7D#TU<B8N](1 ]P?R.D(MP
M5!"TK' 2D>G8]OQ[_P ^QU!#AC[0Z??PC4KJFJ;Y"V)C*%N@$)>X3YK:>  D
M'CYT\J3U(4% \@$#G6MQ$B1B<\E804,02IC<>K5% W4Z;#"8O$8-2)LM:TE+
M*&0MKFJ?+5BU!5H3!E/A(VLRJ:N9;8KBMI)6X'%OS*B.S,6\#TA2W6&PX\LC
MCD+6>K]!KDL7V"X0M1F##R5*6<Q*TAJDT8"SN')UTCT;A/XJ\=P"0B5C\9*,
ML9!EFJ8)O8$!Q9P'9MFCH>$[$81A+"(=145-5&/0I3%76,Q M2#RM3LEM*'7
M>2.!UK44@D#L2-;# ]F\'@T( DRD,H.$H2-U7H2' W8ZT8:+CG;?C/&L0J?B
M,;BIV8,1,FJ4FC-X304;5F<-5AWF*Q'BLMM16T-M,\^6A X2"GGOQV[\\\_F
M>-=8,LL(0  &  %-AU^9:.)FK5-69BB2HER34F[O]TI=HRS:BI )]3S_ '$C
M5R*(GTA%H[)0VM25+2  .W'))4#QP.1R#P?3TX//;4$@7H-S01.4D. ][?/E
MSBV5(0H$\#Y0>P"4]0)X/?GT!3P0?4]NQT*;$*!"G !2*6Y^<4!1&9TD%+%G
MZ\O<6K&FW6*T%R5+F12EUSGK=00@*2GGCK3P&UI2GD!*_E2.XY^N#B\!(Q*7
M6B6I5*E L]031W:O[ #9X'C&-PB@J3/FRLF8) 46KT?R%/<QKT+;#&(+A6TV
ME/4H@AEB,THK "B.I "AP"GGN >>?KWP)?9_ I5F,B42;LEC?E0EJOOZQLL3
MVIXKB4!$[&S2$O3.H%08,Y<TI09=7CH-9%K:M@,PF&XZ4\\]  5SVY4HCCD]
MP"3_ #]>^VD8>1A4!$G*E+6IFTN6%!\XT,_%3,0K--*U*/\ <QY?/WYQE$34
MD] 6.1VX([G[\<>OX^G?MJZE225)!<H+'SK7G^T6210L0^X/,:]-_.HB]:65
M@D\=C]-5Q,5=00"&,(D<2%(4".>Q[?RT "1R'^8D7'6->M&8K[08EMMO,/)<
M:<9>;2\RXVH)2M#C*DJ#B%)44J24D%)*3V5P:6F!86B84T-'I7D*=#$*2E0(
M5:E-7&Q-1ST]A",<V]GGX%=QK]>49MX6-C;_ ")Y]+SMK*V\I6Y#S_\ 'YS_
M +I%82MY8X*UN-]1YY6223K8R>)<0DR\J<1,2DABSL0S7+L[FQ;:+7<HV/J?
MEY]-7#PI[;;:C;C:FG;QO;/!,1P&@CM);8J<1H:N@A$)5\OFLUL:.E]Q()X=
M?\Q[Z%>L2;-F3R3-6I3EZGX7;VU:*T)2D>$&YJ3S^HO'44(2@<)/(_,'_#5L
M "T51/J81 ]@?R.AH"=H1C%V"4\ *//![= [GDCI3\P[C@^OK]/35(6DV-MZ
M;[_+H=1$D%()(+#[O;WBDX\V\D ^CH!4"E*^>2.4])Y'//8@@])_D-4K8@@+
M3=BY>Y;>SM1M(A!J%@Y7#@ZL;4%U,:GJ8T2WPC&K=2UN,I843UK'EMN-J))'
M*6EDH3WZCP$D \GMZC6S^$X.<^=$HE0))*0HU-19FV%#\(W.&X[Q+!%Y6*F!
M( 315&L!9W:[EZB[1;UNW6-02%I8!".#Y:&VFDE7/8DM$*40>2$D\'@\@@=)
MMRN"X"4/#*E@N[I#%R^WETOI&3.[1<3Q0(5B9Y2KQ>)9*7Y.*#Y"K1OC'NT1
MI$=I/EM('*4I0A X///H!\W'KWYX!/ XYUM)*$RTY 7 YZ "O3G[QHIB5J45
ME691))<U)-^0#U?J!K&49D!10D>B@>G\./H?7N#Z_P"'.K@S/H4U8CSH:_ :
M7O%KD:':+S54(-(1;R%MHZ/,*AZ\<)Y'T]?I]NVJ5%J5KM?[.GG"-+R6CQG+
M:V=19/35>245@TIB;47=;$LZZ6ROY7&Y<*:R_&?9()24.LJ3TJ*2"2-0)TR2
M 9*EI+AB"U[U<;M3X1.4&Y3R%-"!TMSK"-W?9I^ !60C*U>$C83X_P";[P)O
M]'="D*=4L++AB(C"">5J3RD1@CT3QWX.9*XKQ$)4D3YJ4D-11;F*V?76K\XC
M(EQ2A.^CM1@&UTKM"R,5Q[$\-J8E#BE%38U2PD>5"IL?JXM/4PFD#I2B)7P&
M&(L5M*?EX:;0D]SW)).(N9B)A*YJBI1+DDYBQ9KDGTT@ !0, Q8$V^'EIIO&
M\MD%""#R"D$'U[<=OH.?SX[ZD6#!A")]3"&'_;"R0P_LJPMJ2XF6[DZ4NLQG
MI*&0A$!0\Y32%%OMR.5  ?<'@:Z[LVDSI,X)(02RG+:BUS[AG (M&JF358?'
MA8+A2<M" 7)]#2C GH=6R-J6BJYJ&V''77C8,NG_ '>0IM#+:FUKY)840> K
M^HKO].W Z?AB%X;$3%*4E0)8=#0\CMI;F\43IDS).E%8=2BIVH':E]-:LVEX
MZCF$^.NNLZ^*)*4RFG8 $F!+8$EEIY!6I#DEEMLJ4I'22DI"DJ]?36SQ&&DJ
MFR9ZEH"A-0$<AF"CL[G9VWBO#SU&6)"E _RY@.Y)#!K$,[$&M]7CSOXYX=<H
MW0WCW'PN!E[V*L8CDMP_+CLL2%.R8DNSF+0]'BQY#;:DA"F@DKZD@K3RE7.N
MCXWVDG\,PF'6A*U(EI'B2000;!F:E"2[6,<IAN!2<7B\004A14SE)) S,0#S
M-WZV>'>O!IX0:[;C(:[*YS5K=WL63[TYD5\A3\M:DI*4JBE] 1"0M Z0EOCY
M".7 1U:\2[5=L^)\43-ERA,ERPF8%!9!*D@$4:H !H_P9O0."\&P."EG,"N:
MP,M(+$K'Z:%Z9@#;S>*'B5\+F [C^('/[_+MP(=*+FGJ[JOJ*>&Q/OD/HCNP
M['WJ'9O(KXLU+,<.5$H^^A3/2^EEH]*7.:X;QN=A9*52U%$P!ZFN:M@=#2[5
M>S/&X'9[$XS^;,0 AV8O9]QH!<$<Z1T7#]C?!#@+V/7N-X%N@]FF-UU<VWD+
MVZ*XTBP?@H*6K&33LPC5,*=6LJ*H\5')"%=:E(2=;8=KL<)*T39RE&8D@L0&
M+6M:H&P;:,B5V7D)6%! "@JOA)J*%CL[U/GL'.]L=PWLA\.\/#L?VW?RC#WW
M\FQ.9#R/-P[93J>[@NIFFPEQX2I+CJW)3[;"E-]7"D!*AY8US,WBJT S%KSE
M2U!GJ'9@3Y\]KQL9W# EI:4%@@5:CU!T%3L_G&>VAJ;S9NE:K<*V74B!8S&&
MGW+;<6^M)\=JL4^[%C1Y$JI*$1D/27NEM!) \H=9Z2=3B.(KQ&&E+*F\1!!<
MF@-7V8;"Y!C(DX 2DH%E.<S UU#?>PUBXW7PV=O+1N5V;;*4TEFQ<=$L3LSN
M>4!])0[RKX6&R%(4I22VXC@CJ"N0!K$/$YLA 7*F,I(IUL^]+:;MJ,S^%87%
MG)-05/0LXL"^SL*DU<&$$Y7X'?#O0VT==CCU[3RH$NIOHE= W'NK2MBN5LMA
M^(D-R$J"$-J2I+C/2$J:6M"@4D:W\GC,Z?AT'$30HFMQH2S!O;F*6C!1P&4C
M$$!+)!+)(KI0%GIO2M(42[;4>?VC#$:JC'W<KB&XC2)RC D>:ESRWXI:++R2
MZ&T^<ZOI5U\ =^!SN)G2YN(\ H]22& - *,*.3\6,;@([I8002]CL*7#$[4-
MC2@OTK#Z?(L9BY"!.0W(+*GX\YIKIZ'4N]1"$D=">EM*TI)' /!_A!&KTZ6>
MXS@N$&H +JWRD4I8G0[FL9!J4R2Y,POF# "FPYU!!:C1M'@XR5V^]H%N^7JZ
M-'56;%X5'78QV^AVW6]8(G>?*4.RW6A(]W2L$@---I^W'08*2I'"OS)((4H#
M+=3D$WLQ-1N^X,>9<=3DXHB46=&8$LSDE)T%1IIUJX>IMFW517?))2\6E);2
M@=RIU 0>!U)X4E)4H'J3PH ]2=4)6ETE0H7UVY_>W,8BDE09)8[^UPQ%[O#'
M?]#WM ,C1$I+.]RF#!I6)]5 M)F>7$1J\:M\KA9.Y89'*Q.ZI\A\ZOC.JQN*
M[%LHZXE=&*>%1U.,JWO?X R%)$L":4L"2"Y 8<P_3XQ:[M;CQD#8.VM&L>9I
M"H8+GBUPK8ZI_9F%DEYN!(W E-O_ +1L8]?9*,3_ &=9;J794*;;LU+4"7D+
M$5%Z\Q8.V-; ?FOL17I("5:\JDJ+, R:U #N1>[@::.8GNU4&8,[V-+:%W(K
MI6G,1R;-;GVDD:7!M:*I38V\''K.P,"+28S%Q-F38V'E,02I,]Z9>Y!2,J5\
M.A6,!=7[L!8HL5REEAO(2C!%)\0!8$AR[T!;K<LU'L69W:W!"@[L.CT!#[VV
MYO&=GYI[1V$<1DL8SCL]NZB9#(R&O8HZY$BD?8B/-UC \V6M94I31G5K\F<R
MW-M7166#;$-0>;EN'A+4S?W9CNX8.=&!H"(LK[P'*[\^M_H[T#58 0N_PK)W
M)&T=6K=E-VG-I%ID4V<,BCUL.Y$&;D5M(IQ-@T\RQJZ]8JEQ BO@SYC$)OIC
MA]:D*XP)P0%>"V^_/WB]*)8@OH:E[^0+TK[0H_5F+L0/8'\CI"+)UXJ:4CI5
MRI/\:2D)'ISP3_I]=-0 '^/I>(!9BNE:T=Z\GT^<(@SG#]ZDY_G6=8O:W)KZ
MABK7B6-QIA<:OUG&959/A&%,FJJ&HR+:4S9.+<@"49,-HH?Z D#D\?(X@K$X
ME6'F"6$FE:%FH*LVA &@>L=CPZ9P7N<.C&D*2NLPV*0[O6M:[5.U#R:%8>,=
MB1,MUU;\BREL5:FXSR89@5BWH./LV"*^ T\B-)<:EIN751Y". Z@N)>2%="=
M+)5VD[Q4P#O4).4 EA8%V(8L2]!9N8'7&5V &&"2M7>$DE20Y&SJ!#::@[QO
MT![Q03,GQ<W[RX=0C)8,BUC4L*K0I=6@R8S[3B),A+\B'(:+$YXA*7FDJ)"5
M!"E#*D?QY6(2<2%2Y)(;FH%-'H"2C,VEVY:?&#LM+PLPX3QSF(#O2BE$OXF(
M4!3_ !"ZXZN&1U+05* Y 4.05#D#@<CD>@[GTXYYYUW"$G(@D9B '50@&H=]
M?*/.RN5G6$D!R0D,S.^C??F8S+7_  T_S_\ O'5R*8MWGQPI!21P1W/X?AJ'
MHYH*OT&O36()8@->$R;\M;HO2\7D[9NR_/AJMS8LM*CKCI]XAL-0W9<1^0RB
M06E%]V.DJY\PJ ![@\YQM>+FI",%,"2!<%P5$BE*AM=3IRZ?L_\ PY,U1XEE
M[J@(-R%6K9CO'!:6P\6$2;=S+./9/H<KUOQXS=?2KCORX56RS$CUWO$A:653
M+#SGY32D*3WY03W.M)+G<=E((G+[PIH%;AC2H!>@!W?5@(ZG%2NR:QEE*2";
ML=SJ0YWTY1FY5AXH)T7#[IN'#B7$&GDF]I678[D:?+E6%<V6K2&MMN+"=1#$
MA]AVO7(\H!74$+*&52<1QJ;*4I"R%TIF!/Z@; :BG05 C DR.S [R7-6KNVH
MJY*@"?#5S6[D&]8QEMG7BHJ*D6;]&EUN''NG[*,*JM1)2N)0E]I] :<EH57,
MW)>3 4RE<FSC(ZWD,](1JR,7Q] :I=W-'K2E-'I346,9.&X?V.Q"%*$Y<M20
MD9%+8EE/4A6HH+$&L:FC(_%/,;AY&J/8MA353.:@16JN%.FMF'E*_=;&L>F/
MU\0)EFB2?)Z5OL.LK4KK0MM.-,F=HI92J8B:DFK:W>M UVZ4UC:2\)V2![I<
MI@725'QLU**%7%0'K2KPH'P[VFZ=B]E%GNE_N\NS30MUL#WJ&MEE4*--:FJC
M,Q''&V525&.](3U<J4"X!P@\]%P'%8F85#$!YI;/X@Z2'<FA:C$[ EVO'(=J
M9/!Y*I:.& E+D$D%R"4FKG2H)9F%W80KEEP#A/'=??L>0.P^OU]>WWUU0)-P
MWW_CX:1R.4@)Z?"+O4PB@XZD=2.._'222  5)Y YYYYX/(''?Z'5*BP/0ORI
M?[ZPA-GBHQW<C*=F\BH]HK2QI\_F/TWP*VJ9:(<R$MFZKI,EY#KI#:XXBLO)
MEMN )6P5H!!4#K(P9E&8GO% ) V>H%/5J?%JQ-R?,ARUS]Z_0MBP=IO'=D>2
MR\ZR*VRO'G&;2%E;F(5.;7;QKTV4NCDV6.XK$J\HK*"Q?J6&9D1,?+*V=6R6
MI,IQMI+B6GM;2?,P>5(EG0)<I(TL1Y<G\XL%W/(D[; >E/KK#N.THR*JV\PN
M%F#S[F6-X_ 9R#X@^U(G.6;3 3(4Z\@EE^4'1Q(6A:@IP*Z5J[:U"P"I135+
MN"Q%P]C4??*+B/TCJ?.IY\MO.T=8C/*=0%JZ"5)YY' /8\$'U]/3\_7Z$T15
M%T#R >./P/TTA$KG(0LCUZ%<=^._!^OT_/Z:7A"'MS/^D QGEU,VW2Z[1OP*
ME<5N3[O+@F1"B3UR8K#;[R?='94IR(AY]'+@<01T@$@\1QN;Q5,Q2<&E8(=B
MDN*MEU/4]=8[O@8[/_E92>+DI7,4740P2FSBQY:6&U.=0[7Q;5=$0(,Z[LX]
MU CL-SJ['_GBE^PE6LJ:^?,?7#6U[G%AJ84VZV%H=4VD@IU@8!':%*%KGE2K
M* -*&KN0]'%0X9S2T;+'X#L>5DX?$@R\I4"DD.'\*4@N ::U I:VP6TGQ,PL
MQR2XIHD2933F*Y#==#,6YA0F6*QHR95#\15!==DI47DH@/H:C2Y[B4N/I;*'
M%7%XOC)4K*D&IH"#T:Y?DPMK:-;)D]FA@3)F&8B:9I6%J!*BFC"C4-Z#=F%(
MP-[N%XI*H,?]3/.BT_9V)%>@4U=)=B3YCJA/CKBF4H*F/-I8>D\O,0:Y7O26
M4N=*5FPO'<:\ 2E14I3:$BA+V8.UJ%]BPC-PF%[**0TZ<0$NRFRA6S5%&+5=
M^8+1CG[#Q>5;DN=$J)]A+E,M-MU<0U,FICO_ !0R;&83-EB0CWEA2XT9EH,>
M2E?2V$^4H:O*7VA"1W045J (2#8W.A:@T#W%ZQM$2NQ NI1*0X=O$:M5ZAZN
M]AO4+&V6_:MC":U&:!_]HTS;M<L2I#4B0EAZYL'("''&RI'4F 8Z4(2I70A/
MEE2E))/5<(GXI4H2L8@HG#]1)!!)<DAK@L*;VCSKCDO#C'35X,9I&;P-9FK6
MUOD8[BGT'Y#_  UN8U$!/ )]> 3P..3P.>W) _4@?<C2$)I\4>'YYG^WD#&M
MN[271W4_+<;3-M8=E=U3L6@18(5<ER?C%W07S,<QA^^%7<092P D/=!4DWY!
MEA9,W].53?\ =I]^QTMS 5!AN*,X^GKY$5=#%[.\>^VTB3A^*,V6X%/CDC'H
M=5DTC'Z.0+NK_P!T,IR);W=]97[CO$BT:O9F01Y[]6(, QY5@[*>DC+1^16V
M=TO5CN:EP">0HWM%G*H64DCH0S7;2E& W.XBEG.+>-JXPG:N=BEGDLO,3B&X
M.%[EM2+.DHNA_*;Q,6!D+$*K?<KE6^-08\*91RXJTOB*VL*9$F2XVC(EGAZ5
MJ$QLH*2@L7% Y9Q_4]M*%S2*DY_" KK3F+5 UOOH7C7-JMH/&)B^?XW?95DF
M7V--<98M_(Z]&:7]DFOJ(^5-RFWLBC7>5V%)#8%!'812HQ6EJ4S&Y=@Q;PUN
M,-/+MXI>"F/W9 (%!EI45LS-IS-3&23;D *_?IRAZ%E7*$ C@A*0>1P/3Z
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MXB<$7!$VW'L.MJ!@[4!;-$"WI#5A):LM'G3XS;T>RI)B^=FZ=$]'8(7=R("
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M_>9:B5<.6F.9W=KK9?2Y?4_3BS0F;^N/(M /P'OYN$?E>!9X_5CWOTJ@AIR
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M$@2[NA9;MWL#Z]R4#T)8+W*;;4_!R5Z&Q+EM3YT$B=_T2DO:C%$=59(,IJB
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M3]0=@KVSY/E6R\2V+ $X&YN)P7_;V&"Z4"4T;74>!KJV IO^>CYEZ013EX[
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MDM#87JK[/+TCT_4E]38[G.J;>\?-**T"GFS8M F'&2BU M.B612=WY*J'(<
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MC7^Q_RI.;.NHA(0AT7\*+L5/!:#:[QVG;N@@$:>?A!BDZTGQ=X/\.7!$L)-
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M0L*"UT_^B?,+B4J+B4L+2S#_1JSR1">_9='V#M)@9=7?X$Y:<JR_C<O3TU/
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MN^VB;##+S>V!@J,&:(HHIF2?[ !:KQM_?=<A^[)3W4][\4A>*NE)S058$]2
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M7TX8O_6F]W&R6V0_%H]Q?&#GY*AA-=R:X.D=U?WNIQ?M!>_+R[KAM#,Y\V1
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M:,+%_9718&C"\^"K%QJW5]0TLRN__U#]&E^T:AJ(,FU7!U/F%?3HM22+CP;
M+F#/\%<1VHO2V/+G@Q0()=3!02/%*FKZX-#GU? MF=F<32CFZGS $D@-3M1+
M\,;_EFUFX9U$Y')M:&5$LIXR>["UQK!*)'M>T6B\0M6:>-OKKV.-;&S#;BT.
MF2H/@0EZQ4,%:N'XN/8T;1S+TTKJ _&D#XA,W?DR U=M43/NY?AOO:[<6WU9
M+L'T*",;S=?XD2L7Q7QMH_G3,^Z:,C Y+>4'C9J\?!!;KH0 Z[)!-L?BZ)7;
M:3H(/R]7NZ<L'<Z\($C#1HXSESXOBH,]A:<SZ8O*WE1:>XI.P>>HJ"EY:KPE
M-7H#=/#CVDTBM57#N:BN]]9 H*+^#G-@C%+B1=(G^4SNO.(#MQRJM"/F*;+O
M=JBC>C3 B8;UU*0U$_"XU X_:);#@8T)D8V>&P>/"XU?2QKS$SU;/_"%H&\!
MN@U:A$",["@S_?C131+7YE?<]ZA#B2FV&MB&K@I%\E[2"'_VS?4#LDI<\-D/
M=]5I,AY[^V_'@$H1&M3J]LR2T"<3?))K@K"V?:'&'GF[H(.LJ3M+9IRS0Q?C
M"K.NW,VIT;"7UNY(O H.5S L-"D:_^%!BV,#@_OPKI!VPCBZL2',DNFDW+
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MM>A:NJE!OB<D+\&Z.MT<VQ]K<N*JM1$NG>B/59+^!&;>EN2'F@D/%)O4=3I
M>G4/DVPJZ\T=X[3,QH!)K,#1(HVLT )^'LJ."F5N[Z7^2 @MJC(G/M?WJS%I
MG+EUBA??TP=.4=LF_+%?C'!I5LQ5<$/KPGH.7^*2>DY.#,WC9-3<RU9Z+6E_
MBP<* E._K\.Y29_\U2?0]R"#//JE?[<EZ;[*U7Q"W'SG <QHS(L*X8MC,78\
M0*-T[F"=E ?)H@&>-SYUF@=YKOHR1DH<S'[24;S D+J=DW!G/V@V8 ;YM5!;
M/ASY9;-V:W3T=.>%SVT?TVHQ=@S8J0U#^/JDYGFT[20KBLOJWQEQ;;B>;O1M
M7T/A2+:^F\1UKYA_J".Q!]4CY:SNW9F7N%-SSYB&G_O:/FG!PAW?.^;<DY;X
MBUT+&E8T"S4+CPOOWT0K$^J"%-R)/WU<O\@>)##X+"0 -+C=?<U0>"ZY*2+:
M:6C?ODC)S%F"O_C.HRV ST<Y"<ZB%W<Z/A8L$@B]73:Z;_[ =UV)"(-=BJVV
MTJ,'*%;VTIU9O]L6A8E8HQ0Q5HX!(]SQT:3:*C*=*+3^I_+0^CEU'MP49]K*
MRFT>G'X"B2^O70\\%J/##U[$LCFV$AO80V[D(9GYWJ^@+H=%P.\1#<_'UI@:
M#>7ED?M$,R!;-5F&MD.=TU-+KT!I8"T<D==\*#01F!I6#7<>,_\/>#Q 8\,4
M')O;81VTK5Y?N^+=VJB\&)-7R+F3$8QHD,J;#.@<?B']Q?<B*3:'>GVB!.#R
M+:8CPY24G.NLC\4IF5"@F[@3?9>H=S!WOV0\244E)N=^?&59:G14:Z5IE5S0
MQD%BN9"U(DTWFK[*#(?)M(UBH<9X>RK;S ,-P>$5ZT:N%ZTR*W9FB 5/'TL)
M[&.5_K2!=Q0,!?=CVOS' 7NIC&Y?IQJ3+1^5":-S"-Z2/ &P ]04"!GYVR:S
MOEVL$$O?5AHC,YTTAO6)T+^2E?59)?1>>BE6PA>$F _"&-/O7WO+/Y,7E!=*
MZ:O$T@B>(S/+R"C9]:'Z3+[2CZW.DT)7$%+&&S7O@J<.;%<?7_!A<%[UOEVJ
M4J2N64&PR&OP6IUPH*-I2"/:3OO5J\C6(SCB_NB8+741_SL1I=!!UG060>&1
M9LKV;B]PC<N:80N$:^:@=[7J!?P%':WUW+"UKYB1@\&<)_7PM &2J]L?*,,%
MK3,JYN4Q)4_.L[  -,JARES&QI_.$$&?2AHV4J[H.:,+2H1G#.Z^2#2!\(=P
M*\H[^HN+X^Y.,U$M-/D[%UX ]B=PHR%<EU<?S,(+AD.XBC4L(M1IUT#59?4%
M4IT^ARD93^1\X-II0P@JQ210OO1$UA91KE5J[&*VISL['E=9%Q\Q>S[?)&F]
M3B28,8U'N7[(\..]#&_[],1"VORDP?=J(P4,E'N\R8^>9V$NW-A.2*@[@*S6
M[3"I?E<KEWMF?IC]=.[VZ<:L]A@0S9;A2O M>BEN6]O[]O?K_?SD39%BU(^I
M@\4550Y7AYL3/C?@#,S((F2?D"E%A;.0)N?1<%]D#RD%XPTIRBG41YBY?&\H
MAQ/Q9K-K@M :4_"]Y.QWCQM@ NJ5D]-'"*RJZ>':1BPMZ;X*:4<V375=#V)B
M37\#5.NP;N?$$FH[VP#!YYF>^,S](G8HSE!(R1Y8$9?3/[)V;WW9W[:1EDU?
MGU&@6^WV5<TR7GM>5S/^1(UTW/1/"-EO5:80-8^<@/#DST4<*MV(=W!.[93B
MW ;"-<_6[H&OCQ TDEK*4.A0/]!>1BIYHL7.8A+1.;Z(FR]1]YU,V.<14;1B
M:3^"7?+S54V-4/O$1S2=C^OFHVX8O8VG<DE K<>:P#_O00N+V=;>KZZ^+^(Y
M!HQPKZ_ ?)"U,:\^[Q<R\[SO<>1>-,']C!-FX6.U4B;C>Y!4-ZWZ]:/?;Z?%
M.,7E0Q%D@#ON]V>6,R0BT(E/:VD;/LM2K]B+6SF;\]G\K8;CNV("=SCA^[3M
ML$6^'D'>X9SW\V-.4*A646\C0DOM B5;F02(V[T:K,!\2.[9GN':+-3>M[MF
M_JU/W-CN@[A-O,FU%"(3?T$>7126)O1E/O03G<90LKCQ+!ENT60\:D!J,"0-
MD9N<UI]QXS9[D_+].7<Q?"#MD1 #EI-@=:A@,XHT.324$J'ZPY%A]MW+-Y :
M1;/:2.]AOMK4U=FPS* ?R7Q!U/EX->,JM17:X1'S2@Z6/(Z2Q*_2+BL%4Z89
M/@C8]3#33&0B4==7U\IMBK;V2A009RO4#NTPS[U?.KAJV.N2I^X]FIA;,PNF
MS)<$2+"PCT87#&]18C6PVR"_^O;O>2W4AUP)EUX.3.'Y<O71>ZWBY.U%X[@K
M#R:C:G6HPUAN:'L>3IN'O'!7[&S0&"QC[9&HD^W;T>_T@=KTMRD7:Z6E>X4:
MIF=Y]>BAAD+Z2K7]7C[4B\_C-WWX[E'3?(^BDO-^6AR':0T[[H_'+0^%J159
MNLE-BJB3@X#)AF0?@CS']]?#HWP!O;KV<=?&U<5GOZM?#5^W\+0+C3O=5VM@
MQMA-]]O&CGX<69'B^&HV>SQS8_*<ZB_<F>$SD [<^29_627CGG'FO9G"X6(P
M8[1>H3:5+0BN+#FQ(6F(]UA!IX?9)\F_(C1DUD/3,?HI1SGJ*&1L/%1K[K99
M&CE*,/@+"!JM]VH%0O;2V+9//_'2IL4:VSX5RU2S]&=N[61X&DFF\AMOTYCT
MHI1P>\>H<6>7?H8;'M*/-'J#4O+#LOCRV5,=)-=C1;6_X,:FVW[X>'>0,H&*
M0ZF77Y[)0]0[Z:Y$1NK@"TE%P@%"C>2'ZG@2[)A6L0KR%8S7K9C1 8LTJ1>W
M;'GC([U31"2F!NVYJ_*5-#Z*QH,D9@J$2)YT-+VP+A^$JD->"2]';'2Y\RI[
M+79Y^<\.9+]+O&A46O9JJTYR\2KK9X3LQYBD1P;K&< D)EDIJZ1IK151T$7<
M<L/WFO#!>23P[4/5>*.&=I<M77'A5ZPI'8=F55,.]XW$FZ6Y\6@T)M91NDV&
MU.ZY>8_%DVR:X# GE5(-PX<P 'MZ;&K+JV/ G7J8),M'?9D95\>,?2P\SLA;
M=,,RY!EM4I<8%7&COW>7C^YS!.-3T=?=#-FS=XM_]-;52B0NHEE[MT-H-R3_
M?8\WEEI+XA;NA+6EZ[6Y_2\3J(89EWG[=H.W$Y#77R!UVNDPP77^9SB1W)?&
M.U[Z^,S9CJ+@S4+UOF' 9)DRXX$J7_<!4)N!75N6T(BE'DIU05H G.-WR)4=
M-M_[P\PV:=I\DMLT4F+RDZ?$559Q^HE/7=99A9H@/4+2( "N6==09E.0I\1$
M44N56T#M+6*-9V#-8ITD6^* /.?6X<9+\B&;=PON#T[-)O_8 K^^1SW+./ZI
M]"9]H@+K\NS(O'?YJUM]3XK[B^1[@;2A^[F*7,:%HG5\^,DTR='IHYCNZP-F
MG$+/L&S4MH=4:*B^+^0YJS=,YI'C#XOO=LQ,!I)[\RW>*)_$GDWTQV+C,:B?
M[HP-9TSX^0UBD"E(8KM:;=PX.2[.P+^B[DKKQI:3W/C1:V<-$$'DIF".M%JS
M$G/FQA+I)@JI.<O[K+)R1?SRN+GX7*@9LXXI:8FWAP^)\RM\RT);K=@V0FY0
M&V;=DQ@^=,L)K-B6)7T,X-J2&F=W6%XP[8P\L-2O^58OM#DXF%S61R(^EV@\
MH%<=K^\;@L +/2*X-\V&GN*4?*CC6V%4W11*<%V:$<&V!C4*-;"_K1,+9&O(
M"=7XE X.@@EB1I&Q-PT?MXA$#)3H&E'PW-MT5QN+7XM"I!QU/*;G)@0GSW(1
M$P$U" _LY&>[A>._@M)G'=1%ZY[$@"BRG/F%(.W]$@],DZ[8<W 3-.EK/)MB
MSS$/@(DMTWO'O/8^+!240^F*T,6@\I_N&?<ZW327UHQJ#,L7'C7@/ZK&EK 8
M*H7*>^D\*%-5,<T5>,3MC%:NG_)__S@QG[N;NJ5G^U+EJC5_)<[E%*>ON;GV
M^!F^&CUL99&,/L1D=4<^LW-9SR@*JS63'@TQA(.Q)[Z\,NJS.O2_?O::*E*P
MB(,^>C*?K:!+F7CSZT1?P5Z'HOS MOJ&_Y**-67J9*]ILL2U ^<'T?ZK$NRQ
MS<@Z"NGXW@<1HWJ7Z$9LU78^&2RZ1,<\;4*ZS OT>5=<7^1^6;1X^'1<J^ZE
MG@=5'U0%I =VITX.)<Z#Y:#>>ZNE77E2"$PW*VJ^MV.(#B$9T]5(W.TL5%<R
M>%0G4Z\G4^,94KB;GG)@52])_QIA/QM'LWV/7(1?A!_%&J-=T?78F+L:QW+#
M-(:Q,D2$55C-J^<=6LUS#IPL6+OE/V=U?8PJVMRV8DM 1]617Z%DB9#F94V4
M,U98!\*L.6(<8Z:DE,-./V.-*GN2?=FBJ+-L<*7<8!M"5"55S%,>*LY3QM(R
M%-%)_?15@$G@!8F&RW,D!UUK,*?WIM=T4:M)G$\+UKR;'+V:\O4S0>":LMGB
M^%IVKN0QU;7)8)@;:W)^L08X.9\KT?"A1J2\?:+VF_XYI6/ R^8?V&T.#$1[
M'!4'\<M\WF3L]O[U$T<X,A7=3$N?K=NM]_H:0CWL=A(#%(\!-G?[T*0;'A,
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MW+VD5W40'!;T/=\CZX=$EH.YNFO]S")[&4C#,#[W'G0/3[K")<&?F_TCXN1
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M:(,98N3L@?9 .7MXLHD+B0#2JCKZ.#@ AIB%'J$]?V<!.R:0-8#-R*7%A 4
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MS(M5!+[B^=Q59E&L36@\LX^:RDLMOI02.K> ^.A65,<6/<:DMXK;Y3%-J7Z
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MW]<-R;>%3?"G*-4FY<=:%I"00%M;AM)).Y:%;4Y] 0=^%\[4CJ$JF Y$,"0
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M'%W:12Z1)DOT5<AE22O,5.Y#J!CA3:$G803Z]W(&[U \CI2LM\1/, #:0+&
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M16FIS)*B4K"2'#,>4JL-1!=@S'"O_$V01E:U"OF*:D!*SR!2">50),%8ACW
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M,)58#E4J=*TJICH4[^+)JU3A5FKUB?A!*85+EMN4J&$93+D-/O %I".LYF.
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MORE0!VC]WL=!8ZVPKQW0$_F /!SGN3_P_NZ94CF/ON SV<7>^"^(I#\CL2;
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M54"XW87GY1@E$/8@F2-#[1V('SPF-*4Q'"@M!+:AN&,@?<'Z #OCI:B'#ZL
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M5X%,2M4R4TRA"%.+*SN(0D94=P!QZ2>#_P"ITN'5<VI@GF2_0-[M<CHU@9Q
MSOB3(9'+_'Y@"VE@89VDP="YZZ+>B.K% OBM7+3:-),QFDLQ@J2XH$NJ\^4R
MLL-K2%F.AUI2$O8*%JW!)X'4'CG!E\,^%S)"55 Y T>0[[@O>8:QQ7\!\6Y?
MQ#4K_!4_P'!+3"F( U#@>\G3%C7II+M;M]1P"F!.2<]N9$97'_XD8'?]^[7
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M-M>F@DAL0Y\2OB"T_P!-[1J4^\[DA6K1?EGG29LYENX*RV@\1*3!\Q3J7GG
MV@GRUJ\MS&4C)&DX+P[.4"FJJDX2H.5 L'!N" ^K#=MHYKXJ\1TTTOZ;*+^(
MX)2E'FJKF E,\KEG4H@,Y9@ 05\'O7PZ_:_>)BOP4OQ+6IEHV33[7H:WDK;I
M].;K%92J4ZVV2A,^H.(+TM2 D$A(.2.*7\1T*IT<DHAG6MFE1@$GMYHNP+/$
MZ'\%/C_UO&Q70W.BC4%R 2I7E ,6+D@!R26&-NVO*R*K;WJ 48,\JSC)(?C)
M!_8#'''6,\/!S6$L4I?T):<>AE2X) @;=>VP^S@ /STL#*T[R#R>3[$X '&
M/VZU'*Y@D/H'OOK],,L$P+# <OR\)D6,\(H9;W%2$*XWIRD\Y'(P?N!D GVZ
MLLA1!JIYP>5@6_0N?YF P<Q,RI?*Z"T@6<RSO=FUV D"^(FV[5JJ[.NFZ)DU
M+[S,J-38*  4->4M$M_<.#DJ*03R3^4DCJZSZTHRZ:='RLY($[@#7<6 W[.9
M&@%?ZE0$J!(#N),F 0#;8CI@YVW?7XDVD2R$/N(0K 7C:O@;"G(QDC\N,<\
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M<CR:C5G&5P6WE^1$<6^%^6_4RM.J&0.6?,>8S )9S9S<O![87EEC+TRL@I4
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MWL[OZ,WUP#)OAJU$D(VMRK;"AC\]2F@<8^E,5W]^KREX@R2 717<V'(F)/\
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MZ_9@B !Y?2(]6/>SZ=6\,>"OQ"Q%A4>IV!Z?RA5?JPXR#W_J\>_OQST1\5Y
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M'WSTGPV:FTJ'!A-L6:Q'B16XC4>-5)+$=AAH;6F8S#-&;:9881M0RVA "$#
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M4KY+-/^7D]=8*$1GLIQLT=-"CXD7V@#;:VHYQB,=V4Y^MRK1C$2C[PMK=+Z
M?W?],6AS,E FT_Y,70RA@%_R;CKKW_;'\^&7OC*:S,^=,JZ;WII8*^H,+2@
M;P_7>##IE-$E!:\&"MK:-ZC,_Z]M4P=_N?^[9[@[\&$-S7 +FT!-,A(3^:&B
MB?1NU?'G_ER!N0.4^M*?+8;=45\!.QGT9S->?-+[.V^%?[J=C&[ZL_E_*OW_
MNA\N?E.^N^D/AKWAXCQ:)'1,G/7 M)^*#PQ1#8F"?ZRJ8'5^JPQ&DZ\GU-DG
M;$4LXP]. F1^0QV-&5O\-EEV/0>*!D-VH9(2C?P574[#T4S;\1B%+Y/99W4\
M_&\^XG*UW/3GO=EPRK^#*KKW<]#8*8VZ<V^S(6PW6<Z-E07S>XU8KJKQF:5A
MK:;0$32#^JHH6%:BC)_VE3&_O[M39[^AW.?#S^,AC%+J>*&HO=[D?KP8CC\K
M4^@QO6'_A-016+08CS@E(?NL!Q)!?]@7=&#5_HC$K?]T1#JCC]3RZ(QJ]DH@
M$Q+-^#U;H%=O]P4ZZW_IC^_[\+\W <,]+7D.B,&^$-.CD^4 +-'2#&)B/)/Q
MF;T_5!PJ))'TU;ZD!^IPIGQ11R!L&"8&8+SCWE =@3,T7\SN^2OT="0_!&_4
M<FT6#LCQ'R02O=Z7Z!!<R/%B,CNI877*;/C)W8$#@;[Z%HUP3/T9@>RA1*+O
M]B4ZG>$L#CQM="C0Z9ZB77ZOC/N+TY$P^ ',HWK_>0N398ISYXF[IJS' \[N
MR" /A@F  \LM7ERBA??[6@"W878/OG7_URE,G_MB/CU9W/9G2N\>YDG@68R&
M:G<X@N'ZE$Q_;+O4F9(=@4FLD'WB%XEX?]@7[WBR )E.U=]4F'R>CO2D$8!@
MVBA[+)'KC_MRS9G2GXZ4#X1LRH9:KE+SOG-@1 A:2&]H:<"(\4BG)O&=X:P'
M$N&FYG&^.(?C'@RR&+><CM03\H?!5<#(\)2R^9JP8(S=^U$BR]14#7P&'O95
MP*-0YK?J[(3&6K ^>T,7Y#ER;Z,?L@5XG9J:@15.[OK*0OWUE%[R,VIBN')*
MP(U=,&(Y1.-+&,%,5_)4(M34+&S6'_&XY51%-W<Q4\=SM<=7+4Y'Q#U[LS%<
M/GL506*,>5$KBH[E%9 (.C4Y ]N]&RY$9-B/&F,@K#\^K2A8L4!CE>#D@2#E
M=6IR5SQ(J7P7-'Y"#D4QJ2]PJE%*3WX-B992D[\R6A)-GY".TH'.N#ZD3R6R
M3\T,,X*A)RCDH1'%XN+BS?A=(MC4U' 8"]6=H$0E8;FX</.+2.2<FASFQ.].
M4.R%(W-Q192M)%%-:FI9+JAW@MJ2!J#BVCE42**-U.0T+_WD]$2?$3*)"UW^
M.%O<[U)3V<RXR@D*>B^6$A=R]B.)@%/3VG2PY02E&PNR)/R6U,\2J68L,$81
MF!.49['Y3>QASW-<$#4#(\:Q@JSH9.D[Y3?4)899:N)4KF&)3NO,@J%P!$'1
M? S?*]L0A6(O%29P*-_Y2,X&LJ='5=<Y:DR;6-ILPQ%5L(?<=B3JKS.]!I\M
MI*C$2)XU+=/0O4.7GCD"'\&9++-F-!6T7KA-B06D)OFE+$!05TPDCYU]ZP-0
MB*4K-(!PBA:1D<5WN*.7K231:2J^D)46>.Z_N8&SL/>!(,EJQ>@*%U;\<DY"
M:U4K2[27BEIDA=V@GPH:V.L25)2 S%F/2"AFV.J#[;GPB!J/W%7E.>9BCNS7
M&S![@\LYC&BN\]5PUX%C=4CA#5.16$8J:))M&?&^3!"-$H/#1^8 4& KRA(@
M*2$FY0E *2&JLR$5&[U+UI$H.16+R5;R>>RNIJJK*KJZDBCK?9%\\</*NCHA
M;1U(%S_<R^HT(-%BE5ST<Q?,3E</79_8;PG]%2PK455>DGO2*8JU>>(J.=RG
MBA:6*"451$HJY=Q/#BQTXM$XNF?2[ D\%$@HJVXC$B6F0D%YBZ70TWQRV-6F
MF;/^[Q6+GN347R+_P]VP2D6)-E-AG7QMGKMHZ47QJ+\5KI)0=AN$),:1B@^5
M7'Q/]GX?E1+ XJ, !Z;XR)08M%.TJ?@VG,.C0.'2$NVFXD>)#3WGSEXDI^*P
MEJI5E:@L%=C)R[\X*["  L.IA>JY:W!L_Z#ZT'$\?NS'Q'/Q"$ \Q%%:OYBN
MFZ(B,8M2:3F)R4^$YWM%(!*C<H1)B8%20E0*AW6*EB3=>59@>;92U6R=_Y"*
M*.5O:#N/!OEY6H>U5[:21&^I&%)V3M=97;GJBM:\L4]-^.$_J@9/>:?*UUJ1
MNA+EI:)*,N7%AE@Q4@HR2D#GK$;1@>"5L^&2P?P$?6&+@"W_Y3,CENLL[/YF
M:]H[RJ<Q8]NBP=>#G;.!MB5FD(IC2?MPA %3('3%M14.([ ' 01_#J'P%W <
MS-E6I-W6X?*C>I4NOU]7HNM4N*MDEW<4G\Y9C5P5?Z>[O9XYM+!+<!@#F_4)
ML\#]Y,F[!_MXI<8DBDY%PF2*!J+ICFU82DA8@;>U@J0[0%L1Q,_:S^B(70+4
M\$!5:CD<B!\:*M>=#[4BT7<JN%6T8W<X025.,8AIG:*6]Q+NHR@DB,G0,*O%
M,#T8__;*)4-9]=J0:#@=X$IG]R=#E)R<R'P1!!6@J"!)!6B*KGS6<4P_*O1)
M+BKHF;C;'3H?=-='8@+'&4-X ^U(=)V*C!W4-9+LZ#Y-11!5(JHG/&['-GI$
M&@I2P>!G>/E1UY&M5U2N+=%L*KB5V$V2U&F8KP9T%$%(^2Y&ZB\GKLXB*_S%
M"F<KZ\?<PU?.08U#G0S3S"P-C)53%L.B9FPQ73<L[[L:76H!3RYZ(?BBZN[P
MG&F/WSE"=<I0:7Z%&50_W$-?G+3$8E+QL)SNG<08#.(^2D50Y5T_<,=\I$H
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M(XJ^]C%XR:1<(<N#$9W.U_:3B.RVRH*$=H6W+2Y4=2=,-RP8J\0TI]T7;PZ
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M:T>6%))L[XV-#05%HDH<LTA=/M0J;^Q_WTRR'F05GB10B=)UQ,RU6B+ /'E
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MWE*X*"ZS='+/\FGW;)^8&<[C,"6X":UOTQX7XA)P1>&GD,[/5UD:#EN[5CT
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M )QO*7DVF&N#\RAK<DW*Q<WAHRE>ES0JRSQ^K$KT&=]GS75=^@:CNB^8_W>
MZH'P/,K0U*R>V*DR>+#O6UJ>;$.V(;E'B9;]$I0/]GVKGR#1/T=T1;8CY5Z8
MOZFH)VK9!FQ(=Z"3'=XSZR,4L$[A 9'N'=L6<LL5?<=">!0O]%5YKWIW#);
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M!+9/L?C 2_\>84=.RZ ))QP#>"ARCRXL0BCX_Y@+^!(D:$L !EAJPI)%^ =
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M1LJ\ZX>O1V_"BV-'#QY=*]\'T 6H$W9"<9"H*]U;Z!YT]C:<0M9TX=&M]7U
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M8/E+'-9(6%Z?-@*C7<<\4C8$V3^3'JC<,L&:^A!P:>:0$ABW.C>$K]V=?7!
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M.I= Z]<APJ>M+"ABA/_]#$+I3^@*4Q]!S.7'HT^SHB4BI2V^9\:G'AQ_3HO
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M^PD8M 99OY&ZR325R9G3C #Z4_%>(';S]1;7X];OS,<@KQ?0P!&IQ=&+XOY
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MG=9Q?<<3?NJI1$AW9%7"PWG$61MJ!H@Q2X/+D#%E:7P 'G[MGA1'CR$ 5NV
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MJVCSE &QJH9.EK^E-1'O^@=45X:.M2G0ZF;0F<1P9O26L8]M%F]K2X-:_,_
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MS_>S_3: :V4F<(DVHS0$(U#'>N6IZI'P* 257:!IRUU:X)QX'#I&&\Y2VR)
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MTH]U(E(I*FL%B$).WP19U03E1G39!(2?6=4$]#SDIM$$!6F"4-P$[M*ZCV9
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M[B3#NML\+\?'[VZ26QH NR==_T+^J^"I6LQM[A:5_N+X4_W8'UE],8D%JF3
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MUT^*O$N@<=U:3[!+#)+.;EU"F+.GC2X1V+3D5!>HJAJOS%AP!<6"*WV;7/G
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M-:+"8/B6)'_I@0(P:<T0A?U!KRI5C1P)8-B]"W;Z%[?E(F X;NFM <<"T=+
MV5[&JN\/PON04>.\CY<1@=AR&4,6R04.RPW,YRS8W:9!(CVD9BSI*AAK9(5L
M!7>40J48HG) I];FL <L)FN.KE94UC&TC.*RH[ID?^R2?0FQF,A!Q63IA)O.
MMZE?69.O:29<XN(N#Z&*]>T%*UOKB 6B124S+Z?G.!6MW3O J6AJ0(!H9S0R
M 4"02*<#8IA()C.00%%/"M1-/F)*\/,[??PH2O#PN8%5%:XF"79V=5%32R./
MYPV3F7A_SP8HL(G#  RV9A!0 #2:2DS52_NI9Q=B?W!+W\8)XN'>P*("5[[
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ML4M;G=&F.@/@RP%+%4JD!T6&'J,4!QD;M5D=\M?+N0HQ&EC0/U)XQ"[RZ1[
M<%NJD)8O]P),<=4*.#H%E5&\<42',' EOMTB:,P"J1KG08XW1.,]3G+6$,LL
MH]LV[(7=\_=CF?O@G;VC^27(-A;+EK'?@%GDC&X9Y9*(2IX]45'4K!\U/T"7
M3,V"Y4<0^XHWRZCYVFE5MA,ZU[33^7NKH%$[ 2W4IN&;8EDW#=E<GB8@G4]?
M+-6<-6\7<WD.H*U?;Y.?_*M\[A;P"6=3)4'WX 4=W=M@%_0R !:UA^"[!0'P
M*#T"WT DZ /,YHKZ@$KU"7UQ?T_QAB*/2M\D-&U.](KIAPR?3E1(.G\Q466%
M_'VZ<A.A%F-I!L!RFD]AD2A/@K/EECFFQ$\AN@&4W0N(-MVP?HERM&-_)2NO
M@$9[MFF&CKW#CWZ@J,;;/I[N%<1KTA+GQ*0HS-=?TO5+>LB)"G?DNP7&B37-
M!U?GBOO#[>WV&ZT)E54AFFVYJ@Q5M;GV%/H@S736_T-E.:CO&(G>ED/Q ;I&
M7F8F"/_XPX>?Q(B=*."39T5C3DO^U9W/DE_][>(EPMNK-QP>Z.=7VVT4XDSJ
M<[02#MR*7NM>F(V61G5Q5)8'<@R3Z0_A!0PA4Q'=$"\S8_P\#;+-:GL993@D
M]>87+T&4[11#JXF0(Z1K=>\E6J,"-'A8BZ!*!A#PUF8<T5X5A8*[&7J:B#>#
MCLM(OB[<)XOVW1H<MYBB<I>Q^RG:HA>,-@C4:^+TM]!G/^9K&$UD7A.85S2,
MT^C\9!SJA>4G(]"(=:E1+EN@Q+7&R5VA$M*>2/99?:I9X+RR=NT(MB\^E*\K
MEDTT_T@*%OE-<H^S*-U\I#G=YAA>55\[A?%6V5J3#\ +5'YO@?@7490@_DWZ
M&_)5L$?KG#0@+XP"-N86*=H3:UY(C>5IH1.;DEB9SDKUL^:,=WEX&]$L!&GR
MD5[,%^2<<4\3=M(HY2+H66SX2<RJ]+YTLFF6WI$Z??.[/F5V$>RC(HCYQ=8'
MG./L%6^NT^SZ4!PRK,AS-*(NI^^"VUNJ.KVY0&4UU27QJB*V_<.K LJ.-(/)
M5=++TF3NQ5'6-'G+38X 4RJ-1G7_ ?*!D)[F7/0#IAO_^?(UB&)Z4(I\3I=O
MS%0:X(RTVAKE2>E2%-6RB A#YAX;:Q8_HYLQ41345E$>01)H  !EQZA=H<_V
M,/7H[LHE_76JZ\>K-YR%48[KN0A+J7.3%!FQ-0I9%IT9%Y1FGS^A%:9A>\ZY
MY*Q5:*XZ:PW$B9%.8PDVL'%YEJBH;H%76H[N:N6M%0PN:S_I-8P-GZ=>U-B0
M^81<9'NM]A=,W_3!F^4KSH)GS/YX&13X.HBRN;VEM28GY#CM6]EMV*[2")4J
M\2*(*H6H5J?L5\>W?25S%I2MP\)!:$-;9TM;I_:Y7VV\R-@QS!M+,O8*$SS+
M]8CW 7U4EBO"=!+M/AC(N'ZD2Z*Y_*VN2J!T$=QA.(YDC[" 3G8J"])&=!XN
M-: )AH3O>,T.(*OGO";J!JCEXS)FM>.-V E=O=$?55,:TPH<SD2,;5)-(.J)
MP=$-TY45$X49Y(>;15<YI5EA<UZ$9S+'<"]RL$%\/9=;FN5R9F%'J^Z$P(Y3
M+E=2M,G+'<[+ UG5/?,Y!YM7,&6?NLIJ3R0,KM+EVF:XW4(?DZ.RL@5?-2S$
M:Y*FZWG"VS1C@>\MCNB> ]!*8[J6*&OA*P/09<!(5/?F\R,A?0JAD7HUL<SS
MPZX*_^QQ2&S^)8U)-7%4O#\0)S9'.,3FZZ<0 K%JS1G"'L?X!6IHP.<[5 =T
M5((>BP2;,< T<-T*09(<R,2CO-+Y6LN=6-!GFL:0FW\2(1Q[!S99V,;>>[G,
M%+S;Q^D[QH\X>XU"+#;RCKX^D=,@$UN\LOEX\^\T(?Y=6OP5%P\X3)^3Z'?2
M FP,)/.7\E>TW ?%X.!:$9>9CEVWL?5"M_YX-4+0KY'?%N@=%^CXP449'F=;
MX8V/PGA$\';EIPO(A _13]#_[IDD:*)J$$+W$F&#L'E$B'NP=V?_\X"K(\\/
M-!I/O'U4:DJ/E. D)-CX2U2\T, \C2&R1I%%SD%4<160AVGGZ6^6\?\]ZH.8
M0HAI5#G)HTZ(*L7W#MG> M,+8#/!C]9OM%K&6NV5M1J<[X3V *U]CU.GO]%V
MBA] ;,Z+6B'EH+V4SAOE]J4;"/A$B=]YR52(9FF@2S_PA?H!MDO.MH:88E-E
M!^HWV-$*EEDDW43;*&06WB1AQOX0Q+)#+!/4Z7Y0&62Y:G003)=Y8J!FG:A1
M*<2YD#D:H6D2/\P1Y"B@EP .<4'16[Q@M&LV0OD[X'WF*5@@\<? %+!TK!-2
MH>/Y&E2@V<W:*(BZN#FYD]**9NJN3N8(=EM]_A2BW7;M:1V[Z'GC1<L=NW_$
M$[C!FL:+]LF)"Z\6TSJ7?I*1W@'TG2S4.X"[I^ 1JS1U>9&Q$2A?$:1DZY<@
M$1Y)G,,K6JMP"I[1OEUGV RLLPC66B"F!O$&Q+%*3TB?F$\=W]0/F,A&;"^,
MWR,Y)!%ID&^_>7C\_,T?3OI\\T!^3^8V!Y+[*W2=(+=-IM?Q*W2^0#=4!GKG
MK_3^BH,^^RB\R +ZT)6/S08Z $Q[Y\7W$>(7MD?:NF,).QRH%?HJ?+^FS>$<
M/5>LZ>B_7F=NV0G\FH#P(N+7Z;5-'(,[%VWB%4[!'Y<[C,3</"JJ RS<*-7Y
MM9F^=PK>5--B,SC+ZO1%^<GJ1,5IAB8LFT_AYIJA7?B3:+,R<#*_9D*_4W!;
M_*(136YT=,)SN"OQ=T[!34E:: ;WQ+^$^*=.-F1JV%Z-J\[<;"(?%3&FB6!#
MG!4TYQDNCX."' N8E5J3^2$5KUS[GR>]_D]=_56W'-8XVVGG3C-]U+5GFJOM
M(*Z!T6^#WOURU9BUQ<4<%IN[:5?VTM^C;]]QD.5_ '?)LWH;H7^>U=5\#9>W
M(.YI?1U7LN:]?;7<I8<$Z#B3RR;C:]Q#TEC/^IS^8W8>.KM>!>#$F'9K\IGF
MH^T"Q],IYS+!4$?#+EIY-(H60+_2(D!O<)FK"9HJ1]3=O8PXHK[V*0J3*\-)
M3/-D(W[W?4@P9M#G?(K)#&LO%=%X(5^?NYO:7O!)^DQDL Z?C& "Q,2<3EKX
M_ICTO5@#&8B)L4!SZXEMF3L3YN7801:Q@YVEVOS,"53\PT;MU:'(BR#9T!N&
MY6XLC;[>5W<2+QJO:W@Q3Y;10CK/E7%BQ'7)^MGTSTE4+$/R4U2\2UFJ%W%U
MV5&MM^ V""^-:'%4E0?BY'@#Q*1T=KO0 #2MRX.N$&-T-W!HP].#[B@HRT]U
M6[FM#%NADI'[ >_C(.2W%8DTSC*\8>3G)6SH:5DE#'UM[=;1FY5&I$+4J!'5
M598/+)7%O/$!\[1"8-0*GKB20010N!HX] ]P1=/U/W=5Q_[/&OV_K_N?W]_A
MQ:"N)Q^O$S$+:3OD#X^?M<L$C9S#I8+. L4%*D[ S_P"%9')_P"\2)C&%LBY
MM1&>NO-K(S"->1@^R!*R..%G&]2#M["HLT?BA7KV=HE)*42*5>=[ ,=/<X7/
MC@K#O1TOAT'[!?F9,6#VCOR0IITLA\]QH9NO$JRFC*2PLZP[$EU5094<D9*0
MQ!FL-%Q"&Q4DVIEJ9L>#60H:JR:NWH=*D^D283446'])S4G4* Q!HJ:N:CR2
MDKZ0R$II+TC4@X241//@P9I$^B:N2%1\25UDDR,*B=Y!TA!M>(4^Y)'3V6R;
M1(Y26/S(&"BS)VP!N85>)H<S K5Q9CAWB!Z=%FX8LOFVGR@G''%"D[UZ9N^;
MIG5,OGNE25W2:;DC.]-%IGGIAB;T0:?B@";U/C-['G[@DIXQP=DVS79!4AZ_
MU#D9O: S?V)@0Y\__((MW5EJ2'D0"1MC32"T!LXMF(*K[0&<(LN,["/[9-_H
MDWQ@?,V/M^0;)W,>TCB^3C/Z1\7VSEP?].DPZ- VF_,!^.81JE_I9U'YW9Y/
M\^KHY2CX3?TPN1I[I\E:?KO9#6&K;YTF5^N6<D33!>)?G'S.P3-G/!9!5LAF
M'BZ;KU%F)E.ODHWGAIZHSVT[CQG=;=MSG)"GO7K#61CEP5.,9_>T@F^=D*<5
MM=2<GK;QO=D\[;SY2RP:KMJBPL>RI^R"I*R:V@5)*75"+HCGK2-KU?HV?TI_
MY7(.:*[""3DLBW:=TX^5"3-I6.&8Y2-EOW8SG73BY$8T=J.!<*.!Z-7Q4_:!
MMK2>VC7:<OJ$/"99V&]Q5!QHOJH9,\VIOG9"?E#<6G.ZO,87YT@^]Q-OMP0_
M!P36<WLVL^8K2YWH^QMZ7DWMG12D.B%'U'"FG93PY<04WV=1B&DP<NLR\FZL
MS FYL4%M[2P4V'OMHE(*,:W0K\NGO,B"L/ U882+UM<TTBF[SN&>8,:HG*4;
M^/H<+[RW_1I=K$=^]2O9>[%L[:]M1V8Z\[_"(0-XG/!Q<)#F8#)YK&FR 6)*
M+7P:)"9MW2$#16XZ4A@\.C?S<#%SLK8I6IP)>QZ7F)[0T^5U&\SF4_*8E0'@
M3M-2D5/RF[9M/*OKK)7Y^KWGV':O_G[:+G00PR?WHH/H[9,C-3^/ !27,-;
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MN3TGN-8_P'[W8N:_@T7,N<UA:<P7/'DQVI=-D8F: E,-,^0E=R,/;', \NC
MP3%1<UI2S"[ HZ4U]R0;(Y5%,!0K(\[IS1(0JBQ54 2ZV*RS(1'+DNEC\AM
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M#6D;H::"!_#ZKFV EP1>-^GC'/!GG7%8"GCHS#_)1KZTXI&F+T6Y*Y^/&_X
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M"FC5!WGU=(LJ!&LM(;Q;RG$91X64_@BRV66>9O&<)2OLLJ=WABV!#'MJ%]6
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M0HK3!K<\R,^9EV7-3QH2B"[Z,9B_H=T@0__@>\"R^<TS_)1Z?B$V=18ILY9
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M6P]?B!5 Y%(B<*.HX74C: G%2'P[5$L]ZL&T]3:FMK9HG0$V\QRBPARFFD>
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M/3R)42]FA]86'8$0!XC@FR?6)VGL\L"'G^!X+3=!2*H@4N*7! >C7E,6MD)
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MTV7'HF^N<\C+8S'N% ,L)T3;%(%8.>8H?I]=#(^)UBWHC9R"K4((ALCJK4\
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M,V<R,W,R,RYJ<&=02P$"% ,4    "  2@7Q4JDHF2,V_  !]#P$ $0
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M,#(Q,3(S,2YX<V102P$"% ,4    "  2@7Q4S#_5JT,.  #@R   %0
M        @ '6B@D :'EP<BTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @
M$H%\5/9(NN0,40  10P% !4              ( !3)D) &AY<'(M,C R,3$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( !*!?%2KO!8CX8H  )\L"  5
M      "  8OJ"0!H>7!R+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  2
M@7Q493-J0]-@  !7BP8 %0              @ &?=0H :'EP<BTR,#(Q,3(S
?,5]P<F4N>&UL4$L%!@     -  T 0P,  *76"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
